TW202321299A - Materials and methods of making or using il-23r binding proteins - Google Patents

Abstract

The present invention relates to monoclonal anti- interleukin-23 receptor (IL-23R) antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and corresponding compositions and methods of making and using antibodies respectively, i.e., e.g., detecting, selecting, enriching, inhibiting, or antagonizing IL-23R. or treat a autoimmune, inflammatory diseases or disorders.

Description

Materials and methods for making or using il-23r binding proteins

The present invention relates to a monoclonal anti-interleukin-23 receptor (IL-23R) antibody, a nucleic acid encoding the antibody and an expression vector, a recombinant cell containing the vector, and corresponding compositions and methods for producing and using the antibody, namely For example, for detecting, selecting, enriching, inhibiting, or antagonizing IL-23R, or treating autoimmune or inflammatory diseases or disorders.

IL-23 is a heterodimer of IL-23p19 and IL-12/23p40 subunits linked by disulfide bonds. Receptors for IL-23 include IL-23R and IL-12Rβ1 subunits. IL-23p19 binds to the N-terminal immunoglobulin (Ig)-like domain of IL-23R, followed by IL-12/23p40 binding to IL-12Rβ1 (Bloch, Y. et al ., Immunity 48: 45-58 e6, 2018) . Ligand binding results in phosphorylation of JAK2 and TYK2, followed by phosphorylation and nuclear translocation of STAT proteins. Although multiple STAT proteins are phosphorylated in response to IL-23, STAT3 is thought to play a major role in mediating IL-23 signaling (Parham, C. et al ., J Immunol 168: 5699-708, 2002).

The IL-23 pathway has been validated as a key driver of various inflammatory diseases by highly potent antibody therapeutics that block IL-23 signaling (reviewed by Gaffen et al ., Nat Rev Immunol 14: 585-600, 2014). IL-23 and IL-23R proteins are expressed at low levels in vivo, and increased IL-23R expression in disease is not always detectable using currently available IL-23R detection reagents, even in IL-23 Blockade is highly effective in diseases. So far, there are no commercially available anti-IL-23Rs validated for detecting IL-23-responsive cells in healthy individuals and disease patients or for studying the regulation, mobilization, and turnover of IL-23R at the cellular level Antibody. Academic and pharmaceutical industry scientists recognize this as a major challenge for research in their technical field. Accordingly, there is a need in the art for improved anti-IL-23R antibodies for receptor detection and other purposes, including applications and methods for disease detection, management, and therapy.

In general, the present invention relates to monoclonal anti-interleukin-23 receptor (IL-23R) antibody, nucleic acid encoding the antibody and expression vector, recombinant cells containing the vector, and corresponding compositions for producing and using the antibody respectively and methods, eg, for detecting, selecting, enriching, inhibiting, or antagonizing IL-23R, or treating autoimmune, inflammatory diseases or disorders.

In a general aspect, the present invention provides novel interleukin-23 receptor (IL-23R) antibodies directed against IL-23R, particularly human IL-23R. In one aspect, provided herein are isolated antibodies, especially antibodies or fragments thereof that specifically recognize IL-23R, including Fab fragments, single chain, or single domain antibodies. In one aspect, provided herein are antibodies or antigen-binding fragments thereof, wherein the antigen-binding fragment is capable of binding or recognizing IL-23R, particularly human IL-23R.

In one aspect, the antibody or antigen-binding fragment thereof binds to or specifically recognizes the extracellular domain (ECD) of IL-23R. In one aspect, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on a mammalian cell. In one aspect, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on human immune cells. In one aspect, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on primary human immune cells. In one aspect, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on the surface of cells, including primary human immune cells. In one aspect, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on T cells. In one aspect, the antibody or antigen-binding fragment thereof binds to or specifically recognizes human IL-23R and rat IL-23R. In one aspect, the antibody or antigen-binding fragment thereof binds to or specifically recognizes human IL-23R ECD and rat IL-23R ECD.

In some embodiments, the antibody or antigen-binding fragment thereof binds the human interleukin-23 receptor (IL-23R) on a mammalian cell. In embodiments, the antibody that binds IL23R on the surface of cells, including primary immune cells, comprises or is selected from the group consisting of antibodies designated herein: I23RB1, I23RB102, I23RB148, I23RB155, I23RB156, I23RB157, I23RB160, I23RB162, I23RB165 , I23RB166, I23RB173, I23RB2, I23RB27, I23RB270, I23RB3, I23RB30, I23RB318, I23RB32, I23RB33, I23RB36, I23RB39, I23RB4, I23RB42, I23RB45 , I23RB47, I23RB58, I23RB65, I23RB7, I23RB71, I23RB73, I23RB74, I23RB76, I23RB77, I23RB81 , I23RB82, I23RB86, I23RB92, I23RB93, or I23RB94. In one embodiment, the mammalian cell is a human cell or a rat cell. In one embodiment, the cell line is an immune cell. In one embodiment, the cell line is a primary immune cell. In one embodiment, the cell line is primary human immune cells or primary immune cells of rats. In one embodiment, the cell line is human T cells or rat T cells. In embodiments, the cell(s) may be of or include αβ T cells (including CD4+ and CD8+ T cells), γδ T cells, natural killer (NK) cells, innate lymphoid cells (ILCs), or monocyte-derived Sexual macrophages. In embodiments, the cell(s) may be or may include αβ T cells (including CD4+ and CD8+ T cells) or γδ T cells. In some embodiments, the cell line is a natural killer (NK) cell. In some embodiments, the cell line is an innate lymphoid cell (ILC). In some embodiments, the cell line is monocyte-derived macrophages.

In one embodiment, an isolated monoclonal antibody or an active fragment thereof that binds to human interleukin-23 receptor (IL-23R) on mammalian cells is provided, wherein the antibody or fragment comprises: a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:236, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:237; b. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; c. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:793; d. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:787; e. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:138, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:139; f. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:144, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:145; g. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:152, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:153; h. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:154, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:155; i. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:156, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:157; j. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:160, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:161; k. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:164, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:165; l. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:166, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:167; m. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:168, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:169; n. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:174, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:175; o. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:788, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:789; p. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:186, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:187; q. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:828, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:829; r. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:790, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:791; s. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:188, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:189; t. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:885; u. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:192, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:193; v. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:194, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:195; w. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:198, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:199; x. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:200, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:201; y. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:202, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:203; z. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:204, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:205; aa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:206, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:207; bb. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:216, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:217; cc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:222, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:223; dd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:230, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:231; ee. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:232, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:233; ff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:234, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:235; gg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:238, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:239; hh. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:246, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:247; ii. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:248, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:249; jj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:254, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:255; kk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:260, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:261; ll. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:262, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:263; or mm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:264, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:265.

In one embodiment, an antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on a mammalian cell is provided, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively, and comprising the amino acid sequences of SEQ ID NO:903, 904, and 905, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:276, 277, and 278, respectively, and comprising the amino acid sequences of SEQ ID NO:279, 280, and 281, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:294, 295, and 296, respectively, and comprising the amino acid sequences of SEQ ID NO:297, 298, and 299, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:318, 319, and 320, respectively, and comprising the amino acid sequences of SEQ ID NO:321, 322, and 323, respectively VL of LCDR1, LCDR2, and LCDR3; e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:324, 325, and 326, respectively, and comprising the amino acid sequences of SEQ ID NO:327, 328, and 329, respectively VL of LCDR1, LCDR2, and LCDR3; f. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:330, 331, and 332, respectively, and comprising the amino acid sequences of SEQ ID NO:333, 334, and 335, respectively VL of LCDR1, LCDR2, and LCDR3; g. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:342, 343, and 344, respectively, and comprising the amino acid sequences of SEQ ID NO:345, 346, and 347, respectively VL of LCDR1, LCDR2, and LCDR3; h. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:354, 355, and 356, respectively, and comprising the amino acid sequences of SEQ ID NO:357, 358, and 359, respectively VL of LCDR1, LCDR2, and LCDR3; i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:360, 361, and 362, respectively, and comprising the amino acid sequences of SEQ ID NO:363, 364, and 365, respectively VL of LCDR1, LCDR2, and LCDR3; j. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:366, 367, and 368, respectively, and comprising the amino acid sequences of SEQ ID NO:369, 370, and 371, respectively VL of LCDR1, LCDR2, and LCDR3; k. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:384, 385, and 386, respectively, and comprising the amino acid sequences of SEQ ID NO:387, 388, and 389, respectively VL of LCDR1, LCDR2, and LCDR3; l. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively, and comprising the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively VL of LCDR1, LCDR2, and LCDR3; m. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:420, 421, and 422, respectively, and comprising the amino acid sequences of SEQ ID NO:423, 424, and 425, respectively VL of LCDR1, LCDR2, and LCDR3; n. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1026, 1027, and 1028, respectively, and comprising the amino acid sequences of SEQ ID NO:1029, 1030, and 1031, respectively VL of LCDR1, LCDR2, and LCDR3; o. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively, and comprising the amino acid sequences of SEQ ID NO:915, 916, and 917, respectively VL of LCDR1, LCDR2, and LCDR3; p. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and comprising the amino acid sequences of SEQ ID NO:429, 430, and 431, respectively VL of LCDR1, LCDR2, and LCDR3; q. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1194, 1195, and 1196, respectively, and comprising the amino acid sequences of SEQ ID NO:1197, 1198, and 1199, respectively VL of LCDR1, LCDR2, and LCDR3; r. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:438, 439, and 440, respectively, and comprising the amino acid sequences of SEQ ID NO:441, 442, and 443, respectively VL of LCDR1, LCDR2, and LCDR3; s. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:444, 445, and 446, respectively, and comprising the amino acid sequences of SEQ ID NO:447, 448, and 449, respectively VL of LCDR1, LCDR2, and LCDR3; t. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:456, 457, and 458, respectively, and comprising the amino acid sequences of SEQ ID NO:459, 460, and 461, respectively VL of LCDR1, LCDR2, and LCDR3; u. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:462, 463, and 464, respectively, and comprising the amino acid sequences of SEQ ID NO:465, 466, and 467, respectively VL of LCDR1, LCDR2, and LCDR3; v. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising the amino acid sequences of SEQ ID NO:921, 922, and 923, respectively VL of LCDR1, LCDR2, and LCDR3; w. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:468, 469, and 470, respectively, and comprising the amino acid sequences of SEQ ID NO:471, 472, and 473, respectively VL of LCDR1, LCDR2, and LCDR3; x. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:474, 475, and 476, respectively, and comprising the amino acid sequences of SEQ ID NO:477, 478, and 479, respectively VL of LCDR1, LCDR2, and LCDR3; y. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:480, 481, and 482, respectively, and comprising the amino acid sequences of SEQ ID NO:483, 484, and 485, respectively VL of LCDR1, LCDR2, and LCDR3; z. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:510, 511, and 512, respectively, and comprising the amino acid sequences of SEQ ID NO:513, 514, and 515, respectively VL of LCDR1, LCDR2, and LCDR3; aa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:528, 529, and 530, respectively, and comprising the amino acid sequences of SEQ ID NO:531, 532, and 533, respectively VL of LCDR1, LCDR2, and LCDR3; bb. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequences of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; cc. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:552, 553, and 554, respectively, and comprising the amino acid sequences of SEQ ID NO:555, 556, and 557, respectively VL of LCDR1, LCDR2, and LCDR3; dd. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:558, 559, and 560, respectively, and comprising the amino acid sequences of SEQ ID NO:561, 562, and 563, respectively VL of LCDR1, LCDR2, and LCDR3; ee. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively, and comprising the amino acid sequences of SEQ ID NO:567, 568, and 569, respectively VL of LCDR1, LCDR2, and LCDR3; ff. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequences of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3; gg. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 576, 577, and 578, respectively, and comprising the amino acid sequences of SEQ ID NOs: 579, 580, and 581, respectively VL of LCDR1, LCDR2, and LCDR3; hh. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:600, 601, and 602, respectively, and comprising the amino acid sequences of SEQ ID NO:603, 604, and 605, respectively VL of LCDR1, LCDR2, and LCDR3; ii. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively, and comprising the amino acid sequences of SEQ ID NO:609, 610, and 611, respectively VL of LCDR1, LCDR2, and LCDR3; jj. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:624, 625, and 626, respectively, and comprising the amino acid sequences of SEQ ID NO:627, 628, and 629, respectively VL of LCDR1, LCDR2, and LCDR3; kk. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:642, 643, and 644, respectively, and comprising the amino acid sequences of SEQ ID NO:645, 646, and 647, respectively VL of LCDR1, LCDR2, and LCDR3; ll. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:648, 649, and 650, respectively, and comprising the amino acid sequences of SEQ ID NO:651, 652, and 653, respectively VL of LCDR1, LCDR2, and LCDR3; or mm. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:654, 655, and 656, respectively, and comprising the amino acid sequence of SEQ ID NO:657, 658, and 659, respectively VL of LCDR1, LCDR2, and LCDR3.

In one embodiment, an antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on a mammalian cell is provided, wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; b. VH comprising the amino acid sequence of SEQ ID NO:138, and VL comprising the amino acid sequence of SEQ ID NO:139; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; d. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153; e. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; f. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; g. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; h. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165; i. VH comprising the amino acid sequence of SEQ ID NO:166, and VL comprising the amino acid sequence of SEQ ID NO:167; j. VH comprising the amino acid sequence of SEQ ID NO:168, and VL comprising the amino acid sequence of SEQ ID NO:169; k. VH comprising the amino acid sequence of SEQ ID NO:174, and VL comprising the amino acid sequence of SEQ ID NO:175; l. VH comprising the amino acid sequence of SEQ ID NO:788, and VL comprising the amino acid sequence of SEQ ID NO:789; m. VH comprising the amino acid sequence of SEQ ID NO:186, and VL comprising the amino acid sequence of SEQ ID NO:187; n. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; o. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; p. VH comprising the amino acid sequence of SEQ ID NO:188, and VL comprising the amino acid sequence of SEQ ID NO:189; q. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; r. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; s. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; t. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; u. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; v. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; w. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; x. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; y. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; z. VH comprising the amino acid sequence of SEQ ID NO:216, and VL comprising the amino acid sequence of SEQ ID NO:217; aa. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; bb. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; cc. VH comprising the amino acid sequence of SEQ ID NO:230, and VL comprising the amino acid sequence of SEQ ID NO:231; dd. VH comprising the amino acid sequence of SEQ ID NO:232, and VL comprising the amino acid sequence of SEQ ID NO:233; ee. VH comprising the amino acid sequence of SEQ ID NO:234, and VL comprising the amino acid sequence of SEQ ID NO:235; ff. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; gg. VH comprising the amino acid sequence of SEQ ID NO:238, and VL comprising the amino acid sequence of SEQ ID NO:239; hh. VH comprising the amino acid sequence of SEQ ID NO:246, and VL comprising the amino acid sequence of SEQ ID NO:247; ii. VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; jj. VH comprising the amino acid sequence of SEQ ID NO:254, and VL comprising the amino acid sequence of SEQ ID NO:255; kk. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; ll. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; or mm. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265.

In some embodiments, the antibody binding to human interleukin-23 receptor (IL-23R) on mammalian cells is selected from antibodies I23RB1, I23RB3, I23RB4, I23RB7, and I23RB76. In one embodiment, the mammalian cell is a human cell or a rat cell. In one embodiment, the cell line is an immune cell. In one embodiment, the cell line is a primary immune cell. In one embodiment, the cell line is primary human immune cells or primary immune cells of rats. In one embodiment, the cell line is human T cells or rat T cells. In embodiments, the cell(s) may be of or include αβ T cells (including CD4+ and CD8+ T cells), γδ T cells, natural killer (NK) cells, innate lymphoid cells (ILCs), or monocyte-derived Sexual macrophages. In embodiments, the cell(s) may be or may include αβ T cells (including CD4+ and CD8+ T cells) or γδ T cells. In some embodiments, the cell line is a natural killer (NK) cell. In some embodiments, the cell line is an innate lymphoid cell (ILC). In some embodiments, the cell line is monocyte-derived macrophages.

In one embodiment, there is provided the monoclonal antibody or its active fragment as described in Claim 1, which binds to the human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises : a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:787; b. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:790, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:791; c. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:793; d. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; or e. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:236, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:237.

In one embodiment, an antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on a mammalian cell is provided, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively, and comprising the amino acid sequences of SEQ ID NO:903, 904, and 905, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively, and comprising the amino acid sequence of SEQ ID NO:915, 916, and 917, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising the amino acid sequence of SEQ ID NO:921, 922, and 923, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequence of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; or e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequence of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3.

In one embodiment, an antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on a mammalian cell is provided, wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; b. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; or e. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237.

In some embodiments, the antibody binding to interleukin-23 receptor (IL-23R) on mammalian cells is selected from I23RB4, I23RB7, and I23RB76. In one embodiment, the mammalian cell is a human cell or a rat cell. In one embodiment, the cell line is an immune cell. In one embodiment, the cell line is a primary immune cell. In one embodiment, the cell line is primary human immune cells or primary immune cells of rats. In one embodiment, the cell line is human T cells or rat T cells. In embodiments, the cell(s) may be of or include αβ T cells (including CD4+ and CD8+ T cells), γδ T cells, natural killer (NK) cells, innate lymphoid cells (ILCs), or monocyte-derived Sexual macrophages. In embodiments, the cell(s) may be or may include αβ T cells (including CD4+ and CD8+ T cells) or γδ T cells. In some embodiments, the cell line is a natural killer (NK) cell. In some embodiments, the cell line is an innate lymphoid cell (ILC). In some embodiments, the cell line is monocyte-derived macrophages.

In an embodiment thereof, an antibody or antigen-binding fragment thereof is provided that binds to the human interleukin-23 receptor (IL-23R) on the surface of cells including primary human immune cells, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising the amino acid sequence of SEQ ID NO:921, 922, and 923, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequence of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; or c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequence of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3.

In one embodiment, an antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on a mammalian cell is provided, wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; b. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; or c. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237.

In another embodiment, provided herein are antibodies and antigen-binding fragments thereof, wherein the antibodies (and binding fragments) recognize and/or bind human and rat IL-23R. In embodiments, the antibodies and fragments recognize and bind rat and human IL-23R extracellular domains (ECD). In some embodiments, the antibody is selected from I23RB42, I23RB85, I23RB157, I23RB7, I23RB153, I23RB45, I23RB318, I23RB30, and I23RB56.

In some embodiments, there is provided an isolated monoclonal antibody or antigen-binding fragment thereof that recognizes human and rat IL-23R, wherein the antibody or fragment comprises: a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:202, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:203; b. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:252, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:253; c. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:156, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:157; d. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; e. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:150, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:151; f. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:204, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:205; g. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:885; h. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:188, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:189; or i. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:212, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:213.

In an embodiment, an antibody or antigen-binding fragment thereof is provided that recognizes human and rat IL-23R, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO:468, 469, and 470, respectively, and comprising amino acid sequences of SEQ ID NO:471, 472, and 473, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:618, 619, and 620, respectively, and comprising the amino acid sequence of SEQ ID NO:621, 622, and 623, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:330, 331, and 332, respectively, and comprising the amino acid sequence of SEQ ID NO:333, 334, and 335, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequence of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:312, 313, and 314, respectively, and comprising the amino acid sequence of SEQ ID NO:315, 316, and 317, respectively VL of LCDR1, LCDR2, and LCDR3; f. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:474, 475, and 476, respectively, and comprising the amino acid sequence of SEQ ID NO:477, 478, and 479, respectively VL of LCDR1, LCDR2, and LCDR3; g. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1194, 1195, and 1196, respectively, and comprising the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively VL of LCDR1, LCDR2, and LCDR3; h. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and comprising the amino acid sequence of SEQ ID NO:429, 430, and 431, respectively VL of LCDR1, LCDR2, and LCDR3; or i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:498, 499, and 500, respectively, and comprising the amino acid sequence of SEQ ID NO:501, 502, and 503, respectively VL of LCDR1, LCDR2, and LCDR3.

In some embodiments, antibodies or antigen-binding fragments thereof are provided that recognize human and rat IL-23R, wherein the antibodies or fragments comprise: a. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; b. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; d. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151; f. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; g. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; h. VH comprising the amino acid sequence of SEQ ID NO: 188, and VL comprising the amino acid sequence of SEQ ID NO: 189; or i. VH comprising the amino acid sequence of SEQ ID NO:212, and VL comprising the amino acid sequence of SEQ ID NO:213.

In other embodiments, antibodies that share a common light chain sequence are provided. In some embodiments, the antibodies have a consensus VL amino acid sequence. In some embodiments, the antibodies have a consensus LC amino acid sequence. In embodiments, the antibodies share light chain CDR1, CDR2, and CDR3 amino acid sequences.

In the first group (group 1), the following antibodies shared the same VL, LC, and light chain CDR sequences: 123RB1, RB2, RB3, RB4, RB8, RB9, RB268, RB270, RB291.

According to one aspect of this embodiment, an antibody or antigen-binding fragment thereof is provided, which binds to IL-23R and comprises: a CDR sequence comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ ID NO: 1254 The VL of, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:900, HCDR2 SEQ ID NO:901, and HCDR3 SEQ ID NO:902; b. HCDR1 SEQ ID NO:906, HCDR2 SEQ ID NO:907, and HCDR3 SEQ ID NO:908; c. HCDR1 SEQ ID NO:912, HCDR2 SEQ ID NO:913, and HCDR3 SEQ ID NO:914; d. HCDR1 SEQ ID NO:918, HCDR2 SEQ ID NO:919, and HCDR3 SEQ ID NO:920; e. HCDR1 SEQ ID NO:942, HCDR2 SEQ ID NO:943, and HCDR3 SEQ ID NO:944; f. HCDR1 SEQ ID NO:948, HCDR2 SEQ ID NO:949, and HCDR3 SEQ ID NO:950; g. HCDR1 SEQ ID NO: 1014, HCDR2 SEQ ID NO: 1015, and HCDR3 SEQ ID NO: 1016; h. HCDR1 SEQ ID NO: 1026, HCDR2 SEQ ID NO: 1027, and HCDR3 SEQ ID NO: 1028; and i. HCDR1 SEQ ID NO: 1152, HCDR2 SEQ ID NO: 1153, and HCDR3 SEQ ID NO: 1154.

In one embodiment, an antibody or antigen-binding fragment thereof is provided, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ ID NO: 1254 or having an amino acid sequence of SEQ ID The VL of NO:1247, and the VH sequence selected from SEQ ID NO:786, 788, 790, 792, 800, 802, 824, 828, and 870.

In the second group (Group 2), the following antibodies shared the same VL, LC, and light chain CDR sequences: I23RB5, I23RB266, I23RB271, I23RB273, I23RB274, I23RB275, I23RB276, I23RB277, I23RB279, I23RB281, I23RB282 , I23RB284, I23RB285 , I23RB286, I23RB289, I23RB290, and I23RB292. According to one aspect of this embodiment, an antibody or antigen-binding fragment thereof is provided, which binds to IL-23R and comprises: a CDR sequence comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ ID NO: 1257 The VL of, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:924, HCDR2 SEQ ID NO:925, and HCDR3 SEQ ID NO:926; b. HCDR1 SEQ ID NO:1002, HCDR2 SEQ ID NO:1003, and HCDR3 SEQ ID NO:1004; c. HCDR1 SEQ ID NO: 1032, HCDR2 SEQ ID NO: 1033, and HCDR3 SEQ ID NO: 1034; d. HCDR1 SEQ ID NO:1044, HCDR2 SEQ ID NO:1045, and HCDR3 SEQ ID NO:1046; e. HCDR1 SEQ ID NO:1050, HCDR2 SEQ ID NO:1051, and HCDR3 SEQ ID NO:1052; f. HCDR1 SEQ ID NO:1056, HCDR2 SEQ ID NO:1057, and HCDR3 SEQ ID NO:1058; g. HCDR1 SEQ ID NO: 1062, HCDR2 SEQ ID NO: 1063, and HCDR3 SEQ ID NO: 1064; h. HCDR1 SEQ ID NO: 1068, HCDR2 SEQ ID NO: 1069, and HCDR3 SEQ ID NO: 1070; i. HCDR1 SEQ ID NO: 1080, HCDR2 SEQ ID NO: 1081, and HCDR3 SEQ ID NO: 1082; j. HCDR1 SEQ ID NO: 1092, HCDR2 SEQ ID NO: 1093, and HCDR3 SEQ ID NO: 1094; k. HCDR1 SEQ ID NO:1098, HCDR2 SEQ ID NO:1099, and HCDR3 SEQ ID NO:1100; l. HCDR1 SEQ ID NO:1110, HCDR2 SEQ ID NO:1111, and HCDR3 SEQ ID NO:1112; m. HCDR1 SEQ ID NO:1122, HCDR2 SEQ ID NO:1123, and HCDR3 SEQ ID NO:1124; n. HCDR1 SEQ ID NO:1140, HCDR2 SEQ ID NO:1141, and HCDR3 SEQ ID NO:1142; o. HCDR1 SEQ ID NO: 1146, HCDR2 SEQ ID NO: 1147, and HCDR3 SEQ ID NO: 1148; and p. HCDR1 SEQ ID NO: 1158, HCDR2 SEQ ID NO: 1159, and HCDR3 SEQ ID NO: 1160.

In some embodiments, an antibody or antigen-binding fragment thereof is provided comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ ID NO: 1257 or having the amino acid sequence of SEQ ID The VL of NO: 1248, and the VH sequence selected from SEQ ID NO: 794, 820, 830, 834, 836, 838, 840, 842, 846, 850, 852, 856, 860, 866, 868, and 872.

In the third group (Group 3), the following antibodies shared the same VL, LC, and light chain CDR sequences: I23RB6 and I23RB10. According to one aspect of this embodiment, an antibody or antigen-binding fragment thereof is provided, which binds to IL-23R and comprises: a CDR sequence comprising LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ ID NO: 1260 The VL of, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:930, HCDR2 SEQ ID NO:931, and HCDR3 SEQ ID NO:932; and b. HCDR1 SEQ ID NO:954, HCDR2 SEQ ID NO:955, and HCDR3 SEQ ID NO:956.

In one embodiment, an antibody or antigen-binding fragment thereof is provided, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ ID NO: 1260 or having an amino acid sequence of SEQ ID The VL of NO:1249, and the VH sequence selected from SEQ ID NO:796 and 804.

In the fourth group (group 2), the following antibodies shared the same VL, LC, and light chain CDR sequences: I23RB259 and I23RB316. According to one aspect of this embodiment, an antibody or antigen-binding fragment thereof is provided, which binds to IL-23R and comprises: a CDR sequence comprising LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ ID NO: 1263 The VL of, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:960, HCDR2 SEQ ID NO:961, and HCDR3 SEQ ID NO:962; and b. HCDR1 SEQ ID NO: 1182, HCDR2 SEQ ID NO: 1183, and HCDR3 SEQ ID NO: 1184.

In one embodiment, an antibody or antigen-binding fragment thereof is provided, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ ID NO: 1263 or having an amino acid sequence of SEQ ID The VL of NO:1250, and the VH sequence selected from SEQ ID NO:806 and 880.

In the fifth group (Group 5), the following antibodies shared the same VL, LC, and light chain CDR sequences: I23RB267, I23RB3269, I23RB272, I23RB278, I23RB280, I23RB283, I23RB287, and I23RB288. According to one aspect of this embodiment, an antibody or antigen-binding fragment thereof is provided, which binds to IL-23R and comprises: a CDR sequence comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ ID NO: 1266 The VL of, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:1008, HCDR2 SEQ ID NO:1009, and HCDR3 SEQ ID NO:1010; b. HCDR1 SEQ ID NO:1020, HCDR2 SEQ ID NO:1021, and HCDR3 SEQ ID NO:1022; c. HCDR1 SEQ ID NO: 1038, HCDR2 SEQ ID NO: 1039, and HCDR3 SEQ ID NO: 1040; d. HCDR1 SEQ ID NO:1074, HCDR2 SEQ ID NO:1075, and HCDR3 SEQ ID NO:1076; e. HCDR1 SEQ ID NO:1086, HCDR2 SEQ ID NO:1087, and HCDR3 SEQ ID NO:1088; f. HCDR1 SEQ ID NO:1104, HCDR2 SEQ ID NO:1105, and HCDR3 SEQ ID NO:1106; g. HCDR1 SEQ ID NO: 1128, HCDR2 SEQ ID NO: 1129, and HCDR3 SEQ ID NO: 1130; and h. HCDR1 SEQ ID NO: 1134, HCDR2 SEQ ID NO: 1135, and HCDR3 SEQ ID NO: 1136.

In one embodiment, an antibody or antigen-binding fragment thereof is provided, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ ID NO: 1266 or having an amino acid sequence of SEQ ID The VL of NO:1251, and the VH sequence selected from SEQ ID NO:806 and 880, 822, 826, 832, 844, 848, 854, 862, and 864.

In one embodiment of the present invention, VHH antibodies (also denoted as heavy chain domain antibodies or nanobodies) are provided, including antibodies or fragments thereof consisting only of heavy chain sequences. In one embodiment, there is provided a VHH antibody or Nanobody that binds to IL-23R and comprises a protein selected from the group consisting of SEQ ID NO: 786, 788, 790, 792, 800, 802, 824, 828, 870, 794, 820, 830 ,834,836,838,840,842,846,850,852,856,860,866,868,872,796,804,806,880,822,826,832,844,848,854,862, and 864 VH sequences.

Provided herein are IL-23R binding antibodies. In some embodiments, there is provided an antibody or antigen-binding fragment thereof that binds IL-23R comprising: a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:138, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:139; b. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:142, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:143; c. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:144, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:145; d. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:148, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:149; e. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:150, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:151; f. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:152, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:153; g. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:154, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:155; h. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:156, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:157; i. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:158, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:159; j. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:160, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:161; k. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:162, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:163; l. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:164, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:165; m. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:166, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:167; n. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:168, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:169; o. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:170, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:171; p. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:172, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:173; q. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:174, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:175; r. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:176, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:177; s. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:178, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:179; t. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:180, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:181; u. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:182, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:183; v. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:186, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:187; w. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:188, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:189; x. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:190, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:191; y. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:192, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:193; z. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:194, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:195; aa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:196, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:197; bb. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:198, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:199; cc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:200, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:201; dd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:202, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:203; ee. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:204, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:205; ff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:206, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:207; gg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:208, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:209; hh. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:210, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:211; ii. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:212, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:213; jj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:214, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:215; kk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:216, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:217; ll. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:218, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:219; mm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:220, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:221; nn. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:222, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:223; oo. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:226, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:227; pp. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:228, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:229; qq. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:230, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:231; rr. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:232, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:233; ss. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:234, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:235; tt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:236, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:237; uu. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:238, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:239; vv. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:240, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:241; ww. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:246, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:247; xx. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:248, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:249; yy. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:250, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:251; zz. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:252, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:253; aaa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:254, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:255; bbb. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:256, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:257; ccc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:258, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:259; ddd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:260, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:261; eee. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:262, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:263; fff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:264, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:265; ggg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:268, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:269; hhh. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:787; iii. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:788, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:789; jjj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:790, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:791; kkk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:793; lll. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; mmm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:806, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:807; nnn. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:808, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:809; ooo. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:810, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:811; ppp. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:812, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:813; qqq. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:814, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:815; rrr. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:816, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:817; sss. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:818, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:819; ttt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:820, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:821; uuu. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:822, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:823; vvv. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:824, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:825; www. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:826, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:827; xxx. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:828, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:829; yyy. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:830, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:831; zzz. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:832, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:833; aaaa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:836, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:837; bbbb. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:838, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:839; cccc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:840, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:841; dddd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 842, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 843; eeee. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:846, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:847; ffff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:848, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:849; gggg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:850, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:851; hhhh. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:852, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:853; iii. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:854, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:855; jjjj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:856, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:857; kkkk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:858, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:859; llll. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:860, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:861; mmmm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:862, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:863; nnnn. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:864, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:865; oooo. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:866, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:867; pppp. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:868, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:869; qqqq. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:870, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:871; rrrr. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:872, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:873; ssss. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:874, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:875; tttt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:876, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:877; uuuu. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:878, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:879; vvvv. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:880, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:881; wwww. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:882, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:883; xxxx. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:885; yyyy. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:886, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:887; zzzz. HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:888, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:889; or aaaaa. HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:890, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:891.

In some embodiments, an antibody or antigen-binding fragment thereof that binds IL-23R is provided, comprising: a. comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 276, 277, and 278, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:279, 280, and 281, respectively; b. comprising the amino acids of SEQ ID NO:288, 289, and 290, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:291, 292, and 293 respectively; c. comprising respectively having SEQ ID NO:294 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , 295, and 296, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:297, 298, and 299, respectively; d . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 306, 307, and 308, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 309, 310, and 311, respectively , LCDR2, and the VL of LCDR3; e. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:312, 313, and 314, respectively, and comprising the VH of SEQ ID NO:315, 316, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of and 317; f. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:318, 319, and 320, and comprises respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequence of SEQ ID NO:321, 322, and 323; g. HCDR1, HCDR2 comprising the amino acid sequence of SEQ ID NO:324, 325, and 326, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:327, 328, and 329 respectively; h. comprising having SEQ ID NO:330, 331, and 332 respectively The amino acid sequence of HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequence of SEQ ID NO:333, 334, and 335; VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 336, 337, and 338, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 339, 340, and 341, respectively The VL of j. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:342, 343, and 344 respectively, and comprising the amine groups having SEQ ID NO:345, 346, and 347 respectively The VL of LCDR1, LCDR2, and LCDR3 of acid sequence; k. comprise the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:348, 349, and 350 respectively, and comprise respectively having SEQ ID NO: 351, 352, and the VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 353; 1. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:354, 355, and 356, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequence of SEQ ID NO:357, 358, and 359 respectively; m. comprising the amino acid sequence having SEQ ID NO:360, 361, and 362, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:363, 364, and 365; n. comprising respectively having SEQ ID NO:366, The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of 367 and 368, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:369, 370, and 371, respectively; o. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 372, 373, and 374, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 375, 376, and 377, respectively LCDR2, and the VL of LCDR3; p. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:378, 379, and 380, respectively, and comprising respectively having SEQ ID NO:381, 382, and The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 383; q. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:384, 385, and 386, and comprise respectively having VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NO:387, 388, and 389; r. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:393, 394, and 395 respectively; s. comprising having SEQ ID NO:396, 397, and 398 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:399, 400, and 401 respectively; The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO: 402, 403, and 404, and the VH of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 405, 406, and 407, respectively VL; u. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:408, 409, and 410, respectively, and comprising the amino acids of SEQ ID NO:411, 412, and 413, respectively VL of LCDR1, LCDR2, and LCDR3 of the sequence; v. VH comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequence having SEQ ID NO:420, 421, and 422 respectively, and comprising having SEQ ID NO:423 respectively , 424, and 425 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; w. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 429, 430, and 431, respectively; x. comprising the amino acid sequences of SEQ ID NOs: 432, 433, and 434, respectively VH of HCDR1, HCDR2, and HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:435, 436, and 437 respectively; y. comprising having SEQ ID NO:438,439 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 440, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:441, 442, and 443; z. comprising VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 444, 445, and 446, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 447, 448, and 449, respectively , and the VL of LCDR3; aa. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:450, 451, and 452, respectively, and comprising having SEQ ID NO:453, 454, and 455, respectively The VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; bb. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:456, 457, and 458, and comprises respectively having SEQ ID NO:456, 457, and the VH of HCDR3 VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 459, 460, and 461; cc. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:465, 466, and 467, respectively; dd. comprising the amine of SEQ ID NO:468, 469, and 470, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:471, 472, and 473 respectively; ee. VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences of 474, 475, and 476, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NOs: 477, 478, and 479, respectively ff. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:480, 481, and 482, respectively, and comprising the amino acid sequence of SEQ ID NO:483, 484, and 485, respectively The VL of LCDR1, LCDR2, and LCDR3; gg. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:486, 487, and 488, respectively, and comprising the VH of SEQ ID NO:489, VL of LCDR1, LCDR2, and LCDR3 having amino acid sequences of 490, and 491; hh. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NOs: 492, 493, and 494, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:495, 496, and 497 respectively; ii. comprising HCDR1 having the amino acid sequences of SEQ ID NO:498, 499, and 500, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:501, 502, and 503, respectively; jj. comprising having SEQ ID NO:504, 505, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of and 506, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:507, 508, and 509 respectively; kk. comprises respectively VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 510, 511, and 512, and LCDR1, LCDR2, and the VL of LCDR3; 11. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:516, 517, and 518 respectively, and comprising the VH of having SEQ ID NO:519, 520, and 521 respectively VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; mm. VH comprising HCDR1, HCDR2, and HCDR3 of amino acid sequences having SEQ ID NO:522, 523, and 524 respectively, and comprising having SEQ ID NO:522, 523, and 524 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of NO: 525, 526, and 527; nn. HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO: 528, 529, and 530, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO:531, 532, and 533, respectively; oo. comprising amino groups having SEQ ID NO:540, 541, and 542, respectively The VH of HCDR1, HCDR2, and HCDR3 of the acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:543, 544, and 545 respectively; pp. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 546, 547, and 548, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 549, 550, and 551, respectively; qq. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 552, 553, and 554, respectively, and comprising the amino acid sequences of SEQ ID NOs: 555, 556, and 557, respectively VL of LCDR1, LCDR2, and LCDR3; rr. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO:558, 559, and 560, respectively, and comprising SEQ ID NO:561, 562 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 563; ss. comprises the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively, and comprises VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:567, 568, and 569 respectively; tt. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:573, 574, and 575; uu. comprising respectively having SEQ ID NO:576, 577, and The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence of 578, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO:579, 580, and 581 respectively; vv. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 582, 583, and 584, and LCDR1, LCDR2, and VL of LCDR3; ww. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:600, 601, and 602, respectively, and comprising the amine of SEQ ID NO:603, 604, and 605, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; xx. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:606, 607, and 608 respectively, and comprising the VH of the amino acid sequences having SEQ ID NO:606, 607, and 608 respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of 609, 610, and 611; yy. comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequences of SEQ ID NO:612, 613, and 614, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:615, 616, and 617, respectively; zz. comprising the amino acids of SEQ ID NO:618, 619, and 620, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:621, 622, and 623 respectively; aaa. comprising respectively having SEQ ID NO:624 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , 625, and 626, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:627, 628, and 629, respectively; bbb . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:630, 631, and 632, respectively, and LCDR1 comprising the amino acid sequence of SEQ ID NO:633, 634, and 635, respectively , LCDR2, and the VL of LCDR3; ccc. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:636, 637, and 638, respectively, and comprising the VH of SEQ ID NO:639, 640, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of and 641; ddd. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:642, 643, and 644 respectively, and comprising respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequence of SEQ ID NO:645, 646, and 647; eee. comprising HCDR1, HCDR2 having the amino acid sequence of SEQ ID NO:648, 649, and 650, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:651, 652, and 653 respectively; fff. comprising having SEQ ID NO:654, 655, and 656 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:657, 658, and 659 respectively; ggg. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 666, 667, and 668, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 669, 670, and 671, respectively VL of hhh. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively, and comprising the amino groups of SEQ ID NO:903, 904, and 905, respectively The VL of LCDR1, LCDR2, and LCDR3 of the acid sequence; iii. comprising the VH of HCDR1, HCDR2, and HCDR3 having respectively the amino acid sequences of SEQ ID NO:906, 907, and 908, and comprising having the VH of SEQ ID NO:906, 907, and 908 respectively, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of 909, 910, and 911; jjj. The VH of HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 915, 916, and 917, respectively; kkk. comprising the amino acid sequences of SEQ ID NOs: 918, 919, and 920, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:921, 922, and 923 respectively; lll. comprising having SEQ ID NO:936, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 937 and 938, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:939, 940, and 941 respectively; mmm. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs:960, 961, and 962, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs:963, 964, and 965, respectively VL of LCDR2, and LCDR3; nnn. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO:966, 967, and 968, respectively, and comprising SEQ ID NO:969, 970, and The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 971; ooo. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:972, 973, and 974, and comprises respectively having VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NO:975, 976, and 977; ppp. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:981, 982, and 983 respectively; qqq. comprising having SEQ ID NO:984, 985, and 986 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:987, 988, and 989 respectively; rrr. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO:990, 991, and 992, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:993, 994, and 995, respectively VL; sss. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:996, 997, and 998, respectively, and comprising the amino acids of SEQ ID NO:999, 1000, and 1001, respectively The VL of LCDR1, LCDR2, and LCDR3 of the sequence; ttt.comprising the VH of HCDR1, HCDR2, and HCDR3 having respectively the amino acid sequences of SEQ ID NO:1002, 1003, and 1004, and comprising having respectively SEQ ID NO:1005 The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , 1006, and 1007; uuu. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1008, 1009, and 1010, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1011, 1012, and 1013, respectively; vvv. comprising the amino acid sequences of SEQ ID NOs: 1014, 1015, and 1016, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1017, 1018, and 1019 respectively; www. comprising having SEQ ID NO: 1020, 1021 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 1022, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1023, 1024, and 1025; xxx. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1026, 1027, and 1028, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 1029, 1030, and 1031, respectively , and the VL of LCDR3; yyy. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1032, 1033, and 1034, respectively, and comprising the VH of SEQ ID NO:1035, 1036, and 1037, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; zzz. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:1038, 1039, and 1040 respectively, and comprising the VH of SEQ ID NO:1038, 1039, and 1040, respectively, VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 1041, 1042, and 1043; aaaa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1050, 1051, and 1052, respectively, and LCDR1, LCDR2, and the VL of LCDR3; bbbb. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1056, 1057, and 1058, respectively, and comprising the VH of SEQ ID NO:1059, 1060, and VL of LCDR1, LCDR2, and LCDR3 having an amino acid sequence of 1061; cccc. VH comprising HCDR1, HCDR2, and HCDR3 having an amino acid sequence of SEQ ID NO: 1062, 1063, and 1064, respectively, and comprising a VH having respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NOs: 1065, 1066, and 1067; dddd. HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1071, 1072, and 1073 respectively; eeee. comprising having SEQ ID NO: 1080, 1081, and 1082 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1083, 1084, and 1085 respectively; ffff. The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of NO:1086, 1087, and 1088, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1089, 1090, and 1091, respectively VL; gggg. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1092, 1093, and 1094, respectively, and comprising the amino acids of SEQ ID NO: 1095, 1096, and 1097, respectively The VL of LCDR1, LCDR2, and LCDR3 of the sequence; hhhh. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1098, 1099, and 1100 respectively, and comprising the VH of SEQ ID NO:1101 respectively , 1102, and 1103 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; iii. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1104, 1105, and 1106, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1107, 1108, and 1109, respectively; The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1113, 1114, and 1115 respectively; kkkk. comprising having SEQ ID NO:1116, 1117, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 1118, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1119, 1120, and 1121 respectively; llll. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1122, 1123, and 1124, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 1125, 1126, and 1127, respectively , and the VL of LCDR3; mmmm. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1128, 1129, and 1130, respectively, and comprising the VH of SEQ ID NO:1131, 1132, and 1133, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; nnnn. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1134, 1135, and 1136 respectively, and comprising the VH of SEQ ID NO:1134, 1135, and 1136, respectively, VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 1137, 1138, and 1139; oooo. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO: 1143, 1144, and 1145, respectively; pppp. comprising amines having SEQ ID NO: 1146, 1147, and 1148, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1149, 1150, and 1151 respectively; VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences of 1152, 1153, and 1154, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NOs: 1155, 1156, and 1157, respectively ; rrrr. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1158, 1159, and 1160, respectively, and comprising the amino acid sequences of SEQ ID NOs: 1161, 1162, and 1163, respectively The VL of LCDR1, LCDR2, and LCDR3; ssss. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1164, 1165, and 1166, respectively, and comprising the VH of SEQ ID NO:1167, VL of LCDR1, LCDR2, and LCDR3 having amino acid sequences of 1168, and 1169; tttt. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NOs: 1170, 1171, and 1172, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1173, 1174, and 1175, respectively; uuuu. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 1176, 1177, and 1178, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1179, 1180, and 1181 respectively; vvvv. comprising having SEQ ID NO:1182, 1183, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence of and 1184, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1185, 1186, and 1187; wwww. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1188, 1189, and 1190, and LCDR1, LCDR2, and the VL of LCDR3; xxxx. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1194, 1195, and 1196, respectively, and comprising the VH of SEQ ID NO:1197, 1198, and 1199, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; yyyy. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1200, 1201, and 1202, respectively, and comprising the VH of SEQ ID NO:1200, 1201, and 1202, respectively VL of LCDR1, LCDR2, and LCDR3 with amino acid sequences of NO:1203, 1204, and 1205; zzzz. HCDR1, HCDR2, and HCDR3 comprising amino acid sequences of SEQ ID NO:1206, 1207, and 1208, respectively and the VH comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1209, 1210, and 1211, respectively; or aaaaa. comprising the amine having SEQ ID NO:1212, 1213, and 1214, respectively VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NO: 1215, 1216, and 1217, respectively.

In some embodiments, antibodies or antigen-binding fragments thereof are provided comprising: a. VH comprising the amino acid sequence of SEQ ID NO:138, and VL comprising the amino acid sequence of SEQ ID NO:139; b. VH comprising the amino acid sequence of SEQ ID NO:142, and VL comprising the amino acid sequence of SEQ ID NO:143; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; d. VH comprising the amino acid sequence of SEQ ID NO:148, and VL comprising the amino acid sequence of SEQ ID NO:149; e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151; f. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153; g. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; h. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; i. VH comprising the amino acid sequence of SEQ ID NO:158, and VL comprising the amino acid sequence of SEQ ID NO:159; j. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; k. VH comprising the amino acid sequence of SEQ ID NO:162, and VL comprising the amino acid sequence of SEQ ID NO:163; l. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165; m. VH comprising the amino acid sequence of SEQ ID NO:166, and VL comprising the amino acid sequence of SEQ ID NO:167; n. VH comprising the amino acid sequence of SEQ ID NO:168, and VL comprising the amino acid sequence of SEQ ID NO:169; o. VH comprising the amino acid sequence of SEQ ID NO:170, and VL comprising the amino acid sequence of SEQ ID NO:171; p. VH comprising the amino acid sequence of SEQ ID NO:172, and VL comprising the amino acid sequence of SEQ ID NO:173; q. VH comprising the amino acid sequence of SEQ ID NO:174, and VL comprising the amino acid sequence of SEQ ID NO:175; r. VH comprising the amino acid sequence of SEQ ID NO:176, and VL comprising the amino acid sequence of SEQ ID NO:177; s. VH comprising the amino acid sequence of SEQ ID NO:178, and VL comprising the amino acid sequence of SEQ ID NO:179; t. VH comprising the amino acid sequence of SEQ ID NO:180, and VL comprising the amino acid sequence of SEQ ID NO:181; u. VH comprising the amino acid sequence of SEQ ID NO:182, and VL comprising the amino acid sequence of SEQ ID NO:183; v. VH comprising the amino acid sequence of SEQ ID NO:186, and VL comprising the amino acid sequence of SEQ ID NO:187; w. VH comprising the amino acid sequence of SEQ ID NO:188, and VL comprising the amino acid sequence of SEQ ID NO:189; x. VH comprising the amino acid sequence of SEQ ID NO:190, and VL comprising the amino acid sequence of SEQ ID NO:191; y. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; z. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; aa. VH comprising the amino acid sequence of SEQ ID NO:196, and VL comprising the amino acid sequence of SEQ ID NO:197; bb. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; cc. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; dd. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; ee. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; ff. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; gg. VH comprising the amino acid sequence of SEQ ID NO:208, and VL comprising the amino acid sequence of SEQ ID NO:209; hh. VH comprising the amino acid sequence of SEQ ID NO:210, and VL comprising the amino acid sequence of SEQ ID NO:211; ii. VH comprising the amino acid sequence of SEQ ID NO:212, and VL comprising the amino acid sequence of SEQ ID NO:213; jj. VH comprising the amino acid sequence of SEQ ID NO:214, and VL comprising the amino acid sequence of SEQ ID NO:215; kk. VH comprising the amino acid sequence of SEQ ID NO:216, and VL comprising the amino acid sequence of SEQ ID NO:217; ll. VH comprising the amino acid sequence of SEQ ID NO:218, and VL comprising the amino acid sequence of SEQ ID NO:219; mm. comprising the VH of the amino acid sequence of SEQ ID NO:220, and the VL comprising the amino acid sequence of SEQ ID NO:221; nn. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; oo. VH comprising the amino acid sequence of SEQ ID NO:226, and VL comprising the amino acid sequence of SEQ ID NO:227; pp. VH comprising the amino acid sequence of SEQ ID NO:228, and VL comprising the amino acid sequence of SEQ ID NO:229; qq. VH comprising the amino acid sequence of SEQ ID NO:230, and VL comprising the amino acid sequence of SEQ ID NO:231; rr. VH comprising the amino acid sequence of SEQ ID NO:232, and VL comprising the amino acid sequence of SEQ ID NO:233; ss. VH comprising the amino acid sequence of SEQ ID NO:234, and VL comprising the amino acid sequence of SEQ ID NO:235; tt. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; uu. VH comprising the amino acid sequence of SEQ ID NO:238, and VL comprising the amino acid sequence of SEQ ID NO:239; vv. VH comprising the amino acid sequence of SEQ ID NO:240, and VL comprising the amino acid sequence of SEQ ID NO:241; ww. comprising the VH of the amino acid sequence of SEQ ID NO:246, and the VL comprising the amino acid sequence of SEQ ID NO:247; xx. VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; yy. VH comprising the amino acid sequence of SEQ ID NO:250, and VL comprising the amino acid sequence of SEQ ID NO:251; zz. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; aaa. VH comprising the amino acid sequence of SEQ ID NO:254, and VL comprising the amino acid sequence of SEQ ID NO:255; bbb. VH comprising the amino acid sequence of SEQ ID NO:256, and VL comprising the amino acid sequence of SEQ ID NO:257; ccc. VH comprising the amino acid sequence of SEQ ID NO:258, and VL comprising the amino acid sequence of SEQ ID NO:259; ddd. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; eee. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; fff. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265; ggg. VH comprising the amino acid sequence of SEQ ID NO:268, and VL comprising the amino acid sequence of SEQ ID NO:269; hhh. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; iii. VH comprising the amino acid sequence of SEQ ID NO:788, and VL comprising the amino acid sequence of SEQ ID NO:789; jjj. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; kkk. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; lll. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; mmm. VH comprising the amino acid sequence of SEQ ID NO:806, and VL comprising the amino acid sequence of SEQ ID NO:807; nnn. VH comprising the amino acid sequence of SEQ ID NO:808, and VL comprising the amino acid sequence of SEQ ID NO:809; ooo. VH comprising the amino acid sequence of SEQ ID NO:810, and VL comprising the amino acid sequence of SEQ ID NO:811; ppp. VH comprising the amino acid sequence of SEQ ID NO:812, and VL comprising the amino acid sequence of SEQ ID NO:813; qqq. VH comprising the amino acid sequence of SEQ ID NO:814, and VL comprising the amino acid sequence of SEQ ID NO:815; rrr. VH comprising the amino acid sequence of SEQ ID NO:816, and VL comprising the amino acid sequence of SEQ ID NO:817; sss. VH comprising the amino acid sequence of SEQ ID NO:818, and VL comprising the amino acid sequence of SEQ ID NO:819; ttt. VH comprising the amino acid sequence of SEQ ID NO:820, and VL comprising the amino acid sequence of SEQ ID NO:821; uuu. VH comprising the amino acid sequence of SEQ ID NO:822, and VL comprising the amino acid sequence of SEQ ID NO:823; vvv. VH comprising the amino acid sequence of SEQ ID NO:824, and VL comprising the amino acid sequence of SEQ ID NO:825; www. VH comprising the amino acid sequence of SEQ ID NO:826, and VL comprising the amino acid sequence of SEQ ID NO:827; xxx. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; yyy. VH comprising the amino acid sequence of SEQ ID NO:830, and VL comprising the amino acid sequence of SEQ ID NO:831; zzz. VH comprising the amino acid sequence of SEQ ID NO:832, and VL comprising the amino acid sequence of SEQ ID NO:833; aaaa VH comprising the amino acid sequence of SEQ ID NO:836, and VL comprising the amino acid sequence of SEQ ID NO:837; bbbb. VH comprising the amino acid sequence of SEQ ID NO:838, and VL comprising the amino acid sequence of SEQ ID NO:839; cccc. VH comprising the amino acid sequence of SEQ ID NO:840, and VL comprising the amino acid sequence of SEQ ID NO:841; dddd. VH comprising the amino acid sequence of SEQ ID NO: 842, and VL comprising the amino acid sequence of SEQ ID NO: 843; eeee. VH comprising the amino acid sequence of SEQ ID NO:846, and VL comprising the amino acid sequence of SEQ ID NO:847; ffff. VH comprising the amino acid sequence of SEQ ID NO:848, and VL comprising the amino acid sequence of SEQ ID NO:849; gggg. VH comprising the amino acid sequence of SEQ ID NO:850, and VL comprising the amino acid sequence of SEQ ID NO:851; hhhh. VH comprising the amino acid sequence of SEQ ID NO:852, and VL comprising the amino acid sequence of SEQ ID NO:853; iii. VH comprising the amino acid sequence of SEQ ID NO:854, and VL comprising the amino acid sequence of SEQ ID NO:855; jjjj. VH comprising the amino acid sequence of SEQ ID NO:856, and VL comprising the amino acid sequence of SEQ ID NO:857; kkkk. VH comprising the amino acid sequence of SEQ ID NO:858, and VL comprising the amino acid sequence of SEQ ID NO:859; llll. VH comprising the amino acid sequence of SEQ ID NO:860, and VL comprising the amino acid sequence of SEQ ID NO:861; mmmm. comprising the VH of the amino acid sequence of SEQ ID NO:862, and the VL comprising the amino acid sequence of SEQ ID NO:863; nnnn. VH comprising the amino acid sequence of SEQ ID NO:864, and VL comprising the amino acid sequence of SEQ ID NO:865; oooo. VH comprising the amino acid sequence of SEQ ID NO:866, and VL comprising the amino acid sequence of SEQ ID NO:867; pppp. VH comprising the amino acid sequence of SEQ ID NO:868, and VL comprising the amino acid sequence of SEQ ID NO:869; qqqq. VH comprising the amino acid sequence of SEQ ID NO:870, and VL comprising the amino acid sequence of SEQ ID NO:871; rrrr. VH comprising the amino acid sequence of SEQ ID NO:872, and VL comprising the amino acid sequence of SEQ ID NO:873; ssss. VH comprising the amino acid sequence of SEQ ID NO:874, and VL comprising the amino acid sequence of SEQ ID NO:875; tttt. VH comprising the amino acid sequence of SEQ ID NO:876, and VL comprising the amino acid sequence of SEQ ID NO:877; uuuu. VH comprising the amino acid sequence of SEQ ID NO:878, and VL comprising the amino acid sequence of SEQ ID NO:879; vvvv. VH comprising the amino acid sequence of SEQ ID NO:880, and VL comprising the amino acid sequence of SEQ ID NO:881; wwww. comprising the VH of the amino acid sequence of SEQ ID NO:882, and the VL comprising the amino acid sequence of SEQ ID NO:883; xxxx. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; yyyy. VH comprising the amino acid sequence of SEQ ID NO:886, and VL comprising the amino acid sequence of SEQ ID NO:887; zzzz. VH comprising the amino acid sequence of SEQ ID NO:888, and VL comprising the amino acid sequence of SEQ ID NO:889; or aaaaa. VH comprising the amino acid sequence of SEQ ID NO:890, and VL comprising the amino acid sequence of SEQ ID NO:891.

基胺螢光素、丹磺醯氯、或藻紅素； 其中可選地發光材料係魯米諾(luminol)； 其中可選地生物發光材料係選自螢光素酶、螢光素、或水母素；且 其中可選地化學發光材料係選自225Acγ發射性、鄂惹發射性(Auger-emitting)、β發射性、α發射性、或正電子發射性放射性同位素。 In some embodiments, the antibodies provided herein, or antigen-binding fragments thereof, are genetically fused or chemically conjugated to an agent. The agent can be a detectable substance or a drug. The agent can be a functional marker or a detectable marker. In some embodiments, the antibody is genetically fused or chemically conjugated to an agent, wherein the optional agent is a detectable substance or is a drug, wherein the optionally detectable substance is selected from the group consisting of enzymes, prosthetic groups, fluorescent materials, Luminescent material, bioluminescent material, or chemiluminescent material, wherein optionally the enzyme system is selected from horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; wherein optionally The prosthetic group is selected from streptavidin/biotin or avidin/biotin; where the optional fluorescent material is selected from umbelliferone, luciferin, fluorescent isothiocyanate, rose bengal, dichloro three

Amino luciferin, dansyl chloride, or phycoerythrin; wherein the optional luminescent material is luminol; wherein the optional bioluminescent material is selected from luciferase, luciferin, or Aequorin; and wherein optionally the chemiluminescent material is selected from 225Ac gamma-emitting, Auger-emitting, beta-emitting, alpha-emitting, or positron-emitting radioactive isotopes.

In some embodiments, the antibodies provided herein are IgG.

基胺螢光素、丹磺醯氯、或藻紅素。在一些實施例中，發光材料係魯米諾。在一些實施例中，生物發光材料係選自螢光素酶、螢光素、或水母素。在一些實施例中，化學發光材料係選自225Acγ發射性、鄂惹發射性(Auger-emitting)、β發射性、α發射性、或正電子發射性放射性同位素。 In some embodiments, the antibodies provided herein are humanized antibodies. In some embodiments, the antibodies provided herein are humanized antibodies or fragments thereof, especially antigen-binding fragments thereof. In some embodiments, the antibodies provided herein are chimeric or chimeric antibodies. In some embodiments, the antibodies provided herein are chimeric or chimeric antibodies or fragments thereof, especially antigen-binding fragments thereof. In some embodiments, the antibody system is antibody F(ab')2, scFv fragment, domain antibody, minibody, diabody, triabody, or tetrabody the form. In some embodiments, the antibodies provided herein are genetically fused or chemically conjugated to an agent. In some embodiments, the agent is a drug. In some embodiments, the agent is a detectable substance. In some embodiments, the detectable substance is selected from enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, or chemiluminescent materials. In some embodiments, the enzyme is selected from horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. In some embodiments, the prosthetic group is selected from streptavidin/biotin or avidin/biotin. In some embodiments, the fluorescent material is selected from the group consisting of umbelliferone, luciferin, fluorescent isothiocyanate, rose bengal, dichlorotris

Amino luciferin, dansyl chloride, or phycoerythrin. In some embodiments, the luminescent material is luminol. In some embodiments, the bioluminescent material is selected from luciferase, luciferin, or aequorin. In some embodiments, the chemiluminescent material is selected from 225Ac gamma-emitting, Auger-emitting, beta-emitting, alpha-emitting, or positron-emitting radioisotopes.

In another aspect, provided herein is a nucleic acid molecule that encodes an antibody provided herein. In one embodiment, provided herein are nucleic acid molecules encoding any antibody or antigen-binding fragment thereof as described herein. A nucleic acid may encode an antibody or fragment thereof. A nucleic acid may encode one or more or two or more antibodies or fragments thereof. The nucleic acid may encode either the heavy chain or the light chain of the antibody. The nucleic acid may encode the heavy or light chain of the antibody or a fragment thereof. The nucleic acid can encode the heavy and light chains of the antibody. A nucleic acid can encode a VHH antibody.

In another aspect, provided herein is a vector comprising a nucleic acid molecule provided herein.

In another aspect, provided herein is a host cell transformed with a vector provided herein.

Further provided is a composition comprising antibody(s) or active fragment(s) thereof, especially further comprising a pharmaceutical excipient. In some embodiments, compositions comprising antibodies or fragments thereof are provided. In some embodiments, compositions comprising nucleic acids are provided. In some embodiments, compositions comprising a carrier and a pharmaceutically acceptable excipient are provided. In another aspect, provided herein is a composition comprising an antibody provided herein, a nucleic acid molecule provided herein, or a carrier provided herein, and a pharmaceutically acceptable excipient.

In another aspect, provided herein is a kit comprising an antibody provided herein.

In another aspect, provided herein is a method for detecting, selecting, and/or enriching for IL-23R in a sample comprising contacting the sample with an antibody provided herein. In some embodiments, the method comprises immunohistochemistry (IHC) assays, immunocytochemistry (ICC) assays, immunoblot assays, immunoprecipitation assays, flow cytometry assays, ELISA, radioimmunoassays, mass spectrometry Antibodies provided herein are used in assays, or high-throughput screening assays. In some embodiments, the method comprises using an antibody provided herein in an AbSeq/CITESeq assay. In some embodiments, the method comprises using an antibody provided herein in a proximity ligation assay. In some embodiments, the methods comprise using the antibodies provided herein in an ELISA or other immunoassay. In some embodiments, the flow cytometry assay comprises three steps of staining: (1) first, incubation of the sample with antibodies provided herein; (2) second, incubation of the sample with biotinylated anti-mouse IgG _2a Culturing; (3) Thirdly, the sample was cultured with streptavidin-PE. In some embodiments, to establish the background of the flow cytometry assay, a cell line cultured with buffer alone or a negative control antibody was used as a control in step (1), and in the absence of biotinylated anti-mouse IgG _2a The cell line cultured under the secondary reagent was used as an additional control group in step (2).

In another aspect, provided herein is a method for detecting, selecting, and/or enriching IL-23R in a sample, comprising subjecting the sample to an antibody that binds to the same epitope as the antibody provided herein, Or contacted with an antibody that competes for IL-23R binding with the antibodies provided herein.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; b. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; or c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; b. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; c. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; d. VH comprising the amino acid sequence of SEQ ID NO:218, and VL comprising the amino acid sequence of SEQ ID NO:219; e. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; f. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; g. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265; h. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; i. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; or j. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; b. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; e. VH comprising the amino acid sequence of SEQ ID NO:826, and VL comprising the amino acid sequence of SEQ ID NO:827; or f. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:196, and VL comprising the amino acid sequence of SEQ ID NO:197; b. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; or c. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising the amino acid sequence of SEQ ID NO:798 VH, and VL comprising the amino acid sequence of SEQ ID NO:799.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; b. VH comprising the amino acid sequence of SEQ ID NO:250, and VL comprising the amino acid sequence of SEQ ID NO:251; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; or d. VH comprising the amino acid sequence of SEQ ID NO:170, and VL comprising the amino acid sequence of SEQ ID NO:171.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising the amino acid sequence of SEQ ID NO: 150 VH, and VL comprising the amino acid sequence of SEQ ID NO:151.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; or b. VH comprising the amino acid sequence of SEQ ID NO:240, and VL comprising the amino acid sequence of SEQ ID NO:241.

In some embodiments, the methods provided herein comprise contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; or b. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885.

In some embodiments, the methods provided herein are used to detect, select, and/or enrich for human IL-23R.

In some embodiments, the methods provided herein are used to detect, select, and/or enrich for cells expressing IL-23R.

In some embodiments, the methods provided herein are used to detect denatured IL-23R.

In some embodiments, the methods provided herein comprise contacting a sample with two or more antibodies, each of which is an antibody provided herein. In some embodiments, the two or more antibodies bind to different epitopes of IL-23R. In some embodiments, the sample is from a human subject. In some embodiments, the human subject has a disease or condition. In some embodiments, the disease or disorder is an IL-23R-related disease or disorder. In some embodiments, the human subject is a healthy human subject.

In another aspect, provided herein is a method of antagonizing or inhibiting IL-23R in a cell comprising contacting the cell with an antibody provided herein.

In another aspect, provided herein is a method of treating a disease or condition in a subject comprising administering to the subject a composition provided herein. In some embodiments, the disease or disorder is an IL-23R-related disease or disorder.

In one aspect, provided herein is a method of antagonizing or inhibiting IL-23R in a cell comprising contacting the cell with an antibody or antigen-binding fragment thereof provided herein.

In one aspect, provided herein is a method of treating a disease or condition in a subject comprising administering to the subject a composition thereof.

According to the methods described herein, the disease or disorder may be an IL-23R-associated disease or disorder. In some embodiments, the disease or disorder is associated with inflammatory, autoimmune inflammatory disease, and/or related disorders. In some embodiments, the disease or condition associated with inflammatory, autoimmune inflammatory disease, and/or related conditions is selected from multiple sclerosis, asthma, rheumatoid arthritis, intestinal inflammation, inflammatory bowel disease disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, ulcerative colitis, celiac disease (non-tropical aphthous), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, and radiation or chemotherapy-associated colitis, colitis associated with innate immune disorders such as leukocyte adhesion molecule deficiency-1, sarcoidosis, systemic lupus erythematosus, ankylosing spondylitis (axial spondyloarthritis), Psoriatic arthritis, psoriasis (eg, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, palmoplantar pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, ectopic Acne, bowel disease associated with seronegative arthropathy, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, bursitis, rectocolon Bursitis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, virus-associated enteropathy, Pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft-versus-host disease.

In some embodiments, the disease or condition associated with an autoimmune disease is selected from ulcerative colitis (UC), Crohn's disease (CD), psoriasis (PsO), or psoriatic arthritis (PsA).

Cross-reference to related applications

This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Patent Application No. 63/227,976, filed July 30, 2021. Incorporated into sequence listing

The Sequence Listing (contains 2,022,624 bytes) is hereby incorporated by reference in its entirety.

The present disclosure is based in part on the surprisingly superior properties of the anti-IL-23R antibodies provided herein for detection and/or measurement of IL-23R by a variety of assays in primary cells and native tissues, as well as in native and recombinant cell lines, etc. Other advantages.

In 2011, a proprietary anti-human IL-23R mAb was briefly described by Pidasheva et al . (PLoS One 6: e25038, 2011) in their study of the R381Q variant of the IL-23 receptor. Then in 2017, Wines et al . (Immunol Cell Biol 95: 272-279, 2017) described three anti-human IL-23R monoclonal antibodies (mAbs) that, when combined as a single staining cocktail, were able to detect both Th17 and Th17 /1 cell line IL-23R on the surface. Two of these mAbs additionally detected IL-23R on the surface of freshly isolated and cultured γδ T cells (Wines et al ., 2017). In addition to these reagents, anti-IL-23R mAbs that report detection of IL-23R by flow cytometry are commercially available from R&D Systems (FAB14001, which is the same strain as MAB14001 but in a labeled form) and abcam ( ab222104). However, experiments described in this application have shown that these commercial antibodies bind weakly to the IL-23R extracellular domain (ECD).

In this application, we describe the discovery and characterization of novel anti-human IL-23R antibodies validated for flow cytometric detection of IL-23R on the surface of primary human CD3 ⁺ CD56 ⁻ T cells. In addition, novel anti-IL-23R antibodies are described and characterized as binding human IL-23R and rat IL-23R. These mAbs have a range of affinities, recognize multiple distinct epitopes on the IL-23R ectodomain, and have the potential for applications beyond flow cytometry, including but not limited to the use of primary cells and native tissues as well as native and recombinant Receptor occupancy and target engagement assays, immunohistochemistry (IHC), western blot, and immunoprecipitation of cell lines. These mAbs have potential for applications including monitoring or modulating IL-23R activity and expression, including in primary cells and native tissues. In addition, antibodies have utility in monitoring or modulating IL-23R-mediated signaling in vitro, in vivo, and ex vivo. Other applications involving IL-23R-mediated signaling and responses include IL-23R-mediated and related diseases and conditions in animals (including animal models), disease assessment, and treatment or alleviation of IL-23R-mediated or related diseases. application. definition

The techniques and procedures described or referenced herein include those commonly known and/or routinely employed by those of ordinary skill in the art using known methods, such as, for example, the widely used methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual (3d ed. 2001); Current Protocols in Molecular Biology (Ausubel et al. eds., 2003); Therapeutic Monoclonal Antibodies: From Bench to Clinic (An ed. 2009); Monoclonal Antibodies: Methods and Protocols (Albitar ed. . 2010); and Antibody Engineering Vols 1 and 2 (Kontermann and Dübel eds., 2d ed. 2010). Unless otherwise defined herein, technical and scientific terms used in this specification have the meaning commonly understood by those of ordinary skill in the art. For the purpose of interpreting this specification, the following description of terms will apply, and where appropriate, terms used in the singular will also include the plural and vice versa. To the extent that any description of stated terms conflicts with any document incorporated herein by reference, the description of stated terms below shall control.

The terms "antibody,""immunoglobulin," or "Ig" are used herein interchangeably and in the broadest sense, and specifically encompass, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length or intact monoclonal antibodies), antibody compositions with polyepitope or monoepitope specificity, polyclonal antibodies, monovalent antibodies, multivalent antibodies, and combinations of at least two Multispecific antibodies (eg, bispecific antibodies, as long as they exhibit the desired biological activity) formed from whole antibodies, single chain antibodies, and fragments thereof (eg, domain antibodies). Antibodies can be human antibodies, humanized antibodies, chimeric antibodies, and/or affinity matured antibodies, as well as antibodies from other species (eg, mouse, rabbit, llama, etc.). The term "antibody" is intended to include polypeptide products of B cells within the immunoglobulin class of polypeptides, which are capable of binding to a specific molecular antigen and are composed of two identical pairs of polypeptide chains, each pair having one heavy chain (approximately 50 to 70 kDa) and one light chain (about 25 kDa), each amino-terminal portion of each chain includes a variable region of about 100 to about 130 or more amino acids, and each carboxy-terminal portion of each chain includes a constant district. See eg Antibody Engineering (Borrebaeck ed., 2d ed. 1995); and Kuby, Immunology (3d ed. 1997). Antibodies also include, but are not limited to, synthetic antibodies, recombinantly produced antibodies, antibodies including humanized variants thereof from Camelidae species (e.g., vicuna or alpaca), intrabodies, anti-idiotypic (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the above, which functional fragment refers to a portion of an antibody heavy or light chain polypeptide that retains some of the antibody from which the fragment is derived. or all binding activity. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fv (single-chain Fv, scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab) ₂ fragment, F(ab') ₂ fragment, disulfide-linked Fv (dsFv), Fd fragment, Fv fragment, diabody, triabody , tetrabody, and minibody. In particular, the antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, e.g., an antigen binding domain or molecule (e.g., one or more CDRs of an antibody) that contains an antigen binding site that binds to an antigen . Such antibody fragments can be found, for example, in Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers ed., 1995); Huston et al. , 1993, Cell Biophysics 22:189 -224; Plückthun and Skerra, 1989, Meth. Enzymol. 178:497-515; and Day, Advanced Immunochemistry (2d ed. 1990). Antibodies provided herein can be of any class (eg, IgG, IgE, IgM, IgD, and IgA) or any subclass (eg, IgG1, IgG2, IgG3, IgG4, IgAl, and IgA2) of immunoglobulin molecules. Antibodies can be agonistic antibodies or antagonistic antibodies. Antibodies can be neither agonistic nor antagonistic.

An "antigen" is a structure to which an antibody can selectively bind. Target antigens can be polypeptides, carbohydrates, nucleic acids, lipids, haptens, or other naturally occurring or synthetic compounds. In some embodiments, the target antigen is a polypeptide. In certain embodiments, the antigen is associated with, eg, present on or in, the cell.

An "intact" antibody is an antibody comprising the antigen binding site as well as CL and at least the heavy chain constant regions CH1, CH2, and CH3. The constant region may comprise a human constant region or amino acid sequence variants thereof. In certain embodiments, intact antibodies have one or more effector functions.

The terms "binds" or "binding" refer to interactions between molecules including, for example, complex formation. Interactions can be, for example, non-covalent interactions including hydrogen bonds, ionic bonds, hydrophobic interactions, and/or Van der Waals interactions. A complex may also include the association of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interaction between a single antigen-binding site on an antibody and a single epitope of a target molecule, such as an antigen, is the affinity of the antibody or functional fragment (antigen-binding fragment) for that epitope. The ratio (koff/kon) of the _off- rate (koff) to the on-rate ( _kon ) of a binding molecule ₍ eg, antibody) to a monovalent antigen is the dissociation constant, _KD , which is inversely related to affinity _. The lower the _KD value, the higher the affinity of the antibody. _KD values vary for different complexes of antibody and antigen and depend on both k _on and k _off . The dissociation constant _KD of the antibodies provided herein can be determined using any of the methods provided herein or any other method known to those of ordinary skill in the art. Affinity at a binding site does not always reflect the true strength of the interaction between antibody and antigen. When a complex antigen containing multiple repeated epitopes, such as a multivalent antigen, is contacted with an antibody containing multiple binding sites, the interaction of the antibody with the antigen at one site will increase the probability of a reaction at the second site. The strength of such multiple interactions between multivalent antibodies and antigens is called avidity.

With respect to the binding molecules described herein, terms such as "bind to", "that specifically bind to", and similar terms are also used herein interchangeably and refer to specifically bind to A binding molecule, such as a polypeptide, of the antigen-binding domain of an antigen. Binding molecules or antigen-binding domains that bind or specifically bind to an antigen can be identified, for example, by immunoassays, ^Octet® , ^Biacore® , or other techniques known to those of ordinary skill in the art. In some embodiments, when the binding molecule or antigen binding domain binds to the antigen with a higher affinity than any cross-reactive antigen as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA), The antibody or antigen binding domain binds or specifically binds to an antigen. Generally, a specific or selective response will be at least two times background signal or noise, and may be more than ten times background. For a discussion of binding specificity, see, eg, Fundamental Immunology 332-36 (Paul ed., 2d ed. 1989). In certain embodiments, the degree of binding of a binding molecule or antigen binding domain to a "non-target" protein is less than about 10% of the binding of the binding molecule or antigen binding domain to its specific target antigen, e.g., as in fluorescence activated cell sorting (FACS) analysis or determined by RIA. A binding molecule or antigen binding domain that binds to an antigen includes a binding molecule or antigen binding domain that is capable of binding the antigen with sufficient affinity such that the binding molecule can be used, for example, as a therapeutic and/or diagnostic agent targeting the antigen. In certain embodiments, the binding molecule or antigen binding domain that binds to the antigen has a concentration of less than or equal to 1 µM, 800 nM, 600 nM, 550 nM, 500 nM, 300 nM, 250 nM, 100 nM, 50 nM, 10 nM , 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM dissociation constant (K _D ) . In certain embodiments, the binding molecule or antigen binding domain binds to an epitope of an antigen that is conserved among antigens from different species.

In certain embodiments, a binding molecule or antigen-binding domain may comprise a "chimeric" sequence in which a portion of the heavy and/or light chain is related to an antibody derived from a particular species or belonging to a particular antibody class or subclass. and the remainder of the chain(s) is identical or homologous to the corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass, and fragments of such antibodies , as long as they exhibit the desired biological activity (see US Patent No. 4,816,567; and Morrison et al. , 1984, Proc. Natl. Acad. Sci. USA 81:6851-55). Chimeric sequences can include humanized sequences.

In certain embodiments, the binding molecule or antigen-binding domain may comprise portions of "humanized" forms of non-human (e.g., camelid, murine, non-human primate) antibodies, including those derived from human immunization. Sequences of globulins (e.g., recipient antibodies) in which native CDR residues are derived from a non-human species (such as camel, mouse, rat, rabbit, or non-human primate) having the desired specificity, affinity, and capacity Substitution of residues in corresponding CDRs (eg, donor antibody) of class). In some instances, one or more FR region residues of the human immunoglobulin sequence are replaced by corresponding non-human residues. In addition, humanized antibodies may comprise residues which are not found in either the recipient antibody or the donor antibody. Such modifications are made to further improve antibody performance. The humanized antibody heavy or light chain may comprise substantially all of at least one or more variable regions, wherein all or substantially all of the CDRs correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs It is the FR of human immunoglobulin sequence. In certain embodiments, a humanized antibody will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details see Jones et al. , Nature 321:522-25 (1986); Riechmann et al. , Nature 332:323-29 (1988); Presta, Curr. Op.Struct.Biol.2:593- 96 (1992); Carter et al. , Proc. Natl. Acad. Sci. USA 89:4285-89 (1992); US Patent Nos. 6,800,738; 6,719,971; 6,639,055; 6,407,213; .

In certain embodiments, a binding molecule or antigen binding domain may comprise a "fully human antibody" or a portion of a "human antibody", where these terms are used interchangeably herein and are Refers to an antibody comprising human variable regions and, for example, human constant regions. A binding molecule may comprise antibody sequences. In particular embodiments, these terms refer to antibodies comprising variable and constant regions of human origin. In certain embodiments, "fully human" antibodies may also encompass polypeptide-binding antibodies encoded by nucleic acid sequences that are naturally occurring somatic variants of human germline immunoglobulin nucleic acid sequences . The term "fully human antibody" includes antibodies having variable and constant regions corresponding to human germline immunoglobulin sequences, as described by Kabat et al. (see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). A "human antibody" is an antibody having an amino acid sequence corresponding to an antibody produced in a human and/or produced using any of the techniques used to produce human antibodies. This definition of a human antibody expressly excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol. 227:381 (1991); Marks et al. , J. Mol. Biol. 222: 581 (1991)) and yeast display library (Chao et al. , Nature Protocols 1: 755-68 (2006)). Methods that can also be used to prepare human monoclonal antibodies are described in Cole et al. , Monoclonal Antibodies and Cancer Therapy 77 (1985); Boerner et al. , J. Immunol. 147(1):86-95 (1991); and van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001). Human antibodies can be produced by administering antigens to genetically modified animals that have been modified to produce such antibodies in response to antigenic challenge but whose endogenous loci have been disabled, such as mice (see See, eg, Jakobovits, Curr. Opin. Biotechnol. 6(5):561-66 (1995); Brüggemann and Taussing, Curr. Opin. Biotechnol. 8(4):455-58 (1997); and U.S. Patent No. 6,075,181 No. 6,150,584, which relates to the XENOMOUSE ^™ technology). See also, eg, Li et al. , Proc. Natl. Acad. Sci. USA 103:3557-62 (2006) on human antibodies produced via human B cell fusion tumor technology.

In certain embodiments, a binding molecule or antigen binding domain may comprise a portion of a "recombinant human antibody", where the phrase includes a human antibody produced, expressed, established, or isolated by recombinant means, Such as antibodies expressed using recombinant expression vectors transfected into host cells; antibodies isolated from recombinant combinatorial human antibody repertoires; mouse or bovine) isolated antibodies (see e.g. Taylor, LD et al. , Nucl. Acids Res. 20:6287-6295 (1992)), or by splicing human immunoglobulin gene sequences to other DNA sequences Antibodies prepared, expressed, established, or isolated by any other means. Such recombinant human antibodies may have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when using animals transgenic for human Ig sequences, in vivo somatic mutagenesis), and thus the The amino acid sequences of the VH and VL regions, while derived from and related to human germline VH and VL sequences, may be sequences that do not naturally occur in the human antibody germline repertoire in vivo.

In certain embodiments, a binding molecule or antigen binding domain may comprise a portion of a "monoclonal antibody," as the term is used herein, refers to an antibody obtained from a substantially homogeneous population of antibodies, e.g., comprising The individual antibodies of this population may be present in minor amounts except for possible naturally occurring mutations or known post-translational modifications such as amino acid isomerization or deamidation, oxidation of methionine, or asparagine or gluten Each monoclonal antibody will generally recognize a single epitope on the antigen if it is identical except for amino acid deamidation). In particular embodiments, as used herein, a "monoclonal antibody" is an antibody produced by a single fused tumor or other cell. The term "monoclonal" is not limited to any particular method for making antibodies. For example, monoclonal antibodies useful in the present disclosure can be prepared by the fusionoma method first described by Kohler et al. , Nature 256:495 (1975), or can be produced using recombinant DNA methods in bacteria or eukaryotic or plant cells made (see eg US Patent No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using techniques such as those described in Clackson et al. , Nature 352:624-28 (1991) and Marks et al. , J. Mol. Biol.222:581 -97 (1991). Other methods for preparing germline cell lines and the monoclonal antibodies expressed thereby are well known in the art. See, eg, Short Protocols in Molecular Biology (Ausubel et al. eds., 5th ed. 2002).

A typical 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, the 4-chain unit is usually about 150,000 Daltons. Each L chain is linked to the H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds (depending on the H chain isotype). Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) for each of the alpha and gamma chains and four CH domains for the mu and epsilon isotypes. Each L chain has a variable domain (VL) at its N-terminus followed by a constant domain (CL) at its other end. VL is aligned with VH, and CL is aligned with the first constant domain (CH1) of the heavy chain. Certain amino acid residues are believed to form the interface between the light and heavy chain variable domains. The pairing of VH and VL together forms a single antigen binding site. For the structure and properties of different classes of antibodies see, eg, Basic and Clinical Immunology 71 (Stites et al. eds., 8th ed. 1994); and Immunobiology (Janeway et al. eds., ^5th ed. 2001).

The term "Fab" or "Fab region" refers to the region of an antibody that binds to an antigen. Conventional IgGs generally comprise two Fab regions, each located on one of the two arms of the Y-shaped IgG structure. Each Fab region generally consists of one variable region and one constant region of each of the heavy and light chains. More specifically, the variable and constant regions of the heavy chain in the Fab region are VH and CH1 regions, and the variable and constant regions of the light chain in the Fab region are VL and CL regions. VH, CH1, VL, and CL in the Fab region can be arranged in various ways to confer antigen-binding ability according to the present disclosure. For example, the VH and CH1 regions can be on one polypeptide, and the VL and CL regions can be on separate polypeptides, similar to the Fab region of conventional IgG. Alternatively, the VH, CH1, VL, and CL regions can all be on the same polypeptide and oriented in a different order, as described in more detail in the sections below.

The terms "variable region", "variable domain", "V region", or "V domain" refer to a portion of the light or heavy chain of an antibody , which is usually located at the amino terminus of the light or heavy chain, and whose heavy chain is about 120 to 130 amino acids in length and the light chain is about 100 to 110 amino acids in length, and is used for each specific antibody on its Binding and specificity of specific antigens. The variable region of the heavy chain can be referred to as "VH". The variable region of the light chain can be referred to as "VL". The term "variable" refers to the fact that certain segments of the variable region vary widely in sequence between antibodies. The V regions mediate antigen binding and define the specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed over the 110 amino acid span of the variable region. Instead, the V regions are composed of less variable (e.g., relatively invariant) stretches of about 15 to 30 amino acids called framework regions (FRs) separated by higher variability (e.g., hypervariable) and called "hypervariable regions", each of which is about 9 to 12 amino acids long. The variable regions of the heavy and light chains each comprise four FRs that primarily adopt a β-sheet configuration, connected by three hypervariable regions that form loops connecting the β-sheet structures and in some cases Forms part of the beta pleated plate structure. The hypervariable regions in each chain are held together in close proximity by FRs and together with the hypervariable regions of the other chain contribute to the antigen-binding site of the antibody (see, e.g., Kabat et al. , Sequences of Proteins of Immunological Interest (5th ed. 1991)). The constant region is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as the participation of the antibody in antibody-dependent cellular cytotoxicity (antibody dependent cellular cytotoxicity, ADCC) and complement-dependent cytotoxicity (complement dependent cytotoxicity, CDC). The sequences of the variable regions vary widely among different antibodies. In specific embodiments, the variable regions are human variable regions.

The term "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat" and variants thereof refer to the above The numbering system for heavy chain variable regions or light chain variable regions used in antibody compilations in Kabat et al . Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortenings or insertions of FRs or CDRs of the variable domains. For example, a heavy chain variable domain may include a single amino acid insertion after residue 52 (residue 52a according to Kabat) and three insertion residues after residue 82 (e.g., residue 82a, 82b, and 82c, etc.). The Kabat residue numbering for a given antibody can be determined by aligning the antibody sequence with regions of homology to the "standard" Kabat numbering sequence. When referring to residues in the variable domain (approximately, residues 1 to 107 of the light chain and residues 1 to 113 of the heavy chain), the Kabat numbering system is generally used (eg, Kabat et al. , supra). When referring to residues in the constant region of an immunoglobulin heavy chain, the "EU numbering system" or "EU index" is generally used (e.g., the EU index reported in Kabat et al. , supra ). "EU index as in Kabat" refers to the residue number of the human IgG 1 EU antibody. Other numbering systems have been described eg by AbM, Chothia, Contact, IMGT, and AHon.

The term "heavy chain" when used in reference to an antibody refers to a polypeptide chain of about 50 to 70 kDa, the amino terminal portion of which includes a variable region of about 120 to 130 or more amino acids , and the carboxy-terminal portion includes the constant region. The constant region can be one of five different types (eg, isotypes), referred to as α, δ, ε, γ, and µ, based on the amino acid sequence of the heavy chain constant region. The different heavy chains vary in size: α, δ, and γ contain approximately 450 amino acids, while µ and ε contain approximately 550 amino acids. When combined with light chains, these different types of heavy chains give rise to the well-known five classes (e.g., isotypes) of antibodies IgA, IgD, IgE, IgG, and IgM, respectively, including four subclasses of IgG, IgG1, IgG2 , IgG3, and IgG4.

When used in reference to an antibody, the term "light chain" refers to a polypeptide chain of about 25 kDa, wherein the amino-terminal portion includes a variable region of about 100 to about 110 or more amino acids, And the carboxy-terminal portion includes a constant region. The approximate length of the light chain is 211 to 217 amino acids. There are two different types, called kappa or lambda, based on the amino acid sequence of the constant domain.

As used herein, the terms "hypervariable region", "HVR", "complementarity determining region", and "CDR" are used interchangeably. "CDR" means one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of the VH β-sheet framework of an immunoglobulin (Ig or antibody), or one of the non-framework regions of the VL β-sheet structure of an antibody. One of the three hypervariable regions (L1, L2, or L3) within the framework region. CDR1, CDR2, and CDR3 in the VH domain are referred to as HCDR1, HCDR2, and HCDR3, respectively. CDR1, CDR2, and CDR3 in the VL domain are referred to as LCDR1, LCDR2, and LCDR3, respectively. Thus, the CDRs are variable region sequences interspersed within the framework region sequences.

The term "gene expression" describes the conversion of DNA gene sequence information into transcribed RNA (primary unspliced RNA transcript or mature mRNA) or an encoded protein product. Gene expression can be monitored by measuring the levels of the entire RNA or protein product of the gene or a subsequence thereof.

CDR regions are well known to those of ordinary skill in the art and have been defined by well known numbering systems. For example, the Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (see eg Kabat et al. supra; Nick Deschacht et al., J Immunol 2010; 184:5696-5704). Chothia then refers to the position of the structural loop (see eg Chothia and Lesk, J. Mol. Biol. 196:901-17 (1987)). When numbered using the Kabat numbering convention, the end of the Chothia CDR-H1 loop varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if neither 35A nor 35B present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). AbM hypervariable regions represent a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (see e.g. Antibody Engineering Vol. 2 (Kontermann and Dübel eds., 2d ed. 2010) ). The "contact" highly variable regions are based on analysis of available complex crystal structures. Another general numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information ^System® (Lafranc et al. , Dev. Comp. Immunol. 27(1):55-77 (2003)). IMGT is an integrated information system dedicated to immunoglobulin (IG), T cell receptor (TCR), and major histocompatibility complex (MHC) in humans and other vertebrates. Herein, CDRs are referred to both in terms of amino acid sequence and position within the light or heavy chain. Since the "position" of the CDRs within the structure of an immunoglobulin variable domain is conserved across species and occurs in structures called loops, by using a numbering system that aligns variable domain sequences according to structural features, Easily identify CDRs and framework residues. This information can be used to graft and replace CDR residues from immunoglobulins of one species into acceptor frameworks generally derived from human antibodies. Honegger and Plückthun developed an additional numbering system (AHon) (Honegger and Plückthun, J. Mol. Biol. 309: 657-70 (2001)). Correspondence between numbering systems (including, for example, Kabat numbering and the IMGT unique numbering system) is well known to those of ordinary skill in the art (see, eg, Kabat, supra; Chothia and Lesk, supra; Martin, supra; Lefranc et al. , supra). Table 1 below exemplifies residues from each of these hypervariable regions or CDRs. Table 1. Exemplary CDRs according to various numbering systems ring Kabat AbM Chothia contact IMGT CDR L1 L24--L34 L24--L34 L26--L32 or L24--L34 L30--L36 L27--L38 CDR L2 L50--L56 L50--L56 L50--L52 or L50--L56 L46--L55 L56--L65 CDR L3 L89--L97 L89--L97 L91--L96 or L89--L97 L89--L96 L105-L117 CDR H1 H31--H35B H26--H35B H26--H32..34 H30--H35B H27--H38 (Kabat number) CDR H1 H31--H35 H26--H35 H26--H32 H30--H35 (Chothia number) CDR H2 H50--H65 H50--H58 H53--H55 or H52--H56 H47--H58 H56--H65 CDR H3 H95--H102 H95--H102 H96--H101 or H95--H102 H93--H101 H105-H117

The boundaries of a given CDR can vary depending on the scheme used for identification. Thus, unless otherwise stated, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (such as a variable region) and the individual CDRs of that antibody or region thereof (e.g., CDR-H1, CDR-H2) Complementarity-determining regions defined by any known scheme as described above are understood to be encompassed. In some cases, a scheme is specified for identifying a particular CDR or CDRs, such as a CDR as defined by the IMGT, Kabat, Chothia, or Contact method. In other cases, the specific amino acid sequences of the CDRs are given. It should be noted that CDR regions may also be defined by a combination of various numbering systems, such as a combination of Kabat and Chothia numbering systems, or a combination of Kabat and IMGT numbering systems. Thus, phrases such as "a CDR1 as set forth in a specific VH" include, but are not limited to, any CDR1 as defined by the exemplary CDR numbering system described above. Once a variable region (eg, VH or VL) is given, one of ordinary skill in the art will understand that the CDRs within this region may be defined by different numbering systems or combinations thereof.

Hypervariable regions may include "extended hypervariable regions" as follows: 24 to 36 or 24 to 34 (L1), 46 to 56 or 50 to 56 (L2), and 89 to 97 or 89 to 96 (L3) in the VL and 26 to 35 or 26 to 35A (H1), 50 to 65 or 49 to 65 (H2), and 93 to 102, 94 to 102, or 95 to 102 (H3) in VH.

The term "constant region" or "constant domain" refers to the carboxy-terminal portion of the light and heavy chains, which are not directly involved in antibody binding to antigen, but which exhibit various effector functions (such as binding to Fc receptors). body interactions). The term refers to a portion of an immunoglobulin molecule that has a more conserved amino acid sequence relative to another portion of the immunoglobulin containing the antigen-binding site (the variable domain). The constant region may contain the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.

The term "framework" or "FR" refers to the variable region residues that flank the CDRs. FR residues are found, for example, in chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are hypervariable region residues or variable domain residues other than CDR residues.

The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, including, for example, native sequence Fc region, recombinant Fc region, and variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is generally defined to extend from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during production or purification of the antibody, or by recombinant engineering of the nucleic acid encoding the heavy chain of the antibody. Thus, the composition of intact antibodies can include antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations with a mixture of antibodies with and without the K447 residue. A "functional Fc region" has the "effector function" of a native sequence Fc region. Exemplary "effector functions" include: Clq binding; CDC; Fc receptor binding; ADCC; phagocytosis; Such effector functions typically require an Fc region in combination with a binding region or domain (eg, an antibody variable region or domain) and can be assessed using various assays known to those of ordinary skill in the art. A "variant Fc region" comprises an amino acid sequence that differs from a native sequence Fc region by at least one amino acid modification (eg, substitution, addition, or deletion). In certain embodiments, the variant Fc region has at least one amino acid substitution compared to the native sequence Fc region or the Fc region of the parent polypeptide, e.g., in the native sequence Fc region or in the Fc region of the parent polypeptide Having about one to about ten amino acid substitutions or about one to about five amino acid substitutions. The variant Fc region herein may be at least about 80% homologous to a native sequence Fc region and/or to the Fc region of the parent polypeptide, or at least about 90% homologous thereto, for example at least about 95% homologous thereto homology.

As used herein, an "epitope" is a term in the art and refers to a localized region of an antigen to which a binding molecule (eg, an antibody) can specifically bind. Epitopes can be linear epitopes or conformational, non-linear, or discontinuous epitopes. For example, in the case of a polypeptide antigen, the epitope may be a contiguous amino acid sequence of the polypeptide ("linear" epitope), or the epitope may comprise amino acids from two or more non-contiguous regions of the polypeptide ("contiguous" epitope). conformational", "non-linear", or "discontinuous" epitopes). Those of ordinary skill in the art will appreciate that, in general, linear epitopes may or may not depend on secondary, tertiary, or quaternary structure. For example, in some embodiments, a binding molecule binds to a group of amino acids, whether or not they are folded into a native three-dimensional protein structure. In other embodiments, binding molecules require amino acid residues that complement the epitope to exhibit a specific configuration (eg, bend, twist, turn, or fold) in order to recognize and bind the epitope.

"Amino acid sequence identity (%) (percent (%) amino acid sequence identity)" and "homology" with respect to peptide, polypeptide, or antibody sequences are defined as the following steps with a specific peptide or the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the polypeptide sequence: aligning the sequences and introducing gaps (gaps), if necessary, to achieve the maximum percentage of sequence identity, and Any conservative substitutions are not considered to be part of the sequence identity. Amino acid sequence identities can be determined by various means within the ordinary knowledge in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN ^™ (DNAStar, Inc.) software) The sex percentage is the comparison for the purpose. Those of ordinary skill in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

The term "specificity" refers to the selective recognition of a specific epitope of an antigen by an antigen binding protein. For example natural antibodies are monospecific. As used herein, the term "multispecific" means that an antigen binding protein has two or more antigen binding sites, at least two of which bind different antigens. As used herein, "bispecific" means that an antigen binding protein has two different antigen binding specificities. As used herein, the term "monospecific" antibody refers to an antigen binding protein that has one or more binding sites that each bind the same antigen.

As used herein, the term "valent" indicates the presence of a specified number of binding sites in an antigen binding protein. For example natural antibodies or full length antibodies have two binding sites and are bivalent. Thus, the terms "trivalent", "tetravalent", "pentavalent", and "hexavalent" denote the presence of two binding sites, three binding sites, and three binding sites, respectively, in an antigen-binding protein. binding sites, four binding sites, five binding sites, and six binding sites.

The terms "polypeptide", "peptide", and "protein" are used interchangeably herein and refer to a polymer of amino acids of any length. Polymers can be linear or branched, they can contain modified amino acids, and they can be interrupted by non-amino acids. The term also encompasses amino acid polymers with natural or insertional modifications; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. Also included within the definition are, for example, polypeptides containing one or more analogs of amino acids (including but not limited to unnatural amino acids), as well as other modifications known in the art. It is to be understood that since the polypeptides of the present disclosure may be based on antibodies or other members of the immunoglobulin superfamily, in certain embodiments a "polypeptide" may exist as a single chain or as two or more associated chains .

"Polynucleotide" or "nucleic acid" are used interchangeably herein to refer to a polymer of nucleotides of any length and includes DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any DNA or RNA polymerase or by a synthetic reaction and substrate into the polymer. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and the like. As used herein, "oligonucleotide" refers to a short, usually single-stranded, synthetic polynucleotide, usually, but not necessarily, less than about 200 nucleotides in length. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. What has been said above for polynucleotides applies equally and fully to oligonucleotides. Cells producing the binding molecules of the present disclosure can include parental hybridoma cells, as well as bacterial and eukaryotic host cells into which nucleic acid encoding an antibody has been introduced. Unless otherwise specified, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5' end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The direction in which nascent RNA transcripts are added from 5' to 3' is called the direction of transcription; the sequence region on the DNA strand that has the same sequence as the RNA transcripts and is 5' at the 5' end of the RNA transcripts is called the "upstream sequence" "; the DNA strand has the same sequence as the RNA transcript, and the 3' sequence region at the 3' end of the RNA transcript is called "downstream sequence (downstream sequence)".

"Isolated nucleic acid" is a nucleic acid, such as RNA, DNA, or mixed nucleic acid. An "isolated" nucleic acid molecule is a nucleic acid molecule that is separated from other nucleic acid molecules present in the natural source of the nucleic acid molecule. Furthermore, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a specific embodiment, one or more nucleic acid molecules encoding an antibody as described herein are isolated or purified. The term includes nucleic acid sequences that have been removed from their naturally occurring environment, and includes recombinant or cloned DNA isolates and analogs that have been chemically synthesized or biologically synthesized by heterologous systems. A substantially pure molecule can include isolated forms of the molecule. In particular, an "isolated" nucleic acid molecule encoding an antibody described herein is one that has been identified and separated from at least one contaminating nucleic acid molecule with which it is ordinarily associated in the environment in which the nucleic acid molecule is produced.

Unless otherwise specified, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. A phrase nucleotide sequence encoding a protein or RNA may also include introns (provided that the nucleotide sequence encoding the protein may, in some versions, contain one or more introns).

The term "control sequences" refers to DNA sequences required for the expression of an operably linked coding sequence in a particular host organism. Control sequences suitable for use in, for example, prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

As used herein, the term "operably linked" and similar phrases (e.g., gene fusions) when used to refer to nucleic acids or amino acids refer to nucleic acid sequences or amino acids, respectively, that are in a functional relationship to each other. Operative linkage of amino acid sequences. For example, operably linked promoters, enhancer elements, open reading frames, 5' and 3' UTRs, and terminator sequences result in proper production of nucleic acid molecules (eg, RNA). In some embodiments, operably linked nucleic acid elements result in the transcription of an open reading frame, which ultimately results in the production of a polypeptide (ie, expression of the open reading frame). As another example, an operably linked peptide is one in which functional domains are placed at an appropriate distance from each other to confer the intended function of each domain.

The term "vector" refers to a substance for carrying or comprising a nucleic acid sequence, including, for example, a nucleic acid sequence encoding a binding molecule (eg, an antibody) as described herein, for introduction of the nucleic acid sequence into a host cell. Vectors suitable for use include, for example, expression vectors, plastids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may include selection sequences or markers operable for stable integration into the host cell chromosome. In addition, the vector may include one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes can be included, for example, to provide resistance to antibiotics or toxins, to complement auxotrophic deficiencies, or to supply critical nutrients not present in the culture medium. Expression control sequences can include constitutive and inducible promoters, transcriptional enhancers, transcriptional terminators, and the like, which are well known in the art. When two or more nucleic acid molecules are to be co-expressed (eg, antibody heavy and light chains or antibody VH and VL), the two nucleic acid molecules can be inserted, eg, into a single expression vector or into separate expression vectors. For single-vector expression, the encoding nucleic acid can be operably linked to one common expression control sequence or to different expression control sequences, such as an inducible promoter and a constitutive promoter. Introduction of nucleic acid molecules into host cells can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis such as northern blot or polymerase chain reaction (PCR) amplified mRNA, immunoblot for gene product expression, or other suitable assays to test for the introduced nucleic acid sequence or its corresponding gene product performance. It will be understood by those of ordinary skill in the art that nucleic acid molecules are expressed in amounts sufficient to produce the desired product, and it will be further understood that expression levels may be optimized for adequate expression using methods well known in the art.

As used herein, the term "host" refers to an animal, such as a mammal (eg, a human).

As used herein, the term "host cell" refers to a specific subject cell that can be transfected with a nucleic acid molecule and the progeny or potential progeny of the cell. The progeny of the cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in subsequent generations or when the nucleic acid molecule integrates into the genome of the host cell.

As used herein, the term "transfected" or "transformed" or "transduced" refers to the procedure of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is a cell that has been transfected, transformed or transduced with an exogenous nucleic acid. The cells include primary target cells and their progeny.

As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the U.S. federal or state government, or listed in the United States Pharmacopeia, European Pharmacopeia, or other recognized pharmacopoeias for use in animals and more particularly in humans.

"Excipient" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, vehicles, coating agents, colorants, diluents, disintegrants, emulsifiers, synergists, fillers, flavoring agents , humectants, lubricants, fragrances, preservatives, propellants, release agents, sterilants, sweeteners, solubilizers, wetting agents, and mixtures thereof. The term "excipient" may also refer to a diluent, an adjuvant (eg, Freunds' adjuvant (complete or incomplete), or a vehicle.

In some embodiments, the excipient is a pharmaceutically acceptable excipient. Examples of pharmaceutically acceptable excipients include buffers, such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid; low molecular weight (e.g., less than about 10 amino acid residues) polypeptides ; proteins, such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, arginine , or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugar alcohols, such as mannitol or sorbitol; salt-forming counterions, such as sodium and/or nonionic surfactants such as TWEEN ^™ , polyethylene glycol (PEG), and PLURONICS ^™ . Further examples of pharmaceutically acceptable excipients are described in Remington and Gennaro, Remington's Pharmaceutical Sciences (18th ed. 1990).

In one embodiment, the components are "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical formulation and suitable for use in contact with human and animal tissues or organs without undue toxicity, irritation, Anaphylaxis, immunogenicity, or other problems or complications, with a reasonable benefit/risk ratio. See, eg, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009. In some embodiments, pharmaceutically acceptable excipients are nontoxic to cells or mammals to which they are exposed at the dosages and concentrations employed. In some embodiments, the pharmaceutically acceptable excipient is a pH buffered aqueous solution.

In some embodiments, excipients are sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is an exemplary excipient when the composition (eg, a pharmaceutical composition) is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions. Excipients may also include starch, dextrose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerin, Propylene, ethylene glycol, water, ethanol, and the like. The composition may also contain small amounts of wetting or emulsifying agents, or pH buffering agents, if desired. The compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, and the like. Oral compositions, including formulations, can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.

Compositions, including pharmaceutical compounds, may contain, for example, a binding molecule (eg, an antibody), in isolated or purified form, together with suitable amounts of excipients.

As used herein, the term "effective amount" or "therapeutically effective amount" refers to an antibody provided herein or a therapeutic molecule or pharmaceutical composition comprising an agent and an antibody sufficient to cause a desired result Quantity of things.

The terms "subject" and "patient" are used interchangeably. As used herein, in certain embodiments, a subject is a mammal, such as a non-primate or a primate (eg, a human). In a specific embodiment, the subject is a human being. In one embodiment, the subject is a mammal, such as a human, diagnosed with a disease or condition. In another embodiment, the subject is a mammal, such as a human, at risk of developing a disease or condition.

"Administer/administration" means the act of injecting or otherwise physically delivering a substance present outside the body into a patient, such as transmucosally, intradermally, intravenously, intramuscularly, and/or as described herein Or any other method of physical delivery known in the art.

As used herein, the terms "treat/treatment/treating" refer to the reduction or amelioration of the progression, severity and/or duration of a disease or condition as a result of administration of one or more therapies. Treatment can be determined by assessing whether one or more symptoms associated with the underlying condition has been reduced, alleviated, and/or alleviated such that improvement in the patient is observed, but the patient may still be afflicted by the underlying condition. The term "treatment" includes both management and amelioration of disease. The terms "manage/managing/management" refer to the beneficial effect that a subject obtains from a therapy that does not necessarily result in a cure of the disease.

The terms "prevent/preventing/prevention" refer to reducing the likelihood of onset (or recurrence) of a disease, disorder, condition, or related symptom(s) (eg, diabetes or cancer).

As used herein, "IL-23R associated disease or disorder (IL-23R associated disease or disorder)" refers to a disease or disorder comprising cells or tissues in which IL-23R expression, activity or function is altered or abnormal, Including: diseases or disorders comprising cells or tissues expressing or overexpressing IL-23R; or cells comprising abnormally expressed IL-23R thereon; or cells comprising cells in or on which IL-23R is abnormally functioning.

The terms "about" and "approximately" mean within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6% of a given value or range , within 5%, within 4%, within 3%, within 2%, within 1%, or less.

As used in this disclosure and claims, the singular forms "a (a/an)" and "the" include plural forms unless the context clearly requires otherwise.

It should be understood that whenever an embodiment is described herein with the term "comprising", the term "consisting of" and/or "consisting essentially of" is also provided. of)" described other similar embodiments. It should also be understood that whenever an embodiment is described herein with the phrase "consisting essentially of, other similar embodiments are also provided that are described with the phrase "consisting of.

The term "between" as used in phrases such as "between A and B" or "between A-B" means Include the range of both A and B.

If used in a phrase such as "A and/or B (A and/or B)", the term "and/or (and/or)" is intended to include both A and B; A or B; A (alone) ; and B (alone). Likewise, the term "and/or" as used in phrases such as "A, B, and/or C (A, B, and/or C)" is intended to cover the Each of: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). IL-23R binding molecules Antibodies that bind to IL-23R

In one aspect, provided herein are antibodies capable of binding to IL-23R. IL-23 is a heterodimer of IL-23p19 and IL-12/23p40 subunits linked by disulfide bonds. The receptors for IL-23 include IL-23R and IL-12Rβ1 subunits. IL-23p19 binds to the N-terminal immunoglobulin (Ig)-like domain of IL-23R, followed by IL-12/23p40 binding to IL-12Rβ1. Ligand binding results in phosphorylation of JAK2 and TYK2, followed by phosphorylation and nuclear translocation of STAT proteins. STAT3 plays a major role in mediating the biological effects of IL-23 signaling. In some embodiments, an antibody provided herein binds human IL-23R. Examples of human IL-23R extracellular domain (ECD) sequences are shown in Table 3. In some embodiments, an antibody provided herein binds rat IL-23R. An example of a human IL-23R extracellular domain (ECD) sequence is provided herein and in SEQ ID NO:1267. In some embodiments, the antibodies provided herein bind to human IL-23R and also bind to rat IL-23R. In some embodiments, the antibodies provided herein bind to human IL-23R ECD and rat IL-23R ECD. In some embodiments, the anti-IL-23R antibodies provided herein modulate IL-23R activity. In some embodiments, the anti-IL-23R antibodies provided herein are antagonistic antibodies.

In some embodiments, the antibodies or fragments thereof provided herein are antagonistic antibodies directed against IL-23R. In some embodiments, an antibody or antigen-binding fragment provided herein binds a protein of interest, IL-23R, and reduces the binding of IL-23 to IL-23R. In some embodiments, an antibody or antigen-binding fragment provided herein binds a protein of interest, IL-23R, and reduces binding of IL-23 to IL-23R to basal levels. In one aspect of this embodiment, the antibody or antigen-binding fragment reduces the amount of IL-23 bound to IL-23R. In a further aspect of this embodiment, the antibody or antigen-binding fragment completely prevents binding of IL-23 to IL-23R. In a further embodiment, the antibody or antigen-binding fragment inhibits STAT activation. In a further embodiment, the antibody or antigen-binding fragment inhibits STAT3 phosphorylation. Antibodies that inhibit one or more of these IL-23R functional properties (e.g., biochemical, immunological, chemical, cellular, physiological or other biological activities, or the like) as determined by methods known in the art and described herein It will be understood as referring to a statistically significant decrease or increase in a specific activity relative to that seen in the absence of the antibody (eg or when a control antibody of irrelevant specificity is present). In some embodiments, antibodies that inhibit IL-23R activity affect such statistically significant reductions of at least 10%, at least 50%, 80%, or 90% of measured parameters, and in certain embodiments, antibodies of the present disclosure may Inhibition of greater than 90%, 95%, 98%, or 99% of IL-23R activity.

In some embodiments, an anti-IL-23R antibody provided herein is present at ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10 ^-8 M or A dissociation constant (K _D ) of less, eg, 10 ⁻⁸ M to 10 ⁻¹³ M, such as 10 ⁻⁹ M to 10 ⁻¹³ M), binds to IL-23R (eg, human IL-23R). In some embodiments, an anti-IL-23R antibody provided herein is present at ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10 ^-8 M or A dissociation constant (K _{D )} of less, eg, 10 ⁻⁸ M to 10 ⁻¹³ M, eg, 10 ⁻⁹ M to 10 ⁻¹³ M), binds to IL-23R ECD (eg, human IL-23R ECD). In some embodiments, an anti-IL-23R antibody provided herein is present at ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10 ^-8 M or Dissociation constants (K _{D )} of less, eg 10 ⁻⁸ M to 10 ⁻¹³ M, eg 10 ⁻⁹ M to 10 ⁻¹³ M), bind to human and rat IL-23R. A variety of methods of measuring binding affinity are known in the art, any of which can be used for the purposes of the present disclosure, including, for example, RIA performed on Fab versions of the antibody of interest and its antigen (Chen et al., 1999, J. Mol Biol 293:865-81); Biolayer interferometry (BLI ⁾ or surface electrophoresis using Octet® such as the ^Octet® Red96 system or using ^Biacore® such as ^Biacore® TM-2000 or ^Biacore® TM-3000 Slurry resonance (SPR) test. The "on-rate/rate of association/association rate", or "kon" can also be used with the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above, using For example, Octet ^® Red96, Biacore ^® TM-2000, Biacore ^® TM-3000 system, Biacore ^® TM-8K, or Biacore ^® TM-8K+ system.

In one aspect, provided herein is an antibody that binds to IL-23R. In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, the IL-23R antibody is not a single domain antibody or Nanobody. In some embodiments, the IL-23R antibody is a humanized antibody.

In certain embodiments, provided herein is an IL-23R antibody comprising the VH region, VL region, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and/or LCDR3 of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising the VH region of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising the VL region of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising the VH region of any of the antibodies described herein, and the VL region of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising HCDR1, HCDR2, and HCDR3 of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising LCDR1, LCDR2, and LCDR3 of any of the antibodies described herein. In some embodiments, provided herein is an IL-23R antibody comprising HCDR1, HCDR2, and HCDR3 of any of the antibodies described herein; and LCDR1, LCDR2, and LCDR3 of any of the antibodies described herein . Representative VH and VL amino acid sequences of the IL-23R antibodies provided herein, including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 amino acid sequences, are provided in the Sequence Listing, and in Tables 4-9.

In some embodiments, the antibody is a humanized antibody. In certain embodiments, the antibody is an IgG antibody. In other embodiments, the IgG antibody is an IgGl, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody is a bispecific antibody. In certain embodiments, antibodies are multivalent. In other embodiments, the antibody is capable of binding at least three antigens. In some embodiments, antibodies are capable of binding at least five antigens.

In specific embodiments, the IL-23R antibody comprises a VH region and a VL region. In some embodiments, the IL-23R antibody is a single chain antibody. In some embodiments, the IL-23R antibody is a single domain antibody. In some embodiments, the IL-23R antibody is a Nanobody. In certain embodiments, the IL-23R antibody is a VHH antibody. In certain embodiments, the IL-23R antibody is a llama antibody. In some embodiments, the IL-23R antibody is not a single chain antibody. In some embodiments, the IL-23R antibody is not a single domain antibody. In some embodiments, the IL-23R antibody is not a Nanobody. In certain embodiments, the IL-23R antibody is not a VHH antibody. In certain embodiments, the IL-23R antibody is not a llama antibody. In some embodiments, the IL-23R antibody is a multispecific antibody. In other embodiments, IL-23R is a bispecific antibody. In certain embodiments, multispecific antibodies comprise antigen-binding fragments of IL-23R antibodies provided herein. In other embodiments, the bispecific antibody comprises an antigen-binding fragment of an IL-23R antibody provided herein.

In some embodiments, the anti-IL-23R antibodies provided herein are those antibodies described in the Examples below. Accordingly, in some embodiments, the antibodies provided herein comprise one or more of the CDR sequences of any one of SEQ ID NOs: 136-269, 786-899. In some embodiments, an antibody provided herein comprises a VH heavy chain CDR (CDR1, CDR2, and CDR3) sequence of any one of SEQ ID NOs: 136-269, 786-899. In some embodiments, an antibody provided herein comprises a VH heavy chain CDR (CDR1, CDR2, and CDR3) sequence and a VL light chain CDR (CDR1, CDR2, and CDR3). CDR sequences can be determined according to well known numbering systems. In some embodiments, CDRs are numbered according to IMGT. In some embodiments, the CDRs are numbered according to Kabat. In some embodiments, the CDRs are numbered according to AbM. In other embodiments, the CDRs are numbered according to Chothia. In other embodiments, the CDRs are numbered according to Contact. In some embodiments, anti-IL-23R antibodies are humanized. In some embodiments, the anti-IL-23R antibody comprises a receptor human framework, such as a human immunoglobulin framework or a human consensus framework.

In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:138, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:139. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:142, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:143. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:144, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:145. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:148, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:149. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:150, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:151. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:152, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:153. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:154, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:155. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:156, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:157. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:158, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:159. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:160, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:161. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:162, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:163. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:164, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:165. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:166, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:167. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:168, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:169. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:170, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:171. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:172, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:173. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:174, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:175. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:176, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:177. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:178, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:179. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:180, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:181. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:182, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:183. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:186, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:187. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:188, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:189. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:190, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:191. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:192, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:193. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:194, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:195. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:196, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:197. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:198, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:199. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:200, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:201. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:202, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:203. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:204, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:205. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:206, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:207. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:208, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:209. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:210, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:211. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:212, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:213. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:214, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:215. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:216, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:217. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:218, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:219. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:220, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:221. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:222, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:223. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:226, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:227. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:228, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:229. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:230, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:231. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:232, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:233. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:234, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:235. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:236, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:237. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:238, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:239. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:240, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:241. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:246, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:247. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:248, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:249. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:250, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:251. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:252, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:253. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:254, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:255. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:256, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:257. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:258, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:259. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:260, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:261. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:262, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:263. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:264, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:265. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:268, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:269. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:787. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:788, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:789. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:790, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:791. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:793. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:799. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:806, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:807. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:808, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:809. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:810, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:811. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:812, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:813. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:814, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:815. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:816, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:817. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:818, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:819. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:820, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:821. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:822, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:823. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:824, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:825. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:826, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:827. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:828, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:829. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:830, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:831. In some embodiments, an antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:832, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:833. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:836, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:837. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:838, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:839. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:840, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:841. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:842, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:843. In some embodiments, an antibody or antigen-binding fragment provided herein comprises HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:846, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:847. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:848, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:849. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:850, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:851. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:852, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:853. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:854, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:855. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:856, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:857. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:858, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:859. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:860, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:861. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:862, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:863. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:864, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:865. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:866, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:867. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:868, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:869. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:870, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:871. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:872, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:873. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:874, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:875. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:876, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:877. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:878, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:879. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:880, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:881. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:882, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:883. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:885. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:886, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:887. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:888, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:889. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:890, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:891. CDR sequences can be determined according to well known numbering systems or combinations thereof. In some embodiments, CDRs are numbered according to IMGT. In some embodiments, the CDRs are numbered according to Kabat. In some embodiments, the CDRs are numbered according to AbM. In other embodiments, the CDRs are numbered according to Chothia. In other embodiments, the CDRs are numbered according to Contact. In other embodiments, provided herein is an antibody that binds to IL-23R comprising: HCDR1 comprising a sequence associated with SEQ ID NO: 276, 288, 294, 306, 312, 318, 324, 330, 336, 342, 348, 354, 360, 366, 372, 378, 384, 390, 396, 402, 408, 420, 426, 432, 438, 444, 450, 456, 462, 468, 474, 480, 486, 492, 498, 504, 510, 516, 522, 528, 540, 546, 552, 558, 564, 570, 576, 582, 600, 606, 612, 618, 624, 630, 636, 642, 648, 654, 666, 900, 906, 912, 918, 936, 960, 966, 972, 978, 984, 990, 996, 1002, 1008, 1014, 1020, 1026, 1032, 1038, 1050, 1056, 1062, 1068, 1080, 1086, 1092, 1098, any of 1104, 1110, 1116, 1122, 1128, 1134, 1140, 1146, 1152, 1158, 1164, 1170, 1176, 1182, 1188, 1194, 1200, 1206, and 1212 have at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity (ii) HCDR2, which comprises the same sequence as SEQ ID NO: 277, 289, 295, 307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367, 373, 379 ,385,391,397,403,409,421,427,433,439,445,451,457,463,469,475,481,487,493,499,505,511,517,523,529,541 ,547,553,559,565,571,577,583,601,607,613,619,625,631,637,643,649,655,667,901,907,913,919,937,961,967 , 973, 979, 985, 991, 997, 1003, 1009, 1015, 1021, 1027, 1033, 1039, 1051, 1057, 1063, 1069, 1081, 1087, 1093, 1099, 1105, 1111, 1117, 1123, 1129 , 1135, 1141, 1147, 1153, 1159, 1165, 1171, 1177, 1183, 1189, 1195, 1201, 1207, and 1213 have at least 75%, 80%, 85%, 86%, 87%, Amino acid sequences with 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, (iii ) HCDR3, which is comprised of SEQ ID NO: 278, 290, 296, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374, 380, 386, 392, 398, 404, 410, 422, 428, 434, 440, 446, 452, 458, 464, 470, 476, 482, 488, 494, 500, 506, 512, 518, 524, 530, 542, 548, 554, 560, 566, 572, 578, 584, 602, 608, 614, 620, 626, 632, 638, 644, 650, 656, 668, 902, 908, 914, 920, 938, 962, 968, 974, 980, 986, 992, 998, 1004, 1010, 1016, 1022, 1028, 1034, 1040, 1052, 1058, 1064, 1070, 1082, 1088, 1094, 1100, 1106, 1112, 1118, 1124, 1130, 1136, 1142, 1148, 11 54. 1160, 1166, 1172, 1178, 1184, 1190, 1196, 1202, 1208, and 1214 have at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 %, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or an amino acid sequence of 100% sequence identity; (iv) LCDR1, which comprises the same sequence as SEQ ID NO: 279, 291 ,297,309,315,321,327,333,339,345,351,357,363,369,375,381,387,393,399,405,411,423,429,435,441,447,453 ,459,465,471,477,483,489,495,501,507,513,519,525,531,543,549,555,561,567,573,579,585,603,609,615,621 , 627, 633, 639, 645, 651, 657, 669, 903, 909, 915, 921, 939, 963, 969, 975, 981, 987, 993, 999, 1005, 1011, 1017, 1023, 1029, 1035 ,1041,1053,1059,1065,1071,1083,1089,1095,1101,1107,1113,1119,1125,1131,1137,1143,1149,1155,1161,1167,1173,1179,1185,1191, 1197 , 1203, 1209, and 1215 have at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% %, 96%, 97%, 98%, 99%, or the amino acid sequence of 100% sequence identity; (v) LCDR2, it comprises and SEQ ID NO: 280,292,298,310,316,322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 424, 430, 436, 442, 448, 454, 460, 466, 472, 478, 484, 490, 496, 502, 508, 514, 520, 526, 532, 544, 550, 556, 562, 568, 574, 580, 586, 604, 610, 616, 622, 628, 634, 640, 646, 652, 658, 670, 904, 910, 916, 922, 940, 964, 970, 976, 982, 988, 994, 1000, 1006, 1012, 1018, 1024, 1030, 1036, 1042, 1054, 1060, 1066, 1072, 1084, 1090, 1096, 1102, 1108, 1114, 1120, 1126, 1132, 1138, 1144, 1150, 1156, 1162, 1168, 1174, 1180, 1186, 1192, 1198, 1204, 1210, and 1216 Ren One has at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% %, 99%, or 100% sequence identity of the amino acid sequence; and/or (vi) LCDR3, which comprises and SEQ ID NO: 281, 293, 299, 311, 317, 323, 329, 335, 341, 347, 353, 359, 365, 371, 377, 383, 389, 395, 401, 407, 413, 425, 431, 437, 443, 449, 455, 461, 467, 473, 479, 485, 491, 497, 503, 509, 515, 521, 527, 533, 545, 551, 557, 563, 569, 575, 581, 587, 605, 611, 617, 623, 629, 635, 641, 647, 653, 659, 671, 905, 911, 917, 923, 941, 965, 971, 977, 983, 989, 995, 1001, 1007, 1013, 1019, 1025, 1031, 1037, 1043, 1055, 1061, 1067, 1073, 1085, 1091, Any of 1097, 1103, 1109, 1115, 1121, 1127, 1133, 1139, 1145, 1151, 1157, 1163, 1169, 1175, 1181, 1187, 1193, 1199, 1205, 1211, and 1217 have at least 75% , 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100 Amino acid sequences for % sequence identity. In some embodiments, anti-IL-23R antibodies are humanized. In some embodiments, the anti-IL-23R antibody comprises a receptor human framework, such as a human immunoglobulin framework or a human consensus framework.

In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 276, 277, and 278, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 279, 280, and 281, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 288, 289, and 290, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:291, 292, and 293, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 294, 295, and 296, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:297, 298, and 299, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 306, 307, and 308, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:309, 310, and 311, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 312, 313, and 314, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:315, 316, and 317, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 318, 319, and 320, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:321, 322, and 323, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 324, 325, and 326, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:327, 328, and 329, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 330, 331, and 332, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:333, 334, and 335, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 336, 337, and 338, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:339, 340, and 341, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 342, 343, and 344, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:345, 346, and 347, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 348, 349, and 350, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:351, 352, and 353, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 354, 355, and 356, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:357, 358, and 359, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 360, 361, and 362, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:363, 364, and 365, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 366, 367, and 368, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:369, 370, and 371, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 372, 373, and 374, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:375, 376, and 377, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 378, 379, and 380, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:381, 382, and 383, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 384, 385, and 386, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:387, 388, and 389, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 390, 391, and 392, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:393, 394, and 395, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 396, 397, and 398, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:399, 400, and 401, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 402, 403, and 404, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:405, 406, and 407, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:408, 409, and 410, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:411, 412, and 413, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:420, 421, and 422, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:423, 424, and 425, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:429, 430, and 431, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:432, 433, and 434, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:435, 436, and 437, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:438, 439, and 440, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:441, 442, and 443, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:444, 445, and 446, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:447, 448, and 449, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:450, 451, and 452, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:453, 454, and 455, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:456, 457, and 458, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:459, 460, and 461, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:462, 463, and 464, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:465, 466, and 467, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:468, 469, and 470, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:471, 472, and 473, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:474, 475, and 476, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:477, 478, and 479, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:480, 481, and 482, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:483, 484, and 485, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:486, 487, and 488, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:489, 490, and 491, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:492, 493, and 494, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:495, 496, and 497, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:498, 499, and 500, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:501, 502, and 503, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:504, 505, and 506, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:507, 508, and 509, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:510, 511, and 512, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:513, 514, and 515, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:516, 517, and 518, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:519, 520, and 521, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:522, 523, and 524, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:525, 526, and 527, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:528, 529, and 530, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:531, 532, and 533, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:540, 541, and 542, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:543, 544, and 545, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:546, 547, and 548, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:549, 550, and 551, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:552, 553, and 554, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:555, 556, and 557, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:558, 559, and 560, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:561, 562, and 563, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:567, 568, and 569, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:573, 574, and 575, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:576, 577, and 578, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:579, 580, and 581, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:582, 583, and 584, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:585, 586, and 587, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:600, 601, and 602, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:603, 604, and 605, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:609, 610, and 611, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:612, 613, and 614, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:615, 616, and 617, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:618, 619, and 620, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:621, 622, and 623, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:624, 625, and 626, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:627, 628, and 629, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:630, 631, and 632, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:633, 634, and 635, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:636, 637, and 638, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:639, 640, and 641, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:642, 643, and 644, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:645, 646, and 647, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:648, 649, and 650, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:651, 652, and 653, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:654, 655, and 656, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:657, 658, and 659, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:666, 667, and 668, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:669, 670, and 671, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:903, 904, and 905, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:915, 916, and 917, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:921, 922, and 923, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:939, 940, and 941, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:960, 961, and 962, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:963, 964, and 965, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:966, 967, and 968, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:969, 970, and 971, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:972, 973, and 974, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:975, 976, and 977, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:978, 979, and 980, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:981, 982, and 983, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:984, 985, and 986, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:987, 988, and 989, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:990, 991, and 992, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:993, 994, and 995, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:996, 997, and 998, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:999, 1000, and 1001, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1002, 1003, and 1004, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1005, 1006, and 1007, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1008, 1009, and 1010, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1011, 1012, and 1013, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1014, 1015, and 1016, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1017, 1018, and 1019, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1020, 1021, and 1022, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1023, 1024, and 1025, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1026, 1027, and 1028, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1029, 1030, and 1031, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1032, 1033, and 1034, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1035, 1036, and 1037, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1038, 1039, and 1040, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1041, 1042, and 1043, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1050, 1051, and 1052, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1053, 1054, and 1055, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1056, 1057, and 1058, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1059, 1060, and 1061, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1062, 1063, and 1064, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1065, 1066, and 1067, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1068, 1069, and 1070, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1071, 1072, and 1073, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1080, 1081, and 1082, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1083, 1084, and 1085, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1086, 1087, and 1088, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1089, 1090, and 1091, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1092, 1093, and 1094, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1095, 1096, and 1097, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1098, 1099, and 1100, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1101, 1102, and 1103, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1104, 1105, and 1106, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1107, 1108, and 1109, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1110, 1111, and 1112, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1113, 1114, and 1115, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1116, 1117, and 1118, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1119, 1120, and 1121, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1122, 1123, and 1124, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1125, 1126, and 1127, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1128, 1129, and 1130, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1131, 1132, and 1133, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1134, 1135, and 1136, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1137, 1138, and 1139, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1140, 1141, and 1142, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1143, 1144, and 1145, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1146, 1147, and 1148, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1149, 1150, and 1151, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1152, 1153, and 1154, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1155, 1156, and 1157, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1158, 1159, and 1160, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1161, 1162, and 1163, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1164, 1165, and 1166, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1167, 1168, and 1169, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1170, 1171, and 1172, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1173, 1174, and 1175, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1176, 1177, and 1178, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1179, 1180, and 1181, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1182, 1183, and 1184, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1185, 1186, and 1187, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1188, 1189, and 1190, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1191, 1192, and 1193, respectively. In some embodiments, provided herein is an IL-23R-binding antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1194, 1195, and 1196, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1197, 1198, and 1199, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1200, 1201, and 1202, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1203, 1204, and 1205, respectively. In some embodiments, provided herein is an antibody that binds to IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1206, 1207, and 1208, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1209, 1210, and 1211, respectively. In some embodiments, provided herein is an antibody that binds IL-23R, comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1212, 1213, and 1214, respectively , and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1215, 1216, and 1217, respectively.

In some embodiments, the antibody further comprises one or more framework regions of SEQ ID NO: 136-269, 786-899. In some embodiments, the antibodies provided herein are humanized antibodies. In some embodiments, the antibody is a chimeric antibody. The architectural regions described in this article are based on the boundary determination of the CDR numbering system. In other words, if the CDRs are determined by, for example, Kabat, IMGT, or Chothia, the framework regions surround the CDRs in the variable region from N-terminus to C-terminus in the form FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 of amino acid residues. For example, FR1 is defined as the amino acid residue N-terminal to the amino acid residue of CDR1, as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system, and FR2 is defined as the amino acid residue between CDR1 and CDR2 Amino acid residues between residues, as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system, FR3 is defined as an amino acid residue between CDR2 and CDR3 amino acid residues group, as defined by, for example, the Kabat numbering system, the IMGT numbering system, or the Chothia numbering system, and FR4 is defined as the amino acid residue C-terminal to a CDR3 amino acid residue, as defined by, for example, the Kabat numbering system, IMGT numbering system, or as defined by the Chothia numbering system.

In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:138, and a VL comprising the amino acid sequence of SEQ ID NO:139. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:142, and a VL comprising the amino acid sequence of SEQ ID NO:143. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:144, and a VL comprising the amino acid sequence of SEQ ID NO:145. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:148, and a VL comprising the amino acid sequence of SEQ ID NO:149. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:150, and a VL comprising the amino acid sequence of SEQ ID NO:151. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:152, and a VL comprising the amino acid sequence of SEQ ID NO:153. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:154, and a VL comprising the amino acid sequence of SEQ ID NO:155. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:156, and a VL comprising the amino acid sequence of SEQ ID NO:157. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:158, and a VL comprising the amino acid sequence of SEQ ID NO:159. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:160, and a VL comprising the amino acid sequence of SEQ ID NO:161. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:162, and a VL comprising the amino acid sequence of SEQ ID NO:163. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:164, and a VL comprising the amino acid sequence of SEQ ID NO:165. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:166, and a VL comprising the amino acid sequence of SEQ ID NO:167. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO: 168, and a VL comprising the amino acid sequence of SEQ ID NO: 169. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:170, and a VL comprising the amino acid sequence of SEQ ID NO:171. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:172, and a VL comprising the amino acid sequence of SEQ ID NO:173. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:174, and a VL comprising the amino acid sequence of SEQ ID NO:175. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:176, and a VL comprising the amino acid sequence of SEQ ID NO:177. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:178, and a VL comprising the amino acid sequence of SEQ ID NO:179. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:180, and a VL comprising the amino acid sequence of SEQ ID NO:181. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:182, and a VL comprising the amino acid sequence of SEQ ID NO:183. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:186, and a VL comprising the amino acid sequence of SEQ ID NO:187. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO: 188, and a VL comprising the amino acid sequence of SEQ ID NO: 189. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:190, and a VL comprising the amino acid sequence of SEQ ID NO:191. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:192, and a VL comprising the amino acid sequence of SEQ ID NO:193. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:194, and a VL comprising the amino acid sequence of SEQ ID NO:195. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO: 196, and a VL comprising the amino acid sequence of SEQ ID NO: 197. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO: 198, and a VL comprising the amino acid sequence of SEQ ID NO: 199. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:200, and a VL comprising the amino acid sequence of SEQ ID NO:201. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:202, and a VL comprising the amino acid sequence of SEQ ID NO:203. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:204, and a VL comprising the amino acid sequence of SEQ ID NO:205. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:206, and a VL comprising the amino acid sequence of SEQ ID NO:207. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:208, and a VL comprising the amino acid sequence of SEQ ID NO:209. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:210, and a VL comprising the amino acid sequence of SEQ ID NO:211. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:212, and a VL comprising the amino acid sequence of SEQ ID NO:213. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:214, and a VL comprising the amino acid sequence of SEQ ID NO:215. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:216, and a VL comprising the amino acid sequence of SEQ ID NO:217. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:218, and a VL comprising the amino acid sequence of SEQ ID NO:219. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:220, and a VL comprising the amino acid sequence of SEQ ID NO:221. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:222, and a VL comprising the amino acid sequence of SEQ ID NO:223. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:226, and a VL comprising the amino acid sequence of SEQ ID NO:227. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:228, and a VL comprising the amino acid sequence of SEQ ID NO:229. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:230, and a VL comprising the amino acid sequence of SEQ ID NO:231. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:232, and a VL comprising the amino acid sequence of SEQ ID NO:233. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:234, and a VL comprising the amino acid sequence of SEQ ID NO:235. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:236, and a VL comprising the amino acid sequence of SEQ ID NO:237. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:238, and a VL comprising the amino acid sequence of SEQ ID NO:239. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:240, and a VL comprising the amino acid sequence of SEQ ID NO:241. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:246, and a VL comprising the amino acid sequence of SEQ ID NO:247. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:248, and a VL comprising the amino acid sequence of SEQ ID NO:249. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:250, and a VL comprising the amino acid sequence of SEQ ID NO:251. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:252, and a VL comprising the amino acid sequence of SEQ ID NO:253. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:254, and a VL comprising the amino acid sequence of SEQ ID NO:255. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:256, and a VL comprising the amino acid sequence of SEQ ID NO:257. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:258, and a VL comprising the amino acid sequence of SEQ ID NO:259. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:260, and a VL comprising the amino acid sequence of SEQ ID NO:261. In some embodiments, the antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:262, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:263. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:264, and a VL comprising the amino acid sequence of SEQ ID NO:265. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:268, and a VL comprising the amino acid sequence of SEQ ID NO:269. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:786, and a VL comprising the amino acid sequence of SEQ ID NO:787. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:788, and a VL comprising the amino acid sequence of SEQ ID NO:789. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:790, and a VL comprising the amino acid sequence of SEQ ID NO:791. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:792, and a VL comprising the amino acid sequence of SEQ ID NO:793. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:798, and a VL comprising the amino acid sequence of SEQ ID NO:799. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:806, and a VL comprising the amino acid sequence of SEQ ID NO:807. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:808, and a VL comprising the amino acid sequence of SEQ ID NO:809. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:810, and a VL comprising the amino acid sequence of SEQ ID NO:811. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:812, and a VL comprising the amino acid sequence of SEQ ID NO:813. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:814, and a VL comprising the amino acid sequence of SEQ ID NO:815. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:816, and a VL comprising the amino acid sequence of SEQ ID NO:817. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:818, and a VL comprising the amino acid sequence of SEQ ID NO:819. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:820, and a VL comprising the amino acid sequence of SEQ ID NO:821. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:822, and a VL comprising the amino acid sequence of SEQ ID NO:823. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:824, and a VL comprising the amino acid sequence of SEQ ID NO:825. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:826, and a VL comprising the amino acid sequence of SEQ ID NO:827. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:828, and a VL comprising the amino acid sequence of SEQ ID NO:829. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:830, and a VL comprising the amino acid sequence of SEQ ID NO:831. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:832, and a VL comprising the amino acid sequence of SEQ ID NO:833. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:836, and a VL comprising the amino acid sequence of SEQ ID NO:837. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:838, and a VL comprising the amino acid sequence of SEQ ID NO:839. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:840, and a VL comprising the amino acid sequence of SEQ ID NO:841. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO: 842, and a VL comprising the amino acid sequence of SEQ ID NO: 843. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:846, and a VL comprising the amino acid sequence of SEQ ID NO:847. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:848, and a VL comprising the amino acid sequence of SEQ ID NO:849. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:850, and a VL comprising the amino acid sequence of SEQ ID NO:851. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:852, and a VL comprising the amino acid sequence of SEQ ID NO:853. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:854, and a VL comprising the amino acid sequence of SEQ ID NO:855. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:856, and a VL comprising the amino acid sequence of SEQ ID NO:857. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:858, and a VL comprising the amino acid sequence of SEQ ID NO:859. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:860, and a VL comprising the amino acid sequence of SEQ ID NO:861. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:862, and a VL comprising the amino acid sequence of SEQ ID NO:863. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:864, and a VL comprising the amino acid sequence of SEQ ID NO:865. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:866, and a VL comprising the amino acid sequence of SEQ ID NO:867. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:868, and a VL comprising the amino acid sequence of SEQ ID NO:869. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:870, and a VL comprising the amino acid sequence of SEQ ID NO:871. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:872, and a VL comprising the amino acid sequence of SEQ ID NO:873. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:874, and a VL comprising the amino acid sequence of SEQ ID NO:875. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:876, and a VL comprising the amino acid sequence of SEQ ID NO:877. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:878, and a VL comprising the amino acid sequence of SEQ ID NO:879. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:880, and a VL comprising the amino acid sequence of SEQ ID NO:881. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:882, and a VL comprising the amino acid sequence of SEQ ID NO:883. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:884, and a VL comprising the amino acid sequence of SEQ ID NO:885. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:886, and a VL comprising the amino acid sequence of SEQ ID NO:887. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:888, and a VL comprising the amino acid sequence of SEQ ID NO:889. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:890, and a VL comprising the amino acid sequence of SEQ ID NO:891.

In certain embodiments, the antibodies described herein, or antigen-binding fragments thereof, comprise antibodies with a certain specificity relative to any of the antibodies provided herein, such as those described in the Examples provided below, including the antibodies set forth in Tables 4-9. Amino acid sequences with certain percentages of identity.

The determination of percent identity between two sequences (eg, amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the following algorithm: Karlin and Altschul, Proc. Natl. Acad. Sci. U.S.A. 87:2264 2268 (1990), modified as Karlin and Altschul, Proc. Natl. Acad. Sci. U.S.A. 90:5873 5877 (1993). This algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., J. Mol. Biol. 215:403 (1990). BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, eg, score=100, wordlength=12, to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed with the XBLAST program parameters set, eg, score 50, wordlength = 3, to obtain amino acid sequences homologous to protein molecules described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res. 25:3389 3402 (1997). Alternatively, an iterative search can be performed using PSI BLAST, which detects distance relationships (Id.) between molecules. When utilizing the BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, e.g., the National Center for Biotechnology Information on the World Wide Web , NCBI), ncbi.nlm.nih.gov). Another non-limiting example of a mathematical algorithm for comparing sequences is the algorithm of Myers and Miller, CABIOS 4:11-17 (1998). This algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software suite. When utilizing the ALIGN program to compare amino acid sequences, a PAM120 weighted residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without gaps. When calculating percent identity, generally only exact matches are counted.

In some embodiments, the antibodies provided herein contain substitutions (eg, conservative substitutions), insertions, or deletions relative to the reference sequence, but the anti-IL-23R antibodies comprise sequences that retain the ability to bind to IL-23R. In some embodiments, the antibodies provided herein contain substitutions (eg, conservative substitutions), insertions, or deletions relative to the reference sequence, but the anti-IL-23R antibodies comprise sequences that retain the ability to bind to the IL-23R ECD. In some embodiments, a total of 1 to 10 amino acids in the reference amino acid sequence have been substituted, inserted, and/or deleted. In some embodiments, a total of 1 to 10 amino acids in the reference amino acid sequence have been substituted. In some embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (ie, in FRs). In some embodiments, substitutions occur in regions outside the CDRs (ie, in the FRs). In some embodiments, the anti-IL-23R antibodies provided herein include post-translational modifications of the reference sequence.

In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 138 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 142 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 144 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 148 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 150 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 152 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 154 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 156 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 158 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 160 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 162 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 164 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 166 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 168 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 170 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 172 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 174 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 176 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 178 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 180 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 182 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 186 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 188 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 190 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 192 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 194 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 196 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 198 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:200 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 202 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 204 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 206 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 208 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 210 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 212 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 214 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 216 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 218 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 220 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 222 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 226 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 228 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 230 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 232 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 234 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 236 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 238 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 240 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 246 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 248 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:250 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 252 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 254 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 256 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 258 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:260 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 262 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and LCDR1, LCDR2, and LCDR3. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:264 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:268 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:786 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:788 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:790 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:792 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:798 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:806 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:808 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 810 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 812 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:814 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 816 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:818 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:820 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:822 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:824 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:826 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:828 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:830 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:832 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:836 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:838 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:840 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 842 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:846 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:848 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:850 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:852 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:854 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:856 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:858 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:860 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:862 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:864 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:866 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:868 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:870 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:872 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:874 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:876 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:878 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:880 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:882 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:884 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:886 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:888 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 890 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In all of the above examples, the antibody binds to IL-23R.

In some embodiments, functional epitopes can be mapped by, for example, combining alanine scanning to identify amino acids in the IL-23R protein that are required to interact with the anti-IL-23R antibodies provided herein. In some embodiments, the conformation and crystal structure of an anti-IL-23R antibody bound to IL-23R can be used to recognize the epitope. In some embodiments, the present disclosure provides antibodies that specifically bind to the same epitope as any of the anti-IL-23R antibodies provided herein. For example, in some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 138, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 138 VL of the amino acid sequence of NO:139. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 142, and comprising SEQ ID NO: The VL of the amino acid sequence of 143. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 144, and comprising SEQ ID NO: The VL of the amino acid sequence of 145. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 148, and comprising SEQ ID NO: The VL of the amino acid sequence of 149. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 150, and comprising SEQ ID NO: The VL of the amino acid sequence of 151. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 152, and comprising SEQ ID NO: The VL of the amino acid sequence of 153. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 154, and comprising SEQ ID NO: The VL of the amino acid sequence of 155. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 156, and comprising SEQ ID NO: The VL of the amino acid sequence of 157. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 158, and comprising SEQ ID NO: The VL of the amino acid sequence of 159. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 160, and comprising SEQ ID NO: The VL of the amino acid sequence of 161. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 162, and comprising SEQ ID NO: The VL of the amino acid sequence of 163. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 164, and comprising SEQ ID NO: The VL of the amino acid sequence of 165. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 166, and comprising SEQ ID NO: The VL of the amino acid sequence of 167. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 168, and comprising SEQ ID NO: The VL of the amino acid sequence of 169. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 170, and comprising SEQ ID NO: VL of the amino acid sequence of 171. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 172, and comprising SEQ ID NO: The VL of the amino acid sequence of 173. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 174, and comprising SEQ ID NO: The VL of the amino acid sequence of 175. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 176, and comprising SEQ ID NO: The VL of the amino acid sequence of 177. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 178, and comprising SEQ ID NO: The VL of the amino acid sequence of 179. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 180, and comprising SEQ ID NO: VL of the amino acid sequence of 181. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 182, and comprising SEQ ID NO: VL of the amino acid sequence of 183. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 186, and comprising SEQ ID NO: The VL of the amino acid sequence of 187. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 188, and comprising SEQ ID NO: The VL of the amino acid sequence of 189. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 190, and comprising SEQ ID NO: VL of the amino acid sequence of 191. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 192, and comprising SEQ ID NO: VL of the amino acid sequence of 193. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 194, and comprising SEQ ID NO: The VL of the amino acid sequence of 195. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 196, and comprising SEQ ID NO: VL of the amino acid sequence of 197. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 198, and comprising SEQ ID NO: The VL of the amino acid sequence of 199. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 200, and comprising SEQ ID NO: VL of the amino acid sequence of 201. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 202, and comprising SEQ ID NO: VL of the amino acid sequence of 203. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 204, and comprising SEQ ID NO: VL of the amino acid sequence of 205. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 206, and comprising SEQ ID NO: VL of the amino acid sequence of 207. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 208, and comprising SEQ ID NO: VL of the amino acid sequence of 209. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 210, and comprising SEQ ID NO: VL of the amino acid sequence of 211. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 212, and comprising SEQ ID NO: VL of the amino acid sequence of 213. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 214, and comprising SEQ ID NO: The VL of the amino acid sequence of 215. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 216, and comprising SEQ ID NO: VL of the amino acid sequence of 217. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 218, and comprising SEQ ID NO: VL of the amino acid sequence of 219. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 220, and comprising SEQ ID NO: VL of the amino acid sequence of 221. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 222, and comprising SEQ ID NO: VL of the amino acid sequence of 223. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 226, and comprising SEQ ID NO: The VL of the amino acid sequence of 227. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 228, and comprising SEQ ID NO: The VL of the amino acid sequence of 229. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 230, and comprising SEQ ID NO: VL of the amino acid sequence of 231. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 232, and comprising SEQ ID NO: The VL of the amino acid sequence of 233. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 234, and comprising SEQ ID NO: The VL of the amino acid sequence of 235. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 236, and comprising SEQ ID NO: The VL of the amino acid sequence of 237. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 238, and comprising SEQ ID NO: The VL of the amino acid sequence of 239. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 240, and comprising SEQ ID NO: VL of the amino acid sequence of 241. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 246, and comprising SEQ ID NO: The VL of the amino acid sequence of 247. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 248, and comprising SEQ ID NO: The VL of the amino acid sequence of 249. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 250, and comprising SEQ ID NO: The VL of the amino acid sequence of 251. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 252, and comprising SEQ ID NO: The VL of the amino acid sequence of 253. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 254, and comprising SEQ ID NO: The VL of the amino acid sequence of 255. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 256, and comprising SEQ ID NO: The VL of the amino acid sequence of 257. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 258, and comprising SEQ ID NO: The VL of the amino acid sequence of 259. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 260, and comprising SEQ ID NO: VL of the amino acid sequence of 261. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 262, and comprising SEQ ID NO: VL of amino acid sequence of 263. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 264, and comprising SEQ ID NO: The VL of the amino acid sequence of 265. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 268, and comprising SEQ ID NO: The VL of the amino acid sequence of 269. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 786, and comprising SEQ ID NO: VL of the amino acid sequence of 787. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 788, and comprising SEQ ID NO: VL of the amino acid sequence of 789. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 790, and comprising SEQ ID NO: VL of the amino acid sequence of 791. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 792, and comprising SEQ ID NO: VL of the amino acid sequence of 793. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 798, and comprising SEQ ID NO: VL of the amino acid sequence of 799. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 806, and comprising SEQ ID NO: VL of the amino acid sequence of 807. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 808, and comprising SEQ ID NO: VL of the amino acid sequence of 809. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 810, and comprising SEQ ID NO: VL of the amino acid sequence of 811. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 812, and comprising SEQ ID NO: VL of the amino acid sequence of 813. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 814, and comprising SEQ ID NO: VL of the amino acid sequence of 815. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 816, and comprising SEQ ID NO: VL of the amino acid sequence of 817. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 818, and comprising SEQ ID NO: VL of the amino acid sequence of 819. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 820, and comprising SEQ ID NO: VL of the amino acid sequence of 821. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 822, and comprising SEQ ID NO: VL of the amino acid sequence of 823. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 824, and comprising SEQ ID NO: VL of the amino acid sequence of 825. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 826, and comprising SEQ ID NO: VL of the amino acid sequence of 827. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 828, and comprising SEQ ID NO: VL of the amino acid sequence of 829. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 830, and comprising SEQ ID NO: VL of the amino acid sequence of 831. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 832, and comprising SEQ ID NO: VL of the amino acid sequence of 833. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 836, and comprising SEQ ID NO: VL of the amino acid sequence of 837. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 838, and comprising SEQ ID NO: VL of the amino acid sequence of 839. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 840, and comprising SEQ ID NO: VL of the amino acid sequence of 841. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 842, and comprising SEQ ID NO: VL of the amino acid sequence of 843. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 846, and comprising SEQ ID NO: VL of the amino acid sequence of 847. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 848, and comprising SEQ ID NO: VL of the amino acid sequence of 849. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 850, and comprising SEQ ID NO: VL of the amino acid sequence of 851. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 852, and comprising SEQ ID NO: VL of the amino acid sequence of 853. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 854, and comprising SEQ ID NO: VL of the amino acid sequence of 855. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 856, and comprising SEQ ID NO: VL of the amino acid sequence of 857. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 858, and comprising SEQ ID NO: VL of the amino acid sequence of 859. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 860, and comprising SEQ ID NO: VL of the amino acid sequence of 861. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 862, and comprising SEQ ID NO: VL of the amino acid sequence of 863. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 864, and comprising SEQ ID NO: VL of the amino acid sequence of 865. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 866, and comprising SEQ ID NO: VL of the amino acid sequence of 867. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 868, and comprising SEQ ID NO: VL of the amino acid sequence of 869. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 870, and comprising SEQ ID NO: VL of the amino acid sequence of 871. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 872, and comprising SEQ ID NO: VL of the amino acid sequence of 873. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 874, and comprising SEQ ID NO: VL of the amino acid sequence of 875. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 876, and comprising SEQ ID NO: VL of the amino acid sequence of 877. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 878, and comprising SEQ ID NO: VL of the amino acid sequence of 879. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 880, and comprising SEQ ID NO: VL of the amino acid sequence of 881. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 882, and comprising SEQ ID NO: VL of the amino acid sequence of 883. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 884, and comprising SEQ ID NO: VL of the amino acid sequence of 885. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 886, and comprising SEQ ID NO: VL of the amino acid sequence of 887. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 888, and comprising SEQ ID NO: VL of the amino acid sequence of 889. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 890, and comprising SEQ ID NO: VL of the amino acid sequence of 891.

In some embodiments, provided herein is an anti-IL-23R antibody, or antigen-binding fragment thereof, that competes for specific binding to IL-23R with any of the anti-IL-23R antibodies described herein. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 138, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 138 VL of the amino acid sequence of NO:139. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 142, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 142 NO: VL of the amino acid sequence of 143. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 144, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 144 NO: VL of the amino acid sequence of 145. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 148, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 148 NO: VL of the amino acid sequence of 149. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 150, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 150 NO: VL of the amino acid sequence of 151. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 152, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 152 NO: VL of the amino acid sequence of 153. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 154, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 154 NO: VL of the amino acid sequence of 155. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 156, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 156 NO: VL of the amino acid sequence of 157. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 158, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 158 NO: VL of the amino acid sequence of 159. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 160, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 160 NO: VL of the amino acid sequence of 161. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 162, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 162 NO: VL of the amino acid sequence of 163. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 164, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 164 NO: VL of the amino acid sequence of 165. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 166, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 166 NO: VL of the amino acid sequence of 167. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 168, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 168 NO: VL of the amino acid sequence of 169. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 170, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 170 VL of the amino acid sequence of NO:171. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 172, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 172 VL of the amino acid sequence of NO:173. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 174, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 174 NO: VL of the amino acid sequence of 175. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 176, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 176 VL of the amino acid sequence of NO:177. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 178, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 178 VL of the amino acid sequence of NO:179. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 180, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 180 NO: VL of the amino acid sequence of 181. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 182, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 182 NO: VL of the amino acid sequence of 183. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 186, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 186 NO: VL of the amino acid sequence of 187. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 188, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 188 NO: VL of the amino acid sequence of 189. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 190, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 190 NO: VL of the amino acid sequence of 191. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 192, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 192 NO: VL of the amino acid sequence of 193. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 194, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 194 NO: VL of the amino acid sequence of 195. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 196, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 196 NO: VL of the amino acid sequence of 197. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 198, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 198 NO: VL of the amino acid sequence of 199. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 200, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 200 NO: VL of the amino acid sequence of 201. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 202, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 202 NO: VL of the amino acid sequence of 203. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 204, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 204 NO: VL of the amino acid sequence of 205. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 206, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 206 NO: VL of the amino acid sequence of 207. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 208, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 208 NO: VL of the amino acid sequence of 209. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 210, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 210 NO: VL of the amino acid sequence of 211. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 212, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 212 NO: VL of the amino acid sequence of 213. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 214, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 214 NO: VL of the amino acid sequence of 215. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 216, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 216; NO: VL of the amino acid sequence of 217. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 218, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 218 NO: VL of the amino acid sequence of 219. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 220, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 220 NO: VL of the amino acid sequence of 221. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 222, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 222 NO: VL of the amino acid sequence of 223. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 226, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 226 NO: VL of the amino acid sequence of 227. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 228, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 228 NO: VL of the amino acid sequence of 229. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 230, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 230 NO: VL of the amino acid sequence of 231. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 232, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 232 NO: VL of the amino acid sequence of 233. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 234, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 234 NO: VL of the amino acid sequence of 235. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 236, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 236. NO: VL of the amino acid sequence of 237. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 238, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 238 NO: VL of the amino acid sequence of 239. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 240, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 240 NO: VL of the amino acid sequence of 241. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 246, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 246. NO: VL of the amino acid sequence of 247. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 248, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 248 NO: VL of the amino acid sequence of 249. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 250, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 250 NO: VL of the amino acid sequence of 251. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 252, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 252 NO: VL of the amino acid sequence of 253. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 254, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 254 NO: VL of the amino acid sequence of 255. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 256, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 256 NO: VL of the amino acid sequence of 257. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 258, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 258 NO: VL of the amino acid sequence of 259. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 260, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 260 NO: VL of the amino acid sequence of 261. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 262, and a VH comprising the amino acid sequence of SEQ ID NO: 262, and LCDR1, LCDR2, and LCDR3 shown in NO:263. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 264, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 264 NO: VL of the amino acid sequence of 265. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 268, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 268 NO: VL of the amino acid sequence of 269. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 786, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 786 VL of the amino acid sequence of NO:787. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:788, and comprising a VH comprising the amino acid sequence of SEQ ID NO:788 VL of the amino acid sequence of NO:789. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:790, and comprising a VH comprising the amino acid sequence of SEQ ID NO:790 VL of the amino acid sequence of NO:791. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 792, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 792 VL of the amino acid sequence of NO:793. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 798, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 798 VL of the amino acid sequence of NO:799. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 806, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 806 NO: VL of the amino acid sequence of 807. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 808, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 808 NO: VL of the amino acid sequence of 809. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 810, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 810 NO: VL of the amino acid sequence of 811. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 812, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 812 NO: VL of the amino acid sequence of 813. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 814, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 814 NO: VL of the amino acid sequence of 815. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 816, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 816 NO: VL of the amino acid sequence of 817. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 818, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 818 NO: VL of the amino acid sequence of 819. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 820, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 820 NO: VL of the amino acid sequence of 821. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 822, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 822 NO: VL of the amino acid sequence of 823. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 824, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 824 NO: VL of the amino acid sequence of 825. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 826, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 826 NO: VL of the amino acid sequence of 827. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 828, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 828 NO: VL of the amino acid sequence of 829. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 830, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 830 NO: VL of the amino acid sequence of 831. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 832, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 832 NO: VL of the amino acid sequence of 833. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 836, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 836 VL of the amino acid sequence of NO:837. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 838, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 838 VL of the amino acid sequence of NO:839. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 840, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 840 NO: VL of the amino acid sequence of 841. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 842, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 842 NO: VL of the amino acid sequence of 843. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 846, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 846 NO: VL of the amino acid sequence of 847. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 848, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 848 NO: VL of the amino acid sequence of 849. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 850, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 850 NO: VL of the amino acid sequence of 851. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 852, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 852 NO: VL of the amino acid sequence of 853. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 854, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 854 NO: VL of the amino acid sequence of 855. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 856, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 856 NO: VL of the amino acid sequence of 857. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 858, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 858 NO: VL of the amino acid sequence of 859. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 860, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 860 NO: VL of the amino acid sequence of 861. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 862, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 862 NO: VL of the amino acid sequence of 863. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 864, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 864 NO: VL of the amino acid sequence of 865. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 866, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 866 NO: VL of the amino acid sequence of 867. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 868, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 868 NO: VL of the amino acid sequence of 869. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 870, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 870 VL of the amino acid sequence of NO:871. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 872, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 872 VL of the amino acid sequence of NO:873. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 874, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 874 NO: VL of the amino acid sequence of 875. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 876, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 876 VL of the amino acid sequence of NO:877. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 878, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 878 VL of the amino acid sequence of NO:879. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 880, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 880 NO: VL of the amino acid sequence of 881. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 882, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 882 VL of the amino acid sequence of NO:883. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:884, and comprising a VH comprising the amino acid sequence of SEQ ID NO:884. NO: VL of the amino acid sequence of 885. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 886, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 886 NO: VL of the amino acid sequence of 887. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 888, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 888 VL of the amino acid sequence of NO:889. In some embodiments, the antibodies or antigen-binding fragments provided herein compete for specific binding to IL-23R with an anti-IL-23R antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 890, and comprising a VH comprising the amino acid sequence of SEQ ID NO: 890 NO: VL of the amino acid sequence of 891.

In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:4, and a light chain comprising the amino acid sequence of SEQ ID NO:5. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:8, and a light chain comprising the amino acid sequence of SEQ ID NO:9. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:10, and a light chain comprising the amino acid sequence of SEQ ID NO:11. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:14, and a light chain comprising the amino acid sequence of SEQ ID NO:15. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:16, and a light chain comprising the amino acid sequence of SEQ ID NO:17. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:18, and a light chain comprising the amino acid sequence of SEQ ID NO:19. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:20, and a light chain comprising the amino acid sequence of SEQ ID NO:21. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:22, and a light chain comprising the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:24, and a light chain comprising the amino acid sequence of SEQ ID NO:25. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:26, and a light chain comprising the amino acid sequence of SEQ ID NO:27. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:28, and a light chain comprising the amino acid sequence of SEQ ID NO:29. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:30, and a light chain comprising the amino acid sequence of SEQ ID NO:31. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:32, and a light chain comprising the amino acid sequence of SEQ ID NO:33. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:34, and a light chain comprising the amino acid sequence of SEQ ID NO:35. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:36, and a light chain comprising the amino acid sequence of SEQ ID NO:37. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:38, and a light chain comprising the amino acid sequence of SEQ ID NO:39. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:40, and a light chain comprising the amino acid sequence of SEQ ID NO:41. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:42, and a light chain comprising the amino acid sequence of SEQ ID NO:43. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:44, and a light chain comprising the amino acid sequence of SEQ ID NO:45. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:46, and a light chain comprising the amino acid sequence of SEQ ID NO:47. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:48, and a light chain comprising the amino acid sequence of SEQ ID NO:49. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:52, and a light chain comprising the amino acid sequence of SEQ ID NO:53. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:54, and a light chain comprising the amino acid sequence of SEQ ID NO:55. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:56, and a light chain comprising the amino acid sequence of SEQ ID NO:57. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:58, and a light chain comprising the amino acid sequence of SEQ ID NO:59. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:60, and a light chain comprising the amino acid sequence of SEQ ID NO:61. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:62, and a light chain comprising the amino acid sequence of SEQ ID NO:63. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:64, and a light chain comprising the amino acid sequence of SEQ ID NO:65. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:66, and a light chain comprising the amino acid sequence of SEQ ID NO:67. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:68, and a light chain comprising the amino acid sequence of SEQ ID NO:69. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:70, and a light chain comprising the amino acid sequence of SEQ ID NO:71. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:72, and a light chain comprising the amino acid sequence of SEQ ID NO:73. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:74, and a light chain comprising the amino acid sequence of SEQ ID NO:75. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:76, and a light chain comprising the amino acid sequence of SEQ ID NO:77. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:78, and a light chain comprising the amino acid sequence of SEQ ID NO:79. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:80, and a light chain comprising the amino acid sequence of SEQ ID NO:81. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:82, and a light chain comprising the amino acid sequence of SEQ ID NO:83. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:84, and a light chain comprising the amino acid sequence of SEQ ID NO:85. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:86, and a light chain comprising the amino acid sequence of SEQ ID NO:87. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:88, and a light chain comprising the amino acid sequence of SEQ ID NO:89. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:92, and a light chain comprising the amino acid sequence of SEQ ID NO:93. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:94, and a light chain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:96, and a light chain comprising the amino acid sequence of SEQ ID NO:97. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:98, and a light chain comprising the amino acid sequence of SEQ ID NO:99. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:100, and a light chain comprising the amino acid sequence of SEQ ID NO:101. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 102, and a light chain comprising the amino acid sequence of SEQ ID NO: 103. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 104, and a light chain comprising the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 106, and a light chain comprising the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:112, and a light chain comprising the amino acid sequence of SEQ ID NO:113. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:114, and a light chain comprising the amino acid sequence of SEQ ID NO:115. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:116, and a light chain comprising the amino acid sequence of SEQ ID NO:117. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:118, and a light chain comprising the amino acid sequence of SEQ ID NO:119. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:120, and a light chain comprising the amino acid sequence of SEQ ID NO:121. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:122, and a light chain comprising the amino acid sequence of SEQ ID NO:123. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:124, and a light chain comprising the amino acid sequence of SEQ ID NO:125. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:126, and a light chain comprising the amino acid sequence of SEQ ID NO:127. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:128, and a light chain comprising the amino acid sequence of SEQ ID NO:129. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:130, and a light chain comprising the amino acid sequence of SEQ ID NO:131. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:134, and a light chain comprising the amino acid sequence of SEQ ID NO:135. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:672, and a light chain comprising the amino acid sequence of SEQ ID NO:673. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:674, and a light chain comprising the amino acid sequence of SEQ ID NO:675. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:676, and a light chain comprising the amino acid sequence of SEQ ID NO:677. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:678, and a light chain comprising the amino acid sequence of SEQ ID NO:679. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:684, and a light chain comprising the amino acid sequence of SEQ ID NO:685. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:692, and a light chain comprising the amino acid sequence of SEQ ID NO:693. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:694, and a light chain comprising the amino acid sequence of SEQ ID NO:695. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:696, and a light chain comprising the amino acid sequence of SEQ ID NO:697. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:698, and a light chain comprising the amino acid sequence of SEQ ID NO:699. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:700, and a light chain comprising the amino acid sequence of SEQ ID NO:701. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:702, and a light chain comprising the amino acid sequence of SEQ ID NO:703. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:704, and a light chain comprising the amino acid sequence of SEQ ID NO:705. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:706, and a light chain comprising the amino acid sequence of SEQ ID NO:707. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:708, and a light chain comprising the amino acid sequence of SEQ ID NO:709. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:710, and a light chain comprising the amino acid sequence of SEQ ID NO:711. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:712, and a light chain comprising the amino acid sequence of SEQ ID NO:713. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:714, and a light chain comprising the amino acid sequence of SEQ ID NO:715. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:716, and a light chain comprising the amino acid sequence of SEQ ID NO:717. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:718, and a light chain comprising the amino acid sequence of SEQ ID NO:719. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:722, and a light chain comprising the amino acid sequence of SEQ ID NO:723. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:724, and a light chain comprising the amino acid sequence of SEQ ID NO:725. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:726, and a light chain comprising the amino acid sequence of SEQ ID NO:727. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:728, and a light chain comprising the amino acid sequence of SEQ ID NO:729. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:732, and a light chain comprising the amino acid sequence of SEQ ID NO:733. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:734, and a light chain comprising the amino acid sequence of SEQ ID NO:735. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:736, and a light chain comprising the amino acid sequence of SEQ ID NO:737. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:738, and a light chain comprising the amino acid sequence of SEQ ID NO:739. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:740, and a light chain comprising the amino acid sequence of SEQ ID NO:741. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:742, and a light chain comprising the amino acid sequence of SEQ ID NO:743. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:744, and a light chain comprising the amino acid sequence of SEQ ID NO:745. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:746, and a light chain comprising the amino acid sequence of SEQ ID NO:747. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:748, and a light chain comprising the amino acid sequence of SEQ ID NO:749. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:750, and a light chain comprising the amino acid sequence of SEQ ID NO:751. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:752, and a light chain comprising the amino acid sequence of SEQ ID NO:753. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:754, and a light chain comprising the amino acid sequence of SEQ ID NO:755. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:756, and a light chain comprising the amino acid sequence of SEQ ID NO:757. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:758, and a light chain comprising the amino acid sequence of SEQ ID NO:759. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:760, and a light chain comprising the amino acid sequence of SEQ ID NO:761. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:762, and a light chain comprising the amino acid sequence of SEQ ID NO:763. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:764, and a light chain comprising the amino acid sequence of SEQ ID NO:765. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:766, and a light chain comprising the amino acid sequence of SEQ ID NO:767. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:768, and a light chain comprising the amino acid sequence of SEQ ID NO:769. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:770, and a light chain comprising the amino acid sequence of SEQ ID NO:771. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:772, and a light chain comprising the amino acid sequence of SEQ ID NO:773. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:774, and a light chain comprising the amino acid sequence of SEQ ID NO:775. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:776, and a light chain comprising the amino acid sequence of SEQ ID NO:777.

In some embodiments, provided herein is an IL-23R binding protein comprising any of the anti-IL-23R antibodies described above. In some embodiments, the IL-23R binding protein is an antibody comprising two heavy chains and two light chains. In some embodiments, the IL-23R binding protein is an antibody comprising two heavy chains and two light chains, the two heavy chains comprise the same VH region, and the two light chains comprise the same VL region.

In a specific embodiment, there is provided an antibody or antigen-binding fragment thereof isolated according to the procedures and processes provided herein that does not exhibit specific or significant affinity or binding to IL-23R in a binding assay, or at least does not exhibit as described herein Binding or related affinities tested, or not, showed binding to the I23R ECD. These can be termed non-binders or weak binders. These antibodies provide for use as matching or related controls in any of a variety of assays or methods, including when used in combination with the IL23R binding antibodies shown herein. For example antibody I23RB5 does not show binding to IL-23R, but is utilized eg in the experiments provided herein (as shown in Figures 4 and 5) as a non-binder or weak binder, eg in this case as a control antibody. Antibodies have unique and novel sequences, including VH, HC, and H chain CDR sequences, and in many or most cases also unique VL, LC, and light chain CDR sequences. The following antibodies that do not significantly or putatively bind IL23R may be denoted as novel antibodies: I23RB5, I23RB6, I23RB8, I23RB9, I23RB10, I23RB80, I23RB101, I23RB104, I23RB149, I23RB189, I23RB273, I23RB278, I2 3RB328, I23RB329, I23RB330, and I23RB332.

These antibodies correspond to antibodies having the sequences shown below:

In some embodiments, the antibodies or antigen-binding fragments provided herein comprise HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO:136, and LCDR1, LCDR2, and LCDR3 set forth in SEQ ID NO:137. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:140, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:141. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:146, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:147. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:184, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:185. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:244, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:245. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:794, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:795. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:796, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:797. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:800, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:801. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:802, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:803. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:804, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:805. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:834, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:835. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:844, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:845. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:892, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:893. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:894, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:895. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:896, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:897. In some embodiments, the antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:898, and LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:899. In other embodiments, an antibody comprising the following is provided: HCDR1, which comprises SEQ ID NO: 270, 282, 300, 414, 594, 924, 930, 942, 948, 954, 1044, 1074, 1218, 1224, Any of 1230, and 1236 has at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96% %, 97%, 98%, 99%, or an amino acid sequence of 100% sequence identity; (ii) HCDR2 comprising the same sequence as SEQ ID NO: 271, 283, 301, 415, 595, 925, 931, 943 , 949, 955, 1045, 1075, 1219, 1225, 1231, and 1237 have at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, An amino acid sequence of 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, (iii) HCDR3 comprising the same sequence as SEQ ID NO: 272, 284, 302, 416, 596, 926, 932, 944, 950, 956, 1046, 1076, 1220, 1226, 1232, and 1238 have at least 75%, 80%, 85%, 86%, 87%, 88%, Amino acid sequences with 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity; (iv) LCDR1, It comprises at least 75%, 80% of any one of SEQ ID NO: 273, 285, 303, 417, 597, 927, 933, 945, 951, 957, 1047, 1077, 1221, 1227, 1233, and 1239 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence The amino acid sequence of identity; (v) LCDR2, it comprises and SEQ ID NO: 274,286,304,418,598,928,934,946,952,958,1048,1078,1222,1228,1234, and any of 1240 has at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or an amino acid sequence of 100% sequence identity; and/or (vi) LCDR3, which comprises the same sequence as SEQ ID NO: 275, 287, 305, 419, 599, 929, 935, Any of 947, 953, 959, 1049, 1079, 1223, 1229, 1235, and 1241 have at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% amino acid sequence identity. In some embodiments, there is provided an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 270, 271, and 272, respectively, and (ii) comprising VLs of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 273, 274, and 275, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 282, 283, and 284, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 285, 286, and 287, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 300, 301, and 302, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 303, 304, and 305, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:414, 415, and 416, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 417, 418, and 419, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:594, 595, and 596, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 597, 598, and 599, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 924, 925, and 926, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 927, 928, and 929, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:930, 931, and 932, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 933, 934, and 935, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 942, 943, and 944, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 945, 946, and 947, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 948, 949, and 950, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 951, 952, and 953, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 954, 955, and 956, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 957, 958, and 959, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1044, 1045, and 1046, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1047, 1048, and 1049, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1074, 1075, and 1076, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1077, 1078, and 1079, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1218, 1219, and 1220, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1221, 1222, and 1223, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1224, 1225, and 1226, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1227, 1228, and 1229, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1230, 1231, and 1232, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1233, 1234, and 1235, respectively. In some embodiments, provided herein is an antibody comprising: (i) a VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1236, 1237, and 1238, respectively, and (ii) VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1239, 1240, and 1241, respectively. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:136, and a VL comprising the amino acid sequence of SEQ ID NO:137. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:140, and a VL comprising the amino acid sequence of SEQ ID NO:141. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:146, and a VL comprising the amino acid sequence of SEQ ID NO:147. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:184, and a VL comprising the amino acid sequence of SEQ ID NO:185. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:244, and a VL comprising the amino acid sequence of SEQ ID NO:245. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:794, and a VL comprising the amino acid sequence of SEQ ID NO:795. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:796, and a VL comprising the amino acid sequence of SEQ ID NO:797. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:800, and a VL comprising the amino acid sequence of SEQ ID NO:801. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:802, and a VL comprising the amino acid sequence of SEQ ID NO:803. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:804, and a VL comprising the amino acid sequence of SEQ ID NO:805. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:834, and a VL comprising the amino acid sequence of SEQ ID NO:835. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:844, and a VL comprising the amino acid sequence of SEQ ID NO:845. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:892, and a VL comprising the amino acid sequence of SEQ ID NO:893. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:894, and a VL comprising the amino acid sequence of SEQ ID NO:895. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:896, and a VL comprising the amino acid sequence of SEQ ID NO:897. In some embodiments, an antibody or antigen-binding fragment provided herein comprises: a VH comprising the amino acid sequence of SEQ ID NO:898, and a VL comprising the amino acid sequence of SEQ ID NO:899.

In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 136 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 140 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 146 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 184 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:794 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:796 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:800 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO: 802 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:804 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:834 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:844 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:892 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:894 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:896 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% of the amino acid sequence of SEQ ID NO:898 , a VH domain of at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, and an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% VL domain of % sequence identity. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 136, and comprising an amine group of SEQ ID NO: 137 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 140, and comprising an amine group of SEQ ID NO: 141 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 146, and comprising an amine group of SEQ ID NO: 147 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO: 184, and comprising an amine group of SEQ ID NO: 185 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:244, and comprising an amine group of SEQ ID NO:245 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:794, and an amine group comprising SEQ ID NO:795 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:796, and an amine group comprising SEQ ID NO:797 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:800, and comprising an amine group of SEQ ID NO:801 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:802, and an amine group comprising SEQ ID NO:803 VL of the acid sequence. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:804, and comprising an amine group of SEQ ID NO:805 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:834, and comprising an amine group of SEQ ID NO:835 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:844, and an amine group comprising SEQ ID NO:845 VL of the acid sequence. In some embodiments, the antibodies or antigen-binding fragments provided herein bind to the same epitope as an antibody comprising: a VH comprising the amino acid sequence of SEQ ID NO:892, and comprising an amine group of SEQ ID NO:893 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:894, and an amine group comprising SEQ ID NO:895 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:896, and an amine group comprising SEQ ID NO:897 VL of the acid sequence. In some embodiments, an antibody or antigen-binding fragment provided herein binds to the same epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:898, and an amine group comprising SEQ ID NO:899 VL of the acid sequence.

In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:2, and a light chain comprising the amino acid sequence of SEQ ID NO:3. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:6, and a light chain comprising the amino acid sequence of SEQ ID NO:7. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:12, and a light chain comprising the amino acid sequence of SEQ ID NO:13. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:50, and a light chain comprising the amino acid sequence of SEQ ID NO:51. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:110, and a light chain comprising the amino acid sequence of SEQ ID NO:111. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:680, and a light chain comprising the amino acid sequence of SEQ ID NO:681. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:682, and a light chain comprising the amino acid sequence of SEQ ID NO:683. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:686, and a light chain comprising the amino acid sequence of SEQ ID NO:687. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:688, and a light chain comprising the amino acid sequence of SEQ ID NO:689. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:690, and a light chain comprising the amino acid sequence of SEQ ID NO:691. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:720, and a light chain comprising the amino acid sequence of SEQ ID NO:721. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:730, and a light chain comprising the amino acid sequence of SEQ ID NO:731. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:778, and a light chain comprising the amino acid sequence of SEQ ID NO:779. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:780, and a light chain comprising the amino acid sequence of SEQ ID NO:781. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:782, and a light chain comprising the amino acid sequence of SEQ ID NO:783. In some embodiments, the antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO:784, and a light chain comprising the amino acid sequence of SEQ ID NO:785.

Accordingly, in an aspect or embodiment of the invention including the methods and assays and kits provided herein, one or more of the non-binder or weak binder antibodies shown and provided above are included as controls. Non-binder or weak binder antibodies can be combined with other antibodies, including antibodies with one or more unique epitope bins, included as controls or to test binding to real IL-23R antigen, or to compare different or unique IL-23R epitope binding or For epitope characterization or comparison.

In some embodiments, the IL-23R binding protein comprises a specifically designated light chain (especially a consensus or common light chain, such as a common LC sequence, a common VL sequence, and/or a common set of light chain CDR1, CDR2, and CDR3 sequences) and antibodies with unique or different heavy chains (comprising unique or different HC sequences, VH sequences, and/or unique heavy chain CDR sets (CDR1, CDR2, and CDR3)). This antibody and such antibodies may have unique and distinct epitope binding (including grouping in different or the same epitope bins) and/or affinity characteristics as determined primarily by their heavy chain sequence(s) or even independently Judgment by this. As described herein, including in Tables 13, 14, and 15, detail the common light chain sequence and its unique heavy chain components in certain antibodies.

Antibodies, particularly human anti-human IL-23R antibodies, can be characterized as having identical LC, VL, and light chain CDR1, CDR2, and CDR3 sequences and grouped according to the following. The antibody identifier and VH sequence of each related antibody are provided. The heavy chain CDRs are provided in this application, including Table 9, and can be determined within the VH sequence by known and available methods and according to antibody standards. There are groups of antibodies in which the antibodies in each group share the same VL, LC, and light chain CDR1, CDR2, and CDR3 sequences, but have different heavy chain sequences. Antibodies are grouped by light chain consensus sequence: Group 1 - VL sequence SEQ ID NO: 1247, or CDR1, CR2, and CDR3 sequences thereof, and a VH sequence selected from the group consisting of: I23RB1 SEQ ID NO:786 I23RB2 SEQ ID NO:788 I23RB3 SEQ ID NO:790 I23RB4 SEQ ID NO:792 I23RB8 SEQ ID NO:800 I23RB9 SEQ ID NO:802 I23RB268 SEQ ID NO:824 I23RB270 SEQ ID NO: 828 I23RB291 SEQ ID NO:870 Group 2 - VL sequence SEQ ID NO: 1248, or CDR1, CR2, and CDR3 sequences thereof, and a VH sequence selected from the group consisting of: I23RB5 SEQ ID NO:794 I23RB266 SEQ ID NO:820 I23RB271 SEQ ID NO: 830 I23RB273 SEQ ID NO: 834 I23RB274 SEQ ID NO: 836 I23RB275 SEQ ID NO: 838 I23RB276 SEQ ID NO:840 I23RB277 SEQ ID NO: 842 I23RB279 SEQ ID NO: 846 I23RB281 SEQ ID NO:850 I23RB282 SEQ ID NO:852 I23RB284 SEQ ID NO: 856 I23RB286 SEQ ID NO:858 I23RB289 SEQ ID NO: 866 I23RB290 SEQ ID NO:868 I23RB292 SEQ ID NO:872 Group 3 - VL sequence SEQ ID NO: 1249, or the CDR1, CR2, and CDR3 sequences thereof, and a VH sequence selected from the group consisting of: I23RB6 SEQ ID NO:796 I23RB10 SEQ ID NO:804 Group 4 - VL sequence SEQ ID NO: 1250, or CDR1, CR2, and CDR3 sequences therein, and a VH sequence selected from the group consisting of: I23RB259 SEQ ID NO: 806 I23RB316 SEQ ID NO:880 Group 5 - VL sequence SEQ ID NO: 1251, or CDR1, CR2, and CDR3 sequences therein, and a VH sequence selected from: I23RB267 SEQ ID NO:822 I23RB269 SEQ ID NO: 826 I23RB272 SEQ ID NO: 832 I23RB278 SEQ ID NO:844 I23RB280 SEQ ID NO:848 I23RB283 SEQ ID NO: 854 I23RB287 SEQ ID NO:862 I23RB288 SEQ ID NO:864

For each of the above groups and specific antibodies, the heavy chain sequences HC, VH, and heavy chain CDR1, CDR2, and CDR3 contribute to and are responsible for differences in epitope binding and affinity between and/or among antibodies. sex. The heavy chain in each case determines the antibody's binding and affinity or uniqueness and epitope specificity and epitope differential binding. Heavy chain domain-only or VHH antibodies based on the heavy chain sequence (VH sequence, HC sequence, or CDR1, CDR2, and CDR3 sequence comprising the heavy chain) of any of these groupings of antibodies may be of particular interest, use, and application, And are the aspects and embodiments provided and described herein. In some embodiments, the IL-23R binding protein is a monoclonal antibody, including mouse, chimeric, humanized, or human antibodies. In some embodiments, the anti-IL-23R antibody is an antibody fragment, such as a scFv. In some embodiments, the IL-23R binding protein is a fusion protein comprising an anti-IL-23R antibody provided herein. In other embodiments, the IL-23R binding protein is a multispecific antibody comprising an anti-IL-23R antibody provided herein. Other exemplary IL-23R binding molecules are described in more detail in the following sections.

In some embodiments, an anti-IL-23R antibody or antigen binding protein according to any of the above embodiments may incorporate any of the features alone or in combination as described below. antibody fragment

As used herein, the term "antibody" also includes various antibody fragments thereof. Antibodies provided herein include, but are not limited to, immunoglobulin molecules and immunologically active portions of immunoglobulin molecules. The immunoglobulin molecules provided herein can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecules . In some embodiments, the antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is an IgG2, IgG3, or IgG4 antibody.

Variants and derivatives of antibodies include functional or antigen-binding fragments of antibodies that retain the ability to bind to antigen. Exemplary functional or antigen-binding fragments include: Fab fragments (e.g., antibody fragments comprising an antigen-binding domain and comprising a portion of a light chain and a heavy chain bridged by a disulfide bond); Fab' (e.g., comprising a single antigen-binding domain Fab' (for example, two Fab' molecules joined by an intrachain disulfide bond in the hinge region of the heavy chain; Fab 'molecules can be directed towards the same or different epitopes); bispecific Fabs (e.g., Fab molecules with two antigen binding domains, each of which can be directed to different epitopes); single chain comprising variable regions, also known as scFv (for example, variable epitope-binding regions of a single light and heavy chain of an antibody linked together by a chain of, for example, 10 to 25 amino acids); disulfide-bonded Fv or dsFv (for example, Single light and heavy chain variable epitopes of an antibody linked together by disulfide bonds); VHH or Nanobodies (e.g., only the variable epitopes or antigen-binding domains of the heavy chain of an antibody) ; camelized VH (e.g., a variable antigen-binding determining region of a single heavy chain of an antibody in which some of the amino acids at the VH interface are amino acids present in the heavy chain of a naturally occurring camelid antibody); bispecific scFv (e.g., a scFv or dsFv molecule with two antigen-binding domains, each of which can be directed to a different epitope); diabodies (e.g., when the VH domain of a first scFv is assembled with the VL domain of a second scFv, and a dimerized scFv formed when the VL domain of a first scFv is assembled with the VH domain of a second scFv; the two antigen-binding regions of a diabody can be directed towards the same or different epitopes); a triabody (e.g. a trimerized scFv, formed in a format similar to diabodies, but in which three antigen-binding domains are produced in a single complex; the three antigen-binding domains can be directed towards the same or different epitopes); four-chain antibodies (e.g., tetrameric scFv , formed in a form similar to a diabody, but in which four antigen-binding domains are produced in a single complex; the four antigen-binding domains can be directed towards the same or different epitopes); and the heavy chains alone or in any combination and /or other non-full-length portions of the light chain.

Nanobodies or VHH antibodies are single domain (heavy chain variable region VHH) antibodies (Ward, E.S. et al., Nature 341, 544-546 (1989)). Single domain antibodies were originally isolated from camelid animals and are interchangeably named camelid antibodies, nanobodies, or VHHs. VHH antibodies correspond to the variable region of the antibody heavy chain and have a very small size of about 15 kDa, hence the name "nanobody". The advantage of these antibody-derived molecules is their small size, which allows binding to cryptic epitopes inaccessible to whole antibodies. In the case of therapeutic applications, small molecular weight also means efficient penetration and fast washout. Both scFv and VHH Nanobodies can be linked to the Fc fragment of a desired species and retain their specificity and binding properties and are then called minibodies.

Nanobodies are small, low-molecular-weight, single-domain, heavy-chain-only antibodies. Due to their small size, the genes for these proteins can be easily cloned and manipulated for presentation on plastids or in integrated form, expression vectors, and the like. Thus, by using molecular cloning techniques, Nanobodies against multiple antigens or against different epitopes on a single antigen can be presented even on single or multiple constructs, and Nanobodies can be provided in vitro or in assays. Cells, target regions, or systemic circulation in in vivo studies.

Embodiments of the invention include antibody(s), including linked Nanobodies, such as multimeric and bispecific versions. Thus, two or more Nanobodies or sequences encoding two or more Nanobodies can be covalently linked via a linker sequence or any such other recognized and applicable means to form a pair of Nanobody(s). specific or multimeric form. In one embodiment, two different Nanobodies are linked. In one embodiment, the single Nanobody system is multimerized through linkage, which can be used to increase binding, avidity, and affinity. In one embodiment, two or more Nanobodies are linked, including Nanobodies directed against different IL-23R protein epitopes, such as epitope bins.

Described and provided herein are a number of IL-23R antibodies, particularly human phage library-derived antibodies, that have identical light chain VL and LCDR1, LCDR2, and LCDR3 sequences and unique heavy chain sequences, including unique and distinct HCDR1, HCDR2, and HCDR3 sequence. Despite the same light chain, these antibodies exhibited different binding affinities and binding characteristics for IL-23R, including the recognition of different epitopes, which were binned into different epitopes in the assays presented herein. The heavy chain sequences of these antibodies, especially the VHH sequences, and the heavy chain CDR1, CDR2, and CDR3 sequences are thus distinguishing features of these antibodies and contribute significantly to or cause differences therefrom. These antibodies show the importance of the heavy chain sequence, especially the heavy chain antigen binding domain. Furthermore, VHH antibodies or Nanobodies have also been shown to be of useful and applicable relevance. In a specific embodiment, provided herein is a VHH antibody comprising a VH sequence or comprising one or more of the CDRs shown in SEQ ID NO: 136-269, 786-899. In one embodiment, provided herein are VHH antibodies comprising a VH sequence or comprising one or more of the CDRs set forth in SEQ ID NOs: 786-899. In one embodiment, provided herein are VHH antibodies comprising a VH sequence or comprising one or more of the CDRs set forth in SEQ ID NO: 786-797, 800-807, 820-873, or 880-881.

Various techniques have been developed for the production of antibody fragments. Traditionally, such fragments have been derived by proteolytic digestion of intact antibodies (see, e.g., Morimoto et al. , 1992, J. Biochem. Biophys. Methods 24:107-17; and Brennan et al. , 1985, Science 229:81 -83). However, these fragments can now be produced directly by recombinant host cells. For example, Fab, Fv, and scFv antibody fragments can all be expressed in and secreted from E. coli or yeast cells, thus allowing the facile production of large quantities of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al. , 1992, Bio/Technology 10:163-67). According to another approach, F(ab')2 fragments can be isolated directly from recombinant host cell culture. Fab and F(ab')2 fragments with increased in vivo half-life of salvage receptor binding epitope residues are described, eg, in US Patent No. 5,869,046. Other techniques for producing antibody fragments will be apparent to those skilled in the art. In certain embodiments, the antibody is a single chain Fv fragment (scFv) (see eg, WO 93/16185; US Patent Nos. 5,571,894 and 5,587,458). Fv and scFv have intact binding sites lacking constant regions; thus, they may be suitable for reducing non-specific binding during in vivo use. scFv fusion proteins can be constructed to produce fusions of effector proteins at the amino or carboxyl termini of the scFv (see eg Borrebaeck ed. supra). Antibody fragments can also be "linear antibodies," as described in the references cited above. Such linear antibodies may be monospecific or multispecific, such as bispecific. Humanized Antibody

Antibodies described herein include humanized antibodies. Humanized antibodies, such as those disclosed herein, can be produced using various techniques known in the art, including but not limited to: CDR grafting (European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (European Patents EP 592,106 and EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al. , Protein Engineering 7(6):805-814 (1994); and Roguska et al. , PNAS 91:969-973 ( 1994)), chain shuffling (chain shuffling) (US Patent No. 5,565,332), and techniques disclosed in, for example, US Patent No. 6,407,213; US Patent No. 5,766,886; WO 9317105; Tan et al. , J. Immunol.169:1119 25 (2002); Caldas et al. , Protein Eng. 13(5):353-60 (2000); Morea et al. , Methods 20(3):267 79 (2000); Baca et al . , J. Biol.Chem.272(16):10678-84 (1997); Roguska et al. , Protein Eng. 9(10):895 904 (1996); Couto et al. , Cancer Res.55 (23 Supp):5973s- 5977s (1995); Couto et al. , Cancer Res.55(8):1717-22 (1995); Sandhu JS, Gene 150(2):409-10 (1994); and Pedersen et al . , J. Mol. Biol. 235(3):959-73 (1994). See also US Patent Publication No. US 2005/0042664 Al (February 24, 2005), the entire contents of each of which are incorporated herein by reference.

In some embodiments, the antibodies provided herein can be humanized antibodies that bind to IL-23R, including human IL-23R. For example, a humanized antibody of the present disclosure may comprise one or more of the CDRs shown in SEQ ID NO: 136-269, 786-899. In some embodiments, a humanized antibody can comprise one or more CDRs as set forth in the mouse antibodies provided herein, including antibodies derived by immunization, which include SEQ ID NOS: 136-269, and SEQ ID NO :784 to 785. Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody can have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are generally taken from an "import" variable domain. Humanization can be performed following, for example, Jones et al. , Nature 321:522-25 (1986); Riechmann et al. , Nature 332:323-27 (1988); and Verhoeyen et al. , Science 239:1534 -36 (1988), by substituting hypervariable region sequences for the corresponding sequences of human antibodies. In a specific embodiment, humanization of the antibodies provided herein is performed as described in Section 6, below.

In some cases, humanized antibodies are constructed by CDR grafting, wherein the amino acid sequences of the CDRs of a parental non-human antibody are grafted onto a human antibody framework. For example, Padlan et al. determined that only about one-third of the residues in the CDRs actually contact the antigen and referred to these as "specificity determining residues" or SDRs (Padlan et al. , FASEB J . 9:133-39 (1995)). In the technique of SDR grafting, only SDR residues are grafted onto human antibody frameworks (see eg Kashmiri et al. , Methods 36:25-34 (2005)).

The choice of human variable domains used to make humanized antibodies can be important in reducing antigenicity. For example, according to the so-called "best-fit" approach, the sequences of the variable domains of non-human antibodies are screened against the entire library of known human variable domain sequences. The human sequence closest to the non-human antibody can be chosen as the human framework for the humanized antibody (Sims et al. , J. Immunol. 151:2296-308 (1993); and Chothia et al. , J. Mol. Biol. 196:901-17 (1987)). Another approach uses a particular framework derived from the consensus sequence of all human antibodies belonging to a particular subgroup of light or heavy chains. The same architecture can be used for several different humanized antibodies (Carter et al. , Proc. Natl. Acad. Sci. USA 89:4285-89 (1992); and Presta et al. , J. Immunol.151:2623-32 (1993)). In some cases, the framework was derived from the consensus sequences of the most abundant human subclasses, _VL6 subgroup I ( _VL6I ) and _VH subgroup III ( _VHIII ). In another approach, human germline genes are used as the source of the framework regions.

In an alternative paradigm based on CDR comparison known as superhumanization, FR homology is irrelevant. The method consists of a comparison of the non-human sequence to a functional human germline gene repertoire. Next, genes encoding canonical structures that are identical or closely related to the murine sequence are selected. Next, within genes sharing canonical structures with non-human antibodies, those with the highest homology within the CDRs were selected as FR donors. Finally, non-human CDRs are grafted onto these FRs (see eg Tan et al. , J. Immunol. 169:1119-25 (2002)).

It is often further desirable that antibodies be humanized while retaining their affinity for antigen and other favorable biological properties. To this end, according to one method, humanized antibodies are prepared by a procedure of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those of ordinary skill in the art. Computer programs are used to illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. These include, for example, WAM (Whitelegg and Rees, Protein Eng. 13:819-24 (2002)), Modeller (Sali and Blundell, J. Mol. Biol. 234:779-815 (1993)), and the Swiss PDB Viewer ( Guex and Peitsch, Electrophoresis 18:2714-23 (1997)). Detection of such displays allows analysis of the likely role of the residues in the function of the candidate immunoglobulin sequence, eg, analysis of residues that affect the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in affecting antigen binding.

Another approach for antibody humanization is based on a measure of antibody humanness called Human Sequence Content (HSC). This method compares mouse sequences to a repertoire of human germline genes, and the difference is scored as HSC. Next, the target sequence is humanized by maximizing its HSC (rather than using a global identity measure) to generate multiple different humanized variants (Lazar et al. , Mol.Immunol.44 :1986-98 (2007)).

In addition to the methods described above, experimental methods can be used to generate and select humanized antibodies. Such methods include methods based on the use of enrichment techniques or high-throughput screening techniques to generate large libraries of humanized variants and select the best clones. Antibody variants can be isolated from phage, ribosome, and yeast display libraries and by bacterial colony selection (see, e.g., Hoogenboom, Nat. Biotechnol. 23:1105-16 (2005); Dufner et al. , Trends Biotechnol 24:523-29 (2006); Feldhaus et al. , Nat. Biotechnol. 21:163-70 (2003); and Schlapschy et al. , Protein Eng. Des. Sel. 17:847-60 (2004)) .

In the FR library approach, a collection of residue variants is introduced at a specific position in a FR, followed by library screening to select the FR that best supports the grafted CDR. Residues to be substituted may include some or all "Vernier" residues identified as likely to contribute to the CDR structure (see, e.g., Foote and Winter, J. Mol. Biol. 224:487-99 (1992)) , or from a more limited set of identified target residues (Baca et al. J. Biol. Chem. 272:10678-84 (1997)).

In FR shuffling (FR shuffling), the overall FR line is combined with non-human CDRs, rather than building a combinatorial library of selected residue variants (see e.g. Dall'Acqua et al. , Methods 36:43-60 (2005)) . A single-step FR shuffling procedure can be used. This procedure has been shown to be effective because the resulting antibodies exhibit improved biochemical and physicochemical properties, including enhanced expression, increased affinity, and thermal stability (see, e.g., Damschroder et al ., Mol. Immunol. 44:3049-60( 2007)).

The "humaneering" approach is based on the experimental identification of essential minimum specificity determinants (MSDs) and is based on the evaluation of sequence replacement and binding of non-human fragments into the human FR repertoire. This approach generally results in epitope retention and recognition by antibodies from multiple subclasses with different human V-segment CDRs.

The "human engineering" approach involves altering a non-human antibody or antibody fragment by making specific changes to the amino acid sequence of the antibody to produce in humans a modified antibody with reduced immunogenicity that retains the original non-human antibody. Desired binding properties of human antibodies. Generally, this technique involves classifying amino acid residues of non-human antibodies as "low risk", "moderate risk", or "high risk" residues. Classification is performed using an overall risk/reward calculation that assesses the expected benefit (e.g., in terms of immunogenicity in humans) of making a particular substitution, relative to the risk that the substitution will affect the folding of the resulting antibody . A given position (eg, low or medium risk) in a non-human antibody sequence can be selected by aligning the amino acid sequence from the variable region of the non-human antibody to the corresponding region of a specific or consensus human antibody sequence. Specific human amino acid residues substituted. Amino acid residues at low or medium risk positions in the non-human sequence can be substituted for corresponding residues in the human antibody sequence based on the alignment. Techniques for making human engineered proteins are described in more detail in Studnicka et al. , Protein Engineering 7:805-14 (1994); U.S. Patent Nos. 5,766,886; 5,770,196; 5,821,123; and 5,869,619 and PCT Publication WO 93/11794.

Composite human antibodies can be produced using, for example, Composite Human Antibody ^™ technology (Antitope Ltd., Cambridge, United Kingdom). To generate composite human antibodies, variable region sequences are designed from fragments of multiple human antibody variable region sequences in a manner that avoids T cell epitopes, thereby minimizing the immunogenicity of the resulting antibodies.

A deimmunized antibody is one in which T cell epitopes have been removed. Methods for making deimmunized antibodies have been described. See, eg, Jones et al., Methods Mol Biol. 525:405-23 (2009), xiv, and De Groot et al. , Cell. Immunol. 244:148-153 (2006)). Deimmunized antibodies comprise T cell depleted variable regions and human constant regions. Briefly, the variable region of the antibody is selected for, and T cell epitopes are then identified by testing overlapping peptides derived from the variable region of the antibody in a T cell proliferation assay. T cell epitopes were identified via in silico methods to recognize peptides that bind to human MHC class II. Mutations were introduced in the variable region to nullify binding to human MHC class II. The mutated variable regions are then used to generate deimmunized antibodies. Antibody variant

In some embodiments, amino acid sequence modification(s) of the antibodies that bind to IL-23R described herein are contemplated. For example, it may be desirable to optimize the binding affinity and/or other biological properties of the antibody, including but not limited to specificity, thermostability, expression level, effector function, glycosylation, reduced immunogenicity, or Solubility. Thus, in addition to the antibodies that bind to IL-23R described herein, it is contemplated that variants of the antibodies that bind to IL-23R described herein can be made. For example, antibody variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA, and/or by synthesizing the desired antibody or polypeptide. Those of ordinary skill in the art understand that amino acid changes can alter the post-translational program of an antibody. chemical modification

In some embodiments, the antibodies provided herein are chemically modified, eg, by covalent attachment of any type of molecule to the antibody. Antibody derivatives may include antibodies that have been chemically modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting/blocking groups, proteolytic cleavage, linkage Linked to cellular ligands or other proteins, or to one or more immunoglobulin domains (eg, Fc or a portion of an Fc). Any of a number of chemical modifications can be performed by known techniques including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, and the like. In addition, antibodies may contain one or more atypical amino acids.

In some embodiments, the antibodies provided herein are altered to increase or decrease the degree of glycosylation of the antibody. Adding or deleting glycosylation sites to an antibody is conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

When an antibody provided herein is fused to an Fc region, the carbohydrate to which it is attached can be altered. Native antibodies produced by mammalian cells generally comprise branched, biantennary oligosaccharides attached, usually by an N-linkage, to Asn297 of the CH2 domain of the Fc region. See, eg, Wright et al. TIBTECH 15:26-32 (1997). Oligosaccharides can include a variety of carbohydrates such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, and fucose attached to GlcNAc in the "backbone" of the biantennary oligosaccharide structure . In some embodiments, the oligosaccharides of the binding molecules provided herein can be modified to produce variants with certain improved properties.

In other embodiments, when an antibody provided herein is fused to an Fc region, the antibody variant provided herein can have a carbohydrate structure that lacks fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is calculated by calculating the fucose at Asn297 within the sugar chain relative to all sugar structures attached to Asn 297 measured by MALDI-TOF mass spectrometry as described in, for example, WO 2008/077546 (e.g., Composite, hybrid, and high mannose structures) were determined by the average amount of the sum. Asn297 refers to the asparagine residue located at approximately position 297 in the Fc region (EU numbering for Fc region residues); however, Asn297 may also be located approximately upstream or downstream of position 297 due to minor sequence variation in the antibody. ± 3 amino acids, i.e. between positions 294 and 300. Such fucosylated variants may have improved ADCC function. See, eg, US Patent Publication Nos. US 2003/0157108 and US 2004/0093621. Examples of publications on "defucosylated" or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; 03/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004). Examples of cell lines capable of producing afucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application US 2003/0157108; and WO 2004/056312, and knockout cell lines, such as α-1,6-fucosyltransferase gene FUT8 knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al. , Biotechnol. Bioeng ., 94(4):680-688 (2006); and WO2003/085107).

Further provided are binding molecules comprising an antibody provided herein that have bisecting oligosaccharides, eg, wherein the biantennary oligosaccharide attached to the Fc region is bisected by a GlcNAc. Such variants may have reduced fucosylation and/or improved ADCC function. Examples of such variants are described, eg, in WO 2003/011878 (Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al .). Variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such variants may have improved CDC function. Such variants are described eg in WO 1997/30087; WO 1998/58964; and WO 1999/22764.

In a molecule comprising the present antibody and an Fc region, one or more amino acid modifications may be introduced in the Fc region, thereby generating an Fc region variant. Fc region variants may comprise a human Fc region sequence (eg, a human IgGl, IgG2, IgG3, or IgG4 Fc region) comprising amino acid modifications (eg, substitutions) at one or more amino acid positions.

In some embodiments, the present application contemplates variants with some but not all effector functions, making the variants where the in vivo half-life of the binding molecule is important but certain effector functions (such as complement and ADCC) are not essential Desired candidates for harmful or harmful applications. In vitro and/or in vivo cytotoxicity assays can be performed to demonstrate reduction/depletion of CDC and/or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the binding molecule lacks FcγR binding (and thus likely lacks ADCC activity), but retains FcRn binding ability. A non-limiting example of an in vitro assay to assess ADCC activity of a molecule of interest is described in U.S. Patent No. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986 )) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); No. 5,821,337 (cf. Bruggemann, M. et al., J. Exp. Med. 166: 1351-1361 (1987)). Alternatively, nonradioactive assays can be used (see, e.g., ACTI ^™ Nonradioactive Cytotoxicity Assay for Flow Cytometry (Cell Technology, Inc. Mountain View, CA; and CytoTox ^96® Nonradioactive Cytotoxicity Assay (Promega, Madison, WI). ). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of the molecule of interest can be assessed in vivo, e.g., in an animal model, Such as disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q binding assays can also be performed to confirm that the antibody is unable to bind C1q and thus lacks CDC activity. See, eg, WO 2006/ 029879 and the C1q and C3c binding ELISA in WO 2005/100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al ., J. Immunol. Methods 202:163 (1996); Cragg, MS et al. al., Blood 101:1045-1052 (2003); and Cragg, MS and MJGlennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half-life determinations can also be performed using methods known in the art (See eg, Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006)).

Binding molecules with reduced effector function include those with substitutions of one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (US Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc in which residues 265 and 297 are substituted with alanine. Mutants (US Patent No. 7,332,581).

Certain variants with improved or impaired FcR binding have been described. (See eg, US Patent No. 6,737,056; WO 2004/056312, and Shields et al. , J. Biol. Chem. 9(2): 6591-6604 (2001 )).

In some embodiments, the variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, eg, substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues). In some embodiments, alterations made to the Fc region result in altered (i.e., improved or impaired) Clq binding and/or complement-dependent cytotoxicity (CDC), as described, for example, in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).

Binding molecules with increased half-life and improved neonatal Fc receptor (FcRn) binding are responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24 :249 (1994)), which is described in US2005/0014934A1 (Hinton et al.). These molecules comprise an Fc region with one or more substitutions therein that improve binding of the Fc region to FcRn. Such Fc variants include those residues in the Fc region: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, Substitutions at one or more of 382, 413, 424, or 434, for example substitution of Fc region residue 434 (US Pat. No. 7,371,826). See also Duncan & Winter, Nature 322:738-40 (1988); US Patent No. 5,648,260; US Patent No. 5,624,821; and WO 94/29351 for additional examples of Fc region variants.

In some embodiments, it is desirable to generate cysteine engineered antibodies wherein one or more residues of the antibody are substituted with a cysteine residue. In some embodiments, the substituted residue occurs at an accessible site of the antibody. By substituting these residues with cysteine, reactive sulfhydryl groups are thereby positioned at accessible sites of the antibody and can be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties parts to generate immunoconjugates, as further described herein. substitution, deletion, or insertion

A variation may be a substitution, deletion, or insertion of one or more codons encoding an antibody or polypeptide, resulting in a change in amino acid sequence compared to the original antibody or polypeptide. Sites of interest for substitution mutagenesis include CDRs and FRs.

Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as serine for leucine, eg, conservative amino acid substitutions. Standard techniques known to those of ordinary skill in the art can be used to introduce mutations into the nucleotide sequences encoding the molecules provided herein, including, for example, site-directed mutagenesis resulting in amino acid substitutions and PCR-mediated mutagenesis. Insertions or deletions can optionally range from about 1 to 5 amino acids. In certain embodiments, the substitution, deletion, or insertion comprises less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, relative to the original molecule Amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions. In one embodiment, the substitutions are conservative amino acid substitutions at one or more amino acid residues that are not expected to be essential. Permissible variation can be determined by systematically making insertions, deletions, or substitutions of amino acids in the sequence, and testing the resulting variants against the activity exhibited by the parental antibody.

Amino acid sequence insertions include amino-terminal and/or carboxy-terminal fusions ranging in length from one residue to polypeptides comprising multiple residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue.

Antibodies produced by conservative amino acid substitutions are included in the present disclosure. In conservative amino acid substitutions, an amino acid residue is replaced by an amino acid residue with a similarly charged side chain. As noted above, families of amino acid residues having side chains with similar charges have been defined in the art. These families include compounds with basic side chains (e.g. lysine, arginine, histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. glycine , asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g. alanine, valine, leucine, isoleucine acid, proline, phenylalanine, methionine, tryptophan), beta branched side chains (e.g. threonine, valine, isoleucine), and aromatic side chains (e.g. tyrosine , phenylalanine, tryptophan, histidine) amino acids. Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity. After mutagenesis, the encoded protein can be expressed and the activity of the protein can be determined. Conservative (eg, within amino acid groups having similar properties and/or side chains) substitutions may be made to maintain or not significantly alter properties. Exemplary substitutions are shown in Table 2 below. Table 2. Amino Acid Substitutions original residue Exemplary substitution original residue Exemplary substitution Ala (A) Val; Leu; Ile Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Arg (R) Lys; Gln; Asn Lys (K) Arg; Gln; Asn Asn (N) Gln; His; Asp, Lys; Arg Met (M) Leu; Phe; Ile Asp (D) Glu;Asn Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Cys (C) Ser; Ala Pro (P) Ala Gln (Q) Asn; Glu Ser (S) Thr Glu (E) Asp; Gln Thr (T) Val; Gly (G) Ala Trp (W) Tyr; Phe His (H) Asn; Gln; Lys; Arg Tyr (Y) Trp; Phe; Thr; Ser Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Val (V) Ile; Leu; Met; Phe; Ala; Norleucine

Amino acids can be grouped according to the similarity of their side chain properties (see e.g. Lehninger, Biochemistry 73-75 (2d ed. 1975)): (1) Nonpolar: Ala (A), Val (V), Leu (L) , Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) Uncharged polarities: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) Acidic: Asp (D), Glu (E); and (4) Basic: Lys (K), Arg (R) , His (H). Alternatively, naturally occurring residues can be grouped based on common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. For example, any cysteine residue not involved in maintaining the proper conformation of the antibody may also be substituted, for example with another amino acid such as alanine or serine, to improve the oxidative stability of the molecule and prevent Unusual crosslinking. Non-conservative substitutions entail exchanging members of one of these classes for the other class.

One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (eg, a humanized or human antibody). Typically, the resulting variant(s) selected for further study will have a modification (e.g. improvement) in certain biological properties (e.g. increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have Certain biological properties of the parent antibody are substantially retained. Exemplary substitutional variants are affinity matured antibodies, which can be conveniently generated, eg, using phage display based affinity maturation techniques such as those described herein. Briefly, one or more CDR residues are mutated and the variant antibodies are displayed on phage and screened for specific biological activity (eg, binding affinity).

Alterations (eg, substitutions) can be made in the CDRs, eg, to improve antibody affinity. Such changes may be in CDR "hotspots" (i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process) (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)) and/or SDR (a-CDR), and test the binding affinity of the resulting variant antibody or fragment thereof. Affinity maturation by construction and reselection from secondary libraries has been described, for example, in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, ( 2001)) described. In some embodiments of affinity maturation, diversity is introduced into variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide site-directed mutagenesis) . A secondary library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity involves CDR site-directed schemes, in which several CDR residues (eg, 4 to 6 residues at a time) are randomly grouped. CDR residues involved in antigen binding can be specifically identified using, for example, alanine scanning mutagenesis or model building. A more detailed description of affinity maturation is provided in the following sections.

In some embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative changes (eg, the conservative substitutions provided herein) can be made in the CDRs that do not substantially reduce binding affinity. In some embodiments of the variant antibody sequences provided herein, each CDR is unchanged, or contains no more than one, two, or three amino acid substitutions.

A useful method for identifying residues or regions of an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells, Science , 244:1081-1085 (1989). In this method, a residue or group of residues of interest (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and identified by neutral or negatively charged amino acids (e.g., alanine or poly alanine) to determine whether the interaction between the antibody and the antigen is affected. Further substitutions can be introduced at amino acid positions showing functional sensitivity to the initial substitution. Alternatively or additionally, the crystal structure of the antigen-antibody complex to identify contact points between antibody and antigen. Such contact residues and neighboring residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired property.

Amino acid sequence insertions include amino-terminal and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues . Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include fusions of the N- or C-terminus of the antibody to enzymes (eg, for ADEPT) or polypeptides that increase the serum half-life of the antibody.

Variations can be made using methods known in the art, such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (see, e.g., Carter, Biochem J. 237:1-7 (1986); and Zoller et al. , Nucl. Acids Res. 10:6487-500 (1982)), cassette mutagenesis (see, e.g., Wells et al. , Gene 34:315-23 (1985)), or other known techniques can be performed on the cloned DNA to produce antibody variant DNA. in vitro affinity maturation

In some embodiments, antibody variants with improved properties (such as affinity, stability, or expression level) compared to a parent antibody can be prepared by in vitro affinity maturation. Like natural prototypes, in vitro affinity maturation is based on the principles of mutation and selection. Antibody repertoires are displayed on the surface of organisms (eg, phage, bacteria, yeast, or mammalian cells) or associated (eg, covalently or non-covalently) with their encoding mRNA or DNA. Affinity selection of the displayed antibodies allows for the isolation of organisms or complexes carrying the genetic information encoding the antibodies. Two or three rounds of mutagenesis and selection using a display method such as phage display usually result in antibody fragments with affinities in the low nanomolar range. Affinity matured antibodies can have nanomolar or even picomolar affinities for the antigen of interest.

Phage display is a widely used method for displaying and selecting antibodies. Antibodies are displayed on the surface of Fd or M13 phage as fusions to phage coat proteins. Selection involves exposure to antigen to allow phage-displayed antibodies to bind to their targets, a procedure known as "panning." Phage bound to the antigen are recovered and used to infect bacteria to generate phage for further selection rounds. For reviews, see eg Hoogenboom, Methods. Mol. Biol. 178:1-37 (2002); and Bradbury and Marks, J. Immunol. Methods 290:29-49 (2004).

In yeast display systems (see, e.g., Boder et al. , Nat. Biotech. 15:553-57 (1997); and Chao et al. , Nat. Protocols 1:755-68 (2006)), antibodies can be expressed by Fused to the adhesion subunit Aga2p of the yeast lectin protein, it attaches to the yeast cell wall through a disulfide bond with Aga1p. Displaying the protein via Aga2p allows the protein to protrude away from the cell surface, minimizing potential interactions with other molecules on the yeast cell wall. Libraries are screened using magnetic separation and flow cytometry to select for antibodies with improved affinity or stability. Binding to the soluble antigen of interest is determined by labeling the yeast with biotinylated antigen and a secondary reagent such as streptavidin conjugated to a fluorophore. Variation in the surface expression of antibodies can be measured by immunofluorescent expression of hemagglutinin or c-Myc epitope tags flanking single chain antibodies (eg, scFv). Performance has been shown to correlate with the stability of the displayed protein, and thus antibodies can be selected for improved stability and affinity (see, e.g., Shusta et al. , J. Mol. Biol. 292:949-56 (1999)) . An additional advantage of yeast display is that the displayed proteins are folded in the endoplasmic reticulum of eukaryotic yeast cells, thereby exploiting endoplasmic reticulum chaperones and quality control mechanisms. Once maturation is complete, antibody affinity can be conveniently "titered" while displayed on the yeast surface, eliminating the need to express and purify individual strains. A theoretical limitation of surface display in yeast is that the size of functional libraries is potentially smaller than other display methods; however, recent methods use the mating system of yeast cells to establish a combinatorial diversity estimated to be ¹⁰ in size (see, e.g., U.S. Pat. Publication No. 2003/0186374; and Blaise et al. , Gene 342:211–18 (2004)).

In ribosome display, antibody-ribosome-mRNA (ARM) complexes are generated for selection in a cell-free system. DNA libraries encoding specific antibody libraries are genetically fused to spacer sequences lacking stop codons. This spacer sequence remains attached to the peptidyl tRNA in translation and occupies the ribosyl channel, and thus allows the protein of interest to protrude from the ribosome and fold. The resulting complex of mRNA, ribosome, and protein can bind to a surface-bound ligand, allowing simultaneous isolation of the antibody and its encoding mRNA by affinity capture of the ligand. The ribosome-bound mRNA is then reverse transcribed into cDNA, which can then undergo mutagenesis and be used in the next round of selection (see, eg, Fukuda et al. , Nucleic Acids Res. 34:e127 (2006)). In mRNA display, puromycin is used as an adapter molecule to establish a covalent bond between the antibody and the mRNA (Wilson et al. , Proc. Natl. Acad. Sci. USA 98:3750-55 (2001)).

Since these methods are performed entirely in vitro, they offer two major advantages over other selection techniques. First, the diversity of the library is not limited by the transformation efficiency of the bacterial cells, but only by the number of ribosomes and different mRNA molecules present in the test tube. Second, random mutations can be easily introduced after each selection round by, for example, non-proofreading polymerases, since there is no need to transform the library after any diversification step.

In some embodiments, mammalian display systems can be used.

Diversity can also be introduced into the CDRs of the antibody repertoire in a targeted manner or via random introduction. The former approach involves sequentially targeting all CDRs of an antibody via high or low degree of mutagenesis or targeting somatic hypermutation hotspots via isolation (see, e.g., Ho et al. , J. Biol. Chem. 280:607- 17 (2005)) or residues suspected of affecting affinity either on an experimental basis or for structural reasons. Diversity can also be introduced by replacing naturally diverse regions by DNA shuffling or similar techniques (see, e.g., Lu et al. , J. Biol. Chem. 278:43496-507 (2003); U.S. Pat. Nos. 5,565,332 and 6,989,250). Alternative techniques target hypervariable loops extending into framework region residues (see e.g. Bond et al. , J. Mol. Biol. 348:699-709 (2005)), employ loop deletions and insertions in the CDRs, or use Cross-based diversification (see eg, US Patent Publication No. 2004/0005709). Additional methods of generating diversity in CDRs are disclosed, eg, in US Patent No. 7,985,840. Further methods useful for generating antibody repertoires and/or antibody affinity maturation are disclosed, for example, in U.S. Patent Nos. 8,685,897 and 8,603,930, and U.S. Publication Nos. 2011/0183855, and 2009/0075378, each of which is incorporated herein by reference.

Screening of libraries can be accomplished by various techniques known in the art. For example, antibodies can be immobilized on various solid supports, columns, pins, or cellulose/poly(vinylidene fluoride) membranes/other filters, expressed on host cells attached to adsorption discs, or used for cell sorting , or conjugated to biotin for capture using streptavidin-coated beads, or in any other method for panning display libraries.

For a review of in vitro affinity maturation methods, see, eg, Hoogenboom, Nature Biotechnology 23:1105-16 (2005); Quiroz and Sinclair, Revista Ingeneria Biomedia 4:39-51 (2010); and references therein. Antibody modification

Covalent modification of antibodies is included within the scope of this disclosure. Covalent modification involves reacting targeted amino acid residues of the antibody with organic derivatizing agents capable of reacting with selected side chains or N- or C-terminal residues of the antibody. Other modifications include deamidation of glutamyl and asparaginyl residues to corresponding glutamyl and asparaginyl residues, respectively; hydroxylation of proline and lysine; serine Phosphorylation of hydroxyl groups of acyl or threonyl residues; methylation of α-amine groups of lysine, arginine, and histidine side chains (see, e.g., Creighton, Proteins: Structure and Molecular Properties 79 -86 (1983)); acetylation of N-terminal amines; and amidation of any C-terminal carboxyl groups.

Other types of covalent modification of antibodies included within the scope of the present disclosure include altering the native glycosylation pattern of an antibody or polypeptide as described above (see, e.g., Beck et al. , Curr. Pharm. Biotechnol. 9:482-501( 2008); and Walsh, Drug Discov. Today 15:773-80 (2010)), and linking the antibody to one of various non-proteinaceous polymers (eg, polyethylene glycol (PEG) , polypropylene glycol, or polyoxyalkylene): U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. Antibodies of the present disclosure that bind to IL-23R may also be genetically fused or joined to one or more immunoglobulin constant regions or portions thereof (e.g., Fc) to extend half-life and/or to confer known Fc-mediated effector functions .

Antibodies of the present disclosure that bind to IL-23R can also be modified to form chimeric molecules comprising fusions to another heterologous polypeptide or amino acid sequence such as an epitope tag (see, e.g., Terpe, Appl. Microbiol. Biotechnol. 60:523-33 (2003)) or the Fc region of an IgG molecule (see eg Aruffo, Antibody Fusion Proteins 221-42 (Chamow and Ashkenazi eds., 1999)) that binds to IL-23R.

Also provided herein are fusion proteins comprising an antibody of the present disclosure that binds to IL-23R and a heterologous polypeptide. In some embodiments, heterologous polypeptides genetically fused or chemically joined to the antibody can be used to target the antibody to cells having cell surface expressing IL-23R.

Also provided herein are panels of antibodies that bind to IL-23R antigens. In specific embodiments, the panels of antibodies have different on-rates for the IL-23R antigen, different off-rates, different affinities, and/or different specificities for the IL-23R antigen. In some embodiments, the panel comprises or consists of about 10 to about 1000 antibodies or more. Antibody panels can be used, for example, in 96-well or 384-well plates for assays such as ELISA. Other binding molecules comprising antibodies

In another aspect, provided herein is a binding molecule comprising an anti-IL-23R antibody provided herein. In some embodiments, the antibodies provided herein to IL-23R are part of other binding molecules. Exemplary binding molecules of the disclosure are described herein. fusion protein

In various embodiments, an antibody provided herein can be genetically fused or chemically conjugated to another agent, such as a protein-based entity. Antibodies can be chemically conjugated to the agent, or otherwise non-covalently conjugated to the agent. Agents can be peptides or antibodies (or fragments thereof).

Thus, in some embodiments, provided herein are recombinant fusions or chemical ligation (covalent or non-covalent) to heterologous proteins or polypeptides (or fragments thereof, e.g., about 10, about 20, about 30, about 40 about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, A polypeptide of about 450, or about 500 amino acids, or more than 500 amino acids) to produce antibodies to fusion proteins and uses thereof. In particular, provided herein are fusion proteins comprising an antigen-binding fragment (eg, CDR1, CDR2, and/or CDR3) of an antibody provided herein and a heterologous protein, polypeptide, or peptide.

In addition, the antibodies provided herein can be fused to a marker or "tag" sequence, such as a peptide, to facilitate purification. In specific embodiments, the tag or tag amino acid sequence is a hexahistidine peptide, a hemagglutinin ("HA") tag, and a "FLAG" tag.

Methods for fusing or conjugating moieties, including polypeptides, to antibodies are known (see, e.g., Arnon et al., Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy, in Monoclonal Antibodies and Cancer Therapy 243-56 (Reisfeld et al. eds., 1985); Hellstrom et al., Antibodies for Drug Delivery, in Controlled Drug Delivery 623-53 (Robinson et al. eds., 2d ed. 1987); Thorpe, Antibody Carriers of Cytotoxic Agents in Cancer Therapy : A Review, in Monoclonal Antibodies: Biological and Clinical Applications 475-506 (Pinchera et al. eds., 1985); Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy, in Monoclonal Antibodies for Cancer D detection and Therapy 303-16 (Baldwin et al. eds., 1985); Thorpe et al., Immunol. Rev. 62:119-58 (1982); U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053 5,447,851; 5,723,125; 5,783,181; 5,908,626; 5,844,095; and 5,112,946; EP 307,434; EP 367,166; 96/04388, WO 96/22024, WO 97/34631, and WO 99/04813; Ashkenazi et al., Proc. Natl. Acad. Sci. USA, 88: 10535-39 (1991); Traunecker et al., Nature, 331:84- 86 (1988); Zheng et al., J. Immunol. 154:5590-600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-41 (1992)).

Fusion proteins can be produced by, for example, techniques of gene shuffling, motif shuffling, exon shuffling, and/or codon shuffling (collectively referred to as "DNA shuffling"). DNA shuffling can be employed to alter the activity of the antibodies as provided herein, including, for example, antibodies with higher affinity and lower off-rates (see, e.g., U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and No. 5,837,458; Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998)). Antibodies, or encoded antibodies, may be altered by undergoing random mutagenesis by error-prone PCR, random nucleotide insertion, or other methods prior to recombination. A polynucleotide encoding an antibody provided herein can be recombined with one or more components, motifs, segments, parts, domains, fragments, etc. of one or more heterologous molecules.

In some embodiments, an antibody provided herein is conjugated to a second antibody to form an antibody heteroconjugate.

In various embodiments, the antibody is genetically fused to the agent. Gene fusion can be achieved by placing a linker (eg, a polypeptide) between the antibody and the agent. The linker can be a flexible linker.

In various embodiments, the antibody is genetically conjugated to the therapeutic molecule, wherein the hinge region connects the antibody to the therapeutic molecule.

Also provided herein are methods for making the various fusion proteins provided herein. Various methods described in Section 5.4 can also be used to make the fusion proteins provided herein.

In one embodiment, the fusion proteins provided herein are expressed recombinantly. Recombinant expression of the fusion proteins provided herein may require the construction of expression vectors containing polynucleotides encoding the proteins or fragments thereof. Once a polynucleotide encoding a protein provided herein or a fragment thereof is obtained, vectors for production of the molecule can be produced by recombinant DNA techniques using techniques well known in the art. Thus, described herein are methods for making proteins by expressing polynucleotides containing encoding nucleotide sequences. Methods well known to those of ordinary skill in the art can be used to construct expression vectors containing the coding sequence and appropriate transcriptional and translational control signals. Such methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Also provided are replicable vectors comprising a nucleotide sequence encoding a fusion protein provided herein, or fragments thereof, or CDRs operably linked to a promoter.

Expression vectors can be transferred to host cells by known techniques, and the transfected cells can be cultured by known techniques to produce fusion proteins provided herein. Accordingly, also provided herein are host cells containing a polynucleotide encoding a fusion protein provided herein, or a fragment thereof, operably linked to a heterologous promoter.

Various host expression vector systems can be used to express the fusion proteins provided herein. Such host expression systems represent not only vehicles by which the coding sequences of interest can be produced and subsequently purified, but also cells that can express the fusion proteins provided herein in situ when transformed or transfected with the appropriate nucleotide coding sequences. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant phage DNA, plastid DNA, or mucin DNA expression vectors containing coding sequences (e.g., Escherichia coli and B. subtilis ); yeast ( For example, Saccharomyces, Pichia), which are transformed with recombinant yeast expression vectors containing coding sequences; insect cell systems, which are infected with recombinant viral expression vectors (e.g., baculovirus) containing coding sequences; Infection with recombinant viral expression vectors containing coding sequences (e.g., cauliflower mosaic virus (CaMV), tobacco mosaic virus (TMV)) or recombinant plastid expression vectors containing sequences encoding antibodies (e.g. , Ti plastids) transformed plant cell systems; or mammalian cell systems (e.g., COS, CHO, BHK, 293, NSO, and 3T3 cells) with recombinant expression constructs containing Promoters from gene bodies of animal cells (eg, metallothionein promoter) or promoters derived from mammalian viruses (eg, adenovirus late promoter; vaccinia virus 7.5K promoter). Bacterial cells, such as E. coli, or eukaryotic cells, especially for expressing fully recombinant antibody molecules, can be used to express recombinant fusion proteins. For example, mammalian cells such as Chinese hamster ovary cells (CHO) in combination with a vector such as the major intermediate early gene promoter element from human cytomegalovirus are efficient expression systems for antibodies or variants thereof. In a specific embodiment, expression of the nucleotide sequences encoding the fusion proteins provided herein is regulated by a persistent promoter, an inducible promoter, or a tissue-specific promoter.

In bacterial systems, several expression vectors may be advantageously chosen depending on the intended use of the expressed fusion protein. For example, when large quantities of such fusion proteins are to be produced for use in producing pharmaceutical compositions for the fusion proteins, a carrier that directs high-level expression of the fusion protein product for ease of purification may be desirable. Such vectors include, but are not limited to, the Escherichia coli expression vector pUR278 (Ruther et al. , EMBO 12:1791 (1983)), wherein the coding sequences can be individually ligated in frame with the lac Z coding region into the vector, to produce fusion proteins; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. The pGEX vector can also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST). In general, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption and binding to the matrix glutathione agarose beads followed by elution in the presence of free glutathione. The pGEX vector is designed to include a thrombin or Factor Xa protease cleavage site, allowing the release of the selected gene product of interest from the GST moiety.

In mammalian host cells, a variety of viral-based expression systems are available. Where adenovirus is used as an expression vector, the coding sequence of interest can be linked to an adenovirus transcription/translation control complex, such as the late promoter and tripartite leader sequence. This chimeric gene can then be inserted into the adenoviral genome by in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e.g., the El or E3 region) will result in a recombinant virus that is viable in the infected host and capable of expressing the fusion protein (see, for example, Logan & Shenk, Proc. Natl. Acad. Sci. USA 8 1:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of various origins, both natural or synthetic. Expression efficiency can be enhanced by including appropriate transcriptional enhancer elements, transcriptional terminators, and the like. (See eg, Bittner et al. , Methods in Enzymol. 153:51-544 (1987)).

In addition, host cell strains can be selected that modulate the expression of the inserted sequence or that modify and process the gene product in the specific manner desired. Such modification (eg, glycosylation) and processing (eg, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure correct modification and processing of the foreign protein expressed. For this purpose, eukaryotic host cells possessing the cellular machinery for proper processing of primary transcripts, glycosylation, and phosphorylation of gene products can be used. Such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NSO (murine myeloma cell lines, which are not endogenous production of any immunoglobulin chain), CRL7O3O, and HsS78Bst cells.

For long-term, high-yield production of recombinant proteins, stable expression can be utilized. For example, cell lines can be engineered to stably express fusion proteins. Instead of using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoters, enhancers, sequences, transcription terminators, polyadenylation sites, etc.) Transformation of selected markers. Following the introduction of foreign DNA, the engineered cells can be allowed to grow in concentrated media for 1 to 2 days, and then switched to selective media. Selectable markers in recombinant plastids confer resistance to selection and allow cells to stably integrate the plastids into their chromosomes and grow to form foci of cells, which in turn can be colonized and expanded into cell lines. This method can be advantageously used to engineer cell lines expressing fusion proteins. Such engineered cell lines may be particularly useful for screening and evaluating components that interact directly or indirectly with binding molecules.

A number of selection systems can be used including, but not limited to, herpes simplex virus thymidine kinase (Wigler et al. , Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad.Sci.USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al. , Cell 22:8-17 (1980)) genes, which can be used for tk-, hgprt- , or aprt-cell. In addition, antimetabolite resistance can be used as a basis for selection of the following genes: dhfr , which confers resistance to methotrexate (Wigler et al. , Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al. , Proc. Natl.Acad.Sci.USA 78:1527 (1981)); gpt , which confers resistance to mycophenolic acid (Mulligan & Berg, Proc.Natl.Acad.Sci.USA 78:2072 ( 1981)); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993 ); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIB TECH 11(5):l55-2 15 (1993) ); and hygro , which confers resistance to hygromycin (Santerre et al. , Gene 30:147 (1984)). Methods generally known in the field of recombinant DNA technology can be routinely applied to select desired recombinant clones and such methods are described, for example, in Ausubel, et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and Dracopoli et al. (eds.), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994 ), Chapters 12 and 13; Colberre-Garapin et al. , J. Mol. Biol. 150:1 (1981), the entire contents of which are incorporated herein by reference.

Expression levels of fusion proteins can be increased by vector amplification (for review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3 (Academic Press, New York, 1987)). When the marker in the vector system expressing the fusion protein is amplifiable, increasing the level of inhibitor present in the host cell culture will increase the copy number of the marker gene. Since the amplified region is associated with the fusion protein gene, production of the fusion protein will also increase (Crouse et al. , Mol. Cell. Biol. 3:257 (1983)).

Host cells can be co-transfected with the various expression vectors provided herein. The vectors may contain identical selectable markers to enable equal expression of separately encoded polypeptides. Alternatively, a single vector encoding and capable of expressing multiple polypeptides may be used. The coding sequence may comprise cDNA or genomic DNA.

Once the fusion proteins provided herein have been produced by recombinant expression, they can be purified by any method known in the art for purifying polypeptides (e.g., immunoglobulin molecules), such as by chromatography (e.g., ion exchange, affinity (particularly after protein A by affinity for specific antigens), size screening column chromatography, and kappa selection affinity chromatography), centrifugation, differential solubility, or by any other method for Standard technique for protein purification. In addition, the fusion protein molecules provided herein can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification. immune conjugate

In some embodiments, the present disclosure also provides immunoconjugates comprising an anti-IL-23R antibody described herein conjugated to any of the following: one or more cytotoxic agents (such as chemotherapeutics or drugs), growth Inhibitors, toxins (eg, protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioisotopes.

In some embodiments, the immunoconjugate is an antibody drug conjugate (ADC), wherein the antibody is conjugated to one or more drugs, including but not limited to maytanoids (see U.S. Pat. Nos. 5,208,020, 5,416,064 No., and European Patent No. EP 0 425 235 B1); auristatins, such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Patent Nos. 5,635,483 and 5,780,588 and 7,498,298 No.); dolastatin; calicheamicin or its derivatives (see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, Nos. 5,773,001, and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-2928 (1998)); anthracyclines ( anthracycline), such as daunomycin or doxorubicin (see Kratz et al., Current Med. Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000) ; Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and US Patent No. 6,630,579) ; methotrexate; vindesine; taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecene; and CC1065.

In some embodiments, the immunoconjugate comprises an antibody described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A-chain (from Pseudomonas aeruginosa), ricin A-chain, gallinin A-chain, modeccin A-chain, alpha-sarcin, tung tree (Aleurites fordii) protein, carnation (dianthin) protein, pokeweed (Phytolacca americana) protein (PAPI, PAPII, and PAP-S), bitter melon (momordica charantia) inhibitor, curcin, crotonin (crotin), sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, ionomycin ( enomycin), and tricothecene.

In some embodiments, an immunoconjugate comprises an antibody described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include At ²¹¹ , I ¹³¹ , I ¹²⁵ , Y ⁹⁰ , Re ¹⁸⁶ , Re ¹⁸⁸ , Sm ¹⁵³ , Bi ²¹² , P ³² , Pb ²¹² , and radioactive isotopes of Lu. When radioactive conjugates are used for detection, they may contain radioactive atoms for scintigraphic studies, such as tc99m or I123, or for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging (mri)). Spin labels, such as the same iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron.

Conjugates of antibodies and cytotoxic agents can be made using various bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl -4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), imidoester (imidoester) bis Functional derivatives (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as valeryl Dialdehydes), bis-azide compounds (such as bis(p-azidobenzoyl)hexamethylenediamine), dinitrogen derivatives (such as bis(p-diazobenzoyl)-ethylenediamine), diisocyanates ( such as toluene 2,6-diisocyanate), and bis-reactive fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO94/11026.

The linker may be a "cleavable linker" that facilitates release of the conjugated agent in the cell, although non-cleavable linkers are also contemplated herein. Linkers useful in the conjugates of the present disclosure include, but are not limited to, acid-labile linkers (e.g., hydrazone linkers), disulfide-containing linkers, peptidase-sensitive linkers (e.g., containing amino acids (e.g., valamine acid and/or citrulline), such as citrulline-valine or phenylalanine-lysine), photolabile linkers, dimethyl linkers, thioether linkers, or engineered Hydrophilic linker to escape multidrug transporter-mediated resistance.

Immunoconjugates or ADCs herein contemplate, but are not limited to, such conjugates prepared with crosslinker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which is commercially available (eg, from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).

基胺螢光素、丹磺醯氯、或藻紅素；發光材料，諸如但不限於魯米諾；生物發光材料，諸如但不限於螢光素酶、蟲螢光素、或水母素；化學發光材料，諸如225Acγ發射性、鄂惹發射性(Auger-emitting)、β發射性、α發射性、或正電子發射性放射性同位素。在一些實施例中，經接合之抗體係用於（多個）篩選目的。在一些實施例中，篩選方法係經接合之抗體之庫的高通量篩選。在一些實施例中，經接合之抗體係用於標記或標示細胞或細胞性目標或抗原以進行診斷、篩選、靶向、單離、定量、或其他此類目的或應用。在一些實施例中，可在一或多個此類應用、篩選方法、等中組合利用獨特或不同抗體，包括接合或融合至不同診斷分子之抗體。 多核苷酸 In other embodiments, the antibodies provided herein are conjugated or recombinantly fused to, for example, a diagnostic molecule. Such diagnosis and detection can be accomplished, for example, by coupling antibodies to detectable substances, including but not limited to various enzymes such as but not limited to horseradish peroxidase, alkaline phosphatase, beta-galactoside Enzymes, or acetylcholinesterase; prosthetic groups, such as but not limited to streptavidin/biotin or avidin/biotin; fluorescent materials, such as but not limited to umbelliferone, luciferin, luciferin Thiocyanate, Rose Bengal, Dichlorotritri

Aminoluciferin, dansyl chloride, or phycoerythrin; luminescent materials, such as, but not limited to, luminol; bioluminescent materials, such as, but not limited to, luciferase, luciferin, or aequorin; chemical Luminescent materials, such as 225Ac gamma-emitting, Auger-emitting, beta-emitting, alpha-emitting, or positron-emitting radioisotopes. In some embodiments, conjugated antibody lines are used for screening purpose(s). In some embodiments, the screening method is through high-throughput screening of libraries of conjugated antibodies. In some embodiments, conjugated antibodies are used to label or label cells or cellular targets or antigens for diagnostic, screening, targeting, isolation, quantification, or other such purposes or applications. In some embodiments, unique or different antibodies may be utilized in combination in one or more of such applications, screening methods, etc., including antibodies conjugated or fused to different diagnostic molecules. polynucleotide

In certain embodiments, the present disclosure provides polynucleotides encoding the present antibodies that bind to IL-23R and fusion proteins comprising antibodies that bind to IL-23R described herein. A polynucleotide of the present disclosure can be in the form of RNA or in the form of DNA. DNA includes cDNA, genomic DNA, and synthetic DNA; and can be double-stranded or single-stranded, and if single-stranded, can be coding or non-coding (antisense). In some embodiments, the polynucleotide is in the form of cDNA. In some embodiments, the polynucleotide is a synthetic polynucleotide.

The present disclosure further pertains to variants of the polynucleotides described herein, wherein the variant encodes, for example, a fragment, analog, and/or derivative of an antibody of the present disclosure that binds to IL-23R. In certain embodiments, the present disclosure provides a polynucleotide comprising a polynucleotide having at least about 75% identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 95% identity, And in some embodiments a polynucleotide of at least about 96%, 97%, 98%, or 99% identical nucleotide sequence: a polynucleotide encoding an antibody of the present disclosure that binds to IL-23R. As used herein, the phrase "a polynucleotide having a nucleotide sequence that is at least, e.g., 95% "identical" to a reference nucleotide sequence" is intended to mean that, except that the polynucleotide sequence may include each The nucleotide sequence of the polynucleotide is identical to the reference sequence except for at most five point mutations in a count of 100 nucleotides. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or the reference The number of nucleotides at which at most 5% of the total nucleotides in the sequence are inserted into the reference sequence. These mutations of the reference sequence may occur at or anywhere between the 5' or 3' terminal positions of the reference nucleotide sequence and are individually interspersed between nucleotides of the reference sequence or at Within the reference sequence are one or more contiguous groups.

A polynucleotide variant may contain changes in coding regions, non-coding regions, or both. In some embodiments, polynucleotide variants contain changes that result in silent substitutions, additions, or deletions that do not alter the property or activity of the encoded polypeptide. In some embodiments, polynucleotide variants comprise silent substitutions that result in no change in the amino acid sequence of the polypeptide (due to genetic code degeneracy). Polynucleotide variants can be produced for various reasons, such as optimizing codon representation for a particular host (ie, changing codons in human mRNA to those preferred by a bacterial host such as E. coli). In some embodiments, polynucleotide variants comprise at least one silent mutation in a non-coding or coding region of the sequence.

In some embodiments, polynucleotide variants are produced to modulate or alter the expression (or expression level) of the encoded polypeptide. In some embodiments, polynucleotide variants are produced to increase expression of the encoded polypeptide. In some embodiments, polynucleotide variants are produced to reduce expression of the encoded polypeptide. In some embodiments, a polynucleotide variant has an increased expression of the encoded polypeptide as compared to a parental polynucleotide sequence. In some embodiments, a polynucleotide variant has a reduced representation of the encoded polypeptide as compared to a parental polynucleotide sequence.

Also provided are vectors comprising the nucleic acid molecules described herein. In one embodiment, nucleic acid molecules can be incorporated into recombinant expression vectors. The disclosure provides recombinant expression vectors comprising any of the nucleic acids of the disclosure. As used herein, the term "recombinant expression vector" refers to a genetically modified oligonucleotide or polynucleotide construct, when the construct comprises a nucleus encoding an mRNA, protein, polypeptide, or peptide nucleotide sequence and the vector allows the host cell to express the mRNA, protein, polypeptide, or peptide when contacted with the cell under conditions sufficient to allow expression of the mRNA, protein, polypeptide, or peptide in the cell. The vectors described herein do not occur in nature in their entirety; however, portions of the vectors may occur in nature. The recombinant expression vector may comprise any type of nucleotide, including but not limited to DNA and RNA, which may be single- or double-stranded, synthetic or partially obtained from natural sources, and which may contain natural, non-natural, or Altered nucleotides. Recombinant expression vectors may contain naturally occurring or non-naturally occurring internucleoside linkages, or both types of linkages. Non-naturally occurring or altered nucleotide or internucleoside linkages do not prevent transcription or replication of the vector.

In one embodiment, the recombinant expression vector of the present disclosure can be any suitable recombinant expression vector, and can be used for transformation or transfection of any suitable host. Suitable vectors include those designed for propagation and amplification or for expression or both, such as plasmids and viruses. Vectors can be selected from the group consisting of: pUC series (Fermentas Life Sciences, Glen Burnie, Md.), pBluescript series (Stratagene, LaJolla, Calif.), pET series (Novagen, Madison, Wis.), pGEX series ( Pharmacia Biotech, Uppsala, Sweden), and pEX series (Clontech, Palo Alto, Calif.). Phage vectors such as λGT10, λGT11, λEMBL4, and λNM1149, λZapII (Stratagene) can be used. Examples of plant expression vectors include pBI01, pBI01.2, pBI121, pBI101.3, and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo (Clontech). The recombinant expression vector may be a viral vector, such as a retroviral vector, such as a gamma retroviral vector.

In one embodiment, recombinant expression vectors are prepared using standard recombinant DNA techniques as described, eg, in Sambrook et al., supra, and Ausubel et al., supra. Constructs of expression vectors can be prepared as circular or linear to contain a replication system functional in prokaryotic or eukaryotic host cells. Replication systems can be derived from, for example, ColE1, SV40, 2µplastids, lambda, bovine papilloma virus, and the like.

Recombinant expression vectors may optionally contain regulatory sequences such as transcriptional and translational start and stop codons specific to the type of host (e.g., bacterial, plant, fungal, or animal) into which the vector is to be introduced, and vectors are contemplated to be DNA-based or based on RNA.

Recombinant expression vectors may include one or more marker genes that allow selection of transformed or transfected hosts. Marker genes include biocide resistance (eg, resistance to antibiotics, heavy metals, etc.), complementation in an auxotrophic host to provide prototrophy, and the like. Suitable marker genes for such expression vectors include, for example, neomycin/G418 resistance gene, histidinol x resistance gene, histidinol resistance gene, tetracycline resistance gene, and ampicillin resistance gene.

Recombinant expression vectors may contain native or normative promoters operably linked to the nucleotide sequences of the present disclosure. The choice of promoters, eg, strong, weak, tissue specific, inducible, and developmental specific, is within the ordinary knowledge of the art. Similarly, combining nucleotide sequences and promoters is also common knowledge in the art. The promoter can be a non-viral promoter or a viral promoter, such as the cytomegalovirus (CMV) promoter, the RSV promoter, the SV40 promoter, or the promoter found in the long terminal repeat of murine stem cell virus.

Recombinant expression vectors can be designed for transient expression, or for stable expression, or both. Likewise, recombinant expression vectors can be produced for constitutive or inducible expression.

In addition, recombinant expression vectors can be manufactured to include suicide genes. As used herein, the term "suicide gene" refers to a gene that causes the death of cells expressing the suicide gene. A suicide gene may be a gene that confers sensitivity to an agent (eg, a drug) in a cell expressing the gene and causes the cell to die when the cell is contacted or exposed to the agent. Suicide genes are known in the art and include, for example, the Herpes Simplex Virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase .

In certain embodiments, polynucleotides are isolated. In certain embodiments, polynucleotides are substantially pure.

Host cells comprising the nucleic acid molecules described herein are also provided. A host cell can be any cell that contains a heterologous nucleic acid. A heterologous nucleic acid can be a vector (eg, an expression vector). For example, a host cell may be a cell from any organism that has been selected, modified, transformed, grown, used, or manipulated in any way for the production of material by the cell, such as by expression of genes, DNA, or RNA by the cell sequence, protein or enzyme. An appropriate host can be determined. For example, host cells can be selected based on the vector backbone and the desired outcome. For example, plastids or cosmids can be introduced into prokaryotic host cells for replication of several types of vectors. Bacterial cells such as, but not limited to, DH5α, JM109, and KCB, ^SURE® competent cells, and SOLOPACK Gold cells can be used as host cells for vector replication and/or expression. In addition, bacterial cells such as E. coli LE392 can be used as host cells for phage viruses. Eukaryotic cells that can be used as host cells include, but are not limited to, yeast (eg, YPH499, YPH500, and YPH501), insects, and mammals. Examples of mammalian eukaryotic host cells for vector replication and/or expression include, but are not limited to, HeLa, NIH3T3, Jurkat, 293, COS, Saos, PC12, SP2/0 (American Type Culture Collection (ATCC), Manassas, VA, CRL-1581), NS0 (European Cell Conservation Center (ECACC), Salisbury, Wiltshire, UK, ECACC No. 85110503), FO (ATCC CRL-1646), and Ag653 (ATCC CRL-1580) murine cell lines. An exemplary human myeloma cell line is U266 (ATCC CRL-TIB-196). Other useful cell lines include those derived from Chinese Hamster Ovary (CHO) cells, such as CHO-K1SV (Lonza Biologics, Walkersville, MD), CHO-K1 (ATCC CRL-61 ), or DG44. Antibody preparation and production method

Methods of making antibodies have been described. See, eg, Els Pardon et al, Nature Protocol , 9(3): 674 (2014). Antibodies (such as scFv fragments) can be obtained using methods known in the art, such as by immunizing camelid species such as camels or llamas and obtaining fusionomas therefrom, or by using molecular biology methods known in the art Techniques Cloning of antibody repertoires and subsequent selection of individual clones of unselected repertoires by ELISA or by selection using phage display.

Antibodies provided herein can be produced by culturing cells transformed or transfected with a vector containing antibody-encoding nucleic acid. Polynucleotide sequences encoding the polypeptide components of the antibodies of the present disclosure can be obtained using standard recombinant techniques. Desired polynucleotide sequences can be isolated and sequenced from antibody producing cells such as fusionoma cells or B cells. Alternatively, polynucleotides can be synthesized using nucleotide synthesizers or PCR techniques. Once obtained, the sequence encoding the polypeptide is inserted into a recombinant vector capable of replicating and expressing the heterologous polynucleotide in a host cell. Many vectors that are available and known in the art can be used for the purposes of this disclosure. Selection of an appropriate vector will depend primarily on the size of the nucleic acid to be inserted into the vector, and the particular host cell to be transformed by the vector. Suitable host cells for expressing the antibodies of the present disclosure include prokaryotes (such as Archaebacteria and Eubacteria, including Gram-negative or Gram-positive organisms), eukaryotes (such as filamentous fungi or yeast), invertebrate cells (such as insect or plant cells), and vertebrate cells (such as mammalian host cell lines). The host cell lines are transformed with the expression vectors described above and cultured in conventional nutrient media adapted to induce promoters, select for transformants, or amplify genes encoding desired sequences. Antibodies produced by host cells are purified using standard protein purification methods known in the art.

Methods for antibody production (including vector construction, expression, and purification) are further described in Plückthun et al. , Antibody Engineering: Producing antibodies in Escherichia coli: From PCR to fermentation 203-52 (McCafferty et al. eds., 1996 ); Kwong and Rader, E. coli Expression and Purification of Fab Antibody Fragments , in Current Protocols in Protein Science (2009); Tachibana and Takekoshi, Production of Antibody Fab Fragments in Escherichia coli , in Antibody Expression and Production (Al-Rubai ed ., 2011); and Therapeutic Monoclonal Antibodies: From Bench to Clinic (An ed., 2009).

Of course, it is contemplated that anti-IL-23R antibodies can be prepared using alternative methods well known in the art. For example, appropriate amino acid sequences, or portions thereof, can be produced by direct peptide synthesis using solid-phase techniques (see, e.g., Stewart et al. , Solid-Phase Peptide Synthesis (1969); and Merrifield, J. Am. Chem. Soc. 85:2149-54 (1963)). In vitro protein synthesis can be performed using manual techniques or by automation. Various parts of an anti-IL-23R antibody can be chemically synthesized separately and combined using chemical or enzymatic methods to produce the desired anti-IL-23R antibody. Alternatively, antibodies can be purified from cells or body fluids (such as milk) of transgenic animals engineered to express antibodies, as disclosed in, eg, US Patent Nos. 5,545,807 and 5,827,690. polyclonal antibody

Polyclonal antibodies in animals are usually raised by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and adjuvant. Use of bifunctional or derivatizing agents such as maleimidobenzyloxysulfosuccinimide (via cysteine residue linkage), N-hydroxysuccinimide (via lysine Acid residues), glutaraldehyde, succinic anhydride, SOCl ₂ , or R ¹ N═C═NR (wherein R and R ¹ are independently lower alkyl groups), conjugating the relevant antigen to an immunogenic species in the species to be immunized Original proteins such as keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitors may be useful. Examples of adjuvants that may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphatidyl A, synthetic trehalose dicorynomycolate). Immunization protocols can be selected by those of ordinary skill in the art without undue experimentation.

For example, animals are immunized against antigen, by combining, for example, 100 µg or 5 µg of protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. The original conjugate, or derivative, is immune. One month later, animals are boosted by subcutaneous injection at multiple sites with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant. Seven to fourteen days later, blood was drawn from the animals and the antibody titer of the serum was assayed. Strengthen the animal until the force value reaches a plateau. Conjugates can also be made as protein fusions in recombinant cell culture. In addition, agglutinating agents such as alum are suitable to enhance the immune response. monoclonal antibody

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translational modifications (e.g., isomerization, amidation) that may be present in minor amounts of. Thus, the modifier "monoclonal" indicates the characteristic that the antibody is not a mixture of discrete antibodies.

For example, monoclonal antibodies can be produced using the fusionoma method first described by Kohler et al ., Nature, 256:495 (1975), or can be produced by recombinant DNA methods (US Patent No. 4,816,567).

In the fusionoma approach, an appropriate host animal is immunized to induce lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form fusionoma cells (Goding, Monoclonal Antibodies: Principles and Practice , pp. 59-103 (Academic Press, 1986).

Immunizing agents will generally include antigenic proteins or fusion variants thereof. Goding, Monoclonal Antibodies: Principles and Practice , Academic Press (1986), pp. 59-103. Immortalized cell lines are usually transformed mammalian cells. Fusoma cells so prepared are inoculated and grown in a suitable medium preferably containing one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. Preferred immortalized myeloma cells are those that fuse efficiently, support stable, high-volume production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.

Assay of monoclonal antibodies against antigens produced in culture medium of fusion tumor cells. The presence of monoclonal antibodies against desired antigens can be assayed in culture medium of fusionoma cells. Such techniques and assays are known in the art. For example, binding affinity can be determined by Scatchard analysis (Munson et al ., Anal. Biochem., 107:220 (1980)).

After identification of fusionoma cells producing antibodies with the desired specificity, affinity, and/or activity, the colonies can be sub-selected by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, fusionoma cells can grow as tumors in mammals.

Monoclonal antibodies secreted by the subclones are suitable for extraction from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-agarose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. , ascites, or serum separation.

Monoclonal antibodies can also be produced by recombinant DNA methods, such as those described in US Patent No. 4,816,567 and supra. DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (eg, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Fusoma cells are a better source of such DNA. Once isolated, the DNA can be placed into an expression vector, which is then transfected into host cells, such as E. coli cells, monkey COS cells, Chinese hamster ovary (CHO) cells, or cells that do not otherwise produce immunoglobulin proteins. myeloma cells to synthesize monoclonal antibodies in such recombinant host cells. Review articles on recombinant expression in bacteria of antibody-encoding DNA include Skerra et al ., Curr. Opinion in Immunol., 5:256-262 (1993) and Pliickthun, Immunol. Revs. 130:151-188 (1992).

In a further embodiment, antibodies can be isolated from antibody phage libraries generated using the techniques described in: McCafferty et al ., Nature, 348:552-554 (1990). Clackson et al ., Nature, 352:624-628 (1991); and Marks et al ., J. Mol. Biol., 222:581-597 (1991). Subsequent literature describes the production of high-affinity (nM range) human antibodies by chain shuffling (Marks et al ., Bio/Technology, 10:779-783 (1992)), as well as combinatorial infection and in vivo recombination as a means of constructing very large phage libraries. Strategy (Waterhouse et al ., Nucl. Acids Res., 21:2265-2266 (1993)). Therefore, these techniques are viable alternatives to traditional monoclonal antibody fusion tumor techniques for isolating monoclonal antibodies.

DNA can also be modified by, for example, substituting the coding sequence (US Pat. No. 4,816,567; Morrison, et al ., Proc. Natl Acad. Sci. USA, 81:6851 (1984)), or converting non-immunoglobulin polypeptides All or part of the coding sequence is covalently linked to the coding sequence. Such non-immunoglobulin polypeptides can be substituted to generate chimeric diabodies comprising one antigen binding site specific for one antigen and another antigen binding site specific for a different antigen.

Chimeric or hybrid antibodies can also be prepared in vitro using methods known in synthetic protein chemistry, including methods involving cross-linking agents. For example, immunotoxins can be constructed using disulfide exchange reactions or by forming thioether bonds. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate. Recombinant production in prokaryotic cells

Multiple nucleic acid sequences encoding the antibodies of the present disclosure can be obtained using standard recombinant techniques. Desired polynucleotide sequences can be isolated and sequenced from antibody producing cells such as fusionoma cells. Alternatively, polynucleotides can be synthesized using nucleotide synthesizers or PCR techniques. Once obtained, the sequence encoding the polypeptide is inserted into a recombinant vector capable of replicating and expressing the heterologous polynucleotide in a prokaryotic host. Many vectors that are available and known in the art can be used for the purposes of this disclosure. Selection of an appropriate vector will depend primarily on the size of the nucleic acid to be inserted into the vector, and the particular host cell to be transformed by the vector. Each vector contains various components depending on its function (amplification or expression or both of the heterologous polynucleotide) and its compatibility with the particular host cell in which it is used. Vector components typically include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, a heterologous nucleic acid insert, and a transcription termination sequence.

In general, plastid vectors containing replicon and control sequences derived from a species compatible with the host cell are used with these hosts. Vectors typically carry replication sites as well as marker sequences capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322 (a plastid derived from E. coli species). Examples of pBR322 derivatives useful for expressing specific antibodies are described in detail in Carter et al . US Patent No. 5,648,237.

In addition, phage vectors containing replicons and control sequences compatible with host microorganisms can be used as transformation vectors with these hosts. For example, phages such as GEM ^™ -11 can be used to make recombinant vectors that can be used to transform susceptible host cells such as E. coli LE392.

The expression vectors of the present application may contain two or more promoter-cistronic pairs encoding each polypeptide component. A promoter is a non-translational regulatory sequence located upstream (5') of a cistron to regulate its expression. Prokaryotic promoters are generally divided into two categories: inducible and constitutive. An inducible promoter is a promoter that initiates an increase in the level of transcription of cistrons under its control in response to changes in culture conditions, such as the presence or absence of nutrients or changes in temperature.

The large number of promoters recognized by a variety of potential host cells is well known. The promoter of choice can be operably linked to the cistron DNA encoding the present antibody by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector of the present application. Both native promoter sequences and many heterologous promoters can be used to direct the amplification and/or expression of a gene of interest. In some embodiments, heterologous promoters are utilized because they generally allow for higher transcription and higher yields of expressed target genes than the native target polypeptide promoter.

Promoters suitable for prokaryotic hosts include the PhoA promoter, the galactosidase and lactose promoter systems, the tryptophan (trp) promoter system, and hybrid promoters such as the tac or trc promoters. However, other promoters that are functional in bacteria, such as other known bacterial or phage promoters, are also suitable. Its nucleic acid sequence has been disclosed, thereby allowing one of ordinary skill in the art to operably link it to a cistron encoding a peptide of interest (Siebenlist et al . Cell 20: 269 (1980)), using a linker or adapters to supply any desired restriction sites.

In one aspect, each cistron within the recombinant vector comprises a secretion signal sequence component that directs translocation of the expressed polypeptide across the membrane. In general, the signal sequence may be a component of the vector, or it may be part of the DNA of the polypeptide of interest inserted into the vector. The signal sequence chosen for the purposes of the present invention should be one that is recognized and processed (ie cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native signal sequence of the heterologous polypeptide, the signal sequence can be replaced by, for example, a prokaryotic signal sequence selected from the group consisting of alkaline phosphatase, penicillinase, Ipp, or thermostable Enterotoxin II (STII) leader, LamB, PhoE, PelB, OmpA, and MBP.

In some embodiments, production of antibodies according to the present disclosure can occur in the cytoplasm of the host cell, and thus no secretion signal sequence needs to be present within each cistron. Certain host strains (eg, E. coli trxB ⁻ strains) provide cytoplasmic conditions favorable for disulfide bond formation, thereby allowing proper folding and assembly of expressed protein subunits.

Prokaryotic host cells suitable for expressing the antibodies of the present disclosure include Archaebacteria and Eubacteria, such as Gram-negative or Gram-positive organisms. Examples of usable bacteria include Escherichia (e.g., Escherichia coli), Bacilli (e.g., B. subtilis ), Enterobacteria, Pseudomonas Species (eg, P. aeruginosa ), Salmonella typhimurium , Serratia marcescans , Klebsiella , Proteus , Shigella , Rhizobia , Vitreoscilla , or Paracoccus . In some embodiments, Gram-negative cells are used. In one embodiment, E. coli cells are used as hosts. Examples of Escherichia coli strains include strain W3110 (Bachmann, Cellular and Molecular Biology , vol. 2 (Washington, DC: American Society for Microbiology, 1987), pp. 1190-1219; ATCC Deposit No. 27,325) and derivatives thereof, including those with Strain 33D3 of genotype W3110 AfhuA (AtonA) ptr3 lac Iq lacL8 AompT A (nmpc-fepE) degP41 kan ^R (US Patent No. 5,639,635). Other strains and derivatives thereof, such as E. coli 294 (ATCC 31,446), E. coli B, E. coli 1776 (ATCC 31,537), and E. coli RV308 (ATCC 31,608) are also suitable. These examples are illustrative rather than limiting. Methods for constructing derivatives of any of the above bacteria with defined genotypes are known in the art and described, for example, in Bass et al ., Proteins, 8:309-314 (1990). Generally, it is necessary to consider the replicability of the replicon in bacterial cells to select suitable bacteria. For example, E. coli, Serratia, or Salmonella species can be suitably used as hosts when well-known plasmids such as pBR322, pBR325, pACYC177, or pKN410 are used to supply the replicon.

Host cells should generally secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors can be incorporated into the cell culture as desired.

The host cell lines are transformed with the expression vectors described above and cultured in conventional nutrient media adapted to induce promoters, select for transformants, or amplify genes encoding desired sequences. Transformation refers to the introduction of DNA into a prokaryotic host so that the DNA can be replicated as an extrachromosomal element or by chromosomal integrants. Depending on the host cell used, transformation is performed using standard techniques applicable to such cells. For bacterial cells containing a parenchymal cell wall barrier, calcium treatment with calcium chloride is commonly used. Another transformation method employs polyethylene glycol/DMSO. Another technique used is electroporation.

Prokaryotic cell lines used to produce the antibodies of the present application are grown in media known in the art and suitable for culturing the host cell of choice. An example of a suitable medium includes Luria Broth (LB) plus necessary nutritional supplements. In some embodiments, the medium also contains a selection agent selected based on the construct of the expression vector to selectively allow the growth of prokaryotic cells containing the expression vector. For example, ampicillin is added to the medium to grow cells expressing the ampicillin resistance gene.

Any necessary supplements other than carbon, nitrogen, and inorganic phosphate sources may also be included, which may be introduced at appropriate concentrations alone or as a mixture with another supplement or medium such as a complex nitrogen source. Optionally, the medium may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate, dithioerythritol, and disulfide Threitol. Cultivate prokaryotic host cells at an appropriate temperature and pH.

If the expression vector of the present application uses an inducible promoter, protein expression can be induced under conditions suitable for activating the promoter. In one aspect of the present application, the PhoA promoter is used to control the transcription of the polypeptide. Therefore, transformed host cells are cultured in phosphate-limiting medium to induce. In some embodiments, the phosphate-limiting medium is CRAP medium (see, eg, Simmons et al ., J. Immunol. Methods 263:133-147 (2002)). A variety of other inducers can be used depending on the vector construct employed, as is known in the art.

The expressed antibody systems of the present disclosure are secreted into and recovered from the periplasm of the host cell. Protein recovery generally involves the destruction of microorganisms, usually by means such as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris or whole cells can be removed by centrifugation or filtration. Proteins can be further purified, eg, by affinity resin chromatography. Alternatively, proteins can be transported to and isolated in culture medium. The cells can be removed from the culture and the culture supernatant filtered and concentrated to further purify the protein produced. Expressed polypeptides can be further isolated and identified using known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot assays.

Alternatively, protein production is carried out in large quantities by fermentation procedures. A variety of large-scale fed-batch fermentation procedures are available for the production of recombinant proteins. In order to improve the production yield and quality of the antibodies of the present disclosure, various fermentation conditions can be modified. For example, chaperone proteins have been shown to promote proper folding and solubility of heterologous proteins produced in bacterial host cells. Chen et al . J Bio Chem 274:19601-19605 (1999); US Patent No. 6,083,715; US Patent No. 6,027,888; Bothmann and Pluckthun, J. Biol. Chem.275:17100-17105 (2000); Ramm and Pluckthun , J. Biol. Chem. 275:17106-17113 (2000); Arie et al ., Mol. Microbiol. 39:199-210 (2001).

To minimize proteolysis of expressed heterologous proteins (particularly proteolytically sensitive proteins), the present invention may use certain host strains lacking proteolytic enzymes, as described, for example, in U.S. Patent No. 5,264,365; U.S. Patent No. 5,264,365; No. 5,508,192; Hara et al ., Microbial Drug Resistance, 2:63-72 (1996). A plastid-transformed E. coli strain lacking proteolytic enzymes and overexpressing one or more chaperone proteins can be used as a host cell in an expression system encoding an antibody of the present application.

Antibodies produced herein can be further purified to obtain a substantially homogeneous preparation for further assay and use. Standard protein purification methods known in the art can be employed. The following procedures are examples of suitable purification procedures: Fractionation on immunoaffinity or ion exchange columns, ethanol precipitation, reverse phase HPLC, silica or cation exchange resin (such as DEAE) chromatography, chromatographic focusing, SDS-PAGE , ammonium sulfate precipitation, and gel filtration using eg Sephadex G-75. Immunoaffinity purification of binding molecules of the present disclosure can be performed in some embodiments using, for example, Protein A immobilized on a solid phase. In some embodiments, the solid phase to which Protein A is immobilized is a column comprising a glass or silica surface. In some embodiments, the solid phase on which protein A is immobilized is a controlled pore glass column or a silicate column. In some embodiments, the column has been coated with a reagent, such as glycerol, in an attempt to prevent non-specific adhesion of contaminants. The solid phase is then washed to remove contaminants non-specifically bound to the solid phase. Finally the antibody of interest is recovered from the solid phase by elution. Recombinant production in eukaryotic cells

For eukaryotic expression, vector components typically include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, and enhancer elements, promoters, and transcription termination sequences.

Vectors for use in eukaryotic hosts may also contain an insert encoding a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence chosen is preferably one that is recognized and processed (ie cleaved by a signal peptidase) by the host cell. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders (such as the herpes simplex gD signal) can be used. The DNA of the precursor region may be joined in frame to the DNA encoding the antibody of the present application.

Typically, mammalian expression vectors do not require an origin of replication component (generally only the SV40 source is used because it contains the early promoter).

Expression and cloning vectors may contain selection genes, also known as selectable markers. Selection genes can encode proteins that confer resistance to antibiotics or other toxins (eg, ampicillin, neomycin, methotrexate, or tetracycline); complement auxotrophic deficiencies; or supply keys that cannot be obtained from complex media Nutrients.

One example of a selection protocol utilizes drugs to suppress host cell growth. These heterologous gene-transformed cells successfully produce a protein that confers drug resistance and thus survive the selection regime. Examples of such dominant selection use the drugs neomycin, mycophenolic acid, and hygromycin.

Another example of suitable selectable markers for use in mammalian cells are those that enable identification of cells capable of taking up nucleic acid encoding an antibody of the present application. For example, cells transformed with a DHFR selection gene are first identified by all transformants cultured in media containing methotrexate (Mtx), a competitive antagonist of DHFR. When wild-type DHFR is employed, an exemplary suitable host cell line is a Chinese hamster ovary (CHO) cell line lacking DHFR activity. Alternatively, the DNA sequence encoding the polypeptide, the wild-type DHFR protein, and another selectable marker (such as an aminoglycoside antibiotic) can be selected for by growing the cells in media containing a selectable marker-selective agent, such as an aminoglycoside antibiotic. glycoside 3'-phosphotransferase (APH)) transformed or co-transformed host cells (especially wild-type hosts containing endogenous DHFR).

Expression and cloning vectors generally contain a promoter recognized by the host organism and operably linked to a nucleic acid encoding the desired polypeptide sequence. Eukaryotic genes have an AT-rich region approximately 25 to 30 bases upstream from the site where transcription begins. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes may be included. The 3' end of most eukaryotes may be a signal for adding a polyA tail to the 3' end of the coding sequence. All of these sequences can be inserted into eukaryotic expression vectors.

Transcription of polypeptides from vectors in mammalian host cells can be controlled, for example, by the following promoters, provided they are compatible with the host cell system: from viruses (such as polyoma virus, fowlpox virus, adenovirus (such as adenovirus 2), promoters obtained from the genomes of bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40), heterologous mammalian promoters (such as , actin promoter or immunoglobulin promoter), heat shock promoter.

Transcription of DNA encoding the disclosed antibodies by higher eukaryotic cells is typically increased by inserting enhancer sequences into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, alpha-fetoprotein, and insulin). Examples include the SV40 enhancer (base pairs 100 to 270) on the late side of the origin of replication, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the origin of replication, and the adenovirus enhancer. See also Yaniv, Nature 297:17-18 (1982) for enhancing elements that activate eukaryotic promoters. The enhancer can be spliced to the 5' or 3' position of the polypeptide coding sequence in the vector, but the preferred site is on the 5' side of the promoter.

Expression vectors for use in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) also contain sequences required to terminate transcription and stabilize mRNA. Such sequences are generally available from the 5' and occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments that are transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the polypeptide. One useful transcription termination component is the bovine growth hormone polyadenylation region.

Suitable host cells for breeding or expressing the DNA in the vectors herein include the higher eukaryotic cells described herein, including vertebrate host cells. Propagation of vertebrate cells in culture (tissue culture) has become routine. Examples of useful mammalian host cell lines are the SV40-transformed monkey kidney CV1 cell line (COS-7, ATCC CRL 1651); the human embryonic kidney cell line (293 or 293 subselected for growth in suspension culture); cells, Graham et al ., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/−DHFR (CHO, Urlaub et al ., Proc.Natl .Acad.Sci.USA 77:4216 (1980)); Mouse Saib cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); Monkey kidney cells (CV1 ATCC CCL 70); African green Monkey kidney cells (VERO-76, ATCC CRL-1587); Human cervical cancer cells (HELA, ATCC CCL 2); Canine kidney cells (MDCK, ATCC CCL 34); Buffalo mouse liver cells (BRL 3A, ATCC CRL 1442) ; human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary gland tumors (MMT 060562, ATCC CCL51); TR1 cells (Mather et al ., Annals NYAcad.Sci. 383: 44-68 (1982)); MRC 5 cells; FS4 cells; and the human liver tumor cell line (Hep G2).

Host cells can be transformed with the expression or cloning vectors described above for antibody production and cultured in conventional nutrient media adapted for induction of promoters, selection of transformants, or amplification of genes encoding desired sequences .

Host cells used to produce the antibodies of the present application can be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM, Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM, Sigma) are suitable for culturing host cells. In addition, any of the compounds described in Ham et al ., Meth. Enz. 58:44 (1979), Barnes et al ., Anal. Biochem. 102:255 (1980), U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762 ; No. 4,560,655; or No. 5,122,469; WO 90/03430; WO 87/00195; or the medium in US Patent Re. 30,985 can be used as a medium for host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES) , nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN ^™ drugs), trace elements (defined as inorganic compounds usually present in final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those of ordinary skill in the art. Culture conditions (such as temperature, pH, and the like) are those previously used by the host cells chosen for expression and will be readily apparent to those of ordinary skill in the art.

Using recombinant techniques, antibodies can be produced intracellularly, in the periplasmic space, or secreted directly into the culture medium. If the antibody is produced intracellularly as a first step, the particulate debris (whether host cells or lysed fragments) is removed by, for example, centrifugation or ultrafiltration. When the antibody is secreted into the culture medium, the supernatant from the expression system is first substantially concentrated using a commercial protein concentration filter such as an Amicon or Millipore Pellicon ultrafiltration unit. Any of the preceding steps may include protease inhibitors such as PMSF to inhibit proteolysis and antibiotics to prevent growth of opportunistic contaminants.

Protein compositions prepared from cells can be purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The most common substrate to which affinity ligands are attached is agarose, but other substrates can also be used. Mechanically stable matrices such as controlled pore glass or poly(styrene-divinyl)benzene allow faster flow rates and shorter processing times than agarose. Depending on the antibody to be recovered, other protein purification techniques such as fractionation on ion exchange columns, ethanol precipitation, reverse phase HPLC, silica chromatography, heparin SEPHAROSE ^™ chromatography, anion or cation exchange resin chromatography can also be used methods (such as polyaspartic acid columns), chromatographic focusing, SDS-PAGE, and ammonium sulfate precipitation. Following any initial purification step(s), the mixture comprising the antibody of interest and contaminants can be subjected to low pH hydrophobic interaction chromatography. Methods of Using Antibodies

In one aspect, provided herein is a method of attenuating the activity of IL-23R on a cell comprising exposing the cell to an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one aspect, provided herein is a method of attenuating the activity of IL-23R in a cell comprising exposing the cell to an effective amount of an antibody or antigen-binding fragment thereof provided herein.

In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 10%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 20%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 30%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 40%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 50%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 60%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 70%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 80%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 90%. In some embodiments, the antibodies provided herein attenuate IL-23R activity by at least about 95%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R activity by at least about 15% to about 65%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R activity by at least about 20% to about 65%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R activity by at least about 30% to about 65%.

A non-limiting example of IL-23R activity is IL-23R mediated signaling. Accordingly, in certain embodiments, provided herein is a method of attenuating (e.g., partially attenuating) IL-23R-mediated signaling in a cell comprising exposing the cell to an effective amount of an antibody provided herein or an antigen thereof Combine fragments.

In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 10%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 20%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 30%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 40%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 50%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 60%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 70%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 80%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 90%. In some embodiments, the antibodies provided herein attenuate IL-23R-mediated signaling by at least about 95%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R-mediated signaling by at least about 15% to about 65%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R-mediated signaling by at least about 20% to about 65%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23R-mediated signaling by at least about 30% to about 65%.

In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to at least one of its ligands.

Another non-limiting example of IL-23R activity is binding to IL-23. Accordingly, in certain embodiments, provided herein is a method of attenuating (eg, partially attenuating) IL-23R binding to IL-23 comprising exposing a cell to an effective amount of an antibody or antigen-binding fragment thereof provided herein.

In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 10%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 20%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 30%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 40%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 50%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 60%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 70%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 80%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 90%. In some embodiments, the antibodies provided herein attenuate the binding of IL-23R to IL-23 by at least about 95%. In certain embodiments, the antibodies described herein can attenuate (eg, partially attenuate) the binding of IL-23R to IL-23 by at least about 15% to about 65%. In certain embodiments, the antibodies described herein can attenuate (eg, partially attenuate) the binding of IL-23R to IL-23 by at least about 20% to about 65%. In certain embodiments, the antibodies described herein can attenuate (eg, partially attenuate) the binding of IL-23R to IL-23 by at least about 30% to about 65%.

Yet another non-limiting example of IL-23R activity is IL-23 mediated signaling. Accordingly, in certain embodiments, provided herein is a method of attenuating (e.g., partially attenuating) IL-23-mediated signaling in a cell comprising exposing the cell to an effective amount of an antibody provided herein or an antigen thereof Combine fragments.

In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 10%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 20%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 30%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 40%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 50%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 60%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 70%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 80%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 90%. In some embodiments, the antibodies provided herein attenuate IL-23-mediated signaling by at least about 95%. In certain embodiments, the antibodies described herein attenuate (eg, partially attenuate) IL-23-mediated signaling by at least about 15% to about 65%. In certain embodiments, an antibody described herein attenuates (eg, partially attenuates) IL-23-mediated signaling by at least about 20% to about 65%. In certain embodiments, the antibodies described herein attenuate (eg, partially attenuate) IL-23-mediated signaling by at least about 30% to about 65%. Diagnostic Assays and Detection Methods

In one aspect, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect the presence of IL-23R in a biological sample. In one aspect, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect the presence of IL-23R on the surface of cells in a biological sample. In another aspect, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect the amount of IL-23R in a biological sample. In one aspect, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect the amount of IL-23R on the surface of cells in a biological sample. Such anti-IL-23R antibodies may include antibodies that bind to human IL-23R without otherwise altering IL-23R signaling activity. As used herein, the term "detecting/detection" encompasses quantitative or qualitative detection and refers to the use of assay readouts or results to make statements about the presence/absence of IL-23R in a sample, IL-23R in a sample, - relative expression level of 23R (eg, relative to one or more reference expressions, relative to other samples, or relative to one or more expression scales), or determination of the concentration of IL-23R in the sample. The readout of the assay detection can be numerical data, such as the result of an immunoassay, or the measured protein concentration; the detection readout can be non-numerical data, such as anti-IL-23R antibody staining of cells or tissues in a microscopic image or Staining of IL-23R in imaging flow cytometry; or the readout of detection can be any experimental data that can be used as a proxy for IL-23R expression, such as fluorescence, as is well known to those of ordinary skill in the art Intensity, luminescence intensity, colorimetric readings, and absorption/emission spectroscopy. The readout of assay detection is referred to herein as the assay signal.

In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure bind to natural receptors on cells. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure bind to and alter natural receptors on cells. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure bind to denatured receptors on Western blots. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to immunoprecipitate receptors in cell lysates. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study the cellular synthesis of IL-23 receptor. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study the movement of IL-23 receptor. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study IL-23 receptor turnover. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study the mechanism of action of how therapeutic agents affect cellular synthesis of IL-23 receptor. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study the mechanism of action of how therapeutic agents affect the movement of the IL-23 receptor. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to study the mechanism of action of how therapeutic agents affect IL-23 receptor turnover. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to predict drug mechanism of action and effective dose/exposure. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to predict the effective dose/exposure of a therapeutic agent.

In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptor on human cells. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptor on human IL-23R transfected cell lines. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on human IL-23R transfected iLite cell lines. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on human IL-23R transfected HEK cell lines. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on primary human CD3 ⁺ CD56 ⁻ T cells. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on primary human CD3 ⁺ CD56 ⁺ cells. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on primary human CD3 ⁻ CD56 ⁺ cells.

In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on human cells to identify IL-23 responsive cells. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on human cells to quantify IL-23 responsive cells. In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof can be used to detect IL-23 receptors on human cells to predict which diseases will respond to IL-23 pathway targeted inhibitors. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to detect IL-23 receptors on human cells to predict which subpopulation of patients will respond to IL-23 pathway-targeted inhibitors.

In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to label IL-23R expressing cells in healthy subjects and diseases. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to sort IL-23R expressing cells in healthy subjects and diseases. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to isolate IL-23R expressing cells in healthy subjects and in diseases. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to characterize IL-23R expressing cells in healthy subjects and in diseases. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to characterize underlying disease pathways. In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof are useful for understanding the mechanism of action of therapeutic agents. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure can be used to identify markers of drug response.

In some embodiments, the anti-IL-23R antibodies and fragments thereof of the disclosure bind to IL-23R in a manner that inhibits IL-23 binding and signaling. In some embodiments, the anti-IL-23R antibodies and fragments thereof of the present disclosure bind to IL-23R in a manner that competes for binding with IL-23R antagonist peptide therapeutics. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure are used in receptor occupancy target engagement assays. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure are used in receptor occupancy target engagement assays in blood and other tissues of patients administered IL-23R antagonist peptides. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure are used in receptor occupancy target engagement assays in blood and other tissues of patients administered other receptor-targeting therapeutics. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure are used in target engagement assays to inform dose prediction in different disease ranges. In some embodiments, anti-IL-23R antibodies and fragments thereof of the present disclosure are used in target engagement assays to inform future therapeutic agent selection in various disease domains.

In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof that bind to different epitopes on IL-23R can be used in different combinations to optimize the detection of IL-23R expressing cells. In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof that bind to different epitopes on IL-23R can be used in different combinations to optimize staining of IL-23R expressing cells. In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof that bind to different epitopes on IL-23R can be used in different combinations to optimize visualization of IL-23R expressing cells. In some embodiments, the disclosed anti-IL-23R antibodies and fragments thereof that bind to different epitopes on IL-23R can be used in different combinations to optimize the quantification of IL-23R expressing cells.

In specific embodiments, IL-23R antibodies and fragments thereof (especially antigen-binding fragments) that bind to different epitopes on IL-23R are used for the evaluation and optimization of IL-23R or IL-23R expressing cells. And/or quantitatively, the different epitopes such as those listed in the different bins including those provided in Table 11. In one embodiment, a combination of an antibody that has strong cell surface IL-23R binding and an antibody that binds to a different epitope (such as from a different epitope bin), is non-competitive, and also shows strong cell surface IL-23R binding is provided , and this combination may be particularly preferable.

In the examples herein, combinations of bin 3 antibodies and non-bin 3 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 1 antibodies and non-bin 1 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 5 antibodies and non-bin 5 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 2 antibodies and non-bin 2 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 4 antibodies and non-bin 4 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 6 antibodies and non-bin 6 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 7 antibodies and non-bin 7 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 8 antibodies and non-bin 8 antibodies are contemplated and can be utilized. In the examples herein, combinations of bin 9 antibodies and non- bin 9 antibodies are contemplated and can be utilized. In embodiments, bin 2 and bin 1 antibodies, or bin 1 and bin 5 antibodies, or bin 1 and bin 4 antibodies, or bin 2 and bin 4 antibodies, or bin 2 and bin 3 antibodies, or bin 1 and bin 5 antibodies, are contemplated and may be utilized. Or bin 2 and bin 5 antibodies, or bin 3 and bin 5 antibodies, or bin 4 and bin 5 antibodies, or bin 3 and bin 7 antibodies, or a combination of bin 1 and bin 7 antibodies, or a combination of bin 3 antibodies and bin 1 antibodies.

Bin 1 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 202 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:203 or comprising its CDR1, CDR2, and CDR3 domain sequences; the VH comprising the amino acid sequence of SEQ ID NO:252 or comprising its CDR1, CDR2, and CDR3 domain sequences , and a VL comprising the amino acid sequence of SEQ ID NO:253 or comprising its CDR1, CDR2, and CDR3 domain sequences; or comprising the amino acid sequence of SEQ ID NO:156 or comprising its CDR1, CDR2, and CDR3 domain sequences and the VH comprising the amino acid sequence of SEQ ID NO: 157 or the VL comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 2 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 192 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:193 or comprising its CDR1, CDR2, and CDR3 domain sequences; the VH comprising the amino acid sequence of SEQ ID NO:194 or comprising its CDR1, CDR2, and CDR3 domain sequences , and VL comprising the amino acid sequence of SEQ ID NO: 195 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO: 200 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and VL comprising the amino acid sequence of SEQ ID NO:201 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:218 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and the VL comprising the amino acid sequence of SEQ ID NO:219 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:222 or comprising its CDR1, CDR2, and CDR3 domains The VH of the sequence, and the VL comprising the amino acid sequence of SEQ ID NO:223 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:260 or comprising its CDR1, CDR2, and CDR3 The VH of the domain sequence, and the VL comprising the amino acid sequence of SEQ ID NO:261 or comprising its CDR1, CDR2, and CDR3 domain sequence; comprising the amino acid sequence of SEQ ID NO:264 or comprising its CDR1, CDR2, and The VH of the CDR3 domain sequence, and the VL comprising the amino acid sequence of SEQ ID NO:265 or comprising its CDR1, CDR2, and CDR3 domain sequence; comprising the amino acid sequence of SEQ ID NO:154 or comprising its CDR1, CDR2, and the VH of the CDR3 domain sequence, and the VL comprising the amino acid sequence of SEQ ID NO:155 or comprising its CDR1, CDR2, and CDR3 domain sequence; comprising the amino acid sequence of SEQ ID NO:160 or comprising its CDR1, CDR2 , and the VH of the CDR3 domain sequence, and the VL comprising the amino acid sequence of SEQ ID NO: 161 or comprising its CDR1, CDR2, and CDR3 domain sequence; or comprising the amino acid sequence of SEQ ID NO: 164 or comprising its CDR1 , CDR2, and CDR3 domain sequences of VH, and comprising the amino acid sequence of SEQ ID NO: 165 or comprising the VL of its CDR1, CDR2, and CDR3 domain sequences. Bin 3 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 786 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:787 or comprising its CDR1, CDR2, and CDR3 domain sequences; the VH comprising the amino acid sequence of SEQ ID NO:790 or comprising its CDR1, CDR2, and CDR3 domain sequences , and VL comprising the amino acid sequence of SEQ ID NO:791 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:792 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and VL comprising the amino acid sequence of SEQ ID NO:793 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:236 or comprising its CDR1, CDR2, and CDR3 domain sequences The VH of, and the VL comprising the amino acid sequence of SEQ ID NO:237 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:826 or comprising its CDR1, CDR2, and CDR3 domains The VH sequence, and the amino acid sequence comprising SEQ ID NO:827 or the VL comprising its CDR1, CDR2, and CDR3 domain sequences; or the amino acid sequence comprising SEQ ID NO:828 or comprising its CDR1, CDR2, and The VH of the CDR3 domain sequence, and the VL comprising the amino acid sequence of SEQ ID NO: 829 or the CDR1, CDR2, and CDR3 domain sequences thereof. Bin 4 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 196 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:197 or comprising its CDR1, CDR2, and CDR3 domain sequences; the VH comprising the amino acid sequence of SEQ ID NO:262 or comprising its CDR1, CDR2, and CDR3 domain sequences , and a VL comprising the amino acid sequence of SEQ ID NO:263 or comprising its CDR1, CDR2, and CDR3 domain sequences; or comprising the amino acid sequence of SEQ ID NO:152 or comprising its CDR1, CDR2, and CDR3 domain sequences and the VH comprising the amino acid sequence of SEQ ID NO: 153 or the VL comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 5 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 798 or comprising its CDR1, CDR2, and CDR3 domain sequences, And a VL comprising the amino acid sequence of SEQ ID NO: 799 or comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 6 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 206 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:207 or comprising its CDR1, CDR2, and CDR3 domain sequences; the VH comprising the amino acid sequence of SEQ ID NO:250 or comprising its CDR1, CDR2, and CDR3 domain sequences , and VL comprising the amino acid sequence of SEQ ID NO:251 or comprising its CDR1, CDR2, and CDR3 domain sequences; comprising the amino acid sequence of SEQ ID NO:144 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and VL comprising the amino acid sequence of SEQ ID NO: 145 or comprising its CDR1, CDR2, and CDR3 domain sequences; or comprising the amino acid sequence of SEQ ID NO: 170 or comprising its CDR1, CDR2, and CDR3 domains The VH sequence, and the VL comprising the amino acid sequence of SEQ ID NO: 171 or comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 7 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 150 or comprising its CDR1, CDR2, and CDR3 domain sequences, And a VL comprising the amino acid sequence of SEQ ID NO: 151 or comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 8 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 198 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO: 199 or comprising its CDR1, CDR2, and CDR3 domain sequences; or comprising the amino acid sequence of SEQ ID NO: 240 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and VL comprising the amino acid sequence of SEQ ID NO: 241 or comprising its CDR1, CDR2, and CDR3 domain sequences. Bin 9 antibodies comprise antibodies that bind to the same epitope and/or compete for binding to IL-23R with antibodies comprising: a VH comprising the amino acid sequence of SEQ ID NO: 204 or comprising its CDR1, CDR2, and CDR3 domain sequences, And the VL comprising the amino acid sequence of SEQ ID NO:205 or comprising its CDR1, CDR2, and CDR3 domain sequences; or comprising the amino acid sequence of SEQ ID NO:884 or comprising its CDR1, CDR2, and CDR3 domain sequences VH, and VL comprising the amino acid sequence of SEQ ID NO: 885 or comprising its CDR1, CDR2, and CDR3 domain sequences.

In embodiments, combinations of bin 3 antibodies and bin 1 antibodies are contemplated and can be utilized. In some embodiments, one or more antibodies selected from I23RB1, I23RB3, I23RB4, I23RB76, I23RB269, or I23RB270, or heavy chains and light chains comprising one or more of I23RB1, I23RB3, I23RB4, I23RB76, I23RB269, or I23RB270 The antibody of the chain CDR, or at least the heavy chain CDR, can be selected from one or more antibodies selected from I23RB42, I23RB85, or I23RB157, or the heavy chain and light chain CDR comprising one or more of I23RB42, I23RB85, or I23RB157, or at least the heavy chain Antibody combination of chain CDRs. In a specific embodiment, antibody I23RB4 or I23RB76, or an antibody system comprising heavy chain and light chain CDR of I23RB4 or I23RB76, or at least heavy chain CDR and antibody I23RB42 or I23RB157, or heavy chain and light chain CDR comprising I23RB42 or I23RB157 , or at least an antibody combination of heavy chain CDRs.

In some embodiments, the surface plasmon resonance (SPR) method can be used to determine the affinity of the anti-IL-23R antibodies and fragments thereof of the present disclosure for human IL-23R. In some embodiments, the biolayer interferometry (BLI) method can be used to determine the affinity of the anti-IL-23R antibodies and fragments thereof of the present disclosure for human IL-23R. In some embodiments, flow cytometry can be used to determine the affinity of the anti-IL-23R antibodies and fragments thereof of the present disclosure for human IL-23R.

In some embodiments, the present disclosure provides a method for detecting, selecting, and/or enriching for IL-23R in a sample comprising contacting the sample with an unlabeled or labeled anti-IL-23R antibody. In certain embodiments, the method comprises using unlabeled or labeled anti-IL- 23R antibody.

In some embodiments, the present disclosure provides methods for detecting IL-23R target engagement by another therapeutic agent targeting IL-23R (such as another antibody, peptide, or small molecule) to support IL-23R target engagement based on how much target engagement is achieved Dosage decision and indication decision.

In one aspect, the present disclosure provides a method of detecting the presence of IL-23R in a biological sample. In certain embodiments, the method comprises contacting a biological sample with an anti-IL-23R antibody under conditions that allow binding of the anti-IL-23R antibody to IL-23R, and detecting the interaction between the anti-IL-23R antibody and IL-23R combination.

As provided herein, a biological sample is a sample or material of biological origin. Biological samples include bodily fluids, cells, or tissue samples. In some embodiments, the cells may be cultured cell lines, engineered cells, in vitro or ex vivo cultures of cells obtained from a subject (eg, a human subject), or cells obtained from a subject. In other embodiments, a tissue sample may comprise bodily fluid or tissue obtained from a subject, including a human subject. In some embodiments, a tissue sample includes a sample from an area of a subject suspected of having a disease. A tissue sample can thus be, but is not limited to, tissue, body fluid, tissue fraction, and/or cells isolated from an organism such as a mammal, especially a human. In one embodiment, tissue samples are prepared as formalin-fixed paraffin-embedded (FFPE) sections. Cells, body fluids, and/or tissues may be obtained from a subject by methods well known to those of ordinary skill in the art, such as biopsies (including liquid biopsies), surgical procedures, cytosmears, and phlebotomy, For example a human object.

As is well known to those of ordinary skill in the art, the amount of antibody bound to an antigen in a biological sample correlates to the amount of antigen in the biological sample. Therefore, the amount of binding of the anti-IL-23R antibodies provided herein to IL-23R in biological samples can be used to measure the amount or expression level of IL-23R in biological samples. In some embodiments, the amount of IL-23R in the biological sample is detected in the linear detection range of the anti-IL-23R antibody. "Linear detection range" refers to the range of antigen amount or concentration within which bound antibody is linearly related to the amount or concentration of antigen in a biological sample. Such linear range depends on factors such as the affinity between the antibody and antigen, the concentration of antibody used for antibody-antigen binding, and the conditions used for antibody-antigen binding.

The concentration of antibody used for antibody-antigen binding can be assessed in a titration experiment. In one example of such a titration experiment, the concentration of the antibody is serially diluted by two-fold, three-fold, five-fold, or ten-fold, and each of the serially diluted antibodies binds to a known amount of the corresponding antigen the control sample. In one embodiment, the desired antibody concentration is the concentration at which the amount of antibody bound differs from the broadest linear detection range.

Expression of IL-23R in a biological sample refers to the amount of IL-23R in a biological sample at a given time. The measured expression of IL-23R reflects the accumulation of IL-23R in a biological sample over a period of time and may include degradation or modification products such as full-length IL-23R, fragments of IL-23R, and naturally modified (e.g., glycosylated ) of IL-23R. Since the protein is translated from mRNA, the amount of mRNA in the biological sample can be used as a proxy for the expression of IL-23R in the biological sample.

Provided herein are methods for assessing IL-23R expression in a tissue sample from a subject suspected of having an IL-23R-associated disease, comprising: (a) contacting the tissue sample with an antibody or antigen-binding fragment thereof provided herein; ( b) detecting the binding of the antibody or antigen-binding fragment thereof to the tissue sample; (c) determining the expression of IL-23R in the tissue sample, wherein the expression level of IL-23R in the tissue sample is a reference to IL-23R Performance level comparison.

Also provided herein are methods for assessing IL-23R expression in a tissue sample from a subject suspected of having an IL-23R-associated disease, comprising: (a) performing IHC on the tissue sample with an antibody or antigen-binding fragment thereof provided herein Assay; (b) determine the expression of IL-23R in the tissue sample, wherein the expression level of IL-23R in the tissue sample is compared with the reference expression level of IL-23R.

Also provided herein is a method of assessing a patient's responsiveness to a therapeutic agent (e.g., an IL-23 pathway-targeting inhibitor) based on IL-23R expression in a tissue sample from the patient comprising: (a) subjecting the tissue to contacting a sample with an antibody or antigen-binding fragment thereof provided herein; (b) detecting binding of the antibody or antigen-binding fragment thereof to the tissue sample; (c) determining the expression of IL-23R in the tissue sample, wherein in the tissue sample The expression level of IL-23R is compared to a reference expression level of IL-23R; wherein an increased expression level of IL-23R compared to the reference indicates a response to the therapy.

Also provided herein are methods of assessing a patient's responsiveness to a therapeutic agent (e.g., an IL-23 pathway-targeted inhibitor) based on IL-23R expression in a tissue sample from the patient, comprising: (a) in a tissue sample (b) determine the expression of IL-23R in the tissue sample, wherein the expression level of IL-23R in the tissue sample is compared with the reference expression level of IL-23R , wherein an increased expression level of IL-23R in a tissue sample compared to a reference is indicative of a response to the therapy.

Provided herein is a method for treating an IL-23R-related disease in a subject, comprising: (a) determining the expression level of IL-23R in a tissue sample from the subject using the antibody or antigen-binding fragment thereof provided herein, wherein IL-23R is present in the tissue The expression level in the sample is higher than the reference expression level of IL-23R; (b) administering the therapeutic agent to the subject.

Provided herein are methods of treating an IL-23R-associated disease in a subject, comprising: (a) contacting a tissue sample from the subject with an antibody or antigen-binding fragment thereof provided herein; (b) treating a tissue sample from the subject with the antibody provided herein The antibody or antigen-binding fragment thereof determines the expression level of IL-23R, wherein the expression level of IL-23R in the tissue sample is higher than the reference expression level of IL-23R; (c) administering a therapeutic agent to the subject.

Provided herein are methods of treating an IL-23R-associated disease in a subject, comprising: (a) obtaining a tissue sample from the subject; (b) contacting the tissue sample from the subject with an antibody or antigen-binding fragment thereof provided herein; (c) Determining the expression level of IL-23R in a tissue sample from a subject using an antibody or antigen-binding fragment thereof provided herein, wherein the expression level of IL-23R in the tissue sample is higher than a reference expression level of IL-23R; (d) A therapeutic agent is administered to a subject.

In any of the methods provided herein the subject can be a human subject, and the subject can suffer from any IL-23R-associated disease, wherein determination of IL-23R expression for the disease can be performed and/or IL-23R expression can provide a diagnosis of the disease, Prognosis, or predictive value. Exemplary IL-23R-associated diseases include multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic elitematodes, catalepsy Spondylitis, autoimmune inflammation such as inflammation (axial spondyloarthritis), psoriatic arthritis, or psoriasis, and related diseases and conditions. In certain embodiments, the disease or condition is psoriasis (e.g., psoriasis vulgaris, guttate psoriasis), psoriasis inverse, pustular psoriasis, palmoplantar psoriasis, psoriasis vulgaris, or psoriatic psoriasis, atopic dermatitis atopic acne, ulcerative colitis, Crohn's disease, celiac's disease Sexual sprue, enteropathy with seronegative arthritis, microscopic colitis, collagen accumulating colitis, eosinophilic gastrointestinal Inflammation/esophagitis, colitis associated with radiation or chemotherapy, leukocyte adhesion molecule deficiency-1 psoriasis with innate immune disorder, chronic granulosis, glycogen storage disease type 1b, Hermannsky-Padrac syndrome, Chediac- East's syndrome, Wiscot-Aldrich's syndrome, proctocolectomy and ileal anastomosis, Later ileal psoriasis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, psoriasis of the breast, psoriasis, cholangitis, primary Episodic biliary cirrhosis, viral-associated enteropathy, periductal inflammation, chronic bronchitis, chronic sinusitis, asthma, psoriasis, or graft-host disease. Exemplary IL-23R-associated diseases include multiple sclerosis, asthma, rheumatoid arthritis, intestinal inflammation, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, ulcerative colitis, chyle Diarrhea (nontropical aphtha), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radiation or chemotherapy, and innate immune disorders such as leukocyte adhesion molecule deficiency-1 Associated colitis, sarcoidosis, systemic lupus erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g. plaque psoriasis, guttate psoriasis, inverse psoriasis, Pustular psoriasis, palmoplantar pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, atopic acne, bowel disease associated with seronegative arthropathy, chronic granulomatous disease, glycogen storage syndrome type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, bursitis, bursitis after proctocolectomy and ileo-anal anastomosis, gastrointestinal cancer, pancreatitis, Insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, virus-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft-resistant host disease. In some embodiments, the IL-23R-associated disease is specifically selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD), or ulcerative colitis (UC). The disease or condition can be an autoimmune disease. In some embodiments, the autoimmune disease is selected from ulcerative colitis (UC), Crohn's disease (CD), psoriasis (PsO), or psoriatic arthritis (PsA).

As used herein, the term "responsiveness" refers to the chance that a cell or individual or patient or subject responds to or responds to treatment with a therapeutic agent. Responsiveness can include the probability of a wide range of responses to a therapeutic agent such as, but not limited to: (i) reducing or ameliorating the severity of the disease, disorder, or condition being treated, or symptoms associated therewith; (ii) reducing Duration of the disease, disorder, or condition to be treated, or symptoms associated therewith; (iii) preventing the progression of the disease, disorder, or condition to be treated, or symptoms associated therewith; (iv) causing the disease, disorder, or condition to be treated, or symptoms associated therewith; Return of a disorder, or condition, or symptoms associated therewith; (v) preventing the development or onset of the disease, disorder, or condition, or symptoms associated therewith; (vi) preventing the disease, disorder, or condition being treated , or recurrence of symptoms associated therewith; (vii) reducing hospitalization of subjects suffering from the disease, disorder, or condition being treated, or symptoms associated therewith; (viii) reducing having the disease, disorder, or condition being treated, or Length of hospital stay of a subject with a symptom associated therewith; (ix) increasing the survival rate of a subject with the disease, disorder, or condition being treated, or symptoms associated therewith; (xi) inhibiting or reducing the disease, disorder being treated in a subject , or a condition, or symptoms associated therewith; and/or (xii) enhance or improve the disease preventive or therapeutic effect(s) of another therapy. In certain embodiments, when a cell, tissue, patient, or subject exhibits a significant expression of IL-23R in its cells, the cell or tissue or individual or patient or subject is more likely to respond to a therapeutic agent (e.g., IL-23 pathway targeted inhibitors) responded. In certain embodiments, reactivity increases with increasing levels of IL-23R in the cell. In certain embodiments, the reactivity correlates with the expression level of IL-23R in the cells. In certain embodiments, the responsiveness is linearly proportional to the expression level of IL-23R in the cells. In other embodiments, the responsiveness of cells, tissues, patients, or subjects to therapeutic agents can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 10% of IL-23R negative cells. 80%, 90%, 100%, 120%, 150%, 200%, 250%, 300%, 400%, 500%, 750%, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times , 60 times, 70 times, 80 times, 90 times, 100 times, or more times.

As used herein, "indicative of responsiveness" refers to the prediction that responsiveness in one cell, tissue, human subject, or subject will be higher than in another cell, tissue, human subject, or subject. Such predictions are made based on certain criteria. In some embodiments, the prediction of responsiveness is based on the expression level of IL-23R in a cell, tissue, human subject, or subject. As described above, in certain embodiments, when a cell, tissue, patient, or object exhibits significant expression of IL-23R in its cells, it is predicted that the cell or tissue or individual or patient or object is more likely to respond to a therapeutic agent (such as , IL-23 pathway targeting inhibitor) responded. In certain embodiments, responsiveness is predicted to increase as the level of IL-23R in the cells increases. In certain embodiments, the predicted responsiveness is correlated with the level of IL-23R in the cells. In certain embodiments, reactivity is predicted to be linearly proportional to the level of IL-23R in the cell. In other embodiments, cells, tissues, patients, or subjects are predicted to be 10%, 20%, 30% responsive to a therapeutic agent (e.g., IL-23 pathway-targeted inhibitor) than IL-23R negative cells , 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, 200%, 250%, 300%, 400%, 500%, 750%, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, or more times.

The therapeutic agent can be any disease therapy in which IL-23R expression provides diagnostic, prognostic, or predictive value for the disease therapy. In certain embodiments, the therapeutic agent is an agent that targets a biological program (eg, a signaling pathway, a metabolic pathway, or a protein synthesis/degradation pathway) in which IL-23R functions. In certain embodiments, the therapeutic agent is an agent that targets IL-23R activity, IL-23R signaling, or IL-23R-mediated disease. In a specific embodiment, the therapeutic agent is an anti-IL-23R antibody or an anti-IL-23R antibody drug conjugate.

To determine the expression of IL-23R in a tissue sample, the expression level of IL-23R in the tissue sample is compared to or correlated with a reference expression level of IL-23R. As used herein, "reference expression level" refers to the expression level in a reference sample that, when compared to the expression level of IL-23R in a test sample, provides information about the expression of IL-23R in a test sample. relative information. A reference expression level can be a known expression level, eg, expression in a reference sample for which the amount, concentration, and/or molar amount of IL-23R is known. For example, the reference expression level can be the expression of IL-23R in a cell line that has been transfected or otherwise engineered to express a known amount of IL-23R. In some embodiments, the reference expression level can be IL-23R. IL-23R expression has been provided by methods provided herein or known to those of ordinary skill in the art (such as ELISA, SDS-PAGE, quantitative immunoprecipitation, and/or or quantitative Western blot) to quantify the expression in cells. In other embodiments, the reference performance level relates to more than one reference, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, 50, 75, 100, and more references. In one embodiment, the reference level has 4 references: one for negative IL-23R expression, one for weak IL-23R expression, one for moderate IL-23R expression, and one for high/strong IL-23R expression.

Alternatively, the reference expression level may be a level where the exact concentration or amount of IL-23R is unknown but the state, activity, and/or function of the reference sample is known. In some embodiments, the reference expression level may be the expression level of non-diseased cells from the same patient suspected of having an IL-23R-related disease. In these embodiments, by comparing the expression of IL-23R in the test sample and the reference sample, it can be determined that the expression of IL-23R in the test sample is relative to (eg, higher than, lower than, or substantially the same) in non-diseased cells The expression of IL-23R in it. In other embodiments, the reference expression level can be the expression level of diseased cells, wherein by comparing the expression of IL-23R in the test sample and the reference sample, it can be determined that the expression of IL-23R in the test sample is relative to (for example, higher than, lower than, or substantially the same as) IL-23R expression in diseased cells. In other embodiments, the reference expression level can be the expression level of cells from the second subject, wherein by comparing the expression of IL-23R in the test sample and the reference sample, it can be determined that the expression of IL-23R in the test sample is relative to ( eg, higher, lower, or substantially the same) of IL-23R expression in cells from the second subject. The second subject can be a normal human subject who does not have an IL-23R-associated disease, a human subject who has the same type of IL-23R-associated disease as the suspected patient, or a different type of IL-23R-related disease than the suspected patient. Human Subjects with 23R-Related Diseases.

Reference samples and reference cells as described herein may be cell lines, in vitro or ex vivo cultures of cells obtained from patients suspected of having an IL-23R-related disease, cells obtained from patients suspected of having an IL-23R-related disease, cells obtained from a patient suspected of having an IL-23R-related disease, In vitro or ex vivo culture of cells from a second subject, cells obtained from a second subject.

Accordingly, in some embodiments of the methods provided herein, the reference expression level of IL-23R may be IL-23R in IL-23R-associated diseased cells, non-diseased cells from the subject, or non-diseased cells from a second subject performance level.

As noted above, in some embodiments, IL-23R expression in a sample can be determined by correlating or comparing binding of an anti-IL-23R antibody to a sample with binding of an anti-IL-23R antibody to a negative and positive reference, wherein in the reference The expression level of IL-23R is known. The reference IL-23R expression can be a positive IL-23R control or a negative IL-23R control. As used herein, "positive IL-23R control (positive IL-23R control)" or "positive control (positive control)" refers to cells, tissues, tumors, humans, and cells known to express significant amounts of IL-23R / or object. "Negative IL-23R control (negative IL-23R control)" or "negative control (negative control)" refers to cells and/or tissues known not to express IL-23R or to express low levels of IL-23R, so that cells or IL-23R in tissues was not biologically significant. IL-23R levels are not biologically significant when: (1) those of ordinary skill in the art would consider the expressed level of IL-23R to be low in view of the protein products of housekeeping genes; (2) low amounts of IL-23R The presence or absence of 23R does not cause a biological difference to the cell or tissue; and (3) if these insignificant amounts of IL-23R are removed or deleted from the cell or tissue, the cell or tissue will substantially continue to interact with the transplanted Acts in the same way as before dividing or deleting. Known IL23R gene expression but not protein expression can be determined independently by qPCR assay. Known expression of IL-23R protein can also be determined independently using any of the immunoassays described below with anti-IL-23R antibodies that have been determined to be specific for IL-23R (eg, identified in the specificity screening methods described above). Suitable immunoassays include, for example and without limitation, IHC assays, immunoblotting assays, FACS assays, or ELISAs. In some embodiments, the IL23R mRNA level in the negative control may not be zero due to background noise of the assay or due to biologically insignificantly low levels of remaining IL-23R. For example, when the IL23R mRNA level in the qPCR assay is substantially similar to the mRNA level detected with a set of non-specific primers, or when the IL23R mRNA level is biologically ineffective given the IL23R mRNA level in the positive IL-23R control When significant, negative IL-23R controls can be appropriately considered IL-23R negative. Similarly, IL-23R detected by an immunoassay using another IL-23R-specific antibody in the negative control may not be zero because of background noise in the assay or because of biologically insignificantly low levels of remaining IL-23R . Background noise can be caused by non-specific interactions between assay reagents other than anti-IL-23R antibody and the sample. For example, when the level of IL-23R in a negative control detected by an anti-IL-23R antibody is substantially similar to the level detected by an isotype control antibody in the same assay, the negative IL-23R control may be appropriately considered as IL-23R. 23R negative. In some assays, background noise can account for a significant percentage of the detected signal from IL-23R expression.

In addition, positive and negative controls have been identified by those of ordinary skill in the art and are disclosed in the literature, and include positive and/or negative tissues, cells (including, for example, cell lines), and pathology samples. Such documents can be readily identified by searching databases such as PubMed (eg, using search terms such as IL-23R, expression, positive, negative, and/or distribution) and analyzing the search hits.

Therefore, the relative amount of antibody or antigen-binding fragment thereof bound to negative control cells without IL-23R expression may be about 50%, 40% of the amount of antibody or antigen-binding fragment thereof bound to sample cells expressing IL-23R , 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.3%, 0.2%, 0.1%, 0.05%, 0.03%, 0.01%, 0.001%, or less.

Accordingly, in some embodiments of the methods provided herein, the reference expression level of IL-23R is the expression level of IL-23R in the negative control, wherein the expression of IL-23R in the negative control is independently determined by qPCR, using IHC assay using a secondary antibody, immunoblot assay using a secondary antibody, FACS assay using a secondary antibody, or ELISA determination using a secondary antibody.

In other embodiments of the methods provided herein, the reference expression level of IL-23R is the expression level of IL-23R in positive control cells expressing IL-23R, wherein the expression of IL-23R in the positive control is determined independently by qPCR assay, IHC assay using a secondary antibody, immunoblotting assay using a secondary antibody, FACS assay using a secondary antibody, or ELISA assay using a secondary antibody.

The expression level of IL-23R in the sample can be different from the expression level in the positive control. The relative amount of antibody or antigen-binding fragment thereof bound to the tissue sample may be about 5%, 10%, 20%, 30%, 40% of the amount of antibody or antigen-binding fragment thereof bound to positive control cells expressing IL-23R %, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, 200%, 250%, 300%, 400%, 500%, 750%, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, 200 times, 500 times, or more times.

Many different PCR or qPCR protocols are known in the art and exemplified herein below, and can be directly applied or adapted for determining IL23R mRNA levels in samples or controls, which can be used as A proxy for the expression level of IL-23R protein. Quantitative PCR (qPCR), also known as real-time PCR, is applied and adapted in some embodiments because it not only provides quantitative measurements, but also reduces time and contamination. As used herein, "quantitative PCR" (or "qPCR") refers to the direct monitoring of the progress of PCR amplification, as it occurs without repeated sampling of the reaction product. In quantitative PCR, reaction products as they are produced can be monitored via signaling mechanisms such as fluorescence and tracked after the signal rises above background levels but before the reaction reaches a plateau. The number of cycles required to achieve a detectable or "threshold" level of fluorescence is directly proportional to the concentration of amplifiable target at the start of the PCR process, allowing a measure of signal strength to provide an immediate measure of the amount of target nucleic acid in the sample . When qPCR is used to determine mRNA expression levels, an additional step of reverse transcription of mRNA into DNA is performed prior to qPCR analysis. Examples of PCR methods can be found in the literature (Wong et al., BioTechniques 39:75-85 (2005); D'haene et al., Methods 50:262-270 (2010)), which are incorporated herein by reference in their entirety . Examples of PCR assays can be found in US Patent No. 6,927,024, which is hereby incorporated by reference in its entirety. Examples of RT-PCR methods can be found in US Patent No. 7,122,799, which is hereby incorporated by reference in its entirety. The method of fluorescent in situ PCR is described in US Patent No. 7,186,507, which is incorporated herein by reference in its entirety.

In a specific embodiment, qPCR can be performed to determine or measure IL23R mRNA levels as follows. Briefly, the average Ct (cycle threshold) value (or interchangeably referred to herein as Cq (quantitative cycle)) of repeated qPCR reactions for IL23R and one or more housekeeping genes was determined. The mean Ct value of IL23R can then be normalized to the Ct value of the housekeeping gene using the following exemplary formula: IL23R -ΔCt=(Mean Ct of IL23R -Mean Ct of housekeeping gene A). The relative IL23R -ΔCt can then be used to determine the relative level of IL23R mRNA, for example by using the formula = 2 ^{- ΔCt} for mRNA expression. For an overview of Ct and Cq values, see MIQE Guidelines (Bustin et al., The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments, Clinical Chemistry 55:4 (2009)).

Other common methods known in the art for quantifying mRNA expression in a sample can also be used, including northern blots and in situ hybridization (Parker & Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNase protection assay (Hod, Biotechniques 13:852-854 (1992)); microarray (Hoheisel et al ., Nature Reviews Genetics 7:200-210 (2006); Jaluria et al ., Microbial Cell Factories 6:4 ( 2007)); and polymerase chain reaction (PCR) (Weis et al , Trends in Genetics 8:263-264 (1992)). Alternatively, mRNA expression levels can be determined by sequencing techniques. Representative methods of sequencing-based gene expression analysis include sequential analysis of gene expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).

As mentioned earlier, a tissue sample may be, but is not limited to, tissue, body fluid, tissue fraction, and/or cells isolated from an organism such as a mammal, especially a human. Thus, tissue samples can be obtained from various organs of a subject, including human subjects. In some embodiments, a tissue sample is obtained from an organ suspected of having a disease, dysfunction, or condition, such as an immune disease. In other embodiments, the tissue sample is obtained from a normal organ of the patient under test or from a second human subject.

Anti-IL-23R antibodies bound to a sample can be detected by various immunoassays known in the art, including IHC methods, immunoblot assays, FACS assays, and ELISA.

IL-23R can be detected by anti-IL-23R antibodies in various IHC methods. IHC staining of tissue sections has been shown to be a reliable method of assessing or detecting the presence of proteins in a sample. IHC techniques usually use antibodies to detect and visualize cellular antigens in situ by chromogenic or fluorescent methods. Expression can be detected in IHC assays using primary antibodies or antisera that specifically target IL-23R, such as polyclonal antisera and monoclonal antibodies. In some embodiments, the tissue sample is contacted with a primary antibody to a specific target for a period of time sufficient for antibody-target binding to occur. As previously discussed in detail, antibodies can be detected by direct labels on the antibodies themselves, such as radioactive labels, fluorescent labels, hapten labels such as biotin, or enzymes such as horseradish peroxidase or alkaline phosphatase ). Alternatively, an unlabeled primary antibody system is used with labeled secondary antibodies comprising antisera, polyclonal antisera, or monoclonal antibodies specific for the primary antibody. IHC protocols and kits are well known in the art and are commercially available. Automated systems for slide preparation and IHC processing are commercially available. The Leica BOND Autostainer and the Leica Bond Refine Detection System are examples of such automated systems.

In some embodiments, an IHC assay is performed using an unlabeled primary antibody paired with a labeled secondary antibody in an indirect assay. Indirect assays use two antibodies to detect a target protein (such as IL-23R) in a tissue sample. First, an unconjugated primary antibody is applied to the tissue (first layer), which reacts with the target antigen in the tissue sample. Next, an enzyme-labeled secondary antibody, which specifically recognizes the antibody isotype of the primary antibody (second layer), is applied. The secondary antibody reacts with the primary antibody, followed by the application of the substrate-chromogen. The second layer of antibodies can be labeled with an enzyme such as peroxidase, which reacts with the chromogen 3,3'-diaminobenzidine (DAB) to produce a brown precipitate at the reaction site. This method is sensitive and versatile since the potential signal is amplified by a signal amplification system.

In some embodiments to increase detection sensitivity, a signal amplification system may be used. As used herein, "signal amplification system" refers to a system of reagents and methods that can be used to increase the signal for detection of bound primary or secondary antibodies. The signal amplification system increases the sensitivity of target protein detection, increases the detection signal, and lowers the lower limit of the detection limit. Several types of signal amplification systems exist, including enzyme labeling systems and macrolabeling systems. These systems/methods are not mutually exclusive and can be used in combination for additive effects.

Megatags or megatag systems are collections of tags attached to or incorporated into a common scaffold, ranging in number from tens (eg, phycobiliproteins) to millions (eg, fluorescent microspheres). Scaffolds can be coupled to target-specific affinity reagents, such as antibodies, and incorporated tags thereby uniformly associate with the target upon binding. A marker in a macromarker can be any marker described herein, such as a fluorophore, hapten, enzyme, and/or radioisotope. In one embodiment of the signal amplification system, labeled chain polymer-conjugated secondary antibodies are used. The polymer technology utilizes HRP enzyme-labeled dextran inert "spine" molecules that can attach 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 , 30, 50, or more secondary antibody molecules, making the system even more sensitive.

Enzyme-based signal amplification systems utilize the catalytic activity of enzymes, such as horseradish peroxidase (HRP) or alkaline phosphatase, to generate in situ high-density labeling of target proteins or nucleic acid sequences. In one embodiment, tyramide can be used to increase the HRP signal. In such systems, HRP enzymatically converts labeled tyramide derivatives into highly reactive, short-lived tyramide free radicals. The labeled reactive tyrosine radicals are then covalently coupled to residues near the HRP antibody-target interaction site (mainly the phenolic moiety of the protein tyrosine residues), resulting in amplification with signal localization and minimal diffusion-related loss. The marked number of parts. Thus, the signal may be amplified 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 15, 20, 25, 30, 50, 75, or 100 times. As known to those of ordinary skill in the art, the label on the tyramide can be any label described herein, including fluorophores, enzymes, haptens, radioisotopes, and/or luminophores. Other enzyme-based reactions can also be used to generate signal amplification. For example, enzyme-labeled fluorescent (ELF) signal amplification can be used with alkaline phosphatase, which enzymatically cleaves the faintly blue fluorescent substrate (ELF 97 phosphate) and converts it into a Bright yellow-green fluorescent precipitate with Stokes shift and excellent photostability. Tyramide-based signal amplification systems and ELF signal amplification are commercially available, eg, from ThermoFisher Scientific (Waltham, MA USA 02451).

Thus, in some embodiments of the methods provided herein, the expression level of IL-23R is detected with a signal amplification system.

In some embodiments, the sample is then contrast stained to identify cellular and subcellular elements.

In some embodiments, the expression level of IL-23R can also be detected using an immunoblotting assay with the antibodies described herein. In some embodiments of immunoblot assays, proteins are usually, but not necessarily, separated by electrophoresis and transferred to a membrane, usually nitrocellulose or PVDF. Similar to IHC assays, primary antibodies or antisera (such as polyclonal antisera and monoclonal antibodies) that specifically target IL-23R can be used to detect protein expression. In some embodiments, the membrane is contacted with a primary antibody of a specific target for a period of time sufficient for antibody-antigen binding to occur, and the bound antibody can be detected by a direct label on the primary antibody itself, e.g. radioactive label, fluorescent markers, hapten markers such as biotin, or enzymes such as horseradish peroxidase or alkaline phosphatase. In other embodiments, an unlabeled primary antibody is used together with a labeled secondary antibody specific for the primary antibody in an indirect assay as described above. As described herein, secondary antibodies can be labeled, for example, with enzymes or other detectable labels such as fluorescent labels, luminescent labels, colorimetric labels, or radioactive isotopes. Immunoblotting protocols and kits are well known in the art and are commercially available. Automated systems for immunoblotting such as the iBind Western system for Western blots (ThermoFisher, Waltham, MA USA 02451 ) are commercially available. Immunoblotting methods include, but are not limited to, Western blots, intracellular Western blots, and spot blots. Dot blot is a simplified procedure in which protein samples are not separated by electrophoresis but are spotted directly on a membrane. Intracellular Western blotting involves seeding cells in microtiter dishes, fixing/permeabilizing the cells, and subsequent primary antibody labeled as described herein or unlabeled primary antibody followed by Detection by labeled secondary antibodies.

In other embodiments, the expression level of IL-23R can also be detected using the antibodies described herein in flow cytometry assays, including fluorescence activated cell sorting (FACS) assays. Similar to IHC or immunoblotting assays, primary antibodies or antisera (such as polyclonal antisera and monoclonal antibodies) that specifically target IL-23R can be used in FACS assays to detect protein expression. In some embodiments, cells are stained with a primary antibody directed against a particular protein of interest for a period of time sufficient for antibody-antigen binding to occur, and the bound antibody can be detected by a direct label on the primary antibody, e.g. Fluorescent markers or hapten markers (such as biotin). In other embodiments, an unlabeled primary antibody is used together with a fluorescently labeled secondary antibody specific for the primary antibody in an indirect assay as described above. FACS provides a method for sorting or analyzing (one cell at a time) a mixture of fluorescently labeled biological cells based on the specific light scattering and fluorescence characteristics of each cell. The flow cytometer thus detects and reports the intensity of the fluorochrome-tagged antibody, which is indicative of the expression level of the target protein. Thus, expression levels of surface proteins such as IL-23R can be detected using antibodies against the protein of interest. Non-fluorescent cytoplasmic proteins can also be visualized by staining permeabilized cells. Methods for performing FACS staining and analysis are well known to those of ordinary skill in the art and are described in Teresa S. Hawley and Robert G. Hawley in Flow Cytometry Protocols, Humana Press, 2011 (ISBN 1617379506, 9781617379505).

In other embodiments, the expression level of IL-23R can also be detected using an immunoassay such as enzyme immunoassay (EIA) or ELISA. EIA and ELISA assays are known in the art, eg, for assaying a wide variety of tissues and samples, including blood, plasma, serum, or bone marrow. A wide range of ELISA assay formats are available, see eg, US Patent Nos. 4,016,043, 4,424,279, and 4,018,653, the entire contents of which are incorporated herein by reference. These include non-competitive types of single-point and two-point or "sandwich" tests as well as traditional competitive combined tests. These assays also involve direct binding of labeled antibodies to the protein of interest. The sandwich test is a commonly used test. There are some variations in the sandwich assay technique. For example, in a typical forward assay, an unlabeled antibody system is immobilized on a solid substrate, and the sample to be tested is contacted with the binding molecules. After a suitable incubation period (i.e., a period of time sufficient to allow formation of the antibody-antigen complex), a second antibody specific for the antigen labeled with a reporter molecule capable of producing a detectable signal is then added and incubated sufficient to allow formation Another antibody-antigen-marker antibody complex time. Any unreacted material is washed away, and the presence of antigen is determined by observing the signal generated by the reporter molecule. Results can be qualitative by simply observing a visual signal, or can be quantified by comparison to a control sample containing known amounts of the protein of interest.

In some embodiments of EIA or ELISA assays, the enzyme is conjugated to a second antibody. In other embodiments, instead of enzyme-labeled secondary antibodies, fluorescently labeled secondary antibodies can be used to generate a detectable signal in an ELISA assay format. When activated by irradiation with light of a specific wavelength, the fluorochrome-labeled antibody absorbs light energy, induces an excitable state of the molecule, and subsequently emits light of a characteristic color that can be visually detected with an optical microscope. As with EIA and ELISA, allows for fluorescently indicated antibody binding to primary antibody-target protein complexes. After washing away unbound reagents, the remaining ternary complex is then exposed to light of the appropriate wavelength, and the observed fluorescence indicates the presence of the target protein of interest. Immunofluorescence and EIA techniques are both well established in the art and are disclosed herein.

For the immunoassays described herein, any of a number of enzymatic or non-enzymatic labels can be utilized as long as the enzymatic activity or non-enzymatic label, respectively, can be detected. The enzyme thereby generates a detectable signal that can be used to detect the target protein. Particularly useful detectable signals are chromogenic or fluorogenic signals. Thus, particularly useful enzymes for use as markers include those for which chromogenic or fluorogenic substrates can be obtained. Such chromogenic or fluorogenic substrates can be converted by enzymatic reactions into readily detectable chromogenic or fluorogenic products, which can be readily detected and/or quantified using microscopy or spectroscopy. Such enzyme systems are well known to those of ordinary skill in the art and include, but are not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, and the like (see Hermanson, Bioconjugate Techniques , Academic Press, San Diego (1996)). Other enzymes with well-known chromogenic or fluorogenic substrates include a variety of peptidases in which the chromogenic or fluorogenic peptide substrates can be used to detect proteolytic cleavage reactions. The use of chromogenic and fluorogenic substrates in bacterial diagnostics is also well known, including but not limited to the use of α- and β-galactosidase, β-glucuronidase, 6-phospho-β-D-galactosidase, Glycoside 6-phosphogalactohydrolase, β-glucosidase, α-glucosidase, amylase, neuraminidase, esterase, lipase, and the like (Manafi et al., Microbiol. Rev. 55 :335-348 (1991)), and such enzymes with known chromogenic or fluorogenic substrates can be readily adapted for use in the methods of the invention.

A variety of chromogenic or fluorogenic substrates that produce a detectable signal are well known to those of ordinary skill in the art and are commercially available. Exemplary substrates that can be used to generate a detectable signal include, but are not limited to, 3,3'-diaminobenzidine (DAB), 3,3',5,5'-tetramethyl, for horseradish peroxidase benzidine (TMB), chloronaphthol (4-CN) (4-chloro-1-naphthol), 2,2'-azo-bis(3-ethylbenzothiazoline-6-sulf acid) (ABTS), o-phenylenediamine dihydrochloride (OPD), and 3-amino-9-ethylcarbazole (AEC); 5-bromo-4-chloro-3 for alkaline phosphatase - Indolyl-1-phosphate (BCIP), nitro blue tetrazolium (NBT), Fast Red (Fast Red TR/AS-MX), and p-nitrophenyl phosphate (PNPP); for beta 1-Methyl-3-indolyl-β-D-galactopyranoside and 2-methoxy-4-(2-nitrovinyl)phenyl β-D-piperinoside of -galactosidase Galactopyranoside; 2-methoxy-4-(2-nitrovinyl)phenyl β-D-glucopyranoside for β-glucosidase; and the like. Exemplary fluorogenic substrates include, but are not limited to, 4-(trifluoromethyl)umbelliferyl phosphate for alkaline phosphatase; 4-methylumbelliferyl phosphate bis(2- amino-2-methyl-1,3-propanediol), 4-methylumbelliferyl phosphate bis(cyclohexylammonium), and 4-methylumbelliferyl phosphate; for horseradish peroxidase QuantaBlu ^™ and QuantaRed ^™ ; 4-methylumbelliferyl β-D-galactopyranoside, luciferin di(β-D-galactopyranoside), and naphthalene for β-galactosidase and luciferin di-(β-D-galactopyranoside); 3-acetylumbelliferyl β-D-glucopyranoside and 4-methylumbelliferyl for β-glucosidase - β-D-glucopyranoside; and 4-methylumbelliferyl-α-D-galactopyranoside for α-galactosidase. Exemplary enzymes and substrates for generating detectable signals are also described, eg, in US Publication 2012/0100540. A variety of detectable enzyme substrates, including chromogenic or fluorogenic substrates, are well known and commercially available (Pierce, Rockford IL; Santa Cruz Biotechnology, Dallas TX; Invitrogen, Carlsbad CA; 42 Life Science; Biocare) . In essence, the substrate is converted to a product, which forms a precipitate that deposits at the target nucleic acid. Other exemplary substrates include, but are not limited to, HRP-Green (42 Life Science), Betazoid DAB, Cardassian DAB, Romulin AEC, Bajoran Violet, Vina Green, Deep Space Black ^™ , Warp Red ^™ , Vulcan Fast Red, and Ferangi Blue ( Biocare, Concord CA; biocare.net/products/detection/chromogens).

唑衍生物及達珀西(dapoxyl)衍生物(Molecular Probes)；螢光黃(3,6-二磺酸酯-4-胺基-萘二甲醯亞胺)及其衍生物；CyDye ^™螢光染料(Amersham/GE Healthcare Life Sciences; Piscataway NJ)、及類似物。例示性發色團包括但不限於酚酞、孔雀綠、硝基芳族（諸如硝基苯基）、重氮染料、達波希(dabsyl)（4-二甲基胺基偶氮苯-4'-磺醯基）、及類似物。 In some embodiments of immunoassays, the detectable label can be directly coupled to the primary antibody or a secondary antibody that can have an unlabeled primary antibody. Exemplary detectable labels are well known to those of ordinary skill in the art and include, but are not limited to, chromogenic or fluorescent labels (see Hermanson, Bioconjugate Techniques , Academic Press, San Diego (1996)). Exemplary fluorophores that can be used for labeling include, but are not limited to, rose bengal derivatives, for example, tetramethyl rose bengal, rose bengal B, rose bengal 6G, sulforhosin B, Texas red (sulforosin Rose Bengal 101), Rose Bengal 110, and its derivatives, such as Tetramethyl Rose Bengal-5-(or 6), Lissamine Rose Bengal B, and the like; 7-nitrobenzene-2-oxa-1 ,3-oxadiazole (NBD); luciferin and its derivatives; naphthalene, such as dansyl (5-dimethylaminonaphthalene-1-sulfonyl); coumarin derivatives, such as 7- Amino-4-methylcoumarin-3-acetic acid (AMCA), 7-diethylamino-3-[(4'-(iodoacetyl)amino)phenyl]-4-methyl Coumarin (DCIA), Alexa fluor dye (Molecular Probes), and the like; 4,4-difluoro-4-bora-3a,4a-diaza-s-dicyclopentadieneacene (BODIPY ^™ ), and its derivatives (Molecular Probes; Eugene Oreg.); pyrene and sulfonated pyrenes, such as Cascade Blue ^™ and its derivatives, including 8-methoxypyrene-1,3,6-trisulfonic acid, and Analogs; pyridyl

Azole derivatives and dapoxyl derivatives (Molecular Probes); Fluorescent yellow (3,6-disulfonate-4-amino-naphthalimide) and its derivatives; CyDye ^™ fluorescent Photodye (Amersham/GE Healthcare Life Sciences; Piscataway NJ), and the like. Exemplary chromophores include, but are not limited to, phenolphthalein, malachite green, nitroaromatics (such as nitrophenyl), diazo dyes, dabsyl (4-dimethylaminoazobenzene-4' -sulfonyl), and the like.

Chromogenic or fluorescently detectable signals associated with bound primary or secondary antibodies can be observed using methods well known to those of ordinary skill in the art, such as microscopy or spectroscopy.

"Determining the expression of IL-23R" refers to placing the expression of IL-23R in the test biological sample in the reference system (or reference scale), so that people familiar with the reference system can judge the test sample Relative performance of IL-23R in relative to other samples that have been placed in the reference system. Thus, the determination involves comparing the expression of IL-23R in the test tissue sample to a reference expression level of IL-23R.

In some embodiments, the reference system can be a quantitative system, wherein the actual molar concentration or molar amount of IL-23R in the test sample is compared to the molar concentration or molar amount of the reference performance level. In some embodiments, other proxy value measurements that are linearly proportional to molar concentration or molar quantity may be used. Examples of such proxy measurements include measurements of fluorescence intensity of bound antibodies, measurements of luminescence intensity of bound antibodies, measurements of radioactivity of bound antibodies, and/or colorimetric or chromogenic measurements of bound antibodies.

In other embodiments, the reference system may be a classification system. Classification systems can have as few as 2 classes and as many as 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more categories. In one embodiment, the reference system has a positive class for samples that are positive for IL-23R (positive) and a negative class for samples that are negative for IL-23R (negative). In such classification systems, determining the expression of IL-23R in a test sample involves comparing the expression of IL-23R in the test sample with the expression of IL-23R in a positive reference sample and/or a negative reference, and if the test sample expresses IL-23R Levels of 23R that are similar to or higher than the positive reference place the test sample in the positive category. In another embodiment, the classification system has 3 categories, such as negative, moderate, and high performance categories. In another embodiment, the classification system has 4 categories, such as negative, low/weak, moderate/moderate, and high/strong manifestation categories. In some aspects, determining the expression of IL-23R in the test sample involves comparing the expression of IL-23R in the test sample to one or more IL-23R expression references of known classes, and based on its relative to the reference(s) The performance of puts the test sample into the category.

In some embodiments, the reference system may be a scoring system. A scoring system can be similar to a classification system, except that the categories are replaced by points. For example, a 2-category system for negative and positive IL-23R expression can be a scoring system of 0 and 1, where 0 means negative and 1 means positive. In another embodiment, the 3-category system may be a scoring system of 0, 1, and 2, where 0 is negative, 1 is low/weak, and 2 is moderate/moderate and high/strong. In another example, the 4-category system may be a scoring system of 0, 1, 2, and 3, where 0 is negative, 1 is low/weak, 2 is moderate/moderate, and 3 is high/strong . Similar to classification systems, determining the expression of IL-23R in a test sample in a scoring system involves comparing the expression of IL-23R in a test sample with one or more IL-23R expression references with known scores, and based on their relative The performance of the reference is assigned a test sample score. However, the scores of the scoring system can be discrete and discrete numbers (such as a system of 0, 2, 4, 6, 8, and 10, or a system of 1, 4, 6, 11, 13, and 19), with decimal points numbers (eg, 1, 1.5, 2, 2.5, 3, 3.5, etc.), negative numbers, numbers starting with any number (eg, 1000, 2000, 3000, etc.), and any number that can be used to track relative protein expression in biological samples Group.

In some embodiments, the reference system can be a cell percentage with a classification or scoring system. Combinations of cell percentages and classification or scoring systems provide finer sample grading. In such combinatorial systems, each cell line from a biological sample is assigned or placed into a classification or scoring system, and the approximate percentage of cells in each class or fraction of the test sample is determined. In one example, the measurement of the percentage of cells can be coupled to a 2-category system of positive and negative IL-23R expression, where the sample is not measured as a whole, but divided into the percentage of IL-23R expressing cells and the IL-23R expressing negative cells percentage. For example, in a class 2 system with positive and negative IL-23R expression, if placed in a class 2 system but with 10% of cells positive for IL-23R expression and 90% of cells negative for IL-23R expression, the test sample May be negative for IL-23R. In one embodiment, the reference system includes cell percentages with a 2-category or 2-score system. In one embodiment, the reference system includes cell percentages with a 3-category or 3-score system. In one embodiment, the reference system includes cell percentages with a 4-category or 4-score system. In one embodiment, the reference system includes cell percentages with a 5-category or 5-point system. In one embodiment, the reference system includes cell percentages with a 6-category or 6-score system. In one embodiment, the reference system includes cell percentages with a 7-category or 7-score system. In one embodiment, the reference system includes cell percentages with an 8-category or 8-score system. In one embodiment, the reference system includes cell percentages with a 9-category or 9-score system. In one embodiment, the reference system includes cell percentages with a 10-category or 10-point system. In one embodiment, the reference system includes cell percentages with any classification or any scoring system. In one embodiment, the reference system includes cell percentages with a 4-point system comprising 0 (IL-23R negative), 1 (low/weak IL-23R expression), 2 (moderate/moderate IL-23R expression ), and 3 (high/strong IL-23R expression).

In some aspects, the reference system can be the ratio of IL-23R expression relative to the expression of at least one reference protein. In some embodiments, the ratio may be a ratio of a quantitative measure of IL-23R expression to a quantitative measure of a reference protein, where quantitative measures include those described herein, such as molar concentration, molar amount, bound antibody Measurement of fluorescence intensity, measurement of luminescence intensity of bound antibody, measurement of radioactivity of bound antibody, and/or colorimetric or chromogenic measurement of bound antibody. In other embodiments, the ratio can also be the ratio of scores assigned to IL-23R expression and reference protein according to any of the scoring systems provided herein. A reference protein can be a protein of ordinary cellular function, such as actin, GAPDH, GDI, or any protein expressed by a housekeeping gene. For example, if a test sample has an IL-23R expression score of 3 and an actin expression score of 1, the ratio can be determined to be 3.

In other aspects, the reference system may utilize the results of mathematical functions using one or more of classifications, scores, ratios, percentages, and quantitative measures as inputs. In some embodiments, the mathematical function combines multiple inputs using compound, add, multiply, or combine operators to produce a finer grading that provides information about the IL-23R expression and/or the size of the IL-23R expression in a sample results of more detailed information. In one embodiment, the mathematical function calculates the H-score based on a combination of percentages and a 4-point system. For example, by summing the product of the percentage of cells (0 to 100) with each IL-23R expression score (0=negative, 1=low/weak, 2=moderate/moderate, and 3=high/strong) Calculate the H-score. For example: a sample with 10% of cells scoring 3, 30% of cells scoring 2, 20% of cells scoring 1, and 40% of cells scoring 0 will have (3 × 10) + (2 × 30) + (1 × 20) + (0 × 40) = H-score of 110.

Thus, as provided herein, the expression level of IL-23R can be determined using the following: classification system, scoring system, ratio of IL-23R expression relative to expression of at least one reference protein, percentage of cells in the classification or scoring system, A quantitative measure of the IL-23R staining signal, or one or more of the classification, fraction, ratio, percentage, and quantitative measure, is used as the result of a mathematical function as input.

Most formalin-fixed tissues require an antigen retrieval step prior to immunohistochemical staining. Methylene bridges formed during fixation cross-link proteins and mask epitopes of antigens. Antigen retrieval methods break these methylene bridges and expose the epitope, allowing antibody binding. In some embodiments, the antigen is retrieved by heat-induced epitope retrieval (HIER) methods. In other embodiments, the antigen is retrieved by enzymatic retrieval (eg, proteolytic digestion) methods. For HIER, formalin-fixed paraffin-embedded (FFPE) tissue sections can be stored at 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, Heating at 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, or 130°C. FFPE tissue sections can be heated at any of these temperatures 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 150, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380, and 1440 minutes. A HIER procedure performed at any of the aforementioned temperatures for any of the aforementioned durations may be performed at pH 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7, 7.2, 7.4, 7.6, 7.8, 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10, 10.2, 10.4, 10.6, 10.8, 11, 11.5, or 12 solutions. In some embodiments, HIER may be at a temperature selected from the group consisting of 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C and at a temperature selected from the group consisting of 8, 8.2, The pH of the group consisting of 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10, 10.2, 10.4 is selected from the group consisting of 5, 10, 15, 20, 25, 30, 35, 40 The duration of the group.

Accordingly, the methods provided herein further comprise the step of restoring epitopes of IL-23R by heat-induced epitope retrieval (HIER).

Unlabeled antibodies, labeled antibodies, and derivatives and analogs thereof that immunospecifically bind to IL-23R antigens can be used for diagnostic purposes to detect, diagnose, or monitor IL-23R-mediated diseases. Accordingly, provided herein are methods for detecting IL-23R-mediated diseases comprising: (a) detecting IL-23R antigen in a subject using one or more antibodies provided herein that immunospecifically bind to IL-23R antigen expression in a cell or tissue sample; and (b) comparing the level of IL-23R antigen to a control level, such as the level in a normal tissue sample (e.g., from a patient without an IL-23R-mediated disease, or from The same patient before the onset of the disease), wherein an increase in the assay level of IL-23R antigen compared to the control level of IL-23R antigen is indicative of IL-23R-mediated disease.

Also provided herein is a diagnostic assay for diagnosing an IL-23R-mediated disease comprising: (a) detecting IL-23R antigen in an individual using one or more antibodies provided herein that immunospecifically bind to IL-23R antigen the level in a cell or tissue sample; and (b) comparing the level of IL-23R antigen to a control level, such as the level in a normal tissue sample, wherein the assayed level of IL-23R antigen is increased compared to the control level of IL-23R antigen Indicates IL-23R mediated disease. In certain embodiments, provided herein is a method of treating an IL-23R-mediated disease in a subject, comprising: (a) detecting IL-23R using the antibodies provided herein that immunospecifically bind to one or more IL-23R antigens; the level of 23R antigen in a cell or tissue sample from the subject; and (b) comparing the level of IL-23R antigen to a control level, such as the level in a normal tissue sample, wherein the assayed level of IL-23R antigen is compared to that of IL-23R Increased control levels of antigen are indicative of IL-23R mediated disease. In some embodiments, the method further comprises (c) administering to a subject identified as having an IL-23R-mediated disease an effective amount of an antibody provided herein. A more definitive diagnosis of IL-23R-mediated diseases may allow health professionals to employ preventive measures or aggressive treatments earlier, thereby preventing the development or further progression of IL-23R-mediated diseases.

Antibodies provided herein can be used to assay levels of IL-23R antigen in biological samples using typical immunohistological methods as described herein or as known to those of ordinary skill in the art (e.g., see Jalkanen et al. , 1985, J. Cell. Biol. 101:976-985; and Jalkanen et al. , 1987, J. Cell. Biol. 105:3087-3096). Other antibody-based methods that can be used to detect protein gene expression include immunoassays such as enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels such as glucose oxidase; radioactive isotopes such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (121In ), and Tc (99Tc); luminescent markers, such as luminol; and fluorescent markers, such as luciferin and rose bengal, and biotin.

One aspect provided herein is the detection and diagnosis of IL-23R-mediated diseases in humans. In one embodiment, the diagnosis comprises: a) administering (e.g., parenterally, subcutaneously, or intraperitoneally) to the subject an effective amount of a labeled antibody that immunospecifically binds to the IL-23R antigen; b) after administering A period of time is then waited to allow the labeled antibody to concentrate in the subject expressing the IL-23R antigen (and clear unbound labeled molecule to background levels); c) determine the background level; and d) detect the subject The labeled antibody is detected in such a way that the detection of the labeled antibody above the background level indicates that the subject has an IL-23R-mediated disease. Background levels can be determined by a variety of methods, including comparing the detected amount of the labeled molecule to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the number of imaging segments needed to produce a diagnostic image. In the case of radioisotopic moieties, the amount of radioactivity injected will generally be in the range of about 5 to 20 millicuries of99Tc for human subjects. The labeled antibody will then accumulate at the location of the cells containing the specific protein. In vivo tumor imaging is described in SW Burchiel et al. , "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, SW Burchiel and BA Rhodes, eds., Masson Publishing Inc. (1982 ).

Depending on several variables, including the type of label used and the mode of administration, the time interval after administration to allow the labeled antibody to concentrate at the site in the subject and for unbound labeled antibody to clear to background levels is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment, the time interval after administration is 5 to 20 days or 5 to 10 days.

In one embodiment, the IL-23R-mediated disease is monitored by repeating the method of diagnosing the IL-23R-mediated disease, e.g., one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc. conduct.

The presence of the labeled molecule can be detected in the subject using methods known in the art for in vivo scanning. These methods depend on the type of marker used. Those of ordinary skill in the art will be able to determine the appropriate method for detecting a particular marker. Methods and devices that may be used in the diagnostic methods provided herein include, but are not limited to, computed tomography (CT), whole body scans such as positron emission tomography (PET), magnetic resonance imaging (MRI), and ultrasound scans.

In one embodiment, the molecule is radiolabeled and detected in the patient using a radioreactive surgical instrument (Thurston et al. , US Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and detected in the patient using a fluorescent reactive scanning instrument. In another embodiment, the molecules are labeled with positron emission metals and detected in the patient using positron emission tomography. In yet another embodiment, the molecule is labeled with a paramagnetic marker and detected in the patient using Magnetic Resonance Imaging (MRI). Method of therapeutic use

In another aspect, provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one embodiment, the disease or disorder is an IL-23R mediated disease or disorder. In one embodiment, the disease or disorder is an IL-23-related disease or disorder. Also provided herein is a method of treating a disease or disorder wherein one or more therapeutic agents in combination with an antibody or antigen-binding fragment thereof provided herein is administered to a subject.

The disclosure also pertains to methods of inhibiting (ie, antagonizing) the function of IL-23R to inhibit STAT activation using the antibodies provided herein. In some embodiments, the antibodies provided herein inhibit the function of IL-23R to inhibit STAT3 activation. In some embodiments, the antibodies provided herein inhibit STAT3 phosphorylation.

The disclosure also relates to a method of treating or preventing an IL-23R-related disease or disorder in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof or the present invention that specifically binds IL-23R. The pharmaceutical composition of the invention. The present disclosure also relates to a method for treating or preventing an autoimmune disease in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or an antigen-binding fragment thereof or the medicament of the present invention Composition. In some embodiments, the autoimmune disease is selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD ), or ulcerative colitis (UC).

The pharmaceutical composition comprises a therapeutically effective amount of an anti-IL-23R antibody or an antigen-binding fragment thereof. As used herein, the term "therapeutically effective amount" refers to the amount of an active ingredient or component that elicits a desired biological or medical response in a subject. A therapeutically effective amount can be determined empirically and in a routine manner with reference to the stated purpose.

As used herein with reference to an anti-IL-23R antibody or antigen-binding fragment thereof, a therapeutically effective amount means the amount of an anti-IL-23R antibody or antigen-binding fragment thereof that modulates an immune response in a subject in need thereof.

A therapeutically effective amount means a therapeutically sufficient amount to achieve one, two, three, four, or more of the following effects: (i) reducing or ameliorating the severity of the disease, disorder, or condition being treated, or symptoms associated therewith; (ii) reducing the duration of the disease, disorder, or condition being treated, or symptoms associated therewith; (iii) preventing the progression of the disease, disorder, or condition being treated, or symptoms associated therewith; return of the disease, disorder, or condition being treated, or symptoms associated therewith; (v) preventing the development or onset of the disease, disorder, or condition being treated, or symptoms associated therewith; (vi) preventing the disease, disorder, or condition being treated, recurrence of a disease, or condition, or symptoms associated therewith; (vii) reducing hospitalization of subjects suffering from the disease, disease, or condition being treated, or symptoms associated therewith; (viii) reducing or condition, or symptoms associated therewith; (ix) increase the survival rate of subjects suffering from the disease, disorder, or condition, or symptoms associated therewith; (xi) inhibit or decrease the subject's disease, disease, or condition, or symptoms associated therewith; and/or (xii) enhancing or improving the disease-preventive or therapeutic effect(s) of another therapy.

A therapeutically effective amount or dose can vary depending on various factors, such as the disease, disorder or condition to be treated, the means of administration, the target site, the physiological state of the subject (including, for example, age, weight, health), whether the subject is human or animal, Other administrations, and treatments are disease prophylactic or therapeutic. Optimal titration of treatment doses to optimize safety and efficacy.

According to particular embodiments, the compositions described herein are formulated for the intended route of administration to a subject. For example, the compositions described herein can be formulated for intravenous, subcutaneous, or intramuscular administration.

As used herein, the terms "treat, treating, and treatment" are all intended to mean ameliorating or reversing at least one measurable physical parameter associated with an autoimmune disease or condition (e.g., psoriasis), which may not necessarily be present in Perceived in objects, but can be perceivable in objects. The term "treating" can also refer to causing regression of a disease, disorder, or condition, preventing the progression of a disease, disorder, or condition, or at least delaying the progression of a disease, disorder, or condition. In one embodiment, "treating" means alleviating one or more symptoms associated with a disease, disorder, or condition, preventing the development or onset of one or more symptoms associated with a disease, disorder, or condition, or reducing A period of one or more symptoms associated with a disease, disorder, or condition, such as an autoimmune disorder (eg, psoriasis). In one embodiment, "treating" refers to preventing recurrence of a disease, disorder, or condition. In one embodiment, "treating" refers to increasing the survival of a subject with a disease, disorder, or condition. In one embodiment, "treating" refers to excluding a disease, disorder, or condition in a subject.

According to certain embodiments, compositions for treating or preventing autoimmune diseases are provided. For autoimmune therapy, the composition may be used in combination with another treatment, including but not limited to chemotherapy, anti-HLA-Cw6 mAb, anti-IL-23 mAb, anti-TNF-α mAb, anti-IL-17A mAb, other Autoimmune disease drugs, antibody drug conjugates (ADCs), or targeted therapies. Anti-IL-23R antibodies can be used to construct bispecific antibodies with partner mAbs directed against HLA-Cw6, TNF-α, IL-17A, and/or other cell surface antigens to treat expression of both IL-23R and specific cell surface antigens of autoimmune diseases.

As used herein, the term "in combination" in the context of administering two or more different therapies to a subject refers to the use of more than one therapy. Use of the term "combination" does not limit the order in which the therapies are administered to a subject. For example, a first therapy (e.g., a composition described herein) can be administered to a subject prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours) a second therapy. hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks before), at the same time or after (for example, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks later).

As used herein, in aspects, after administering to a subject two or more different antibodies (especially comprising two or more different IL-23R antibodies or a first IL-23R antibody and an IL-23R-binding antibody) or a second antibody that may not bind IL-23R), the term "in combination" refers to the use of more than one antibody together. The use of the term "combination" does not limit the order in which antibodies are provided or administered to a subject in a particular instance. For example, a primary antibody (e.g., a composition comprising an IL-23R antibody described herein) can be administered to a subject prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks ago), at the same time as or after (e.g. 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week , 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks later) administration.

Methods of administration and administration are described in more detail below.

In another aspect, provided herein is a use of an antibody provided herein, or an antigen-binding fragment thereof, in the manufacture of a medicament for treating a disease or disorder in a subject.

In another aspect, provided herein is a use of a pharmaceutical composition provided herein in the manufacture of a medicament for treating a disease or condition in a subject.

In another aspect, provided herein is a use of an antibody or antigen-binding fragment thereof provided herein in the manufacture of a medicament for use in a method for detecting the presence of IL-23R in a biological sample, the medicament The method comprises contacting the biological sample with the antibody under conditions that allow the antibody to bind to the IL-23R protein, and detecting whether a complex is formed between the antibody and the IL-23R protein.

In one embodiment, provided herein is a composition for preventing and/or treating a disease or condition, comprising the antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a composition for preventing a disease or condition, wherein the composition comprises an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a composition for treating a disease or condition, wherein the composition comprises an antibody or antigen-binding fragment thereof provided herein. In some embodiments, the disease or condition is an IL-23R-mediated disease. In some embodiments, the disease or condition is an IL-23-mediated disease. In some embodiments, the disease or disorder is associated with IL-23R. In some embodiments, the disease or disorder is an autoimmune disease. In certain embodiments, the disease or disorder is multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic elitematodes , ankylosing spondylitis, autoimmune inflammation such as inflammation (axial spondyloarthritis), psoriatic arthritis, or psoriasis, and related diseases and conditions. In certain embodiments, the disease or condition is psoriasis (e.g., psoriasis vulgaris, guttate psoriasis), psoriasis inverse, pustular psoriasis, palmoplantar psoriasis, psoriasis vulgaris, or psoriatic psoriasis, atopic dermatitis atopic acne, ulcerative colitis, Crohn's disease, celiac's disease Sexual sprue, enteropathy with seronegative arthritis, microscopic colitis, collagen accumulating colitis, eosinophilic gastrointestinal Inflammation/esophagitis, colitis associated with radiation or chemotherapy, leukocyte adhesion molecule deficiency-1 psoriasis with innate immune disorder, chronic granulosis, glycogen storage disease type 1b, Hermannsky-Padrac syndrome, Chediac- East's syndrome, Wiscot-Aldrich's syndrome, proctocolectomy and ileal anastomosis, advanced ileal psoriasis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, breast psoriasis, psoriasis, cholangitis, primary biliary liver disease Cirrhosis, viral-associated enteropathy, periductal inflammation, chronic bronchitis, chronic sinusitis, asthma, psoriasis, or graft-host disease. In some embodiments, the disease or condition is selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD) , or ulcerative colitis (UC).

In some embodiments, a subject is a subject in need. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administration results in the prevention, management, treatment, or amelioration of the disease or condition.

In one embodiment, provided herein is a composition for preventing and/or treating symptoms of a disease or condition, wherein the composition comprises an antibody provided herein or an antigen-binding fragment thereof. In one embodiment, provided herein is a composition for preventing a symptom of a disease or condition, wherein the composition comprises an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a composition for treating a symptom of a disease or condition, wherein the composition comprises an antibody or antigen-binding fragment thereof provided herein. In some embodiments, the disease or condition is an IL-23R-mediated and/or IL-23-mediated disease. In some embodiments, the disease or disorder is associated with IL-23R. In some embodiments, the disease or disorder is an autoimmune disease. In certain embodiments, the disease or disorder is multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic elitematodes , ankylosing spondylitis, autoimmune inflammation such as inflammation (axial spondyloarthritis), psoriatic arthritis, or psoriasis, and related diseases and conditions. In certain embodiments, the disease or condition is psoriasis (e.g., psoriasis vulgaris, guttate psoriasis), psoriasis inverse, pustular psoriasis, palmoplantar psoriasis, psoriasis vulgaris, or psoriatic psoriasis, atopic dermatitis atopic acne, ulcerative colitis, Crohn's disease, celiac's disease Sexual sprue, enteropathy with seronegative arthritis, microscopic colitis, collagen accumulating colitis, eosinophilic gastrointestinal Inflammation/esophagitis, colitis associated with radiation or chemotherapy, leukocyte adhesion molecule deficiency-1 psoriasis with innate immune disorder, chronic granulosis, glycogen storage disease type 1b, Hermannsky-Padrac syndrome, Chediac- East's syndrome, Wiscot-Aldrich's syndrome, proctocolectomy and ileal anastomosis, advanced ileal psoriasis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, breast psoriasis, psoriasis, cholangitis, primary biliary liver disease Cirrhosis, viral-associated enteropathy, periductal inflammation, chronic bronchitis, chronic sinusitis, asthma, psoriasis, or graft-host disease. In some embodiments, the disease or condition is selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD) , or ulcerative colitis (UC). In some embodiments, a subject is a subject in need. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administering results in the prevention or treatment of symptoms of the disease or condition.

In another embodiment, provided herein is a method of preventing and/or treating a disease or condition in a subject, comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a method of preventing a disease or condition in a subject comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a method of treating a disease or condition in a subject comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In some embodiments, the disease or condition is an IL-23R-mediated and/or IL-23-mediated disease. In some embodiments, the disease or disorder is associated with IL-23R. In some embodiments, the disease or disorder is an autoimmune disease. In certain embodiments, the disease or disorder is multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic elitematodes , ankylosing spondylitis, autoimmune inflammation such as inflammation (axial spondyloarthritis), psoriatic arthritis, or psoriasis, and related diseases and conditions. In certain embodiments, the disease or condition is psoriasis (e.g., psoriasis vulgaris, guttate psoriasis), psoriasis inverse, pustular psoriasis, palmoplantar psoriasis, psoriasis vulgaris, or psoriatic psoriasis, atopic dermatitis atopic acne, ulcerative colitis, Crohn's disease, celiac's disease Sexual sprue, enteropathy with seronegative arthritis, microscopic colitis, collagen accumulating colitis, eosinophilic gastrointestinal Inflammation/esophagitis, colitis associated with radiation or chemotherapy, leukocyte adhesion molecule deficiency-1 psoriasis with innate immune disorder, chronic granulosis, glycogen storage disease type 1b, Hermannsky-Padrac syndrome, Chediac- East's syndrome, Wiscot-Aldrich's syndrome, proctocolectomy and ileal anastomosis, advanced ileal psoriasis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, breast psoriasis, psoriasis, cholangitis, primary biliary liver disease Cirrhosis, viral-associated enteropathy, periductal inflammation, chronic bronchitis, chronic sinusitis, asthma, psoriasis, or graft-host disease. In some embodiments, the disease or condition is selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD) , or ulcerative colitis (UC). In some embodiments, a subject is a subject in need. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, administering results in the prevention or treatment of a disease or condition.

In another aspect, provided herein is a method of preventing and/or treating symptoms of a disease or condition in a subject comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a method of preventing symptoms of a disease or condition in a subject comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In one embodiment, provided herein is a method of treating a symptom of a disease or condition in a subject comprising administering an effective amount of an antibody or antigen-binding fragment thereof provided herein. In some embodiments, the disease or condition is an IL-23R-mediated and/or IL-23-mediated disease. In some embodiments, the disease or disorder is associated with IL-23R. In some embodiments, the disease or disorder is an autoimmune disease. In certain embodiments, the disease or disorder is multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic elitematodes , ankylosing spondylitis, autoimmune inflammation such as inflammation (axial spondyloarthritis), psoriatic arthritis, or psoriasis, and related diseases and conditions. In certain embodiments, the disease or condition is psoriasis (e.g., psoriasis vulgaris, guttate psoriasis), psoriasis inverse, pustular psoriasis, palmoplantar psoriasis, psoriasis vulgaris, or psoriatic psoriasis, atopic dermatitis atopic acne, ulcerative colitis, Crohn's disease, celiac's disease Sexual sprue, enteropathy with seronegative arthritis, microscopic colitis, collagen accumulating colitis, eosinophilic gastrointestinal Inflammation/esophagitis, colitis associated with radiation or chemotherapy, leukocyte adhesion molecule deficiency-1 psoriasis with innate immune disorder, chronic granulosis, glycogen storage disease type 1b, Hermannsky-Padrac syndrome, Chediac- East's syndrome, Wiscot-Aldrich's syndrome, proctocolectomy and ileal anastomosis, advanced ileal psoriasis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, breast psoriasis, psoriasis, cholangitis, primary biliary liver disease Cirrhosis, viral-associated enteropathy, periductal inflammation, chronic bronchitis, chronic sinusitis, asthma, psoriasis, or graft-host disease. In some embodiments, the disease or condition is selected from a subset of inflammatory diseases including, but not limited to, psoriasis (PSO), psoriatic arthritis (PSA), inflammatory bowel disease (IBD), Crohn's disease (CD) , or ulcerative colitis (UC). In some embodiments, a subject is a subject in need. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, the administering results in the prevention or treatment of symptoms of the disease or condition.

Also provided herein are methods of preventing and/or treating a disease or condition by administering to a subject an effective amount of an antibody or antigen-binding fragment thereof provided herein, or a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof provided herein. In one aspect, the antibody or antigen-binding fragment thereof is substantially purified (ie, substantially free of substances that limit its effect or produce undesired side effects). The subject for administration of therapy can be a mammal, such as a non-primate (eg, cow, pig, horse, cat, dog, rat, etc.) or a primate (eg, a monkey such as a cynomolgus monkey, or a human). In one embodiment, the subject is a human. In another embodiment, the subject is a human suffering from a disease or condition.

Various delivery systems are known and can be used to administer prophylactic or therapeutic agents (e.g., antibodies provided herein, or antigen-binding fragments thereof), including, but not limited to, encapsulation in liposomes, microparticles, microcapsules, antibodies capable of expressing or antigen-binding fragments thereof, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of nucleic acids as retroviruses or other vectors some etc. Methods of administering prophylactic or therapeutic agents (e.g., antibodies or antigen-binding fragments thereof provided herein), or pharmaceutical compositions include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). In one embodiment, the prophylactic or therapeutic agent (eg, an antibody or antigen-binding fragment thereof provided herein) or pharmaceutical composition is administered intranasally, intramuscularly, intravenously, or subcutaneously. The prophylactic or therapeutic agent or composition may be administered by any convenient route, such as by infusion or bolus injection, absorbed through epithelial or mucocutaneous linings (such as oral mucosa, nasal mucosa, rectal and intestinal mucosa, etc.) , and can be administered with other bioactive agents. Administration can be systemic or localized. Additionally, pulmonary administration can also be employed, for example, by use of an inhaler or nebulizer and formulations with nebulized agents. See for example, for example, for example, for example, the US Patent No. 6,019968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and No. 4,880,078; , WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903, each of which is incorporated herein by reference in its entirety.

In some embodiments, nanoparticles containing anti-IL-23R antibodies are used to deliver therapeutic agents to IL-23R expressing cells. In some embodiments, the therapeutic agent antagonizes a different target than IL-23R (eg, siRNA to TNFa, etc.).

In one embodiment, it is desirable to administer a prophylactic or therapeutic agent or pharmaceutical composition provided herein locally to an area in need of treatment. This can be achieved by, for example but not limited to, local infusion, local administration (e.g., by intranasal spray), injection, or implants of porous, non-porous, or gelatin materials, including membranes (such as silicone rubber membranes), or fibers. In some embodiments, when administering the antibodies or antigen-binding fragments thereof provided herein, care must be taken to use materials that do not adsorb the antibodies or antigen-binding fragments thereof.

In another embodiment, the prophylactic or therapeutic agents or compositions provided herein can be delivered in vesicles, especially liposomes (see Langer, 1990, Science 249:1527-1533; Treat et al. , in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally at the same place) .

In another embodiment, a prophylactic or therapeutic agent or composition provided herein can be delivered in a controlled release or sustained release system. In one embodiment, controlled or sustained release can be achieved using a pump (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:20; Buchwald et al. , 1980, Surgery 88:507; Saudek et al. al. , 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used to achieve controlled or sustained release of prophylactic or therapeutic agents (e.g., antibodies provided herein) or compositions provided herein (see, e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J., Macromol. Sci.Rev. Macromol.Chem.23:61; see also Levy et al. , 1985, Science 228:190; During et al. , 1989, Ann.Neurol.25:351; Howard et al. , 1989, J. Neurosurg.7 1:105); U.S. Patent No. 5,679,377; U.S. Patent No. 5,916,597; U.S. Patent No. 5,912,015; U.S. Patent No. 5,989,463; U.S. Patent No. 5,128,326; 15154; and PCT Publication No. WO 99/20253. Examples of polymers for sustained release formulations include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate) , poly(methacrylic acid), polyglycolide (PLG), polyanhydride, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactic acid ( PLA), poly(lactide-co-glycolide) (PLGA), and polyorthoesters. In one embodiment, the polymer used in the sustained release formulation is inert, free of leachable impurities, storage stable, sterile, and biodegradable. In yet another embodiment, a controlled or sustained release system can be placed close to the target of treatment, i.e., the nasal passages or lungs, thus requiring only a fraction of the systemic dose (see, e.g., Goodson in Medical Applications of Controlled Release, supra. , vol. 2, pp. 115-138 (1984)). Controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533). Sustained release formulations comprising one or more antibodies or antigen-binding fragments thereof as provided herein can be produced using any technique known to those of ordinary skill in the art. See, eg, U.S. Patent No. 4,526,938, PCT Publication WO 91/05548, PCT Publication WO 96/20698, Ning et al. , 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel," Radiotherapy & Oncology 39:179-189, Song et al. , 1995, “Antibody Mediated Lung Targeting of Long-Circulating Emulsions,” PDA Journal of Pharmaceutical Science & Technology 50:372-397, Cleek et al. , 1997, “Biodegradable Po Lymeric Carriers for a bFGF Antibody for Cardiovascular Application,"Pro.Int'l.Symp.Control.Rel.Bioact.Mater.24:853-854, and Lam et al. , 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery ," Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760, each of which is incorporated herein by reference in its entirety.

In one embodiment, when the composition provided herein is a nucleic acid encoding a prophylactic or therapeutic agent (e.g., an antibody or antigen-binding fragment thereof provided herein), the nucleic acid can be administered in vivo to facilitate its encoding of a prophylactic or therapeutic agent. expression of the agent by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, for example by using a retroviral vector (see U.S. Patent No. 4,980,286), or by Injection directly, or by impingement using microparticles (e.g., gene gun; Biolistic, Dupont), or coating of lipid or cell surface receptors or transfection agents, or by linking them to homologous cassettes known to enter the nucleus Peptides (see, eg, Joliot et al. , 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868) and the like. Alternatively, the nucleic acid can be introduced into the cell and expressed by incorporation into host cell DNA by homologous recombination.

In a specific embodiment, the compositions provided herein comprise one, two or more antibodies or antigen-binding fragments thereof provided herein. In another embodiment, the compositions provided herein comprise one, two or more antibodies or antigen-binding fragments thereof provided herein and a prophylactic or therapeutic agent in addition to the antibodies or antigen-binding fragments thereof provided herein. In one embodiment, the known agent is used or has been used or is currently used to prevent, manage, treat, and/or ameliorate a disease or condition. In addition to prophylactic or therapeutic agents, the compositions provided herein may also contain excipients.

The compositions provided herein include bulk pharmaceutical compositions suitable for use in the manufacture of pharmaceutical compositions (eg, compositions suitable for administration to an individual or patient), which can be used to prepare unit dosage forms. In one embodiment, the compositions provided herein are pharmaceutical compositions. Such compositions comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic agents (eg, antibodies or antigen-binding fragments thereof provided herein or other prophylactic or therapeutic agents), and a pharmaceutically acceptable excipient. Pharmaceutical compositions can be formulated to suit the route of administration for a subject.

In one embodiment, the term "excipient" may also refer to a diluent, an adjuvant (e.g., Freunds' adjuvant (complete or incomplete), or a vehicle. A pharmaceutical excipient may be Sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. When administering the pharmaceutical composition intravenously, water is exemplary Excipients. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid excipients, especially for injectable solutions. Suitable pharmaceutical excipients include starch, dextrose, lactose, sucrose, gelatin, malt, rice, Flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerin, propylene, glycol, water, ethanol, and the like. Where desired, the composition is also Can contain small amounts of wetting agents, or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, lozenges, pills, capsules, powders, sustained release formulations, and the like. Oral formulations can include Standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences (1990) Mack Publishing Co. , Easton, PA. Such compositions will contain a prophylactically or therapeutically effective amount of an antibody or antigen-binding fragment thereof provided herein (such as in purified form), together with an appropriate amount of excipients to provide a form suitable for administration to a patient The formulation should suit the mode of administration.

In one embodiment, the composition is formulated according to routine procedures as a pharmaceutical composition adapted for intravenous administration to humans. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. The composition may also include co-solvents and local anesthetics (such as lignocamne) as necessary to relieve pain at the injection site. However, such compositions may be administered by routes other than intravenous.

Typically, the ingredients of the compositions provided herein are supplied separately or mixed together in unit dosage form, for example, as a lyophilized powder or lyophilized powder in a hermetically sealed container such as an ampoule or sachette indicating the amount of active agent. Anhydrous concentrate. Where the composition is to be administered by infusion, it may be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

Antibodies provided herein, or antigen-binding fragments thereof, can be packaged in hermetically sealed containers, such as ampoules or packs indicating the quantity of antibody. In one embodiment, the antibody or antigen-binding fragment thereof is supplied as a dry sterilized lyophilized powder or anhydrous concentrate in an air-tight sealed container, and can be reconstituted, eg, with water or saline, to an appropriate concentration for administration to a subject. The lyophilized antibody, or antigen-binding fragment thereof, may be stored in its original container at between 2 and 8°C, and may be within 12 hours, such as within 6 hours, within 5 hours, within 3 hours, or 1 hour after reconstitution The antibody or antigen-binding fragment thereof is administered internally. In an alternative embodiment, an antibody or antigen-binding fragment thereof provided herein is supplied in liquid form in a sealed container indicating the quantity and concentration of the antibody.

The compositions provided herein can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions, such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, and those formed with cations, such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, Triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.

The amount of a disease prophylactic or therapeutic agent (eg, an antibody provided herein or an antigen-binding fragment thereof), or a composition provided herein, that will be effective in preventing and/or treating a disease or condition can be determined by standard clinical techniques. In addition, in vitro assays can optionally be employed to assist in identifying optimal dosage ranges. The precise dosage to be employed in the formulation will also depend on the route of administration, and the severity of the disease or condition, and should be decided according to the judgment of the practicing physician and each patient's circumstances.

Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

In certain embodiments, doses of the antibodies or antigen-binding fragments provided herein are administered to a patient intranasally, intramuscularly, intravenously, subcutaneously, or a combination thereof, although other routes described herein are also acceptable. of. Each dose may or may not be administered by the same route of administration. In some embodiments, an antibody or antigen-binding fragment thereof provided herein can be administered via multiple routes of administration simultaneously, or after other doses of the same or a different antibody or antigen-binding fragment thereof provided herein.

In certain embodiments, antibodies provided herein, or antigen-binding fragments thereof, are administered prophylactically or therapeutically to a subject. Antibodies provided herein, or antigen-binding fragments thereof, can be administered prophylactically or therapeutically to a subject to prevent, reduce, or ameliorate a disease or symptom thereof. Pharmaceutical composition

In one aspect, the present disclosure further provides a pharmaceutical composition comprising at least one antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, pharmaceutical compositions comprise a therapeutically effective amount of an antibody or antigen-binding fragment thereof provided herein and a pharmaceutically acceptable excipient.

Pharmaceuticals comprising antibodies or antigen-binding fragments thereof are prepared by mixing fusion proteins of desired purity with optional physiologically acceptable excipients (see, e.g., Remington, Remington's Pharmaceutical Sciences (18th ed. 1980)) Compositions for storage in aqueous solution or in lyophilized or other dry form.

Antibodies of the present disclosure, or antigen-binding fragments thereof, can be formulated in any form suitable for delivery to target cells/tissues, for example, as microcapsules or macroemulsions (Remington, supra; Park et al. , 2005, Molecules 10:146-61; Malik et al. , 2007, Curr. Drug. Deliv. 4:141-51), sustained release formulations (Putney and Burke, 1998, Nature Biotechnol.16:153-57), or liposomes (Maclean et al. , 1997 , Int. J. Oncol.11:325-32; Kontermann, 2006, Curr. Opin.Mol.Ther.8:39-45).

Antibodies provided herein, or antigen-binding fragments thereof, can also be embedded in microcapsules prepared by, for example, agglomeration techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly-(methacrylic acid, respectively). methyl ester) microcapsules), colloidal drug delivery systems (eg, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or macroemulsions. Such techniques are disclosed, for example, in Remington, supra.

Various compositions and delivery systems are known and can be used with antibodies or antigen-binding fragments thereof as described herein, including but not limited to encapsulation in liposomes, microparticles, microcapsules, capable of expressing antibodies or antigen-binding fragments thereof Recombination of fragments into cells, receptor-mediated endocytosis (see eg Wu and Wu, 1987, J. Biol. Chem. 262:4429-32), construction of nucleic acids as part of retroviruses or other vectors, etc. In another embodiment, the composition may be provided as a controlled release or sustained release system. In one embodiment, a pump can be used to achieve controlled or sustained release (see, e.g., Langer, supra; Sefton, 1987, Crit. Ref. Biomed. Eng. 14:201-40; Buchwald et al. , 1980, Surgery 88:507-40; 16; and Saudek et al. , 1989, N. Engl. J. Med. 321:569-74). In another embodiment, polymeric materials can be used to achieve controlled or sustained release of disease prophylactic or therapeutic agents (eg, antibodies or antigen-binding fragments thereof as described herein) or compositions provided herein (see, eg, Medical Applications of Controlled Release (Langer and Wise, eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem.23:61-126; Levy et al. , 1985, Science 228:190-92; During et al. , 1989, Ann. Neurol.25:351-56; Howard et al. , 1989, J. Neurosurg. 71:105-12; US Patent Nos. 5,679,377; 5,916,597; 5,912,015; 5,989,463; and 5,128,326; PCT Publications WO 99/15154 and WO 99/20253). Examples of polymers for sustained release formulations include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate) , poly(methacrylic acid), polyglycolide (PLG), polyanhydride, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactic acid ( PLA), poly(lactide-co-glycolide) (PLGA), and polyorthoesters. In one embodiment, the polymer used in the sustained release formulation is inert, free of leachable impurities, storage stable, sterile, and biodegradable.

In yet another embodiment, a controlled or sustained release system can be placed close to a specific target tissue, such as the nasal passages or lungs, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, Medical Applications of Controlled Release Vol. . 2, 115-38 (1984)). Controlled release systems are discussed, eg, in Langer, 1990, Science 249:1527-33. Sustained release formulations comprising one or more antibodies or antigen-binding fragments thereof as described herein can be produced using any technique known to those of ordinary skill in the art (see, e.g., U.S. Patent No. 4,526,938, PCT Publication No. 91/05548 and WO 96/20698, Ning et al. , 1996, Radiotherapy & Oncology 39:179-89; Song et al. , 1995, PDA J. of Pharma. Sci. & Tech. 50:372-97; Cleek et al. , 1997, Pro. Int'l. Symp. Control. Rel. Bioact. Mater.24:853-54; and Lam et al. , 1997, Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-60). gene therapy

In one embodiment, a nucleic acid comprising a sequence encoding an antibody or functional derivative thereof is administered to a subject for use in the methods provided herein, e.g., for prevention, management, treatment, and/or by means of gene therapy Improve IL-23R mediated diseases, disorders or conditions. Such therapy encompasses therapy performed by administering expressed or expressible nucleic acid to a subject. In one embodiment, the nucleic acid produces an antibody that encodes it, and the antibody mediates a prophylactic or therapeutic effect.

Any method of recombinant gene expression (or gene therapy) available in the art may be used.

For a general review of approaches to gene therapy, see Goldspiel et al. , 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol .Toxicol.32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann.Rev. Biochem.62:191-217; May, 1993, TIBTECH 11(5):155 -215. Methods that can use recombinant DNA techniques generally known in the art are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In one embodiment, a composition comprises nucleic acid encoding an antibody provided herein as part of an expression vector that expresses the antibody or chimeric protein or its heavy or light chain in a suitable host. In particular, such nucleic acids have a promoter, such as a heterologous promoter, which is inducible or constitutive and optionally tissue specific, operably linked to the antibody coding region. In another embodiment, nucleic acid molecules are used in which the antibody coding sequence and any other desired sequences are flanked by regions that promote homologous recombination at desired locations in the genome, thus providing intrachromosomal expression of the nucleic acid encoding the antibody ( Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al. , 1989, Nature 342:435-438).

Nucleic acids can be delivered directly to a subject, in which case the subject is directly exposed to the nucleic acid or a nucleic acid-carrying vehicle, or indirectly, in which case cells are first transformed in vitro with the nucleic acid and then transplanted into the subject. These two approaches are called in vivo or ex vivo gene therapy, respectively.

In one embodiment, the nucleic acid sequence is administered directly in vivo, wherein the sequence is expressed to produce the encoded product. This can be accomplished by any of a number of methods known in the art, for example by constructing it as part of an appropriate nucleic acid expression vector and administering it so that the sequence becomes intracellular, for example by using a defective or infection with attenuated retroviruses or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by impact using microparticles (e.g., gene gun; Biolistic, Dupont), or coated with lipids or cell surface receptors or transfection agents, encapsulated in liposomes, microparticles, or microcapsules, or administered by linking them to peptides known to enter the nucleus, by linking them to receptor-mediated Ligands for endocytosis (see eg Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) (which can be used to target cell types specifically expressing the receptor) and the like. In another example, a nucleic acid-ligand complex can be formed wherein the ligand comprises a fusogenic viral peptide to disrupt endosomes, thereby allowing the nucleic acid to avoid lysosomal degradation. In yet another example, nucleic acids can be targeted for cell-specific uptake and expression in vivo by targeting specific receptors (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO 92/20316; WO93 /14188, WO 93/20221). Alternatively, the nucleic acid can be introduced into the cell and expressed by homologous recombination into the host cell DNA (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; and Zijlstra et al. , 1989, Nature 342:435-438).

In one embodiment, viral vectors containing nucleic acid sequences encoding antibodies are used. For example, retroviral vectors can be used (see Miller et al. , 1993, Meth. Enzymol. 217:581-599). These retroviral vectors contain the components required for proper packaging of the viral genome and integration into the host cell DNA. Nucleic acid sequences encoding antibodies for gene therapy can be cloned into one or more vectors, which facilitate gene delivery into a subject. More details on retroviral vectors can be found in Boesen et al. , 1994, Biotherapy 6:291-302, which describe the use of retroviral vectors to deliver the MDR1 gene to hematopoietic stem cells to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy: Clowes et al. , 1994, J. Clin. Invest. 93:644-651; Klein et al. , 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.

Adenoviruses are other viral vectors that can be used for the recombinant production of antibodies. Adenoviruses are particularly attractive vehicles for gene delivery to the respiratory epithelium. Adenoviruses naturally infect the respiratory epithelium where they cause mild disease. Other targets of adenovirus-based delivery systems are the liver, central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being able to infect non-dividing cells. Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503 present a review of adenovirus-based gene therapy. Bout et al. , 1994, Human Gene Therapy 5:3-10 showed the use of adenoviral vectors to transfer genes to the respiratory epithelium of rhesus monkeys. Additional references to the use of adenoviruses in gene therapy can be found in Rosenfeld et al. , 1991, Science 252:431-434; Rosenfeld et al. , 1992, Cell 68:143-155; Mastrangeli et al. , 1993, J. Clin Invest. 91:225-234; PCT Publication WO94/12649; and Wang et al. , 1995, Gene Therapy 2:775-783. In a specific embodiment, an adenoviral vector is used.

Adeno-associated virus (AAV) can also be used (Walsh et al. , 1993, Proc. Soc. Exp. Biol. Med. 204:289-300; and US Patent No. 5,436,146). In a specific embodiment, an AAV vector is used to express the anti-IL-23R antibodies provided herein. In certain embodiments, AAV comprises nucleic acid encoding a VH domain. In other embodiments, the AAV comprises nucleic acid encoding a VL domain. In certain embodiments, AAV comprises nucleic acid encoding a VH domain and a VL domain. In some embodiments of the methods provided herein, an AAV comprising a nucleic acid encoding a VH domain and an AAV comprising a nucleic acid encoding a VL domain are administered to a subject. In other embodiments, an AAV comprising nucleic acid encoding a VH domain and a VL domain is administered to a subject. In certain embodiments, the VH and VL domains are overrepresented.

Another method of gene therapy involves the transfer of genes into cells in tissue culture by methods such as electroporation, lipofection, calcium phosphate-mediated transfection, or viral infection. Typically, methods of transfer involve transferring a selectable marker to the cell. The cells are then placed under selection to isolate those cells that have taken up and express the transferred gene. The cells are then delivered to the subject.

In this example, the nucleic acid is introduced into the resulting recombinant cells prior to in vivo administration to the cells. Such introduction can be performed by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with viral or phage vectors containing nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, Microcell-mediated gene transfer, spherical plastid fusion, etc. Many techniques for introducing foreign genes into cells are known in the art (see, e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen et al. , 1993, Meth. Enzymol. 217:618-644; Clin. Pharma. Ther. 29:69-92 (1985)) and may be used according to the methods provided herein, provided that the essential developmental and physiological functions of the recipient cells are not disrupted. Techniques should provide for the stable transfer of nucleic acids into cells such that the nucleic acids can be expressed by the cells, such as be inherited and expressed by their cellular progeny.

The resulting recombinant cells can be delivered to a subject by various methods known in the art. Recombinant blood cells (eg, hematopoietic stem or progenitor cells) can be administered intravenously. The amount of cells contemplated for use depends on the desired effect, the state of the patient, etc., and can be determined by one of ordinary skill in the art.

Cells into which nucleic acids may be introduced for the purpose of gene therapy encompass any desired, available cell type and include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, liver cells; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, especially hematopoietic stem or progenitor cells, e.g. obtained from bone marrow, Umbilical cord blood, peripheral blood, fetal liver, etc.

In one embodiment, the cell lines used for gene therapy are autologous cells of the subject.

In one embodiment of gene therapy using recombinant cells, a nucleic acid sequence encoding an antibody is introduced into a cell such that it can be expressed by the cell or its progeny, and the recombinant cell is then administered in vivo for a therapeutic effect. In a specific embodiment, stem cells or progenitor cells are used. Any stem and/or progenitor cells that can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the methods provided herein (see, e.g., PCT Publication WO 94/08598; Stemple and Anderson, 1992, Cell 7 1 :973-985; Rheinwald, 1980, Meth. Cell Bio. 21A:229; and Pittelkow and Scott, 1986, Mayo Clinic Proc.61:771).

In one embodiment, a nucleic acid introduced for the purpose of gene therapy comprises an inducible promoter operably linked to the coding region such that expression of the nucleic acid can be controlled by the presence or absence of an appropriate transcriptional inducer. control. set

Also provided herein are kits comprising an antibody provided herein (eg, an anti-IL-23R antibody) or a composition thereof (eg, a pharmaceutical composition) packaged in a suitable packaging material. The kit optionally includes a label or package insert including a description of the components or instructions for in vitro, in vivo, or ex vivo use of the components therein.

The term "packaging material" refers to the physical structure that houses the components of the kit. Packaging materials maintain the sterility of the components and can be made from materials commonly used for such purposes (eg, paper, corrugated fibers, glass, plastic, foil, ampoules, vials, test tubes, etc.).

The kits provided herein may include markers or inserts. Labels or inserts include "printed matter," such as paper or cardboard, that is separate or attached to a component, kit, or packaging material (e.g., box), or to, for example, an ampoule, Test tubes, or vials. The label or insert may additionally include computer-readable media such as magnetic disks (e.g., hard disks, cards, memory disks), optical disks such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or electronic Storage media, such as RAM and ROM or a combination thereof, such as magnetic/optical storage media, FLASH media, or memory cards. The marking or insert may include information identifying the manufacturer, lot number, manufacturer's address, and date.

The kits provided herein can additionally include other components. The components of the kit can be enclosed in individual containers, and all of the various containers can be in a single package. Kits can also be designed for refrigeration. Kits can be further designed to contain the antibodies provided herein, or cells containing nucleic acid encoding the antibodies provided herein. The cells in the kit can be maintained under proper storage conditions until ready for use.

Also provided herein are panels of antibodies that immunospecifically bind to IL-23R antigens. In specific embodiments, provided herein are panels of antibodies that have different on-rate constants for the IL-23R antigen, different off-rate constants, different affinities, and/or different specificities for the IL-23R antigen. In certain embodiments, provided herein are about 10, preferably about 25, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 250, about 300, about 350, about A panel of 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, or about 1000 or more antibodies. Antibody panels can be used, for example, in 96-well or 384-well plates, such as for assays such as ELISA.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the technical field to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

As used herein, numerical values are generally presented in range format throughout this document. The use of the range format is used merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention unless the context clearly dictates otherwise. Thus, expressly used ranges include all possible subranges, all individual values within that range, and all values or numerical ranges within such ranges including integers, and fractions or integers within the range, unless the context dictates otherwise Clear instructions. This construct applies regardless of breadth of scope and in all contexts throughout this patent document. Thus, for example, a reference to a range of 90 to 100% includes 91 to 99%, 92 to 98%, 93 to 95%, 91 to 98%, 91 to 97%, 91 to 96%, 91 to 95%, 91 to 94 %, 91 to 93%, etc. The range referring to 90 to 100% also includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., and 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1 %, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so on.

Additionally, ranges 1 to 3, 3 to 5, 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100, 100 to 110, 110 to 120, 120 to 130, 130 to 140, 140 to 150, 150 to 160, 160 to 170, 170 to 180, 180 to 190, 190 to 200, 200 to 225, 225 to 250 Including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. In a further example, reference to the range 25 to 250, 250 to 500, 500 to 1,000, 1,000 to 2,500, 2,500 to 5,000, 5,000 to 25,000, 25,000 to 50,000 includes any value or range within or encompasses such values Equal values, such as 25, 26, 27, 28, 29...250, 251, 252, 253, 254...500, 501, 502, 503, 504...etc.

Throughout this document are disclosed series ranges which are also used herein. The use of a series of ranges includes combining upper and lower ranges to provide another range. This construct applies regardless of breadth of scope and in all contexts throughout this patent document. Thus, for example, reference to a series of ranges such as 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 75, 75 to 100, 100 to 150 includes ranges such as 5 to 20, 5 to 30, 5 to 40, 5 to 50, 5 to 75, 5 to 100, 5 to 150, and 10 to 30, 10 to 40, 10 to 50, 10 to 75, 10 to 100, 10 to 150, and 20 to 40, Ranges of 20 to 50, 20 to 75, 20 to 100, 20 to 150, and so on.

For the sake of brevity, certain abbreviations are used herein. One example is a single letter abbreviation representing an amino acid residue. Amino acids and their corresponding three-letter and one-letter abbreviations are as follows: Alanine Ala (A) arginine Arg (R) Asparagine Asn (N) aspartic acid Asp (D) cysteine Cys (C) glutamic acid Glu (E) Glutamine Gln (Q) Glycine Gly (G) Histidine His (H) Isoleucine Ile (I) Leucine Leu (L) Lysine Lys (K) Methionine met (M) Phenylalanine Phe (F) Proline Pro (P) serine Ser (S) Threonine Thr (T) Tryptophan Trp (W) Tyrosine Tyr (Y) Valine Val (V)

The invention is generally disclosed herein using positive language to describe a number of embodiments. The invention also specifically includes embodiments in which certain subject matters, such as substances or materials, method steps and conditions, protocols, procedures, assays, or analyses, are excluded in whole or in part. Thus, even though the invention is generally not expressly described herein in terms of excluded aspects, aspects not expressly included in the invention are disclosed herein. Aspects of the invention

The following aspects illustrate and are not intended to limit the scope of the present invention. Instead, these aspects provide guidance to any person of ordinary skill in the art on how to make and use the compounds, compositions, and methods taught by the present invention, which such skilled person will understand can be obtained without departing from the present disclosure. Modifications are made without departing from the spirit and scope of the invention.

基胺螢光素、丹磺醯氯、或藻紅素； 其中可選地發光材料係魯米諾(luminol)； 其中可選地生物發光材料係選自螢光素酶、螢光素、或水母素；且 其中可選地化學發光材料係選自225Acγ發射性、鄂惹發射性(Auger-emitting)、β發射性、α發射性、或正電子發射性放射性同位素。 32.    一種核酸分子，其編碼態樣1至30中任一者所述之抗體或其可變區或抗原結合片段。 33.    一種載體，其包含如態樣32所述之核酸分子。 34.    一種宿主細胞，其經如態樣33所述之載體轉形。 35.    一種組成物，其包含如態樣1至31中任一者所述之抗體、如請求項30所述之核酸分子、或如請求項31所述之載體、及醫藥上可接受之賦形劑。 36.    一種套組，其包含如態樣1至31中任一者所述之抗體。 37.    一種用於偵測、選擇、及/或富集樣本中之介白素-23受體(IL-23R)之方法，其包含使該樣本與如態樣1至31中任一者所述之抗體接觸， 其中可選地該方法包含在免疫組織化學(IHC)檢定、免疫細胞化學(ICC)檢定、免疫墨點法檢定、免疫沉澱檢定、流式細胞術檢定、ELISA、放射免疫檢定、質譜法檢定、或高通量篩選檢定中使用如態樣1至31中任一者所述之抗體； 其中： 可選地該流式細胞術檢定包含三步驟染色：(1)第一，將該樣本與如態樣1至31中任一者所述之抗體培養；(2)第二，將該樣本與生物素化抗小鼠IgG _2a培養；(3)第三，將該樣本與鏈黴親和素-PE培養；且其中可選地，為了建立流式細胞術檢定之背景，與單獨的緩衝劑或陰性對照抗體培養之細胞係用作為步驟(1)中之對照組，且在無生物素化抗小鼠IgG _2a二級試劑下培養之細胞係用作為步驟(2)中之額外對照組。 38.    一種用於偵測、選擇、及/或富集樣本中之介白素-23受體(IL-23R)之方法，其包含使該樣本與結合至與如態樣1至31中任一者所述之抗體相同的表位之抗體、或與如態樣1至31中任一者所述之抗體競爭結合IL-23R之抗體接觸。 39.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:202之胺基酸序列的VH、及包含SEQ ID NO:203之胺基酸序列的VL； b.      包含SEQ ID NO:252之胺基酸序列的VH、及包含SEQ ID NO:253之胺基酸序列的VL；或 c.      包含SEQ ID NO:156之胺基酸序列的VH、及包含SEQ ID NO:157之胺基酸序列的VL。 40.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:192之胺基酸序列的VH、及包含SEQ ID NO:193之胺基酸序列的VL； b.      包含SEQ ID NO:194之胺基酸序列的VH、及包含SEQ ID NO:195之胺基酸序列的VL； c.      包含SEQ ID NO:200之胺基酸序列的VH、及包含SEQ ID NO:201之胺基酸序列的VL； d.      包含SEQ ID NO:218之胺基酸序列的VH、及包含SEQ ID NO:219之胺基酸序列的VL； e.      包含SEQ ID NO:222之胺基酸序列的VH、及包含SEQ ID NO:223之胺基酸序列的VL； f.      包含SEQ ID NO:260之胺基酸序列的VH、及包含SEQ ID NO:261之胺基酸序列的VL； g.      包含SEQ ID NO:264之胺基酸序列的VH、及包含SEQ ID NO:265之胺基酸序列的VL； h.      包含SEQ ID NO:154之胺基酸序列的VH、及包含SEQ ID NO:155之胺基酸序列的VL； i.       包含SEQ ID NO:160之胺基酸序列的VH、及包含SEQ ID NO:161之胺基酸序列的VL；或 j.       包含SEQ ID NO:164之胺基酸序列的VH、及包含SEQ ID NO:165之胺基酸序列的VL。 41.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:786之胺基酸序列的VH、及包含SEQ ID NO:787之胺基酸序列的VL； b.      包含SEQ ID NO:790之胺基酸序列的VH、及包含SEQ ID NO:791之胺基酸序列的VL； c.      包含SEQ ID NO:792之胺基酸序列的VH、及包含SEQ ID NO:793之胺基酸序列的VL； d.      包含SEQ ID NO:236之胺基酸序列的VH、及包含SEQ ID NO:237之胺基酸序列的VL； e.      包含SEQ ID NO:826之胺基酸序列的VH、及包含SEQ ID NO:827之胺基酸序列的VL；或 f.      包含SEQ ID NO:828之胺基酸序列的VH、及包含SEQ ID NO:829之胺基酸序列的VL。 42.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:196之胺基酸序列的VH、及包含SEQ ID NO:197之胺基酸序列的VL； b.      包含SEQ ID NO:262之胺基酸序列的VH、及包含SEQ ID NO:263之胺基酸序列的VL；或 c.      包含SEQ ID NO:152之胺基酸序列的VH、及包含SEQ ID NO:153之胺基酸序列的VL。 43.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:798之胺基酸序列的VH、及包含SEQ ID NO:799之胺基酸序列的VL。 44.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:206之胺基酸序列的VH、及包含SEQ ID NO:207之胺基酸序列的VL； b.      包含SEQ ID NO:250之胺基酸序列的VH、及包含SEQ ID NO:251之胺基酸序列的VL； c.      包含SEQ ID NO:144之胺基酸序列的VH、及包含SEQ ID NO:145之胺基酸序列的VL；或 d.      包含SEQ ID NO:170之胺基酸序列的VH、及包含SEQ ID NO:171之胺基酸序列的VL。 45.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:150之胺基酸序列的VH、及包含SEQ ID NO:151之胺基酸序列的VL。 46.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:198之胺基酸序列的VH、及包含SEQ ID NO:199之胺基酸序列的VL；或 b.      包含SEQ ID NO:240之胺基酸序列的VH、及包含SEQ ID NO:241之胺基酸序列的VL。 47.    如態樣38所述之方法，其包含使該樣本與結合至該相同表位及/或與包含下列之抗體競爭結合IL-23R之抗體接觸： a.      包含SEQ ID NO:204之胺基酸序列的VH、及包含SEQ ID NO:205之胺基酸序列的VL；或 b.      包含SEQ ID NO:884之胺基酸序列的VH、及包含SEQ ID NO:885之胺基酸序列的VL。 48.    如態樣37至47中任一者所述之方法，其中該方法係用於偵測、選擇、及/或富集人類IL-23R。 49.    如態樣37至47中任一者所述之方法，其中該方法係用於偵測、選擇、及/或富集表現IL-23R之細胞。 50.    如態樣37至47中任一者所述之方法，其中該方法係用於偵測變性IL-23R。 51.    如態樣37至47中任一者所述之方法，其中該方法包含使該樣本與二或更多種抗體接觸，該二或更多種抗體各為如態樣1至29中任一者所述之抗體。 52.    如態樣49所述之方法，其中該二或更多種抗體結合至IL-23R之不同表位。 53.    如態樣37至52中任一者所述之方法，其中該樣本係來自人類對象。 54.    如態樣53所述之方法，其中該人類對象患有疾病或病症。 55.    如態樣54所述之方法，其中該疾病或病症係IL-23R相關疾病或病症。 56.    如態樣53所述之方法，其中該人類對象係健康人類對象。 57.    一種拮抗或抑制細胞中之IL-23R之方法，其包含使該細胞與如態樣1至31中任一者所述之抗體接觸。 58.    一種治療對象之疾病或病症之方法，其包含向該對象投予如態樣35所述之組成物或如態樣1至31中任一者所述之抗體。 59.    如態樣58所述之方法，其中該疾病或病症係IL-23R相關疾病或病症。 60.    如態樣58所述之方法，其中該疾病或病症係與發炎性、自體免疫發炎疾病、及/或相關病症相關聯。 61.    如態樣60所述之方法，其中與發炎性、自體免疫發炎疾病、及/或相關病症相關聯之疾病或病症係選自多發性硬化症、氣喘、類風濕性關節炎、腸道發炎、發炎性腸疾病(IBD)、幼年型IBD、青少年IBD、克隆氏病、潰瘍性結腸炎、乳糜瀉（非熱帶性口瘡）、顯微鏡性結腸炎、膠原性結腸炎、嗜酸性胃腸炎/食道炎、與放射或化學療法相關聯之結腸炎、與先天性免疫病症如白血球黏附分子缺乏症-1相關聯之結腸炎、類肉瘤病、全身性紅斑性狼瘡、僵直性脊椎炎（中軸型脊椎關節炎）、乾癬性關節炎、乾癬（例如斑塊性乾癬、滴狀乾癬、反轉型乾癬、膿疱性乾癬、掌蹠膿疱症、尋常性乾癬、或紅皮性乾癬）、異位性皮膚炎、異位性痤瘡、與血清陰性關節病變相關聯之腸病變、慢性肉芽腫疾病、肝醣儲積症第1b型、Hermansky-Pudlak氏症候群、Chediak-Higashi氏症候群、Wiskott-Aldrich氏症候群、囊炎、直腸結腸切除術及迴腸袋肛門吻合術之後導致之囊炎、胃腸道癌、胰臟炎、胰島素依賴性糖尿病、乳腺炎、膽囊炎、膽管炎、原發性膽汁性肝硬化、病毒相關性腸病變、膽管週圍炎、慢性支氣管炎、慢性鼻竇炎、氣喘、葡萄膜炎、或移植物抗宿主病。 62.    如態樣61所述之方法，其中與自體免疫疾病相關聯之該疾病或病症係選自潰瘍性結腸炎(UC)、克隆氏病(CD)、乾癬(PsO)、或乾癬性關節炎(PsA)。 63.    一種如態樣1至31中任一者所述之抗體或其抗原結合片段或如態樣35所述之組成物在製造用於治療IL-23R相關疾病或病症之藥劑中的用途，該IL-23R相關疾病或病症尤其是與發炎性、自體免疫發炎疾病、及/或相關病症相關聯之疾病或病症。 64.    如態樣1至31中任一者所述之抗體或抗原結合片段或如態樣35所述之組成物用於治療IL-23R相關疾病或病症，尤其是與發炎性、自體免疫發炎疾病、及/或相關病症相關聯之疾病或病症 1. An isolated monoclonal antibody or an antigen-binding fragment thereof, which binds to human interleukin-23 receptors (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. as SEQ ID NO HCDR1, HCDR2, and HCDR3 shown in: 236, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:237; b. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:798, and SEQ ID NO:798 LCDR1, LCDR2, and LCDR3 shown in ID NO:799; c. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:793; d HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:787; e. HCDR1, HCDR2, and HCDR1 as shown in SEQ ID NO:138, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:139; f. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:144, and LCDR1, LCDR2 as shown in SEQ ID NO:145 , and LCDR3; g. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:152, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:153; h. as shown in SEQ ID NO:154 HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:155; i. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:156, and as shown in SEQ ID NO:157 LCDR1, LCDR2, and LCDR3 shown; j. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:160, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:161; k. HCDR1, HCDR2, and HCDR3 shown in :164, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:165; 1. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:166, and as shown in SEQ ID NO:166 LCDR1, LCDR2, and LCDR3 shown in ID NO:167; m. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:168, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:169; n HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:174, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:175; o. HCDR1, HCDR2, and as shown in SEQ ID NO:788 HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:789; p. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:186, and LCDR1, LCDR2 as shown in SEQ ID NO:187 , and LCDR3; q. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:828, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:829; r. as shown in SEQ ID NO:790 HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:791; s. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:188, and as shown in SEQ ID NO:189 LCDR1, LCDR2, and LCDR3 shown; t. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:885; u. HCDR1, HCDR2, and HCDR3 shown in :192, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:193; v. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:194, and as shown in SEQ ID NO:194 LCDR1, LCDR2, and LCDR3 shown in ID NO:195; w. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:198, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:199; x HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:200, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:201; y. HCDR1, HCDR2, and as shown in SEQ ID NO:202 HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:203; z. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:204, and LCDR1, LCDR2 as shown in SEQ ID NO:205 , and LCDR3; aa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:206, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:207; bb. as shown in SEQ ID NO:216 HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:217; cc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:222, and as shown in SEQ ID NO:223 LCDR1, LCDR2, and LCDR3 shown; dd. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:230, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:231; ee. HCDR1, HCDR2, and HCDR3 shown in :232, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:233; ff. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:234, and as shown in SEQ ID NO:234 LCDR1, LCDR2, and LCDR3 shown in ID NO:235; gg. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:238, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:239; hh HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:246, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:247; ii. HCDR1, HCDR2, and as shown in SEQ ID NO:248 HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:249; jj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:254, and LCDR1, LCDR2 as shown in SEQ ID NO:255 , and LCDR3; kk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:260, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:261; ll. as shown in SEQ ID NO:262 HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:263; or mm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:264, and as shown in SEQ ID NO:265 LCDR1, LCDR2, and LCDR3 are shown. 2. The isolated monoclonal antibody or antigen-binding fragment thereof as described in aspect 1, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: nn. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequence of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3; oo. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 936, 937, and 938, respectively, and comprising SEQ ID NOs: 939, 940, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 941; pp. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:921, 922, and 923 respectively; qq. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:903, 904, and 905; rr. comprising respectively having SEQ ID NO:276, 277, and The VH of HCDR1, HCDR2, and HCDR3 having an amino acid sequence of 278, and the VL comprising LCDR1, LCDR2, and LCDR3 having an amino acid sequence of SEQ ID NO:279, 280, and 281 respectively; ss. The VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 294, 295, and 296, and LCDR1, LCDR2, and VL of LCDR3; tt. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:318, 319, and 320, respectively, and comprising the amine of SEQ ID NO:321, 322, and 323, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; uu. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:324, 325, and 326 respectively, and comprising the VH of the amino acid sequences having SEQ ID NO:324, 325, and 326 respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 327, 328, and 329; vv. comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequence of SEQ ID NO:330, 331, and 332, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:333, 334, and 335, respectively; ww. comprising the amino acids of SEQ ID NO:342, 343, and 344, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:345, 346, and 347 respectively; xx.comprising respectively having SEQ ID NO:354 The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of , 355, and 356, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:357, 358, and 359, respectively; yy . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 360, 361, and 362, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 363, 364, and 365, respectively , LCDR2, and the VL of LCDR3; zz. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:366, 367, and 368, respectively, and comprising the VH of SEQ ID NO:369, 370, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of and 371; aaa. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:384, 385, and 386, respectively, and comprising, respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 387, 388, and 389; bbb. comprising HCDR1, HCDR2 having the amino acid sequences of SEQ ID NOs: 906, 907, and 908, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:909, 910, and 911 respectively; ccc. comprising having SEQ ID NO:420, 421, and 422 respectively The amino acid sequence of HCDR1, HCDR2, and the VH of HCDR3, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:423, 424, and 425 respectively; ddd. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 1026, 1027, and 1028, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 1029, 1030, and 1031, respectively VL of; eee. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively, and comprising the amino groups of SEQ ID NO:915, 916, and 917, respectively VL of LCDR1, LCDR2, and LCDR3 of acid sequence; fff. VH comprising HCDR1, HCDR2, and HCDR3 of amino acid sequences having SEQ ID NO:426, 427, and 428 respectively, and comprising having SEQ ID NO: VL of LCDR1, LCDR2, and LCDR3 having amino acid sequences of 429, 430, and 431; ggg. VHs of HCDR1, HCDR2, and HCDR3 comprising amino acid sequences of SEQ ID NOs: 1194, 1195, and 1196, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively; hhh. comprising the amino acid sequences of SEQ ID NOs: 438, 439, and 440, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:441, 442, and 443; iii. comprising having SEQ ID NO:444, The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of 445 and 446, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:447, 448, and 449, respectively; jjj. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 456, 457, and 458, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 459, 460, and 461, respectively VL of LCDR2, and LCDR3; kkk. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:462, 463, and 464, respectively, and comprising SEQ ID NO:465, 466, and The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 467; lll. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:468, 469, and 470, and comprise respectively having VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NOs: 471, 472, and 473; mmm. HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:477, 478, and 479, respectively; nnn. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:483, 484, and 485 respectively; ooo. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO:510, 511, and 512, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:513, 514, and 515, respectively VL; ppp. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:528, 529, and 530, respectively, and comprising the amino acids of SEQ ID NO:531, 532, and 533, respectively The VL of LCDR1, LCDR2, and LCDR3 of the sequence; qqq. comprising the VH of HCDR1, HCDR2, and HCDR3 having respectively the amino acid sequences of SEQ ID NO:552, 553, and 554, and comprising respectively having SEQ ID NO:555 The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , 556, and 557; rrr. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:558, 559, and 560, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:561, 562, and 563, respectively; sss. comprising the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively VH of HCDR1, HCDR2, and HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:567, 568, and 569, respectively; ttt. comprising having SEQ ID NO:576, 577, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 578, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:579, 580, and 581 respectively; uuu.comprising VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 600, 601, and 602, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 603, 604, and 605, respectively , and the VL of LCDR3; vvv. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively, and comprising the VH of SEQ ID NO:609, 610, and 611, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of the amino acid sequence; www. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:624, 625, and 626 respectively, and comprising the VH of SEQ ID NO:624, 625, and 626 respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs:627, 628, and 629; xxx.comprising HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO:645, 646, and 647, respectively; yyy. comprising amines of SEQ ID NO:648, 649, and 650, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:651, 652, and 653 respectively; or zzz. comprising having SEQ ID respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO:654, 655, and 656, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:657, 658, and 659, respectively VL. 3. The isolated monoclonal antibody or antigen-binding fragment thereof as described in aspect 1 or 2, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment Comprising: a. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; b. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. comprising SEQ ID The VH of the amino acid sequence of NO:786, and the VL comprising the amino acid sequence of SEQ ID NO:787; e. the VH comprising the amino acid sequence of SEQ ID NO:138, and the VH comprising the amino acid sequence of SEQ ID NO:139 VL of amino acid sequence; f. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; g. comprising the amino acid of SEQ ID NO:152 The VH of the sequence, and the VL comprising the amino acid sequence of SEQ ID NO:153; h. the VH comprising the amino acid sequence of SEQ ID NO:154, and the VL comprising the amino acid sequence of SEQ ID NO:155; i. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; j. comprising the VH of the amino acid sequence of SEQ ID NO:160, and comprising SEQ ID NO:160 The VL of the amino acid sequence of ID NO:161; k. comprise the VH of the amino acid sequence of SEQ ID NO:164, and comprise the VL of the amino acid sequence of SEQ ID NO:165; l. comprise SEQ ID NO: The VH of the amino acid sequence of 166, and the VL comprising the amino acid sequence of SEQ ID NO:167; m. the VH comprising the amino acid sequence of SEQ ID NO:168, and the amino group comprising SEQ ID NO:169 VL of the acid sequence; n. VH comprising the amino acid sequence of SEQ ID NO:174, and VL comprising the amino acid sequence of SEQ ID NO:175; o. comprising the amino acid sequence of SEQ ID NO:788 VH, and VL comprising the amino acid sequence of SEQ ID NO:789; p. VH comprising the amino acid sequence of SEQ ID NO:186, and VL comprising the amino acid sequence of SEQ ID NO:187; q. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; r. VH comprising the amino acid sequence of SEQ ID NO:790, and comprising SEQ ID NO VL comprising the amino acid sequence of SEQ ID NO: 791; s. comprising the VH of the amino acid sequence of SEQ ID NO: 188, and comprising the VL of the amino acid sequence of SEQ ID NO: 189; t. comprising the VL of the amino acid sequence of SEQ ID NO: 884 VH of amino acid sequence, and VL comprising the amino acid sequence of SEQ ID NO:885; u. VH comprising the amino acid sequence of SEQ ID NO:192, and comprising the amino acid sequence of SEQ ID NO:193 VL of v. comprising the VH of the amino acid sequence of SEQ ID NO:194, and comprising the VL of the amino acid sequence of SEQ ID NO:195; w. comprising the VH of the amino acid sequence of SEQ ID NO:198, And comprise the VL of the amino acid sequence of SEQ ID NO:199; x. comprise the VH of the amino acid sequence of SEQ ID NO:200, and comprise the VL of the amino acid sequence of SEQ ID NO:201; y. comprise SEQ VH of the amino acid sequence of ID NO:202, and the VL comprising the amino acid sequence of SEQ ID NO:203; z. VH comprising the amino acid sequence of SEQ ID NO:204, and comprising the VH of the amino acid sequence of SEQ ID NO:205 VL comprising the amino acid sequence of SEQ ID NO:206; aa. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; bb. comprising the amino group of SEQ ID NO:216 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:217; cc. the VH comprising the amino acid sequence of SEQ ID NO:222, and the VL comprising the amino acid sequence of SEQ ID NO:223 dd. VH comprising the amino acid sequence of SEQ ID NO:230, and VL comprising the amino acid sequence of SEQ ID NO:231; ee. comprising the VH of the amino acid sequence of SEQ ID NO:232, and comprising VL of the amino acid sequence of SEQ ID NO:233; ff. comprise the VH of the amino acid sequence of SEQ ID NO:234 and comprise the VL of the amino acid sequence of SEQ ID NO:235; gg. comprise SEQ ID NO VH of the amino acid sequence of: 238, and the VL comprising the amino acid sequence of SEQ ID NO: 239; hh. VH comprising the amino acid sequence of SEQ ID NO: 246, and the amine comprising SEQ ID NO: 247 VL of amino acid sequence; ii. VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; jj. comprising the amino acid sequence of SEQ ID NO:254 VH, and VL comprising the amino acid sequence of SEQ ID NO:255; kk. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; ll . VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; or mm. comprising the VH of the amino acid sequence of SEQ ID NO:264, and comprising SEQ ID NO:264 VL of the amino acid sequence of ID NO:265. 4. An isolated monoclonal antibody or its active fragment as described in Aspect 1, which binds to the human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:787; b. HCDR1 as shown in SEQ ID NO:790, and HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:791; c. HCDR1, and HCDR2, and HCDR3 as shown in SEQ ID NO:792, and as shown in SEQ ID NO:793 LCDR1, LCDR2, and LCDR3; d. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; or e. as SEQ ID HCDR1, HCDR2, and HCDR3 shown in NO:236, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:237. 5. The isolated monoclonal antibody or antigen-binding fragment thereof as described in aspect 2, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 570, 571, and 572, respectively, and comprising the amino acid sequences of SEQ ID NOs: 573, 574, and 575, respectively The VL of LCDR1, LCDR2, and LCDR3; b. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938 respectively, and comprising having SEQ ID NO:939 respectively , 940, and 941 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; c. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 921, 922, and 923, respectively; d. comprising the amino acid sequences of SEQ ID NOs: 900, 901, and 902, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:903, 904, and 905; or e. comprising having SEQ ID NO: The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 912, 913, and 914, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:915, 916, and 917, respectively . 6. The isolated monoclonal antibody or antigen-binding fragment thereof as described in aspect 3, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. the VH comprising the amino acid sequence of SEQ ID NO:236, and the VL comprising the amino acid sequence of SEQ ID NO:237; b. the VH comprising the amino acid sequence of SEQ ID NO:798, and comprising the VH of the amino acid sequence of SEQ ID NO:798 The VL of the amino acid sequence of ID NO:799; c. comprise the VH of the amino acid sequence of SEQ ID NO:792, and comprise the VL of the amino acid sequence of SEQ ID NO:793; d. comprise SEQ ID NO: The VH of the amino acid sequence of 786, and the VL comprising the amino acid sequence of SEQ ID NO:787; or e. the VH comprising the amino acid sequence of SEQ ID NO:790, and the amine comprising SEQ ID NO:791 VL of the amino acid sequence. 7. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of aspects 1 to 6, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein The antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising having SEQ ID NO:921, 922, and The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 923; b. comprising the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:936, 937, and 938, and comprising respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 939, 940, and 941; or c. comprising HCDR1, and the VH of HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:573, 574, and 575, respectively. 8. The isolated monoclonal antibody or antigen-binding fragment thereof as described in any one of aspects 1 to 7, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein The antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; b. comprising the amino acid sequence of SEQ ID NO:798 c. the VH comprising the amino acid sequence of SEQ ID NO:799; or c. the VH comprising the amino acid sequence of SEQ ID NO:236, and the VL comprising the amino acid sequence of SEQ ID NO:237. 9. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of aspects 1 to 8, wherein the mammalian cell is a human or rat cell. 10. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of aspects 1 to 9, wherein the cell is a primary immune cell. 11. An isolated monoclonal antibody or an antigen-binding fragment thereof, which recognizes human and rat interleukin-23 receptors (IL-23R), wherein the antibody or fragment comprises: a. as shown in SEQ ID NO:202 HCDR1, HCDR2, and HCDR3 shown, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:203; b. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:252, and SEQ ID NO:252 LCDR1, LCDR2, and LCDR3 shown in NO:253; c. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:156, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:157; d HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:798, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; e. HCDR1 and HCDR2 as shown in SEQ ID NO:150 , and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:151; f. HCDR1, and HCDR2, and HCDR3 as shown in SEQ ID NO:204, and as shown in SEQ ID NO:205 LCDR1, LCDR2, and LCDR3; g. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:884, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:885; h. As SEQ ID NO: HCDR1, HCDR2, and HCDR3 shown in 188, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:189; or i. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:212, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:213. 12. The isolated monoclonal antibody or antigen-binding fragment thereof of aspect 11, which recognizes human and rat IL-23R, wherein the antibody or fragment comprises: a. comprising SEQ ID NO: 468, 469, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 470, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:471, 472, and 473, respectively; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 618, 619, and 620, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 621, 622, and 623, respectively , LCDR2, and the VL of LCDR3; c. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:330, 331, and 332, respectively, and comprising the VH of SEQ ID NO:333,334 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 335; d. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 939, 940, and 941, respectively; e. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 312, 313, and 314, respectively , and the VH of HCDR2 and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:315, 316, and 317 respectively; f. comprising having SEQ ID NO:474,475 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 476, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:477, 478, and 479, respectively; g. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1194, 1195, and 1196, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively , LCDR2, and the VL of LCDR3; h. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and comprising the VH of SEQ ID NO:429,430, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 431; or i. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:498, 499, and 500, respectively, and a VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:501, 502, and 503, respectively. 13. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of aspects 11 or 12 that recognizes human and rat IL-23R, wherein the antibody or fragment comprises: a. comprising SEQ ID NO VH of the amino acid sequence of: 202, and the VL comprising the amino acid sequence of SEQ ID NO:203; b. VH comprising the amino acid sequence of SEQ ID NO:252, and the amine comprising SEQ ID NO:253 VL of the amino acid sequence; c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; d. comprising the amino acid sequence of SEQ ID NO:798 VH, and VL comprising the amino acid sequence of SEQ ID NO:799; e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151; f . comprising the VH of the amino acid sequence of SEQ ID NO:204, and the VL comprising the amino acid sequence of SEQ ID NO:205; g. comprising the VH of the amino acid sequence of SEQ ID NO:884, and comprising the VH of the amino acid sequence of SEQ ID NO:884 The VL of the amino acid sequence of NO:885; h. comprise the VH of the amino acid sequence of SEQ ID NO:188, and comprise the VL of the amino acid sequence of SEQ ID NO:189; Or i. comprise SEQ ID NO: The VH of the amino acid sequence of 212, and the VL comprising the amino acid sequence of SEQ ID NO:213. 14. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ The VL of the CDR sequence of ID NO:1254, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:900, HCDR2 SEQ ID NO:901, and HCDR3 SEQ ID NO:902; b. HCDR1 SEQ ID NO:906, HCDR2 SEQ ID NO:907, and HCDR3 SEQ ID NO:908; c. HCDR1 SEQ ID NO:912, HCDR2 SEQ ID NO:913, and HCDR3 SEQ ID NO:914; d. HCDR1 SEQ ID NO: 918, HCDR2 SEQ ID NO:919, and HCDR3 SEQ ID NO:920; e. HCDR1 SEQ ID NO:942, HCDR2 SEQ ID NO:943, and HCDR3 SEQ ID NO:944; f. HCDR1 SEQ ID NO:948, HCDR2 SEQ ID NO:949, and HCDR3 SEQ ID NO:950; g. HCDR1 SEQ ID NO:1014, HCDR2 SEQ ID NO:1015, and HCDR3 SEQ ID NO:1016; h. HCDR1 SEQ ID NO:1026, HCDR2 SEQ ID NO: 1027, and HCDR3 SEQ ID NO: 1028; and i. HCDR1 SEQ ID NO: 1152, HCDR2 SEQ ID NO: 1153, and HCDR3 SEQ ID NO: 1154. 15. The isolated monoclonal antibody or antigen-binding fragment thereof according to aspect 13, comprising: one of the CDR sequences comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ ID NO: 1254 VL or a VL having an amino acid sequence of SEQ ID NO: 1247, and a VH sequence selected from SEQ ID NO: 786, 788, 790, 792, 800, 802, 824, 828, and 870. 16. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ The VL of the CDR sequence of ID NO:1257, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:924, HCDR2 SEQ ID NO:925, and HCDR3 SEQ ID NO:926; b. HCDR1 SEQ ID NO:1002, HCDR2 SEQ ID NO:1003, and HCDR3 SEQ ID NO:1004; c. HCDR1 SEQ ID NO:1032, HCDR2 SEQ ID NO:1033, and HCDR3 SEQ ID NO:1034; d. HCDR1 SEQ ID NO: 1044, HCDR2 SEQ ID NO:1045, and HCDR3 SEQ ID NO:1046; e. HCDR1 SEQ ID NO:1050, HCDR2 SEQ ID NO:1051, and HCDR3 SEQ ID NO:1052; f. HCDR1 SEQ ID NO:1056, HCDR2 SEQ ID NO:1057, and HCDR3 SEQ ID NO:1058; g. HCDR1 SEQ ID NO:1062, HCDR2 SEQ ID NO:1063, and HCDR3 SEQ ID NO:1064; h. HCDR1 SEQ ID NO:1068, HCDR2 SEQ ID NO:1069, and HCDR3 SEQ ID NO:1070; i. HCDR1 SEQ ID NO:1080, HCDR2 SEQ ID NO:1081, and HCDR3 SEQ ID NO:1082; j. HCDR1 SEQ ID NO:1092, HCDR2 SEQ ID NO : 1093, and HCDR3 SEQ ID NO: 1094; k. HCDR1 SEQ ID NO: 1098, HCDR2 SEQ ID NO: 1099, and HCDR3 SEQ ID NO: 1100; l. HCDR1 SEQ ID NO: 1110, HCDR2 SEQ ID NO: 1111 , and HCDR3 SEQ ID NO:1112; m. HCDR1 SEQ ID NO:1122, HCDR2 SEQ ID NO:1123, and HCDR3 SEQ ID NO:1124; n. HCDR1 SEQ ID NO:1140, HCDR2 SEQ ID NO:1141, and HCDR3 SEQ ID NO:1142; o. HCDR1 SEQ ID NO:1146, HCDR2 SEQ ID NO:1147, and HCDR3 SEQ ID NO:1148; and p. HCDR1 SEQ ID NO:1158, HCDR2 SEQ ID NO:1159, and HCDR3 SEQ ID NO: 1160. 17. The isolated monoclonal antibody or antigen-binding fragment thereof according to aspect 16, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ ID NO: 1257 or VL having the amino acid sequence of SEQ ID NO: 1248, and selected from the group consisting of SEQ ID NO: 794, 820, 830, 834, 836, 838, 840, 842, 846, 850, 852, 856, 860, 866, 868, and the VH sequence of 872. 18. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to an interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ A VL of the CDR sequence of ID NO:1260, and a VH comprising a CDR sequence selected from the group consisting of: a. HCDR1 SEQ ID NO:930, HCDR2 SEQ ID NO:931, and HCDR3 SEQ ID NO:932; and b. HCDR1 SEQ ID NO:954, HCDR2 SEQ ID NO:955, and HCDR3 SEQ ID NO:956. 19. The isolated monoclonal antibody or antigen-binding fragment thereof according to aspect 18, comprising: one of the CDR sequences comprising LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ ID NO: 1260 VL or a VL having the amino acid sequence of SEQ ID NO: 1249; and a VH sequence selected from SEQ ID NO: 796 and 804. 20. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ A VL of the CDR sequence of ID NO:1263, and a VH comprising a CDR sequence selected from the group consisting of: a. HCDR1 SEQ ID NO:960, HCDR2 SEQ ID NO:961, and HCDR3 SEQ ID NO:962; and b. HCDR1 SEQ ID NO: 1182, HCDR2 SEQ ID NO: 1183, and HCDR3 SEQ ID NO: 1184. 21. The isolated monoclonal antibody or antigen-binding fragment thereof according to aspect 20, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ ID NO: 1263 or VL having the amino acid sequence of SEQ ID NO: 1250, and a VH sequence selected from SEQ ID NO: 806 and 880. 22. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to an interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ The VL of the CDR sequence of ID NO:1266, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:1008, HCDR2 SEQ ID NO:1009, and HCDR3 SEQ ID NO:1010; b. HCDR1 SEQ ID NO:1020, HCDR2 SEQ ID NO:1021, and HCDR3 SEQ ID NO:1022; c. HCDR1 SEQ ID NO:1038, HCDR2 SEQ ID NO:1039, and HCDR3 SEQ ID NO:1040; d. HCDR1 SEQ ID NO: 1074, HCDR2 SEQ ID NO:1075, and HCDR3 SEQ ID NO:1076; e. HCDR1 SEQ ID NO:1086, HCDR2 SEQ ID NO:1087, and HCDR3 SEQ ID NO:1088; f. HCDR1 SEQ ID NO:1104, HCDR2 SEQ ID NO: 1105, and HCDR3 SEQ ID NO: 1106; g. HCDR1 SEQ ID NO: 1128, HCDR2 SEQ ID NO: 1129, and HCDR3 SEQ ID NO: 1130; and h. HCDR1 SEQ ID NO: 1134, HCDR2 SEQ ID NO: 1135, and HCDR3 SEQ ID NO: 1136. 23. The isolated monoclonal antibody or antigen-binding fragment thereof according to aspect 22, comprising: one of the CDR sequences comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ ID NO: 1266 VL or VL having the amino acid sequence of SEQ ID NO:1251; 24. A VHH antibody or Nanobody, which binds to an interleukin-23 receptor (IL-23R) and comprises a protein selected from the group consisting of SEQ ID NO: 786, 788, 790, 792, 800, 802, 824, 828, 870, 794, 820, 830, 834, 836, 838, 840, 842, 846, 850, 852, 856, 860, 866, 868, 872, 796, 804, 806, 880, 822, 826, 832, 844, 848, VH sequences of 854, 862, and 864. 25. An isolated monoclonal antibody or an antigen-binding fragment thereof, which binds to an interleukin-23 receptor (IL-23R) and comprises: a. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:138, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:139; b. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:142, and LCDR1, LCDR2, and as shown in SEQ ID NO:143 LCDR3; c. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:144, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:145; d. HCDR1, HCDR2, and LCDR3 as shown in SEQ ID NO:148 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:149; e. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:150, and as shown in SEQ ID NO:151 LCDR1, LCDR2, and LCDR3; f. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:152, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:153; g. as SEQ ID NO:154 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:155; h. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:156, and as SEQ ID NO:156 LCDR1, LCDR2, and LCDR3 shown in :157; i. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:158, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:159; j. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:160, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:161; k. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:162, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:163; l. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:164, and LCDR1, LCDR2, and as shown in SEQ ID NO:165 LCDR3; m. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:166, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:167; n. HCDR1, HCDR2, and LCDR3 as shown in SEQ ID NO:168 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:169; o. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:170, and as shown in SEQ ID NO:171 LCDR1, LCDR2, and LCDR3; p. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:172, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:173; q. as shown in SEQ ID NO:174 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:175; r. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:176, and as SEQ ID NO:176 LCDR1, LCDR2, and LCDR3 shown in :177; s. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:178, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:179; t. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:180, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:181; u. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:182, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:183; v. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:186, and LCDR1, LCDR2, and as shown in SEQ ID NO:187 LCDR3; w. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:188, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:189; x. HCDR1, HCDR2, and LCDR3 as shown in SEQ ID NO:190 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:191; y. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:192, and as shown in SEQ ID NO:193 LCDR1, LCDR2, and LCDR3; z. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:194, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:195; aa. As shown in SEQ ID NO:196 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:197; bb. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:198, and as shown in SEQ ID NO LCDR1, LCDR2, and LCDR3 shown in :199; cc. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:200, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:201; dd. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:202, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:203; ee. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:204, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:205; ff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:206, and LCDR1, LCDR2, and as shown in SEQ ID NO:207 LCDR3; gg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:208, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:209; hh. HCDR1, HCDR1, as shown in SEQ ID NO:210 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:211; ii. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:212, and as shown in SEQ ID NO:213 LCDR1, LCDR2, and LCDR3; jj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:214, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:215; kk. as shown in SEQ ID NO:216 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:217; 11. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:218, and as SEQ ID NO:218 LCDR1, LCDR2, and LCDR3 shown in :219; mm. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:220, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:221; nn. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:222, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:223; oo. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:226, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:227; pp. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:228, and LCDR1, LCDR2, and as shown in SEQ ID NO:229 LCDR3; qq. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:230, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:231; rr. HCDR1, as shown in SEQ ID NO:232 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:233; ss. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:234, and as shown in SEQ ID NO:235 LCDR1, LCDR2, and LCDR3; tt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:236, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:237; uu. As shown in SEQ ID NO:238 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:239; vv. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:240, and as SEQ ID NO:240 LCDR1, LCDR2, and LCDR3 shown in :241; ww. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:246, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:247; xx. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:248, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:249; yy. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:250, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:251; zz. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:252, and LCDR1, LCDR2, and as shown in SEQ ID NO:253 LCDR3; aaa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:254, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:255; bbb. HCDR1, HCDR1, as shown in SEQ ID NO:256 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:257; ccc. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:258, and as shown in SEQ ID NO:259 LCDR1, LCDR2, and LCDR3; ddd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:260, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:261; eee. Such as SEQ ID NO:262 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:263; fff. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:264, and as shown in SEQ ID NO LCDR1, LCDR2, and LCDR3 shown in :265; ggg. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:268, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:269; hhh. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:786, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:787; iii. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:788, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:789; jjj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:790, and LCDR1, LCDR2, and as shown in SEQ ID NO:791 LCDR3; kkk. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:792, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:793; lll. HCDR1, HCDR1, as shown in SEQ ID NO:798 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:799; mmm. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:806, and as shown in SEQ ID NO:807 LCDR1, LCDR2, and LCDR3; nnn. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:808, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:809; ooo. as SEQ ID NO:810 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:811; ppp. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:812, and as SEQ ID NO:812 LCDR1, LCDR2, and LCDR3 shown in :813; qqq. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:814, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:815; rrr. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:816, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:817; sss. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:818, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:819; ttt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:820, and LCDR1, LCDR2, and as shown in SEQ ID NO:821 LCDR3; uuu. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:822, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:823; vvv. HCDR1, HCDR1, as shown in SEQ ID NO:824 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:825; www. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:826, and as shown in SEQ ID NO:827 LCDR1, LCDR2, and LCDR3; xxx. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:828, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:829; yyy. As shown in SEQ ID NO:830 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:831; zzz. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:832, and as SEQ ID NO:831 LCDR1, LCDR2, and LCDR3 shown in :833; aaaa. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:836, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:837; bbbb. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:838, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:839; cccc. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:840, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:841; dddd. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:842, and LCDR1, LCDR2, and as shown in SEQ ID NO:843 LCDR3; eeee. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:846, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:847; ffff. HCDR1, as shown in SEQ ID NO:848 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:849; gggg. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:850, and as shown in SEQ ID NO:851 LCDR1, LCDR2, and LCDR3; hhhh. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:852, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:853; iii. As shown in SEQ ID NO:854 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:855; jjjj. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:856, and as SEQ ID NO: LCDR1, LCDR2, and LCDR3 shown in :857; kkkk. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:858, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:859; llll. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:860, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:861; mmmm. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:862, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:863; nnnn. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:864, and LCDR1, LCDR2, and as shown in SEQ ID NO:865 LCDR3; oooo. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:866, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:867; pppp. HCDR1, as shown in SEQ ID NO:868 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:869; qqqq. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:870, and as shown in SEQ ID NO:871 LCDR1, LCDR2, and LCDR3; rrrr. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:872, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:873; ssss. as shown in SEQ ID NO:874 HCDR1, HCDR2, and HCDR3 as shown, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:875; tttt. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:876, and as shown in SEQ ID NO LCDR1, LCDR2, and LCDR3 shown in :877; uuuu. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:878, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:879; vvvv. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:880, and LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO:881; wwww. HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO:882, And LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:883; xxxx. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:884, and LCDR1, LCDR2, and as shown in SEQ ID NO:885 LCDR3; yyyy. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:886, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:887; zzzz. HCDR1, HCDR1, as shown in SEQ ID NO:888 HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:889; or aaaaa. HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:890, and as shown in SEQ ID NO:891 LCDR1, LCDR2, and LCDR3. 26. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to an interleukin-23 receptor (IL-23R) and comprising: a. comprising an amine group having SEQ ID NOs: 276, 277, and 278, respectively The VH of HCDR1, HCDR2, and HCDR3 of the acid sequence, and the VL comprising LCDR1, LCDR2, and LCDR3 of the amino acid sequence of SEQ ID NO:279, 280, and 281 respectively; b. comprising respectively having SEQ ID NO: The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 288, 289, and 290, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 291, 292, and 293, respectively; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 294, 295, and 296, respectively, and comprising the amino acid sequences of SEQ ID NOs: 297, 298, and 299, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:306, 307, and 308 respectively, and comprising having SEQ ID NO:309,310 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 311; e. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:312, 313, and 314, respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:315, 316, and 317 respectively; f. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:321, 322, and 323, respectively; g. comprising having SEQ ID NO:324, 325, and The VH of HCDR1, HCDR2, and HCDR3 having an amino acid sequence of 326, and the VL comprising LCDR1, LCDR2, and LCDR3 having an amino acid sequence of SEQ ID NO:327, 328, and 329, respectively; h. comprising having respectively VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 330, 331, and 332, and LCDR1, LCDR2, and VL of LCDR3; i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:336, 337, and 338, respectively, and comprising the amine of SEQ ID NO:339, 340, and 341, respectively The VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; j. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:342,343, and 344, and comprise respectively having SEQ ID NO: VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 345, 346, and 347; k. comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequence of SEQ ID NO:348, 349, and 350, respectively VH, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:351, 352, and 353 respectively; 1. comprising the amino acids of SEQ ID NO:354, 355, and 356, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:357, 358, and 359 respectively; m. comprising respectively having SEQ ID NO:360 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , 361, and 362, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:363, 364, and 365, respectively; n . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 366, 367, and 368, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 369, 370, and 371, respectively , LCDR2, and the VL of LCDR3; o. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:372, 373, and 374, respectively, and comprising the VH of SEQ ID NO:375, 376, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of and 377; p. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:378, 379, and 380, and comprises respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 381, 382, and 383; q. HCDR1, HCDR2 comprising the amino acid sequences of SEQ ID NOs: 384, 385, and 386, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:387, 388, and 389 respectively; r. comprising having SEQ ID NO:390, 391, and 392 respectively The amino acid sequence of HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequence of SEQ ID NO:393, 394, and 395 respectively; s. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 396, 397, and 398, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 399, 400, and 401, respectively VL of t. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:402, 403, and 404, respectively, and comprising the amino groups of SEQ ID NO:405, 406, and 407, respectively The VL of LCDR1, LCDR2, and LCDR3 of acid sequence; u. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:408, 409, and 410, and comprise respectively having SEQ ID NO: The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of 411, 412, and 413; v. the VH of HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:420, 421, and 422, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequence of SEQ ID NO:423, 424, and 425 respectively; w. comprising the amino acid sequence having SEQ ID NO:426, 427, and 428, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:429, 430, and 431 respectively; x. comprising having SEQ ID NO:432, The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of 433 and 434, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:435, 436, and 437, respectively; y. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 438, 439, and 440, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 441, 442, and 443, respectively LCDR2, and the VL of LCDR3; z. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:444, 445, and 446, respectively, and comprising the VH of SEQ ID NO:447, 448, and The VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequence of 449; aa. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:450, 451, and 452, respectively, and comprising having respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NOs: 453, 454, and 455; bb. HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:459, 460, and 461, respectively; cc. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:465, 466, and 467 respectively; dd. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO:468, 469, and 470, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:471, 472, and 473, respectively VL; ee. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 474, 475, and 476, respectively, and comprising the amino acids of SEQ ID NOs: 477, 478, and 479, respectively The VL of the sequence LCDR1, LCDR2, and LCDR3; ff. comprises the VH of HCDR1, HCDR2, and HCDR3 having respectively the amino acid sequence of SEQ ID NO:480, 481, and 482, and comprises respectively having SEQ ID NO:483 , 484, and 485 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; gg. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:486, 487, and 488, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 489, 490, and 491, respectively; hh. comprising the amino acid sequences of SEQ ID NOs: 492, 493, and 494, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:495, 496, and 497 respectively; ii. comprising having SEQ ID NO:498,499 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 500, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:501, 502, and 503; jj. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 504, 505, and 506, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 507, 508, and 509, respectively , and the VL of LCDR3; kk. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:510, 511, and 512, respectively, and comprising having SEQ ID NO:513, 514, and 515, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; 11. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:516, 517, and 518 respectively, and comprising the VH of SEQ ID NO:516, 517, and 518 VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 519, 520, and 521; mm. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO:525, 526, and 527, respectively; nn. comprising amines of SEQ ID NO:528, 529, and 530, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:531, 532, and 533 respectively; oo. VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences of 540, 541, and 542, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NO:543, 544, and 545, respectively pp. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:546, 547, and 548, respectively, and comprising the amino acid sequence of SEQ ID NO:549, 550, and 551, respectively The VL of LCDR1, LCDR2, and LCDR3; qq. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:552, 553, and 554 respectively, and comprising respectively having SEQ ID NO:555, VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of 556 and 557; rr. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:558, 559, and 560, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 561, 562, and 563, respectively; ss. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 564, 565, and 566, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:567, 568, and 569 respectively; tt. comprising having SEQ ID NO:570, 571, The VH of HCDR1, HCDR2, and HCDR3 with amino acid sequences of 572 and 572, and the VL of LCDR1, LCDR2, and LCDR3 with amino acid sequences of SEQ ID NO:573, 574, and 575; uu. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 576, 577, and 578, and LCDR1, LCDR2, and the VL of LCDR3; vv. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:582, 583, and 584, respectively, and comprising the VH of SEQ ID NO:585, 586, and 587, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; ww. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:600, 601, and 602 respectively, and comprising respectively having SEQ ID The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of NO:603, 604, and 605; xx. HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:609, 610, and 611, respectively; yy. comprising amino groups having SEQ ID NO:612, 613, and 614, respectively The VH of HCDR1, HCDR2, and HCDR3 of the acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:615, 616, and 617 respectively; zz. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 618, 619, and 620, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 621, 622, and 623, respectively; aaa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:624, 625, and 626, respectively, and comprising the amino acid sequence of SEQ ID NO:627, 628, and 629, respectively VL of LCDR1, LCDR2, and LCDR3; bbb. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:630, 631, and 632, respectively, and comprising having SEQ ID NO:633, 634, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 635; ccc. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:636, 637, and 638, respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:639, 640, and 641 respectively; ddd. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:645, 646, and 647; eee. comprising respectively having SEQ ID NO:648, 649, and The VH of HCDR1, HCDR2, and HCDR3 having an amino acid sequence of 650, and the VL comprising LCDR1, LCDR2, and LCDR3 having an amino acid sequence of SEQ ID NO:651, 652, and 653 respectively; fff. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 654, 655, and 656, and LCDR1, LCDR2, and VL of LCDR3; ggg. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:666, 667, and 668, respectively, and comprising the amine of SEQ ID NO:669, 670, and 671, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; hhh. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902 respectively, and comprising the VH of the amino acid sequences having SEQ ID NO:900, 901, and 902 respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 903, 904, and 905; iii. comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequence of SEQ ID NO:906, 907, and 908, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively; jjj. comprising the amino acids of SEQ ID NO:912, 913, and 914, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:915, 916, and 917 respectively; The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , 919, and 920, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:921, 922, and 923, respectively; lll . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 936, 937, and 938, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 939, 940, and 941, respectively , LCDR2, and the VL of LCDR3; mmm. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:960, 961, and 962, respectively, and comprising the VH of SEQ ID NO:963, 964, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of and 965; nnn. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:966, 967, and 968, and comprises respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 969, 970, and 971; ooo. comprising HCDR1, HCDR2 having the amino acid sequences of SEQ ID NOs: 972, 973, and 974, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:975, 976, and 977 respectively; ppp. comprises having SEQ ID NO:978, 979, and 980 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:981, 982, and 983 respectively; qqq. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 984, 985, and 986, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 987, 988, and 989, respectively VL of rrr. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:990, 991, and 992, respectively, and comprising the amino groups of SEQ ID NO:993, 994, and 995, respectively The VL of LCDR1, LCDR2, and LCDR3 of the acid sequence; sss. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:996, 997, and 998 respectively, and comprising the VH of respectively having the SEQ ID NO:996, 997, and 998 VL of LCDR1, LCDR2, and LCDR3 with amino acid sequences of 999, 1000, and 1001; ttt. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO: 1002, 1003, and 1004, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1005, 1006, and 1007, respectively; uuu. comprising the amino acid sequences of SEQ ID NOs: 1008, 1009, and 1010, respectively VH of HCDR1, HCDR2, and HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1011, 1012, and 1013 respectively; vvv. comprising having SEQ ID NO:1014, The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of 1015 and 1016, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1017, 1018, and 1019, respectively; www. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1020, 1021, and 1022, respectively, and LCDR1, LCDR2, and the VL of LCDR3; xxx. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1026, 1027, and 1028, respectively, and comprising the VH of SEQ ID NO: 1029, 1030, and VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequence of 1031; yyy. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:1032, 1033, and 1034, respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NO:1035, 1036, and 1037; zzz. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1041, 1042, and 1043, respectively; aaaa. The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1053, 1054, and 1055 respectively; bbbb. The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of NO: 1056, 1057, and 1058, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1059, 1060, and 1061, respectively VL; cccc. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1062, 1063, and 1064, respectively, and comprising the amino acids of SEQ ID NO: 1065, 1066, and 1067, respectively VL of LCDR1, LCDR2, and LCDR3 of sequence; dddd. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1068, 1069, and 1070 respectively, and comprising having SEQ ID NO:1071 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , 1072, and 1073; eeee. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1080, 1081, and 1082, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1083, 1084, and 1085, respectively; ffff. comprising the amino acid sequences of SEQ ID NOs: 1086, 1087, and 1088, respectively VH of HCDR1, HCDR2, and HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1089, 1090, and 1091, respectively; gggg. comprising having SEQ ID NO: 1092, 1093, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 1094, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1095, 1096, and 1097; hhhh.comprising VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1098, 1099, and 1100, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 1101, 1102, and 1103, respectively , and the VL of LCDR3; iii. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1104, 1105, and 1106 respectively, and comprising having SEQ ID NO: 1107, 1108, and 1109 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; jjjj. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:1110, 1111, and 1112, respectively, and comprising the VH of SEQ ID NO:1110, 1111, and 1112, respectively, VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 1113, 1114, and 1115; kkkk. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1119, 1120, and 1121, respectively; 1111. comprising the amine of SEQ ID NO:1122, 1123, and 1124 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1125, 1126, and 1127 respectively; mmmm. VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences of 1128, 1129, and 1130, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NOs: 1131, 1132, and 1133, respectively nnnn. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1134, 1135, and 1136, respectively, and comprising the amino acid sequences of SEQ ID NOs: 1137, 1138, and 1139, respectively VL of LCDR1, LCDR2, and LCDR3; oooo. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1140, 1141, and 1142, respectively, and comprising having SEQ ID NO:1143, VL of LCDR1, LCDR2, and LCDR3 having amino acid sequences of 1144, and 1145; pppp. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO: 1146, 1147, and 1148, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1149, 1150, and 1151, respectively; qqqq. comprising HCDR1 having the amino acid sequences of SEQ ID NOs: 1152, 1153, and 1154, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1155, 1156, and 1157 respectively; rrrr. comprising having SEQ ID NO:1158, 1159, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of and 1160, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1161, 1162, and 1163 respectively; ssss.comprising respectively VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1164, 1165, and 1166, and LCDR1, LCDR2, and the VL of LCDR3; tttt. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1170, 1171, and 1172, respectively, and comprising the VH of SEQ ID NO:1173, 1174, and 1175, respectively VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; uuuu. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO:1176, 1177, and 1178, respectively, and comprising SEQ ID NO:1176, 1177, and 1178 respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of NO:1179, 1180, and 1181; vvvv. HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1182, 1183, and 1184, respectively and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1185, 1186, and 1187, respectively; wwww. comprising amino groups having SEQ ID NO:1188, 1189, and 1190, respectively The VH of HCDR1, HCDR2, and HCDR3 of the acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1191, 1192, and 1193 respectively; xxxx.comprising respectively having the SEQ ID NO: The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 1194, 1195, and 1196, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively; yyyy. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO: 1200, 1201, and 1202, respectively, and comprising the amino acid sequence of SEQ ID NO: 1203, 1204, and 1205, respectively VL of LCDR1, LCDR2, and LCDR3; zzzz. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1206, 1207, and 1208, respectively, and comprising having SEQ ID NO: 1209, 1210, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 1211; or aaaaa. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1212, 1213, and 1214, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1215, 1216, and 1217, respectively. 27. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of aspects 25 or 26, comprising: a. VH comprising the amino acid sequence of SEQ ID NO: 138, and comprising SEQ ID VL of the amino acid sequence of NO:139; b. VH comprising the amino acid sequence of SEQ ID NO:142, and VL comprising the amino acid sequence of SEQ ID NO:143; c. comprising SEQ ID NO:144 VH of the amino acid sequence of and comprising the VL of the amino acid sequence of SEQ ID NO:145; d. VH comprising the amino acid sequence of SEQ ID NO:148 and the amino acid comprising SEQ ID NO:149 The VL of the sequence; e. the VH comprising the amino acid sequence of SEQ ID NO:150, and the VL comprising the amino acid sequence of SEQ ID NO:151; f. the VH comprising the amino acid sequence of SEQ ID NO:152 , and VL comprising the amino acid sequence of SEQ ID NO:153; g. comprising the VH of the amino acid sequence of SEQ ID NO:154, and comprising the VL of the amino acid sequence of SEQ ID NO:155; h. comprising The VH of the amino acid sequence of SEQ ID NO:156, and the VL comprising the amino acid sequence of SEQ ID NO:157; i. the VH comprising the amino acid sequence of SEQ ID NO:158, and comprising the VH of the amino acid sequence of SEQ ID NO:158: The VL of the amino acid sequence of 159; j. the VH comprising the amino acid sequence of SEQ ID NO:160, and the VL comprising the amino acid sequence of SEQ ID NO:161; k. the amine comprising SEQ ID NO:162 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:163; 1. the VH comprising the amino acid sequence of SEQ ID NO:164, and the VH comprising the amino acid sequence of SEQ ID NO:165 VL; m. VH comprising the amino acid sequence of SEQ ID NO:166, and VL comprising the amino acid sequence of SEQ ID NO:167; n. VH comprising the amino acid sequence of SEQ ID NO:168, and VL comprising the amino acid sequence of SEQ ID NO:169; o. comprising the VH of the amino acid sequence of SEQ ID NO:170, and comprising the VL of the amino acid sequence of SEQ ID NO:171; p. comprising SEQ ID The VH of the amino acid sequence of NO:172, and the VL comprising the amino acid sequence of SEQ ID NO:173; q. the VH comprising the amino acid sequence of SEQ ID NO:174, and the VH comprising the amino acid sequence of SEQ ID NO:175 VL of amino acid sequence; r. VH comprising the amino acid sequence of SEQ ID NO:176, and VL comprising the amino acid sequence of SEQ ID NO:177; s. comprising the amino acid of SEQ ID NO:178 The VH of the sequence, and the VL comprising the amino acid sequence of SEQ ID NO:179; t. the VH comprising the amino acid sequence of SEQ ID NO:180, and the VL comprising the amino acid sequence of SEQ ID NO:181; u. VH comprising the amino acid sequence of SEQ ID NO:182, and VL comprising the amino acid sequence of SEQ ID NO:183; v. VH comprising the amino acid sequence of SEQ ID NO:186, and comprising SEQ ID NO:186 The VL of the amino acid sequence of ID NO:187; w. comprise the VH of the amino acid sequence of SEQ ID NO:188, and comprise the VL of the amino acid sequence of SEQ ID NO:189; x. comprise SEQ ID NO: The VH of the amino acid sequence of 190, and the VL comprising the amino acid sequence of SEQ ID NO:191; y. the VH comprising the amino acid sequence of SEQ ID NO:192, and the amino group comprising SEQ ID NO:193 VL of the acid sequence; z. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; aa. comprising the amino acid sequence of SEQ ID NO:196 VH, and VL comprising the amino acid sequence of SEQ ID NO:197; bb. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; cc. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; dd. VH comprising the amino acid sequence of SEQ ID NO:202, and comprising SEQ ID NO VL of the amino acid sequence of: 203; ee. comprise the VH of the amino acid sequence of SEQ ID NO:204, and comprise the VL of the amino acid sequence of SEQ ID NO:205; ff. comprise the VL of the amino acid sequence of SEQ ID NO:206; VH of amino acid sequence, and VL comprising the amino acid sequence of SEQ ID NO:207; gg. VH comprising the amino acid sequence of SEQ ID NO:208, and comprising the amino acid sequence of SEQ ID NO:209 hh. VH comprising the amino acid sequence of SEQ ID NO:210, and VL comprising the amino acid sequence of SEQ ID NO:211; ii. VH comprising the amino acid sequence of SEQ ID NO:212, And comprise the VL of the amino acid sequence of SEQ ID NO:213; jj. comprise the VH of the amino acid sequence of SEQ ID NO:214, and comprise the VL of the amino acid sequence of SEQ ID NO:215; kk. comprise SEQ The VH of the amino acid sequence of ID NO:216, and the VL comprising the amino acid sequence of SEQ ID NO:217; ll. the VH comprising the amino acid sequence of SEQ ID NO:218, and comprising the VH of the amino acid sequence of SEQ ID NO:219 VL comprising the amino acid sequence of SEQ ID NO:220; mm. VH comprising the amino acid sequence of SEQ ID NO:220, and VL comprising the amino acid sequence of SEQ ID NO:221; nn. comprising the amino group of SEQ ID NO:222 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:223; oo. The VH comprising the amino acid sequence of SEQ ID NO:226, and the VL comprising the amino acid sequence of SEQ ID NO:227 pp. VH comprising the amino acid sequence of SEQ ID NO:228, and VL comprising the amino acid sequence of SEQ ID NO:229; qq. comprising the VH of the amino acid sequence of SEQ ID NO:230, and comprising VL of the amino acid sequence of SEQ ID NO:231; rr. VH comprising the amino acid sequence of SEQ ID NO:232, and VL comprising the amino acid sequence of SEQ ID NO:233; ss. comprising SEQ ID NO VH of the amino acid sequence of: 234, and the VL comprising the amino acid sequence of SEQ ID NO: 235; tt. VH comprising the amino acid sequence of SEQ ID NO: 236, and the amine comprising SEQ ID NO: 237 VL of amino acid sequence; uu. VH comprising the amino acid sequence of SEQ ID NO:238, and VL comprising the amino acid sequence of SEQ ID NO:239; vv. comprising the amino acid sequence of SEQ ID NO:240 VH, and VL comprising the amino acid sequence of SEQ ID NO:241; ww. VH comprising the amino acid sequence of SEQ ID NO:246, and VL comprising the amino acid sequence of SEQ ID NO:247; xx . VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; yy. VH comprising the amino acid sequence of SEQ ID NO:250, and comprising SEQ ID VL of the amino acid sequence of NO:251; zz. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; aaa. comprising SEQ ID NO:254 The VH of the amino acid sequence of, and the VL comprising the amino acid sequence of SEQ ID NO:255; bbb. The VH of the amino acid sequence comprising SEQ ID NO:256, and the amino acid comprising SEQ ID NO:257 The VL of the sequence; ccc. the VH comprising the amino acid sequence of SEQ ID NO:258, and the VL comprising the amino acid sequence of SEQ ID NO:259; ddd. the VH comprising the amino acid sequence of SEQ ID NO:260 , and VL comprising the amino acid sequence of SEQ ID NO:261; eee. comprising the VH of the amino acid sequence of SEQ ID NO:262, and comprising the VL of the amino acid sequence of SEQ ID NO:263; fff. comprising The VH of the amino acid sequence of SEQ ID NO:264, and the VL comprising the amino acid sequence of SEQ ID NO:265; ggg. The VH comprising the amino acid sequence of SEQ ID NO:268, and comprising the VH of the amino acid sequence of SEQ ID NO: The VL of the amino acid sequence of 269; hhh. the VH comprising the amino acid sequence of SEQ ID NO:786, and the VL comprising the amino acid sequence of SEQ ID NO:787; iii. the amine comprising SEQ ID NO:788 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:789; jjj. The VH comprising the amino acid sequence of SEQ ID NO:790, and the VL comprising the amino acid sequence of SEQ ID NO:791 VL; kkk. comprising the VH of the amino acid sequence of SEQ ID NO:792, and the VL comprising the amino acid sequence of SEQ ID NO:793; lll. comprising the VH of the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; mmm. VH comprising the amino acid sequence of SEQ ID NO:806, and VL comprising the amino acid sequence of SEQ ID NO:807; nnn. comprising SEQ ID The VH of the amino acid sequence of NO:808, and the VL comprising the amino acid sequence of SEQ ID NO:809; ooo. The VH comprising the amino acid sequence of SEQ ID NO:810, and the VH comprising the amino acid sequence of SEQ ID NO:811 VL of amino acid sequence; ppp. VH comprising the amino acid sequence of SEQ ID NO:812, and VL comprising the amino acid sequence of SEQ ID NO:813; qqq. comprising the amino acid of SEQ ID NO:814 VH of sequence, and VL comprising the amino acid sequence of SEQ ID NO:815; rrr. VH comprising the amino acid sequence of SEQ ID NO:816, and VL comprising the amino acid sequence of SEQ ID NO:817; sss. VH comprising the amino acid sequence of SEQ ID NO:818, and VL comprising the amino acid sequence of SEQ ID NO:819; ttt. comprising the VH of the amino acid sequence of SEQ ID NO:820, and comprising SEQ ID NO:820 VL of the amino acid sequence of ID NO:821; uuu. VH comprising the amino acid sequence of SEQ ID NO:822, and VL comprising the amino acid sequence of SEQ ID NO:823; vvv. comprising SEQ ID NO: The VH of the amino acid sequence of 824, and the VL comprising the amino acid sequence of SEQ ID NO:825; www. the VH comprising the amino acid sequence of SEQ ID NO:826, and the amino group comprising SEQ ID NO:827 VL of the acid sequence; xxx. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; yyy. comprising the amino acid sequence of SEQ ID NO:830 VH, and VL comprising the amino acid sequence of SEQ ID NO:831; zzz. VH comprising the amino acid sequence of SEQ ID NO:832, and VL comprising the amino acid sequence of SEQ ID NO:833; aaaa. The VH comprising the amino acid sequence of SEQ ID NO:836, and the VL comprising the amino acid sequence of SEQ ID NO:837; bbbb. The VH comprising the amino acid sequence of SEQ ID NO:838, and comprising the VH of the amino acid sequence of SEQ ID NO:838 VL comprising the amino acid sequence of SEQ ID NO:839; cccc. comprising the VH of the amino acid sequence of SEQ ID NO:840, and comprising the VL of the amino acid sequence of SEQ ID NO:841; dddd. comprising the VL of the amino acid sequence of SEQ ID NO:842 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:843; eeee. The VH comprising the amino acid sequence of SEQ ID NO:846, and the amino acid sequence comprising SEQ ID NO:847 VL of ffff. VH comprising the amino acid sequence of SEQ ID NO:848, and VL comprising the amino acid sequence of SEQ ID NO:849; gggg. VH comprising the amino acid sequence of SEQ ID NO:850, And comprise the VL of the amino acid sequence of SEQ ID NO:851; hhhh. comprise the VH of the amino acid sequence of SEQ ID NO:852, and comprise the VL of the amino acid sequence of SEQ ID NO:853; iii. comprise SEQ The VH of the amino acid sequence of ID NO:854, and the VL comprising the amino acid sequence of SEQ ID NO:855; jjjj. The VH comprising the amino acid sequence of SEQ ID NO:856, and the VH comprising the amino acid sequence of SEQ ID NO:857 VL of the amino acid sequence of kkkk. comprising the VH of the amino acid sequence of SEQ ID NO:858, and the VL comprising the amino acid sequence of SEQ ID NO:859; llll. comprising the amino group of SEQ ID NO:860 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:861; mmmm. The VH comprising the amino acid sequence of SEQ ID NO:862, and the VL comprising the amino acid sequence of SEQ ID NO:863 ; nnnn. comprising the VH of the amino acid sequence of SEQ ID NO:864, and the VL comprising the amino acid sequence of SEQ ID NO:865; oooo. comprising the VH of the amino acid sequence of SEQ ID NO:866, and comprising VL of the amino acid sequence of SEQ ID NO:867; pppp. VH comprising the amino acid sequence of SEQ ID NO:868, and VL comprising the amino acid sequence of SEQ ID NO:869; qqqq. comprising SEQ ID NO The VH of the amino acid sequence of: 870, and the VL comprising the amino acid sequence of SEQ ID NO: 871; rrrr. The VH of the amino acid sequence comprising SEQ ID NO: 872, and the amine comprising SEQ ID NO: 873 VL of amino acid sequence; ssss. VH comprising the amino acid sequence of SEQ ID NO:874, and VL comprising the amino acid sequence of SEQ ID NO:875; tttt. comprising the amino acid sequence of SEQ ID NO:876 VH, and VL comprising the amino acid sequence of SEQ ID NO:877; uuuu. VH comprising the amino acid sequence of SEQ ID NO:878, and VL comprising the amino acid sequence of SEQ ID NO:879; vvvv . comprising the VH of the amino acid sequence of SEQ ID NO:880, and the VL comprising the amino acid sequence of SEQ ID NO:881; wwww. comprising the VH of the amino acid sequence of SEQ ID NO:882, and comprising the VH of the amino acid sequence of SEQ ID NO:882 VL of the amino acid sequence of NO:883; xxxx. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; yyyy. comprising SEQ ID NO:886 VH comprising the amino acid sequence of SEQ ID NO:887, and VL comprising the amino acid sequence of SEQ ID NO:887; zzzz. comprising the VH of the amino acid sequence of SEQ ID NO:888, and comprising the amino acid of SEQ ID NO:889 VL of the sequence; or aaaaa. VH comprising the amino acid sequence of SEQ ID NO:890, and VL comprising the amino acid sequence of SEQ ID NO:891. 28. The antibody or fragment according to any one of aspects 1 to 27, wherein the antibody is IgG. 29. The antibody or fragment of any one of aspects 1 to 28, wherein the antibody is a humanized or chimeric antibody or fragment thereof. 30. The isolated antibody or fragment as described in any one of aspects 1 to 28, which is an antibody or a fragment thereof, wherein the isolated antibody F(ab') 2, scFv fragment, domain antibody, Minibodies, diabodies, triabodies, or tetrabodies in the form of antibodies. 31. The antibody of any one of aspects 1 to 30, wherein the antibody is genetically fused or chemically conjugated to an agent, wherein optionally the agent is a detectable substance or a drug, wherein optionally the agent is detectable The substance system is selected from enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, or chemiluminescent materials, wherein optionally the enzyme system is selected from horseradish peroxidase, alkaline phosphatase, β-galactosidase , or acetylcholinesterase; wherein the optional prosthetic group is selected from streptavidin/biotin or avidin/biotin; wherein the optional fluorescent material is selected from umbelliferone, luciferin, Fluorescent isothiocyanate, rose bengal, dichlorotri

Amino luciferin, dansyl chloride, or phycoerythrin; wherein the optional luminescent material is luminol; wherein the optional bioluminescent material is selected from luciferase, luciferin, or Aequorin; and wherein optionally the chemiluminescent material is selected from 225Ac gamma-emitting, Auger-emitting, beta-emitting, alpha-emitting, or positron-emitting radioactive isotopes. 32. A nucleic acid molecule encoding the antibody or variable region or antigen-binding fragment thereof according to any one of aspects 1 to 30. 33. A vector comprising the nucleic acid molecule as described in aspect 32. 34. A host cell transformed with the carrier as described in aspect 33. 35. A composition comprising the antibody as described in any one of aspects 1 to 31, the nucleic acid molecule as described in claim 30, or the carrier as described in claim 31, and a pharmaceutically acceptable endower Forming agent. 36. A set comprising the antibody as described in any one of aspects 1 to 31. 37. A method for detecting, selecting, and/or enriching an interleukin-23 receptor (IL-23R) in a sample, comprising making the sample and any one of aspects 1 to 31 Said antibody exposure, wherein optionally the method comprises immunohistochemistry (IHC) assay, immunocytochemistry (ICC) assay, immunoblotting assay, immunoprecipitation assay, flow cytometry assay, ELISA, radioimmunoassay , mass spectrometry assay, or high-throughput screening assay using the antibody as described in any one of aspects 1 to 31; wherein: Optionally, the flow cytometry assay comprises three steps of staining: (1) first, The sample is incubated with the antibody described in any one of aspects 1 to 31; (2) second, the sample is incubated with biotinylated anti-mouse IgG _2a ; (3) third, the sample is incubated with Streptavidin-PE culture; and wherein optionally, in order to establish the background of flow cytometry assay, the cell line cultured with a separate buffer or negative control antibody is used as a control group in step (1), and in Cell lines cultured without biotinylated anti-mouse IgG _2a secondary reagent were used as an additional control group in step (2). 38. A method for detecting, selecting, and/or enriching an interleukin-23 receptor (IL-23R) in a sample, comprising making the sample bind to any of aspects 1 to 31 An antibody that shares the same epitope as the antibody of one, or an antibody that competes for binding to IL-23R with the antibody of any one of aspects 1-31. 39. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:202 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:203; b. the VH comprising the amino acid sequence of SEQ ID NO:252, and the VH comprising the amino acid sequence of SEQ ID NO:253 VL; or c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157. 40. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:192 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:193; b. the VH comprising the amino acid sequence of SEQ ID NO:194, and the VH comprising the amino acid sequence of SEQ ID NO:195 VL; c. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; d. VH comprising the amino acid sequence of SEQ ID NO:218, and VL comprising the amino acid sequence of SEQ ID NO:219; e. comprising the VH of the amino acid sequence of SEQ ID NO:222, and comprising the VL of the amino acid sequence of SEQ ID NO:223; f. comprising SEQ ID The VH of the amino acid sequence of NO:260, and the VL comprising the amino acid sequence of SEQ ID NO:261; g. the VH comprising the amino acid sequence of SEQ ID NO:264, and the VH comprising the amino acid sequence of SEQ ID NO:265 VL of amino acid sequence; h. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; i. comprising the amino acid of SEQ ID NO:160 The VH of the sequence, and the VL comprising the amino acid sequence of SEQ ID NO:161; or j. the VH comprising the amino acid sequence of SEQ ID NO:164, and the VL comprising the amino acid sequence of SEQ ID NO:165 . 41. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:786 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:787; b. the VH comprising the amino acid sequence of SEQ ID NO:790, and the VH comprising the amino acid sequence of SEQ ID NO:791 VL; c. comprising the VH of the amino acid sequence of SEQ ID NO:792, and the VL comprising the amino acid sequence of SEQ ID NO:793; d. comprising the VH of the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; e. comprising the VH of the amino acid sequence of SEQ ID NO:826, and comprising the VL of the amino acid sequence of SEQ ID NO:827; or f. comprising SEQ The VH of the amino acid sequence of ID NO:828, and the VL comprising the amino acid sequence of SEQ ID NO:829. 42. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:196 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:197; b. the VH comprising the amino acid sequence of SEQ ID NO:262, and the VH comprising the amino acid sequence of SEQ ID NO:263 VL; or c. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153. 43. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:798 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:799. 44. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:206 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:207; b. the VH comprising the amino acid sequence of SEQ ID NO:250, and the VH comprising the amino acid sequence of SEQ ID NO:251 VL; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; or d. VH comprising the amino acid sequence of SEQ ID NO:170, and a VL comprising the amino acid sequence of SEQ ID NO:171. 45. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for IL-23R binding with an antibody comprising: a. an amine comprising SEQ ID NO:150 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:151. 46. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:198 The VH of the amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:199; or b. the VH comprising the amino acid sequence of SEQ ID NO:240, and the amino acid sequence comprising SEQ ID NO:241 The VL. 47. The method of aspect 38, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. an amine comprising SEQ ID NO:204 The VH of amino acid sequence, and the VL comprising the amino acid sequence of SEQ ID NO:205; or b. the VH comprising the amino acid sequence of SEQ ID NO:884, and the amino acid sequence comprising SEQ ID NO:885 The VL. 48. The method of any one of aspects 37 to 47, wherein the method is used to detect, select, and/or enrich human IL-23R. 49. The method of any one of aspects 37 to 47, wherein the method is used to detect, select, and/or enrich IL-23R expressing cells. 50. The method of any one of aspects 37 to 47, wherein the method is used to detect denatured IL-23R. 51. The method of any one of aspects 37 to 47, wherein the method comprises contacting the sample with two or more antibodies each of any of aspects 1 to 29 The antibody described in one. 52. The method of aspect 49, wherein the two or more antibodies bind to different epitopes of IL-23R. 53. The method of any one of aspects 37 to 52, wherein the sample is from a human subject. 54. The method of aspect 53, wherein the human subject suffers from a disease or condition. 55. The method of aspect 54, wherein the disease or disorder is an IL-23R-associated disease or disorder. 56. The method of aspect 53, wherein the human subject is a healthy human subject. 57. A method of antagonizing or inhibiting IL-23R in a cell, comprising contacting the cell with the antibody of any one of aspects 1-31. 58. A method for treating a disease or condition in a subject, comprising administering the composition as described in aspect 35 or the antibody as described in any one of aspects 1 to 31 to the subject. 59. The method of aspect 58, wherein the disease or disorder is an IL-23R-associated disease or disorder. 60. The method of aspect 58, wherein the disease or disorder is associated with inflammation, autoimmune inflammatory disease, and/or related disorders. 61. The method of aspect 60, wherein the disease or condition associated with inflammatory, autoimmune inflammatory disease, and/or related conditions is selected from multiple sclerosis, asthma, rheumatoid arthritis, intestinal Inflammatory bowel disease, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, ulcerative colitis, celiac disease (non-tropical aphtha), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis /Esophagitis, colitis associated with radiation or chemotherapy, colitis associated with innate immune disorders such as leukocyte adhesion molecule deficiency-1, sarcoidosis, systemic lupus erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (such as plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, palmoplantar pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), ectopic Dermatitis vulgaris, atopic acne, enteropathy associated with seronegative arthropathy, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome , bursitis, bursitis after proctocolectomy and ileo-anal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, Viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft-versus-host disease. 62. The method of aspect 61, wherein the disease or condition associated with an autoimmune disease is selected from ulcerative colitis (UC), Crohn's disease (CD), psoriasis (PsO), or psoriatic Arthritis (PsA). 63. A use of the antibody or antigen-binding fragment thereof as described in any one of aspects 1 to 31 or the composition as described in aspect 35 in the manufacture of a medicament for treating IL-23R-related diseases or disorders, The IL-23R-associated disease or disorder is especially a disease or disorder associated with inflammatory, autoimmune inflammatory disease, and/or related disorders. 64. The antibody or antigen-binding fragment as described in any one of Aspects 1 to 31 or the composition as described in Aspect 35 is used to treat IL-23R related diseases or disorders, especially with inflammatory, autoimmune Diseases or conditions associated with inflammatory diseases, and/or related conditions

Several embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the following examples are intended to illustrate but not limit the scope of the invention described in the claims. example

The following are descriptions of the various methods and materials used in this study, and are stated to provide a complete disclosure and illustration of how one of ordinary skill in the art would make and use the present disclosure, and are not intended to limit the inventors' knowledge of The scope of its disclosure is not intended to represent that the following experiments have been performed and are all experiments that can be performed. It should be understood that an exemplary description written in the present tense is not necessarily performed, but that the description can be performed to produce material associated with the teachings of the present disclosure and the like. Efforts have been made to ensure accuracy with respect to numbers used (eg, amounts, percentages, etc.), but some experimental errors and deviations should be accounted for. Summary of IL-23R Antibody Discovery and Characterization

Discovery of monoclonal antibodies (mAbs) binding to the human interleukin (IL)-23 (IL-23) receptor was performed by both wild-type mouse immunization and phage display and using a proprietary Janssen de novo Human and mouse Fab library selection. Recombinant human IL-23 receptor (IL-23R) extracellular domain (ECD) protein (sequence shown in Table 3) was used as an antigen in both immunization and phage display methods, where IL-23R ECD protein was bound by IL-23 verify. A panel of human IL-23R binding mAbs were identified by two methods, including mouse antibodies from both immunization and phage display and human antibodies from phage display only. Table 3. Amino acid sequence of human IL-23R ECD sequence Q5VWK5| 24-355 ECD GITNINCSGHIWVEPATIFKMGMNISIYCQAAIKNCQPRKLHFYKNGIKERFQITRINKTTARLWYKNFLEPHASMYCTAECPKHFQETLICGKDISSGYPPDIPDEVTCVIYEYSGNMTCTWNAGKLTYIDTKYVVHVKSLETEEEQQYLTSSYINISTDSLQGGKKYLVW VQAANALGMEESKQLQIHLDDIVIPSAAVISRAETINATVPKTIIYWDSQTTIEKVSCEMRYKATTNQTWNVKEFDTNFTYVQQSEFYLEPNIKYVFQVRCQETGKRYWQPWSSLFFHKTPETVPQVTSKAFQHDTWNSGLTVASISTGHLTSDNRGDIG (SEQ ID NO: 1)

All human IL-23R binding mAbs found were cloned with mouse IgG _2a and mouse kappa constant domains and expressed recombinantly from mammalian cells for detailed characterization. Those mAbs that were originally recognized as mouse antibodies were recombinantly produced as whole mouse mAbs, and those that were originally recognized as human antibodies were recombinantly produced as human/mouse chimeric mAbs. Recombinant IL-23R binding mAbs expressed in mammalian cells were characterized as unpurified protein in crude mammalian expression supernatant, as purified protein, or as both forms, most of which did not require purification of protein. Characterization of IL-23R mAbs included determination of affinity for human and rat IL-23R ECD proteins, determination of binding to recombinant cell lines expressing cell surface human IL-23R or primary human cells expressing IL-23R, and determination of binding to recombinant cell lines expressing human IL-23R on the cell surface, and determination of binding by this Number of human IL-23R ECD epitopes/competing bins coated with group mAbs.

The human IL-23R binding mAbs discovered, cloned, expressed, characterized, and described herein have a range of affinities for the human IL-23R ECD. The activity and binding ability exhibited by the antibodies are unique and/or superior to other known IL-23R antibodies, including commercially available IL-23R antibodies. Most of the human IL-23R binding antibodies herein displayed and had higher affinities, some with substantially higher affinities, than the commercial IL-23R mAbs tested. The antibodies recognize multiple different epitopes on the IL-23R ectodomain. Some antibodies have cross-reactive binding to rat IL-23R ECD and bind to both human IL-23R and rat IL-23R, especially to human IL-23R ECD and rat IL-23R ECD. Many of these mAbs showed binding to both recombinant cell lines and primary human cells expressing human IL-23R, and showed and had better cell binding than commercial IL-23R mAbs tested. The novel IL-23R antibodies provided herein comprise unique sequences and distinct and correlated binding characteristics and affinities even among each other and compared to other known and available antibodies, including commercially available antibodies. Example 1 : IL-23R mAb Discovery

The discovery of monoclonal antibodies (mAbs) that bind to the human interleukin (IL)-23 (IL-23) receptor was performed by both wild-type mouse immunization and phage display. Immunization-based IL-23R mAb discovery

Recombinant human IL-23R extracellular (ECD) protein antigen for immunization was prepared with adjuvant. AJ and C3H mice were injected with prepared IL-23R antigen + CL413 IP on days 0, 14, 28, and 47. Surviving mice were euthanized on day 54 (7 days after the final boost), and spleens and serum were collected. Splenocytes from harvested spleens of a total of 9 individual mice (three A/J and six C3H) were stained with biotinylated human IL-23R/Fc and ILT4/Fc labeled with AF647 (to exclude Fc binders ). A total of 7040 single B cells were sorted into 20 384-well plates containing single B cell (SBC) medium with the gates set for IL-23R+ and ILT4/Fc-. Six days after sorting, supernatants were collected and B cells were lysed from all 20 plates of cultured single B cells. The supernatant was diluted 1:2 in PBS/BSA (0.4%) and stored at 4°C. Store lysate discs at -80 °C. Supernatants were then screened for binding to human IL-23R ECD protein and IgG concentration using a Meso Scale Discovery (MSD) based assay.

876 SBC colonies were identified with >10-fold IL-23R binding compared to background, and the IgG quantification assay identified 451 colonies with >2 ng/ml IgG, 421 of which met double criteria. From 421 of these colonies, 384 were selected based on IL-23R binding >63-fold compared to background and IgG expression >10 ng/ml. Antibody heavy chain (HC) and light chain (LC) variable regions (VH and VL, respectively) were cloned from frozen lysates of cultured single B cells using the 5' RACE V region selection method. The obtained VH and VL regions were cloned into separate mammalian cell expression vectors with mouse IgG _2a and mouse kappa constant regions, respectively. Not all V regions were successfully amplified and cloned. Plastid DNA was prepared for all expression constructs generated using multiple expression scales of recombinant antibodies. Expression constructs were not sequenced and were considered non-cloning strains at this stage. IL-23R mAb Discovery Based on Phage Display

Human IL-23 receptor binding Fabs were selected from mouse de novo Fab-pIX phage display library or human de novo Fab-pIX display library generated in-house as described in Shi et al., J Mol Biol 397:385-96 , 2010 and International Patent Publication No. WO2009/085462; US Patent Publication No. US2010/0021477, and followed standard procedures (Cheadle, EJ et al. Antibody Engineering.907, 645–666 (2012).

Phage panning. In phage selection, biotinylated purified recombinant biotinylated human IL-23 receptor (IL-23R) extracellular domain (ECD) was used as antigen to capture and immobilize phage binders. 42 panning experiments with mouse pools (I23RXP1 to 36, I23RXP53 to 57) and 8 panning experiments with human pools (I23RXP37 and 38, I23RXP47 to 52) were run. In each panning experiment, a specific combination of library(s) and panning conditions was used. Briefly, phage pools and paramagnetic streptavidin (SA) beads were blocked for one hour in 50% Chemiblocker (Millipore cat# 2170)/50% 1xTBST (Teknova cat# T0310). The library was added to the SA beads to absorb colonies that bound non-specifically to the beads. The SA beads were discarded and the pre-cleared pool was added to biotinylated human IL-23R ECD. Binders were extracted by adding SA beads to form bead/antigen/phage complexes, which were washed in 1xTBST. After the final wash, phages were rescued by infecting log-phase TG1 E. coli cells (OD600 nm = 0.4 to 0.6). Phage-infected TG1 cells were spread on three 150 mm LB agaric dishes containing 75 µg/ml carbenicillin and 1% glucose and grown overnight at 37°C. Phage were produced and subjected to additional panning. To increase the selection pressure, reduce the antigen concentration for each subsequent round: R1 100 nM, R2 50 nM, R3 10 nM, R4 10 nM, all R1 to R4 at room temperature for 1 hour; R5 5 nM, overnight at 4 °C; R6 2.5 nM, overnight at 4 °C.

After multiple rounds of selection, a multi-phage ELISA using human IL-23R ECD was performed to determine the enrichment of antigen-specific binders in individual panning experiments (representative multi-phage ELISA in Figure 1).

Multi-strain phage ELISA . Briefly, 100 µl of 20 nM biotinylated human IL-23R ECD diluted in 1xTBS (Teknova cat# T9530) was captured on NA coated plates (Thermo cat# 15217). After incubation for one hour at 37°C, the plates were washed 3 times with 300 µl per well of 1x TBST. 300 μl of blocking buffer 50% Chemiblocker/50% 1xTBST was added to each well of the plate and incubated for 1 hour at room temperature. After blocking, the plates were washed 3 times with 300 µl per well of 1xTBST. The multi-strain phage output from each panning round of each panning experiment was diluted 1/100 in assay buffer (10% Chemiblocker/90% 1xTBST). 100 µL of these diluted phage outputs were added to blocked ELISA plates and incubated for 1 hour at room temperature to allow binding of Fab displayed on phage particles to immobilized human IL-23R ECD. After incubation, the plates were washed 3 times with 1x TBST. 100 μl of HRP-conjugated anti-M13 (pVIII) antibody (GE Healthcare cat# 27942101 ) diluted 1:2500 in assay buffer was added to the plate and incubated at room temperature. After 1 hour of incubation, the plates were washed 6 times with 300 μl per well of 1xTBST. 100 µL of prepared BM chemiluminescence ELISA substrate (Roche cat# 11582950001 ) was added to the plate. Chemiluminescence or relative light units (RLU) were measured in an Envision plate reader.

Phage lines showing enrichment for human IL-23R ECD binders collected from panning experiments were used to express individual Fab proteins in E. coli for primary screening.

Fab production. Briefly, plastid DNA was isolated and purified from glycerol broth from a specific round of phage panning experiments identified as showing enrichment for human IL-23 receptor binders, and transformed into TG-1 E. coli cells and cultured in LB Grow overnight on agar dish. Plates of transformants were used for (i) colony PCR and sequencing of V regions and (ii) initial culture for Fab production. For Fab production, overnight cultures were diluted 10 to 100 fold in new medium, grown at 37°C for 5 to 6 hours, and Fab production was induced by adding fresh medium containing IPTG. Induced cultures were grown overnight at 30°C. The culture was centrifuged and the bacterial pellet was lysed using BugBuster ^™ ( Millipore ) to release the soluble Fab protein. Cell lysates were cleared by centrifugation and supernatants were used for Fab ELISA.

Individual Fab lysates prepared from the enriched Fab library were screened for binding to the human IL-23 receptor and lack of binding to the negative control antigen mouse IL-6 by ELISA.

Single plant Fab screening . Black maxisorp dishes (ThermoFisher Scientific, Cat#437111) were filled with 100 µl of 10 ng/µl goat anti-mouse Fab2 (Jackson Immuno Research, cat# 115-005-072) or 4 ng/µl sheep anti-human Fd (The Binding Site Group, product number AU075) coating. After overnight incubation at 4°C, coated plates were blocked with 250 µl of Chemiblocker (Milipore, Cat# 2170) and incubated for 1 hour at room temperature. 100 μl of each Fab sample was added to the wells and the plates were incubated for 1 hour at room temperature with shaking at 20 rpm, followed by 5 washes with IX TBST. 100 µl of 20 nM biotinylated human IL-23 receptor ECD or murine IL-6 (counter selection) was added to the wells and incubated for 1 hour at room temperature with shaking at 20 rpm, followed by 5 washes with 1X TBST. 100 μl of 1:5000 streptavidin HRP was added and the plate was incubated at room temperature for 40 minutes, followed by three washes with IX TBST. 100 µL per well of prepared BM chemiluminescence ELISA substrate (Roche cat# 11582950001) was added to the plate. Chemiluminescence or relative light units (RLU) were measured in an Envision plate reader.

Fab colonies meeting the selection criteria for binding to the human IL-23 receptor and not binding to the negative control antigen mouse IL-6 were sequenced to identify unique Fabs (representative single-clonal Fab ELISA in Figure 2).

The heavy chain (HC) and light chain (LC) variable (V) regions (VH and VL, respectively) of unique Fabs were cloned into mammalian expression vectors to express murine IgG _2a /murine kappa constant regions Recombinant mAbs. Plastid DNA was prepared for all expression constructs generated using multiple expression scales of recombinant antibodies.

VH and VL of IL-23R binding Fab hits were cloned . Two pcDNA3.1-derived mammalian expression vectors (vDR000368 and vDR000961 ) were used to generate a single gene construct encoding the heavy chain (HC) or light chain (LC) of each Fab hit. Each vector contained a human cytomegalovirus (hCMV) promoter to drive expression of HC and LC and both contained an ampicillin resistance gene (Amp(R)) to facilitate colonization. vDR000368 has unique HindIII and DraIII restriction enzyme sites and mouse IgG _2a constant region for VH colonization; vDR000961 has unique HindIII and Tth111I restriction enzyme sites and mouse κ constant region for VL colonization. Expression and purification of IL-23R mAb

Recombinant IL-23R binding mAbs discovered from both immunization and phage display strategies were used in ExpiCHO or HEK Expi293 ^™ cells using heavy chain (HC) and light chain (LC) mammalian expression constructs generated for these mAbs Prepared and quantified plastid DNA is temporally expressed in various expression volumes from 2 ml to 500 ml.

Expression in transiently transfected HEK Expi293 ^™ cells. HEK Expi293 ^™ cells (Thermo cat # A14527) were grown in Expi293 ^™ Expression Medium (Thermo cat # A1435101) at 37°C in 8% _CO2 with shaking at 125 RPM. Cell transfection was performed at 2.5 × 10 ⁶ cells/ml using the Expi293 ^™ Expression Kit (Thermo cat# A14524). For each liter of transfected cells, dilute 1 mg of total DNA in 25 ml of Opti-MEM (Thermo cat # 319850620) and 2.6 ml of Expi293 ^™ Reagent in 25 ml of Opti-MEM and Incubate for 5 minutes at room temperature. Combine diluted DNA with diluted Expi293 reagent and incubate at room temperature for 20 minutes. The DNA complexes were then added to the cells and the cells were placed in a shaking incubator overnight. The day after transfection, 5 ml of Enhancer 1 was diluted into 50 ml of Enhancer 2, and the total volume of both enhancers was added to the cells. The transfected cells were returned to the incubator for 4 days until harvested. Cells were removed by centrifugation at 4,500 g for 35 min, and the cleared culture was filtered through a 0.2 µm filter before checking expression levels. This procedure can be used for various expression volumes by adjusting the reagents in a linear fashion. When transfection was performed in 96-well plates, culture was performed in an incubator with a 3 mm shaker diameter set at 1,000 RPM. Expression was quantified by Octet using a protein A biosensor. Murine IgG2 (Sigma Cat #M9144) was used as standard. Dilute samples and standards with spent Expi293 medium. Using the linear portion, a standard curve was generated with two-fold dilutions starting at 100 µg/ml. Samples were diluted 1:10 for measurement. Calculations were performed by Forte Biosystems software.

Expression in transiently transfected ExpiCHO cells. ExpiCHO-S ^™ cells (ThermoFisher Scientific, Cat # A29127) were transiently transfected with purified DNA plasmids following the manufacturer's recommendations. Briefly, ExpiCHO-S ^™ cell suspensions were maintained in ExpiCHO ^™ Expression Medium (ThermoFisher Scientific, Cat # A29100) in a shaking incubator set at 37°C, 8% CO ₂ , and 125 RPM. Cells were passaged such that dilution to 6.0 x ¹⁰⁶ cells per ml was achievable on the day of transfection, maintaining 98% or better cell viability. Transient transfections were performed using the ExpiFectamine ^™ CHO Transfection Kit (ThermoFisher Scientific Cat # A29131). One microgram of plastid DNA was used per ml of diluted cells to be transfected, and the plastid DNA was diluted in OptiPRO ^™ SFM Mixture Medium. ExpiFectamine ^™ CHO Reagent was used in a 1:3 ratio (v/v, DNA:reagent) and was also diluted in OptiPRO ^™ . The diluted DNA and transfection reagent were combined for one minute to allow the DNA/lipid complex to form before adding to the cells. After overnight culture, ExpiCHO ^™ feed and ExpiFectamine ^™ CHO enhancer were added to the cells. The cells were cultured with shaking at 32°C for five days, after which the culture supernatant was collected. Culture supernatants from transiently transfected ExpiCHO-S ^™ cells were collected by clarification by centrifugation (35 min, 6,500 rpm) followed by filtration (0.2 µ PES membrane, Corning).

After quantification of mAb concentration, the crude mammalian expression supernatant was used directly for some characterization of the unpurified mAb contained therein. Some IL-23R mAbs were purified using routine Protein A purification procedures and were characterized as purified mAbs.

Protein A purification of mAbs expressed in transient transfections . Pilot scale (0.3 to 3 mg) purifications were performed on an AKTA XPress chromatography system and large scale (3 mg or greater) purifications were performed using an AKTA FPLC chromatography system. The purification procedures for the precursor and large-scale preparations were the same. Briefly, harvested, clarified, and filtered supernatants from transiently transfected mammalian cells were loaded onto equilibrated (PBS, pH 7.2) HiTrap MabSelect Sure Protein at a relative concentration of approximately 30 mg protein per ml of resin On the A column (GE Healthcare). After loading, the column was washed with PBS, pH 7.2, and the protein was eluted with 10 column volumes of 0.1 M Na-acetate pH 3.5. The protein fraction was immediately neutralized by elution into a tube containing 20% of the eluate volume in 2.0 M Tris, pH 7. Spike fractions were pooled, further neutralized (if necessary), filtered (0.2 µm), and dialyzed overnight at 4°C in 3 changes of PBS, pH 7.2. The next day, samples were removed from dialysis, filtered (0.2 µm), and protein concentration determined by absorbance at 280 nm. Purified protein quality was assessed by SDS-PAGE and analytical size exclusion HPLC (Dionex HPLC system). Endotoxin levels were measured using the LAL assay (Pyrotell ^® -T, Associates of Cape Cod). Purified protein was stored at 4°C. Exemplary IL-23R mAbs

Examples of immunization-based IL-23R antibodies or antigen-binding fragments of the present disclosure are summarized in Table 4, Table 5, and Table 6: Table 4. Exemplary immune-based IL-23R Antibody HC and LC AA sequence name HC AA sequence LC AA sequence I23RB101 EVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGYRYGPLDGFDIWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 2) DIVMTQSHKFMSTSIGDRVSITCKTSQDVRTAVAWYQQKPGQSPKLLIYSASYRYIGVPDRFTGSGSGTDFTFTISDVQAEDLALYYCQQHYSTPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:3) I23RB102 QVQLQQPGAELVKPGASVKVSCKASGYTFTKYWINWMNQRPGQGLEWIGNIYPGSISTNYNEKFKSKVTLTVDISSSTAYMQLSSLTSDDDSAVYYCARGDFYALDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 4) DIQMTQSPASLSVSVGETVTITCRASENIYSHITWYQLKQGKSPQLLVYASTNLADDVPSRFSGSGSGTQYSLKINSLLSEDFGTYYCQHFWGTPWTFGGGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:5) I23RB104 EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLDWVASISTGGSTYYPDSVKGGFTISRDIARNTLSLQMTSLRSEDTAMYYCARGPHYYGGSYPFAYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 6) DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPPTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:7) I23RB144 EVQLQQSGPELVKPGASVKMSCKASGYTFTSYIIHWVKQKPGQGLEWIGYIDPYNDDTKYNEKFKGKATLTSDKSSSTAYMEFSLTSEDSAVYYCARLGSINYYDGSYFDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 8) DIVMTQSPLTLSVIIGQSASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLMYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGIHFPLTFGSGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSST LTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:9) I23RB148 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHSSGTTNYSPSLRSRLSIRTSKNQFFLQLNSVTTEDTATYYCTRQLGLKAMEYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 10) DIVMTQSHKFMSTSVGDRVSLTCKASQEVRTAVAWYQQKPGQPPKLLIYSASYRYTGVPDRFTGSGSGTDFFTIISVQAEDLAVYYCQQHYTTPYSFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 11) I23RB149 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHFSDRTNYNPSLKSRISITRDTSKNQFFLQLNSVTSEDTATYYCSRQLGLKALDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 12) DVQMIQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPLTFGAGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSST LTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 13) I23RB150 QIQLVQSGPELKKPGETVKISCKASAYTFTNYGMNWVKQAPGKGLKWMGWIKTNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARSRQLGLRYYFDYWGQGTTLTVSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 14) DIVMTQSHKFMSTSVGGRVSITCKASQDVSTAVAWYQQKPGQSPRLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVFYCQQHYSTPYTFGSGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 15) I23RB153 EVKLVESGGGLVQPGGSLKLSCAASGFTFSSDTMSWVRQTPEKRLELVAEISSNGGSTYHIDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASPGYPWFAYWGQGTTVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 16) DIVMTQSHRFMSTSVGERVSITCKASQDVGNAVAWYQQKPGQSPKLLIYWTSTRHNGVPDRFTGSGSGTDFLTISNVQGEDLADYFCQQYNRYPLTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 17) I23RB155 QVQLKESGPGLVKPSQSLSLTCSVTGYSITSGHSWNWIRQFPGNKLEWMGYISYDGTNDYNPSLKNRISITRDTSKNQFFLNLNSVTTEDTVTYYCARGGGYYGGTYRVFADWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAV LQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEE MTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 18) QIVLSQSPASLAVSLGQRATISCRTSEVDTYGNSFIYWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFLTINPVEADDVATYYCQQGNKDPYTFGSGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 19) I23RB156 QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYAINWVRQPPGKGLEWLGVIWTGGGTNYNSVFKSRLSISKDNSKSQIFLKMISLQTDDTARYYCARNRDYSNYRWYFDVWGAGTTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 20) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGRSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTIGSVQAEDLAVYYCQQHYSIPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 21) I23RB157 EVKLVESGGGSVKPGGSLKLSCAASGFTFSRYTMSWVRQTPEKRLEWVAYISTGGGDTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARRTSYSYYNYVFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 22) DIVMTQSPASLAVSLGQRATISCRASEVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 23) I23RB159 EVQLQQSGGGLVKPGGSLKLSCAASGFTFSDYGMAWVRQTPRKGPEWIAFISNLAYSVYYSDTVTGRFTISRENAKNTLYLEMSSLRSEDTAMYYCARHGDYRNYGFAYWGLGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 24) DIVMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 25) I23RB160 QVQLKESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHYSSGTIYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTGTYYCARQLGLKAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 26) DIVMTQSHKFMSTSVGDRVSITCKASQDVRTAVAWYQQKPGQSPKLLIHSASYRYTGVPDRFTGSGSGTDFFTISSVQVEDLAVYYCQQHYTTPYTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 27) I23RB161 EFQLQQSGPELVKPGASVKISCKASVYAFSSSWMNWVKQRPGKGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARRYDFGSAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 28) DIVMTQSPAILSASSPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSDLASGAPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 29) I23RB162 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARSRTGTRWYFDVWGAGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 30) DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFLTISNVQSEDLAEYFCQQYNSYPFTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTT KDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 31) I23RB165 EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGKTKYAPKFQDKATITADTSSNTAYLQLSSLTSEDTAIYYCARREVLDYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 32) DIVMTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 33) I23RB166 DVQLQESGPGLVKPSQTVSLTCTVTGYSITNGNHWWNWIRQVSGSKLEWIGYIRSSGSTDSNPSLKSRISITRDTSKNQLFLQLNSVTAEDIATYYCARERLRLRWSYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 34) DIVMTQSHKFMSTSVGARVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 35) I23RB168 QIQLVQSGPELVKPGASVKMSCKTSGYTFTDYYINWVKQRPGQGLEWIGWIYPAINNTNYNEKFKGKATLTVDTSSRTAYMQLNSLTSEDSAVYFCAISRKPYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 36) DIQMTQSSSSFSVSLGDRVTITCKASEDLYNRLAWYQQKPGNAPRLLISGATSLGTGVLSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSIPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 37) I23RB169 QIQLVQSGPELKKPGETVKISCKASGYTFTTVGMQWVQKMPGKGFKWIGWINTHSGEPKYTDDFKGRFAFSLETSASTAYLQISNLKSEDTATYFCARSSALTGAFAYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 38) DIKMTQSPASLAVSLGQRATISCRASKSVSTSDYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPRTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 39) I23RB173 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGGNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCARDAGLLPYYAMDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 40) DIKMTQSPAIMSASSPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPLTFGDGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 41) I23RB177 EVQLQQSGPELLKPGASVKISCKASGYTITDYTMHWVKQSHGKSLEWIGGINPNYGGTSYNEKFKDKATLTVDKSSSTAYMELRSLTSEDSAVFYCVRGNIYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 42) NTQMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKALIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCQQYDEFPRTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 43) I23RB180 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVGWIRQPSGKGLEWLANIWWNDSKYHNAALKSRLTISKDTSKNQVFLKIASVDTADTATYYCGRIDGYYECVDVWGTGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 44) DIQMTQSPASLSASVGETVTITCRASVNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWTTPYMYTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTK DEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 45) I23RB182 EVQLQQSGPGLVKPSQSLSLTCSVTGYSITSGYFWNWLRQFPGSKLEWMGFIDNDGSNDYNPSLKNRISITRDTSKNQFFLRLNSVTTEDTATYYCARGRLGFFDSWGPGTTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 46) DIVMTQSPAIMSASLGEKVTMSCRASSSVNYMYWYQQKSDASPKLWIYYTSNLAPGVPARFSGSGSGNSYSLTISSMEGEDAATYYCQQFTNSPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEA THKTSTSPIVKSFNRNEC (SEQ ID NO: 47) I23RB188 QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGAPTYADDFKGRFAFSLETSASTAYLQINNFKNEDTATYFCARGNGYPYYYGINYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 48) DVQMIQSPSSLSASLGERVSLTCRASQEISGNLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGAGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 49) I23RB189 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHSSGTTNYSPSLRSRLSIRTSKNQFFLQLNSVTTEDTATYYCTRQLGLKAMEYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 50) DIVLTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLMYGASNRYTGVPDRFTGSGSATDFLTISSVQAEDLADYHCGQSYSYPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:51) I23RB27 QVQLKESGPDLVQPSQTLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWVGTLGWDDKKSYNSALKSRLSISRDTSKSQVFLKLSSLQTEDTAMYYCTKEDVSYAMDFWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 52) DIQMTQSPTSLAVSLGQRATISCRASESVEYYGTSLMHWYQQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEEDIAMYFCQQGKKVPWTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:53) I23RB30 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSSNQIFLKITSVDTADTATYYCARRTLGGPPFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 54) DIVLTQSQRFMSTSVGDRVSITCKASQNIRTAVAWYQQKPGQSPKALIYLPSNRHTGVPDRFTGSGSGTDFLTISNVQSEDLADYFCLQHWNYPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 55) I23RB31 EFQLQQSGAEMVRPGASVKLSCKASGYTFTGYWMNWVKQRPGQGLEWIGKIDPSTETHYNQNFKDKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARWGLGRNFAMDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 56) DIVLTQSPATLSVTPGDRVSLSCRASQSISDHLHWYQQKSHESPRLLIKFASQSISGIPSRFSGSGSGSDFTLSIDSVEPEDVGVYYCQNGHSFPLTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 57) I23RB32 EFQLQQSGPELVKPGASVKLSCKASGYTFTDYALHWVKQSPGQGLEWIGWIYPGGGNTYYNDKFKGKATMTADKSSSTAYMQLSSLTSEDSAVYFCARGRLRRDYPMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 58) DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDLAVYYCQNDYTYPLTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLT KDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:59) I23RB33 EVQLQQSGAELVKPGASVKLSCTASGFNIRDIYIHWVKQRPEQGLEWIGRIDPANGHSIYAAKFQGKATITADTSLNIAYMQLSSLTSGDTAVYYCARGSDNDYGRVLAYWGLGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 60) DIVLTQSPAIMSASPGKVTMTCRASSSVRSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTITSVEAEDAATYYCQQYTGNPIFTFGSGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 61) I23RB35 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGHNWNWIRQFPGNKLEWLGYISYDGSNNYDPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCARGGGYFGNSYRVFASWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVL QSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISSLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMT KKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 62) DIVLTQSPASLAVSLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESEIPARFSGRGSGTDFLTINPVEDDVATYYCQQSNADPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 63) I23RB36 QIQLVQSGAELVKPGASVKLSCTTSGFNIKDTYIHWMKQRPEQGLEWIGRIDPANGNTIYASKFQGKATLTTDTSSNTAYMLLSSLTSGDTAVYYCTRGTSWFAYWGQGTTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 64) DIVMTQSPKSMSMSVGERVTLSCKASENVGTSVSWFQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFLTISSVQAEDLADYHCGQSYSYPRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 65) I23RB39 EVQLQQSGPELVKPGAPVKISCKASGYTFTNYYIHWVKQRPGQGLEWIGYIYPGNGGTAYNQKFKDKATLTADNPSSTAYMQLSSLTSEDSAVYFCARSRGGSRNYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 66) DIQMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSSPRTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 67) I23RB42 EVQLQQSGAELVKPGASVKISCKASGYSFTDYIMNWVKQSHGKSLEWIGNINPYFGFTSYNQEFKGKATLTVDKSSSTAYMLLNSEDSAVYYCSRGSYYGYETFFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 68) DIVLTQTAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPYTFGSGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:69) I23RB45 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSNNQVFLKITSVDTADTATYYCAQRALPLLGQKAPFDYWGQGTTLTVSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 70) DIVLTQSQKFISTSVGDRVSITCKASQNVRTAVAWYQQKPGQSPKLLIYLPSNRHTGVPDRFTGSGSGTVFTLTISNVQSEDQADYFCLQHWNYPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 71) I23RB47 QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYDIHWVRQSPGKGLEWLGVIWSDGRTDYKGAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARNNYYRYGRNTMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 72) DIVLTQSPASQSASLGESVTITCLASQTIGSWLAWYQQKPGKSPQLLIYAATRLADGVPSRFSGSGSGTKFSFKISSLQAEDFVFYYCHQLYSIPLTFGGGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 73) I23RB51 QVQLQQSGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYVHYRDSTHYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARQLGLKAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 74) DIVLTQSPASLSASVGETVTITCRASGNIHNYLAWYQHKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQYFWTTRTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 75) I23RB54 EVQLQQSGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSYIYYPDNVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARKKSDYGAMDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 76) DIQMTQSPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPRLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYSSLPTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:77) I23RB56 EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAAINSNDGSTYYPDTVKDRFTISRDNAKNTLYLQMSSLRSEDTALYYCARHFLYFSNFYYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 78) DIVMTQSPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTVFTFTISTVQAEDLAVYFCQQDYSSPFTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:79) I23RB57 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYYMHWVKQSHGKTIEWIGYIYPNSGDTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYNCARFGGFYDAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 80) DIVMTQSPAIMSASLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPFTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 81) I23RB58 EVKLVESGGGLVKPGGSLKLSCAASGFSFIIYTMSWVRQTPEKRLEWVAYITSGGGITYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARHEGDYYDDYYRIGYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 82) DIVMTQTPASLAVSLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGSRTDFLTINPVEDDVATYYCQQSNEDPLTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 83) I23RB60 DVQLQESGPELVKPGDSVKMSCEASGYTFTDYYYIDWVKQSHGKSLEWIGYIYPNNGGISFNQKFEGKATLTVDKSSSTAYMELHSLTSEDSAVYYCAREKLRGRDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 84) DIVMTQSTSSLSASLGDRVTISCRASQDIRNNLNWYQQKPDGTVKLLIFYSSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGHTLPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 85) I23RB61 DVQLQESGAELVKPGASVKLSCKSFDYTFTSFDINWMKQRPGQGLEWIGWIFPGSGTTNYNEKFKGKATLTADKSSSTAYMHLTSLTSEDSAVYFCARRLTGTRYFDVWGTGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 86) DIQMTQSHKFLSTSVGDRITITCKASQDVITAVAWYQQKSGQSPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTISNVQAEDLALYYCQQHYTTPPTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 87) I23RB65 EVQLQQSGPELVKPGASVKISCKASGYTFTDHTMDWVKQSHGKSLEWIGYIYPKSGNAAYSQKFKSEATLTVDKSSSTAYMEFHSLTSEDSAVYYCARWGLRRDGFTYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 88) QIVLTQSPASLAVSLGQRATISCRASQSVSTSSYNYIHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEDDTATYYCQHTWEIPYTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:89) I23RB66 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSNMGIGWIRQPSGKGLEWLAHIWWNSDKYYNPSLKSRLTISKDTSNNQVFLTITSVDTADTATYYCAQIRWLRFYFDYWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 90) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTFSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:91) I23RB67 EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPGSSSTNYNEKFKSKATLTVDTSSSTAYMQLSSLTSDDSAVYYCARSAYGNRLAMDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 92) DVVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTK DEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:93) I23RB69 EVQLQQSGAELVKPGASVKISCKASGYSFTGYNMNWVKQSHGKSLEWIGNINPFYDKTSYNQKFKGKATLTVDKASSTAYMQLNSLTSEDSAVYYCARQLGLKGFAYWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 94) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:95) I23RB71 DVQLQESGPDLVKPSQSLSLTCTVTDYSITRGYNWHWIRQFPGNKLEWMGYIHYSGSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARQYGLKAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 96) DIVMTQSHKFMSTSVGDRVSITCKASQDVITAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYFCQQHFGTPYTFGSGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:97) I23RB73 EVQLQQSGAELVKPGASVKISCKASGYTFTDHAIHWVKQRPEQGLEWIGYISLGNGDIKYSEKFRGKATLTADKTSNTAYMQLNSLTSEDSAVYFCKRSRVLRWTTYWYFDVWGAGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 98) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRLTGVPDRFTGSGSGTDYTLTISSVQAEDLALYYCQQYYNTPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:99) I23RB74 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSFNYNPSLKNRLSITRDTSMNQFFLKLNSVTSEDTATYYCARAEIYYDYDGDFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 100) DIVLTQSPASLAVSLGQRATISCRASKSVSTSGSNFLHWYQQKPGQPPKLLIYFASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPHTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 101) I23RB76 EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMNWMKQSHGKSLEWIGYISPKNGRTGYNQKFKGKATLTVDKSSTTAYMELRSLTSEDSAVYYCAKSNGYYALDYWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 102) DIVLTQSPATLCVTPGETVSLSCRASQNIYKNLHWFQQKSHRSPRLLIKYASDSISGIPSRFTGSGSGTDYTLSINSVKPEDEGIYYCLQGYSTPWTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 103) I23RB77 DVQLQESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWGSGSTDYNSALKSRLSINKDNSKSQVFLKMNSLQTDDTAMYYCARVYYGGSPYAMDYWGQGTTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 104) DIVMTQSPASLASLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFLTTIDPVEADDAAIYYCQQNNEEPNTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 105) I23RB78 EFQLQQSGGGLVKPGGSLKLSCAASGFTFSNYTMSWVRQTPEKRLKWVACISSGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARRNYRRAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 106) DIVMTQSPASLAVSLGQRATISCRASEVDSYGISFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGSRTDFLTINPVEADDVATYYCQQSNEDPWTFGAGTGLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 107) I23RB79 DVQLQESGPELVRPGASVKMSCKASGYTFTDYYYMNWVKQSHGKSLEWIGYIYPNNGDTVYNQKFKGKATLTVDKSSNTAYMELRSLTSEDSAVYYCARGTLTGMYYFDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVL QSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISSLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMT KKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 108) DIQMTQSPKFLHVSAGDRVTITCKASQSVINDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAIYFCQQDYSSPPTFGAGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 109) I23RB80 DVQLQESGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGVSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRGSYYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 110) DIVMTQSQKFMSTSEGDRVNITCKASQNIRTAVAWYQQKPGQSPKPLIYLASNRHTGVPDRFTGSGSGTDFLTISNVQSEDLAEYFCLQHWNYPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 111) I23RB81 DVQLQESGPGLVAPSQSLSITCTVSGFSLTSYAINWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQLFLKMNSLQTDDTARYYCARNRDYSNYRWYFDVWGAGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 112) DIVMTQSHKFMSTSVGDRVSIICKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPLTFGAGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 113) I23RB82 QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYALHWFRQSPGKGLEWLGVIWSDGSTDYNSPFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRSNYGRWYFDVWGAGTTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 114) QIVLSQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 115) I23RB83 DVQLQESGPGLVAPSQSLSITCTVSGFSLTNYDVHWVRQSPGKGLEWLGVIWSSDGSTDYNAAFISRLSFSKDNSKRQVFFKMNSLQPDDTAIYYCARNNYYRYGRNPMDYWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 116) DIQMTQSPASQSASLGESVTITCLASQTIGSWLAWYQQKPGKSPQLLIYAATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQLYSSPLTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 117) I23RB85 DVQLQESGPGLVAPSQSLSITCTVSGFSFNTYAITWVRQPPGRGLEWLGVLWPGGGISYNLALKSRLTISRDSSKSQVFLEMNSLQTDDTARYYCARNWRHYDGSYAMDFWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 118) DIVLTQSPLSLFVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYS MSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 119) I23RB86 EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWLHWVKQRPGQGLEWIGEIDPSDSYTYYNQKFKGKATLTVDKSSSTAYMQLSLTSEDSAVYYCARSPYDYDWGAYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 120) DIVMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFKGLIYHGTNLEDEVPSRFSGSGSGADYSLTIGSLESEDFADYYCVQYAQFPWTFGAGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 121) I23RB87 EFQLQQSGPELVKPGTSVKMSCKASGYTFTNYVMHWVKQKPGQGLEWIGYINPYDASPKYNEKFKGKAILTSDKSSSTAYMELSSLTSEDSAVYYCTRDAKLDYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 122) DIVMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTISNLEQEDIATYFCQQGITLPWTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 123) I23RB91 EFQLQQFGPELLKPGASVKISCKASGYTFTDYIMHWVKQSHGKSLEWIGGISPNYGGTGYNGKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARFNNYYYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 124) DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWCQQKPGKSPKALIYRANSLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 125) I23RB92 EVQLQQSGPEVVKPGASVKISCKASGYTFTDHTMDWVKQSHGKNLEWIGYIYPKSGGTGYNQKFKNKATLTVDKSSSTAYMEFHSLTSDDSAVYYCARWGLRRDGFVYWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 126) DIKMTQSPASLAVSLGQRATISCRASQSVSTSKYDYIHWYQQKSGQPPRLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEEDTATYYCQHTWEIPYTFGSGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 127) I23RB93 QVQLKESGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGVSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRGSYYFDYWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 128) DIKMTQSPATLSVTPGDSVSLFCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFLTLSINSVETEDFGMYFCQQSNSWPLTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 129) I23RB94 DVQLQESGPELKKPGETVKISCKASGYTFTNYGMNWVRQAPGKSLKWMGWINTNTGEPAYAEEFKGRFAFSLETSASTAYLQINNLKNEDMATYFCARVRQTARATRGYFDVWGTGTTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 130) DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGQSPKLLIYSAFYRYPGVPDRFTGSGSGTDFFTINSVQAEDDFFTINSVQAEDLAVYCCQQHYTSPLTFGDGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 131) I23RB95 EVKLVESGGGLVQPGSSMKLSCTASGFTFSDYYMAWVRQVPEKGLEWVANINYDGSNTYYLDSLKSRFIISRDNAKNILYLQMSSLKSEDTATYYCAREGYDEAMDYWGQGTTLTVSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 132) DIVLTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFLTISNVQSEDLADYFCQQYSTYPYTVGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 133) I23RB98 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYYMHWVKQSHGKTIEWIGYIYPNSGDTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYTCARFGGFYDAMDYWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 134) DIVLTQSPAIMSASLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPFTFGSGTKLEMKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERH NSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 135) table 5. Exemplary immune-based IL-23R Antibody VH and VL AA sequence name VH AA sequence VLA A sequence I23RB101 EVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGYRYGPLDGFDIWGQGTTLTVSS (SEQ ID NO: 136) DIVMTQSHKFMSTSIGDRVSITCKTSQDVRTAVAWYQQKPGQSPKLLIYSASYRYIGVPDRFTGSGSGTDFTFTISDVQAEDLALYYCQQHYSTPYTFGGGTKLEIK (SEQ ID NO: 137) I23RB102 QVQLQQPGAELVKPGASVKVSCKASGYTFTKYWINWMNQRPGQGLEWIGNIYPGSISTNYNEKFKSKVTLTVDISSSTAYMQLSLTSDDSAVYYCARGDFYALDYWGQGTTLTVSS (SEQ ID NO: 138) DIQMTQSPASLSVSVGETVTITCRASENIYSHITWYQLKQGKSPQLLVYASTNLADDVPSRFSGSGSGTQYSLKINSLLSEDFGTYYCQHFWGTPWTFGGGTKLEMK (SEQ ID NO: 139) I23RB104 EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLDWVASISTGGSTYYPDSVKGGFTISRDIARNTLSLQMTSLRSEDTAMYYCARGPHYYGGSYPFAYWGQGTTLTVSS (SEQ ID NO: 140) DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPPTFGSGTKLEIK (SEQ ID NO: 141) I23RB144 EVQLQQSGPELVKPGASVKMSCKASGYTFTSYIIHWVKQKPGQGLEWIGYIDPYNDDTKYNEKFKGKATLTSDKSSSTAYMEFSLTSEDSAVYYCARLGSINYYDGSYFDYWGQGTSVTVSS (SEQ ID NO: 142) DIVMTQSPLTLSVIIGQSASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLMYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGIHFPLTFGSGTRLEIK (SEQ ID NO: 143) I23RB148 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHSSGTTNYSPSLRSRLSIRTTSKNQFFLQLNSVTTEDTATYYCTRQLGLKAMEYWGQGTTLTVSS (SEQ ID NO: 144) DIVMTQSHKFMSTSVGDRVSLTCKASQEVRTAVAWYQQKPGQPPKLLIYSASYRYTGVPDRFTGSGSGTDFFTIISVQAEDLAVYYCQQHYTTPYSFGSGTKLEIK (SEQ ID NO: 145) I23RB149 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHFSDRTNYNPSLKSRISITRDTSKNQFFLQLNSVTSEDTATYYCSRQLGLKALDYWGQGTTLTVSS (SEQ ID NO: 146) DVQMIQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPLTFGAGTRLEIK (SEQ ID NO: 147) I23RB150 QIQLVQSGPELKKPGETVKISCKASAYTFTNYGMNWVKQAPGKGLKWMGWIKTNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARSRQLGLRYYFDYWGQGTTLTVSS (SEQ ID NO: 148) DIVMTQSHKFMSTSVGGRVSITCKASQDVSTAVAWYQQKPGQSPRLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVFYCQQHYSTPYTFGSGTRLEIK (SEQ ID NO: 149) I23RB153 EVKLVESGGGLVQPGGSLKLSCAASGFFSSDTMSWVRQTPEKRLELVAEISSNGGSTYHIDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASPGYPWFAYWGQGTTVTVSA (SEQ ID NO: 150) DIVMTQSHRFMSTSVGERVSITCKASQDVGNAVAWYQQKPGQSPKLLIYWTSTRHNGVPDRFTGSGSGTDFLTISNVQGEDLADYFCQQYNRYPLTFGSGTKLEIK (SEQ ID NO: 151) I23RB155 QVQLKESGPGLVKPSQSLSLTCSVTGYSITSGHSWNWIRQFPGNKLEWMGYISYDGTNDYNPSLKNRISITRDTSKNQFFLNLNSVTTEDTVTYYCARGGGYYGGTYRVFADWGQGTTLTVSS (SEQ ID NO: 152) QIVLSQSPASLAVSLGQRATISCRTSEVDTYGNSFIYWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFLTINPVEADDVATYYCQQGNKDPYTFGSGTKLEMK (SEQ ID NO: 153) I23RB156 QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYAINWVRQPPGKGLEWLGVIWTGGGTNYNSVFKSRLSISKDNSKSQIFLKMISLQTDDTARYYCARNRDYSNYRWYFDVWGAGTTLTVSS (SEQ ID NO: 154) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGRSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTIGSVQAEDLAVYYCQQHYSIPLTFGAGTKLELK (SEQ ID NO: 155) I23RB157 EVKLVESGGGSVKPGGSLKLSCAASGFTFSRYTMSWVRQTPEKRLEWVAYISTGGGDTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARRTSYSYYNYVFDYWGQGTTLTVSS (SEQ ID NO: 156) DIVMTQSPASLAVSLGQRATISCRASEVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGAGTKLELK (SEQ ID NO: 157) I23RB159 EVQLQQSGGGLVKPGGSLKLSCAASGFTFSDYGMAWVRQTPRKGPEWIAFISNLAYSVYYSDTVTGRFTISRENAKNTLYLEMSSLRSEDTAMYYCARHGDYRNYGFAYWGLGTTVTVSS (SEQ ID NO: 158) DIVMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGAGTKLELK (SEQ ID NO: 159) I23RB160 QVQLKESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHYSSGTIYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTGTYYCARQLGLKAMDYWGQGTSVTVSS (SEQ ID NO: 160) DIVMTQSHKFMSTSVGDRVSITCKASQDVRTAVAWYQQKPGQSPKLLIHSASYRYTGVPDRFTGSGSGTDFFTISSVQVEDLAVYYCQQHYTTPYTFGSGTKLEIK (SEQ ID NO: 161) I23RB161 EFQLQQSGPELVKPGASVKISCKASVYAFSSSWMNWVKQRPGKGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSLTSEDSAVYFCARRYDFGSAMDYWGQGTSVTVSS (SEQ ID NO: 162) DIVMTQSPAILSASSPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSDLASGAPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPPTFGGGTKLEIK (SEQ ID NO: 163) I23RB162 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARSRTGTRWYFDVWGAGTTVTVSS (SEQ ID NO: 164) DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFLTISNVQSEDLAEYFCQQYNSYPFTFGSGTKLEIK (SEQ ID NO: 165) I23RB165 EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGKTKYAPKFQDKATITADTSSNTAYLQLSSLTSEDTAIYYCARREVLDYFDYWGQGTTLTVSS (SEQ ID NO: 166) DIVMTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTKLEMK (SEQ ID NO: 167) I23RB166 DVQLQESGPGLVKPSQTVSLTCTVTGYSITNGNHWWNWIRQVSGSKLEWIGYIRSSGSTDSNPSLKSRISITRDTSKNQLFLQLNSVTAEDIATYYCARERLLRWSYFDYWGQGTTLTVSS (SEQ ID NO: 168) DIVMTQSHKFMSTSVGARVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPRTFGGGTKLEIK (SEQ ID NO: 169) I23RB168 QIQLVQSGPELVKPGASVKMSCKTSGYTFTDYYINWVKQRPGQGLEWIGWIYPAINNTNYNEKFKGKATLTVDTSSRTAYMQLNSLTSEDSAVYFCAISRKPYFDYWGQGTTLTVSS (SEQ ID NO: 170) DIQMTQSSSSFSVSLGDRVTITCKASEDLYNRLAWYQQKPGNAPRLLISGATSLGTGVLSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSIPWTFGAGTKLELK (SEQ ID NO: 171) I23RB169 QIQLVQSGPELKKPGETVKISCKASGYTFTTVGMQWVQKMPGKGFKWIGWINTHSGEPKYTDDFKGRFAFSLETSASTAYLQISNLKSEDTATYFCARSSALTGAFAYWGQGTLVTVSS (SEQ ID NO: 172) DIKMTQSPASLAVSLGQRATISCRASKSVSTSDYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPRTFGAGTKLELK (SEQ ID NO: 173) I23RB173 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGGNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCARDAGLLPYYAMDYWGQGTTLTVSS (SEQ ID NO: 174) DIKMTQSPAIMSASSPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPLTFGDGTKLEMK (SEQ ID NO: 175) I23RB177 EVQLQQSGPELLKPGASVKISCKASGYTITDYTMHWVKQSHGKSLEWIGGINPNYGGTSYNEKFKDKATLTVDKSSSTAYMELRSLTSEDSAVFYCVRGNIYFDYWGQGTTLTVSS (SEQ ID NO: 176) NTQMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKALIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCQQYDEFPRTFGAGTKLELK (SEQ ID NO: 177) I23RB180 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVGWIRQPSGKGLEWLANIWWNDSKYHNAALKSRLTISKDTSKNQVFLKIASVDTADTATYYCGRIDGYYECVDVWGTGTSVTVSS (SEQ ID NO: 178) DIQMTQSPASLSASVGETVTITCRASVNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWTTPYMYTFGAGTKLELK (SEQ ID NO: 179) I23RB182 EVQLQQSGPGLVKPSQSLSLTCSVTGYSITSGYFWNWLRQFPGSKLEWMGFIDNDGSNDYNPSLKNRISITRDTSKNQFFLRLNSVTTEDTATYYCARGRLGFFDSWGPGTTLTVSS (SEQ ID NO: 180) DIVMTQSPAIMSASLGEKVTMSCRASSSVNYMYWYQQKSDASPKLWIYYTSNLAPGVPARFSGSGSGNSYSLTISSMEGEDAATYYCQQFTNSPWTFGAGTKLELK (SEQ ID NO: 181) I23RB188 QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGAPTYADDFKGRFAFSLETSASTAYLQINNFKNEDTATYFCARGNGYPYYYGINYWGQGTSVTVSS (SEQ ID NO: 182) DVQMIQSPSSLSASLGERVSLTCRASQEISGNLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGAGTRLEIK (SEQ ID NO: 183) I23RB189 DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHSSGTTNYSPSLRSRLSIRTTSKNQFFLQLNSVTTEDTATYYCTRQLGLKAMEYWGQGTTLTVSS (SEQ ID NO: 184) DIVLTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLMYGASNRYTGVPDRFTGSGSGSATDFLTISSVQAEDLADYHCGQSYSYPPTFGGGTKLEIK (SEQ ID NO: 185) I23RB27 QVQLKESGPDLVQPSQTLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWVGTLGWDDKKSYNSALKSRLSISRDTSKSQVFLKLSSLQTEDTAMYYCTKEDVSYAMDFWGQGTTLTVSS (SEQ ID NO: 186) DIQMTQSPTSLAVSLGQRATISCRASESVEYYGTSLMHWYQQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEEDIAMYFCQQGKKVPWTFGAGTKLEMK (SEQ ID NO: 187) I23RB30 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSSNQIFLKITSVDTADTATYYCARRTLGGPPFDYWGQGTTLTVSS (SEQ ID NO: 188) DIVLTQSQRFMSTSVGDRVSITCKASQNIRTAVAWYQQKPGQSPKALIYLPSNRHTGVPDRFTGSGSGTDFLTISNVQSEDLADYFCLQHWNYPLTFGAGTKLELK (SEQ ID NO: 189) I23RB31 EFQLQQSGAEMVRPGASVKLSCKASGYTFTGYWMNWVKQRPGQGLEWIGKIDPSTETHYNQNFKDKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARWGLGRNFAMDYWGQGTTLTVSS (SEQ ID NO: 190) DIVLTQSPATLSVTPGDRVSLSCRASQSISDHLHWYQQKSHESPRLLIKFASQSISGIPSRFSGSGSGSDFTLSIDSVEPEDVGVYYCQNGHSFPLTFGSGTKLEIK (SEQ ID NO: 191) I23RB32 EFQLQQSGPELVKPGASVKLSCKASGYTFTDYALHWVKQSPGQGLEWIGWIYPGGGNTYYNDKFKGKATMTADKSSSTAYMQLSLTSEDSAVYFCARGRLRRDYPMDYWGQGTSVTVSS (SEQ ID NO: 192) DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFLTTISSVQAEDLAVYYCQNDYTYPLTFGSGTKLEIK (SEQ ID NO: 193) I23RB33 EVQLQQSGAELVKPGASVKLSCTASGFNIRDIYIHWVKQRPEQGLEWIGRIDPANGHSIYAAKFQGKATITADTSLNIAYMQLSSLTSGDTAVYYCARGSDNDYGRVLAYWGLGTSVTVSS (SEQ ID NO: 194) DIVLTQSPAIMSASPGKVTMTCRASSSVRSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTITSVEAEDAATYYCQQYTGNPITFGSGTKLELK (SEQ ID NO: 195) I23RB35 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGHNWNWIRQFPGNKLEWLGYISYDGSNNYDPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCARGGGYFGNSYRVFASWGQGTTVTVSS (SEQ ID NO: 196) DIVLTQSPASLAVSLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESEIPARFSGRGSGTDFLTINPVEADDVATYYCQQSNADPYTFGGGTKLEIK (SEQ ID NO: 197) I23RB36 QIQLVQSGAELVKPGASVKLSCTTSGFNIKDTYIHWMKQRPEQGLEWIGRIDPANGNTIYASKFQGKATLTTDTSSNTAYMLLSSLTSGDTAVYYCTRGTSWFAYWGQGTTVTVSS (SEQ ID NO: 198) DIVMTQSPKSMSMSVGERVTLSCKASENVGTSVSWFQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFLTISSVQAEDLADYHCGQSYSYPRTFGGGTKLEIK (SEQ ID NO: 199) I23RB39 EVQLQQSGPELVKPGAPVKISCKASGYTFTNYYIHWVKQRPGQGLEWIGYIYPGNGGTAYNQKFKDKATLTADNPSSTAYMQLSLTSEDSAVYFCARSRGGSRNYFDYWGQGTTLTVSS (SEQ ID NO: 200) DIQMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSSPRTFGAGTKLELK (SEQ ID NO: 201) I23RB42 EVQLQQSGAELVKPGASVKISCKASGYSFTDYIMNWVKQSHGKSLEWIGNINPYFGFTSYNQEFKGKATLTVDKSSSTAYMLLNSLTSEDSAVYYCSRGSYYGYETFFDYWGQGTTLTVSS (SEQ ID NO: 202) DIVLTQTAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPYTFGSGTRLEIK (SEQ ID NO: 203) I23RB45 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSNNQVFLKITSVDTADTATYYCAQRALPLLGQKAPFDYWGQGTTLTVSS (SEQ ID NO: 204) DIVLTQSQKFISTSVGDRVSITCKASQNVRTAVAWYQQKPGQSPKLLIYLPSNRHTGVPDRFTGSGSGTVFTLTISNVQSEDQADYFCLQHWNYPLTFGAGTKLELK (SEQ ID NO: 205) I23RB47 QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYDIHWVRQSPGKGLEWLGVIWSDGRTDYKGAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARNNYYRYGRNTMDYWGQGTSVTVSS (SEQ ID NO: 206) DIVLTQSPASQSASLGESVTITCLASQTIGSWLAWYQQKPGKSPQLLIYAATRLADGVPSRFSGSGSGTKFSFKISSLQAEDFVFYYCHQLYSIPLTFGGGTKLEMK (SEQ ID NO: 207) I23RB51 QVQLQQSGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYVHYRDSTHYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARQLGLKAMDYWGQGTSVTVSS (SEQ ID NO: 208) DIVLTQSPASLSASVGETVTITCRASGNIHNYLAWYQHKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQYFWTTRTFGAGTKLELK (SEQ ID NO: 209) I23RB54 EVQLQQSGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSYIYYPDNVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARKKSDYGAMDYWGQGTTLTVSS (SEQ ID NO: 210) DIQMTQSPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPRLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYSSLPTFGAGTKLEMK (SEQ ID NO: 211) I23RB56 EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAAINSNDGSTYYPDTVKDRFTISRDNAKNTLYLQMSSLRSEDTALYYCARHFLYFSNFYYFDYWGQGTTLTVSS (SEQ ID NO: 212) DIVMTQSPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTVFTFTISTVQAEDLAVYFCQQDYSSPFTFGSGTKLEIK (SEQ ID NO: 213) I23RB57 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYYMHWVKQSHGKTIEWIGYIYPNSGDTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYNCARFGGFYDAMDYWGQGTSVTVSS (SEQ ID NO: 214) DIVMTQSPAIMSASLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPFTFGSGTKLEIK (SEQ ID NO: 215) I23RB58 EVKLVESGGGLVKPGGSLKLSCAASGFSFIIYTMSWVRQTPEKRLEWVAYITSGGGITYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARHEGDYYDDYYRIGYAMDYWGQGTSVTVSS (SEQ ID NO: 216) DIVMTQTPASLAVSLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFLTINPVEDDVATYYCQQSNEDPLTFGAGTKLEMK (SEQ ID NO: 217) I23RB60 DVQLQESGPELVKPGDSVKMSCEASGYTFTDYYYIDWVKQSHGKSLEWIGYIYPNNGGISFNQKFEGKATLTVDKSSSTAYMELHSLTSEDSAVYYCAREKLRGRDYWGQGTTLTVSS (SEQ ID NO: 218) DIVMTQSTSSLSASLGDRVTISCRASQDIRNNLNWYQQKPDGTVKLLIFYSSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGHTLPWTFGAGTKLELK (SEQ ID NO: 219) I23RB61 DVQLQESGAELVKPGASVKLSCKSFDYTFTSFDINWMKQRPGQGLEWIGWIFPGSGTTNYNEKFKGKATLTADKSSSTAYMHLTSLTSEDSAVYFCARRLTGTRYFDVWGTGTTLTVSS (SEQ ID NO: 220) DIQMTQSHKFLSTSVGDRITITCKASQDVITAVAWYQQKSGQSPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTISNVQAEDLALYYCQQHYTTPPTFGAGTKLELK (SEQ ID NO: 221) I23RB65 EVQLQQSGPELVKPGASVKISCKASGYTFTDHTMDWVKQSHGKSLEWIGYIYPKSGNAAYSQKFKSEATLTVDKSSSTAYMEFHSLTSEDSAVYYCARWGLRRDGFTYWGQGTSVTVSS (SEQ ID NO: 222) QIVLTQSPASLAVSLGQRATISCRASQSVSTSSYNYIHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEDDTATYYCQHTWEIPYTFGSGTKLEIK (SEQ ID NO: 223) I23RB66 QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSNMGIGWIRQPSGKGLEWLAHIWWNSDKYYNPSLKSRLTISKDTSNNQVFLTITSVDTADTATYYCAQIRWLRFYFDYWGQGTTVTVSS (SEQ ID NO: 224) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTFSSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIK (SEQ ID NO: 225) I23RB67 EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPGSSSTNYNEKFKSKATLTVDTSSSTAYMQLSLTSDDSAVYYCARSAYGNRLAMDYWGQGTTLTVSS (SEQ ID NO: 226) DVVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLELK (SEQ ID NO: 227) I23RB69 EVQLQQSGAELVKPGASVKISCKASGYSFTGYNMNWVKQSHGKSLEWIGNINPFYDKTSYNQKFKGKATLTVDKASSTAYMQLNSLTSEDSAVYYCARQLGLKGFAYWGQGTLVTVSA (SEQ ID NO: 228) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLEMK (SEQ ID NO: 229) I23RB71 DVQLQESGPDLVKPSQSLSLTCTVTDYSITRGYNWHWIRQFPGNKLEWMGYIHYSGSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARQYGLKAMDYWGQGTSVTVSS (SEQ ID NO: 230) DIVMTQSHKFMSTSVGDRVSITCKASQDVITAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYFCQQHFGTPYTFGSGTKLEMK (SEQ ID NO: 231) I23RB73 EVQLQQSGAELVKPGASVKISCKASGYTFTDHAIHWVKQRPEQGLEWIGYISLGNGDIKYSEKFRGKATLTADKTSNTAYMQLNSLTSEDSAVYFCKRSRVLRWTTYWYFDVWGAGTSVTVSS (SEQ ID NO: 232) DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRLTGVPDRFTGSGSGTDYTLTISSVQAEDLALYYCQQYYNTPLTFGAGTKLELK (SEQ ID NO: 233) I23RB74 DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSFNYNPSLKNRLSITRDTSMNQFFLKLNSVTSEDTATYYCARAEIYYDYDGDFDYWGQGTTLTVSS (SEQ ID NO: 234) DIVLTQSPASLAVSLGQRATISCRASKSVSTSGSNFLHWYQQKPGQPPKLLIYFASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPHTFGAGTKLELK (SEQ ID NO: 235) I23RB76 EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMNWMKQSHGKSLEWIGYISPKNGRTGYNQKFKGKATLTVDKSSTTAYMELRSLTSEDSAVYYCAKSNGYYALDYWGQGTTVTVSS (SEQ ID NO: 236) DIVLTQSPATLCVTPGETVSLSCRASQNIYKNLHWFQQKSHRSPRLLIKYASDSISGIPSRFTGSGSGTDYTLSINSVKPEDEGIYYCLQGYSTPWTFGGGTKLEIK (SEQ ID NO: 237) I23RB77 DVQLQESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWGSGSTDYNSALKSRLSINKDNSKSQVFLKMNSLQTDDTAMYYCARVYYGGSPYAMDYWGQGTTVTVSS (SEQ ID NO: 238) DIVMTQSPASLASLGQRATISCRASEVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFLTTIDPVEADDAAIYYCQQNNEEPNTFGAGTKLEMK (SEQ ID NO: 239) I23RB78 EFQLQQSGGGLVKPGGSLKLSCAASGFTFSNYTMSWVRQTPEKRLKWVACISSGGGNTYYPDSVKGRFTISRDNARNNTLYLQMSSLRSEDTAMYYCARRNYRRAMDYWGQGTSVTVSS (SEQ ID NO: 240) DIVMTQSPASLAVSLGQRATISCRASEVDSYGISFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFLTINPVEADDVATYYCQQSNEDPWTFGAGTGLEIK (SEQ ID NO: 241) I23RB79 DVQLQESGPELVRPGASVKMSCKASGYTFTDYYYMNWVKQSHGKSLEWIGYIYPNNGDTVYNQKFKGKATLTVDKSSNTAYMELRSLTSEDSAVYYCARGTLTGMYYFDYWGQGTSVTVSS (SEQ ID NO: 242) DIQMTQSPKFLHVSAGDRVTITCKASQSVINDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAIYFCQQDYSSPPTFGAGTRLEIK (SEQ ID NO: 243) I23RB80 DVQLQESGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGVSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRGSYYFDYWGQGTTLTVSS (SEQ ID NO: 244) DIVMTQSQKFMSTSEGDRVNITCKASQNIRTAVAWYQQKPGQSPKPLIYLASNRHTGVPDRFTGSGSGTDFLTISNVQSEDLAEYFCLQHWNYPLTFGAGTKLELK (SEQ ID NO: 245) I23RB81 DVQLQESGPGLVAPSQSLSITCTVSGFSLTSYAINWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQLFLKMNSLQTDDTARYYCARNRDYSNYRWYFDVWGAGTSVTVSS (SEQ ID NO: 246) DIVMTQSHKFMSTSVGDRVSIICKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPLTFGAGTRLEIK (SEQ ID NO: 247) I23RB82 QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYALHWFRQSPGKGLEWLGVIWSDGSTDYNSPFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRSNYGRWYFDVWGAGTTLTVSS (SEQ ID NO: 248) QIVLSQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSAFYRYTGVPDRFTGSGSGTDFFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIK (SEQ ID NO: 249) I23RB83 DVQLQESGPGLVAPSQSLSITCTVSGFSLTNYDVHWVRQSPGKGLEWLGVIWSDGSTDYNAAFISRLFSKDNSKRQVFFKMNSLQPDDTAIYYCARNNYYRYGRNPMDYWGQGTTVTVSS (SEQ ID NO: 250) DIQMTQSPASQSASLGESVTITCLASQTIGSWLAWYQQKPGKSPQLLIYAATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQLYSSPLTFGGGTKLEIK (SEQ ID NO: 251) I23RB85 DVQLQESGPGLVAPSQSLSITCTVSGFSFNTYAITWVRQPPGRGLEWLGVLWPGGGISYNLALKSRLTISRDSSKSQVFLEMNSLQTDDTARYYCARNWRHYDGSYAMDFWGQGTSVTVSS (SEQ ID NO: 252) DIVLTQSPLSLFVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTRLEIK (SEQ ID NO: 253) I23RB86 EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWLHWVKQRPGQGLEWIGEIDPSDSYTYYNQKFKGKATLTVDKSSSTAYMQLSLTSEDSAVYYCARSPYDYDWGAYWGQGTSVTVSS (SEQ ID NO: 254) DIVMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFKGLIYHGTNLEDEVPSRFSGSGSGADYSLTIGSLESEDFADYYCVQYAQFPWTFGAGTKLEMK (SEQ ID NO: 255) I23RB87 EFQLQQSGPELVKPGTSVKMSCKASGYTFTNYVMHWVKQKPGQGLEWIGYINPYDASPKYNEKFKGKAILTSDKSSSTAYMELSSLTSEDSAVYYCTRDAKLDYFDYWGQGTTLTVSS (SEQ ID NO: 256) DIVMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTISNLEQEDIATYFCQQGITLPWTFGAGTKLELK (SEQ ID NO: 257) I23RB91 EFQLQQFGPELLKPGASVKISCKASGYTFTDYIMHWVKQSHGKSLEWIGGISPNYGGTGYNGKFKDKATLTVDKSSSTAYMELRSLTSEDSAVYYCARFNNYYYFDYWGQGTTLTVSS (SEQ ID NO: 258) DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWCQQKPGKSPKALIYRANSLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEMK (SEQ ID NO: 259) I23RB92 EVQLQQSGPEVVKPGASVKISCKASGYTFTDHTMDWVKQSHGKNLEWIGYIYPKSGGTGYNQKFKNKATLTVDKSSSTAYMEFHSLTSDDSAVYYCARWGLRRDGFVYWGQGTLVTVSA (SEQ ID NO: 260) DIKMTQSPASLAVSLGQRATISCRASQSVSTSKYDYIHWYQQKSGQPPRLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEEDTATYYCQHTWEIPYTFGSGTKLELK (SEQ ID NO: 261) I23RB93 QVQLKESGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGVSTDYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSRGSYYFDYWGQGTTLTVSS (SEQ ID NO: 262) DIKMTQSPATLSVTPGDSVSLFCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPLTFGGGTKLEIK (SEQ ID NO: 263) I23RB94 DVQLQESGPELKKPGETVKISCKASGYTFTNYGMNWVRQAPGKSLKWMGWINTNTGEPAYAEEFKGRFAFSLETSASTAYLQINNLKNEDMATYFCARVRQTARATRGYFDVWGTGTTVTVSS (SEQ ID NO: 264) DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGQSPKLLIYSAFYRYPGVPDRFTGSGSGTDFFTINSVQAEDLAVYCCQQHYTSPLTFGDGTRLEIK (SEQ ID NO: 265) I23RB95 EVKLVESGGGLVQPGSSMKLSCTASGFTFSDYYMAWVRQVPEKGLEWVANINYDGSNTYYLDSLKSRFIISRDNAKNILYLQMSSLKSEDTATYYCAREGYDEAMDYWGQGTTLTVSS (SEQ ID NO: 266) DIVLTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFLTISNVQSEDLADYFCQQYSTYPYTVGGGTKLEIK (SEQ ID NO: 267) I23RB98 EFQLQQSGPELVKPGASVKMSCKASGYTFTNYYMHWVKQSHGKTIEWIGYIYPNSGDTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYTCARFGGFYDAMDYWGQGTTVTVSS (SEQ ID NO: 268) DIVLTQSPAIMSASLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPFTFGSGTKLEMK (SEQ ID NO: 269) Table 6. Exemplary immune-based IL-23R Antibody CDR AA sequence name HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 I23RB101 GGTFSSYA (SEQ ID NO: 270) INPNSGGT (SEQ ID NO: 271) ARGYRYGPLDGFDI (SEQ ID NO: 272) QDVRTA (SEQ ID NO: 273) SAS (SEQ ID NO: 274) QQHYSTPYT (SEQ ID NO: 275) I23RB102 GYTFTKYW (SEQ ID NO: 276) IYPGSIST (SEQ ID NO: 277) ARGDFYALDY (SEQ ID NO: 278) ENIYSH (SEQ ID NO:279) AST (SEQ ID NO: 280) QHFWGTPWT (SEQ ID NO: 281) I23RB104 GFTFSSYA (SEQ ID NO: 282) ISTGGST (SEQ ID NO: 283) ARGPHYYGGSYPFAY (SEQ ID NO: 284) ENIYSN (SEQ ID NO: 285) AAT (SEQ ID NO: 286) QHFWGTPPT (SEQ ID NO: 287) I23RB144 GYTFTSYI (SEQ ID NO: 288) IDPYNDDT (SEQ ID NO: 289) ARLGSINYYDGSYFDY (SEQ ID NO: 290) QSLLDSDGKTY (SEQ ID NO: 291) LVS (SEQ ID NO: 292) WQGIHFPLT (SEQ ID NO: 293) I23RB148 GYSITSGYN (SEQ ID NO: 294) IHSSGTT (SEQ ID NO: 295) TRQLGLKAMEY (SEQ ID NO: 296) QEVRTA (SEQ ID NO: 297) SAS (SEQ ID NO: 298) QQHYTTPYS (SEQ ID NO: 299) I23RB149 GYSITSGYN (SEQ ID NO: 300) IHFSDRT (SEQ ID NO: 301) SRQLGLKALDY (SEQ ID NO: 302) QSLVHSNGNTY (SEQ ID NO: 303) KVS (SEQ ID NO: 304) SQSTHVPLT (SEQ ID NO: 305) I23RB150 AYTFTNYG (SEQ ID NO: 306) IKTNTGEP (SEQ ID NO: 307) ARSRQLGLRYYFDY (SEQ ID NO: 308) QDVSTA (SEQ ID NO: 309) SAS (SEQ ID NO: 310) QQHYSTPYT (SEQ ID NO: 311) I23RB153 GFTFSSDT (SEQ ID NO: 312) ISSNGGST (SEQ ID NO: 313) ASPGYPWFAY (SEQ ID NO: 314) QDVGNA (SEQ ID NO: 315) WTS (SEQ ID NO: 316) QQYNRYPLT (SEQ ID NO: 317) I23RB155 GYSITSGHS (SEQ ID NO: 318) ISYDGTN (SEQ ID NO: 319) ARGGGYYGGTYRVFAD (SEQ ID NO: 320) ESVDTYGNSF (SEQ ID NO: 321) RAS (SEQ ID NO: 322) QQGNKDPYT (SEQ ID NO: 323) I23RB156 GFSLTSYA (SEQ ID NO: 324) IWTGGGT (SEQ ID NO: 325) ARNRDYSNYRWYFDV (SEQ ID NO: 326) QDVSTA (SEQ ID NO: 327) SAF (SEQ ID NO: 328) QQHYSIPLT (SEQ ID NO: 329) I23RB157 GFTFSRYT (SEQ ID NO: 330) ISTGGGDT (SEQ ID NO: 331) ARRTSYSYYNYVFDY (SEQ ID NO: 332) ESVDNYGISF (SEQ ID NO: 333) AAS (SEQ ID NO: 334) QQSKEVPWT (SEQ ID NO: 335) I23RB159 GFTSDYG (SEQ ID NO: 336) ISNLAYSV (SEQ ID NO: 337) ARHGDYRNYGFAY (SEQ ID NO: 338) QDISNY (SEQ ID NO:339) YTS (SEQ ID NO: 340) QQGNTLPWT (SEQ ID NO: 341) I23RB160 GYSITSGYN (SEQ ID NO: 342) IHYSSGT (SEQ ID NO: 343) ARQLGLKAMDY (SEQ ID NO: 344) QDVRTA (SEQ ID NO: 345) SAS (SEQ ID NO: 346) QQHYTTPYT (SEQ ID NO: 347) I23RB161 VYAFSSSW (SEQ ID NO: 348) IYPGDGDT (SEQ ID NO: 349) ARRYDFGSAMDY (SEQ ID NO: 350) SSVSY (SEQ ID NO: 351) ATS (SEQ ID NO: 352) QQWSSNPPT (SEQ ID NO: 353) I23RB162 GYTFTNYV (SEQ ID NO: 354) INPYNDGT (SEQ ID NO: 355) ARSRTGTRWYFDV (SEQ ID NO: 356) QNVGTN (SEQ ID NO: 357) SAS (SEQ ID NO: 358) QQYNSYPFT (SEQ ID NO: 359) I23RB165 GFNIKDSL (SEQ ID NO: 360) IDPEDGKT (SEQ ID NO: 361) ARREVLDYFDY (SEQ ID NO: 362) KSVSTSGYSY (SEQ ID NO: 363) LAS (SEQ ID NO: 364) QHSRELPLT (SEQ ID NO: 365) I23RB166 GYSITN GNHW (SEQ ID NO: 366) IRSSGST (SEQ ID NO: 367) ARERLRLRWSYFDY (SEQ ID NO: 368) QDVSTA (SEQ ID NO: 369) SAS (SEQ ID NO: 370) QQHYSTPRT (SEQ ID NO: 371) I23RB168 GYTFTDYY (SEQ ID NO: 372) IYPAINNT (SEQ ID NO: 373) AISRKPYFDY (SEQ ID NO: 374) EDLYNR (SEQ ID NO: 375) GAT (SEQ ID NO: 376) QQYWSIPWT (SEQ ID NO: 377) I23RB169 GYTFTTVG (SEQ ID NO: 378) INTHSGEP (SEQ ID NO: 379) ARSSALTGAFAY (SEQ ID NO: 380) KSVSTSDYSY (SEQ ID NO: 381) LAS (SEQ ID NO: 382) QHSRELPRT (SEQ ID NO: 383) I23RB173 GYSITSGYY (SEQ ID NO: 384) ISYDGGN (SEQ ID NO: 385) ARDAGLLPYYAMDY (SEQ ID NO: 386) SSVSY (SEQ ID NO: 387) STS (SEQ ID NO: 388) QQRSSYPLT (SEQ ID NO: 389) I23RB177 GYTITDYT (SEQ ID NO: 390) INPNYGGT (SEQ ID NO: 391) VRGNIYFDY (SEQ ID NO: 392) QDINSY (SEQ ID NO: 393) RAN (SEQ ID NO: 394) QQYDEFPRT (SEQ ID NO: 395) I23RB180 GFSLSTYGMG (SEQ ID NO: 396) IWWNDSK (SEQ ID NO: 397) GRIDGYYECVDV (SEQ ID NO: 398) VNIHNY (SEQ ID NO:399) NAK (SEQ ID NO: 400) QHFWTTPYMYT (SEQ ID NO: 401) I23RB182 GYSITSGYF (SEQ ID NO: 402) IDNDGSN (SEQ ID NO: 403) ARGRLGFFDS (SEQ ID NO: 404) SSVNY (SEQ ID NO: 405) YTS (SEQ ID NO: 406) QQFTNSPWT (SEQ ID NO: 407) I23RB188 GYTFTNYG (SEQ ID NO: 408) INTYTGAP (SEQ ID NO: 409) ARGNGYPYYYGINY (SEQ ID NO: 410) QEISGN (SEQ ID NO: 411) AAS (SEQ ID NO: 412) LQYASYPWT (SEQ ID NO: 413) I23RB189 GYSITSGYN (SEQ ID NO: 414) IHSSGTT (SEQ ID NO: 415) TRQLGLKAMEY (SEQ ID NO: 416) ENVGTY (SEQ ID NO: 417) GAS (SEQ ID NO: 418) GQSYSYPPT (SEQ ID NO: 419) I23RB27 GFSLTSYG (SEQ ID NO: 420) LGWDDKK (SEQ ID NO: 421) TKEDVSYAMDF (SEQ ID NO: 422) ESVEYYGTSL (SEQ ID NO: 423) AAS (SEQ ID NO: 424) QQGKKVPWT (SEQ ID NO: 425) I23RB30 GFSLSTSGMG (SEQ ID NO: 426) IYWDDDK (SEQ ID NO: 427) ARRTLGGPPFDY (SEQ ID NO: 428) QNIRTA (SEQ ID NO: 429) LPS (SEQ ID NO: 430) LQHWNYPLT (SEQ ID NO: 431) I23RB31 GYTFTGYW (SEQ ID NO: 432) IDPSDTET (SEQ ID NO: 433) ARWGLGRNFAMDY (SEQ ID NO: 434) QSISDH (SEQ ID NO: 435) FAS (SEQ ID NO: 436) QNGHSFPLT (SEQ ID NO: 437) I23RB32 GYTFTDYA (SEQ ID NO: 438) IYPGGGNT (SEQ ID NO: 439) ARGRLRRDYPMDY (SEQ ID NO: 440) QSLLNSGNQKNY (SEQ ID NO: 441) WAS (SEQ ID NO: 442) QNDYTYPLT (SEQ ID NO: 443) I23RB33 GFNIRDIY (SEQ ID NO: 444) IDPANGHS (SEQ ID NO: 445) ARGSDNDYGRVLAY (SEQ ID NO: 446) SSVRSSY (SEQ ID NO: 447) STS (SEQ ID NO: 448) QQYTGNPIFT (SEQ ID NO: 449) I23RB35 GYSITSGHN (SEQ ID NO: 450) ISYDGSN (SEQ ID NO: 451) ARGGGYFGNSYRVFAS (SEQ ID NO: 452) ESVDSYGNSF (SEQ ID NO: 453) RAS (SEQ ID NO: 454) QQSNADPYT (SEQ ID NO: 455) I23RB36 GFNIKDTY (SEQ ID NO: 456) IDPANGNT (SEQ ID NO: 457) TRGTSWFAY (SEQ ID NO: 458) ENVGTS (SEQ ID NO: 459) GAS (SEQ ID NO: 460) GQSYSYPRT (SEQ ID NO: 461) I23RB39 GYTFTNYY (SEQ ID NO: 462) IYPGNGGT (SEQ ID NO: 463) ARSRGGSRNYFDY (SEQ ID NO: 464) QDVSTA (SEQ ID NO: 465) SAF (SEQ ID NO: 466) QQHYSSPRT (SEQ ID NO: 467) I23RB42 GYSFTDYI (SEQ ID NO: 468) INPYFGFT (SEQ ID NO: 469) SRGSYYGYETFFDY (SEQ ID NO: 470) KSLLHSNGNTY (SEQ ID NO: 471) RMS (SEQ ID NO: 472) MQHLEYPYT (SEQ ID NO: 473) I23RB45 GFSLSTYGMG (SEQ ID NO: 474) IYWDDDK (SEQ ID NO: 475) AQRALPLLGQKAPFDY (SEQ ID NO: 476) QNVRTA (SEQ ID NO: 477) LPS (SEQ ID NO: 478) LQHWNYPLT (SEQ ID NO: 479) I23RB47 GFSLTNYD (SEQ ID NO: 480) IWSDGRT (SEQ ID NO: 481) ARNNYYRYGRNTMDY (SEQ ID NO: 482) QTIGSW (SEQ ID NO: 483) AAT (SEQ ID NO: 484) HQLYSIPLT (SEQ ID NO: 485) I23RB51 GYSITSGYN (SEQ ID NO: 486) VHYRDST (SEQ ID NO: 487) ARQLGLKAMDY (SEQ ID NO: 488) GNIHNY (SEQ ID NO: 489) NAK (SEQ ID NO: 490) QYFWTTRT (SEQ ID NO: 491) I23RB54 GFTFSSYA (SEQ ID NO: 492) ISSGGSYI (SEQ ID NO: 493) ARKKSDYGAMDY (SEQ ID NO: 494) QSVSND (SEQ ID NO: 495) YAS (SEQ ID NO: 496) QQDYSSLPT (SEQ ID NO: 497) I23RB56 GFTFSSYA (SEQ ID NO: 498) INSNDGST (SEQ ID NO: 499) ARHFLYFSNFYYFDY (SEQ ID NO: 500) QSVSND (SEQ ID NO: 501) YAS (SEQ ID NO: 502) QQDYSSPFT (SEQ ID NO: 503) I23RB57 GYTFTNYY (SEQ ID NO:504) IYPNSGDT (SEQ ID NO: 505) ARFGGFYDAMDY (SEQ ID NO: 506) SSVSSSY (SEQ ID NO: 507) STS (SEQ ID NO: 508) HQYHRSPFT (SEQ ID NO: 509) I23RB58 GFSFIIYT (SEQ ID NO: 510) ITSGGGIT (SEQ ID NO: 511) ARHEGDYYDDYYRIGYAMDY (SEQ ID NO:512) ESVDSYGNSF (SEQ ID NO: 513) RAS (SEQ ID NO: 514) QQSNEDPLT (SEQ ID NO: 515) I23RB60 GYTFTDYY (SEQ ID NO: 516) IYPNNGGI (SEQ ID NO: 517) AREKLRGRDY (SEQ ID NO: 518) QDIRNN (SEQ ID NO: 519) YSS (SEQ ID NO: 520) QQGHTLPWT (SEQ ID NO: 521) I23RB61 DYTFTSFD (SEQ ID NO: 522) IFPGSGTT (SEQ ID NO: 523) ARRLTGTRYFDV (SEQ ID NO: 524) QDVITA (SEQ ID NO:525) WAS (SEQ ID NO: 526) QQHYTTPPT (SEQ ID NO: 527) I23RB65 GYTFTDHT (SEQ ID NO: 528) IYPKSGNA (SEQ ID NO: 529) ARWGLRRDGFTY (SEQ ID NO: 530) QSVSTSSYNY (SEQ ID NO: 531) YAS (SEQ ID NO: 532) QHTWEIPYT (SEQ ID NO: 533) I23RB66 GFSLSTSNMG (SEQ ID NO: 534) IWWNSDK (SEQ ID NO: 535) AQIRWLRFYFDY (SEQ ID NO: 536) QDVSTA (SEQ ID NO: 537) SAS (SEQ ID NO: 538) QQHYSTPYT (SEQ ID NO: 539) I23RB67 GYTFTSYW (SEQ ID NO: 540) IYPGSSST (SEQ ID NO: 541) ARSAYGNRLAMDY (SEQ ID NO: 542) QDVSTA (SEQ ID NO: 543) SAF (SEQ ID NO: 544) QQHYSTPYT (SEQ ID NO: 545) I23RB69 GYSFTGYN (SEQ ID NO: 546) INPFYDKT (SEQ ID NO: 547) ARQLGLKGFAY (SEQ ID NO: 548) QDVSTA (SEQ ID NO: 549) SAS (SEQ ID NO: 550) QQHYSTPWT (SEQ ID NO: 551) I23RB71 DYSITRGYN (SEQ ID NO: 552) IHYSGST (SEQ ID NO: 553) ARQYGLKAMDY (SEQ ID NO: 554) QDVITA (SEQ ID NO: 555) SAS (SEQ ID NO: 556) QQHFGTPYT (SEQ ID NO: 557) I23RB73 GYTFTDHA (SEQ ID NO: 558) ISLGNGDI (SEQ ID NO: 559) KRSRVLRWTTYWYFDV (SEQ ID NO: 560) QDVSTA (SEQ ID NO: 561) WAS (SEQ ID NO: 562) QQYYNTPLT (SEQ ID NO: 563) I23RB74 GYSITSGYY (SEQ ID NO: 564) ISYDGSF (SEQ ID NO: 565) ARAEIYYDYDGDFDY (SEQ ID NO: 566) KSVSTSGSNF (SEQ ID NO: 567) FAS (SEQ ID NO: 568) QHSRELPHT (SEQ ID NO: 569) I23RB76 GYTFTDYY (SEQ ID NO: 570) ISPKNGRT (SEQ ID NO: 571) AKSNGYYALDY (SEQ ID NO:572) QNIYKN (SEQ ID NO: 573) YAS (SEQ ID NO: 574) LQGYSTPWT (SEQ ID NO: 575) I23RB77 GFSLSRYS (SEQ ID NO: 576) IWGSGST (SEQ ID NO: 577) ARVYYGGSPYAMDY (SEQ ID NO:578) ESVDSYGNSF (SEQ ID NO: 579) LAS (SEQ ID NO: 580) QQNNEEPNT (SEQ ID NO: 581) I23RB78 GFTFSNYT (SEQ ID NO: 582) ISSGGGNT (SEQ ID NO: 583) ARRNYRRAMDY (SEQ ID NO: 584) ESVDSYGISF (SEQ ID NO: 585) RAS (SEQ ID NO: 586) QQSNEDPWT (SEQ ID NO: 587) I23RB79 GYTFTDYY (SEQ ID NO: 588) IYPNNGDT (SEQ ID NO: 589) ARGTLTGMYYFDY (SEQ ID NO: 590) QSVIND (SEQ ID NO: 591) YAS (SEQ ID NO: 592) QQDYSSPPT (SEQ ID NO: 593) I23RB80 GFSLTSYG (SEQ ID NO: 594) IWSGVST (SEQ ID NO: 595) ARSRGSYYFDY (SEQ ID NO: 596) QNIRTA (SEQ ID NO: 597) LAS (SEQ ID NO: 598) LQHWNYPLT (SEQ ID NO: 599) I23RB81 GFSLTSYA (SEQ ID NO: 600) IWTGGGT (SEQ ID NO: 601) ARNRDYSNYRWYFDV (SEQ ID NO: 602) QDVSTA (SEQ ID NO: 603) SAS (SEQ ID NO: 604) QQHYSTPLT (SEQ ID NO: 605) I23RB82 GFSLTNYA (SEQ ID NO: 606) IWSDGST (SEQ ID NO: 607) ARSRSNYGRWYFDV (SEQ ID NO: 608) QDVSTA (SEQ ID NO: 609) SAF (SEQ ID NO: 610) QQHYSTPYT (SEQ ID NO: 611) I23RB83 GFSLTNYD (SEQ ID NO: 612) IWSDGST (SEQ ID NO: 613) ARNNYYRYGRNPMDY (SEQ ID NO:614) QTIGSW (SEQ ID NO: 615) AAT (SEQ ID NO: 616) QQLYSSPLT (SEQ ID NO: 617) I23RB85 GFSFNTYA (SEQ ID NO: 618) LWPGGGI (SEQ ID NO: 619) ARNWRHYDGSYAMDF (SEQ ID NO: 620) QSLVHSNGNTY (SEQ ID NO: 621) KVS (SEQ ID NO:622) SQSTHVPWT (SEQ ID NO: 623) I23RB86 GYTFTSYW (SEQ ID NO: 624) IDPSDSYT (SEQ ID NO: 625) ARSPYDYDWGAY (SEQ ID NO:626) QGISSN (SEQ ID NO: 627) HGT (SEQ ID NO: 628) VQYAQFPWT (SEQ ID NO: 629) I23RB87 GYTFTNYV (SEQ ID NO:630) INPYDASP (SEQ ID NO: 631) TRDAKLDYFDY (SEQ ID NO: 632) QDISNY (SEQ ID NO:633) YTS (SEQ ID NO: 634) QQGITLPWT (SEQ ID NO: 635) I23RB91 GYTFTDYI (SEQ ID NO: 636) ISPNYGGT (SEQ ID NO: 637) ARFNNYYYFDY (SEQ ID NO:638) QDINSY (SEQ ID NO:639) RAN (SEQ ID NO: 640) LQYDEFPYT (SEQ ID NO: 641) I23RB92 GYTFTDHT (SEQ ID NO: 642) IYPKSGGT (SEQ ID NO: 643) ARWGLRRDGFVY (SEQ ID NO: 644) QSVSTSKYDY (SEQ ID NO: 645) YAS (SEQ ID NO: 646) QHTWEIPYT (SEQ ID NO:647) I23RB93 GFSLTSYG (SEQ ID NO: 648) IWSGVST (SEQ ID NO: 649) ARSRGSYYFDY (SEQ ID NO: 650) QSISNN (SEQ ID NO: 651) YAS (SEQ ID NO: 652) QQSNSWPLT (SEQ ID NO: 653) I23RB94 GYTFTNYG (SEQ ID NO: 654) INTNTGEP (SEQ ID NO: 655) ARVRQTARATRGYFDV (SEQ ID NO: 656) QDVNTA (SEQ ID NO: 657) SAF (SEQ ID NO: 658) QQHYTSPLT (SEQ ID NO: 659) I23RB95 GFTFSDYY (SEQ ID NO: 660) INYDGSNT (SEQ ID NO: 661) AREGYDEAMDY (SEQ ID NO:662) QDVGTA (SEQ ID NO:663) WAS (SEQ ID NO:664) QQYSTYPYT (SEQ ID NO: 665) I23RB98 GYTFTNYY (SEQ ID NO:666) IYPNSGDT (SEQ ID NO: 667) ARFGGFYDAMDY (SEQ ID NO: 668) SSVSSSY (SEQ ID NO: 669) STS (SEQ ID NO: 670) HQYHRSPFT (SEQ ID NO: 671)

Examples of phage display-based IL-23R antibodies or antigen-binding fragments of the present disclosure are summarized in Table 7, Table 8, and Table 9. All phage display based antibodies except I23RB332 and I23RB7 were derived from human phage display and were human antibodies. Antibody I23RB332 (corresponding to VH SEQ ID NO:898 and VL SEQ ID NO:899) and antibody I23RB7 (corresponding to VH SEQ ID NO:798 and VL SEQ ID NO:799) are mouse antibodies. Table 7. HC and LC AA sequences of exemplary phage display-based IL-23R antibodies name HC sequence LC sequence I23RB1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKNYAISWVRQAPGQGLEWMGWIRPIFGTAYYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSGSRYAGRYAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 672) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 673) I23RB2 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRYRYLGANGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 674) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 675) I23RB3 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKSYSIHWVRQAPGQGLEWMGGIIPYFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARERGYYGSIYYGGGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 676) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 677) I23RB4 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKTYAIHWVRQAPGQGLEWMGWIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGGYYGSRYYPRSYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 678) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 679) I23RB5 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYYSTVTYYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 680) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 681) I23RB6 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRYIRSYDYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 682) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTK DEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 683) I23RB7 QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGLKWMGWINTYSGVPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYYCARRDRYGYVAGAFAYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 684) QIVLTQSPAIMSASSPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSYPWTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 685) I23RB8 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKTDYINWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPSYAYGSRTYGYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 686) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 687) I23RB9 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRSYSYGLSGLGYYGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 688) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 689) I23RB10 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIHWVRQAPGQGLEWMGRIIPISGRANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYPSYGSGGAFGYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 690) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTK DEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:691) I23RB259 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQSLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:692) DIQMTQSPSSLSASVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 693) I23RB260 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDFGWSLWFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 694) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYSASTRESGVPDRFSGSGSGTDFLTISSLQAEDVAVYYCQQSFHVPWTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLT LTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 695) I23RB261 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWISPYFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMYRQGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 696) DIQMTQSPSSLSASVGDRVTITCRASQSINDDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 697) I23RB262 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMLKQGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTS STWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTKKQVTLTCMVTDFM PEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 698) DIQMTQSPSSLSASVGDRVTITCRASQSINKDLNWYQQKPGKAPKLLIYFASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 699) I23RB263 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARFHRFWLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:700) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQPYSVPFTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:701) I23RB264 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRSSPGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:702) DIQMTQSPSSLSASVGDRVTITCRASQSIDNDLNWYQQKPGKAPKLLIYNASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQPYSIPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 703) I23RB265 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGFVPTQGSLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 704) DIQMTQSPSSLSASVGDRVTITCRASQSISTWLNWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQYNSPPPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:705) I23RB266 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYSMSWVRQAPGKGLEWVSVISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHSMAGNSFLRFLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 706) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 707) I23RB267 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVWYSSWDLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 708) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 709) I23RB268 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYIHWVRQAPGQGLEWMGGIIPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPGSYGSVYYRRSYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 710) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 711) I23RB269 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSDASISWVRQAPGQGLEWMGTIIPISGNANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRYVWYYWDGYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 712) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 713) I23RB270 QVQLVQSGAEVKKPGSSVKVSCKASGGTFDSYAISWVRQAPGQGLEWMGGIIPISGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLSGGYLGLRTLYYYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAV LQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEE MTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 714) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 715) I23RB271 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGSAETFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 716) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 717) I23RB272 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFGEPNGGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTS STWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTKKQVTLTCMVTDFM PEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 718) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 719) I23RB273 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPSSYYYNGYLGSYAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 720) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 721) I23RB274 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDATDSSDYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 722) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 723) I23RB275 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDSGMSWVRQAPGKGLEWVSAIDGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGGYVGYGGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 724) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 725) I23RB276 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGSYGYRGRRRRYYDYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 726) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 727) I23RB277 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRRRRYRYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 728) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 729) I23RB278 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRGGSLGGGFYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 730) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 731) I23RB279 EVQLLESGGGLVQPGGSLRLSCAASGFTFDTYAMHWVRQAPGKGLEWVSWISGEGGSTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGAYNRPFYAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 732) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 733) I23RB280 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAAMHWVRQAPGKGLEWVSRIDGSGGYTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELYSYLGSSYYYGYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVL QSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISSLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMT KKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 734) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 735) I23RB281 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPYYSGTSGYRSGGGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 736) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 737) I23RB282 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNDAMNWVRQAPGKGLEWVSAIDGNGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGGYYGRRRRYYGMDVWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ SDLYTLSSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTK KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 738) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 739) I23RB283 EVQLLESGGGLVQPGGSLRLSCAAIGFTFSSSAMHWVRQAPGKGLEWVSAIDGEGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVSSYGRYGFGYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTL SSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 740) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 741) I23RB284 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLAGNSSGGGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTC MVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 742) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 743) I23RB285 EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMNWVRQAPGKGLEWVSAIAGNGGSTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGYPLTAVTGIYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 744) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 745) I23RB286 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDAGMSWVRQAPGKGLEWVSAISGNGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRRRRASFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 746) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 747) I23RB287 EVQLVQSGAEVKKPGESLKISCKGSGYSFTDAAIHWVRQMPGKGLEWMGTIDPGDSTTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDLYYTLEYNWYYDAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 748) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 749) I23RB288 EVQLVQSGAEVKKPGESLKISCKGSGYSFKSDWISWVRQMPGKGLEWMGWIYPGDSRTYYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDSSYGTGNRGGRSGAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFP AVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPE EEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 750) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 751) I23RB289 EVQLVQSGAEVKKPGESLKISCKGSGYSFDSAGINWVRQMPGKGLEWMGNIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARGGGSLGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 752) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 753) I23RB290 EVQLVQSGAEVKKPGESLKISCKGSGYSFKNDGIHWVRQMPGKGLEWMGWIAPGESTTGYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDLGGYGSASGRSDYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHT FPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPP PEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 754) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 755) I23RB291 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYISWVRQMPGKGLEWMGNIYPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDRYYGIPFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 756) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 757) I23RB292 EVQLVQSGAEVKKPGESLKISCKGSGYSFDTDYINWVRQMPGKGLEWMGYILPGESDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARGGGYGLVNRRRRSYAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSG VHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYV LPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 758) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 759) I23RB313 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGTVPGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSSVTVTS STWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTKKQVTLTCMVTDFM PEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 760) DIQMTQSPSSLSASVGDRVTITCRASQSIGEDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 761) I23RB314 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:762) DIQMTQSPSSLSASVGDRVTITCRASQSISEDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 763) I23RB315 QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAISWVRQAPGQGLEWMGWISAIFGNANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGAGWTLLLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 764) EIVLTQSPATLSSLSPGERATLSCRASQSVRKWLAWYQQKPGQAPRLLIYAASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNNAPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 765) I23RB316 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQSLDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSST WPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:766) DIQMTQSPSSLSASVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 767) I23RB317 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGNGVNYHSELDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 768) EIVLTQSPATLSSLSPGERATLSCRASQSVDSFLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQGNSAPFTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 769) I23RB318 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVRARHRGSFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 770) DIQMTQSPSSLSASVGDRVTITCRASQSIDRWLNWYQQKPGKAPKLLIYYASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:771) I23RB319 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTALYYCARPLKQAFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTS STWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPPEEEMTKKQVTLTCMVTDFM PEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 772) DIQMTQSPSSLSASVGDRVTITCRASQSITDDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 773) I23RB320 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARNGTGNSFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 774) DIQMTQSPSSLSASVGDRVTITCRASQSITSDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 775) I23RB321 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHWLQSFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 776) DIQMTQSPSSLSASVGDRVTITCRASQSIGGDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO:777) I23RB328 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRYIRSYDYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLY TLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQV TLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 778) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGVPARFSGSGTGTDFLTISSLQPEDVAVYYCQQRNSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 779) I23RB329 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYYSTVTYYYFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 780) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGTGSGTDFLTISSLEPEDFATYYCQQRSNTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEA THKTSTSPIVKSFNRNEC (SEQ ID NO: 781) I23RB330 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRSYSYGLSGLGYYGFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 782) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEA THKTSTSPIVKSFNRNEC (SEQ ID NO: 783) I23RB332 QVQLQQPGAELVMPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKGKSTLTVDKSSSTAYMQLSSLTSEDSAVYYCARSYAFDYWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV TSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 784) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDE YERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 785) Table 8. VH and VL AA sequences of exemplary phage display-based IL-23R antibodies name VH sequence VL sequence I23RB1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKNYAISWVRQAPGQGLEWMGWIRPIFGTAYYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSGSRYAGRYAFDYWGQGTLVTVSS (SEQ ID NO: 786) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 787) I23RB2 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRYRYLGANGFDYWGQGTLVTVSS (SEQ ID NO: 788) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 789) I23RB3 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKSYSIHWVRQAPGQGLEWMGGIIPYFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARERGYYGSIYYGGGFDYWGQGTLVTVSS (SEQ ID NO: 790) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 791) I23RB4 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKTYAIHWVRQAPGQGLEWMGWIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDGGYYGSRYYPRSYYFDYWGQGTLVTVSS (SEQ ID NO: 792) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 793) I23RB5 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYYSTVTYYYFDYWGQGTLVTVSS (SEQ ID NO: 794) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 795) I23RB6 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRYIRSYDYFDYWGQGTLVTVSS (SEQ ID NO: 796) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIK (SEQ ID NO: 797) I23RB7 QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGLKWMGWINTYSGVPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYYCARRDRYGYVAGAFAYWGQGTLVTVSS (SEQ ID NO: 798) QIVLTQSPAIMSASPGKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSYPWTFGGGTKLEIK (SEQ ID NO: 799) I23RB8 QVQLVQSGAEVKKPGSSVKVSCKASGGTFKTDYINWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPSYAYGSRTYGYFDYWGQGTLVTVSS (SEQ ID NO: 800) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 801) I23RB9 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRSYSYGLSGLGYYGFDYWGQGTLVTVSS (SEQ ID NO: 802) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 803) I23RB10 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIHWVRQAPGQGLEWMGRIIPISGRANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYPSYGSGGAFGYWGQGTLVTVSS (SEQ ID NO: 804) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIK (SEQ ID NO: 805) I23RB259 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQSLDYWGQGTLVTVSS (SEQ ID NO: 806) DIQMTQSPSSLSASSVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 807) I23RB260 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDFGWSLWFDYWGQGTLVTVSS (SEQ ID NO: 808) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYSASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSFHVPWTFGQGTKVEIK (SEQ ID NO: 809) I23RB261 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWISPYFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMYRQGFDYWGQGTLVTVSS (SEQ ID NO: 810) DIQMTQSPSSLSASSVGDRVTITCRASQSINDDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 811) I23RB262 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMLKQGFDYWGQGTLVTVSS (SEQ ID NO: 812) DIQMTQSPSSLSASSVGDRVTITCRASQSINKDLNWYQQKPGKAPKLLIYFASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 813) I23RB263 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARFHRFWLDYWGQGTLVTVSS (SEQ ID NO: 814) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQPYSVPFTFGQGTKVEIK (SEQ ID NO: 815) I23RB264 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRSSPGFDYWGQGTLVTVSS (SEQ ID NO: 816) DIQMTQSPSSLSASSVGDRVTITCRASQSIDNDLNWYQQKPGKAPKLLIYNASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQPYSIPLTFGQGTKVEIK (SEQ ID NO: 817) I23RB265 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGFVPTQGSLDYWGQGTLVTVSS (SEQ ID NO: 818) DIQMTQSPSSLSASVGDRVTITCRASQSISTWLNWYQQKPGKAPKLLIYKASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSPPLTFGQGTKVEIK (SEQ ID NO: 819) I23RB266 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYSMSWVRQAPGKGLEWVSVISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHSMAGNSFLRFLDYWGQGTLVTVSS (SEQ ID NO: 820) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 821) I23RB267 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVWYSSWDLDYWGQGTLVTVSS (SEQ ID NO: 822) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 823) I23RB268 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYIHWVRQAPGQGLEWMGGIIPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPGSYGSVYYRRSYYFDYWGQGTLVTVSS (SEQ ID NO: 824) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 825) I23RB269 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSDASISWVRQAPGQGLEWMGTIIPISGNANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRYVWYYWDGYFDYWGQGTLVTVSS (SEQ ID NO: 826) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 827) I23RB270 QVQLVQSGAEVKKPGSSVKVSCKASGGTFDSYAISWVRQAPGQGLEWMGGIIPISGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLSGGYLGLRTLYYYYFDYWGQGTLVTVSS (SEQ ID NO: 828) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 829) I23RB271 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGSAETFDYWGQGTLVTVSS (SEQ ID NO: 830) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 831) I23RB272 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFGEPNGGFDYWGQGTLVTVSS (SEQ ID NO: 832) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 833) I23RB273 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPSSYYYNGYLGSYAFDYWGQGTLVTVSS (SEQ ID NO: 834) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 835) I23RB274 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDATDSSDYYFDYWGQGTLVTVSS (SEQ ID NO: 836) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 837) I23RB275 EVQLLESGGGLVQPGGSLRLSCAASGFTFSDSGMSWVRQAPGKGLEWVSAIDGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGGYVGYGGFDYWGQGTLVTVSS (SEQ ID NO: 838) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 839) I23RB276 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGSYGYRGRRRRYYDYFDYWGQGTLVTVSS (SEQ ID NO: 840) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 841) I23RB277 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRRRRYRYFDYWGQGTLVTVSS (SEQ ID NO: 842) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 843) I23RB278 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRGGSLGGGFYFDYWGQGTLVTVSS (SEQ ID NO: 844) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 845) I23RB279 EVQLLESGGGLVQPGGSLRLSCAASGFTFDTYAMHWVRQAPGKGLEWVSWISGEGGSTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGAYNRPFYAFDYWGQGTLVTVSS (SEQ ID NO: 846) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 847) I23RB280 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAAMHWVRQAPGKGLEWVSRIDGSGGYTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELYSYLGSSYYYGYFDYWGQGTLVTVSS (SEQ ID NO: 848) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 849) I23RB281 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPYYSGTSGYRSGGGFDYWGQGTLVTVSS (SEQ ID NO: 850) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 851) I23RB282 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNDAMNWVRQAPGKGLEWVSAIDGNGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGGYYGRRRRYYGMDVWGQGTLVTVSS (SEQ ID NO: 852) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 853) I23RB283 EVQLLESGGGLVQPGGSLRLSCAAIGFTFSSSAMHWVRQAPGKGLEWVSAIDGEGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVSSYGRYGFGYWGQGTLVTVSS (SEQ ID NO: 854) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 855) I23RB284 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLAGNSSGGGFDYWGQGTLVTVSS (SEQ ID NO: 856) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 857) I23RB285 EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMNWVRQAPGKGLEWVSAIAGNGGSTEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGYPLTAVTGIYFDYWGQGTLVTVSS (SEQ ID NO: 858) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 859) I23RB286 EVQLLESGGGLVQPGGSLRLSCAASGFFSDAGMSWVRQAPGKGLEWVSAISGNGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRRRASFDYWGQGTLVTVSS (SEQ ID NO: 860) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 861) I23RB287 EVQLVQSGAEVKKPGESLKISCKGSGYSFTDAAIHWVRQMPGKGLEWMGTIDPGDSTTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDLYYTLEYNWYYDAFDYWGQGTLVTVSS (SEQ ID NO: 862) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 863) I23RB288 EVQLVQSGAEVKKPGESLKISCKGSGYSFKSDWISWVRQMPGKGLEWMGWIYPGDSRTYYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDSSYGTGNRGGRSGAFDYWGQGTLVTVSS (SEQ ID NO: 864) EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 865) I23RB289 EVQLVQSGAEVKKPGESLKISCKGSGYSFDSAGINWVRQMPGKGLEWMGNIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARGGGSLGFDYWGQGTLVTVSS (SEQ ID NO: 866) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 867) I23RB290 EVQLVQSGAEVKKPGESLKISCKGSGYSFKNDGIHWVRQMPGKGLEWMGWIAPGESTTGYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDLGGYGSASGRRSDYFDYWGQGTLVTVSS (SEQ ID NO: 868) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 869) I23RB291 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYISWVRQMPGKGLEWMGNIYPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARDRYYGIPFDYWGQGTLVTVSS (SEQ ID NO: 870) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 871) I23RB292 EVQLVQSGAEVKKPGESLKISCKGSGYSFDTDYINWVRQMPGKGLEWMGYILPGESDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARGGGYGLVNRRRRSYAFDYWGQGTLVTVSS (SEQ ID NO: 872) DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 873) I23RB313 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGTVPGFDYWGQGTLVTVSS (SEQ ID NO: 874) DIQMTQSPSSLSASSVGDRVTITCRASQSIGEDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 875) I23RB314 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQGFDYWGQGTLVTVSS (SEQ ID NO: 876) DIQMTQSPSSLSASSVGDRVTITCRASQSISEDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 877) I23RB315 QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAISWVRQAPGQGLEWMGWISAIFGNANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGAGWTLLLDYWGQGTLVTVSS (SEQ ID NO: 878) EIVLTQSPATLSSLSPGERATLSCRASQSVRKWLAWYQQKPGQAPRLLIYAASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNNAPLTFGQGTKVEIK (SEQ ID NO: 879) I23RB316 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARMMMQSLDYWGQGTLVTVSS (SEQ ID NO: 880) DIQMTQSPSSLSASSVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 881) I23RB317 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGNGVNYHSELDYWGQGTLVTVSS (SEQ ID NO: 882) EIVLTQSPATLSSLSPGERATLSCRASQSVDSFLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQGNSAPFTFGQGTKVEIK (SEQ ID NO: 883) I23RB318 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVRARHRGSFDYWGQGTLVTVSS (SEQ ID NO: 884) DIQMTQSPSSLSASVGDRVTITCRASQSIDRWLNWYQQKPGKAPKLLIYYASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 885) I23RB319 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTALYYCARPLKQAFDYWGQGTLVTVSS (SEQ ID NO: 886) DIQMTQSPSSLSASSVGDRVTITCRASQSITDDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 887) I23RB320 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARNGTGNSFDYWGQGTLVTVSS (SEQ ID NO: 888) DIQMTQSPSSLSASSVGDRVTITCRASQSITSDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 889) I23RB321 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGWISAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHWLQSFDYWGQGTLVTVSS (SEQ ID NO: 890) DIQMTQSPSSLSASSVGDRVTITCRASQSIGGDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 891) I23RB328 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRYIRSYDYFDYWGQGTLVTVSS (SEQ ID NO: 892) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGVPARFSGSGTGTDFTLTISSLQPEDVAVYYCQQRNSTPLTFGQGTKVEIK (SEQ ID NO: 893) I23RB329 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDSYYSTVTYYYFDYWGQGTLVTVSS (SEQ ID NO: 894) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGTGSGTDFLTISSLEPEDFATYYCQQRSNTPLTFGQGTKVEIK (SEQ ID NO: 895) I23RB330 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRSYSYGLSGLGYYGFDYWGQGTLVTVSS (SEQ ID NO: 896) EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNTPLTFGQGTKVEIK (SEQ ID NO: 897) I23RB332 QVQLQQPGAELVMPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKGKSTLTVDKSSSTAYMQLSLTSEDSAVYYCARSYAFDYWGQGTTVTVSS (SEQ ID NO: 898) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK (SEQ ID NO: 899) Table 9. CDR AA sequences of exemplary phage display-based IL-23R antibodies name HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 I23RB1 GGTFKNYA (SEQ ID NO: 900) IRPIFGTA (SEQ ID NO: 901) ARDSGSRYAGRYAFDY (SEQ ID NO:902) QSVSSY (SEQ ID NO:903) DAS (SEQ ID NO: 904) QQRSNWPLT (SEQ ID NO: 905) I23RB2 GGTFSSYA (SEQ ID NO: 906) IIPIFGTA (SEQ ID NO: 907) ARDRYRYLGANGFDY (SEQ ID NO:908) QSVSSY (SEQ ID NO:909) DAS (SEQ ID NO: 910) QQRSNWPLT (SEQ ID NO: 911) I23RB3 GGTFKSYS (SEQ ID NO: 912) IIPYFGYA (SEQ ID NO:913) ARERGYYGSIYYGGGFDY (SEQ ID NO:914) QSVSSY (SEQ ID NO:915) DAS (SEQ ID NO: 916) QQRSNWPLT (SEQ ID NO: 917) I23RB4 GGTFKTYA (SEQ ID NO:918) IIPIFGTA (SEQ ID NO: 919) ARDGGYYGSRYYPRSYYFDY (SEQ ID NO:920) QSVSSY (SEQ ID NO:921) DAS (SEQ ID NO: 922) QQRSNWPLT (SEQ ID NO: 923) I23RB5 GGTFSSYA (SEQ ID NO: 924) IIPIFGTA (SEQ ID NO: 925) ARDSYYSTVTYYYFDY (SEQ ID NO:926) QSISSY (SEQ ID NO:927) AAS (SEQ ID NO: 928) QQSYSTPLT (SEQ ID NO: 929) I23RB6 GGTFSSYA (SEQ ID NO: 930) IIPIFGTA (SEQ ID NO: 931) ARGRYIRSYDYFDY (SEQ ID NO:932) QSVLYSSNNKNY (SEQ ID NO: 933) WAS (SEQ ID NO:934) QQYYSTPLT (SEQ ID NO: 935) I23RB7 GYTFTTYG (SEQ ID NO: 936) INTYSGVP (SEQ ID NO:937) ARRDRYGYVAGAFAY (SEQ ID NO:938) SSVSY (SEQ ID NO:939) DTS (SEQ ID NO: 940) QQWSSYPWT (SEQ ID NO: 941) I23RB8 GGTFKTDY (SEQ ID NO: 942) IIPIFGTA (SEQ ID NO: 943) ARGPSYAYGSRTYGYFDY (SEQ ID NO: 944) QSVSSY (SEQ ID NO: 945) DAS (SEQ ID NO: 946) QQRSNWPLT (SEQ ID NO: 947) I23RB9 GGTFSSYA (SEQ ID NO: 948) IIPIFGTA (SEQ ID NO: 949) ARDRSYSYGLSGLGYYGFDY (SEQ ID NO:950) QSVSSY (SEQ ID NO:951) DAS (SEQ ID NO: 952) QQRSNWPLT (SEQ ID NO: 953) I23RB10 GGTFSSYA (SEQ ID NO: 954) IIPISGRA (SEQ ID NO: 955) ARDSYPSYGSGGAFGY (SEQ ID NO: 956) QSVLYSSNNKNY (SEQ ID NO: 957) WAS (SEQ ID NO: 958) QQYYSTPLT (SEQ ID NO: 959) I23RB259 GGTFSSYG (SEQ ID NO: 960) ISPIFGTT (SEQ ID NO: 961) ARMMMQSLDY (SEQ ID NO: 962) QSISND (SEQ ID NO: 963) AAS (SEQ ID NO: 964) QQSYSTPLT (SEQ ID NO: 965) I23RB260 GGTFSSYG (SEQ ID NO: 966) IIPIFGTA (SEQ ID NO: 967) ARDFGWSLWFDY (SEQ ID NO: 968) QSVLYSSNNKNY (SEQ ID NO: 969) SAS (SEQ ID NO:970) QQSFHVPWT (SEQ ID NO: 971) I23RB261 GGTFSSYA (SEQ ID NO: 972) ISPYFGTA (SEQ ID NO:973) ARMYRQGFDY (SEQ ID NO: 974) QSINDD (SEQ ID NO: 975) AAS (SEQ ID NO: 976) QQSYSTPLT (SEQ ID NO: 977) I23RB262 GGTFSSYG (SEQ ID NO: 978) ISAIFGTA (SEQ ID NO: 979) ARMLKQGFDY (SEQ ID NO: 980) QSINKD (SEQ ID NO:981) FAS (SEQ ID NO:982) QQSYSTPLT (SEQ ID NO: 983) I23RB263 GGTFSSYA (SEQ ID NO: 984) IIPIFGTA (SEQ ID NO: 985) ARFHRFWLDY (SEQ ID NO: 986) QSISSY (SEQ ID NO:987) AAS (SEQ ID NO: 988) QQPYSVPFT (SEQ ID NO: 989) I23RB264 GGTFSSYA (SEQ ID NO: 990) IIPIFGTA (SEQ ID NO: 991) ARRSSPGFDY (SEQ ID NO: 992) QSIDND (SEQ ID NO: 993) NAS (SEQ ID NO:994) QQPYSIPLT (SEQ ID NO: 995) I23RB265 GGTFSSYA (SEQ ID NO:996) IIPIFGTA (SEQ ID NO: 997) ARGFVPTQGSLDY (SEQ ID NO: 998) QSISTW (SEQ ID NO:999) KAS (SEQ ID NO: 1000) QQYNSPPLT (SEQ ID NO: 1001) I23RB266 GFTSDYS (SEQ ID NO: 1002) ISGSGGST (SEQ ID NO: 1003) AKHSMAGNSFLRFLDY (SEQ ID NO: 1004) QSISSY (SEQ ID NO: 1005) AAS (SEQ ID NO: 1006) QQSYSTPLT (SEQ ID NO: 1007) I23RB267 GYSFTSYW (SEQ ID NO: 1008) IYPGDSDT (SEQ ID NO: 1009) ARVWYSSWDLDY (SEQ ID NO: 1010) QSVSSSY (SEQ ID NO: 1011) GAS (SEQ ID NO: 1012) QQYGSSPLT (SEQ ID NO: 1013) I23RB268 GGTFSSYY (SEQ ID NO: 1014) IIPIFGYA (SEQ ID NO: 1015) ARDPGSYGSVYYRRSYYFDY (SEQ ID NO: 1016) QSVSSY (SEQ ID NO: 1017) DAS (SEQ ID NO: 1018) QQRSNWPLT (SEQ ID NO: 1019) I23RB269 GGTFSDAS (SEQ ID NO: 1020) IIPISGNA (SEQ ID NO: 1021) ARDRYVWYYWDGYFDY (SEQ ID NO: 1022) QSVSSSY (SEQ ID NO: 1023) GAS (SEQ ID NO: 1024) QQYGSSPLT (SEQ ID NO: 1025) I23RB270 GGTFDSYA (SEQ ID NO: 1026) IIPISGYA (SEQ ID NO: 1027) ARDLSGGYLGLRTLYYYYFDY (SEQ ID NO: 1028) QSVSSY (SEQ ID NO: 1029) DAS (SEQ ID NO: 1030) QQRSNWPLT (SEQ ID NO: 1031) I23RB271 GFTFSSYA (SEQ ID NO: 1032) ISGSGGST (SEQ ID NO: 1033) ARDRGSAETFDY (SEQ ID NO: 1034) QSISSY (SEQ ID NO: 1035) AAS (SEQ ID NO: 1036) QQSYSTPLT (SEQ ID NO: 1037) I23RB272 GFTFSSYA (SEQ ID NO: 1038) ISGSGGST (SEQ ID NO: 1039) ARDFGEPNGGFDY (SEQ ID NO: 1040) QSVSSSY (SEQ ID NO: 1041) GAS (SEQ ID NO: 1042) QQYGSSPLT (SEQ ID NO: 1043) I23RB273 GFTFSSYA (SEQ ID NO: 1044) ISGSGGST (SEQ ID NO: 1045) ARDPSSYYYNGYLGSYAFDY (SEQ ID NO: 1046) QSISSY (SEQ ID NO: 1047) AAS (SEQ ID NO: 1048) QQSYSTPLT (SEQ ID NO: 1049) I23RB274 GFTFSSYA (SEQ ID NO: 1050) ISGSGGST (SEQ ID NO: 1051) AREDATDSSDYYFDY (SEQ ID NO: 1052) QSISSY (SEQ ID NO: 1053) AAS (SEQ ID NO: 1054) QQSYSTPLT (SEQ ID NO: 1055) I23RB275 GFTFSDSG (SEQ ID NO: 1056) IDGSGGTT (SEQ ID NO: 1057) ARGSGGYVGYGGFDY (SEQ ID NO: 1058) QSISSY (SEQ ID NO: 1059) AAS (SEQ ID NO: 1060) QQSYSTPLT (SEQ ID NO: 1061) I23RB276 GFTFSNYA (SEQ ID NO: 1062) ISGSGGST (SEQ ID NO: 1063) ARDGSYGYRGRRRRYYDYFDY (SEQ ID NO: 1064) QSISSY (SEQ ID NO: 1065) AAS (SEQ ID NO: 1066) QQSYSTPLT (SEQ ID NO: 1067) I23RB277 GFTFSSYA (SEQ ID NO: 1068) ISGSGGST (SEQ ID NO: 1069) ARRRRYRYFDY (SEQ ID NO: 1070) QSISSY (SEQ ID NO: 1071) AAS (SEQ ID NO: 1072) QQSYSTPLT (SEQ ID NO: 1073) I23RB278 GFTFSSYA (SEQ ID NO: 1074) ISGSGGST (SEQ ID NO: 1075) VRGGSLGGGFYFDY (SEQ ID NO: 1076) QSVSSSY (SEQ ID NO: 1077) GAS (SEQ ID NO: 1078) QQYGSSPLT (SEQ ID NO: 1079) I23RB279 GFTFDTYA (SEQ ID NO: 1080) ISGEGGST (SEQ ID NO: 1081) ARDLGAYNRPFYAFDY (SEQ ID NO: 1082) QSISSY (SEQ ID NO: 1083) AAS (SEQ ID NO: 1084) QQSYSTPLT (SEQ ID NO: 1085) I23RB280 GFTFSNAA (SEQ ID NO: 1086) IDGSGGYT (SEQ ID NO: 1087) ARELYSYLGSSYYYGYFDY (SEQ ID NO: 1088) QSVSSSY (SEQ ID NO: 1089) GAS (SEQ ID NO: 1090) QQYGSSPLT (SEQ ID NO: 1091) I23RB281 GFTFSSYA (SEQ ID NO: 1092) ISGSGGST (SEQ ID NO: 1093) ARGPYYSGTSGYRSGGGFDY (SEQ ID NO: 1094) QSISSY (SEQ ID NO: 1095) AAS (SEQ ID NO: 1096) QQSYSTPLT (SEQ ID NO: 1097) I23RB282 GFTFSNDA (SEQ ID NO: 1098) IDGNGGST (SEQ ID NO: 1099) ARDLGGYYGRRRRYYGMDV (SEQ ID NO: 1100) QSISSY (SEQ ID NO: 1101) AAS (SEQ ID NO: 1102) QQSYSTPLT (SEQ ID NO: 1103) I23RB283 GFTFSSSA (SEQ ID NO: 1104) IDGEGGST (SEQ ID NO: 1105) AREVSSYGRYGFGY (SEQ ID NO: 1106) QSVSSSY (SEQ ID NO: 1107) GAS (SEQ ID NO: 1108) QQYGSSPLT (SEQ ID NO: 1109) I23RB284 GFTFSSYA (SEQ ID NO: 1110) ISGSGGST (SEQ ID NO: 1111) ARGLAGNSSGGGFDY (SEQ ID NO: 1112) QSISSY (SEQ ID NO: 1113) AAS (SEQ ID NO: 1114) QQSYSTPLT (SEQ ID NO: 1115) I23RB285 GFTFDDYA (SEQ ID NO: 1116) IAGNGGST (SEQ ID NO: 1117) ARDGGYPLTAVTGIYFDY (SEQ ID NO: 1118) QSISSY (SEQ ID NO: 1119) AAS (SEQ ID NO: 1120) QQSYSTPLT (SEQ ID NO: 1121) I23RB286 GFTFSDAG (SEQ ID NO: 1122) ISGNGGST (SEQ ID NO: 1123) ARRRRASFDY (SEQ ID NO: 1124) QSISSY (SEQ ID NO: 1125) AAS (SEQ ID NO: 1126) QQSYSTPLT (SEQ ID NO: 1127) I23RB287 GYSFTDAA (SEQ ID NO: 1128) IDPGDSTT (SEQ ID NO: 1129) ARDLYYTLEYNWYYDAFDY (SEQ ID NO: 1130) QSVSSSY (SEQ ID NO: 1131) GAS (SEQ ID NO: 1132) QQYGSSPLT (SEQ ID NO: 1133) I23RB288 GYSFKSDW (SEQ ID NO: 1134) IYPGDSRT (SEQ ID NO: 1135) ARDSSYGTGNRGGRSGAFDY (SEQ ID NO: 1136) QSVSSSY (SEQ ID NO: 1137) GAS (SEQ ID NO: 1138) QQYGSSPLT (SEQ ID NO: 1139) I23RB289 GYSFDSAG (SEQ ID NO: 1140) IYPGDSDT (SEQ ID NO: 1141) ARGGGSLGFDY (SEQ ID NO: 1142) QSISSY (SEQ ID NO: 1143) AAS (SEQ ID NO: 1144) QQSYSTPLT (SEQ ID NO: 1145) I23RB290 GYSFKNDG (SEQ ID NO: 1146) IAPGESTT (SEQ ID NO: 1147) ARDLGGYGSASGRRSDYFDY (SEQ ID NO: 1148) QSISSY (SEQ ID NO: 1149) AAS (SEQ ID NO: 1150) QQSYSTPLT (SEQ ID NO: 1151) I23RB291 GYSFTSYY (SEQ ID NO: 1152) IYPGDSRT (SEQ ID NO: 1153) ARDRYYGIPFDY (SEQ ID NO: 1154) QSVSSY (SEQ ID NO: 1155) DAS (SEQ ID NO: 1156) QQRSNWPLT (SEQ ID NO: 1157) I23RB292 GYSFDTDY (SEQ ID NO: 1158) ILPGESDT (SEQ ID NO: 1159) ARGGGYGLVNRRRRSYAFDY (SEQ ID NO: 1160) QSISSY (SEQ ID NO: 1161) AAS (SEQ ID NO: 1162) QQSYSTPLT (SEQ ID NO: 1163) I23RB313 GGTFSSYG (SEQ ID NO: 1164) ISAIFGTT (SEQ ID NO: 1165) ARGTVPGFDY (SEQ ID NO: 1166) QSIGED (SEQ ID NO: 1167) AAS (SEQ ID NO: 1168) QQSYSTPLT (SEQ ID NO: 1169) I23RB314 GGTFSSYG (SEQ ID NO: 1170) ISPIFGTA (SEQ ID NO: 1171) ARMMMQGFDY (SEQ ID NO: 1172) QSISED (SEQ ID NO: 1173) AAS (SEQ ID NO: 1174) QQSYSTPLT (SEQ ID NO: 1175) I23RB315 GDTFSSYA (SEQ ID NO: 1176) ISAIFGNA (SEQ ID NO: 1177) ARGAGWTLLLDY (SEQ ID NO: 1178) QSVRKW (SEQ ID NO: 1179) AAS (SEQ ID NO: 1180) QQYNNAPLT (SEQ ID NO: 1181) I23RB316 GGTFSSYG (SEQ ID NO: 1182) IIPIFGTT (SEQ ID NO: 1183) ARMMMQSLDY (SEQ ID NO: 1184) QSISND (SEQ ID NO: 1185) AAS (SEQ ID NO: 1186) QQSYSTPLT (SEQ ID NO: 1187) I23RB317 GGTFSSYA (SEQ ID NO: 1188) IIPIFGTA (SEQ ID NO: 1189) ARGNGVNYHSELDY (SEQ ID NO: 1190) QSVDSF (SEQ ID NO: 1191) TAS (SEQ ID NO: 1192) QQGNSAPFT (SEQ ID NO: 1193) I23RB318 GGTFSSYA (SEQ ID NO: 1194) IIPIFGTA (SEQ ID NO: 1195) ARVRARHRGSFDY (SEQ ID NO: 1196) QSIDRW (SEQ ID NO: 1197) YAS (SEQ ID NO: 1198) QQSYSTPLT (SEQ ID NO: 1199) I23RB319 GGTFSSYG (SEQ ID NO: 1200) ISAIFGTT (SEQ ID NO: 1201) ARPLKQAFDY (SEQ ID NO: 1202) QSITDD (SEQ ID NO: 1203) AAS (SEQ ID NO: 1204) QQSYSTPLT (SEQ ID NO: 1205) I23RB320 GGTFSSYG (SEQ ID NO: 1206) ISAIFGTT (SEQ ID NO: 1207) ARNGTGNSFDY (SEQ ID NO: 1208) QSITSD (SEQ ID NO: 1209) AAS (SEQ ID NO: 1210) QQSYSTPLT (SEQ ID NO: 1211) I23RB321 GGTFSSYG (SEQ ID NO: 1212) ISAIFGTT (SEQ ID NO: 1213) ARHWLQSFDY (SEQ ID NO: 1214) QSIGGD (SEQ ID NO: 1215) AAS (SEQ ID NO: 1216) QQSYSTPLT (SEQ ID NO: 1217) I23RB328 GGTFSSYA (SEQ ID NO: 1218) IIPIFGTA (SEQ ID NO: 1219) ARGRYIRSYDYFDY (SEQ ID NO: 1220) QSVSSY (SEQ ID NO: 1221) DAS (SEQ ID NO: 1222) QQRNSTPLT (SEQ ID NO: 1223) I23RB329 GGTFSSYA (SEQ ID NO: 1224) IIPIFGTA (SEQ ID NO: 1225) ARDSYYSTVTYYYFDY (SEQ ID NO: 1226) QSVSSY (SEQ ID NO: 1227) DAS (SEQ ID NO: 1228) QQRSNTPLT (SEQ ID NO: 1229) I23RB330 GGTFSSYA (SEQ ID NO: 1230) IIPIFGTA (SEQ ID NO: 1231) ARDRSYSYGLSGLGYYGFDY (SEQ ID NO: 1232) QSVSSY (SEQ ID NO: 1233) DAS (SEQ ID NO: 1234) QQRSNTPLT (SEQ ID NO: 1235) I23RB332 GYTFTSYW (SEQ ID NO: 1236) IDPSDSYT (SEQ ID NO: 1237) ARSYAFDY (SEQ ID NO: 1238) QSVDYDGDSY (SEQ ID NO: 1239) AAS (SEQ ID NO: 1240) QQSNEDPWT (SEQ ID NO: 1241) Example 2 : Binding Kinetics and Affinity Measurements

The affinity of IL-23R mAbs for human and rat IL-23R ECD proteins was determined by surface plasmon resonance (SPR) and biolayer interferometry (BLI) methods using purified and unpurified mAbs. BLI was also used to determine how many different epitopes on the human IL-23R ECD were bound by a panel of immunized and phage display-derived IL-23R mAbs through competition binding experiments. A commercially available IL-23R mAb was included in the binding study to the IL-23R protein for comparison. Commercially available antibody systems evaluated: anti-IL23R, Rab Mab, strain EPR22838-4, AbCam cat #222104; anti-IL23R, mouse IgG2b, strain #218213, R&D cat #MAB14001; anti-IL23R, mouse IgG1, strain Strain #15N6C6, ThermoFisher cat #MA5-24804; Anti-IL23R, Mouse IgG1, Colony #ABM25G4, Abcam cat #ABM25G4; Anti-IL23R, Mouse IgG2b, LSBio cat #LS-C37068; Anti-IL23R, Mouse IgG2a, LSBio cat #LS-C308468; and anti-IL23R, mouse IgG1, strain #5H9, LSBio cat #LS-C340289. Affinity measurement

Surface plasmon resonance (SPR) and biolayer interferometry are calibration-free detection methods for exploring biomolecular interactions. These direct and real-time binding assays provide qualitative and quantitative data on interactions between biomolecules by monitoring small changes in mass on the sensor surface; i.e. determination of equilibrium binding constants (affinity, KD) and kinetic rate constants (ka/kd; complex association rate ka and complex dissociation rate kd). This method is useful for studying protein-protein and protein-nucleic acid interactions, as well as interactions between proteins and small molecules. Here, the interaction between IL-23R antibody and human IL-23R and rat IL-23R extracellular domain (ECD) proteins is explored.

The human IL-23R ECD sequence (SEQ ID NO: 1) is provided in Table 3 above. Sequence comparison and alignment of human and rat IL-23R ectodomain sequences showed 76.74% sequence identity. The rat IL-23R ECD sequence (F1LX96 amino acids 24 to 354) is provided below: GIATINCSGNMWVEPGEIFQMGMNVSVYCQEALKNCRPRNLHFYKNGFKERFHITRINRTTARVWYKGFSEPHASMYCTAECPGRFQETLICGKDISSGYPPDAPSNMTCVIYEYSGNMTCTWNTGKPTYIDTKYTVHVKSLETEEQQQYLASNYVNISTDSLQGGRKYLVW VQAVNAGMENSQQLQVHLDDIVIPSPSIISRAETTNANVPKTIIYWKSKIMTGKVFCEMRYKATTNQTWNVKEFDTNYTYVQQSEFYLEPNSKYVFQVRCQGTGKRNWQPWSSPFVHQTPQTASQVTSKPPHEPQKIEMLTATIFKGHSTSDNSQDIG (SEQ ID NO: 126 7)

Affinity measured by SPR using ProteOn . Affinity measurements using surface plasmon resonance (SPR) were performed using the ProteOn XPR36 system (BioRad). Prepared by coupling anti-mouse IgG Fc (Jackson cat# 315-005-046) to the surface of a modified alginate polymer layer of a GLC wafer (BioRad, Cat# 176-5011) using the manufacturer's instructions for amine coupling chemistry Biosensor surface. Approximately 6000 RU (response units) of mAb were immobilized. Kinetic experiments were performed in electrophoresis buffer (DPBS+0.01%P20+100 µg/ml BSA) at 25°C. To perform kinetic experiments, approximately 250 RU of mAb were captured and subsequently injected with human IL-23R at concentrations ranging from 1.56 nM to 400 nM (in 4-fold serial dilutions). Monitor the association phase at 50 µL/min for 3 min, followed by 10 min of buffer flow (dissociation phase). The wafer surface was regenerated using two 18 sec pulses of 100 mM H3PO4 (Sigma, Cat#7961) at 100 µL/min. The collected data is processed using ProteOn Manager software. First, the data were corrected for background using interpoints. Next, double reference subtraction of the data was performed by using buffer injection for analyte injection. Kinetic analysis of the data was performed using the Langmuir 1:1 binding model. Results for each mAb are presented in Ka (on rate), Kd (off rate), and KD (equilibrium dissociation constant) formats.

Affinity measured by SPR using Biacore 8K . Affinity measurements using surface plasmon resonance (SPR) were performed using a Biacore 8K system (Cytiva). The biosensor surface was prepared by coupling anti-mouse IgG Fc (Jackson cat# 315-005-046) to the surface of a CM5 wafer using the manufacturer's instructions for amine coupling chemistry. Approximately 9000 to 10000 RU (response units) of mAb were immobilized. Kinetic experiments were performed in electrophoresis buffer 1X (HBS-P + buffer 10X (Cytiva# BR100671) + 100 µg/ml BSA) at 25°C. To perform kinetic experiments, approximately 150 RU of mAb were captured and subsequently injected with either human IL-23R or rat IL-23R at concentrations ranging from 0.8 nM to 500 nM (in 5-fold serial dilutions). Monitor the association phase at 50 µL/min for 3 min, followed by 30 min of buffer flow (dissociation phase). The wafer surface was regenerated using four 20 sec pulses of 0.85% H3PO4 (Sigma, Cat#7961) at 100 µL/min. The collected data were processed using Biacore insight Evaluation software (version 3.0.12.15655). Kinetic analysis of the data was performed using the Langmuir 1:1 binding model. Results for each mAb are presented in Ka (on rate), Kd (off rate), and KD (equilibrium dissociation constant) formats.

Affinity determined by BLI using Octet Red 384 . Affinity measurements using biolayer interferometry (BLI) were performed using an Octet Red 384 system (Sartorius). Antibodies were loaded onto a protein A biosensor (Sartorius, Cat#18-5010) to an offset of approximately 1 nm. Kinetic experiments were performed in electrophoresis buffer (DPBS + 0.02% P20 + 1 mg/ml BSA) at 25°C. To perform kinetic experiments, both human and rat IL-23R were associated at concentrations ranging from 1.37 nM to 1000 nM (in 3-fold serial dilutions). The association phase was monitored by shaking at 1000 rpm for 3 minutes, followed by dissociation in the buffer by shaking at 1000 rpm for 5 minutes. The collected data were processed using Octet Evaluation software (version 10). Kinetic analysis of the data was performed using the Langmuir 1:1 binding model. Results for each mAb are presented in Ka (on rate), Kd (off rate), and KD (equilibrium dissociation constant) formats.

Six of seven commercially available mAbs tested for binding kinetics by SPR or BLI were mouse IgG mAbs with weak signal above background at the highest concentration of 4 uM tested for human IL-23R ectodomain protein (ECD) or No binding. A commercially available Abcam Rabbit Monoclonal Antibody (RabMab) (Cat# 222104) showed slightly stronger binding to human IL-23R ECD than the other 6 commercially available mAbs, but with a KD value >100nM. The mAbs derived from phage panning and human IL-23R immunization had affinities ranging from <51 pM to >263 nM and all had better human IL-23R ECD binding affinity than the commercially available R&D Systems human IL-23R mAb MAB14001. MAB14001 shows no binding to human IL-23R ECD in SPR, but has measurable binding to human IL-23R expressing cells in flow cytometry experiments. Most phage-displayed and immune-derived mAbs also have better binding affinity to human IL-23R ECD than Abcam mAb (catalog # 222104). Only some human IL-23R mAbs showed binding to rat IL-23R ECD. The commercially available human IL-23R binding mAbs and the affinity determinations of those derived from phage panning and human IL-23R immunizations are summarized in Table 10.

Antibodies I23RB5, I23RB101, I23RB6, I23RB8, I23RB9, I23RB10, and I23RB80 showed no binding or undetectable or very weak binding in the assays provided in Table 10. Other antibodies I23RB104, I23RB149, I23RB189, I23RB273, I23RB278, I23RB328, I23RB329, I23RB330, and I23RB332 showed no binding or undetectable or very weak binding. These antibodies can be used in experiments and assays including as negative control antibodies, providing "true" negatives that are procedurally isolated from the IL23R binders herein. For example, I23RB5 is used as a negative control in a variety of experiments and assays including those provided herein. Table 10. Affinity of IL-23R mAb to human and rat IL-23R ECD Using BIACORE 8K SPR data Binds to human IL-23R ECD (Assay 1 ) Binding to human IL-23R ECD (Assay 2 ) Binds to rat IL-23R ECD sample type mAb ID ka (1/Ms) kd (1/s) KD (M) annotation ka (1/Ms) kd (1/s) KD (M) annotation ka (1/Ms) kd (1/s) KD (M) purified protein I23RB1 3.99E+05 1.11E-03 2.80E-09 undetectable bond I23RB3 5.36E+04 2.55E-04 4.76E-09 undetectable bond I23RB4 2.30E+05 1.35E-04 5.88E-10 undetectable bond I23RB5 non-conjugate undetectable bond I23RB7 1.99E+05 2.46E-04 1.23E-09 2.42E+04 1.27E-02 5.24E-07 I23RB94 7.87E+05 6.30E-04 8.00E-10 6.56E+05 7.53E-04 1.15E-09 undetectable bond I23RB92 2.65E+05 <2.89E-05 <1.09E-10 slow dissociation rate 2.40E+05 <2.89E-05 <1.20E-10 slow dissociation rate undetectable bond I23RB76 6.31E+05 5.62E-05 8.91E-11 4.82E+05 4.14E-05 8.59E-11 undetectable bond I23RB65 4.84E+05 <2.89E-05 <5.97E-11 slow dissociation rate 4.00E+05 <2.89E-05 <7.23E-11 slow dissociation rate undetectable bond I23RB42 7.95E+05 5.76E-05 7.25E-11 5.35E+05 6.25E-05 1.17E-10 1.26E+05 8.77E-02 9.51E-07 I23RB32 5.50E+05 1.82E-04 3.32E-10 5.06E+05 1.72E-04 3.40E-10 undetectable bond I23RB157 3.04E+05 8.68E-04 2.86E-09 2.30E+05 9.47E-04 4.12E-09 6.91E+04 5.48E-03 8.11E-08 I23RB33 9.57E+05 1.55E-04 1.62E-10 6.91E+05 1.49E-04 2.16E-10 undetectable bond I23RB47 4.53E+05 5.17E-05 1.14E-10 undetectable bond I23RB35 5.49E+05 <2.89E-05 <5.27E-11 slow dissociation rate 4.21E+05 <2.89E-05 <6.87E-11 slow dissociation rate undetectable bond I23RB101 no binding non-conjugate undetectable bond Unpurified protein in crude supernatant expressed in mammalian cells I23RB1 3.76E+05 9.82E-04 2.62E-09 undetectable bond I23RB3 5.83E+04 2.33E-04 3.99E-09 undetectable bond I23RB4 2.54E+05 1.21E-04 4.77E-10 undetectable bond I23RB5 non-conjugate undetectable bond I23RB7 2.00E+05 2.47E-04 1.23E-09 undetectable bond I23RB94 6.85E+05 6.86E-04 1.00E-09 undetectable bond I23RB92 2.33E+05 <2.89E-05 <1.24E-10 slow dissociation rate undetectable bond I23RB76 4.84E+05 3.90E-05 8.05E-11 undetectable bond I23RB65 4.16E+05 4.58E-05 1.10E-10 undetectable bond I23RB42 5.82E+05 6.29E-05 1.08E-10 undetectable bond I23RB32 non-conjugate undetectable bond I23RB157 2.38E+05 9.46E-04 3.97E-09 2.97E+03 5.83E-03 1.96E-06 I23RB33 6.72E+05 1.46E-04 2.18E-10 undetectable bond I23RB47 5.66E+05 <2.89E-05 <5.10E-11 slow dissociation rate 4.45E+05 5.32E-05 1.19E-10 undetectable bond I23RB35 3.72E+05 <2.89E-05 <7.77E-11 slow dissociation rate undetectable bond I23RB318 7.84E+04 1.67E-03 2.13E-08 7.29E+04 1.56E-03 2.14E-08 undetectable bond I23RB313 5.80E+03 <2.89E-05 <4.98E-09 slow dissociation rate 2.23E+04 1.08E-04 4.85E-09 undetectable bond I23RB270 5.35E+05 1.02E-03 1.91E-09 4.09E+05 1.01E-03 2.46E-09 undetectable bond I23RB269 4.73E+05 5.14E-04 1.09E-09 3.85E+05 5.42E-04 1.41E-09 undetectable bond I23RB268 2.28E+04 2.73E-04 1.20E-08 1.63E+04 3.08E-04 1.89E-08 undetectable bond I23RB267 1.08E+04 1.96E-04 1.81E-08 2.35E+04 1.78E-04 7.56E-09 undetectable bond I23RB102 4.71E+05 8.73E-03 1.85E-08 undetectable bond I23RB98 7.51E+04 2.94E-03 3.91E-08 1.36E+05 3.50E-03 2.58E-08 undetectable bond I23RB93 4.80E+05 1.38E-03 2.88E-09 4.23E+05 1.23E-03 2.90E-09 undetectable bond I23RB87 8.65E+04 9.45E-04 1.09E-08 undetectable bond I23RB86 7.28E+04 5.87E-04 8.06E-09 7.03E+04 5.72E-04 8.14E-09 undetectable bond I23RB85 2.10E+05 2.26E-04 1.08E-09 1.24E+05 1.78E-04 1.43E-09 undetectable bond I23RB83 3.25E+05 1.19E-04 3.66E-10 1.72E+05 5.91E-05 3.45E-10 undetectable bond I23RB82 5.29E+05 2.47E-03 4.67E-09 3.97E+05 1.36E-02 3.44E-08 undetectable bond I23RB81 Nonconjugates (possibly switched with I23RB80**) 1.95E+05 1.73E-03 8.89E-09 undetectable bond I23RB80 7.74E+05 1.04E-02 1.34E-08 ** no binding undetectable bond I23RB78 1.79E+05 7.74E-04 4.33E-09 undetectable bond I23RB77 1.39E+06 2.14E-03 1.54E-09 5.56E+05 1.00E-02 1.80E-08 undetectable bond I23RB74 non-conjugate 9.54E+05 2.22E-03 2.33E-09 undetectable bond I23RB73 3.22E+05 3.78E-03 1.17E-08 2.13E+05 2.93E-03 1.37E-08 undetectable bond I23RB71 7.04E+05 2.31E-04 3.28E-10 3.58E+05 4.63E-05 1.29E-10 undetectable bond I23RB67 6.77E+05 1.72E-02 2.54E-08 undetectable bond I23RB61 4.59E+05 1.01E-02 2.21E-08 3.55E+05 1.95E-03 5.50E-09 undetectable bond I23RB60 2.98E+05 2.18E-04 7.31E-10 3.62E+05 1.69E-04 4.66E-10 undetectable bond I23RB58 3.28E+05 5.32E-03 1.62E-08 2.33E+05 5.23E-03 2.25E-08 undetectable bond I23RB57 1.02E+05 2.99E-03 2.92E-08 8.07E+04 3.07E-03 3.81E-08 undetectable bond I23RB56 1.68E+05 1.15E-02 6.84E-08 3.52E+05 8.98E-03 2.55E-08 8.97E+04 6.42E-02 7.15E-07 I23RB54 5.34E+05 9.79E-02 1.83E-07 undetectable bond I23RB45 1.58E+05 3.32E-03 2.10E-08 2.03E+05 4.56E-03 2.25E-08 2.01E+03 3.43E-03 1.71E-07 I23RB39 2.31E+05 7.39E-03 3.20E-08 4.82E+05 7.16E-03 1.49E-08 undetectable bond I23RB36 8.64E+04 1.18E-03 1.37E-08 5.92E+05 1.29E-03 2.18E-09 undetectable bond I23RB31 6.55E+04 1.23E-03 1.89E-08 9.13E+04 7.81E-04 8.55E-09 undetectable bond I23RB30 2.20E+05 1.01E-02 4.62E-08 2.12E+05 7.63E-03 3.59E-08 2.98E+04 9.09E-03 3.06E-07 I23RB27 3.25E+05 3.72E-03 1.14E-08 2.23E+05 4.16E-03 1.87E-08 undetectable bond I23RB188 9.82E+04 1.30E-03 1.33E-08 7.98E+04 1.51E-03 1.89E-08 undetectable bond I23RB182 3.89E+04 1.94E-03 4.98E-08 9.02E+04 3.94E-03 4.37E-08 undetectable bond I23RB173 2.96E+05 7.59E-03 2.57E-08 2.85E+05 1.03E-02 3.61E-08 undetectable bond I23RB169 1.28E+05 1.16E-02 9.13E-08 1.23E+05 4.27E-03 3.48E-08 undetectable bond I23RB168 4.24E+05 1.18E-04 2.79E-10 3.68E+05 1.55E-04 4.22E-10 undetectable bond I23RB166 4.47E+05 1.93E-02 4.31E-08 2.14E+05 9.42E-03 4.41E-08 undetectable bond I23RB165 4.46E+05 8.06E-03 1.81E-08 3.24E+05 9.41E-03 2.91E-08 undetectable bond I23RB162 5.31E+05 2.37E-02 4.46E-08 3.47E+05 2.16E-02 6.22E-08 undetectable bond I23RB160 5.67E+05 9.55E-03 1.69E-08 1.02E+06 1.42E-02 1.38E-08 undetectable bond I23RB156 5.42E+05 2.18E-04 4.03E-10 4.41E+05 2.59E-04 5.88E-10 undetectable bond I23RB155 3.69E+05 <2.89E-05 <7.84E-11 slow dissociation rate 2.39E+05 <2.89E-05 <1.21E-10 slow dissociation rate undetectable bond I23RB153 1.38E+05 2.26E-04 1.64E-09 1.37E+05 3.18E-04 2.33E-09 5.95E+04 5.48E-03 9.21E-08 I23RB150 3.41E+05 3.29E-02 9.65E-08 3.34E+05 3.76E-02 1.12E-07 undetectable bond I23RB148 5.25E+05 4.59E-04 8.74E-10 4.98E+05 3.82E-04 7.66E-10 undetectable bond I23RB144 8.90E+04 2.72E-03 3.06E-08 5.20E+04 2.77E-03 5.33E-08 undetectable bond I23RB260 1.84E+04 8.72E-05 4.75E-09 I23RB91 2.14E+04 1.10E-04 5.15E-09 I23RB177 1.88E+04 1.07E-04 5.70E-09 I23RB319 8.85E+03 8.01E-05 9.05E-09 I23RB259 5.59E+04 7.52E-04 1.34E-08 I23RB264 4.74E+04 8.47E-04 1.79E-08 I23RB321 2.09E+04 3.84E-04 1.84E-08 I23RB261 1.79E+04 4.02E-04 2.25E-08 I23RB317 2.36E+04 5.96E-04 2.52E-08 I23RB161 3.24E+05 2.74E-02 8.45E-08 I23RB180 2.01E+05 3.02E-02 1.50E-07 I23RB69 1.88E+05 4.93E-02 2.63E-07 SPR data using ProteOn BLI data using Octet Binds to human IL-23R ECD Binds to human IL-23R ECD Binds to rat IL-23R ECD sample type mAb ID ka (1/Ms) kd (1/s) KD (M) ka (1/Ms) kd (1/s) KD (M) annotation ka (1/Ms) kd (1/s) KD (M) purified protein I23RB1 3.45E+06 2.29E-03 6.67E-10 I23RB2 weak binding >4.00E-6 I23RB3 1.74E+05 3.35E-04 1.92E-09 I23RB4 1.56E+06 2.35E-04 1.51E-10 I23RB5 undetectable bond I23RB6 undetectable bond I23RB7 5.81E+05 2.26E-04 3.90E-10 I23RB8 undetectable bond I23RB9 undetectable bond I23RB10 undetectable bond I23RB157 8.56E+04 6.60E-05 7.71E-10 estimated value 7.34E+04 5.81E-03 7.91E-08 Commercially available antibodies Anti-IL-23R, Rab Mab, clone EPR22838-4, AbCam cat #222104 weak binding >1.00E-7 3.42E+04 6.78E-04 3.13E-08 Anti-IL-23R, Mouse IgG2b, strain #218213, R&D cat #MAB14001 undetectable bond Anti-IL-23R, Mouse IgG1, strain #15N6C6, ThermoFisher cat #MA5-24804 weak binding >4.00E-6 Anti-IL-23R, mouse IgG1, strain #ABM25G4, Abcam cat #ABM25G4 weak binding >4.00E-6 Anti-IL-23R, Mouse IgG2b, LSBio cat #LS-C37068 undetectable bond Anti-IL-23R, Mouse IgG2a, LSBio cat #LS-C308468 undetectable bond Anti-IL-23R, mouse IgG1, strain #5H9, LSBio cat #LS-C340289 weak binding >4.00E-6 Note: Sample not analyzed * If koff is slower than the dissociation limit imposed by the time of data collection, then koff is reported as < koff limit (Koff is < 2.89E-05) * Undetectable binding = not measurable at up to the highest concentration of test antigen Binding Signal * Weak Binding = weak binding signal above background at the highest concentration of test antigen IL-23R mAb epitope binning

Recombinant mAbs derived from human IL-23R phage panning and immunization were paired and evaluated for competitive binding to human IL-23R ECD using biolayer interferometry (BLI) performed on a Sartorius Octet Red 384 instrument to combine them with Grouping into epitope bins where competing mAbs are grouped in the same bin or overlapping bins. If any mAb showed no competition when paired with other mAbs, they were classified into their own unique bin. Sufficient binding affinities and/or concentrations were required to interpret competitive binding results, and mAbs with too low affinities and/or concentrations were not included in the bin of epitopes considered indeterminate. The 4 purified antibodies from phage panning and 11 purified antibodies from immunization campaigns that exhibited the strongest binding to IL-23R protein were paired with each other into a full matrix. The remaining mAbs derived from immunization or phage display were evaluated as unpurified mAb protein in the supernatant and only binned against the highest affinity purified mAb from each bin.

Binning of epitopes detected by BLI using Octet Red 384 . Epitope binning using biolayer interferometry (BLI) was performed using the Octet Red 384 system (Sartorius). To perform epitope binning, experiments were performed at 25°C in electrophoresis buffer (DPBS + 0.02% P20 + 1 mg/ml BSA). Biotinylated human IL-23R was loaded onto a streptavidin biosensor (Sartorius, Cat#18-5019) to an offset of approximately 1 nm. Antibodies were diluted to an allowable concentration of 333nM. Antibody 1 was allowed to associate for 2 minutes. Excess was removed by washing with 20 sec immersion in assay buffer. Antibody 2 was allowed to associate for 2 minutes. The collected data were processed using the epitope binning module and Octet Evaluation software (version 10).

Thirty-seven anti-IL-23R mAbs derived from phage panning and immunization were evaluated in epitope binning experiments, resulting in at least nine unique bins covering 32 of the 37 tested mAbs. Three of the remaining five mAbs belonged to unique bins and these mAbs were not paired with each other, so it is not possible to know whether they share the same epitope bin or if there are additional bins within this group. The epitope bins and the mAbs included in each are summarized in Table 11. The diverse set of IL-23R binding sites reflected in these 9(+) epitope bins indicates that the set of IL-23R mAbs provides a range of IL-23R mAb:IL-23R interactions in contrast to the single binding site of MAB14001 , which can improve receptor binding/detection through multiplexing (using a cocktail of multiple IL-23R mAbs that act in a non-competitive manner to enhance signal) or by targeting specific epitopes that are more accessible to mAb binding. Table 11. Epitope binning of human IL-23R binding mAbs on human IL-23R warehouse mAb ID 1 I23RB42* I23RB85 I23RB157* 2 I23RB32* I23RB33* I23RB39 I23RB60 I23RB65* I23RB92* I23RB94* I23RB156 I23RB160 I23RB162 3 I23RB1* I23RB3* I23RB4* I23RB76* I23RB269 I23RB270 4 I23RB35* I23RB93 I23RB155 5 I23RB7* 6 (2 & 5) I23RB47* I23RB83 I23RB148 I23RB168 7 (2) I23RB153 8 (3 & 4) I23RB36 I23RB78 9 (3, 5 & 6) I23RB45 I23RB318 unique I23RB74 I23RB77 I23RB102 uncertain I23RB71 I23RB313 AbCam Ab222104

Anti-IL-23R mAbs (unpurified and purified* in supernatant) were grouped into 9 bins using BLI (Octet RED384) as shown in Table 11. mAbs in bins 6, 7, 8, and 9 were defined as showing competition with at least one mAb in the previously identified bin(s) shown in brackets. I23RB74, I23RB77, and I23RB102 were listed as unique based on not competing with the purified antibodies of the tested alignments. These antibodies have not been tested against each other, so they may or may not be in separate bins. mAbs listed as indeterminate were samples that were likely too low in concentration or too weak in affinity to determine the results. Binding to human IL-23R transfected cell lines

Recombinant human IL-23R binding mAbs derived from phage panning and immunization were tested for binding to cell surface human IL-23R expressed on stably transfected iLite and/or HEK cell lines using flow cytometry. mAbs were tested using single or multiple mAb concentrations as purified protein or unpurified protein in crude mammalian cell expression supernatants. Whether IL-23R mAbs can bind primary human cells expressing IL-23R was also determined by flow cytometry, but only purified mAbs were used. A commercially available IL-23R mAb was included in the binding study to IL-23R expressing cells for comparison.

Single concentration mAb binding to human IL-23R iLiTe cells . Anti-IL-23R mouse IgG _2a mAb derived from phage panning was tested for binding to human IL-23R expressing iLiTe cells, in which a PE-conjugated anti-mouse secondary antibody detected the mAb bound to the receptor on the cells. Human IL-23R expressing iLite ^® IL-23 Assay Ready Cells (Eurodiagnostica, catalog # BM4023) were thawed from cryopreservation and placed in 10% FBS (Gibco Life-Technologies, catalog # 16140-063) and 1% penicillin- Streptomycin (Gibco Life-Technologies, catalog # 15140-122) in 25 mL RPMI-1640 plus GlutaMAX-1 (ThermoFisher Scientific, catalog # 72400-047) and incubated overnight at 37°C, 5% CO ₂ . The next day, 100,000 cells were added to each well of a 96-well V-chassis plate (Costar, cat# 3357), centrifuged at 450x gravity for 2 minutes, and the supernatant was decanted. Cells were then resuspended in 100 µL/well of 10% Human Serum (Valley Biomedical, Cat# HP1022) in 1xDPBS (Gibco Life-Technologies, Cat# 14190-136) and incubated on ice for 30 minutes, followed by centrifugation and decanting. Analyze the supernatant. Antibody diluted to 3 µg/mL in Staining Buffer (BSA) (BD Pharmagen, Cat# 554657) was added at 100 µL/well and incubated on ice for 50 minutes, then the disc was centrifuged and the supernatant decanted . Goat anti-mouse PE-conjugated secondary antibody (Jackson ImmunoResearch, catalog # 115-116-146) diluted 1:200 in staining buffer was added at 100 µL/well and incubated on ice for 30 minutes, followed by centrifugation and Decant the supernatant. Cells were washed by adding 100 µL/well of staining buffer, followed by centrifugation and decanting of the supernatant. Cells were resuspended in 100 µL/well of staining buffer and analyzed on a Becton Dickenson LSR II FACS instrument equipped with an HTS module. Data were analyzed using FlowJo software (Treestar) to obtain geometric mean fluorescence intensities.

Human IL-23R iLiTe cellular concentration in response to mAb binding. Concentration dependence of anti-IL-23R mouse IgG _2a mAb derived from phage panning tested against mouse IgG _2a isotype negative control mAb and commercially available MAB14001 positive control mAb from R&D Systems and human IL-23R expressing iLiTe cells Binding, where PE-conjugated anti-mouse secondary antibody detects mAb binding to the receptor on the cell. Thaw human IL-23R expressing iLite ^® IL-23 Assay Ready Cells (Eurodiagnostica, catalog # BM4023) from cryopreservation in a culture medium containing 10% FBS (Gibco Life-Technologies, catalog # 16140-063) and 1% penicillin- Streptomycin (Gibco Life-Technologies, catalog # 15140-122) in 25 mL RPMI-1640 plus GlutaMAX-1 (ThermoFisher Scientific, catalog # 72400-047) and incubated overnight at 37°C, 5% CO ₂ . The next day, 100,000 cells were added to each well of a 96-well V-chassis plate (Costar, cat# 3357), centrifuged at 450x gravity for 2 minutes, and the supernatant was decanted. Antibodies were diluted in Staining Buffer (BSA) (BD Pharmagen, Cat# 554657) and added at 50 µL/well and mixed. The discs were incubated on ice for 50 minutes, then the discs were centrifuged and the supernatant decanted. Goat anti-mouse PE-conjugated secondary antibody (Jackson ImmunoResearch, catalog # 115-116-146) diluted 1:200 in staining buffer was added at 100 µL/well and incubated on ice for 30 minutes, followed by centrifugation and Decant the supernatant. Cells were washed by adding 200 µL/well of staining buffer, followed by centrifugation and decanting of the supernatant. Cells were resuspended in 100 µL/well of staining buffer, transferred in quadruplicate to 384-well plates (Greiner, cat# 781281 ), and analyzed on a Becton Dickenson LSR II FACS instrument equipped with an HTS module. Data were analyzed using FlowJo software (Treestar) to obtain geometric mean fluorescence intensity, and a plot of geometric mean fluorescence intensity versus log mAb concentration was fitted to a sigmoid dose-response curve with variable slope using GraphPad Prism.

Five of the initial 10 phage-derived anti-IL-23R mAbs had measurable binding signals on human IL-23R iLite cells in single concentration flow cytometry experiments using purified mAb proteins, including I23RB1, I23RB2, I23RB3, I23RB4, I23RB7 (Table 12, Experiments A and B). Subsequent concentration-response binding experiments showed that all five of these mAbs bound to human IL-23R iLite cells better than the R&D Systems MAB14001 mAb, where binding was ranked in the following order: I23RB1 = I23RB4 > I23RB7 > I23RB3 > I23RB2 > MAB14001 (Table 12, Experiment C). The lack of binding repeats in I23RB5 gave the same signal as the mouse IgG _2a isotype control.

Eighty-three additional human IL-23R binding mAbs from phage panning and immunization were also tested for human IL-23R expression as purified proteins or unpurified proteins in crude expression supernatants from transiently transfected CHO cells Binding of HEK cells.

HEK-IL-23R cell concentration in response to mAb binding ( 8 -point, 96 -well assay) . Test the concentration of immunized and phage-derived anti-IL-23R mouse IgG _2a mAb relative to mouse IgG _2a negative control mAb I23RB5 that does not bind to IL-23R on cells and human IL-23R expressing HEK-IL-23R cells Dependent binding, where 647 engages an anti-mouse secondary antibody to detect antibody binding to the receptor on the cell. HEK-IL-23R and HEK parental (prelabeled with CellTrackerBlue, ThermoFisher, Cat# C2110) cells were washed with dPBS (Gibco, Cat# 14190-136), stripped with Accutase (StemCell Technologies, Cat# 7920), and resuspended In assay medium (RPMI-1640 (ThermoFisher, Cat# 11875135) with 10% fetal bovine serum (Gibco, Cat# A31604-01)), centrifuge to pellet (3 min, 600 g) and resuspend at 4800 cells/µL. HEK-IL-23R and HEK parental cells (12.5 µL each, a total of 120,000 cells) were plated in 2X replicates in 96-well V-chassis (Corning, Cat# 3357) containing serially diluted IL-23R mAb at 37°C. Heat assay medium to a final volume of 150 µL. The IL-23R mAb was allowed to bind to the cells for 30 minutes at 37°C. Cells were then washed twice with ice-cold staining buffer (BD Biosciences, Cat# 554657) and then exposed on ice to anti-mouse 647 detection antibody (Jackson ImmunoResearch, Cat# 115-606-062) 30 minutes. Cells were then washed twice with ice-cold staining buffer and then resuspended in Sytox Green viability dye (ThermoFisher, Cat # S7020) in a final volume of 30 µL. Keep the dish on ice until analytical run on the iQue. All washes were performed by centrifugation (800 rcf, 3 minutes) followed by flick decantation to remove the supernatant. Cell binding to HEK-IL-23R cells was measured by gated single, viable cells with FlowJo and determined by the geometric mean fluorescence intensity (MFI) of the 647 detection antibody. A plot of geometric mean fluorescence intensity versus log mAb concentration was fitted to a dose response curve with variable slope using GraphPad Prism. Cell binders were scored as those mAbs with an MFI signal [S] greater than the baseline MFI signal [B] + 3*StDev at the maximum concentration used, where [B] was detected by the negative control I23RB5 at an equivalent concentration to the MFI signal.

HEK-IL-23R cell concentration in response to mAb binding ( 11 points, 384- well assay) . Test the concentration of immunized and phage-derived anti-IL-23R mouse IgG _2a mAb relative to mouse IgG _2a negative control mAb I23RB5 that does not bind to IL-23R on cells and human IL-23R expressing HEK-IL-23R cells Dependent binding, where 647 engages an anti-mouse secondary antibody to detect antibody binding to the receptor on the cell. HEK-IL-23R and HEK parental (prelabeled with CellTrackerBlue, ThermoFisher, Cat# C2110) cells were washed with dPBS (Gibco, Cat# 14190-136), stripped with Accutase (StemCell Technologies, Cat# 7920), and resuspended In assay medium (RPMI-1640 (ThermoFisher, Cat# 11875135) with 10% fetal bovine serum (Gibco, Cat# A31604-01)), centrifuge to pellet (3 min, 600 g) and resuspend at 2500 cells/uL. HEK-IL-23R and HEK parental cells (10 µL each, a total of 50,000 cells) were seeded in 4X replicates in 384-well V-chassis (Greiner, Cat# 781281) containing serially diluted IL-23R mAb at 37°C Warm assay medium to a final volume of 80 µL. The IL-23R mAb was allowed to bind to the cells for 30 minutes at 37°C. Cells were then washed once with ice-cold staining buffer (BD Biosciences, Cat# 554657) and then exposed on ice to an anti-mouse 647 detection antibody (Jackson ImmunoResearch, Cat#) diluted 1:350 in ice-cold staining buffer. #115-606-062) for 30 minutes. Cells were then washed twice with ice-cold staining buffer and then resuspended in Sytox Green viability dye (ThermoFisher, Cat # S7020) in a final volume of 10 µL. Keep the dish on ice until analytical run on the iQue. All washes were performed by centrifugation (800 rcf, 3 min) followed by automatic aspiration using a dish washer to remove the supernatant. Cell binding to HEK-IL-23R cells was measured by gated single, viable cells with FlowJo and determined by the geometric mean fluorescence intensity (MFI) of the 647 detection antibody. A plot of geometric mean fluorescence intensity versus log mAb concentration was fitted to a dose response curve with variable slope using GraphPad Prism. Cell binders were scored as those mAbs with an MFI signal [S] greater than the baseline MFI signal [B] + 3*StDev at the maximum concentration used, where [B] was detected by the negative control I23RB5 at an equivalent concentration to the MFI signal.

Eleven of the 83 additional human IL-23R binding mAbs did not bind cells at a threshold above background (MFI > background * 3X Stdev). Of the 72 IL-23R mAbs that did exhibit above-background binding to IL-23R cells, EC50 values ranged from 0.1 nM to >50 nM (Table 12, Experiments D and E). Among these cell conjugates, 34 mAbs exhibited MFI (@ 6.4 nM) values exceeding I23RB3 (Table 12, Experiment E), and both I23RB3 and I23RB2 showed superior binding compared to MAB14001 [Table 12, Experiment A to C (higher MFI, lower EC50)], indicating that these 34 mAbs are also better than MAB14001 in detecting IL-23R on cells. These 34 mAbs include I23RB1, I23RB102, I23RB148, I23RB155, I23RB156, I23RB157, I23RB160, I23RB162, I23RB166, I23RB27, I23RB270, I23RB30, I23RB318, I 23RB32, I23RB33, I23RB36, I23RB39, I23RB4, I23RB42, I23RB45, I23RB47, I23RB58, I23RB65, I23RB7, I23RB73, I23RB74, I23RB76, I23RB77, I23RB81, I23RB82, I23RB86, I23RB92, I23RB93, and I23RB94. Human IL-23R binding mAbs I23RB71, I23RB165, and I23RB173 had EC50 values < 9.7 nM (Table 12, Experiment E), placing them at the > 72 percentile (ranking of mAb Experiment E EC50), and showing that their equal It is also superior to MAB14001 in detecting IL-23R on cells.

The affinity results of IL-23R binding mAbs for human IL-23R expressed on stably transfected iLite and HEK cell lines are shown in Table 12. Table 12. Binding of IL-23R mAbs to Human IL-23R Expressing Cell Lines Human IL-23R iLite Cell Binding Experiment A (1 point) Experiment B (1 point) Example C (12 points) mAb ID MFI @ 20nM MFI @ 0.7nM S ＞ B*3xStD Gate 1+2 EC50 (nM) Gate 2 EC50 (nM) commercially available MAB14001 NT 280 Y ~2.96 ~12.75 Phage-derived mAbs purified protein I23RB1 5086 2994 Y 0.26 0.02 I23RB2 4107 670 Y 1.09 1.11 I23RB3 4323 1461 Y 0.66 0.37 I23RB4 4393 2990 Y 0.04 0.03 I23RB5 105 94 N I23RB6 139 NT NT NT NT I23RB7 4315 2231 Y 0.07 0.10 I23RB8 105 NT NT NT NT I23RB9 86 NT NT NT NT I23RB10 359 NT NT NT NT Human IL-23R HEK cell binding Experiment D (8 points, 96 wells) Experiment E (11 points, 384 wells) Percentile Ranking of mAbs (Top Performers = 100%) mAb ID S ＞ B*3xStD EC50 (nM) MFI (6.4 nM) EC50 (nM) Experiment D (EC50) Experiment E (MFI @ 6.4 nM) Experiment E (EC50) commercially available MAB14001 NT NT NT NT NT NT NT Phage-derived mAbs purified protein I23RB1 NT NT 286726 NT NT 92 NT I23RB2 NT NT NT NT NT NT NT I23RB3 NT NT 148614 NT NT 61 NT I23RB4 NT NT 224800 NT NT 84 NT I23RB5 NT NT 3915 NT NT <31 NT I23RB6 NT NT NT NT NT NT NT I23RB7 NT NT 171633 NT NT 68 NT I23RB8 NT NT NT NT NT NT NT I23RB9 NT NT NT NT NT NT NT I23RB10 NT NT NT NT NT NT NT Unpurified protein in crude supernatant expressed in mammalian cells I23RB321 Y 18.6 NT NT 32 <31 <32 I23RB319 Y 8.7 NT NT 38 <31 <32 I23RB318 Y 0.5 196302 7.1 71 80 83 I23RB317 Y 31.0 NT NT 25 <31 <32 I23RB313 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB278 N NT NT <14 <31 <32 I23RB277 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB273 N NT NT <14 <31 <32 I23RB270 Y 0.5 243373 7.2 74 86 80 I23RB269 Y 0.6 96789 14.7 66 49 60 I23RB268 Y 20.6 51882 38.2 31 36 46 I23RB267 Y 9.4 NT NT 35 <31 <32 I23RB264 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB261 Y 9.2 NT NT 36 <31 <32 I23RB260 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB259 Y 29.7 30882 > 50.0 27 33 33 to 45 I23RB332 N NT NT <14 <31 <32 I23RB330 N NT NT <14 <31 <32 I23RB329 N NT NT <14 <31 <32 I23RB328 N NT NT <14 <31 <32 immune-derived mAb purified protein I23RB94 Y 0.1 363988 2.8 99 99 99 I23RB92 Y 0.2 375866 4.0 97 100 94 I23RB76 Y 0.4 321510 11.9 79 95 63 I23RB65 Y 0.3 274916 4.0 86 90 93 I23RB42 Y 0.2 352620 3.1 92 97 98 I23RB32 Y 0.4 292423 5.1 77 93 88 I23RB157 NT NT 180188 11.0 NT 71 68 I23RB33 Y 0.2 305792 5.6 95 94 85 I23RB47 Y 0.2 363504 4.1 91 98 91 I23RB35 Y 0.2 NT NT 96 NT NT I23RB101 N NT NT <14 <31 <32 Unpurified protein in crude supernatant expressed in mammalian cells I23RB104 N NT NT <14 <31 <32 I23RB102 NT NT 257715 8.6 NT 87 76 I23RB98 Y 1.9 59393 28.7 47 38 50 I23RB95 NT NT NT NT NT NT NT I23RB93 Y 0.5 192659 8.9 73 79 73 I23RB91 Y 30.3 NT NT 26 <31 <32 I23RB87 NT NT 86143 > 50.0 NT 46 33 to 45 I23RB86 Y 1.2 164436 22.8 52 66 52 I23RB85 Y ~0.6 64033 13.5 68 40 61 I23RB83 Y 0.7 120645 31.5 60 59 49 I23RB82 Y 0.6 180983 9.8 69 74 71 I23RB81 Y 0.9 180907 7.2 55 72 82 I23RB80 N NT NT <14 <31 <32 I23RB79 NT NT NT NT NT NT NT I23RB78 NT NT 84244 15.8 NT 45 57 I23RB77 Y 0.2 183687 4.8 94 75 89 I23RB74 Y 0.3 184983 13.0 84 77 62 I23RB73 Y 1.8 157826 11.6 48 64 67 I23RB71 Y ~6.7 109959 3.4 39 54 96 I23RB69 Y 0.6 NT NT 65 <31 <32 I23RB67 NT NT 80940 18.0 NT 44 55 I23RB66 NT NT NT NT NT NT NT I23RB61 Y 0.6 117821 > 50.0 70 57 33 to 45 I23RB60 Y 0.6 93733 27.7 62 48 51 I23RB58 Y 23.1 149794 11.6 30 62 65 I23RB57 Y 5.0 99600 > 50.0 40 51 33 to 45 I23RB56 Y 0.7 117690 > 50.0 61 56 33 to 45 I23RB54 NT NT 63092 35.2 NT 39 48 I23RB45 Y 0.4 227725 4.5 78 85 90 I23RB39 Y 0.3 277390 3.8 90 91 95 I23RB36 Y 0.4 170901 7.3 81 67 79 I23RB31 Y 1.7 78646 > 50.0 49 43 33 to 45 I23RB30 Y 1.2 184569 8.3 51 76 77 I23RB27 Y 3.5 152591 > 50.0 43 63 33 to 45 I23RB189 N NT NT <14 <31 <32 I23RB188 Y 2.0 90088 > 50.0 45 47 33 to 45 I23RB182 Y 36.4 26205 > 50.0 twenty three 32 33 to 45 I23RB180 Y 27.6 NT NT 29 <31 <32 I23RB177 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB173 Y 0.4 100271 7.4 82 52 78 I23RB169 Y 0.7 131724 15.4 58 60 59 I23RB168 Y 3.4 73043 22.1 44 41 54 I23RB166 Y 0.3 197533 11.6 87 82 66 I23RB165 Y 0.6 116290 9.7 64 55 72 I23RB162 Y 0.1 269100 2.8 100 89 100 I23RB161 Y 0.8 NT NT 56 <31 <32 I23RB160 Y 0.4 185189 5.6 75 78 87 I23RB159 Y > 50.0 NT NT 16 to 22 <31 <32 I23RB156 Y 0.4 174305 8.9 83 69 74 I23RB155 Y 0.9 177295 10.1 53 70 70 I23RB153 Y 4.4 52771 > 50.0 42 37 33 to 45 I23RB150 Y 0.8 102513 16.2 57 53 56 I23RB149 N NT NT <14 <31 <32 I23RB148 Y 0.3 202907 6.0 88 83 84 I23RB144 Y 13.4 46250 > 50.0 34 34 33 to 45 * NT - not tested in this experiment * N - cell binding not observed * S - geometric mean fluorescence intensity value of I23RB mAb at maximum concentration * B - geometric mean fluorescence intensity of I23RB5 negative control at equivalent concentration Values * StD - standard deviation in replicate wells of I23RB5 negative control * MFI - geometric mean fluorescence intensity of detection antibody * Black filled cells indicate EC50 could not be calculated as no cell binding was observed * Exceeded the maximum used in the experiment [ The EC50 value of mAb] could not be quantified correctly and the series was ">50"

The mAb rankings are shown in Table 12. For Experiment D, the 77 tested mAbs were ranked in ascending order of EC50. The relative positions of all mAbs are expressed as %, with the top performers (lowest EC50) showing the highest %. Percentage ranges are included for mAbs that could not be quantified correctly due to poor cell binding or EC50 > 50. For Experiment E (MFI), the 61 tested mAbs were ranked in descending order of MFI at 6.4 nM. The relative position of the mAbs is expressed in %, with top performers (highest MFI) showing the highest %. The 26 mAbs not tested in Experiment D due to poor cell binding were included in the ranking and pre-ranked at the bottom (range <31%). For Experiment E (EC50), the 56 tested mAbs were ranked in ascending order of EC50 value. Relative positions of mAbs are expressed in % with top performers (lowest EC50) showing highest %. The 26 mAbs that were not tested in Experiment D due to poor cell binding were included in the ranking and pre-ranked at the bottom (range <32%). Percentage ranges are included for mAbs that could not be quantified correctly because of EC50 > 50. Example 3 : IL-23R mAb detects IL-23R on the surface of primary human immune cells

Primary cell culture . Cryopreserved peripheral blood mononuclear cells (PBMC) from healthy donors (AllCells) were thawed and treated with ImmunoCult-XF T Cell Expansion Medium (XF-TCEM) (StemCell Technologies cat# 10981) (supplemented with CTL anticoagulant Collect washing solution (Cellular Technology Limited cat# CTL-AA-001)) and wash twice. Count cells from 2 to 6 x ¹⁰⁵ per mL of XF-TCEM supplemented with penicillin and streptomycin (Sigma-Aldrich cat# P0781-100ML) and 100 ng/mL IL-1β (Biolegend cat# 579404) Cells were resuspended and cultured in culture flasks coated with 10 µg/mL anti-CD3 (strain UCHT1) (BD Pharmingen cat# 555329) at 37°C in 5% _CO2 for 4 days. On day 4 of culture, PBMCs were collected, washed twice with RPMI-1640 (RPMI-BSA) supplemented with 0.1% BSA, and counted. Cells were directly stained with anti-IL-23R mAb or cultured in RPMI-BSA in upright tissue culture flasks for >4 hours at 37°C in 5% CO ₂ prior to staining. When assessing functional IL-23R expression (ie, IL-23 responsiveness), cells were cultured in RPMI-BSA in upright tissue culture flasks for >4 hours at 37°C in 5% CO ₂ .

IL-23- induced STAT3 phosphorylation was measured. To assess IL-23 reactivity, a total of 6 x ¹⁰⁴ "cytokine-starved" cells in 30 µL of RPMI-BSA were transferred to each well of a 384-well plate. Cells were stimulated with serial titration of IL-23 (in-house from Janssen). After incubation for 30 minutes at 37°C in 5% _CO2 , cells were transferred to ice for 10 minutes followed by lysis. Cell lysates were stored at -80°C. After thawing at room temperature, 25 µL of each lysate was transferred to the "Blocker A"-treated MSD plate provided with the MSD phospho-STAT kit (Meso Scale Discovery cat# K15202D). After one hour of incubation with shaking, the plates were washed with Tris wash buffer. A total of 25 µL of detection antibody was added to each well, and the plate was incubated with shaking for an additional hour. Dishes were then washed three times. After the final wash, 150 µL of read buffer was added to each well, and the plate was read on a Meso Sector S 600 plate reader. Phosphorylated STAT3 levels (ie, raw MSD plate reads) were plotted against IL-23 concentrations in GraphPad Prism. _EC50 values for IL-23-induced STAT3 phosphorylation were calculated in GraphPad Prism using nonlinear regression (curve fitting) - [inhibitor] versus response (four parameters) - robust regression.

Detection of IL-23R on the surface of primary immune cells by testing the naive panel of phage display-derived anti-IL-23R mAbs by staining PBMCs that had been exposed to IL-1β (inducing IL-23 reactivity and thereby Conditions for IL-23R expression) Stimulated with anti-CD3 for 4 days.

Surface IL-23R staining . For the detection of IL-23R by flow cytometry, up to about 10 ⁶ cells were incubated with FcR blocking reagent (Miltenyi Biotec cat# 130-059-901) and Ghost red dye 780 (Tonbo Biosciences cat# 13-0865 -T100) in 50 to 100 µL of Dulbecco's phosphate-buffered saline (PBS) supplemented with 0.2% bovine serum albumin (BSA) or in FACS staining buffer (BD Pharmingen cat# 554657) containing BSA. After incubation on ice for 5 minutes, 50 µL of FACS staining buffer containing 20 to 30 µg/mL anti-IL-23R mAb was added to each sample for a final antibody concentration of 10 µg/mL. Cells were incubated on ice for 60 minutes and washed with FACS staining buffer. Cell pellets were resuspended in 100 µL of FACS staining buffer containing biotinylated anti-mouse IgG _2a secondary antibody (BD Pharmingen cat# 550332) and incubated on ice for 30 minutes. After the second wash, cells were plated in 100 µL containing streptavidin (SAV)-PE (BD Pharmingen cat# 349023 or Biolegend cat# 405203) and fluorescently labeled antibodies against relevant cell surface markers (Miltenyi Biotec and BD Pharmingen) in FACS staining buffer. Cells were acquired on a BD FACSCanto or FACSymphony cell analyzer, and data were analyzed using FlowJo software.

To amplify the IL-23R signal, a three-step staining strategy was employed in which bound anti-IL-23R was detected with a biotinylated anti-mouse IgG _2a secondary antibody and streptavidin-PE. To establish a "cutoff" for anti-IL-23R mAb binding, cells were incubated with buffer alone or the negative control mAb I23RB5 during the first step of a three-step staining procedure. As an additional control, omit the biotinylated anti-mouse IgG _2a secondary reagent for the second staining step.

As shown in Figure 4, omission of the first or second step antibody and three-step staining using I23RB5 resulted in low or no background staining on CD8 ⁺ and CD8 ⁻ CD3 ^{+ CD56−} T cells and CD3 ⁻ CD56 ⁺ cells, respectively. A moderate amount of non-specific SAV-PE binding was detected on the surface of CD3 ⁺ CD56 ⁺ cells (Figure 4). Phage display-derived anti-IL-23R mAbs I23RB1, I23RB2, I23RB3, I23RB4, and I23RB7 bound CD8 ⁺ and CD8 ^- CD3 ^{+ CD56-} T cells (Figure 5, part A) and CD3 ^- CD56 ⁺ in small but detectable amounts cells (Figure 5, part C). The majority of CD3 ⁺ CD56 ⁺ cell lines were stained with each phage display-derived anti-IL-23R mAb evaluated (Figure 5, part B).

Two additional panels of anti-IL-23R mAbs derived from mice immunized with the human IL-23R ectodomain were tested for flow cytometric detection of IL-23R on the surface of primary human immune cells as described above. Of the 26 mouse immune-derived mAbs tested, 22 bound to CD8 ⁺ and CD8 ^- CD3 ⁺ CD56 ^- T cells to varying degrees, including I23RB42, I23RB32, I23RB33, I23RB47, I23RB65, I23RB92, I23RB94, I23RB76, I23RB35 , I23RB36, I23RB45, I23RB77, I23RB78, I23RB83, I23RB85, I23RB148, I23RB153, I23RB155, I23RB156, I23RB168, I23RB269 (representative information shown in Figure 6 To. Of the immune-derived mAbs, only I23RB76 gave equivalent (or improved) signal-to-noise relative to I23RB1, I23RB3, and I23RB4, the strongest cell binders among previously identified phage-display-derived mAbs. Notably, these four mAbs compete for binding to the IL-23R ectodomain and thus belong to the same "epitope bin". Example 4 : Confirmation of IL-23R mAb Binding Specificity by siRNA -mediated IL23R Knockdown

To confirm the specificity of anti-IL-23R mAbs for IL-23R, PBMCs that had been stimulated for 3 days with anti-CD3 and IL-Ιβ were electroporated with a mixture of siRNAs targeting IL23R transcripts. After electroporation, the cells were placed back into culture on anti-CD3 coated flasks for approximately 24 hours at which time the cells were pelleted for RNA isolation or subjected to surface IL-23R and IL- Staining for 12Rβ1 expression.

siRNA- mediated knockdown of IL23R. PBMC were cultured in serum-free medium supplemented with 100 ng/mL IL-1β on anti-CD3-coated culture flasks. On day 3 of culture, approximately 10 ⁷ cells were resuspended in 200 µL of electroporation buffer with P3 Primary Cell 4D Nucleofector X Kit S (Lonza cat# V4XP-3032). A mixture of three siRNA molecules targeting the IL23R gene (Thermo Fisher Scientific cat# AM16708 Assay ID 110064, 110065, 110066) or a negative control siRNA (Thermo Fisher Scientific cat# AM4611) was added to the cells so that the final concentration of siRNA was 300 nM (100 nM of each individual IL23R siRNA or 300 nM of negative control siRNA). Following electroporation, cells were returned to the anti-CD3 coated culture flasks and incubated for an additional approximately 24 hours. At this point, cells were stained for surface IL-23R and IL-12Rβ1 expression or pelleted for RNA isolation (Qiagen cat# 74004). The isolated RNA was reverse transcribed into cDNA (Applied Biosystems cat# 4374967), and by using IL23R (Hs00332759_m1), IL12RB1 (Hs01106578_m1), ACTB (Hs99999903_m1), B2M (Hs00187842_m1), GAPDH (Hs02786624_g1), and HPRT1 ( Quantitative polymerase chain reaction (qPCR) with Hs02800695_m1) probe (Thermo Fisher Scientific cat# 4304437) to analyze IL23R and IL12RB1 transcript levels.

siRNA-mediated knockdown of IL23R resulted in approximately 1.9- to 38-fold reduction in IL23R transcript levels compared to cells electroporated with negative control siRNA (Figure 7, part A). IL23R knockdown either reduced or increased the transcript levels of IL12RB1 , depending on the housekeeping genes used for normalization (Fig. 7, part A).

IL23R knockdown reduced I23RB4, I23RB7, and I23RB76 binding to CD4 ⁺ and CD8 ⁺ CD3 ^{+ CD56-} T cells relative to cells electroporated with negative control siRNA (Figure 7, panels B and C). Cells electroporated with IL23R or control siRNA exhibited equivalent IL-12Rβ1 surface levels (Fig. 7, part D). Thus, I23RB4, I23RB7, and I23RB76 specifically detect IL-23R on the surface of primary human CD3 ^{+ CD56-} T cells. Example 5 : Antibodies that cross-reactively bind to rat IL-23R

Rat IL-23R cross-reactive binding was shown in seven anti-human IL-23R antibodies that fell into several epitope bins, especially into different epitope bins. Cross-reactive binding is important and can be used to apply IL-23R antibodies to rats for in vivo, ex vivo, or in vitro (flow cytometry or other) studies without the need to produce antibodies with approximately matching characteristics of any particular anti-human IL-23R of interest. Specific anti-rat IL-23R proxy antibody of mAb nature. The generation of such proxy mAbs can often be very challenging and require as much or even more work than was required to generate the naive human IL-23R antibody. For these reasons, anti-human IL-23R antibodies with rat IL-23R cross-reactive binding are of particular value.

Table 13 below is modified from Tables 10 and 11 to indicate antibody epitope binning results and also focuses on human and rat IL-23R binding for antibodies showing rat IL-23R binding. The antibody binding characteristics available for each epitope bin antibody are provided. Antibodies in each of bins 1, 5, 7, and 9 and non-binned antibodies I23RB30 and I23RB56 also showed rat IL-23R binding. Antibodies I23RB30 and I23RB56 were not epitope binned because they did not meet the criteria for including mAbs in epitope binning experiments. Inspection of this binding information revealed that two of these mAbs (I23RB7, I23RB153) were the only mAbs in their respective epitope bins (#5, #7). Both mAbs (I23RB42, I23RB157) fell into the same bin (bin 1). Bin 1 contained a third mAb (I23RB85) that did not show rat IL-23R cross-reactivity in these studies, but was predicted to bind rat IL-23R. Based on the phenotype of the other Bin 1 mAbs, the mAbs within Bin 1 are expected to be rat cross-reactive. The lack of rat IL-23R binding by I23RB85 in the study could be explained by two plausible ways. Binding of I23RB85 to rat IL-23R was assessed using unpurified protein in expressed culture supernatants. In this format, the amount of antibody may be lower than estimated and thus its concentration may not allow detection of binding. This was observed for I23RB42, which showed rat IL-23R binding when the purified protein was used, but not when the unpurified protein in the expressed supernatant was used (Table 10). In addition, I23RB85 may have a lower affinity for rat IL-23R than for human IL-23R since this lower affinity did not show detectable binding under the experimental conditions used in the binding studies. 123RB7 is an example of a mAb that has a lower affinity for rat IL-23R than for human IL-23R. The rat cross-reactive mAb I23RB45 fell into a different epitope bin (9). Epitope bin 9 contained a second mAb I23RB318, which showed no binding to rat IL-23R. This unexpected lack of rat IL-23R binding can be explained in the same way as explained above for I23RB85.

Overall, therefore, based on rat binding studies and epitope binning, the following nine IL-23R antibodies were shown to bind and/or predicted to bind rat IL-23R: I23RB42, I23RB85, I23RB157, I23RB7, I23RB153, I23RB45, I23RB318, I23RB30, and I23RB56. Table 13. Epitope Binning of Human IL-23R Binding mAbs and Rat IL-23R Binding warehouse mAb ID Rat IL-23R ECD Conjugate Affinity to hu IL-23R ECD (nm) 1 I23RB42* yes ≤0.1 I23RB85 1 I23RB157* yes 3 to 4 2 I23RB32* I23RB33* I23RB39 I23RB60 I23RB65* I23RB92* I23RB94* I23RB156 I23RB160 I23RB162 3 I23RB1* I23RB3* I23RB4* I23RB76* I23RB269 I23RB270 4 I23RB35* I23RB93 I23RB155 5 I23RB7* yes 1 6 (2 & 5) I23RB47* I23RB83 I23RB148 I23RB168 7 (2) I23RB153 yes 2 8 (3 & 4) I23RB36 I23RB78 9 (3, 5 & 6) I23RB45 yes 2 I23RB318 twenty one unique I23RB74 I23RB77 I23RB102 uncertain I23RB71 I23RB313 Undivided I23RB30 yes 36 to 46 I23RB56 yes 26 to 68 Example 6 : Antibody CDR and variable region sequences

Tables 4 to 6 and 7 to 9 provide the heavy chain (HC), light chain (LC), variable region heavy chain (VH) and light chain (VL), and heavy chain and light chain (VL) of the IL-23R antibodies described and provided herein. Light chain CDR sequences. Antibody fragments (especially active or functional fragments or antigen-binding fragments) may comprise or comprise the respective CDR sequences or VH or VL sequences or HC or LC sequences of the antibodies disclosed herein, or portions thereof. A review of sequences identifies antibodies with related, similar, or identical sequences. Antibodies were designated as five groups below, wherein the antibodies had identical LC, VH, and light chain CDR1, CDR2, and CDR3 sequences. In each case, however, the antibodies have different or unique HC, VH, and heavy chain CDR1, CDR2, and CDR3 sequences.

For example, some antibodies share light chain CDRs and may also share LC and/or VL sequences. It is worth noting that these antibodies have different and unique heavy chain sequences, including heavy chain CDRs and HC and VH sequences. The heavy chain sequences (including, inter alia, the CDR sequences provided by or for these antibodies) are responsible, inter alia, for the binding differences or characteristics of these antibodies. Some were binned together in the same epitope bin, while some belonged to different epitope bins or were not characterized by the binning analysis performed. Table 13 below identifies the consensus light chain LC amino acid sequence and the corresponding IL-23R antibodies comprising the LC sequence. Table 14 identifies consensus VL sequences and corresponding IL-23R antibodies comprising VL sequences. Table 14 identifies the corresponding IL-23R antibodies that share consensus light chain CDR1, CDR2, and CDR3 sequences and include the CDR sequences. Table 13 - Consensus Antibody LC Amino Acid Sequences LC sequence and consensus SEQ ID Corresponding to the same sequence and SEQ ID Antibodies containing LC sequences EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTC EATHKTSTSPIVKSFNRNEC (SEQ ID NO: 1242) SEQ ID NO:673 SEQ ID NO:675 SEQ ID NO:677 SEQ ID NO:679 SEQ ID NO:687 SEQ ID NO:689 SEQ ID NO:711 SEQ ID NO:715 SEQ ID NO:757 I23RB1 I23RB2 I23RB3 I23RB4 I23RB8 I23RB9 I23RB268 I23RB270 I23RB291 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 1243) SEQ ID NO:681 SEQ ID NO:707 SEQ ID NO:717 SEQ ID NO:721 SEQ ID NO:723 SEQ ID NO:725 SEQ ID NO:727 SEQ ID NO:729 SEQ ID NO:733 SEQ ID NO:737 SEQ ID NO:739 SEQ ID NO:743 SEQ ID NO:745 SEQ ID NO:753 SEQ ID NO:755 SEQ ID NO:759 I23RB5 I23RB266 I23RB271 I23RB273 I23RB274 I23RB275 I23RB276 I23RB277 I23RB279 I23RB281 I23RB282 I23RB284 I23RB286 I23RB289 I23RB290 I23R B292 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTK DEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 1244) SEQ ID NO:683 SEQ ID NO:691 I23RB6 I23RB10 DIQMTQSPSSLSASVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYER HNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 1245) SEQ ID NO:693 SEQ ID NO:767 I23RB259 I23RB316 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 1246) SEQ ID NO:709 SEQ ID NO:713 SEQ ID NO:719 SEQ ID NO:731 SEQ ID NO:735 SEQ ID NO:741 SEQ ID NO:749 SEQ ID NO:751 I23RB267 I23RB269 I23RB272 I23RB278 I23RB280 I23RB283 I23RB287 I23RB288 Table 14 - Consensus Antibody VL Amino Acid Sequences VL sequence and consensus SEQ ID Corresponding to the same sequence and SEQ ID Antibodies containing VL sequences EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ ID NO: 1247) SEQ ID NO:787 SEQ ID NO:789 SEQ ID NO:791 SEQ ID NO:793 SEQ ID NO:801 SEQ ID NO:803 SEQ ID NO:825 SEQ ID NO:829 SEQ ID NO:871 I23RB1 I23RB2 I23RB3 I23RB4 I23RB8 I23RB9 I23RB268 I23RB270 I23RB291 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 1248) SEQ ID NO:795 SEQ ID NO:821 SEQ ID NO:831 SEQ ID NO:835 SEQ ID NO:837 SEQ ID NO:839 SEQ ID NO:841 SEQ ID NO:843 SEQ ID NO:847 SEQ ID NO:851 SEQ ID NO:853 SEQ ID NO:857 SEQ ID NO:859 SEQ ID NO:867 SEQ ID NO:869 SEQ ID NO:873 I23RB5 I23RB266 I23RB271 I23RB273 I23RB274 I23RB275 I23RB276 I23RB277 I23RB279 I23RB281 I23RB282 I23RB284 I23RB286 I23RB289 I23RB290 I23R B292 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIK (SEQ ID NO: 1249) SEQ ID NO:797 SEQ ID NO:805 I23RB6 I23RB10 DIQMTQSPSSLSASSVGDRVTITCRASQSISNDLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK (SEQ ID NO: 1250) SEQ ID NO:807 SEQ ID NO:881 I23RB259 I23RB316 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK (SEQ ID NO: 1251) SEQ ID NO:823 SEQ ID NO:827 SEQ ID NO:833 SEQ ID NO:845 SEQ ID NO:849 SEQ ID NO:855 SEQ ID NO:863 SEQ ID NO:865 I23RB267 I23RB269 I23RB272 I23RB278 I23RB280 I23RB283 I23RB287 I23RB288 Table 15 - Consensus Antibody Light Chain CDR1, CDR2, and CDR3 Amino Acid Sequences CDR1, CDR2, and CDR3 sequences and consensus SEQ ID Corresponding to the same CDR sequence and SEQ ID Antibodies comprising CDR1, CDR2, and CDR3 sequences CDR1 QSVSSY (SEQ ID NO: 1252) CDR2 DAS (SEQ ID NO: 1253) CDR3 QQRSNWPLT (SEQ ID NO: 1254) SEQ ID NO:903 SEQ ID NO:909 SEQ ID NO:915 SEQ ID NO:921 SEQ ID NO:945 SEQ ID NO:951 SEQ ID NO:1017 SEQ ID NO:1029 SEQ ID NO:1155 SEQ ID NO:904 SEQ ID NO:910 SEQ ID NO:916 SEQ ID NO:922 SEQ ID NO:946 SEQ ID NO:952 SEQ ID NO:1018 SEQ ID NO:1030 SEQ ID NO:1156 SEQ ID NO:905 SEQ ID NO:911 SEQ ID NO:917 SEQ ID NO:923 SEQ ID NO:947 SEQ ID NO:953 SEQ ID NO:1019 SEQ ID NO:1031 SEQ ID NO:1157 I23RB1 I23RB2 I23RB3 I23RB4 I23RB8 I23RB9 I23RB268 I23RB270 I23RB291 CDR1 QSISSY (SEQ ID NO: 1255) CDR2 AAS (SEQ ID NO: 1256) CDR3 QQSYSTPLT (SEQ ID NO: 1257) SEQ ID NO:927 SEQ ID NO:1005 SEQ ID NO:1035 SEQ ID NO:1047 SEQ ID NO:1053 SEQ ID NO:1059 SEQ ID NO:1065 SEQ ID NO:1071 SEQ ID NO:1083 SEQ ID NO:1095 SEQ ID NO:1101 SEQ ID NO:1113 SEQ ID NO:1125 SEQ ID NO:1143 SEQ ID NO:1149 SEQ ID NO:1161 SEQ ID NO:928 SEQ ID NO:1006 SEQ ID NO:1036 SEQ ID NO:1048 SEQ ID NO:1054 SEQ ID NO:1060 SEQ ID NO:1066 SEQ ID NO:1072 SEQ ID NO:1084 SEQ ID NO:1096 SEQ ID NO:1102 SEQ ID NO:1114 SEQ ID NO:1126 SEQ ID NO:1144 SEQ ID NO:1150 SEQ ID NO:1162 SEQ ID NO:929 SEQ ID NO:1007 SEQ ID NO:1037 SEQ ID NO:1049 SEQ ID NO:1055 SEQ ID NO:1061 SEQ ID NO:1067 SEQ ID NO:1073 SEQ ID NO:1085 SEQ ID NO:1097 SEQ ID NO:1103 SEQ ID NO:1115 SEQ ID NO:1127 SEQ ID NO:1145 SEQ ID NO:1151 SEQ ID NO:1163 I23RB5 I23RB266 I23RB271 I23RB273 I23RB274 I23RB275 I23RB276 I23RB277 I23RB279 I23RB281 I23RB282 I23RB284 I23RB286 I23RB289 I23RB290 I23R B292 CDR1 QSVLYSSNNKNY (SEQ ID NO: 1258) CDR2 WAS (SEQ ID NO: 1259) CDR3 QQYYSTPLT (SEQ ID NO: 1260) SEQ ID NO:933 SEQ ID NO:957 SEQ ID NO:934 SEQ ID NO:958 SEQ ID NO:935 SEQ ID NO:959 I23RB6 I23RB10 CDR1 QSISND (SEQ ID NO: 1261) CDR2 AAS (SEQ ID NO: 1262) CDR3 QQSYSTPLT (SEQ ID NO: 1263) SEQ ID NO:963 SEQ ID NO:1185 SEQ ID NO:964 SEQ ID NO:1186 SEQ ID NO:965 SEQ ID NO:1187 I23RB259 I23RB316 CDR1 QSVSSSY (SEQ ID NO: 1264) CDR2 GAS (SEQ ID NO: 1265) CDR3 QQYGSSPLT (SEQ ID NO: 1266) SEQ ID NO:1011 SEQ ID NO:1023 SEQ ID NO:1041 SEQ ID NO:1077 SEQ ID NO:1089 SEQ ID NO:1107 SEQ ID NO:1131 SEQ ID NO:1137 SEQ ID NO:1012 SEQ ID NO:1024 SEQ ID NO:1042 SEQ ID NO:1078 SEQ ID NO:1090 SEQ ID NO:1108 SEQ ID NO:1132 SEQ ID NO:1138 SEQ ID NO:1013 SEQ ID NO:1025 SEQ ID NO:1043 SEQ ID NO:1079 SEQ ID NO:1091 SEQ ID NO:1109 SEQ ID NO:1133 SEQ ID NO:1139 I23RB267 I23RB269 I23RB272 I23RB278 I23RB280 I23RB283 I23RB287 I23RB288

none

[ Figure 1 ] Representative multi-strain phage ELISA. Phage panning experiment XP37 showed enrichment for IL-23R binding starting at round 4 (R4). [ Figure 2 ] Representative single-plant Fab ELISA for primary screening. A number of individual Fabs from round 5 (R5) of XP37 were shown to bind to IL-23R ECD but not to mouse IL-6. Mouse IL-6 binding Fab was used as a positive control for mouse IL-6 protein binding. [ FIG. 3 ] IL-23 reactivity of peripheral blood mononuclear cells (PBMC) from 3 human donors. PBMCs from 3 donors were cultured in serum-free medium supplemented with 100 ng/mL IL-1β on anti-CD3 coated flasks. On day 4, cells were transferred to RPMI-1640 supplemented with 0.1% BSA for >4 hours, followed by stimulation with serial titrations of IL-23. Phosphorylated STAT3 in cell lysates was measured by Meso Scale Discovery (MSD). Each point represents the mean (±SD) of replicate points. [ Figure 4 ] PBMC flow cytometry gating strategy and showing lack of background binding of second and third step detection reagents. PBMC were cultured in serum-free medium supplemented with 100 ng/mL IL-1β on anti-CD3-coated culture flasks. On day 4, cells were stained with viability dye in the presence of FcR blocking reagents, followed by incubation with 10 µg/mL anti-IL-23R or buffer alone for 60 min on ice. Cells were washed and incubated with biotinylated anti-mouse IgG _2a or buffer alone for 30 minutes on ice. After the second wash, cells were incubated with SAV-PE and FITC-anti-human CD3, PE-Vio770-anti-human CD56, and APC-anti-human CD8. Cells were acquired on a FACSCanto cell analyzer, and data were analyzed using FlowJo software. ( A ) Gating strategy to identify live single CD3 ^{+ CD56-} T cells, CD3 ⁺ CD56 ⁺ cells, and CD3 ^- CD56 ⁺ cells. PE versus CD8-APC under the following conditions: ( B ) Absence of primary anti-IL-23R mAb, ( C ) Absence of primary anti-IL-23R mAb and secondary biotinylated anti-mouse IgG _2a , or negative in use ( D ) Secondary biotinylated anti-mouse IgG _2a presence or ( E ) absence after control mAb I23RB5 staining. [ FIG. 5 ] IL-23R detection by IL-23R mAb from the same experiment shown in FIG. 4 . The indicated phage display-derived anti-human IL-23R mAbs were tested, and in particular results were shown for antibodies I23RB5, I23RB1, I23RB2, I23RB3, I23RB4, and I23RB7. IL-23R versus CD8 staining on gated CD3 ⁺ CD56 ⁺ T cells ( A ), CD3 ⁺ CD56 ⁺ cells ( B ), and CD3 ⁻ CD56 ⁺ cells ( C ). [ FIG. 6 ] Detection of IL-23R by IL-23R mAb on primary CD3 ⁺ CD56 ^- T cells. Detection of IL-23R expression in PBMCs (stimulated with anti-CD3 and IL-1β for 4 days) derived from IL-23R mAb from mice immunized with the human IL-23R ectodomain was tested in flow cytometry. IL-23R versus CD8 staining on gated CD3 ⁺ CD56 ⁻ T cells is shown. ( A ) I23RB101 does not show binding beyond background staining. ( B ) I23RB42 and I23RB157 compete for IL-23R ECD protein binding and belong to epitope bin 1 (Table 11). I23RB157 did not show binding beyond background staining. ( C ) I23RB32, I23RB33, I23RB47, I23RB65, I23RB92, and I23RB94 belong to bin 2. ( D ) I23RB1, I23RB3, I23RB4, and I23RB76 belong to bin 3. ( E ) I23RB35 belongs to bin 4. ( F ) I23RB7 (and I23RB47 shown in part C) belong to bin 5. *Note that I23RB47 falls into bins 2 and 5. [ FIG. 7 ] Expressed gene knockdown by IL23R siRNA specifically reduces binding of IL-23R mAb. PBMC were cultured in serum-free medium supplemented with 100 ng/mL IL-1β on anti-CD3-coated culture flasks. On day 3, cells were electroporated with siRNA targeting IL23R transcript or negative control siRNA. Following electroporation, cells were cultured for approximately 24 additional hours in serum-free medium on anti-CD3 coated flasks. At this point, cells were pelleted for RNA isolation and real-time PCR analysis of IL23R and IL12RB1 transcript levels or cells were stained for surface IL-23R and IL-12Rβ1. ( A ) Relative IL23R and IL12RB1 transcript levels in control and IL23R siRNA electroporated PBMCs. ( B ) Gating strategy to identify live single CD4 ⁺ and CD8 ⁺ CD3 ^{+ CD56-} T cells. ( C ) I23RB4, I23RB7, or I23RB76 (unfilled histogram) or I23RB5 (shaded histogram) staining on cells electroporated with control (red) or IL23R (blue) siRNA. ( D ) IL-12Rβ1 (unfilled histogram) or fluorescence minus one (FMO) (shaded histogram) staining on cells electroporated with control (red) or IL23R (blue) siRNA.

         
           <![CDATA[ <110> JANSSEN BIOTECH, INC.]]>
           <![CDATA[ <120> Materials and methods for making or using IL-23R binding protein]]>
           <![CDATA[ <130]]>> 2948-32-WO]]>
           <br/>
           <br/> &lt;![CDATA[ &lt;150&gt; US 63/227,976]]&gt;
           <br/> &lt;![CDATA[ &lt;151&gt;2021-07-30]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;160&gt; 1267 ]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;170&gt; Align Sequences Software Suite Ver. 1.183]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;210&gt;1]]&gt;
           <br/> &lt;![CDATA[ &lt;211&gt;332]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Sequence Description: Human IL-23R ECD Sequence]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: IL-23R ectodomain sequence]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1]]&gt;
           <br/>
           <br/> <![CDATA[Gly Ile Thr Asn Ile Asn Cys Ser Gly His Ile Trp Val Glu Pro Ala
          1 5 10 15
          Thr Ile Phe Lys Met Gly Met Asn Ile Ser Ile Tyr Cys Gln Ala Ala
                      20 25 30
          Ile Lys Asn Cys Gln Pro Arg Lys Leu His Phe Tyr Lys Asn Gly Ile
                  35 40 45
          Lys Glu Arg Phe Gln Ile Thr Arg Ile Asn Lys Thr Thr Ala Arg Leu
              50 55 60
          Trp Tyr Lys Asn Phe Leu Glu Pro His Ala Ser Met Tyr Cys Thr Ala
          65 70 75 80
          Glu Cys Pro Lys His Phe Gln Glu Thr Leu Ile Cys Gly Lys Asp Ile
                          85 90 95
          Ser Ser Gly Tyr Pro Pro Asp Ile Pro Asp Glu Val Thr Cys Val Ile
                      100 105 110
          Tyr Glu Tyr Ser Gly Asn Met Thr Cys Thr Trp Asn Ala Gly Lys Leu
                  115 120 125
          Thr Tyr Ile Asp Thr Lys Tyr Val Val His Val Lys Ser Leu Glu Thr
              130 135 140
          Glu Glu Glu Gln Gln Tyr Leu Thr Ser Ser Tyr Ile Asn Ile Ser Thr
          145 150 155 160
          Asp Ser Leu Gln Gly Gly Lys Lys Tyr Leu Val Trp Val Gln Ala Ala
                          165 170 175
          Asn Ala Leu Gly Met Glu Glu Ser Lys Gln Leu Gln Ile His Leu Asp
                      180 185 190
          Asp Ile Val Ile Pro Ser Ala Ala Val Ile Ser Arg Ala Glu Thr Ile
                  195 200 205
          Asn Ala Thr Val Pro Lys Thr Ile Ile Tyr Trp Asp Ser Gln Thr Thr
              210 215 220
          Ile Glu Lys Val Ser Cys Glu Met Arg Tyr Lys Ala Thr Thr Asn Gln
          225 230 235 240
          Thr Trp Asn Val Lys Glu Phe Asp Thr Asn Phe Thr Tyr Val Gln Gln
                          245 250 255
          Ser Glu Phe Tyr Leu Glu Pro Asn Ile Lys Tyr Val Phe Gln Val Arg
                      260 265 270
          Cys Gln Glu Thr Gly Lys Arg Tyr Trp Gln Pro Trp Ser Ser Leu Phe
                  275 280 285
          Phe His Lys Thr Pro Glu Thr Val Pro Gln Val Thr Ser Lys Ala Phe
              290 295 300
          Gln His Asp Thr Trp Asn Ser Gly Leu Thr Val Ala Ser Ile Ser Thr
          305 310 315 320
          Gly His Leu Thr Ser Asp Asn Arg Gly Asp Ile Gly
                          325 330
           <![CDATA[ <210> 2]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 2]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Tyr Arg Tyr Gly Pro Leu Asp Gly Phe Asp Ile Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 3]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400>]]> 3
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Ile Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Thr Ser Gln Asp Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Ile Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Asp Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 4]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 4]]>
          Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Lys Tyr
                      20 25 30
          Trp Ile Asn Trp Met Asn Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Ser Ile Ser Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Ser Lys Val Thr Leu Thr Val Asp Ile Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Asp Phe Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 5]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 5]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser His
                      20 25 30
          Ile Thr Trp Tyr Gln Leu Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Ala Ser Thr Asn Leu Ala Asp Asp Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Leu Ser
          65 70 75 80
          Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 6]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 6]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Asp Trp Val
                  35 40 45
          Ala Ser Ile Ser Thr Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys
              50 55 60
          Gly Gly Phe Thr Ile Ser Arg Asp Ile Ala Arg Asn Thr Leu Ser Leu
          65 70 75 80
          Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala
                          85 90 95
          Arg Gly Pro His Tyr Tyr Gly Gly Ser Tyr Pro Phe Ala Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 7]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 7]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 8]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 8]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Ile Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asp Pro Tyr Asn Asp Asp Thr Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Leu Gly Ser Ile Asn Tyr Tyr Asp Gly Ser Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 9]]>
           <![CDATA[ <211> 219]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 9]]>
          Asp Ile Val Met Thr Gln Ser Pro Leu Thr Leu Ser Val Ile Ile Gly
          1 5 10 15
          Gln Ser Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
                      20 25 30
          Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
                  35 40 45
          Pro Lys Arg Leu Met Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly
                          85 90 95
          Ile His Phe Pro Leu Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
          Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
                  115 120 125
          Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
              130 135 140
          Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
          145 150 155 160
          Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
                          165 170 175
          Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
                      180 185 190
          Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
                  195 200 205
          Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 10]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 10]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Ser Ser Gly Thr Thr Asn Tyr Ser Pro Ser Leu
              50 55 60
          Arg Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 11]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 11]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Leu Thr Cys Lys Ala Ser Gln Glu Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ile Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Tyr
                          85 90 95
          Ser Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 12]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400]]>> 12]]>
           <br/>
           <br/> <![CDATA[Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Phe Ser Asp Arg Thr Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ser Arg Gln Leu Gly Leu Lys Ala Leu Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 13]]>
           <![CDATA[ <211> 219]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 13]]>
          Asp Val Gln Met Ile Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly
          1 5 10 15
          Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
                  35 40 45
          Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                          85 90 95
          Thr His Val Pro Leu Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
          Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
                  115 120 125
          Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
              130 135 140
          Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
          145 150 155 160
          Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
                          165 170 175
          Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
                      180 185 190
          Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
                  195 200 205
          Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 14]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 14]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Ala Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Lys Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Arg Gln Leu Gly Leu Arg Tyr Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 15]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 15]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Gly Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Phe Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 16]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 16]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Asp
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val
                  35 40 45
          Ala Glu Ile Ser Ser Asn Gly Gly Ser Thr Tyr His Ile Asp Thr Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Ser Pro Gly Tyr Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 17]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light]]> chain
           <![CDATA[ <400> 17]]>
          Asp Ile Val Met Thr Gln Ser His Arg Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Glu Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Asn Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Thr Ser Thr Arg His Asn Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Gly
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Arg Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 18]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 18]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          His Ser Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Thr Asn Asp Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Asn Leu Asn Ser Val Thr Thr Glu Asp Thr Val Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Tyr Gly Gly Thr Tyr Arg Val Phe Ala Asp
                      100 105 110
          Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 19]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 19]]>
          Gln Ile Val Leu Ser Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Thr Ser Glu Ser Val Asp Thr Tyr
                      20 25 30
          Gly Asn Ser Phe Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Asn
                          85 90 95
          Lys Asp Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 20]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 20]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Ala Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Val Phe Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Ile Phe Leu
          65 70 75 80
          Lys Met Ile Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val Trp Gly
                      100 105 110
          Ala Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 21]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 21]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Gly Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 22]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 22]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Ser Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Tyr Ile Ser Thr Gly Gly Gly Asp Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Thr Ser Tyr Ser Tyr Tyr Asn Tyr Val Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 23]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 23]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
                      20 25 30
          Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
          65 70 75 80
          Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Lys
                          85 90 95
          Glu Val Pro Trp Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 24]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 24]]>
          Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Gly Met Ala Trp Val Arg Gln Thr Pro Arg Lys Gly Pro Glu Trp Ile
                  35 40 45
          Ala Phe Ile Ser Asn Leu Ala Tyr Ser Val Tyr Tyr Ser Asp Thr Val
              50 55 60
          Thr Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Glu Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg His Gly Asp Tyr Arg Asn Tyr Gly Phe Ala Tyr Trp Gly Leu
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 25]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 25]]>
          Asp Ile Val Met Thr Gln Thr Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 26]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 26]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Tyr Ser Ser Gly Thr Ile Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Gly Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 27]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 27]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          His Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Val
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 28]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus muscu]]>lus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 28]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Val Tyr Ala Phe Ser Ser Ser Ser
                      20 25 30
          Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Arg Tyr Asp Phe Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 29]]>
           <![CDATA[ <211> 213]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 29]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
                  35 40 45
          Ala Thr Ser Asp Leu Ala Ser Gly Ala Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr
                          85 90 95
          Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro
                      100 105 110
          Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly
                  115 120 125
          Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn
              130 135 140
          Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn
          145 150 155 160
          Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser
                          165 170 175
          Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr
                      180 185 190
          Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe
                  195 200 205
          Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 30]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of peptide type:]]>heavy chain
           <![CDATA[ <400> 30]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Arg Thr Gly Thr Arg Trp Tyr Phe Asp Val Trp Gly Ala
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 31]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 31]]>
          Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Phe
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 32]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 32]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Ser
                      20 25 30
          Leu Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Asp Pro Glu Asp Gly Lys Thr Lys Tyr Ala Pro Lys Phe
              50 55 60
          Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Glu Val Leu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 33]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 33]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 34]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 34]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Thr Val Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Asn Gly
                      20 25 30
          Asn His Trp Trp Asn Trp Ile Arg Gln Val Ser Gly Ser Lys Leu Glu
                  35 40 45
          Trp Ile Gly Tyr Ile Arg Ser Ser Gly Ser Thr Asp Ser Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Leu
          65 70 75 80
          Phe Leu Gln Leu Asn Ser Val Thr Ala Glu Asp Ile Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Arg Glu Arg Leu Arg Leu Arg Trp Ser Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 35]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 35]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Ala Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Arg
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 36]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 36]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Tyr Pro Ala Ile Asn Asn Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Arg Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Ile Ser Arg Lys Pro Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 37]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 37]]>
          Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Ser Phe Ser Val Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Leu Tyr Asn Arg
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile
                  35 40 45
          Ser Gly Ala Thr Ser Leu Gly Thr Gly Val Leu Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr
          65 70 75 80
          Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Ile Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 38]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 38]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Val
                      20 25 30
          Gly Met Gln Trp Val Gln Lys Met Pro Gly Lys Gly Phe Lys Trp Ile
                  35 40 45
          Gly Trp Ile Asn Thr His Ser Gly Glu Pro Lys Tyr Thr Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Ser Asn Leu Lys Ser Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Ser Ala Leu Thr Gly Ala Phe Ala Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 39]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 39]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Asp Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro Arg Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 40]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 40]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Gly Asn Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ala Gly Leu Leu Pro Tyr Tyr Ala Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 41]]>
           <![CDATA[ <211> 213]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 41]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr
                  35 40 45
          Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr
                          85 90 95
          Phe Gly Asp Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala Pro
                      100 105 110
          Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly
                  115 120 125
          Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn
              130 135 140
          Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn
          145 150 155 160
          Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser
                          165 170 175
          Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr
                      180 185 190
          Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe
                  195 200 205
          Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 42]]>
           <![CDATA[ <211> 446]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 42]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Leu Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Ile Thr Asp Tyr
                      20 25 30
          Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Gly Ile Asn Pro Asn Tyr Gly Gly Thr Ser Tyr Asn Glu Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Tyr Cys
                          85 90 95
          Val Arg Gly Asn Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu
                      100 105 110
          Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala
                  115 120 125
          Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu
              130 135 140
          Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly
          145 150 155 160
          Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp
                          165 170 175
          Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro
                      180 185 190
          Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys
                  195 200 205
          Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro
              210 215 220
          Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe
          225 230 235 240
          Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro
                          245 250 255
          Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val
                      260 265 270
          Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr
                  275 280 285
          Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala
              290 295 300
          Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys
          305 310 315 320
          Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser
                          325 330 335
          Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro
                      340 345 350
          Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val
                  355 360 365
          Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly
              370 375 380
          Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp
          385 390 395 400
          Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp
                          405 410 415
          Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His
                      420 425 430
          Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 43]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 43]]>
          Asn Thr Gln Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr
                      20 25 30
          Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr
          65 70 75 80
          Glu Asp Met Gly Ile Tyr Tyr Cys Gln Gln Tyr Asp Glu Phe Pro Arg
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 44]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 44]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Tyr
                      20 25 30
          Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala Asn Ile Trp Trp Asn Asp Ser Lys Tyr His Asn Ala Ala
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
          65 70 75 80
          Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Gly Arg Ile Asp Gly Tyr Tyr Glu Cys Val Asp Val Trp Gly Thr
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 45]]>
           <![CDATA[ <211> 216]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 45]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Val Asn Ile His Asn Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Thr Thr Pro Tyr
                          85 90 95
          Met Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp
                      100 105 110
          Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr
                  115 120 125
          Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys
              130 135 140
          Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly
          145 150 155 160
          Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser
                          165 170 175
          Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn
                      180 185 190
          Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val
                  195 200 205
          Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 46]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 46]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Phe Trp Asn Trp Leu Arg Gln Phe Pro Gly Ser Lys Leu Glu Trp
                  35 40 45
          Met Gly Phe Ile Asp Asn Asp Gly Ser Asn Asp Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Arg Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Leu Gly Phe Phe Asp Ser Trp Gly Pro Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 47]]>
           <![CDATA[ <211> 213]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <21]]>3> Mice (Mus musculus)]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB182]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: light chain]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;47]]&gt;
           <br/>
           <br/> <![CDATA[Asp Ile Val Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn Tyr Met
                      20 25 30
          Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr
                  35 40 45
          Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Asn Ser Pro Trp Thr
                          85 90 95
          Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro
                      100 105 110
          Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly
                  115 120 125
          Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn
              130 135 140
          Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn
          145 150 155 160
          Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser
                          165 170 175
          Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr
                      180 185 190
          Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe
                  195 200 205
          Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 48]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 48]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Tyr Thr Gly Ala Pro Thr Tyr Ala Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Phe Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Gly Asn Gly Tyr Pro Tyr Tyr Tyr Gly Ile Asn Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 49]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 49]]>
          Asp Val Gln Met Ile Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Asn
                      20 25 30
          Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
              50 55 60
          Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
          65 70 75 80
          Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 50]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 50]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Ser Ser Gly Thr Thr Asn Tyr Ser Pro Ser Leu
              50 55 60
          Arg Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 51]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 51]]>
          Asp Ile Val Leu Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
          1 5 10 15
          Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
                      20 25 30
          Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Met
                  35 40 45
          Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Pro
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 52]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 52]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Gly Thr Leu Gly Trp Asp Asp Lys Lys Ser Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Lys Leu Ser Ser Ser Leu Gln Thr Glu Asp Thr Ala Met Tyr Tyr Cys Thr
                          85 90 95
          Lys Glu Asp Val Ser Tyr Ala Met Asp Phe Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 53]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 53]]>
          Asp Ile Gln Met Thr Gln Ser Pro Thr Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr
                      20 25 30
          Gly Thr Ser Leu Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ile Ala Met Tyr Phe Cys Gln Gln Gly Lys
                          85 90 95
          Lys Val Pro Trp Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 54]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 54]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
                      20 25 30
          Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Ile
          65 70 75 80
          Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Arg Arg Thr Leu Gly Gly Pro Pro Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 55]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <21]]>2> PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Mouse (Mus musculus)]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB30]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: light chain]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;55]]&gt;
           <br/>
           <br/> <![CDATA[Asp Ile Val Leu Thr Gln Ser Gln Arg Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Ile Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Leu Pro Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 56]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 56]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Ala Glu Met Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
                      20 25 30
          Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Lys Ile Asp Pro Ser Asp Thr Glu Thr His Tyr Asn Gln Asn Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Gly Arg Asn Phe Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 57]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 57]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
          1 5 10 15
          Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp His
                      20 25 30
          Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Phe Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asp Ser Val Glu Pro
          65 70 75 80
          Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Leu
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 58]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 58]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Ala Leu His Trp Val Lys Gln Ser Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Tyr Pro Gly Gly Gly Asn Thr Tyr Tyr Asn Asp Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Met Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Gly Arg Leu Arg Arg Asp Tyr Pro Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 59]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 59]]>
          Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
          1 5 10 15
          Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
                      20 25 30
          Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
                          85 90 95
          Asp Tyr Thr Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
                      100 105 110
          Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
                  115 120 125
          Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
              130 135 140
          Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu
          145 150 155 160
          Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp
                          165 170 175
          Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr
                      180 185 190
          Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr
                  195 200 205
          Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215 220
           <![CDATA[ <210> 60]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 60]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Arg Asp Ile
                      20 25 30
          Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Asp Pro Ala Asn Gly His Ser Ile Tyr Ala Ala Lys Phe
              50 55 60
          Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Leu Asn Ile Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ser Asp Asn Asp Tyr Gly Arg Val Leu Ala Tyr Trp Gly
                      100 105 110
          Leu Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 61]]>
           <![CDATA[ <211> 216]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 61]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Arg Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Val Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Thr Gly Asn Pro
                          85 90 95
          Ile Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp
                      100 105 110
          Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr
                  115 120 125
          Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys
              130 135 140
          Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly
          145 150 155 160
          Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser
                          165 170 175
          Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn
                      180 185 190
          Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val
                  195 200 205
          Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 62]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 62]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          His Asn Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Leu Gly Tyr Ile Ser Tyr Asp Gly Ser Asn Asn Tyr Asp Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Phe Gly Asn Ser Tyr Arg Val Phe Ala Ser
                      100 105 110
          Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 63]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 63]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Glu Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Ala Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 64]]>
           <![CDATA[ <211> 446]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 64]]>
          Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Thr
                      20 25 30
          Tyr Ile His Trp Met Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Ile Tyr Ala Ser Lys Phe
              50 55 60
          Gln Gly Lys Ala Thr Leu Thr Thr Thr Asp Thr Ser Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Leu Leu Ser Ser Ser Leu Thr Ser Gly Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Thr Arg Gly Thr Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val
                      100 105 110
          Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala
                  115 120 125
          Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu
              130 135 140
          Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly
          145 150 155 160
          Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp
                          165 170 175
          Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro
                      180 185 190
          Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys
                  195 200 205
          Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro
              210 215 220
          Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe
          225 230 235 240
          Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro
                          245 250 255
          Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val
                      260 265 270
          Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr
                  275 280 285
          Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala
              290 295 300
          Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys
          305 310 315 320
          Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser
                          325 330 335
          Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro
                      340 345 350
          Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val
                  355 360 365
          Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly
              370 375 380
          Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp
          385 390 395 400
          Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp
                          405 410 415
          Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His
                      420 425 430
          Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 65]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 65]]>
          Asp Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
          1 5 10 15
          Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Ser
                      20 25 30
          Val Ser Trp Phe Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Arg
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 66]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 66]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Pro Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Gly Asn Gly Gly Thr Ala Tyr Asn Gln Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Ala Asp Asn Pro Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Arg Gly Gly Ser Arg Asn Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 67]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 67]]>
          Asp Ile Gln Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Ser Ser Pro Arg
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 68]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ Description of <223> Peptides]]> Type: Heavy Chain
           <![CDATA[ <400> 68]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
                      20 25 30
          Ile Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Asn Pro Tyr Phe Gly Phe Thr Ser Tyr Asn Gln Glu Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Leu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ser Arg Gly Ser Tyr Tyr Gly Tyr Glu Thr Phe Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 69]]>
           <![CDATA[ <211> 219]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 69]]>
          Asp Ile Val Leu Thr Gln Thr Ala Pro Ser Val Pro Val Thr Pro Gly
          1 5 10 15
          Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
                  35 40 45
          Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
                          85 90 95
          Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
          Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
                  115 120 125
          Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
              130 135 140
          Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
          145 150 155 160
          Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
                          165 170 175
          Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
                      180 185 190
          Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
                  195 200 205
          Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 70]]>
           <![CDATA[ <211> 454]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 70]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Tyr
                      20 25 30
          Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Asn Gln Val
          65 70 75 80
          Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Gln Arg Ala Leu Pro Leu Leu Gly Gln Lys Ala Pro Phe Asp
                      100 105 110
          Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr
                  115 120 125
          Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly
              130 135 140
          Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro
          145 150 155 160
          Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr
                          165 170 175
          Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val
                      180 185 190
          Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val
                  195 200 205
          Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Lys Ile Glu Pro Arg
              210 215 220
          Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn
          225 230 235 240
          Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp
                          245 250 255
          Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp
                      260 265 270
          Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
                  275 280 285
          Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
              290 295 300
          Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp
          305 310 315 320
          Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
                          325 330 335
          Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala
                      340 345 350
          Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys
                  355 360 365
          Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile
              370 375 380
          Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn
          385 390 395 400
          Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys
                          405 410 415
          Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys
                      420 425 430
          Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe
                  435 440 445
          Ser Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 71]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 71]]>
          Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Ile Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Leu Pro Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Val Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Gln Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 72]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 72]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Asp Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Arg Thr Asp Tyr Lys Gly Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Thr Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 73]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 73]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Ser Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala
          65 70 75 80
          Glu Asp Phe Val Phe Tyr Tyr Cys His Gln Leu Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 74]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <21]]>2> PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Mouse (Mus musculus)]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB51]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: heavy chain]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;74]]&gt;
           <br/>
           <br/> <![CDATA[Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Val His Tyr Arg Asp Ser Thr His Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 75]]>
           <![CDATA[ <211> 213]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 75]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln His Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln Tyr Phe Trp Thr Thr Arg Thr
                          85 90 95
          Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro
                      100 105 110
          Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly
                  115 120 125
          Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn
              130 135 140
          Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn
          145 150 155 160
          Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser
                          165 170 175
          Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr
                      180 185 190
          Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe
                  195 200 205
          Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 76]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 76]]>
          Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Gly Ile Ser Ser Ser Gly Gly Ser Tyr Ile Tyr Tyr Pro Asp Asn Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Lys Lys Ser Asp Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 77]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 77]]>
          Asp Ile Gln Met Thr Gln Ser Pro Lys Phe Leu Leu Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Leu Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 78]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 78]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Ala Ile Asn Ser Asn Asp Gly Ser Thr Tyr Tyr Pro Asp Thr Val
              50 55 60
          Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
                          85 90 95
          Ala Arg His Phe Leu Tyr Phe Ser Asn Phe Tyr Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 79]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 79]]>
          Asp Ile Val Met Thr Gln Ser Pro Lys Phe Leu Leu Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Val Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Pro Phe
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 80]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 80]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Met His Trp Val Lys Gln Ser His Gly Lys Thr Ile Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Ser Gly Asp Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Asn Cys
                          85 90 95
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 81]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 81]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Ser Met Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                          85 90 95
          Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 82]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 82]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ile Ile Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Tyr Ile Thr Ser Gly Gly Gly Ile Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg His Glu Gly Asp Tyr Tyr Asp Asp Tyr Tyr Arg Ile Gly Tyr
                      100 105 110
          Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 83]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 83]]>
          Asp Ile Val Met Thr Gln Thr Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 84]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 84]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Asp
          1 5 10 15
          Ser Val Lys Met Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Ile Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Asn Gly Gly Ile Ser Phe Asn Gln Lys Phe
              50 55 60
          Glu Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Lys Leu Arg Gly Arg Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 85]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 85]]>
          Asp Ile Val Met Thr Gln Ser Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Asn
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Phe Tyr Ser Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly His Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 86]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 86]]>
          Asp Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ser Phe Asp Tyr Thr Phe Thr Ser Phe
                      20 25 30
          Asp Ile Asn Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Phe Pro Gly Ser Gly Thr Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met His Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Arg Leu Thr Gly Thr Arg Tyr Phe Asp Val Trp Gly Thr Gly
                      100 105 110
          Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 87]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 87]]>
          Asp Ile Gln Met Thr Gln Ser His Lys Phe Leu Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Ile Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ile Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Asn Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 88]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 88]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Thr Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Lys Ser Gly Asn Ala Ala Tyr Ser Gln Lys Phe
              50 55 60
          Lys Ser Glu Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Thr Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 89]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 89]]>
          Gln Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser
                      20 25 30
          Ser Tyr Asn Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Asp Asp Thr Ala Thr Tyr Tyr Cys Gln His Thr Trp
                          85 90 95
          Glu Ile Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 90]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 90]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
                      20 25 30
          Asn Met Gly Ile Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Trp Trp Asn Ser Asp Lys Tyr Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Asn Gln Val
          65 70 75 80
          Phe Leu Thr Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Gln Ile Arg Trp Leu Arg Phe Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 91]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 91]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Phe Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 9]]>2
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 92]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Ser Ser Ser Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Ala Tyr Gly Asn Arg Leu Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 93]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 93]]>
          Asp Val Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 94]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 94]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
                      20 25 30
          Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Asn Pro Phe Tyr Asp Lys Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ala Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Gly Phe Ala Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 95]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 95]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 96]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 96]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Asp Tyr Ser Ile Thr Arg Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Tyr Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 97]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 97]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ile Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln His Phe Gly Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 98]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 98]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Ala Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Ser Leu Gly Asn Gly Asp Ile Lys Tyr Ser Glu Lys Phe
              50 55 60
          Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys Thr Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Lys Arg Ser Arg Val Leu Arg Trp Thr Thr Tyr Trp Tyr Phe Asp Val
                      100 105 110
          Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 99]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 99]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg Leu Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln Tyr Tyr Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 100]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 100]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Ser Phe Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Leu Ser Ile Thr Arg Asp Thr Ser Met Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Ala Glu Ile Tyr Tyr Asp Tyr Asp Gly Asp Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 101]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 101]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Gly Ser Asn Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Phe Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro His Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 102]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 102]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Met Asn Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Ser Pro Lys Asn Gly Arg Thr Gly Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Lys Ser Asn Gly Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 103]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 103]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Cys Val Thr Pro Gly
          1 5 10 15
          Glu Thr Val Ser Leu Ser Cys Arg Ala Ser Gln Asn Ile Tyr Lys Asn
                      20 25 30
          Leu His Trp Phe Gln Gln Lys Ser His Arg Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Tyr Ala Ser Asp Ser Ile Ser Gly Ile Pro Ser Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Ser Ile Asn Ser Val Lys Pro
          65 70 75 80
          Glu Asp Glu Gly Ile Tyr Tyr Cys Leu Gln Gly Tyr Ser Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 104]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 104]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Arg Tyr
                      20 25 30
          Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Met Ile Trp Gly Ser Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala
                          85 90 95
          Arg Val Tyr Tyr Gly Gly Ser Pro Tyr Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 105]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 105]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Leu Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp
          65 70 75 80
          Pro Val Glu Ala Asp Asp Ala Ala Ile Tyr Tyr Cys Gln Gln Asn Asn
                          85 90 95
          Glu Glu Pro Asn Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 106]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 106]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Lys Trp Val
                  35 40 45
          Ala Cys Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Asn Tyr Arg Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 107]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 107]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Ile Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Trp Thr Phe Gly Ala Gly Thr Gly Leu Glu Ile Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 108]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 108]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Asn Gly Asp Thr Val Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Thr Leu Thr Gly Met Tyr Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 109]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 109]]>
          Asp Ile Gln Met Thr Gln Ser Pro Lys Phe Leu His Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ile Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Ile Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Pro Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 110]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 110]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Gly Val Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 111]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 111]]>
          Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Glu Gly
          1 5 10 15
          Asp Arg Val Asn Ile Thr Cys Lys Ala Ser Gln Asn Ile Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile
                  35 40 45
          Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Glu Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 112]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 112]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Ala Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Leu Phe Leu
          65 70 75 80
          Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val Trp Gly
                      100 105 110
          Ala Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 113]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial Description]]>: I23RB81
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 113]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 114]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 114]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Ala Leu His Trp Phe Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ser Pro Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Ser Asn Tyr Gly Arg Trp Tyr Phe Asp Val Trp Gly Ala
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 115]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PR]]>T
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 115]]>
          Gln Ile Val Leu Ser Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 116]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 116]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Asp Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Phe Ser Lys Asp Asn Ser Lys Arg Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Pro Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Pro Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 117]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 117]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Ser Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala
          65 70 75 80
          Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Ser Ser Ser Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 118]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 118]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Phe Asn Thr Tyr
                      20 25 30
          Ala Ile Thr Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Leu Trp Pro Gly Gly Gly Ile Ser Tyr Asn Leu Ala Leu Lys
              50 55 60
          Ser Arg Leu Thr Ile Ser Arg Asp Ser Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Glu Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Trp Arg His Tyr Asp Gly Ser Tyr Ala Met Asp Phe Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 119]]>
           <![CDATA[ <211> 219]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 119]]>
          Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Phe Val Ser Leu Gly
          1 5 10 15
          Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
                  35 40 45
          Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                          85 90 95
          Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
          Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
                  115 120 125
          Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
              130 135 140
          Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
          145 150 155 160
          Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
                          165 170 175
          Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
                      180 185 190
          Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
                  195 200 205
          Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 120]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 120]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Leu His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Tyr Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Pro Tyr Asp Tyr Asp Trp Gly Ala Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 121]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 121]]>
          Asp Ile Val Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly
          1 5 10 15
          Asp Thr Val Ser Ile Thr Cys His Ala Ser Gln Gly Ile Ser Ser Ser Asn
                      20 25 30
          Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile
                  35 40 45
          Tyr His Gly Thr Asn Leu Glu Asp Glu Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Gly Ser Leu Glu Ser
          65 70 75 80
          Glu Asp Phe Ala Asp Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 122]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 122]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asn Pro Tyr Asp Ala Ser Pro Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Ile Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Thr Arg Asp Ala Lys Leu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 123]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 123]]>
          Asp Ile Val Met Thr Gln Thr Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ile Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 124]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 124]]>
          Glu Phe Gln Leu Gln Gln Phe Gly Pro Glu Leu Leu Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Ile Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Gly Ile Ser Pro Asn Tyr Gly Gly Thr Gly Tyr Asn Gly Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Phe Asn Asn Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 125]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 125]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr
                      20 25 30
          Leu Ser Trp Cys Gln Gln Lys Pro Gly Lys Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Arg Ala Asn Ser Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr
          65 70 75 80
          Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 126]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 126]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Thr Met Asp Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Lys Ser Gly Gly Thr Gly Tyr Asn Gln Lys Phe
              50 55 60
          Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe His Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Val Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 127]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 127]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser
                      20 25 30
          Lys Tyr Asp Tyr Ile His Trp Tyr Gln Gln Lys Ser Gly Gln Pro Pro
                  35 40 45
          Arg Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Thr Trp
                          85 90 95
          Glu Ile Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 128]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 128]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Gly Val Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 129]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 129]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
          1 5 10 15
          Asp Ser Val Ser Leu Phe Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn
                      20 25 30
          Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr
          65 70 75 80
          Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 130]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 130]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Ser Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Ala Tyr Ala Glu Glu Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Val Arg Gln Thr Ala Arg Ala Thr Arg Gly Tyr Phe Asp Val
                      100 105 110
          Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 131]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 131]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Cys Cys Gln Gln His Tyr Thr Ser Pro Leu
                          85 90 95
          Thr Phe Gly Asp Gly Thr Arg Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 132]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 132]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ser
          1 5 10 15
          Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val
                  35 40 45
          Ala Asn Ile Asn Tyr Asp Gly Ser Asn Thr Tyr Tyr Leu Asp Ser Leu
              50 55 60
          Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Gly Tyr Asp Glu Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 133]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 133]]>
          Asp Ile Val Leu Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Thr Tyr Pro Tyr
                          85 90 95
          Thr Val Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 134]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 134]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Met His Trp Val Lys Gln Ser His Gly Lys Thr Ile Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Ser Gly Asp Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Thr Cys
                          85 90 95
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Thr Val Thr Val Ser Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 135]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 135]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Ser Met Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                          85 90 95
          Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 136]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 136]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Tyr Arg Tyr Gly Pro Leu Asp Gly Phe Asp Ile Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 137]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 137]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Ile Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Thr Ser Gln Asp Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Ile Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Asp Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 138]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 138]]>
          Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Lys Tyr
                      20 25 30
          Trp Ile Asn Trp Met Asn Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Ser Ile Ser Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Ser Lys Val Thr Leu Thr Val Asp Ile Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Asp Phe Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 139]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 139]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser His
                      20 25 30
          Ile Thr Trp Tyr Gln Leu Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Ala Ser Thr Asn Leu Ala Asp Asp Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Leu Ser
          65 70 75 80
          Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 140]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 140]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Asp Trp Val
                  35 40 45
          Ala Ser Ile Ser Thr Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys
              50 55 60
          Gly Gly Phe Thr Ile Ser Arg Asp Ile Ala Arg Asn Thr Leu Ser Leu
          65 70 75 80
          Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala
                          85 90 95
          Arg Gly Pro His Tyr Tyr Gly Gly Ser Tyr Pro Phe Ala Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 141]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 141]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 142]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 142]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Ile Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asp Pro Tyr Asn Asp Asp Thr Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Leu Gly Ser Ile Asn Tyr Tyr Asp Gly Ser Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 143]]>
           <![CDATA[ <211> 112]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 143]]>
          Asp Ile Val Met Thr Gln Ser Pro Leu Thr Leu Ser Val Ile Ile Gly
          1 5 10 15
          Gln Ser Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
                      20 25 30
          Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
                  35 40 45
          Pro Lys Arg Leu Met Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly
                          85 90 95
          Ile His Phe Pro Leu Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 144]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 144]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Ser Ser Gly Thr Thr Asn Tyr Ser Pro Ser Leu
              50 55 60
          Arg Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 145]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 145]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Leu Thr Cys Lys Ala Ser Gln Glu Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ile Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Tyr
                          85 90 95
          Ser Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 146]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus]]> musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 146]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Phe Ser Asp Arg Thr Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ser Arg Gln Leu Gly Leu Lys Ala Leu Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 147]]>
           <![CDATA[ <211> 112]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 147]]>
          Asp Val Gln Met Ile Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly
          1 5 10 15
          Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
                  35 40 45
          Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                          85 90 95
          Thr His Val Pro Leu Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 148]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 148]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Ala Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Lys Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Arg Gln Leu Gly Leu Arg Tyr Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 149]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus m]]>usculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 149]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Gly Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Phe Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 150]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 150]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Asp
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val
                  35 40 45
          Ala Glu Ile Ser Ser Asn Gly Gly Ser Thr Tyr His Ile Asp Thr Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Ser Pro Gly Tyr Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Val Thr Val Ser Ala
                  115
           <![CDATA[ <210> 151]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB153
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 151]]>
          Asp Ile Val Met Thr Gln Ser His Arg Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Glu Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Asn Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Thr Ser Thr Arg His Asn Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Gly
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Arg Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 152]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 152]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          His Ser Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Thr Asn Asp Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Asn Leu Asn Ser Val Thr Thr Glu Asp Thr Val Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Tyr Gly Gly Thr Tyr Arg Val Phe Ala Asp
                      100 105 110
          Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 153]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 153]]>
          Gln Ile Val Leu Ser Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Thr Ser Glu Ser Val Asp Thr Tyr
                      20 25 30
          Gly Asn Ser Phe Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Asn
                          85 90 95
          Lys Asp Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys
                      100 105 110
           <![CDATA[ <210> 154]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 154]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Ala Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Val Phe Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Ile Phe Leu
          65 70 75 80
          Lys Met Ile Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val Trp Gly
                      100 105 110
          Ala Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 155]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 155]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Gly Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 156]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 156]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Ser Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Tyr Ile Ser Thr Gly Gly Gly Asp Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Thr Ser Tyr Ser Tyr Tyr Asn Tyr Val Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 157]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> ]]> 157
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
                      20 25 30
          Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
          65 70 75 80
          Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Lys
                          85 90 95
          Glu Val Pro Trp Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105 110
           <![CDATA[ <210> 158]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 158]]>
          Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Gly Met Ala Trp Val Arg Gln Thr Pro Arg Lys Gly Pro Glu Trp Ile
                  35 40 45
          Ala Phe Ile Ser Asn Leu Ala Tyr Ser Val Tyr Tyr Ser Asp Thr Val
              50 55 60
          Thr Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Glu Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg His Gly Asp Tyr Arg Asn Tyr Gly Phe Ala Tyr Trp Gly Leu
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 159]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 159]]>
          Asp Ile Val Met Thr Gln Thr Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 160]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 160]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Tyr Ser Ser Gly Thr Ile Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Gly Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 161]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 161]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          His Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Val
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 162]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 162]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Val Tyr Ala Phe Ser Ser Ser Ser
                      20 25 30
          Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Arg Tyr Asp Phe Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 163]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 163]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
                  35 40 45
          Ala Thr Ser Asp Leu Ala Ser Gly Ala Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr
                          85 90 95
          Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 164]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 164]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Arg Thr Gly Thr Arg Trp Tyr Phe Asp Val Trp Gly Ala
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 165]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 165]]>
          Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Phe
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 166]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 166]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Ser
                      20 25 30
          Leu Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Asp Pro Glu Asp Gly Lys Thr Lys Tyr Ala Pro Lys Phe
              50 55 60
          Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Glu Val Leu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 167]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 167]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105 110
           <![CDATA[ <210> 168]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 168]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Thr Val Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Asn Gly
                      20 25 30
          Asn His Trp Trp Asn Trp Ile Arg Gln Val Ser Gly Ser Lys Leu Glu
                  35 40 45
          Trp Ile Gly Tyr Ile Arg Ser Ser Gly Ser Thr Asp Ser Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Leu
          65 70 75 80
          Phe Leu Gln Leu Asn Ser Val Thr Ala Glu Asp Ile Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Arg Glu Arg Leu Arg Leu Arg Trp Ser Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 169]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 169]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Ala Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Arg
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 170]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 170]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Tyr Pro Ala Ile Asn Asn Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Arg Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Ile Ser Arg Lys Pro Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 171]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 171]]>
          Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Ser Phe Ser Val Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Leu Tyr Asn Arg
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile
                  35 40 45
          Ser Gly Ala Thr Ser Leu Gly Thr Gly Val Leu Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr
          65 70 75 80
          Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Ile Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 172]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 172]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Val
                      20 25 30
          Gly Met Gln Trp Val Gln Lys Met Pro Gly Lys Gly Phe Lys Trp Ile
                  35 40 45
          Gly Trp Ile Asn Thr His Ser Gly Glu Pro Lys Tyr Thr Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Ser Asn Leu Lys Ser Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Ser Ala Leu Thr Gly Ala Phe Ala Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 173]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 173]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Asp Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro Arg Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105 110
           <![CDATA[ <210> 174]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 174]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Gly Asn Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ala Gly Leu Leu Pro Tyr Tyr Ala Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 175]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 175]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr
                  35 40 45
          Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr
                          85 90 95
          Phe Gly Asp Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 176]]>
           <![CDATA[ <211> 116]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 176]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Leu Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Ile Thr Asp Tyr
                      20 25 30
          Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Gly Ile Asn Pro Asn Tyr Gly Gly Thr Ser Tyr Asn Glu Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Tyr Cys
                          85 90 95
          Val Arg Gly Asn Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu
                      100 105 110
          Thr Val Ser Ser
                  115
           <![CDATA[ <210> 177]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 177]]>
          Asn Thr Gln Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr
                      20 25 30
          Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr
          65 70 75 80
          Glu Asp Met Gly Ile Tyr Tyr Cys Gln Gln Tyr Asp Glu Phe Pro Arg
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 178]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 178]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Tyr
                      20 25 30
          Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala Asn Ile Trp Trp Asn Asp Ser Lys Tyr His Asn Ala Ala
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
          65 70 75 80
          Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Gly Arg Ile Asp Gly Tyr Tyr Glu Cys Val Asp Val Trp Gly Thr
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 179]]>
           <![CDATA[ <211> 109]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 179]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Val Asn Ile His Asn Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Thr Thr Pro Tyr
                          85 90 95
          Met Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 180]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 180]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Phe Trp Asn Trp Leu Arg Gln Phe Pro Gly Ser Lys Leu Glu Trp
                  35 40 45
          Met Gly Phe Ile Asp Asn Asp Gly Ser Asn Asp Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Arg Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Leu Gly Phe Phe Asp Ser Trp Gly Pro Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 181]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 181]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn Tyr Met
                      20 25 30
          Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr
                  35 40 45
          Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Asn Ser Pro Trp Thr
                          85 90 95
          Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 182]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 182]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Tyr Thr Gly Ala Pro Thr Tyr Ala Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Phe Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Gly Asn Gly Tyr Pro Tyr Tyr Tyr Gly Ile Asn Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 183]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 183]]>
          Asp Val Gln Met Ile Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Asn
                      20 25 30
          Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
              50 55 60
          Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
          65 70 75 80
          Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 184]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 184]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Ser Ser Gly Thr Thr Asn Tyr Ser Pro Ser Leu
              50 55 60
          Arg Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 185]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 185]]>
          Asp Ile Val Leu Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
          1 5 10 15
          Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
                      20 25 30
          Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Met
                  35 40 45
          Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Pro
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 186]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 186]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Gly Thr Leu Gly Trp Asp Asp Lys Lys Ser Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Lys Leu Ser Ser Ser Leu Gln Thr Glu Asp Thr Ala Met Tyr Tyr Cys Thr
                          85 90 95
          Lys Glu Asp Val Ser Tyr Ala Met Asp Phe Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 187]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 187]]>
          Asp Ile Gln Met Thr Gln Ser Pro Thr Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr
                      20 25 30
          Gly Thr Ser Leu Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ile Ala Met Tyr Phe Cys Gln Gln Gly Lys
                          85 90 95
          Lys Val Pro Trp Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105 110
           <![CDATA[ <210> 188]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 188]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
                      20 25 30
          Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Ile
          65 70 75 80
          Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Arg Arg Thr Leu Gly Gly Pro Pro Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 189]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 189]]>
          Asp Ile Val Leu Thr Gln Ser Gln Arg Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Ile Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Leu Pro Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 190]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 190]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Ala Glu Met Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
                      20 25 30
          Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Lys Ile Asp Pro Ser Asp Thr Glu Thr His Tyr Asn Gln Asn Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Gly Arg Asn Phe Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 191]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 191]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
          1 5 10 15
          Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp His
                      20 25 30
          Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Phe Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asp Ser Val Glu Pro
          65 70 75 80
          Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Leu
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 192]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 192]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Ala Leu His Trp Val Lys Gln Ser Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Tyr Pro Gly Gly Gly Asn Thr Tyr Tyr Asn Asp Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Met Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Gly Arg Leu Arg Arg Asp Tyr Pro Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 193]]>
           <![CDATA[ <211> ]]> 113
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 193]]>
          Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
          1 5 10 15
          Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
                      20 25 30
          Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
                          85 90 95
          Asp Tyr Thr Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
                      100 105 110
          Lys
           <![CDATA[ <210> 194]]>
           <![CDATA[ <211> ]]>121
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 194]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Arg Asp Ile
                      20 25 30
          Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Asp Pro Ala Asn Gly His Ser Ile Tyr Ala Ala Lys Phe
              50 55 60
          Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Leu Asn Ile Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Gly Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ser Asp Asn Asp Tyr Gly Arg Val Leu Ala Tyr Trp Gly
                      100 105 110
          Leu Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 195]]>
           <![CDATA[ <211> 109]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 195]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Arg Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Val Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Thr Gly Asn Pro
                          85 90 95
          Ile Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 196]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 196]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          His Asn Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Leu Gly Tyr Ile Ser Tyr Asp Gly Ser Asn Asn Tyr Asp Pro Ser Leu
              50 55 60
          Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Phe Gly Asn Ser Tyr Arg Val Phe Ala Ser
                      100 105 110
          Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 197]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 197]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Glu Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Ala Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 198]]>
           <![CDATA[ <211> 116]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 198]]>
          Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Phe Asn Ile Lys Asp Thr
                      20 25 30
          Tyr Ile His Trp Met Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Ile Tyr Ala Ser Lys Phe
              50 55 60
          Gln Gly Lys Ala Thr Leu Thr Thr Thr Asp Thr Ser Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Leu Leu Ser Ser Ser Leu Thr Ser Gly Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Thr Arg Gly Thr Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val
                      100 105 110
          Thr Val Ser Ser
                  115
           <![CDATA[ <210> 199]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 199]]>
          Asp Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
          1 5 10 15
          Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Ser
                      20 25 30
          Val Ser Trp Phe Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Arg
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 200]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 200]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Pro Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Gly Asn Gly Gly Thr Ala Tyr Asn Gln Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Ala Asp Asn Pro Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Ser Arg Gly Gly Ser Arg Asn Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 201]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I23R]]>B39
           <![CDATA[ <220>]]>
           <![CDATA[ <22]]>3> Description of peptide type: light chain variable region]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;201]]&gt;
           <br/>
           <br/> <![CDATA[Asp Ile Gln Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Ser Ser Pro Arg
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 202]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 202]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
                      20 25 30
          Ile Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Asn Pro Tyr Phe Gly Phe Thr Ser Tyr Asn Gln Glu Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Leu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ser Arg Gly Ser Tyr Tyr Gly Tyr Glu Thr Phe Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <21]]>0> 203]]&gt;
           <br/> &lt;![CDATA[ &lt;211&gt;112]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Mouse (Mus musculus)]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB42]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt;]]&gt; <![CDATA[ Explanation of Peptide Type: Light Chain Variable Region
           <![CDATA[ <400> 203]]>
          Asp Ile Val Leu Thr Gln Thr Ala Pro Ser Val Pro Val Thr Pro Gly
          1 5 10 15
          Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
                  35 40 45
          Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
                          85 90 95
          Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 204]]>
           <![CDATA[ <211> 124]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 204]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Tyr
                      20 25 30
          Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Asn Gln Val
          65 70 75 80
          Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Gln Arg Ala Leu Pro Leu Leu Gly Gln Lys Ala Pro Phe Asp
                      100 105 110
          Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 205]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 205]]>
          Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Ile Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Leu Pro Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Val Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Gln Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 206]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 206]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Asp Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Arg Thr Asp Tyr Lys Gly Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Thr Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 207]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 207]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Ser Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala
          65 70 75 80
          Glu Asp Phe Val Phe Tyr Tyr Cys His Gln Leu Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 208]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence]]> Description: I23RB51
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 208]]>
          Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Val His Tyr Arg Asp Ser Thr His Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 209]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <22]]>0>]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB51]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: light chain variable region]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;209]]&gt;
           <br/>
           <br/> <![CDATA[Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln His Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
                  35 40 45
          Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Gly Ser Tyr Tyr Cys Gln Tyr Phe Trp Thr Thr Arg Thr
                          85 90 95
          Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 210]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 210]]>
          Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Gly Ile Ser Ser Ser Gly Gly Ser Tyr Ile Tyr Tyr Pro Asp Asn Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Lys Lys Ser Asp Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 211]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 211]]>
          Asp Ile Gln Met Thr Gln Ser Pro Lys Phe Leu Leu Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Leu Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 212]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 212]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Ala Ile Asn Ser Asn Asp Gly Ser Thr Tyr Tyr Pro Asp Thr Val
              50 55 60
          Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
                          85 90 95
          Ala Arg His Phe Leu Tyr Phe Ser Asn Phe Tyr Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 213]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of peptide type:]]>light chain variable region
           <![CDATA[ <400> 213]]>
          Asp Ile Val Met Thr Gln Ser Pro Lys Phe Leu Leu Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Val Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Pro Phe
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 214]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 214]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Met His Trp Val Lys Gln Ser His Gly Lys Thr Ile Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Ser Gly Asp Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Asn Cys
                          85 90 95
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 215]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 215]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Ser Met Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                          85 90 95
          Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 216]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 216]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ile Ile Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
                  35 40 45
          Ala Tyr Ile Thr Ser Gly Gly Gly Ile Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg His Glu Gly Asp Tyr Tyr Asp Asp Tyr Tyr Arg Ile Gly Tyr
                      100 105 110
          Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 217]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 217]]>
          Asp Ile Val Met Thr Gln Thr Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105 110
           <![CDATA[ <210> 218]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 218]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Asp
          1 5 10 15
          Ser Val Lys Met Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Ile Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Asn Gly Gly Ile Ser Phe Asn Gln Lys Phe
              50 55 60
          Glu Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Lys Leu Arg Gly Arg Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 219]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 219]]>
          Asp Ile Val Met Thr Gln Ser Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Asn
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Phe Tyr Ser Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly His Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 220]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 220]]>
          Asp Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ser Phe Asp Tyr Thr Phe Thr Ser Phe
                      20 25 30
          Asp Ile Asn Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Trp Ile Phe Pro Gly Ser Gly Thr Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met His Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Ala Arg Arg Leu Thr Gly Thr Arg Tyr Phe Asp Val Trp Gly Thr Gly
                      100 105 110
          Thr Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 221]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 221]]>
          Asp Ile Gln Met Thr Gln Ser His Lys Phe Leu Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Ile Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ile Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Asn Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 222]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 222]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Thr Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Lys Ser Gly Asn Ala Ala Tyr Ser Gln Lys Phe
              50 55 60
          Lys Ser Glu Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Thr Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 223]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 223]]>
          Gln Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser
                      20 25 30
          Ser Tyr Asn Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Asp Asp Thr Ala Thr Tyr Tyr Cys Gln His Thr Trp
                          85 90 95
          Glu Ile Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 224]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of peptide type:]]> Heavy chain variable region
           <![CDATA[ <400> 224]]>
          Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
          1 5 10 15
          Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser
                      20 25 30
          Asn Met Gly Ile Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
                  35 40 45
          Trp Leu Ala His Ile Trp Trp Asn Ser Asp Lys Tyr Tyr Asn Pro Ser
              50 55 60
          Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Asn Gln Val
          65 70 75 80
          Phe Leu Thr Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
                          85 90 95
          Cys Ala Gln Ile Arg Trp Leu Arg Phe Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 225]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 225]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Phe Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 226]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 226]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Ser Ser Ser Thr Asn Tyr Asn Glu Lys Phe
              50 55 60
          Lys Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Ala Tyr Gly Asn Arg Leu Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 227]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 227]]>
          Asp Val Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 228]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 228]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
                      20 25 30
          Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Asn Ile Asn Pro Phe Tyr Asp Lys Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ala Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Leu Gly Leu Lys Gly Phe Ala Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ala
                  115
           <![CDATA[ <210> 229]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 229]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 230]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 230]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Thr Val Thr Asp Tyr Ser Ile Thr Arg Gly
                      20 25 30
          Tyr Asn Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
          65 70 75 80
          Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Gln Tyr Gly Leu Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 231]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 231]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ile Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln His Phe Gly Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 232]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 232]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Ala Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Ser Leu Gly Asn Gly Asp Ile Lys Tyr Ser Glu Lys Phe
              50 55 60
          Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys Thr Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                          85 90 95
          Lys Arg Ser Arg Val Leu Arg Trp Thr Thr Tyr Trp Tyr Phe Asp Val
                      100 105 110
          Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 233]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 233]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg Leu Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln Tyr Tyr Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 234]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 234]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly
                      20 25 30
          Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
                  35 40 45
          Met Gly Tyr Ile Ser Tyr Asp Gly Ser Phe Asn Tyr Asn Pro Ser Leu
              50 55 60
          Lys Asn Arg Leu Ser Ile Thr Arg Asp Thr Ser Met Asn Gln Phe Phe
          65 70 75 80
          Leu Lys Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Ala Glu Ile Tyr Tyr Asp Tyr Asp Gly Asp Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 235]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ Description of <223> Peptide]]> Type: Light Chain Variable Region
           <![CDATA[ <400> 235]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
                      20 25 30
          Gly Ser Asn Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Phe Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
                          85 90 95
          Glu Leu Pro His Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105 110
           <![CDATA[ <210> 236]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I23RB]]>76
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 236]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Met Asn Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Ser Pro Lys Asn Gly Arg Thr Gly Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Lys Ser Asn Gly Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 237]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 237]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Cys Val Thr Pro Gly
          1 5 10 15
          Glu Thr Val Ser Leu Ser Cys Arg Ala Ser Gln Asn Ile Tyr Lys Asn
                      20 25 30
          Leu His Trp Phe Gln Gln Lys Ser His Arg Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Tyr Ala Ser Asp Ser Ile Ser Gly Ile Pro Ser Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Tyr Thr Leu Ser Ile Asn Ser Val Lys Pro
          65 70 75 80
          Glu Asp Glu Gly Ile Tyr Tyr Cys Leu Gln Gly Tyr Ser Thr Pro Trp
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 238]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 238]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Arg Tyr
                      20 25 30
          Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Met Ile Trp Gly Ser Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala
                          85 90 95
          Arg Val Tyr Tyr Gly Gly Ser Pro Tyr Ala Met Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 239]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 239]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Leu Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp
          65 70 75 80
          Pro Val Glu Ala Asp Asp Ala Ala Ile Tyr Tyr Cys Gln Gln Asn Asn
                          85 90 95
          Glu Glu Pro Asn Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105 110
           <![CDATA[ <210> 240]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 240]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
          1 5 10 15
          Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
                      20 25 30
          Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Lys Trp Val
                  35 40 45
          Ala Cys Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Asn Tyr Arg Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 241]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 241]]>
          Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
                      20 25 30
          Gly Ile Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
          65 70 75 80
          Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Trp Thr Phe Gly Ala Gly Thr Gly Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 242]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 242]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Arg Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Asn Gly Asp Thr Val Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Thr Leu Thr Gly Met Tyr Tyr Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 243]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 243]]>
          Asp Ile Gln Met Thr Gln Ser Pro Lys Phe Leu His Val Ser Ala Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ile Asn Asp
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Ile Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Ser Pro Pro
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 244]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 244]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Gly Val Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 245]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 245]]>
          Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Glu Gly
          1 5 10 15
          Asp Arg Val Asn Ile Thr Cys Lys Ala Ser Gln Asn Ile Arg Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile
                  35 40 45
          Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Glu Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 246]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 246]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Ala Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Leu Phe Leu
          65 70 75 80
          Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val Trp Gly
                      100 105 110
          Ala Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 247]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> sequence description]]> Ming: I23RB81
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 247]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Ala Gly Thr Arg Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 248]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 248]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Ala Leu His Trp Phe Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ser Pro Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Ser Asn Tyr Gly Arg Trp Tyr Phe Asp Val Trp Gly Ala
                      100 105 110
          Gly Thr Thr Leu Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 249]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 249]]>
          Gln Ile Val Leu Ser Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 250]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 250]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
                      20 25 30
          Asp Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Phe Ser Lys Asp Asn Ser Lys Arg Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Pro Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Pro Met Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 251]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 251]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Ser Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala
          65 70 75 80
          Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Ser Ser Ser Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 252]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 252]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Phe Asn Thr Tyr
                      20 25 30
          Ala Ile Thr Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Leu Trp Pro Gly Gly Gly Ile Ser Tyr Asn Leu Ala Leu Lys
              50 55 60
          Ser Arg Leu Thr Ile Ser Arg Asp Ser Ser Lys Ser Gln Val Phe Leu
          65 70 75 80
          Glu Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
                          85 90 95
          Arg Asn Trp Arg His Tyr Asp Gly Ser Tyr Ala Met Asp Phe Trp Gly
                      100 105 110
          Gln Gly Thr Ser Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 253]]>
           <![CDATA[ <211> 112]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 253]]>
          Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Phe Val Ser Leu Gly
          1 5 10 15
          Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
                      20 25 30
          Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
                  35 40 45
          Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
              50 55 60
          Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          65 70 75 80
          Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
                          85 90 95
          Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 254]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 254]]>
          Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Leu His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Tyr Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Pro Tyr Asp Tyr Asp Trp Gly Ala Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Ser Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 255]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 255]]>
          Asp Ile Val Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly
          1 5 10 15
          Asp Thr Val Ser Ile Thr Cys His Ala Ser Gln Gly Ile Ser Ser Ser Asn
                      20 25 30
          Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile
                  35 40 45
          Tyr His Gly Thr Asn Leu Glu Asp Glu Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Gly Ser Leu Glu Ser
          65 70 75 80
          Glu Asp Phe Ala Asp Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 256]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 256]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Asn Pro Tyr Asp Ala Ser Pro Lys Tyr Asn Glu Lys Phe
              50 55 60
          Lys Gly Lys Ala Ile Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Thr Arg Asp Ala Lys Leu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 257]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 257]]>
          Asp Ile Val Met Thr Gln Thr Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
          1 5 10 15
          Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Asn Leu Glu Gln
          65 70 75 80
          Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ile Thr Leu Pro Trp
                          85 90 95
          Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
                      100 105
           <![CDATA[ <210> 258]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 258]]>
          Glu Phe Gln Leu Gln Gln Phe Gly Pro Glu Leu Leu Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
                      20 25 30
          Ile Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
                  35 40 45
          Gly Gly Ile Ser Pro Asn Tyr Gly Gly Thr Gly Tyr Asn Gly Lys Phe
              50 55 60
          Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Phe Asn Asn Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 259]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 259]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr
                      20 25 30
          Leu Ser Trp Cys Gln Gln Lys Pro Gly Lys Ser Pro Lys Ala Leu Ile
                  35 40 45
          Tyr Arg Ala Asn Ser Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr
          65 70 75 80
          Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 260]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 260]]>
          Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
                      20 25 30
          Thr Met Asp Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Lys Ser Gly Gly Thr Gly Tyr Asn Gln Lys Phe
              50 55 60
          Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Phe His Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Val Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ala
                  115
           <![CDATA[ <210> 261]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 261]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser
                      20 25 30
          Lys Tyr Asp Tyr Ile His Trp Tyr Gln Gln Lys Ser Gly Gln Pro Pro
                  35 40 45
          Arg Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Thr Trp
                          85 90 95
          Glu Ile Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
                      100 105 110
           <![CDATA[ <210> 262]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I23RB]]>93
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 262]]>
          Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
          1 5 10 15
          Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
                      20 25 30
          Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
                  35 40 45
          Gly Val Ile Trp Ser Gly Val Ser Thr Asp Tyr Asn Ala Ala Phe Ile
              50 55 60
          Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
          65 70 75 80
          Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                          85 90 95
          Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
                      100 105 110
          Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 263]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 263]]>
          Asp Ile Lys Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
          1 5 10 15
          Asp Ser Val Ser Leu Phe Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn
                      20 25 30
          Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
                  35 40 45
          Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr
          65 70 75 80
          Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 264]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 264]]>
          Asp Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Ser Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Ala Tyr Ala Glu Glu Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys
                          85 90 95
          Ala Arg Val Arg Gln Thr Ala Arg Ala Thr Arg Gly Tyr Phe Asp Val
                      100 105 110
          Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 265]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 265]]>
          Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ser Ala Phe Tyr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Ser Val Gln Ala
          65 70 75 80
          Glu Asp Leu Ala Val Tyr Cys Cys Gln Gln His Tyr Thr Ser Pro Leu
                          85 90 95
          Thr Phe Gly Asp Gly Thr Arg Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 266]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 266]]>
          Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ser
          1 5 10 15
          Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val
                  35 40 45
          Ala Asn Ile Asn Tyr Asp Gly Ser Asn Thr Tyr Tyr Leu Asp Ser Leu
              50 55 60
          Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr
          65 70 75 80
          Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Gly Tyr Asp Glu Ala Met Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Thr Leu Thr Val Ser Ser
                  115
           <![CDATA[ <210> 267]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 267]]>
          Asp Ile Val Leu Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
          1 5 10 15
          Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
                      20 25 30
          Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
          65 70 75 80
          Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Thr Tyr Pro Tyr
                          85 90 95
          Thr Val Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 268]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 268]]>
          Glu Phe Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
          1 5 10 15
          Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
                      20 25 30
          Tyr Met His Trp Val Lys Gln Ser His Gly Lys Thr Ile Glu Trp Ile
                  35 40 45
          Gly Tyr Ile Tyr Pro Asn Ser Gly Asp Thr Ser Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Thr Cys
                          85 90 95
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Thr Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 269]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 269]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
          1 5 10 15
          Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
                  35 40 45
          Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Ser Met Glu
          65 70 75 80
          Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro
                          85 90 95
          Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Met Lys
                      100 105
           <![CDATA[ <210> 270]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 270]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 271]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 271]]>
          Ile Asn Pro Asn Ser Gly Gly Thr
          1 5
           <![CDATA[ <210> 272]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 272]]>
          Ala Arg Gly Tyr Arg Tyr Gly Pro Leu Asp Gly Phe Asp Ile
          1 5 10
           <![CDATA[ <210> 273]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 273]]>
          Gln Asp Val Arg Thr Ala
          1 5
           <![CDATA[ <210> 274]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 274]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 275]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB101]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 275]]>
          Gln Gln His Tyr Ser Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 276]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 276]]>
          Gly Tyr Thr Phe Thr Lys Tyr Trp
          1 5
           <![CDATA[ <210> 277]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 277]]>
          Ile Tyr Pro Gly Ser Ile Ser Thr
          1 5
           <![CDATA[ <210> 278]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 278]]>
          Ala Arg Gly Asp Phe Tyr Ala Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 279]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> small]]> mouse (Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 279]]>
          Glu Asn Ile Tyr Ser His
          1 5
           <![CDATA[ <210> 280]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 280]]>
          Ala Ser Thr
          1           
           <![CDATA[ <210> 281]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB102]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 281]]>
          Gln His Phe Trp Gly Thr Pro Trp Thr
          1 5
           <![CDATA[ <210> 282]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 282]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 283]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 283]]>
          Ile Ser Thr Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 284]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 284]]>
          Ala Arg Gly Pro His Tyr Tyr Gly Gly Ser Tyr Pro Phe Ala Tyr
          1 5 10 15
           <![CDATA[ <210> 285]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 285]]>
          Glu Asn Ile Tyr Ser Asn
          1 5
           <![CDATA[ <210> 286]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <22]]>0>]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB104]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: LCDR2]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;286]]&gt;
           <br/>
           <br/> <![CDATA[Ala Ala Thr
          1           
           <![CDATA[ <210> 287]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB104]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 287]]>
          Gln His Phe Trp Gly Thr Pro Pro Thr
          1 5
           <![CDATA[ <210> 288]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 288]]>
          Gly Tyr Thr Phe Thr Ser Tyr Ile
          1 5
           <![CDATA[ <210> 289]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type:]]>HCDR2
           <![CDATA[ <400> 289]]>
          Ile Asp Pro Tyr Asn Asp Asp Thr
          1 5
           <![CDATA[ <210> 290]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 290]]>
          Ala Arg Leu Gly Ser Ile Asn Tyr Tyr Asp Gly Ser Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 291]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 291]]>
          Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr
          1 5 10
           <![CDATA[ <210> 292]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 292]]>
          Leu Val Ser
          1           
           <![CDATA[ <210> 293]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB144]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 293]]>
          Trp Gln Gly Ile His Phe Pro Leu Thr
          1 5
           <![CDATA[ <210> 294]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 294]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Asn
          1 5
           <![CDATA[ <210> 295]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 295]]>
          Ile His Ser Ser Gly Thr Thr
          1 5
           <![CDATA[ <210> 296]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 296]]>
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr
          1 5 10
           <![CDATA[ <210> 297]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 297]]>
          Gln Glu Val Arg Thr Ala
          1 5
           <![CDATA[ <210> 298]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 298]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 299]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (]]>Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB148]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 299]]>
          Gln Gln His Tyr Thr Thr Pro Tyr Ser
          1 5
           <![CDATA[ <210> 300]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 300]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Asn
          1 5
           <![CDATA[ <210> 301]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 301]]>
          Ile His Phe Ser Asp Arg Thr
          1 5
           <![CDATA[ <210> 302]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 302]]>
          Ser Arg Gln Leu Gly Leu Lys Ala Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 303]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 303]]>
          Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr
          1 5 10
           <![CDATA[ <210> 304]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 304]]>
          Lys Val Ser
          1           
           <![CDATA[ <210> 305]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB149]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 305]]>
          Ser Gln Ser Thr His Val Pro Leu Thr
          1 5
           <![CDATA[ <210> 306]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus musculu]]>s)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 306]]>
          Ala Tyr Thr Phe Thr Asn Tyr Gly
          1 5
           <![CDATA[ <210> 307]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 307]]>
          Ile Lys Thr Asn Thr Gly Glu Pro
          1 5
           <![CDATA[ <210> 308]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB150
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 308]]>
          Ala Arg Ser Arg Gln Leu Gly Leu Arg Tyr Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 309]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 309]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 310]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 310]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 311]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB150]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223]]>> Description of peptide type: LCDR3]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;311]]&gt;
           <br/>
           <br/> <![CDATA[Gln Gln His Tyr Ser Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 312]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 312]]>
          Gly Phe Thr Phe Ser Ser Asp Thr
          1 5
           <![CDATA[ <210> 313]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 313]]>
          Ile Ser Ser Asn Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 314]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 314]]>
          Ala Ser Pro Gly Tyr Pro Trp Phe Ala Tyr
          1 5 10
           <![CDATA[ <210> 315]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 315]]>
          Gln Asp Val Gly Asn Ala
          1 5
           <![CDATA[ <210> 316]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 316]]>
          Trp Thr Ser
          1           
           <![CDATA[ <210> 317]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB153]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 317]]>
          Gln Gln Tyr Asn Arg Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 318]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 318]]>
          Gly Tyr Ser Ile Thr Ser Gly His Ser
          1 5
           <![CDATA[ <210> 319]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 319]]>
          Ile Ser Tyr Asp Gly Thr Asn
          1 5
           <![CDATA[ <210> 320]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I]]>23RB155
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 320]]>
          Ala Arg Gly Gly Gly Tyr Tyr Gly Gly Thr Tyr Arg Val Phe Ala Asp
          1 5 10 15
           <![CDATA[ <210> 321]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 321]]>
          Glu Ser Val Asp Thr Tyr Gly Asn Ser Phe
          1 5 10
           <![CDATA[ <210> 322]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 322]]>
          Arg Ala Ser
          1           
           <![CDATA[ <210> 323]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB155]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 323]]>
          Gln Gln Gly Asn Lys Asp Pro Tyr Thr
          1 5
           <![CDATA[ <210> 324]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 324]]>
          Gly Phe Ser Leu Thr Ser Tyr Ala
          1 5
           <![CDATA[ <210> 325]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 325]]>
          Ile Trp Thr Gly Gly Gly Thr
          1 5
           <![CDATA[ <210> 326]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 326]]>
          Ala Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val
          1 5 10 15
           <![CDATA[ <210> 327]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 327]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 328]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 328]]>
          Ser Ala Phe
          1           
           <![CDATA[ <210> 329]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB156]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 329]]>
          Gln Gln His Tyr Ser Ile Pro Leu Thr
          1 5
           <![CDATA[ <210> 330]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 330]]>
          Gly Phe Thr Phe Ser Arg Tyr Thr
          1 5
           <![CDATA[ <210> 331]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 331]]>
          Ile Ser Thr Gly Gly Gly Asp Thr
          1 5
           <![CDATA[ <210> 332]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 332]]>
          Ala Arg Arg Thr Ser Tyr Ser Tyr Tyr Asn Tyr Val Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 333]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 333]]>
          Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe
          1 5 10
           <![CDATA[ <210> 334]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 334]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 335]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB157]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 335]]>
          Gln Gln Ser Lys Glu Val Pro Trp Thr
          1 5
           <![CDATA[ <210> 336]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 336]]>
          Gly Phe Thr Phe Ser Asp Tyr Gly
          1 5
           <![CDATA[ <210> 337]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 337]]>
          Ile Ser Asn Leu Ala Tyr Ser Val
          1 5
           <![CDATA[ <210> 338]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 338]]>
          Ala Arg His Gly Asp Tyr Arg Asn Tyr Gly Phe Ala Tyr
          1 5 10
           <![CDATA[ <210> 339]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 339]]>
          Gln Asp Ile Ser Asn Tyr
          1 5
           <![CDATA[ <210> 340]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 340]]>
          Tyr Thr Ser
          1           
           <![CDATA[ <210> 341]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB159]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 341]]>
          Gln Gln Gly Asn Thr Leu Pro Trp Thr
          1 5
           <![CDATA[ <210> 342]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 342]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Asn
          1 5
           <![CDATA[ <210> 343]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 343]]>
          Ile His Tyr Ser Ser Gly Thr
          1 5
           <![CDATA[ <210> 344]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 344]]>
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 345]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 345]]>
          Gln Asp Val Arg Thr Ala
          1 5
           <![CDATA[ <210> 346]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 346]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 347]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB160]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 347]]>
          Gln Gln His Tyr Thr Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 348]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 348]]>
          Val Tyr Ala Phe Ser Ser Ser Trp
          1 5
           <![CDATA[ <210> 349]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 349]]>
          Ile Tyr Pro Gly Asp Gly Asp Thr
          1 5
           <![CDATA[ <210> 350]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 350]]>
          Ala Arg Arg Tyr Asp Phe Gly Ser Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 351]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 351]]>
          Ser Ser Val Ser Tyr
          1 5
           <![CDATA[ <210> 352]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 352]]>
          Ala Thr Ser
          1           
           <![CDATA[ <210> 353]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB161]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 353]]>
          Gln Gln Trp Ser Ser Asn Pro Pro Thr
          1 5
           <![CDATA[ <210> 354]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 354]]>
          Gly Tyr Thr Phe Thr Asn Tyr Val
          1 5
           <![CDATA[ <210> 355]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 355]]>
          Ile Asn Pro Tyr Asn Asp Gly Thr
          1 5
           <![CDATA[ <210> 356]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 356]]>
          Ala Arg Ser Arg Thr Gly Thr Arg Trp Tyr Phe Asp Val
          1 5 10
           <![CDATA[ <210> 357]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 357]]>
          Gln Asn Val Gly Thr Asn
          1 5
           <![CDATA[ <210> 358]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 358]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 359]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB162]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 359]]>
          Gln Gln Tyr Asn Ser Tyr Pro Phe Thr
          1 5
           <![CDATA[ <210> 360]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Peptide]]> Description of type: HCDR1
           <![CDATA[ <400> 360]]>
          Gly Phe Asn Ile Lys Asp Ser Leu
          1 5
           <![CDATA[ <210> 361]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 361]]>
          Ile Asp Pro Glu Asp Gly Lys Thr
          1 5
           <![CDATA[ <210> 362]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 362]]>
          Ala Arg Arg Glu Val Leu Asp Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 363]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 363]]>
          Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
          1 5 10
           <![CDATA[ <210> 364]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 364]]>
          Leu Ala Ser
          1           
           <![CDATA[ <210> 365]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB165]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 365]]>
          Gln His Ser Arg Glu Leu Pro Leu Thr
          1 5
           <![CDATA[ <210> 366]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 366]]>
          Gly Tyr Ser Ile Thr Asn Gly Asn His Trp
          1 5 10
           <![CDATA[ <210> 367]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 367]]>
          Ile Arg Ser Ser Gly Ser Thr
          1 5
           <![CDATA[ <210> 368]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 368]]>
          Ala Arg Glu Arg Leu Arg Leu Arg Trp Ser Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 369]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 369]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 370]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 370]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 371]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB166]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 371]]>
          Gln Gln His Tyr Ser Thr Pro Arg Thr
          1 5
           <![CDATA[ <210> 372]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 372]]>
          Gly Tyr Thr Phe Thr Asp Tyr Tyr
          1 5
           <![CDATA[ <210> 373]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 373]]>
          Ile Tyr Pro Ala Ile Asn Asn Thr
          1 5
           <![CDATA[ <210> 374]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 374]]>
          Ala Ile Ser Arg Lys Pro Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 375]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 375]]>
          Glu Asp Leu Tyr Asn Arg
          1 5
           <![CDATA[ <210> 376]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 376]]>
          Gly Ala Thr
          1           
           <![CDATA[ <210> 377]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB168]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 377]]>
          Gln Gln Tyr Trp Ser Ile Pro Trp Thr
          1 5
           <![CDATA[ <210> 378]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 378]]>
          Gly Tyr Thr Phe Thr Thr Val Gly
          1 5
           <![CDATA[ <210> 379]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 379]]>
          Ile Asn Thr His Ser Gly Glu Pro
          1 5
           <![CDATA[ <210> 380]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 380]]>
          Ala Arg Ser Ser Ala Leu Thr Gly Ala Phe Ala Tyr
          1 5 10
           <![CDATA[ <210> 381]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 381]]>
          Lys Ser Val Ser Thr Ser Asp Tyr Ser Tyr
          1 5 10
           <![CDATA[ <210> 382]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 382]]>
          Leu Ala Ser
          1           
           <![CDATA[ <210> 383]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB169]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 383]]>
          Gln His Ser Arg Glu Leu Pro Arg Thr
          1 5
           <![CDATA[ <210> 384]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 384]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr
          1 5
           <![CDATA[ <210> 385]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 385]]>
          Ile Ser Tyr Asp Gly Gly Asn
          1 5
           <![CDATA[ <210> 386]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 386]]>
          Ala Arg Asp Ala Gly Leu Leu Pro Tyr Tyr Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 387]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 387]]>
          Ser Ser Val Ser Tyr
          1 5
           <![CDATA[ <210> 388]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 388]]>
          Ser Thr Ser
          1           
           <![CDATA[ <210> 389]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB173]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 389]]>
          Gln Gln Arg Ser Ser Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 390]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 390]]>
          Gly Tyr Thr Ile Thr Asp Tyr Thr
          1 5
           <![CDATA[ <210> 391]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 391]]>
          Ile Asn Pro Asn Tyr Gly Gly Thr
          1 5
           <![CDATA[ <210> 392]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 392]]>
          Val Arg Gly Asn Ile Tyr Phe Asp Tyr
          1 5
           <![CDATA[ <210> 393]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 393]]>
          Gln Asp Ile Asn Ser Tyr
          1 5
           <![CDATA[ <210> 394]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 394]]>
          Arg Ala Asn
          1           
           <![CDATA[ <210> 395]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB177]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 395]]>
          Gln Gln Tyr Asp Glu Phe Pro Arg Thr
          1 5
           <![CDATA[ <210> 396]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 396]]>
          Gly Phe Ser Leu Ser Thr Tyr Gly Met Gly
          1 5 10
           <![CDATA[ <210> 397]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 397]]>
          Ile Trp Trp Asn Asp Ser Lys
          1 5
           <![CDATA[ <210> 398]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 398]]>
          Gly Arg Ile Asp Gly Tyr Tyr Glu Cys Val Asp Val
          1 5 10
           <![CDATA[ <210> 399]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 399]]>
          Val Asn Ile His Asn Tyr
          1 5
           <![CDATA[ <210> 400]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 400]]>
          Asn Ala Lys
          1           
           <![CDATA[ <210> 401]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB180]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 401]]>
          Gln His Phe Trp Thr Thr Pro Tyr Met Tyr Thr
          1 5 10
           <![CDATA[ <210> 402]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 402]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Phe
          1 5
           <![CDATA[ <210> 403]]>
           <![CDATA[ <211>]]> 7
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 403]]>
          Ile Asp Asn Asp Gly Ser Asn
          1 5
           <![CDATA[ <210> 404]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 404]]>
          Ala Arg Gly Arg Leu Gly Phe Phe Asp Ser
          1 5 10
           <![CDATA[ <210> 405]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus]]> musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 405]]>
          Ser Ser Val Asn Tyr
          1 5
           <![CDATA[ <210> 406]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 406]]>
          Tyr Thr Ser
          1           
           <![CDATA[ <210> 407]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB182]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 407]]>
          Gln Gln Phe Thr Asn Ser Pro Trp Thr
          1 5
           <![CDATA[ <210> 408]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 408]]>
          Gly Tyr Thr Phe Thr Asn Tyr Gly
          1 5
           <![CDATA[ <210> 409]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 409]]>
          Ile Asn Thr Tyr Thr Gly Ala Pro
          1 5
           <![CDATA[ <210> 410]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 410]]>
          Ala Arg Gly Asn Gly Tyr Pro Tyr Tyr Tyr Gly Ile Asn Tyr
          1 5 10
           <![CDATA[ <210> 411]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 411]]>
          Gln Glu Ile Ser Gly Asn
          1 5
           <![CDATA[ <210> 412]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 412]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 413]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB188]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 413]]>
          Leu Gln Tyr Ala Ser Tyr Pro Trp Thr
          1 5
           <![CDATA[ <210> 414]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 414]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Asn
          1 5
           <![CDATA[ <210> 415]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Description of peptide type: HCDR2
           <![CDATA[ <400> 415]]>
          Ile His Ser Ser Gly Thr Thr
          1 5
           <![CDATA[ <210> 416]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 416]]>
          Thr Arg Gln Leu Gly Leu Lys Ala Met Glu Tyr
          1 5 10
           <![CDATA[ <210> 417]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 417]]>
          Glu Asn Val Gly Thr Tyr
          1 5
           <![CDATA[ <210> 418]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 418]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 419]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB189]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 419]]>
          Gly Gln Ser Tyr Ser Tyr Pro Pro Thr
          1 5
           <![CDATA[ <210> 420]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 420]]>
          Gly Phe Ser Leu Thr Ser Tyr Gly
          1 5
           <![CDATA[ <210> 421]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 421]]>
          Leu Gly Trp Asp Asp Lys Lys
          1 5
           <![CDATA[ <210> 422]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 422]]>
          Thr Lys Glu Asp Val Ser Tyr Ala Met Asp Phe
          1 5 10
           <![CDATA[ <210> 423]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 423]]>
          Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu
          1 5 10
           <![CDATA[ <210> 424]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB27
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 424]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 425]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB27]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 425]]>
          Gln Gln Gly Lys Lys Val Pro Trp Thr
          1 5
           <![CDATA[ <210> 426]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 426]]>
          Gly Phe Ser Leu Ser Thr Ser Gly Met Gly
          1 5 10
           <![CDATA[ <210> 427]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 427]]>
          Ile Tyr Trp Asp Asp Asp Lys
          1 5
           <![CDATA[ <210> 428]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 428]]>
          Ala Arg Arg Thr Leu Gly Gly Pro Pro Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 429]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 429]]>
          Gln Asn Ile Arg Thr Ala
          1 5
           <![CDATA[ <210> 430]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB30]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 430]]>
          Leu Pro Ser
          1           
           <![CDATA[ <210> 431]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB30
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 431]]>
          Leu Gln His Trp Asn Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 432]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 432]]>
          Gly Tyr Thr Phe Thr Gly Tyr Trp
          1 5
           <![CDATA[ <210> 433]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 433]]>
          Ile Asp Pro Ser Asp Thr Glu Thr
          1 5
           <![CDATA[ <210> 434]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 434]]>
          Ala Arg Trp Gly Leu Gly Arg Asn Phe Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 435]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 435]]>
          Gln Ser Ile Ser Asp His
          1 5
           <![CDATA[ <210> 436]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 436]]>
          Phe Ala Ser
          1           
           <![CDATA[ <210> 437]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB31]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 437]]>
          Gln Asn Gly His Ser Phe Pro Leu Thr
          1 5
           <![CDATA[ <210> 438]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 438]]>
          Gly Tyr Thr Phe Thr Asp Tyr Ala
          1 5
           <![CDATA[ <210> 439]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 439]]>
          Ile Tyr Pro Gly Gly Gly Asn Thr
          1 5
           <![CDATA[ <210> 440]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 440]]>
          Ala Arg Gly Arg Leu Arg Arg Asp Tyr Pro Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 441]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 441]]>
          Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr
          1 5 10
           <![CDATA[ <210> 442]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 442]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 443]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB32]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 443]]>
          Gln Asn Asp Tyr Thr Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 444]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 444]]>
          Gly Phe Asn Ile Arg Asp Ile Tyr
          1 5
           <![CDATA[ <210> 445]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 445]]>
          Ile Asp Pro Ala Asn Gly His Ser
          1 5
           <![CDATA[ <210> 446]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 446]]>
          Ala Arg Gly Ser Asp Asn Asp Tyr Gly Arg Val Leu Ala Tyr
          1 5 10
           <![CDATA[ <210> 447]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 447]]>
          Ser Ser Val Arg Ser Ser Tyr
          1 5
           <![CDATA[ <210> 448]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 448]]>
          Ser Thr Ser
          1           
           <![CDATA[ <210> 449]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB33]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 449]]>
          Gln Gln Tyr Thr Gly Asn Pro Ile Phe Thr
          1 5 10
           <![CDATA[ <210> 450]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> ]]> mouse (Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 450]]>
          Gly Tyr Ser Ile Thr Ser Gly His Asn
          1 5
           <![CDATA[ <210> 451]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (]]>Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 451]]>
          Ile Ser Tyr Asp Gly Ser Asn
          1 5
           <![CDATA[ <210> 452]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 452]]>
          Ala Arg Gly Gly Gly Tyr Phe Gly Asn Ser Tyr Arg Val Phe Ala Ser
          1 5 10 15
           <![CDATA[ <210> 453]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 453]]>
          Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe
          1 5 10
           <![CDATA[ <210> 454]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 454]]>
          Arg Ala Ser
          1           
           <![CDATA[ <210> 455]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB35]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 455]]>
          Gln Gln Ser Asn Ala Asp Pro Tyr Thr
          1 5
           <![CDATA[ <210> 456]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 456]]>
          Gly Phe Asn Ile Lys Asp Thr Tyr
          1 5
           <![CDATA[ <210> 457]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 457]]>
          Ile Asp Pro Ala Asn Gly Asn Thr
          1 5
           <![CDATA[ <210> 458]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 458]]>
          Thr Arg Gly Thr Ser Trp Phe Ala Tyr
          1 5
           <![CDATA[ <210> 459]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 459]]>
          Glu Asn Val Gly Thr Ser
          1 5
           <![CDATA[ <210> 460]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 460]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 461]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB36]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 461]]>
          Gly Gln Ser Tyr Ser Tyr Pro Arg Thr
          1 5
           <![CDATA[ <210> 462]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 462]]>
          Gly Tyr Thr Phe Thr Asn Tyr Tyr
          1 5
           <![CDATA[ <210> 463]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 463]]>
          Ile Tyr Pro Gly Asn Gly Gly Thr
          1 5
           <![CDATA[ <210> 464]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 464]]>
          Ala Arg Ser Arg Gly Gly Ser Arg Asn Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 465]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 465]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 466]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 466]]>
          Ser Ala Phe
          1           
           <![CDATA[ <210> 467]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB39]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 467]]>
          Gln Gln His Tyr Ser Ser Pro Arg Thr
          1 5
           <![CDATA[ <210> 468]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 468]]>
          Gly Tyr Ser Phe Thr Asp Tyr Ile
          1 5
           <![CDATA[ <210> 469]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 469]]>
          Ile Asn Pro Tyr Phe Gly Phe Thr
          1 5
           <![CDATA[ <210> 470]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 470]]>
          Ser Arg Gly Ser Tyr Tyr Gly Tyr Glu Thr Phe Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 471]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 471]]>
          Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr
          1 5 10
           <![CDATA[ <210> 472]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 472]]>
          Arg Met Ser
          1           
           <![CDATA[ <210> 473]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB42]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 473]]>
          Met Gln His Leu Glu Tyr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 474]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 474]]>
          Gly Phe Ser Leu Ser Thr Tyr Gly Met Gly
          1 5 10
           <![CDATA[ <210> 475]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 475]]>
          Ile Tyr Trp Asp Asp Asp Lys
          1 5
           <![CDATA[ <210> 476]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 476]]>
          Ala Gln Arg Ala Leu Pro Leu Leu Gly Gln Lys Ala Pro Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 477]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220]]>>]]>
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB45]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: LCDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;477]]&gt;
           <br/>
           <br/> <![CDATA[Gln Asn Val Arg Thr Ala
          1 5
           <![CDATA[ <210> 478]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 478]]>
          Leu Pro Ser
          1           
           <![CDATA[ <210> 479]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB45]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 479]]>
          Leu Gln His Trp Asn Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 480]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 480]]>
          Gly Phe Ser Leu Thr Asn Tyr Asp
          1 5
           <![CDATA[ <210> 481]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 481]]>
          Ile Trp Ser Asp Gly Arg Thr
          1 5
           <![CDATA[ <210> 482]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 482]]>
          Ala Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Thr Met Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 483]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 483]]>
          Gln Thr Ile Gly Ser Trp
          1 5
           <![CDATA[ <210> 484]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 484]]>
          Ala Ala Thr
          1           
           <![CDATA[ <210> 485]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB47]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 485]]>
          His Gln Leu Tyr Ser Ile Pro Leu Thr
          1 5
           <![CDATA[ <210> 486]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 486]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Asn
          1 5
           <![CDATA[ <210> 487]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 487]]>
          Val His Tyr Arg Asp Ser Thr
          1 5
           <![CDATA[ <210> 488]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 488]]>
          Ala Arg Gln Leu Gly Leu Lys Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 489]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 489]]>
          Gly Asn Ile His Asn Tyr
          1 5
           <![CDATA[ <210> 490]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 490]]>
          Asn Ala Lys
          1           
           <![CDATA[ <210> 491]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> ]]> PRT
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB51]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 491]]>
          Gln Tyr Phe Trp Thr Thr Arg Thr
          1 5
           <![CDATA[ <210> 492]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 492]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 493]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 493]]>
          Ile Ser Ser Gly Gly Ser Tyr Ile
          1 5
           <![CDATA[ <210> 494]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 494]]>
          Ala Arg Lys Lys Ser Asp Tyr Gly Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 495]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 495]]>
          Gln Ser Val Ser Asn Asp
          1 5
           <![CDATA[ <210> 496]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 496]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 497]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB54]]>
           <![CDATA[ <220]]>>]]>
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: LCDR3]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;497]]&gt;
           <br/>
           <br/> <![CDATA[Gln Gln Asp Tyr Ser Ser Leu Pro Thr
          1 5
           <![CDATA[ <210> 498]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 498]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 499]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 499]]>
          Ile Asn Ser Asn Asp Gly Ser Thr
          1 5
           <![CDATA[ <210> 500]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 500]]>
          Ala Arg His Phe Leu Tyr Phe Ser Asn Phe Tyr Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 501]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 501]]>
          Gln Ser Val Ser Asn Asp
          1 5
           <![CDATA[ <210> 502]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213>]]> mouse (Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 502]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 503]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB56]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 503]]>
          Gln Gln Asp Tyr Ser Ser Pro Phe Thr
          1 5
           <![CDATA[ <210> 504]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 504]]>
          Gly Tyr Thr Phe Thr Asn Tyr Tyr
          1 5
           <![CDATA[ <210> 505]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 505]]>
          Ile Tyr Pro Asn Ser Gly Asp Thr
          1 5
           <![CDATA[ <210> 506]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 506]]>
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 507]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 507]]>
          Ser Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 508]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 508]]>
          Ser Thr Ser
          1           
           <![CDATA[ <210> 509]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB57]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 509]]>
          His Gln Tyr His Arg Ser Pro Phe Thr
          1 5
           <![CDATA[ <210> 510]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 510]]>
          Gly Phe Ser Phe Ile Ile Tyr Thr
          1 5
           <![CDATA[ <210> 511]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 511]]>
          Ile Thr Ser Gly Gly Gly Ile Thr
          1 5
           <![CDATA[ <210> 512]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 512]]>
          Ala Arg His Glu Gly Asp Tyr Tyr Asp Asp Tyr Tyr Arg Ile Gly Tyr
          1 5 10 15
          Ala Met Asp Tyr
                      20
           <![CDATA[ <210> 513]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 513]]>
          Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe
          1 5 10
           <![CDATA[ <210> 514]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 514]]>
          Arg Ala Ser
          1           
           <![CDATA[ <210> 515]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB58]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 515]]>
          Gln Gln Ser Asn Glu Asp Pro Leu Thr
          1 5
           <![CDATA[ <210> 516]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 516]]>
          Gly Tyr Thr Phe Thr Asp Tyr Tyr
          1 5
           <![CDATA[ <210> 517]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 517]]>
          Ile Tyr Pro Asn Asn Gly Gly Ile
          1 5
           <![CDATA[ <210> 518]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 518]]>
          Ala Arg Glu Lys Leu Arg Gly Arg Asp Tyr
          1 5 10
           <![CDATA[ <210> 519]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <40]]>0> 519]]&gt;
           <br/>
           <br/> <![CDATA[Gln Asp Ile Arg Asn Asn
          1 5
           <![CDATA[ <210> 520]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 520]]>
          Tyr Ser Ser
          1           
           <![CDATA[ <210> 521]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB60]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 521]]>
          Gln Gln Gly His Thr Leu Pro Trp Thr
          1 5
           <![CDATA[ <210> 522]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 522]]>
          Asp Tyr Thr Phe Thr Ser Phe Asp
          1 5
           <![CDATA[ <210> 523]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 523]]>
          Ile Phe Pro Gly Ser Gly Thr Thr
          1 5
           <![CDATA[ <210> 524]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 524]]>
          Ala Arg Arg Leu Thr Gly Thr Arg Tyr Phe Asp Val
          1 5 10
           <![CDATA[ <210> 525]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 525]]>
          Gln Asp Val Ile Thr Ala
          1 5
           <![CDATA[ <210> 526]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 526]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 527]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB61]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 527]]>
          Gln Gln His Tyr Thr Thr Pro Pro Thr
          1 5
           <![CDATA[ <210> 528]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 528]]>
          Gly Tyr Thr Phe Thr Asp His Thr
          1 5
           <![CDATA[ <210> 529]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 529]]>
          Ile Tyr Pro Lys Ser Gly Asn Ala
          1 5
           <![CDATA[ <210> 530]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223>]]> Serial description: I23RB65
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 530]]>
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Thr Tyr
          1 5 10
           <![CDATA[ <210> 531]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 531]]>
          Gln Ser Val Ser Thr Ser Ser Tyr Asn Tyr
          1 5 10
           <![CDATA[ <210> 532]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (M]]>us musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 532]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 533]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB65]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 533]]>
          Gln His Thr Trp Glu Ile Pro Tyr Thr
          1 5
           <![CDATA[ <210> 534]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 534]]>
          Gly Phe Ser Leu Ser Thr Ser Asn Met Gly
          1 5 10
           <![CDATA[ <210> 535]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 535]]>
          Ile Trp Trp Asn Ser Asp Lys
          1 5
           <![CDATA[ <210> 536]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 536]]>
          Ala Gln Ile Arg Trp Leu Arg Phe Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 537]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 537]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 538]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 538]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 539]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB66]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 539]]>
          Gln Gln His Tyr Ser Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 540]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 540]]>
          Gly Tyr Thr Phe Thr Ser Tyr Trp
          1 5
           <![CDATA[ <210> 541]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 541]]>
          Ile Tyr Pro Gly Ser Ser Ser Thr
          1 5
           <![CDATA[ <210> 542]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 542]]>
          Ala Arg Ser Ala Tyr Gly Asn Arg Leu Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 543]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 543]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 544]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 544]]>
          Ser Ala Phe
          1           
           <![CDATA[ <210> 545]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB67]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 545]]>
          Gln Gln His Tyr Ser Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 546]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 546]]>
          Gly Tyr Ser Phe Thr Gly Tyr Asn
          1 5
           <![CDATA[ <210> 547]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 547]]>
          Ile Asn Pro Phe Tyr Asp Lys Thr
          1 5
           <![CDATA[ <210> 548]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 548]]>
          Ala Arg Gln Leu Gly Leu Lys Gly Phe Ala Tyr
          1 5 10
           <![CDATA[ <210> 549]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 549]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 550]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 550]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 551]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB69]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 551]]>
          Gln Gln His Tyr Ser Thr Pro Trp Thr
          1 5
           <![CDATA[ <210> 552]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 552]]>
          Asp Tyr Ser Ile Thr Arg Gly Tyr Asn
          1 5
           <![CDATA[ <210> 553]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 553]]>
          Ile His Tyr Ser Gly Ser Thr
          1 5
           <![CDATA[ <210> 554]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 554]]>
          Ala Arg Gln Tyr Gly Leu Lys Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 555]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 555]]>
          Gln Asp Val Ile Thr Ala
          1 5
           <![CDATA[ <210> 556]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 556]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 557]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB71]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 557]]>
          Gln Gln His Phe Gly Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 558]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 558]]>
          Gly Tyr Thr Phe Thr Asp His Ala
          1 5
           <![CDATA[ <210> 559]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 559]]>
          Ile Ser Leu Gly Asn Gly Asp Ile
          1 5
           <![CDATA[ <210> 560]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 560]]>
          Lys Arg Ser Arg Val Leu Arg Trp Thr Thr Tyr Trp Tyr Phe Asp Val
          1 5 10 15
           <![CDATA[ <210> 561]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 561]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 562]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 562]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 563]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB73]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Peptide]]> Type Description: LCDR3
           <![CDATA[ <400> 563]]>
          Gln Gln Tyr Tyr Asn Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 564]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus musc]]>ulus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 564]]>
          Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr
          1 5
           <![CDATA[ <210> 565]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 565]]>
          Ile Ser Tyr Asp Gly Ser Phe
          1 5
           <![CDATA[ <210> 566]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 566]]>
          Ala Arg Ala Glu Ile Tyr Tyr Asp Tyr Asp Gly Asp Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 567]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> ]]> 567
          Lys Ser Val Ser Thr Ser Gly Ser Asn Phe
          1 5 10
           <![CDATA[ <210> 568]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 568]]>
          Phe Ala Ser
          1           
           <![CDATA[ <210> 569]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB74]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 569]]>
          Gln His Ser Arg Glu Leu Pro His Thr
          1 5
           <![CDATA[ <210> 570]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 570]]>
          Gly Tyr Thr Phe Thr Asp Tyr Tyr
          1 5
           <![CDATA[ <210> 571]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse]]>(Mus musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 571]]>
          Ile Ser Pro Lys Asn Gly Arg Thr
          1 5
           <![CDATA[ <210> 572]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 572]]>
          Ala Lys Ser Asn Gly Tyr Tyr Ala Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 573]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 573]]>
          Gln Asn Ile Tyr Lys Asn
          1 5
           <![CDATA[ <210> 574]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 574]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 575]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB76]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 575]]>
          Leu Gln Gly Tyr Ser Thr Pro Trp Thr
          1 5
           <![CDATA[ <210> 576]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 576]]>
          Gly Phe Ser Leu Ser Arg Tyr Ser
          1 5
           <![CDATA[ <210> 577]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 577]]>
          Ile Trp Gly Ser Gly Ser Thr
          1 5
           <![CDATA[ <210> 578]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 578]]>
          Ala Arg Val Tyr Tyr Gly Gly Ser Pro Tyr Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 579]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus ]]>musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 579]]>
          Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe
          1 5 10
           <![CDATA[ <210> 580]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 580]]>
          Leu Ala Ser
          1           
           <![CDATA[ <210> 581]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB77]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 581]]>
          Gln Gln Asn Asn Glu Glu Pro Asn Thr
          1 5
           <![CDATA[ <210> 582]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 582]]>
          Gly Phe Thr Phe Ser Asn Tyr Thr
          1 5
           <![CDATA[ <210> 583]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 583]]>
          Ile Ser Ser Gly Gly Gly Asn Thr
          1 5
           <![CDATA[ <210> 584]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 584]]>
          Ala Arg Arg Asn Tyr Arg Arg Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 585]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 585]]>
          Glu Ser Val Asp Ser Tyr Gly Ile Ser Phe
          1 5 10
           <![CDATA[ <210> 586]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 586]]>
          Arg Ala Ser
          1           
           <![CDATA[ <210> 587]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB78]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 587]]>
          Gln Gln Ser Asn Glu Asp Pro Trp Thr
          1 5
           <![CDATA[ <210> 588]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 588]]>
          Gly Tyr Thr Phe Thr Asp Tyr Tyr
          1 5
           <![CDATA[ <210> 589]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 589]]>
          Ile Tyr Pro Asn Asn Gly Asp Thr
          1 5
           <![CDATA[ <210> 590]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR]]>3
           <![CDATA[ <400> 590]]>
          Ala Arg Gly Thr Leu Thr Gly Met Tyr Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 591]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 591]]>
          Gln Ser Val Ile Asn Asp
          1 5
           <![CDATA[ <210> 592]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 592]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 593]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB79]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 593]]>
          Gln Gln Asp Tyr Ser Ser Pro Pro Thr
          1 5
           <![CDATA[ <210> 594]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 594]]>
          Gly Phe Ser Leu Thr Ser Tyr Gly
          1 5
           <![CDATA[ <210> 595]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 595]]>
          Ile Trp Ser Gly Val Ser Thr
          1 5
           <![CDATA[ <210> 596]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 596]]>
          Ala Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 597]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 597]]>
          Gln Asn Ile Arg Thr Ala
          1 5
           <![CDATA[ <210> 598]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 598]]>
          Leu Ala Ser
          1           
           <![CDATA[ <210> 599]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB80]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type:]]>LCDR3
           <![CDATA[ <400> 599]]>
          Leu Gln His Trp Asn Tyr Pro Leu Thr
          1 5
           <![CDATA[ <210> 600]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 600]]>
          Gly Phe Ser Leu Thr Ser Tyr Ala
          1 5
           <![CDATA[ <210> 601]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 601]]>
          Ile Trp Thr Gly Gly Gly Thr
          1 5
           <![CDATA[ <210> 602]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 602]]>
          Ala Arg Asn Arg Asp Tyr Ser Asn Tyr Arg Trp Tyr Phe Asp Val
          1 5 10 15
           <![CDATA[ <210>]]> 603
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 603]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 604]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 604]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 605]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB81]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 605]]>
          Gln Gln His Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 606]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 606]]>
          Gly Phe Ser Leu Thr Asn Tyr Ala
          1 5
           <![CDATA[ <210> 607]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 607]]>
          Ile Trp Ser Asp Gly Ser Thr
          1 5
           <![CDATA[ <210> 608]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 608]]>
          Ala Arg Ser Arg Ser Asn Tyr Gly Arg Trp Tyr Phe Asp Val
          1 5 10
           <![CDATA[ <210> 609]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 609]]>
          Gln Asp Val Ser Thr Ala
          1 5
           <![CDATA[ <210> 610]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 610]]>
          Ser Ala Phe
          1           
           <![CDATA[ <210> 611]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB82]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 611]]>
          Gln Gln His Tyr Ser Thr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 612]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 612]]>
          Gly Phe Ser Leu Thr Asn Tyr Asp
          1 5
           <![CDATA[ <210> 613]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 613]]>
          Ile Trp Ser Asp Gly Ser Thr
          1 5
           <![CDATA[ <210> 614]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 614]]>
          Ala Arg Asn Asn Tyr Tyr Arg Tyr Gly Arg Asn Pro Met Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 615]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> sequence]]> column description: I23RB83
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 615]]>
          Gln Thr Ile Gly Ser Trp
          1 5
           <![CDATA[ <210> 616]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 616]]>
          Ala Ala Thr
          1           
           <![CDATA[ <210> 617]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB83]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 617]]>
          Gln Gln Leu Tyr Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 618]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 618]]>
          Gly Phe Ser Phe Asn Thr Tyr Ala
          1 5
           <![CDATA[ <210> 6]]>19
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 619]]>
          Leu Trp Pro Gly Gly Gly Ile
          1 5
           <![CDATA[ <210> 620]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 620]]>
          Ala Arg Asn Trp Arg His Tyr Asp Gly Ser Tyr Ala Met Asp Phe
          1 5 10 15
           <![CDATA[ <210> 621]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 621]]>
          Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr
          1 5 10
           <![CDATA[ <210> 622]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 622]]>
          Lys Val Ser
          1           
           <![CDATA[ <210> 623]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB85]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 623]]>
          Ser Gln Ser Thr His Val Pro Trp Thr
          1 5
           <![CDATA[ <210> 624]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 624]]>
          Gly Tyr Thr Phe Thr Ser Tyr Trp
          1 5
           <![CDATA[ <210> 625]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 625]]>
          Ile Asp Pro Ser Asp Ser Tyr Thr
          1 5
           <![CDATA[ <210> 626]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Peptide type]]> Description: HCDR3
           <![CDATA[ <400> 626]]>
          Ala Arg Ser Pro Tyr Asp Tyr Asp Trp Gly Ala Tyr
          1 5 10
           <![CDATA[ <210> 627]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 627]]>
          Gln Gly Ile Ser Ser Asn
          1 5
           <![CDATA[ <210> 628]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 628]]>
          His Gly Thr
          1           
           <![CDATA[ <210> 629]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB86]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 629]]>
          Val Gln Tyr Ala Gln Phe Pro Trp Thr
          1 5
           <![CDATA[ <210> 630]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 630]]>
          Gly Tyr Thr Phe Thr Asn Tyr Val
          1 5
           <![CDATA[ <210> 631]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 631]]>
          Ile Asn Pro Tyr Asp Ala Ser Pro
          1 5
           <![CDATA[ <210> 632]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 632]]>
          Thr Arg Asp Ala Lys Leu Asp Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 633]]>
           <![CDATA[ <211> ]]>6
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 633]]>
          Gln Asp Ile Ser Asn Tyr
          1 5
           <![CDATA[ <210> 634]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 634]]>
          Tyr Thr Ser
          1           
           <![CDATA[ <210> 635]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB87]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 635]]>
          Gln Gln Gly Ile Thr Leu Pro Trp Thr
          1 5
           <![CDATA[ <210> 636]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 636]]>
          Gly Tyr Thr Phe Thr Asp Tyr Ile
          1 5
           <![CDATA[ <210> 637]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 637]]>
          Ile Ser Pro Asn Tyr Gly Gly Thr
          1 5
           <![CDATA[ <210> 638]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 638]]>
          Ala Arg Phe Asn Asn Tyr Tyr Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 639]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 639]]>
          Gln Asp Ile Asn Ser Tyr
          1 5
           <![CDATA[ <210> 640]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 640]]>
          Arg Ala Asn
          1           
           <![CDATA[ <210> 641]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB91]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 641]]>
          Leu Gln Tyr Asp Glu Phe Pro Tyr Thr
          1 5
           <![CDATA[ <210> 642]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 642]]>
          Gly Tyr Thr Phe Thr Asp His Thr
          1 5
           <![CDATA[ <210> 643]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 643]]>
          Ile Tyr Pro Lys Ser Gly Gly Thr
          1 5
           <![CDATA[ <210> 644]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 644]]>
          Ala Arg Trp Gly Leu Arg Arg Asp Gly Phe Val Tyr
          1 5 10
           <![CDATA[ <210> 645]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 645]]>
          Gln Ser Val Ser Thr Ser Lys Tyr Asp Tyr
          1 5 10
           <![CDATA[ <210> 646]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB92]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 646]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 647]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence]]> Column description: I23RB92
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 647]]>
          Gln His Thr Trp Glu Ile Pro Tyr Thr
          1 5
           <![CDATA[ <210> 648]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 648]]>
          Gly Phe Ser Leu Thr Ser Tyr Gly
          1 5
           <![CDATA[ <210> 649]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 649]]>
          Ile Trp Ser Gly Val Ser Thr
          1 5
           <![CDATA[ <210> 650]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 650]]>
          Ala Arg Ser Arg Gly Ser Tyr Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 651]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 651]]>
          Gln Ser Ile Ser Asn Asn
          1 5
           <![CDATA[ <210> 652]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 652]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 653]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB93]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 653]]>
          Gln Gln Ser Asn Ser Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 654]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 654]]>
          Gly Tyr Thr Phe Thr Asn Tyr Gly
          1 5
           <![CDATA[ <210> 655]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 655]]>
          Ile Asn Thr Asn Thr Gly Glu Pro
          1 5
           <![CDATA[ <210> 656]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 656]]>
          Ala Arg Val Arg Gln Thr Ala Arg Ala Thr Arg Gly Tyr Phe Asp Val
          1 5 10 15
           <![CDATA[ <210> 657]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 657]]>
          Gln Asp Val Asn Thr Ala
          1 5
           <![CDATA[ <210> 658]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 658]]>
          Ser Ala Phe
          1           
           <![CDATA[ <210> 659]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB94]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 659]]>
          Gln Gln His Tyr Thr Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 660]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 660]]>
          Gly Phe Thr Phe Ser Asp Tyr Tyr
          1 5
           <![CDATA[ <210> 661]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 661]]>
          Ile Asn Tyr Asp Gly Ser Asn Thr
          1 5
           <![CDATA[ <210> 662]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 662]]>
          Ala Arg Glu Gly Tyr Asp Glu Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 663]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> mouse (Mus]]> musculus)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 663]]>
          Gln Asp Val Gly Thr Ala
          1 5
           <![CDATA[ <210> 664]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 664]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 665]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB95]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 665]]>
          Gln Gln Tyr Ser Thr Tyr Pro Tyr Thr
          1 5
           <![CDATA[ <210> 666]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 666]]>
          Gly Tyr Thr Phe Thr Asn Tyr Tyr
          1 5
           <![CDATA[ <210> 667]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 667]]>
          Ile Tyr Pro Asn Ser Gly Asp Thr
          1 5
           <![CDATA[ <210> 668]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 668]]>
          Ala Arg Phe Gly Gly Phe Tyr Asp Ala Met Asp Tyr
          1 5 10
           <![CDATA[ <210> 669]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 669]]>
          Ser Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 670]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 670]]>
          Ser Thr Ser
          1           
           <![CDATA[ <210> 671]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB98]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 671]]>
          His Gln Tyr His Arg Ser Pro Phe Thr
          1 5
           <![CDATA[ <210> 672]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 672]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Asn Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Arg Pro Ile Phe Gly Thr Ala Tyr Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Gly Ser Arg Tyr Ala Gly Arg Tyr Ala Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 673]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 673]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 674]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 674]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Arg Tyr Leu Gly Ala Asn Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 675]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 675]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 676]]>
           <![CDATA[ <211> 455]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 676]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Ser Tyr
                      20 25 30
          Ser Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Tyr Phe Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Arg Gly Tyr Tyr Gly Ser Ile Tyr Tyr Gly Gly Gly Gly Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr
                  115 120 125
          Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr
              130 135 140
          Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu
          145 150 155 160
          Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His
                          165 170 175
          Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser
                      180 185 190
          Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn
                  195 200 205
          Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro
              210 215 220
          Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro
          225 230 235 240
          Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
                          245 250 255
          Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val
                      260 265 270
          Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn
                  275 280 285
          Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr
              290 295 300
          Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp
          305 310 315 320
          Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu
                          325 330 335
          Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg
                      340 345 350
          Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys
                  355 360 365
          Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp
              370 375 380
          Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys
          385 390 395 400
          Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser
                          405 410 415
          Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser
                      420 425 430
          Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser
                  435 440 445
          Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 677]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I]]>23RB3
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 677]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 678]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 678]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Thr Tyr
                      20 25 30
          Ala Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Gly Tyr Tyr Gly Ser Arg Tyr Tyr Pro Arg Ser Tyr
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 679]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 679]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 680]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 680]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 681]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 681]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 682]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (Ho]]>mo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 682]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 683]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 683]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
                  115 120 125
          Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
              130 135 140
          Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu
          145 150 155 160
          Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp
                          165 170 175
          Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr
                      180 185 190
          Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr
                  195 200 205
          Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215 220
           <![CDATA[ <210> 684]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Peptide type]]> Description: heavy chain
           <![CDATA[ <400> 684]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
                      20 25 30
          Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Asp Arg Tyr Gly Tyr Val Ala Gly Ala Phe Ala Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 685]]>
           <![CDATA[ <211> 213]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 685]]>
          Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr
                  35 40 45
          Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Trp Thr
                          85 90 95
          Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro
                      100 105 110
          Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly
                  115 120 125
          Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn
              130 135 140
          Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn
          145 150 155 160
          Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser
                          165 170 175
          Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr
                      180 185 190
          Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe
                  195 200 205
          Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 686]]>
           <![CDATA[ <211> 455]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 686]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Thr Asp
                      20 25 30
          Tyr Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Pro Ser Tyr Ala Tyr Gly Ser Arg Thr Tyr Gly Tyr Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr
                  115 120 125
          Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr
              130 135 140
          Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu
          145 150 155 160
          Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His
                          165 170 175
          Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser
                      180 185 190
          Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn
                  195 200 205
          Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro
              210 215 220
          Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro
          225 230 235 240
          Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
                          245 250 255
          Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val
                      260 265 270
          Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn
                  275 280 285
          Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr
              290 295 300
          Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp
          305 310 315 320
          Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu
                          325 330 335
          Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg
                      340 345 350
          Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys
                  355 360 365
          Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp
              370 375 380
          Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys
          385 390 395 400
          Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser
                          405 410 415
          Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser
                      420 425 430
          Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser
                  435 440 445
          Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 687]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 687]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 688]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 688]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 689]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 689]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 690]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB10
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 690]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Arg Ile Ile Pro Ile Ser Gly Arg Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Pro Ser Tyr Gly Ser Gly Gly Ala Phe Gly Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 691]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> ]]>691
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
                  115 120 125
          Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
              130 135 140
          Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu
          145 150 155 160
          Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp
                          165 170 175
          Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr
                      180 185 190
          Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr
                  195 200 205
          Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215 220
           <![CDATA[ <210> 692]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 692]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 693]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 693]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 694]]>
           <![CDATA[ <211> 4]]>49
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 694]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Phe Gly Trp Ser Leu Trp Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 695]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 695]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Ser Phe His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
                  115 120 125
          Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
              130 135 140
          Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu
          145 150 155 160
          Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp
                          165 170 175
          Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr
                      180 185 190
          Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr
                  195 200 205
          Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215 220
           <![CDATA[ <210> 696]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 696]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Tyr Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Tyr Arg Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 697]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 697]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Asp Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 698]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 698]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Leu Lys Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 699]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 699]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Lys Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Phe Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 700]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 700]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Phe His Arg Phe Trp Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 701]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 701]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Tyr Ser Val Pro Phe
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 702]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (Hom]]>o sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 702]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Ser Ser Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 703]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 703]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Asn Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 704]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 704]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Phe Val Pro Thr Gln Gly Ser Leu Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 705]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 705]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Trp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Lys Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Pro Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 706]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 706]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Lys His Ser Met Ala Gly Asn Ser Phe Leu Arg Phe Leu Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 707]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 707]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 708]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 708]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
                      20 25 30
          Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Val Trp Tyr Ser Ser Trp Asp Leu Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 709]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 709]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 710]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 710]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Pro Gly Ser Tyr Gly Ser Val Tyr Tyr Arg Arg Ser Tyr
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 711]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 711]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 712]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 712]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asp Ala
                      20 25 30
          Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Thr Ile Ile Pro Ile Ser Gly Asn Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Val Trp Tyr Tyr Trp Asp Gly Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 713]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 713]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 714]]>
           <![CDATA[ <211> 458]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 714]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Ser Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Ser Gly Gly Tyr Leu Gly Leu Arg Thr Leu Tyr Tyr
                      100 105 110
          Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
          Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
              130 135 140
          Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
          145 150 155 160
          Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser
                          165 170 175
          Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
                      180 185 190
          Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile
                  195 200 205
          Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
              210 215 220
          Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys
          225 230 235 240
          Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro
                          245 250 255
          Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
                      260 265 270
          Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp
                  275 280 285
          Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg
              290 295 300
          Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
          305 310 315 320
          His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
                          325 330 335
          Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly
                      340 345 350
          Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Glu
                  355 360 365
          Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met
              370 375 380
          Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu
          385 390 395 400
          Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
                          405 410 415
          Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn
                      420 425 430
          Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
                  435 440 445
          Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 715]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 715]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 716]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (Ho]]>mo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 716]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Gly Ser Ala Glu Thr Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 717]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 717]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 718]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 718]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Phe Gly Glu Pro Asn Gly Gly Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 719]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 719]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 720]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 720]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Pro Ser Ser Tyr Tyr Tyr Asn Gly Tyr Leu Gly Ser Tyr
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 721]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 721]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 722]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 722]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Asp Ala Thr Asp Ser Ser Asp Tyr Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 723]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>(Homo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 723]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 724]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 724]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser
                      20 25 30
          Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ser Gly Gly Tyr Val Gly Tyr Gly Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 725]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 725]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 726]]>
           <![CDATA[ <211> 458]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 726]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Ser Tyr Gly Tyr Arg Gly Arg Arg Arg Arg Arg Tyr Tyr
                      100 105 110
          Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
          Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
              130 135 140
          Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
          145 150 155 160
          Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser
                          165 170 175
          Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
                      180 185 190
          Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile
                  195 200 205
          Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
              210 215 220
          Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys
          225 230 235 240
          Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro
                          245 250 255
          Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
                      260 265 270
          Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp
                  275 280 285
          Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg
              290 295 300
          Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
          305 310 315 320
          His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
                          325 330 335
          Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly
                      340 345 350
          Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Glu
                  355 360 365
          Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met
              370 375 380
          Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu
          385 390 395 400
          Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
                          405 410 415
          Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn
                      420 425 430
          Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
                  435 440 445
          Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 727]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 727]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 728]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 728]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Arg Arg Tyr Arg Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 729]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 729]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 730]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 730]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Val Arg Gly Gly Ser Leu Gly Gly Gly Phe Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 731]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 731]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 732]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 732]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Thr Tyr
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Trp Ile Ser Gly Glu Gly Gly Ser Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Ala Tyr Asn Arg Pro Phe Tyr Ala Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 733]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 733]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 734]]>
           <![CDATA[ <211> 456]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 734]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Arg Ile Asp Gly Ser Gly Gly Tyr Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Leu Tyr Ser Tyr Leu Gly Ser Ser Tyr Tyr Tyr Gly Tyr
                      100 105 110
          Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys
                  115 120 125
          Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr
              130 135 140
          Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro
          145 150 155 160
          Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val
                          165 170 175
          His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser
                      180 185 190
          Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys
                  195 200 205
          Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu
              210 215 220
          Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala
          225 230 235 240
          Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile
                          245 250 255
          Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val
                      260 265 270
          Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val
                  275 280 285
          Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp
              290 295 300
          Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln
          305 310 315 320
          Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp
                          325 330 335
          Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val
                      340 345 350
          Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr
                  355 360 365
          Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu
              370 375 380
          Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr
          385 390 395 400
          Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
                          405 410 415
          Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
                      420 425 430
          Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr Lys
                  435 440 445
          Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 735]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 735]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 736]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220]]>>]]>
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: heavy chain]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;736]]&gt;
           <br/>
           <br/> <![CDATA[Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Pro Tyr Tyr Ser Gly Thr Ser Gly Tyr Arg Ser Gly Gly
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 737]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 737]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 738]]>
           <![CDATA[ <211> 456]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 738]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Asp
                      20 25 30
          Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Asn Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Gly Tyr Tyr Gly Arg Arg Arg Arg Tyr Tyr Gly
                      100 105 110
          Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys
                  115 120 125
          Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr
              130 135 140
          Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro
          145 150 155 160
          Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val
                          165 170 175
          His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser
                      180 185 190
          Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys
                  195 200 205
          Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu
              210 215 220
          Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala
          225 230 235 240
          Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile
                          245 250 255
          Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val
                      260 265 270
          Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val
                  275 280 285
          Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp
              290 295 300
          Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln
          305 310 315 320
          Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp
                          325 330 335
          Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val
                      340 345 350
          Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr
                  355 360 365
          Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu
              370 375 380
          Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr
          385 390 395 400
          Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
                          405 410 415
          Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
                      420 425 430
          Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr Lys
                  435 440 445
          Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 739]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 739]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 740]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 740]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ile Gly Phe Thr Phe Ser Ser Ser Ser
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Glu Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Val Ser Ser Tyr Gly Arg Tyr Gly Phe Gly Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 741]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 741]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 742]]>
           <![CDATA[ <211> 452]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 742]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Leu Ala Gly Asn Ser Ser Gly Gly Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro
                  115 120 125
          Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser
              130 135 140
          Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
          145 150 155 160
          Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro
                          165 170 175
          Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
                      180 185 190
          Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His
                  195 200 205
          Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro
              210 215 220
          Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu
          225 230 235 240
          Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu
                          245 250 255
          Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser
                      260 265 270
          Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu
                  275 280 285
          Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
              290 295 300
          Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
          305 310 315 320
          Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro
                          325 330 335
          Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln
                      340 345 350
          Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val
                  355 360 365
          Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val
              370 375 380
          Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu
          385 390 395 400
          Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg
                          405 410 415
          Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
                      420 425 430
          Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg
                  435 440 445
          Thr Pro Gly Lys
              450
           <![CDATA[ <210> 743]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 743]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 744]]>
           <![CDATA[ <211> 455]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 744]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
                      20 25 30
          Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ala Gly Asn Gly Gly Ser Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Gly Tyr Pro Leu Thr Ala Val Thr Gly Ile Tyr Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr
                  115 120 125
          Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr
              130 135 140
          Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu
          145 150 155 160
          Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His
                          165 170 175
          Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser
                      180 185 190
          Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn
                  195 200 205
          Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro
              210 215 220
          Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro
          225 230 235 240
          Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
                          245 250 255
          Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val
                      260 265 270
          Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn
                  275 280 285
          Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr
              290 295 300
          Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp
          305 310 315 320
          Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu
                          325 330 335
          Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg
                      340 345 350
          Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys
                  355 360 365
          Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp
              370 375 380
          Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys
          385 390 395 400
          Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser
                          405 410 415
          Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser
                      420 425 430
          Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser
                  435 440 445
          Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 745]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 745]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 746]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 746]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala
                      20 25 30
          Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Asn Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Arg Arg Arg Arg Ala Ser Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 747]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 747]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 748]]>
           <![CDATA[ <211> 456]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sap]]>iens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 748]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Ala
                      20 25 30
          Ala Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Thr Ile Asp Pro Gly Asp Ser Thr Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Tyr Tyr Thr Leu Glu Tyr Asn Trp Tyr Tyr Asp Ala
                      100 105 110
          Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys
                  115 120 125
          Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr
              130 135 140
          Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro
          145 150 155 160
          Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val
                          165 170 175
          His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser
                      180 185 190
          Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys
                  195 200 205
          Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu
              210 215 220
          Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala
          225 230 235 240
          Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile
                          245 250 255
          Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val
                      260 265 270
          Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val
                  275 280 285
          Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp
              290 295 300
          Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln
          305 310 315 320
          Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp
                          325 330 335
          Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val
                      340 345 350
          Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr
                  355 360 365
          Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu
              370 375 380
          Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr
          385 390 395 400
          Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
                          405 410 415
          Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
                      420 425 430
          Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr Lys
                  435 440 445
          Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 749]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 749]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 750]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 750]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Lys Ser Asp
                      20 25 30
          Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Tyr Pro Gly Asp Ser Arg Thr Tyr Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Ser Tyr Gly Thr Gly Asn Arg Gly Gly Arg Ser Gly
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 751]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 751]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 752]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 752]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Asp Ser Ala
                      20 25 30
          Gly Ile Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Ser Leu Gly Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 753]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 753]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 754]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 754]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Lys Asn Asp
                      20 25 30
          Gly Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ala Pro Gly Glu Ser Thr Thr Gly Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Gly Tyr Gly Ser Ala Ser Gly Arg Arg Ser Asp
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 755]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 755]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 756]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 756]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
                      20 25 30
          Tyr Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Asp Ser Arg Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Tyr Gly Ile Pro Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 757]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 757]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 758]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 758]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Asp Thr Asp
                      20 25 30
          Tyr Ile Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Tyr Ile Leu Pro Gly Glu Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Gly Leu Val Asn Arg Arg Arg Arg Arg Ser Tyr
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 759]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 759]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 760]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 760]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Thr Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 761]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo ]]> sapiens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 761]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Glu Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 762]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 762]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 763]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 763]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Glu Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 764]]>
           <![CDATA[ <211> 449]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 764]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Asn Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ala Gly Trp Thr Leu Leu Leu Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
                  115 120 125
          Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
              130 135 140
          Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
          145 150 155 160
          Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                          165 170 175
          Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
                      180 185 190
          Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
                  195 200 205
          Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
              210 215 220
          Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
          225 230 235 240
          Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
                          245 250 255
          Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
                      260 265 270
          Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
                  275 280 285
          Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
              290 295 300
          Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
          305 310 315 320
          Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
                          325 330 335
          Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
                      340 345 350
          Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
                  355 360 365
          Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
              370 375 380
          Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
          385 390 395 400
          Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
                          405 410 415
          Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
                      420 425 430
          Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
                  435 440 445
          Lys
           <![CDATA[ <210> 765]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 765]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Lys Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Ala Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 766]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 766]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 767]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 767]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 768]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 768]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Asn Gly Val Asn Tyr His Ser Glu Leu Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 769]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 769]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Phe
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Thr Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Asn Ser Ala Pro Phe
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 770]]>
           <![CDATA[ <211> 450]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 770]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Val Arg Ala Arg His Arg Gly Ser Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
                  115 120 125
          Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
              130 135 140
          Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
          145 150 155 160
          Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val
                          165 170 175
          Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr Ser
                      180 185 190
          Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
                  195 200 205
          Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
              210 215 220
          Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
          225 230 235 240
          Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
                          245 250 255
          Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
                      260 265 270
          Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
                  275 280 285
          Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
              290 295 300
          Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
          305 310 315 320
          Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
                          325 330 335
          Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
                      340 345 350
          Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
                  355 360 365
          Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
              370 375 380
          Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
          385 390 395 400
          Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
                          405 410 415
          Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
                      420 425 430
          Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
                  435 440 445
          Gly Lys
              450
           <![CDATA[ <210> 771]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 771]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Arg Trp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 772]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 772]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
                          85 90 95
          Ala Arg Pro Leu Lys Gln Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 773]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 773]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Asp Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 774]]>
           <![CDATA[ <211> 448]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 774]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asn Gly Thr Gly Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro
                  115 120 125
          Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
              130 135 140
          Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn
          145 150 155 160
          Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                          165 170 175
          Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Val Thr Ser Ser Ser Thr
                      180 185 190
          Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser
                  195 200 205
          Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro
              210 215 220
          Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
          225 230 235 240
          Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
                          245 250 255
          Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
                      260 265 270
          Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
                  275 280 285
          Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
              290 295 300
          Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
          305 310 315 320
          Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
                          325 330 335
          Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
                      340 345 350
          Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys
                  355 360 365
          Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
              370 375 380
          Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
          385 390 395 400
          Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
                          405 410 415
          Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
                      420 425 430
          Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 775]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 775]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Ser Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 776]]>
           <![CDATA[ <211> 447]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 776]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg His Trp Leu Gln Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu
                  115 120 125
          Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
              130 135 140
          Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser
          145 150 155 160
          Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                          165 170 175
          Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp
                      180 185 190
          Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Ser Thr
                  195 200 205
          Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
              210 215 220
          Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
          225 230 235 240
          Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
                          245 250 255
          Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
                      260 265 270
          Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
                  275 280 285
          Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
              290 295 300
          Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
          305 310 315 320
          Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile
                          325 330 335
          Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro
                      340 345 350
          Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
                  355 360 365
          Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
              370 375 380
          Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser
          385 390 395 400
          Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn
                          405 410 415
          Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
                      420 425 430
          His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 777]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 777]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Gly Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 778]]>
           <![CDATA[ <211> 451]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 778]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
                  115 120 125
          Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Ser Val
              130 135 140
          Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
          145 150 155 160
          Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly Val His Thr Phe Pro Ala
                          165 170 175
          Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr Val Thr
                      180 185 190
          Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
                  195 200 205
          Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
              210 215 220
          Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
          225 230 235 240
          Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
                          245 250 255
          Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
                      260 265 270
          Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
                  275 280 285
          His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
              290 295 300
          Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
          305 310 315 320
          Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
                          325 330 335
          Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
                      340 345 350
          Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
                  355 360 365
          Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
              370 375 380
          Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
          385 390 395 400
          Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
                          405 410 415
          Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
                      420 425 430
          His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
                  435 440 445
          Pro Gly Lys
              450
           <![CDATA[ <210> 779]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 779]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Thr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Arg Asn Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 780]]>
           <![CDATA[ <211> 453]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 780]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala
                  115 120 125
          Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
              130 135 140
          Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
          145 150 155 160
          Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
                          165 170 175
          Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Ser Val Thr
                      180 185 190
          Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
                  195 200 205
          His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
              210 215 220
          Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
          225 230 235 240
          Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
                          245 250 255
          Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
                      260 265 270
          Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
                  275 280 285
          Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
              290 295 300
          Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
          305 310 315 320
          Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
                          325 330 335
          Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
                      340 345 350
          Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
                  355 360 365
          Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
              370 375 380
          Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
          385 390 395 400
          Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
                          405 410 415
          Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
                      420 425 430
          Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
                  435 440 445
          Arg Thr Pro Gly Lys
              450
           <![CDATA[ <210> 781]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 781]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 782]]>
           <![CDATA[ <211> 457]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 782]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
                  115 120 125
          Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp
              130 135 140
          Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe
          145 150 155 160
          Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Gly
                          165 170 175
          Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser
                      180 185 190
          Ser Ser Val Thr Val Thr Ser Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr
                  195 200 205
          Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile
              210 215 220
          Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
          225 230 235 240
          Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
                          245 250 255
          Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
                      260 265 270
          Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
                  275 280 285
          Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
              290 295 300
          Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
          305 310 315 320
          Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
                          325 330 335
          Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
                      340 345 350
          Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
                  355 360 365
          Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
              370 375 380
          Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
          385 390 395 400
          Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
                          405 410 415
          Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
                      420 425 430
          Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Thr
                  435 440 445
          Lys Ser Phe Ser Arg Thr Pro Gly Lys
              450 455
           <![CDATA[ <210> 783]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 783]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 784]]>
           <![CDATA[ <211> 44]]>5
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain]]>
           <![CDATA[ <400> 784]]>
          Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Met Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ser Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Tyr Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
                      100 105 110
          Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro
                  115 120 125
          Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val
              130 135 140
          Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser
          145 150 155 160
          Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu
                          165 170 175
          Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser
                      180 185 190
          Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val
                  195 200 205
          Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro
              210 215 220
          Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile
          225 230 235 240
          Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile
                          245 250 255
          Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln
                      260 265 270
          Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln
                  275 280 285
          Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu
              290 295 300
          Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys
          305 310 315 320
          Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys
                          325 330 335
          Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Pro
                      340 345 350
          Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr
                  355 360 365
          Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys
              370 375 380
          Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly
          385 390 395 400
          Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val
                          405 410 415
          Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn
                      420 425 430
          His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
                  435 440 445
           <![CDATA[ <210> 785]]>
           <![CDATA[ <211> 218]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain]]>
           <![CDATA[ <400> 785]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
                      20 25 30
          Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
                      100 105 110
          Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
                  115 120 125
          Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Asn Phe Tyr
              130 135 140
          Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
          145 150 155 160
          Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
                          165 170 175
          Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
                      180 185 190
          His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
                  195 200 205
          Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 786]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 786]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Asn Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Arg Pro Ile Phe Gly Thr Ala Tyr Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Gly Ser Arg Tyr Ala Gly Arg Tyr Ala Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 787]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 787]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 788]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Peptide Type Description: Heavy Chain Variable Region
           <![CDATA[ <400> 788]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Arg Tyr Leu Gly Ala Asn Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 789]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 789]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 790]]>
           <![CDATA[ <211> 125]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 790]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Ser Tyr
                      20 25 30
          Ser Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Tyr Phe Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Arg Gly Tyr Tyr Gly Ser Ile Tyr Tyr Gly Gly Gly Gly Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 791]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 791]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 792]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 792]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Thr Tyr
                      20 25 30
          Ala Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Gly Tyr Tyr Gly Ser Arg Tyr Tyr Pro Arg Ser Tyr
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 793]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 793]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 794]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 794]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 795]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> ]]> 795
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 796]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 796]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 797]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 797]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys
           <![CDATA[ <210> 798]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 798]]>
          Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
          1 5 10 15
          Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
                      20 25 30
          Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
                  35 40 45
          Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe
              50 55 60
          Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Asp Arg Tyr Gly Tyr Val Ala Gly Ala Phe Ala Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 799]]>
           <![CDATA[ <211> 106]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 799]]>
          Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
          1 5 10 15
          Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
                      20 25 30
          Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr
                  35 40 45
          Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
              50 55 60
          Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu
          65 70 75 80
          Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Trp Thr
                          85 90 95
          Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105
           <![CDATA[ <210> 800]]>
           <![CDATA[ <211> 125]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 800]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Thr Asp
                      20 25 30
          Tyr Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Pro Ser Tyr Ala Tyr Gly Ser Arg Thr Tyr Gly Tyr Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 801]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 801]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 802]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 802]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 803]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 803]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 804]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 804]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Arg Ile Ile Pro Ile Ser Gly Arg Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Pro Ser Tyr Gly Ser Gly Gly Ala Phe Gly Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 805]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 805]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys
           <![CDATA[ <210> 806]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 806]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 807]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 807]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 808]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 808]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Phe Gly Trp Ser Leu Trp Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 809]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 809]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Ser Phe His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys
           <![CDATA[ <210> 810]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 810]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Tyr Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Tyr Arg Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 811]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 811]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Asp Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 812]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 812]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Leu Lys Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 813]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 813]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Lys Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Phe Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 814]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 814]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Phe His Arg Phe Trp Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 815]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 815]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Tyr Ser Val Pro Phe
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 816]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 816]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Ser Ser Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 817]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 817]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Asn Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Tyr Ser Ile Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 818]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 818]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Phe Val Pro Thr Gln Gly Ser Leu Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 819]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 819]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Trp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Lys Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Pro Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 820]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 820]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                      20 25 30
          Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Lys His Ser Met Ala Gly Asn Ser Phe Leu Arg Phe Leu Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 821]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 821]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 822]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo ]]> sapiens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 822]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
                      20 25 30
          Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
                          85 90 95
          Ala Arg Val Trp Tyr Ser Ser Trp Asp Leu Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 823]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212>]]> PRT
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 823]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 824]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB268
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 824]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Pro Gly Ser Tyr Gly Ser Val Tyr Tyr Arg Arg Ser Tyr
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 825]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> ]]> Homo sapiens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 825]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 826]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 826]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asp Ala
                      20 25 30
          Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Thr Ile Ile Pro Ile Ser Gly Asn Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Val Trp Tyr Tyr Trp Asp Gly Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 827]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 827]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 828]]>
           <![CDATA[ <211> 128]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: heavy chain variable]]> region
           <![CDATA[ <400> 828]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Ser Gly Tyr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Ser Gly Gly Tyr Leu Gly Leu Arg Thr Leu Tyr Tyr
                      100 105 110
          Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 829]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB270
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 829]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 830]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 830]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Gly Ser Ala Glu Thr Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 831]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 831]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 832]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 832]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Phe Gly Glu Pro Asn Gly Gly Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 833]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 833]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 834]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220]]>>]]>
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: heavy chain variable region]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;834]]&gt;
           <br/>
           <br/> <![CDATA[Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Pro Ser Ser Tyr Tyr Tyr Asn Gly Tyr Leu Gly Ser Tyr
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 835]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 835]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 836]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 836]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Asp Ala Thr Asp Ser Ser Asp Tyr Tyr Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 837]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 837]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 838]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 838]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser
                      20 25 30
          Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ser Gly Gly Tyr Val Gly Tyr Gly Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 839]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 839]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 840]]>
           <![CDATA[ <211> 128]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 840]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Ser Tyr Gly Tyr Arg Gly Arg Arg Arg Arg Arg Tyr Tyr
                      100 105 110
          Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 841]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 841]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 842]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 842]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Arg Arg Tyr Arg Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 843]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 843]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 844]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 844]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Val Arg Gly Gly Ser Leu Gly Gly Gly Phe Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 845]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 845]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 846]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> ]]> PRT
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 846]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Thr Tyr
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Trp Ile Ser Gly Glu Gly Gly Ser Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Ala Tyr Asn Arg Pro Phe Tyr Ala Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 847]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 847]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 848]]>
           <![CDATA[ <211> 126]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 848]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Arg Ile Asp Gly Ser Gly Gly Tyr Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Leu Tyr Ser Tyr Leu Gly Ser Ser Tyr Tyr Tyr Gly Tyr
                      100 105 110
          Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 849]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 849]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 850]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 850]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Pro Tyr Tyr Ser Gly Thr Ser Gly Tyr Arg Ser Gly Gly
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 851]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 851]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 852]]>
           <![CDATA[ <211> 126]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 852]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Asp
                      20 25 30
          Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Asn Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Gly Tyr Tyr Gly Arg Arg Arg Arg Tyr Tyr Gly
                      100 105 110
          Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 853]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 853]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 854]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 854]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ile Gly Phe Thr Phe Ser Ser Ser Ser
                      20 25 30
          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Asp Gly Glu Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Glu Val Ser Ser Tyr Gly Arg Tyr Gly Phe Gly Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 855]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>83
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 855]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 856]]>
           <![CDATA[ <211> 122]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 856]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Leu Ala Gly Asn Ser Ser Gly Gly Gly Phe Asp Tyr Trp
                      100 105 110
          Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 857]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 857]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 858]]>
           <![CDATA[ <211> 125]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 858]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
                      20 25 30
          Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ala Gly Asn Gly Gly Ser Thr Glu Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Gly Gly Tyr Pro Leu Thr Ala Val Thr Gly Ile Tyr Phe
                      100 105 110
          Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 859]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 859]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 860]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 860]]>
          Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
          1 5 10 15
          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala
                      20 25 30
          Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                  35 40 45
          Ser Ala Ile Ser Gly Asn Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val
              50 55 60
          Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
          65 70 75 80
          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Arg Arg Arg Arg Arg Ala Ser Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 861]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 861]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 862]]>
           <![CDATA[ <211> 126]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (]]>Homo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 862]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Ala
                      20 25 30
          Ala Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Thr Ile Asp Pro Gly Asp Ser Thr Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Tyr Tyr Thr Leu Glu Tyr Asn Trp Tyr Tyr Asp Ala
                      100 105 110
          Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 863]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 863]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 864]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 864]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Lys Ser Asp
                      20 25 30
          Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Tyr Pro Gly Asp Ser Arg Thr Tyr Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Ser Tyr Gly Thr Gly Asn Arg Gly Gly Arg Ser Gly
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 865]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 865]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 866]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 866]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Asp Ser Ala
                      20 25 30
          Gly Ile Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Ser Leu Gly Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 867]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 867]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 868]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 868]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Lys Asn Asp
                      20 25 30
          Gly Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ala Pro Gly Glu Ser Thr Thr Gly Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Leu Gly Gly Tyr Gly Ser Ala Ser Gly Arg Arg Ser Asp
                      100 105 110
          Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 869]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 869]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 870]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of peptide type: heavy chain can]]> variable region
           <![CDATA[ <400> 870]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
                      20 25 30
          Tyr Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Asn Ile Tyr Pro Gly Asp Ser Arg Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Tyr Tyr Gly Ile Pro Phe Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 871]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 871]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 872]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 872]]>
          Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
          1 5 10 15
          Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Asp Thr Asp
                      20 25 30
          Tyr Ile Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
                  35 40 45
          Gly Tyr Ile Leu Pro Gly Glu Ser Asp Thr Arg Tyr Ser Pro Ser Phe
              50 55 60
          Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
          65 70 75 80
          Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Gly Gly Tyr Gly Leu Val Asn Arg Arg Arg Arg Arg Ser Tyr
                      100 105 110
          Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 873]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 873]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 874]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 874]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Thr Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 875]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 875]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Glu Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 876]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 876]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 877]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 877]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Glu Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 878]]>
           <![CDATA[ <211> 119]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 878]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Asn Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Ala Gly Trp Thr Leu Leu Leu Asp Tyr Trp Gly Gln Gly
                      100 105 110
          Thr Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 879]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 879]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Lys Trp
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Ala Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 880]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 880]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 881]]>
           <![CDATA[ <21]]>1> 107]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB316]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: light chain variable region]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;881]]&gt;
           <br/>
           <br/> <![CDATA[Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 882]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 882]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Asn Gly Val Asn Tyr His Ser Glu Leu Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 883]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (H]]>omo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 883]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Phe
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Thr Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Asn Ser Ala Pro Phe
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 884]]>
           <![CDATA[ <211> 120]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 884]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Val Arg Ala Arg His Arg Gly Ser Phe Asp Tyr Trp Gly Gln
                      100 105 110
          Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 885]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 885]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Arg Trp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Tyr Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 886]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 886]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
                          85 90 95
          Ala Arg Pro Leu Lys Gln Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 887]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: light chain variable]]> region
           <![CDATA[ <400> 887]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Asp Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 888]]>
           <![CDATA[ <211> 118]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 888]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asn Gly Thr Gly Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr
                      100 105 110
          Leu Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 889]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 889]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Ser Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 890]]>
           <![CDATA[ <211> 117]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 890]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Trp Ile Ser Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg His Trp Leu Gln Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu
                      100 105 110
          Val Thr Val Ser Ser
                  115
           <![CDATA[ <210> 891]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 891]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Gly Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 892]]>
           <![CDATA[ <211> 121]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 892]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr Trp Gly
                      100 105 110
          Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 893]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 893]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Thr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Arg Asn Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 894]]>
           <![CDATA[ <211> 123]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 894]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
                      100 105 110
          Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120
           <![CDATA[ <210> 895]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 895]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 896]]>
           <![CDATA[ <211> 127]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 896]]>
          Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
          1 5 10 15
          Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
                      20 25 30
          Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
                  35 40 45
          Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
              50 55 60
          Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
          65 70 75 80
          Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
                      100 105 110
          Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                  115 120 125
           <![CDATA[ <210> 897]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 897]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 898]]>
           <![CDATA[ <211> 115]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Heavy Chain Variable Region]]>
           <![CDATA[ <400> 898]]>
          Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Met Pro Gly Ala
          1 5 10 15
          Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                      20 25 30
          Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
                  35 40 45
          Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
              50 55 60
          Lys Gly Lys Ser Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
          65 70 75 80
          Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                          85 90 95
          Ala Arg Ser Tyr Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
                      100 105 110
          Val Ser Ser
                  115
           <![CDATA[ <210> 899]]>
           <![CDATA[ <211> 111]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region]]>
           <![CDATA[ <400> 899]]>
          Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
                      20 25 30
          Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
                  35 40 45
          Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
              50 55 60
          Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
          65 70 75 80
          Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                          85 90 95
          Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
                      100 105 110
           <![CDATA[ <210> 900]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <40]]>0> 900]]&gt;
           <br/>
           <br/> <![CDATA[Gly Gly Thr Phe Lys Asn Tyr Ala
          1 5
           <![CDATA[ <210> 901]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 901]]>
          Ile Arg Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 902]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 902]]>
          Ala Arg Asp Ser Gly Ser Arg Tyr Ala Gly Arg Tyr Ala Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 903]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 903]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 904]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB1]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 904]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 905]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <21]]>3> Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: LCDR3]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;905]]&gt;
           <br/>
           <br/> <![CDATA[Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 906]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 906]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 907]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 907]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 908]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 908]]>
          Ala Arg Asp Arg Tyr Arg Tyr Leu Gly Ala Asn Gly Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 909]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LC]]>DR1
           <![CDATA[ <400> 909]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 910]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 910]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 911]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB2]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 911]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 912]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 912]]>
          Gly Gly Thr Phe Lys Ser Tyr Ser
          1 5
           <![CDATA[ <210> 913]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <21]]>3> Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB3]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: HCDR2]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;913]]&gt;
           <br/>
           <br/> <![CDATA[Ile Ile Pro Tyr Phe Gly Tyr Ala
          1 5
           <![CDATA[ <210> 914]]>
           <![CDATA[ <211> 18]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 914]]>
          Ala Arg Glu Arg Gly Tyr Tyr Gly Ser Ile Tyr Tyr Gly Gly Gly Gly Phe
          1 5 10 15
          Asp Tyr
           <![CDATA[ <210> 915]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223]]>> Description of peptide type: LCDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;915]]&gt;
           <br/>
           <br/> <![CDATA[Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 916]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 916]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 917]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB3]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 917]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 918]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 918]]>
          Gly Gly Thr Phe Lys Thr Tyr Ala
          1 5
           <![CDATA[ <210> 919]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 919]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 920]]>
           <![CDATA[ <211>]]> 20
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 920]]>
          Ala Arg Asp Gly Gly Tyr Tyr Gly Ser Arg Tyr Tyr Pro Arg Ser Tyr
          1 5 10 15
          Tyr Phe Asp Tyr
                      20
           <![CDATA[ <210> 921]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 921]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 922]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>(Homo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB4]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 922]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 923]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> sequence description]]> Ming: I23RB4
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 923]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 924]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 924]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 925]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 925]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 926]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 926]]>
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 927]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 927]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 928]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 928]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 929]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB5]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 929]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 930]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 930]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 931]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 931]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 932]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 932]]>
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 933]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 933]]>
          Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr
          1 5 10
           <![CDATA[ <210> 934]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 934]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 935]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB6]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 935]]>
          Gln Gln Tyr Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 936]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 936]]>
          Gly Tyr Thr Phe Thr Thr Tyr Gly
          1 5
           <![CDATA[ <210> 937]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 937]]>
          Ile Asn Thr Tyr Ser Gly Val Pro
          1 5
           <![CDATA[ <210> 938]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 938]]>
          Ala Arg Arg Asp Arg Tyr Gly Tyr Val Ala Gly Ala Phe Ala Tyr
          1 5 10 15
           <![CDATA[ <210> 939]]>
           <![CDATA[ <211> 5]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 939]]>
          Ser Ser Val Ser Tyr
          1 5
           <![CDATA[ <210> 940]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 940]]>
          Asp Thr Ser
          1           
           <![CDATA[ <210> 941]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB7]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 941]]>
          Gln Gln Trp Ser Ser Tyr Pro Trp Thr
          1 5
           <![CDATA[ <210> 942]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 942]]>
          Gly Gly Thr Phe Lys Thr Asp Tyr
          1 5
           <![CDATA[ <210> 943]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 943]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 944]]>
           <![CDATA[ <211> 18]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 944]]>
          Ala Arg Gly Pro Ser Tyr Ala Tyr Gly Ser Arg Thr Tyr Gly Tyr Phe
          1 5 10 15
          Asp Tyr
           <![CDATA[ <210> 945]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 945]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 946]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 946]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 947]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (Ho]]>mo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB8]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 947]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 948]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 948]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 949]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 949]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 950]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 950]]>
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
          1 5 10 15
          Gly Phe Asp Tyr
                      20
           <![CDATA[ <210> 951]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PR]]>T
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 951]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 952]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 952]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 953]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB9]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 953]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 954]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 954]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 955]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 955]]>
          Ile Ile Pro Ile Ser Gly Arg Ala
          1 5
           <![CDATA[ <210> 956]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 956]]>
          Ala Arg Asp Ser Tyr Pro Ser Tyr Gly Ser Gly Gly Ala Phe Gly Tyr
          1 5 10 15
           <![CDATA[ <210> 957]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 957]]>
          Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr
          1 5 10
           <![CDATA[ <210> 958]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> ]]>PRT
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 958]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 959]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB10]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 959]]>
          Gln Gln Tyr Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 960]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 960]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 961]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 961]]>
          Ile Ser Pro Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 962]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 962]]>
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 963]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 963]]>
          Gln Ser Ile Ser Asn Asp
          1 5
           <![CDATA[ <210> 964]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 964]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 965]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB259]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 965]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 966]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 966]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 967]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 967]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> ]]>968
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 968]]>
          Ala Arg Asp Phe Gly Trp Ser Leu Trp Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 969]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 969]]>
          Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr
          1 5 10
           <![CDATA[ <210> 970]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 970]]>
          Ser Ala Ser
          1           
           <![CDATA[ <210> 971]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB260]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 971]]>
          Gln Gln Ser Phe His Val Pro Trp Thr
          1 5
           <![CDATA[ <210> 972]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 972]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 973]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 973]]>
          Ile Ser Pro Tyr Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 974]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 974]]>
          Ala Arg Met Tyr Arg Gln Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> ]]> 975
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 975]]>
          Gln Ser Ile Asn Asp Asp
          1 5
           <![CDATA[ <210> 976]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 976]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 977]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB261]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 977]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 978]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 978]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 979]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 979]]>
          Ile Ser Ala Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 980]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 980]]>
          Ala Arg Met Leu Lys Gln Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 981]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Description of peptide type: LCDR1
           <![CDATA[ <400> 981]]>
          Gln Ser Ile Asn Lys Asp
          1 5
           <![CDATA[ <210> 982]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 982]]>
          Phe Ala Ser
          1           
           <![CDATA[ <210> 983]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB262]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 983]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 984]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 984]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 985]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 985]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 986]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 986]]>
          Ala Arg Phe His Arg Phe Trp Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 987]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 987]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 988]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 988]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 989]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB263]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 989]]>
          Gln Gln Pro Tyr Ser Val Pro Phe Thr
          1 5
           <![CDATA[ <210> 990]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <21]]>2> PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB264]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: HCDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;990]]&gt;
           <br/>
           <br/> <![CDATA[Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 991]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 991]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 992]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 992]]>
          Ala Arg Arg Ser Ser Pro Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 993]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 993]]>
          Gln Ser Ile Asp Asn Asp
          1 5
           <![CDATA[ <210> 994]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 994]]>
          Asn Ala Ser
          1           
           <![CDATA[ <210> 995]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB264]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 995]]>
          Gln Gln Pro Tyr Ser Ile Pro Leu Thr
          1 5
           <![CDATA[ <210> 996]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 996]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 997]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 997]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 998]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 998]]>
          Ala Arg Gly Phe Val Pro Thr Gln Gly Ser Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 999]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 999]]>
          Gln Ser Ile Ser Thr Trp
          1 5
           <![CDATA[ <210> 1000]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1000]]>
          Lys Ala Ser
          1           
           <![CDATA[ <210> 1001]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB265]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1001]]>
          Gln Gln Tyr Asn Ser Pro Pro Leu Thr
          1 5
           <![CDATA[ <210> 1002]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1002]]>
          Gly Phe Thr Phe Ser Asp Tyr Ser
          1 5
           <![CDATA[ <210> 1003]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Peptide]]> Description of type: HCDR2
           <![CDATA[ <400> 1003]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1004]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1004]]>
          Ala Lys His Ser Met Ala Gly Asn Ser Phe Leu Arg Phe Leu Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1005]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1005]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1006]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1006]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1007]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB266]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1007]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1008]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1008]]>
          Gly Tyr Ser Phe Thr Ser Tyr Trp
          1 5
           <![CDATA[ <210> 1009]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1009]]>
          Ile Tyr Pro Gly Asp Ser Asp Thr
          1 5
           <![CDATA[ <210> 1010]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1010]]>
          Ala Arg Val Trp Tyr Ser Ser Trp Asp Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 1011]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1011]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1012]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1012]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1013]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB267]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1013]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1014]]>
           <![CDATA[ <211> ]]>8
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1014]]>
          Gly Gly Thr Phe Ser Ser Tyr Tyr
          1 5
           <![CDATA[ <210> 1015]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1015]]>
          Ile Ile Pro Ile Phe Gly Tyr Ala
          1 5
           <![CDATA[ <210> 1016]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1016]]>
          Ala Arg Asp Pro Gly Ser Tyr Gly Ser Val Tyr Tyr Arg Arg Ser Tyr
          1 5 10 15
          Tyr Phe Asp Tyr
                      20
           <![CDATA[ <210> 1017]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1017]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1018]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1018]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1019]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (]]>Homo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB268]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1019]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 1020]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1020]]>
          Gly Gly Thr Phe Ser Asp Ala Ser
          1 5
           <![CDATA[ <210> 1021]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1021]]>
          Ile Ile Pro Ile Ser Gly Asn Ala
          1 5
           <![CDATA[ <210> 1022]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1022]]>
          Ala Arg Asp Arg Tyr Val Trp Tyr Tyr Trp Asp Gly Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1023]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1023]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1024]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1024]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1025]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB269]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1025]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1026]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1026]]>
          Gly Gly Thr Phe Asp Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1027]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1027]]>
          Ile Ile Pro Ile Ser Gly Tyr Ala
          1 5
           <![CDATA[ <210> 1028]]>
           <![CDATA[ <211> 21]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1028]]>
          Ala Arg Asp Leu Ser Gly Gly Tyr Leu Gly Leu Arg Thr Leu Tyr Tyr
          1 5 10 15
          Tyr Tyr Phe Asp Tyr
                      20
           <![CDATA[ <210> 1029]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1029]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1030]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1030]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1031]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB270]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1031]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 1032]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1032]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1033]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1033]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1034]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1034]]>
          Ala Arg Asp Arg Gly Ser Ala Glu Thr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1035]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial Description]]>: I23RB271
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1035]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1036]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1036]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1037]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB271]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1037]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1038]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1038]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1039]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1039]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1040]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1040]]>
          Ala Arg Asp Phe Gly Glu Pro Asn Gly Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1041]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1041]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1042]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1042]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1043]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB272]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1043]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1044]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1044]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1045]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1045]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1]]>046
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1046]]>
          Ala Arg Asp Pro Ser Ser Tyr Tyr Tyr Asn Gly Tyr Leu Gly Ser Tyr
          1 5 10 15
          Ala Phe Asp Tyr
                      20
           <![CDATA[ <210> 1047]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1047]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1048]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1048]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1049]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB273]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1049]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1050]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1050]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1051]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1051]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1052]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1052]]>
          Ala Arg Glu Asp Ala Thr Asp Ser Ser Asp Tyr Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1053]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1053]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1054]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1054]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1055]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB274]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1055]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1056]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1056]]>
          Gly Phe Thr Phe Ser Asp Ser Gly
          1 5
           <![CDATA[ <210> 1057]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1057]]>
          Ile Asp Gly Ser Gly Gly Thr Thr
          1 5
           <![CDATA[ <210> 1058]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1058]]>
          Ala Arg Gly Ser Gly Gly Tyr Val Gly Tyr Gly Gly Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1059]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: I23RB]]>275
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1059]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1060]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1060]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1061]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB275]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1061]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1062]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1062]]>
          Gly Phe Thr Phe Ser Asn Tyr Ala
          1 5
           <![CDATA[ <210> 1063]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence]]> Column description: I23RB276
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1063]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1064]]>
           <![CDATA[ <211> 21]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1064]]>
          Ala Arg Asp Gly Ser Tyr Gly Tyr Arg Gly Arg Arg Arg Arg Arg Tyr Tyr
          1 5 10 15
          Asp Tyr Phe Asp Tyr
                      20
           <![CDATA[ <210> 1065]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1065]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1066]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1066]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1067]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB276]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1067]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1068]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1068]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1069]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1069]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1070]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1070]]>
          Ala Arg Arg Arg Arg Tyr Arg Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1071]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1071]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1072]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1072]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1073]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB277]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1073]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1074]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1074]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1075]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1075]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1076]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <22]]>3> Description of peptide type: HCDR3]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1076]]&gt;
           <br/>
           <br/> <![CDATA[Val Arg Gly Gly Ser Leu Gly Gly Gly Phe Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1077]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1077]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1078]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1078]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1079]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB278]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1079]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1080]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1080]]>
          Gly Phe Thr Phe Asp Thr Tyr Ala
          1 5
           <![CDATA[ <210> 1081]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens (H]]>omo sapiens)
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1081]]>
          Ile Ser Gly Glu Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1082]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1082]]>
          Ala Arg Asp Leu Gly Ala Tyr Asn Arg Pro Phe Tyr Ala Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1083]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1083]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1084]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> ]]> Homo sapiens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1084]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1085]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB279]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1085]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1086]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1086]]>
          Gly Phe Thr Phe Ser Asn Ala Ala
          1 5
           <![CDATA[ <210> 1087]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1087]]>
          Ile Asp Gly Ser Gly Gly Tyr Thr
          1 5
           <![CDATA[ <210> 1088]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1088]]>
          Ala Arg Glu Leu Tyr Ser Tyr Leu Gly Ser Ser Tyr Tyr Tyr Gly Tyr
          1 5 10 15
          Phe Asp Tyr
           <![CDATA[ <210> 1089]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1089]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1090]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1090]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1091]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB280]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1091]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1092]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1092]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1093]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1093]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1094]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1094]]>
          Ala Arg Gly Pro Tyr Tyr Ser Gly Thr Ser Gly Tyr Arg Ser Gly Gly
          1 5 10 15
          Gly Phe Asp Tyr
                      20
           <![CDATA[ <210> 1095]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1095]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1096]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1096]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1097]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB281]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1097]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1098]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1098]]>
          Gly Phe Thr Phe Ser Asn Asp Ala
          1 5
           <![CDATA[ <210> 1099]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1099]]>
          Ile Asp Gly Asn Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1100]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1100]]>
          Ala Arg Asp Leu Gly Gly Tyr Tyr Gly Arg Arg Arg Arg Tyr Tyr Gly
          1 5 10 15
          Met Asp Val
           <![CDATA[ <210> 1101]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1101]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1102]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence]]> Description: I23RB282
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1102]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1103]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB282]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1103]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1104]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1104]]>
          Gly Phe Thr Phe Ser Ser Ser Ala
          1 5
           <![CDATA[ <210> 1105]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1105]]>
          Ile Asp Gly Glu Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1106]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1106]]>
          Ala Arg Glu Val Ser Ser Tyr Gly Arg Tyr Gly Phe Gly Tyr
          1 5 10
           <![CDATA[ <210> 1107]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1107]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1108]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1108]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1109]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB283]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1109]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1110]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1110]]>
          Gly Phe Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1111]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1111]]>
          Ile Ser Gly Ser Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1112]]>
           <![CDATA[ <211> 15]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1112]]>
          Ala Arg Gly Leu Ala Gly Asn Ser Ser Gly Gly Gly Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1113]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1113]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1114]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1114]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1115]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB284]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1115]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1116]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1116]]>
          Gly Phe Thr Phe Asp Asp Tyr Ala
          1 5
           <![CDATA[ <210> 1117]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1117]]>
          Ile Ala Gly Asn Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1118]]>
           <![CDATA[ <211> ]]> 18
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1118]]>
          Ala Arg Asp Gly Gly Tyr Pro Leu Thr Ala Val Thr Gly Ile Tyr Phe
          1 5 10 15
          Asp Tyr
           <![CDATA[ <210> 1119]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1119]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1120]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB285]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1120]]>
          Ala Ala Ser
          1           
           <![CDATA[ <21]]>0> 1121]]&gt;
           <br/> &lt;![CDATA[ &lt;211&gt;9]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Sequence description: I23]]&gt; <![CDATA[RB285
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1121]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1122]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1122]]>
          Gly Phe Thr Phe Ser Asp Ala Gly
          1 5
           <![CDATA[ <210> 1123]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1123]]>
          Ile Ser Gly Asn Gly Gly Ser Thr
          1 5
           <![CDATA[ <210> 1124]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1124]]>
          Ala Arg Arg Arg Arg Arg Arg Ala Ser Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1125]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1125]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1126]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1126]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1127]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB286]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1127]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1128]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1128]]>
          Gly Tyr Ser Phe Thr Asp Ala Ala
          1 5
           <![CDATA[ <210> 1129]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212]]>> PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB287]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: HCDR2]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1129]]&gt;
           <br/>
           <br/> <![CDATA[Ile Asp Pro Gly Asp Ser Thr Thr
          1 5
           <![CDATA[ <210> 1130]]>
           <![CDATA[ <211> 19]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1130]]>
          Ala Arg Asp Leu Tyr Tyr Thr Leu Glu Tyr Asn Trp Tyr Tyr Asp Ala
          1 5 10 15
          Phe Asp Tyr
           <![CDATA[ <210> 1131]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB287]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1131]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1132]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223>]]> Serial description: I23RB287
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1132]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1133]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> ]]> Serial description: I23RB287
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1133]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1134]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1134]]>
          Gly Tyr Ser Phe Lys Ser Asp Trp
          1 5
           <![CDATA[ <210> 1135]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1135]]>
          Ile Tyr Pro Gly Asp Ser Arg Thr
          1 5
           <![CDATA[ <210> 1136]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1136]]>
          Ala Arg Asp Ser Ser Tyr Gly Thr Gly Asn Arg Gly Gly Arg Ser Gly
          1 5 10 15
          Ala Phe Asp Tyr
                      20
           <![CDATA[ <210> 1137]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1137]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1138]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1138]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1139]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB288]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1139]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1140]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1140]]>
          Gly Tyr Ser Phe Asp Ser Ala Gly
          1 5
           <![CDATA[ <210> 1141]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1141]]>
          Ile Tyr Pro Gly Asp Ser Asp Thr
          1 5
           <![CDATA[ <210> 1142]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1142]]>
          Ala Arg Gly Gly Gly Ser Leu Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1143]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1143]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1144]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1144]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1145]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB289]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1145]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1146]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1146]]>
          Gly Tyr Ser Phe Lys Asn Asp Gly
          1 5
           <![CDATA[ <210> 1147]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1147]]>
          Ile Ala Pro Gly Glu Ser Thr Thr Thr
          1 5
           <![CDATA[ <210> 1148]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1148]]>
          Ala Arg Asp Leu Gly Gly Tyr Gly Ser Ala Ser Gly Arg Arg Ser Asp
          1 5 10 15
          Tyr Phe Asp Tyr
                      20
           <![CDATA[ <210> 1149]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1149]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1150]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1150]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1151]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB290]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1151]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1152]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1152]]>
          Gly Tyr Ser Phe Thr Ser Tyr Tyr
          1 5
           <![CDATA[ <210> 1153]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1153]]>
          Ile Tyr Pro Gly Asp Ser Arg Thr
          1 5
           <![CDATA[ <210> 1154]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1154]]>
          Ala Arg Asp Arg Tyr Tyr Gly Ile Pro Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1155]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1155]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1156]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1156]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1157]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB291]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1157]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 1]]>158
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1158]]>
          Gly Tyr Ser Phe Asp Thr Asp Tyr
          1 5
           <![CDATA[ <210> 1159]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1159]]>
          Ile Leu Pro Gly Glu Ser Asp Thr
          1 5
           <![CDATA[ <210> 1160]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1160]]>
          Ala Arg Gly Gly Gly Tyr Gly Leu Val Asn Arg Arg Arg Arg Arg Ser Tyr
          1 5 10 15
          Ala Phe Asp Tyr
                      20
           <![CDATA[ <210> 1161]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1161]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1162]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1162]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1163]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB292]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1163]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1164]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1164]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 1165]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1165]]>
          Ile Ser Ala Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 1166]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1166]]>
          Ala Arg Gly Thr Val Pro Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1167]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1167]]>
          Gln Ser Ile Gly Glu Asp
          1 5
           <![CDATA[ <210> 1168]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1168]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1169]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB313]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1169]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1170]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1170]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 1171]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1171]]>
          Ile Ser Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1172]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1172]]>
          Ala Arg Met Met Met Gln Gly Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1173]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1173]]>
          Gln Ser Ile Ser Glu Asp
          1 5
           <![CDATA[ <210> 1174]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1174]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1175]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB314]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1175]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1176]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1176]]>
          Gly Asp Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1177]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1177]]>
          Ile Ser Ala Ile Phe Gly Asn Ala
          1 5
           <![CDATA[ <210> 1178]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1178]]>
          Ala Arg Gly Ala Gly Trp Thr Leu Leu Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 1179]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1179]]>
          Gln Ser Val Arg Lys Trp
          1 5
           <![CDATA[ <210> 1180]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223>]]> Description of peptide type: LCDR2
           <![CDATA[ <400> 1180]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1181]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB315]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1181]]>
          Gln Gln Tyr Asn Asn Ala Pro Leu Thr
          1 5
           <![CDATA[ <210> 1182]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1182]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> ]]>1183
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1183]]>
          Ile Ile Pro Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 1184]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1184]]>
          Ala Arg Met Met Met Gln Ser Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 1185]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1185]]>
          Gln Ser Ile Ser Asn Asp
          1 5
           <![CDATA[ <210> 1186]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1186]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1187]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB316]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1187]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1188]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1188]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1189]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1189]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1190]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1190]]>
          Ala Arg Gly Asn Gly Val Asn Tyr His Ser Glu Leu Asp Tyr
          1 5 10
           <![CDATA[ <210> 1191]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> ]]> PRT
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1191]]>
          Gln Ser Val Asp Ser Phe
          1 5
           <![CDATA[ <210> 1192]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1192]]>
          Thr Ala Ser
          1           
           <![CDATA[ <210> 1193]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB317]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1193]]>
          Gln Gln Gly Asn Ser Ala Pro Phe Thr
          1 5
           <![CDATA[ <210> 1194]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1194]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1195]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1195]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1196]]>
           <![CDATA[ <211> 13]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1196]]>
          Ala Arg Val Arg Ala Arg His Arg Gly Ser Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1197]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1197]]>
          Gln Ser Ile Asp Arg Trp
          1 5
           <![CDATA[ <210> 1198]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1198]]>
          Tyr Ala Ser
          1           
           <![CDATA[ <210> 1199]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB318]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1199]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1200]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1200]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 1201]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1201]]>
          Ile Ser Ala Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 1202]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1202]]>
          Ala Arg Pro Leu Lys Gln Ala Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1203]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1203]]>
          Gln Ser Ile Thr Asp Asp
          1 5
           <![CDATA[ <210> 1204]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1204]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1205]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB319]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1205]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> ]]>1206
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1206]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 1207]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1207]]>
          Ile Ser Ala Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 1208]]>
           <![CDATA[ <211> 11]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1208]]>
          Ala Arg Asn Gly Thr Gly Asn Ser Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1209]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1209]]>
          Gln Ser Ile Thr Ser Asp
          1 5
           <![CDATA[ <210> 1210]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1210]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1211]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB320]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1211]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1212]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1212]]>
          Gly Gly Thr Phe Ser Ser Tyr Gly
          1 5
           <![CDATA[ <210> 1213]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1213]]>
          Ile Ser Ala Ile Phe Gly Thr Thr
          1 5
           <![CDATA[ <210> 1214]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1214]]>
          Ala Arg His Trp Leu Gln Ser Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1215]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1215]]>
          Gln Ser Ile Gly Gly Asp
          1 5
           <![CDATA[ <210> 1216]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1216]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1217]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB321]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1217]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1218]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1218]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1219]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1219]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1220]]>
           <![CDATA[ <211> 14]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> ]]> Homo sapiens
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1220]]>
          Ala Arg Gly Arg Tyr Ile Arg Ser Tyr Asp Tyr Phe Asp Tyr
          1 5 10
           <![CDATA[ <210> 1221]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1221]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1222]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1222]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1223]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB328]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1223]]>
          Gln Gln Arg Asn Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1224]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR1]]>
           <![CDATA[ <400> 1224]]>
          Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1225]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1225]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1226]]>
           <![CDATA[ <211> 16]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1226]]>
          Ala Arg Asp Ser Tyr Tyr Ser Thr Val Thr Tyr Tyr Tyr Tyr Phe Asp Tyr
          1 5 10 15
           <![CDATA[ <210> 1227]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1227]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1228]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1228]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1229]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB329]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1229]]>
          Gln Gln Arg Ser Asn Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1230]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <21]]>2> PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; Homo sapiens]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB330]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: HCDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1230]]&gt;
           <br/>
           <br/> <![CDATA[Gly Gly Thr Phe Ser Ser Tyr Ala
          1 5
           <![CDATA[ <210> 1231]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1231]]>
          Ile Ile Pro Ile Phe Gly Thr Ala
          1 5
           <![CDATA[ <210> 1232]]>
           <![CDATA[ <211> 20]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1232]]>
          Ala Arg Asp Arg Ser Tyr Ser Tyr Gly Leu Ser Gly Leu Gly Tyr Tyr
          1 5 10 15
          Gly Phe Asp Tyr
                      20
           <![CDATA[ <210> 1233]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1233]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1234]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1234]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1235]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Homo sapiens]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB330]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1235]]>
          Gln Gln Arg Ser Asn Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1236]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <22]]>0>]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Serial description: I23RB332]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: HCDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1236]]&gt;
           <br/>
           <br/> <![CDATA[Gly Tyr Thr Phe Thr Ser Tyr Trp
          1 5
           <![CDATA[ <210> 1237]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR2]]>
           <![CDATA[ <400> 1237]]>
          Ile Asp Pro Ser Asp Ser Tyr Thr
          1 5
           <![CDATA[ <210> 1238]]>
           <![CDATA[ <211> 8]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: HCDR3]]>
           <![CDATA[ <400> 1238]]>
          Ala Arg Ser Tyr Ala Phe Asp Tyr
          1 5
           <![CDATA[ <210> 1239]]>
           <![CDATA[ <211> 10]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR1]]>
           <![CDATA[ <400> 1239]]>
          Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr
          1 5 10
           <![CDATA[ <210> 1240]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR2]]>
           <![CDATA[ <400> 1240]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1241]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Mouse (Mus musculus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Serial description: I23RB332]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: LCDR3]]>
           <![CDATA[ <400> 1241]]>
          Gln Gln Ser Asn Glu Asp Pro Trp Thr
          1 5
           <![CDATA[ <210> 1242]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of Peptide Type: Light Chain and Consensus Sequence]]>
           <![CDATA[ <400> 1242]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 1243]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of Peptide Type: Light Chain and Consensus Sequence]]>
           <![CDATA[ <400> 1243]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 1244]]>
           <![CDATA[ <211> 220]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of Peptide Type: Light Chain and Consensus Sequence]]>
           <![CDATA[ <400> 1244]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
                  115 120 125
          Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn
              130 135 140
          Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu
          145 150 155 160
          Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp
                          165 170 175
          Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr
                      180 185 190
          Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr
                  195 200 205
          Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
              210 215 220
           <![CDATA[ <210> 1245]]>
           <![CDATA[ <211> 214]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of Peptide Type: Light Chain and Consensus Sequence]]>
           <![CDATA[ <400> 1245]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala
                      100 105 110
          Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
                  115 120 125
          Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile
              130 135 140
          Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
          145 150 155 160
          Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
                          165 170 175
          Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
                      180 185 190
          Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
                  195 200 205
          Phe Asn Arg Asn Glu Cys
              210
           <![CDATA[ <210> 1246]]>
           <![CDATA[ <211> 215]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: light chain and]]> consensus sequence
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Explanation of Peptide Type: Light Chain and Consensus Sequence]]>
           <![CDATA[ <400> 1246]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala
                      100 105 110
          Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
                  115 120 125
          Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
              130 135 140
          Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
          145 150 155 160
          Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                          165 170 175
          Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
                      180 185 190
          Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
                  195 200 205
          Ser Phe Asn Arg Asn Glu Cys
              210 215
           <![CDATA[ <210> 1247]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain Variable Region and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region and Consensus Sequence]]>
           <![CDATA[ <400> 1247]]>
          Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
                      20 25 30
          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
                  35 40 45
          Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
          65 70 75 80
          Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 1248]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain Variable Region and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region and Consensus Sequence]]>
           <![CDATA[ <400> 1248]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 1249]]>
           <![CDATA[ <211> 113]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain Variable Region and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region and Consensus Sequence]]>
           <![CDATA[ <400> 1249]]>
          Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
          1 5 10 15
          Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
                      20 25 30
          Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
                  35 40 45
          Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
              50 55 60
          Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
          65 70 75 80
          Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
                          85 90 95
          Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                      100 105 110
          Lys
           <![CDATA[ <210> 1250]]>
           <![CDATA[ <211> 107]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain Variable Region and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region and Consensus Sequence]]>
           <![CDATA[ <400> 1250]]>
          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
          1 5 10 15
          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
                      20 25 30
          Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
                  35 40 45
          Tyr Ala Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
              50 55 60
          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
          65 70 75 80
          Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
                          85 90 95
          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 1251]]>
           <![CDATA[ <211> 108]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Light Chain Variable Region and Consensus Sequence ]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of Peptide Type: Light Chain Variable Region and Consensus Sequence]]>
           <![CDATA[ <400> 1251]]>
          Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
          1 5 10 15
          Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
                      20 25 30
          Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
                  35 40 45
          Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
              50 55 60
          Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65 70 75 80
          Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
                          85 90 95
          Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                      100 105
           <![CDATA[ <210> 1252]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR1]]>
           <![CDATA[ <400> 1252]]>
          Gln Ser Val Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1253]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR2]]>
           <![CDATA[ <400> 1253]]>
          Asp Ala Ser
          1           
           <![CDATA[ <210> 1254]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR3]]>
           <![CDATA[ <400> 1254]]>
          Gln Gln Arg Ser Asn Trp Pro Leu Thr
          1 5
           <![CDATA[ <210> 1255]]>
           <![CDATA[ <211> 6]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR1]]>
           <![CDATA[ <400> 1255]]>
          Gln Ser Ile Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1256]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR2]]>
           <![CDATA[ <400> 1256]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1257]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR3]]>
           <![CDATA[ <400> 1257]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1258]]>
           <![CDATA[ <211> 12]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR1]]>
           <![CDATA[ <400> 1258]]>
          Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr
          1 5 10
           <![CDATA[ <210> 1259]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR2]]>
           <![CDATA[ <400> 1259]]>
          Trp Ala Ser
          1           
           <![CDATA[ <210> 1260]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR3]]>
           <![CDATA[ <400> 1260]]>
          Gln Gln Tyr Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1261]]>
           <![CDATA[ <21]]>1> 6]]&gt;
           <br/> &lt;![CDATA[ &lt;212&gt;PRT]]&gt;
           <br/> &lt;![CDATA[ &lt;213&gt; consensus sequence]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Sequence description: CDR consensus sequence]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;220&gt;]]&gt;
           <br/> &lt;![CDATA[ &lt;223&gt; Description of peptide type: CDR1]]&gt;
           <br/>
           <br/> &lt;![CDATA[ &lt;400&gt;1261]]&gt;
           <br/>
           <br/> <![CDATA[Gln Ser Ile Ser Asn Asp
          1 5
           <![CDATA[ <210> 1262]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR2]]>
           <![CDATA[ <400> 1262]]>
          Ala Ala Ser
          1           
           <![CDATA[ <210> 1263]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR3]]>
           <![CDATA[ <400> 1263]]>
          Gln Gln Ser Tyr Ser Thr Pro Leu Thr
          1 5
           <![CDATA[ <210> 1264]]>
           <![CDATA[ <211> 7]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: CDR]]> Consensus Sequence
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR1]]>
           <![CDATA[ <400> 1264]]>
          Gln Ser Val Ser Ser Ser Tyr
          1 5
           <![CDATA[ <210> 1265]]>
           <![CDATA[ <211> 3]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consistent]]> sequence
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR2]]>
           <![CDATA[ <400> 1265]]>
          Gly Ala Ser
          1           
           <![CDATA[ <210> 1266]]>
           <![CDATA[ <211> 9]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence description: CDR consensus sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: CDR3]]>
           <![CDATA[ <400> 1266]]>
          Gln Gln Tyr Gly Ser Ser Pro Leu Thr
          1 5
           <![CDATA[ <210> 1267]]>
           <![CDATA[ <211> 331]]>
           <![CDATA[ <212> PRT]]>
           <![CDATA[ <213> Rat (Rattus norvegicus)]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Sequence Description: Rat IL-23R ECD Sequence]]>
           <![CDATA[ <220>]]>
           <![CDATA[ <223> Description of peptide type: IL-23R ectodomain sequence]]>
           <![CDATA[ <400> 1267]]>
          Gly Ile Ala Thr Ile Asn Cys Ser Gly Asn Met Trp Val Glu Pro Gly
          1 5 10 15
          Glu Ile Phe Gln Met Gly Met Asn Val Ser Val Tyr Cys Gln Glu Ala
                      20 25 30
          Leu Lys Asn Cys Arg Pro Arg Asn Leu His Phe Tyr Lys Asn Gly Phe
                  35 40 45
          Lys Glu Arg Phe His Ile Thr Arg Ile Asn Arg Thr Thr Ala Arg Val
              50 55 60
          Trp Tyr Lys Gly Phe Ser Glu Pro His Ala Ser Met Tyr Cys Thr Ala
          65 70 75 80
          Glu Cys Pro Gly Arg Phe Gln Glu Thr Leu Ile Cys Gly Lys Asp Ile
                          85 90 95
          Ser Ser Gly Tyr Pro Pro Asp Ala Pro Ser Asn Met Thr Cys Val Ile
                      100 105 110
          Tyr Glu Tyr Ser Gly Asn Met Thr Cys Thr Trp Asn Thr Gly Lys Pro
                  115 120 125
          Thr Tyr Ile Asp Thr Lys Tyr Thr Val His Val Lys Ser Leu Glu Thr
              130 135 140
          Glu Glu Gln Gln Gln Tyr Leu Ala Ser Asn Tyr Val Asn Ile Ser Thr
          145 150 155 160
          Asp Ser Leu Gln Gly Gly Arg Lys Tyr Leu Val Trp Val Gln Ala Val
                          165 170 175
          Asn Ala Leu Gly Met Glu Asn Ser Gln Gln Leu Gln Val His Leu Asp
                      180 185 190
          Asp Ile Val Ile Pro Ser Pro Ser Ile Ile Ser Arg Ala Glu Thr Thr
                  195 200 205
          Asn Ala Asn Val Pro Lys Thr Ile Ile Tyr Trp Lys Ser Lys Ile Met
              210 215 220
          Thr Gly Lys Val Phe Cys Glu Met Arg Tyr Lys Ala Thr Thr Asn Gln
          225 230 235 240
          Thr Trp Asn Val Lys Glu Phe Asp Thr Asn Tyr Thr Tyr Val Gln Gln
                          245 250 255
          Ser Glu Phe Tyr Leu Glu Pro Asn Ser Lys Tyr Val Phe Gln Val Arg
                      260 265 270
          Cys Gln Gly Thr Gly Lys Arg Asn Trp Gln Pro Trp Ser Ser Pro Phe
                  275 280 285
          Val His Gln Thr Pro Gln Thr Ala Ser Gln Val Thr Ser Lys Pro Pro
              290 295 300
          His Glu Pro Gln Lys Ile Glu Met Leu Thr Ala Thr Ile Phe Lys Gly
          305 310 315 320
          His Ser Thr Ser Asp Asn Ser Gln Asp Ile Gly
                          325 330
          
      

Claims (48)

An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequences of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequences of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising the amino acid sequences of SEQ ID NO:921, 922, and 923, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively, and comprising the amino acid sequences of SEQ ID NO:903, 904, and 905, respectively VL of LCDR1, LCDR2, and LCDR3; e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:276, 277, and 278, respectively, and comprising the amino acid sequences of SEQ ID NO:279, 280, and 281, respectively VL of LCDR1, LCDR2, and LCDR3; f. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:294, 295, and 296, respectively, and comprising the amino acid sequences of SEQ ID NO:297, 298, and 299, respectively VL of LCDR1, LCDR2, and LCDR3; g. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:318, 319, and 320, respectively, and comprising the amino acid sequences of SEQ ID NO:321, 322, and 323, respectively VL of LCDR1, LCDR2, and LCDR3; h. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:324, 325, and 326, respectively, and comprising the amino acid sequences of SEQ ID NO:327, 328, and 329, respectively VL of LCDR1, LCDR2, and LCDR3; i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:330, 331, and 332, respectively, and comprising the amino acid sequences of SEQ ID NO:333, 334, and 335, respectively VL of LCDR1, LCDR2, and LCDR3; j. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:342, 343, and 344, respectively, and comprising the amino acid sequences of SEQ ID NO:345, 346, and 347, respectively VL of LCDR1, LCDR2, and LCDR3; k. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:354, 355, and 356, respectively, and comprising the amino acid sequences of SEQ ID NO:357, 358, and 359, respectively VL of LCDR1, LCDR2, and LCDR3; l. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:360, 361, and 362, respectively, and comprising the amino acid sequences of SEQ ID NO:363, 364, and 365, respectively VL of LCDR1, LCDR2, and LCDR3; m. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:366, 367, and 368, respectively, and comprising the amino acid sequences of SEQ ID NO:369, 370, and 371, respectively VL of LCDR1, LCDR2, and LCDR3; n. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:384, 385, and 386, respectively, and comprising the amino acid sequences of SEQ ID NO:387, 388, and 389, respectively VL of LCDR1, LCDR2, and LCDR3; o. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively, and comprising the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively VL of LCDR1, LCDR2, and LCDR3; p. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:420, 421, and 422, respectively, and comprising the amino acid sequences of SEQ ID NO:423, 424, and 425, respectively VL of LCDR1, LCDR2, and LCDR3; q. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1026, 1027, and 1028, respectively, and comprising the amino acid sequences of SEQ ID NO:1029, 1030, and 1031, respectively VL of LCDR1, LCDR2, and LCDR3; r. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively, and comprising the amino acid sequences of SEQ ID NO:915, 916, and 917, respectively VL of LCDR1, LCDR2, and LCDR3; s. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and comprising the amino acid sequences of SEQ ID NO:429, 430, and 431, respectively VL of LCDR1, LCDR2, and LCDR3; t. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1194, 1195, and 1196, respectively, and comprising the amino acid sequences of SEQ ID NO: 1197, 1198, and 1199, respectively VL of LCDR1, LCDR2, and LCDR3; u. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:438, 439, and 440, respectively, and comprising the amino acid sequences of SEQ ID NO:441, 442, and 443, respectively VL of LCDR1, LCDR2, and LCDR3; v. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:444, 445, and 446, respectively, and comprising the amino acid sequences of SEQ ID NO:447, 448, and 449, respectively VL of LCDR1, LCDR2, and LCDR3; w. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:456, 457, and 458, respectively, and comprising the amino acid sequences of SEQ ID NO:459, 460, and 461, respectively VL of LCDR1, LCDR2, and LCDR3; x. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:462, 463, and 464, respectively, and comprising the amino acid sequences of SEQ ID NO:465, 466, and 467, respectively VL of LCDR1, LCDR2, and LCDR3; y. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:468, 469, and 470, respectively, and comprising the amino acid sequences of SEQ ID NO:471, 472, and 473, respectively VL of LCDR1, LCDR2, and LCDR3; z. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:474, 475, and 476, respectively, and comprising the amino acid sequences of SEQ ID NO:477, 478, and 479, respectively VL of LCDR1, LCDR2, and LCDR3; aa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:480, 481, and 482, respectively, and comprising the amino acid sequences of SEQ ID NO:483, 484, and 485, respectively VL of LCDR1, LCDR2, and LCDR3; bb. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:510, 511, and 512, respectively, and comprising the amino acid sequences of SEQ ID NO:513, 514, and 515, respectively VL of LCDR1, LCDR2, and LCDR3; cc. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:528, 529, and 530, respectively, and comprising the amino acid sequences of SEQ ID NO:531, 532, and 533, respectively VL of LCDR1, LCDR2, and LCDR3; dd. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:552, 553, and 554, respectively, and comprising the amino acid sequences of SEQ ID NO:555, 556, and 557, respectively VL of LCDR1, LCDR2, and LCDR3; ee. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:558, 559, and 560, respectively, and comprising the amino acid sequences of SEQ ID NO:561, 562, and 563, respectively VL of LCDR1, LCDR2, and LCDR3; ff. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively, and comprising the amino acid sequences of SEQ ID NO:567, 568, and 569, respectively VL of LCDR1, LCDR2, and LCDR3; gg. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NO:576, 577, and 578, respectively, and comprising amino acid sequences of SEQ ID NO:579, 580, and 581, respectively VL of LCDR1, LCDR2, and LCDR3; hh. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:600, 601, and 602, respectively, and comprising the amino acid sequences of SEQ ID NO:603, 604, and 605, respectively VL of LCDR1, LCDR2, and LCDR3; ii. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively, and comprising the amino acid sequences of SEQ ID NO:609, 610, and 611, respectively VL of LCDR1, LCDR2, and LCDR3; jj. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:624, 625, and 626, respectively, and comprising the amino acid sequences of SEQ ID NO:627, 628, and 629, respectively VL of LCDR1, LCDR2, and LCDR3; kk. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:642, 643, and 644, respectively, and comprising the amino acid sequences of SEQ ID NO:645, 646, and 647, respectively VL of LCDR1, LCDR2, and LCDR3; ll. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:648, 649, and 650, respectively, and comprising the amino acid sequences of SEQ ID NO:651, 652, and 653, respectively VL of LCDR1, LCDR2, and LCDR3; or mm. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:654, 655, and 656, respectively, and comprising the amino acid sequences of SEQ ID NO:657, 658, and 659, respectively VL of LCDR1, LCDR2, and LCDR3. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; b. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; e. VH comprising the amino acid sequence of SEQ ID NO:138, and VL comprising the amino acid sequence of SEQ ID NO:139; f. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; g. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153; h. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; i. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; j. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; k. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165; l. VH comprising the amino acid sequence of SEQ ID NO:166, and VL comprising the amino acid sequence of SEQ ID NO:167; m. VH comprising the amino acid sequence of SEQ ID NO:168, and VL comprising the amino acid sequence of SEQ ID NO:169; n. VH comprising the amino acid sequence of SEQ ID NO:174, and VL comprising the amino acid sequence of SEQ ID NO:175; o. VH comprising the amino acid sequence of SEQ ID NO:788, and VL comprising the amino acid sequence of SEQ ID NO:789; p. VH comprising the amino acid sequence of SEQ ID NO:186, and VL comprising the amino acid sequence of SEQ ID NO:187; q. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; r. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; s. VH comprising the amino acid sequence of SEQ ID NO:188, and VL comprising the amino acid sequence of SEQ ID NO:189; t. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; u. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; v. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; w. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; x. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; y. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; z. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; aa. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; bb. VH comprising the amino acid sequence of SEQ ID NO:216, and VL comprising the amino acid sequence of SEQ ID NO:217; cc. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; dd. VH comprising the amino acid sequence of SEQ ID NO:230, and VL comprising the amino acid sequence of SEQ ID NO:231; ee. VH comprising the amino acid sequence of SEQ ID NO:232, and VL comprising the amino acid sequence of SEQ ID NO:233; ff. VH comprising the amino acid sequence of SEQ ID NO:234 and VL comprising the amino acid sequence of SEQ ID NO:235; gg. VH comprising the amino acid sequence of SEQ ID NO:238, and VL comprising the amino acid sequence of SEQ ID NO:239; hh. VH comprising the amino acid sequence of SEQ ID NO:246, and VL comprising the amino acid sequence of SEQ ID NO:247; ii. VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; jj. VH comprising the amino acid sequence of SEQ ID NO:254, and VL comprising the amino acid sequence of SEQ ID NO:255; kk. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; ll. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; or mm. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:570, 571, and 572, respectively, and comprising the amino acid sequence of SEQ ID NO:573, 574, and 575, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequence of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:918, 919, and 920, respectively, and comprising the amino acid sequence of SEQ ID NO:921, 922, and 923, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902, respectively, and comprising the amino acid sequence of SEQ ID NO:903, 904, and 905, respectively VL of LCDR1, LCDR2, and LCDR3; or e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively, and comprising the amino acid sequence of SEQ ID NO:915, 916, and 917, respectively VL of LCDR1, LCDR2, and LCDR3. The isolated monoclonal antibody or antigen-binding fragment thereof as described in claim 2, which binds to human interleukin-23 receptor (IL-23R) on mammalian cells, wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; b. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; or e. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the mammalian cell is a human or rat cell. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the cell is a primary immune cell. An isolated monoclonal antibody or antigen-binding fragment thereof that recognizes human and rat interleukin-23 receptor (IL-23R), wherein the antibody or fragment comprises: a. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:468, 469, and 470, respectively, and comprising the amino acid sequence of SEQ ID NO:471, 472, and 473, respectively VL of LCDR1, LCDR2, and LCDR3; b. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:618, 619, and 620, respectively, and comprising the amino acid sequence of SEQ ID NO:621, 622, and 623, respectively VL of LCDR1, LCDR2, and LCDR3; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:330, 331, and 332, respectively, and comprising the amino acid sequence of SEQ ID NO:333, 334, and 335, respectively VL of LCDR1, LCDR2, and LCDR3; d. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:936, 937, and 938, respectively, and comprising the amino acid sequence of SEQ ID NO:939, 940, and 941, respectively VL of LCDR1, LCDR2, and LCDR3; e. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:312, 313, and 314, respectively, and comprising the amino acid sequence of SEQ ID NO:315, 316, and 317, respectively VL of LCDR1, LCDR2, and LCDR3; f. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:474, 475, and 476, respectively, and comprising the amino acid sequence of SEQ ID NO:477, 478, and 479, respectively VL of LCDR1, LCDR2, and LCDR3; g. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1194, 1195, and 1196, respectively, and comprising the amino acid sequences of SEQ ID NOs: 1197, 1198, and 1199, respectively VL of LCDR1, LCDR2, and LCDR3; h. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:426, 427, and 428, respectively, and comprising the amino acid sequence of SEQ ID NO:429, 430, and 431, respectively VL of LCDR1, LCDR2, and LCDR3; or i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:498, 499, and 500, respectively, and comprising the amino acid sequence of SEQ ID NO:501, 502, and 503, respectively VL of LCDR1, LCDR2, and LCDR3. The isolated monoclonal antibody or antigen-binding fragment thereof as described in claim 7, which recognizes human and rat interleukin-23 receptors (IL-23R), wherein the antibody or fragment comprises: a. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; b. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; d. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151; f. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; g. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; h. VH comprising the amino acid sequence of SEQ ID NO: 188, and VL comprising the amino acid sequence of SEQ ID NO: 189; or i. VH comprising the amino acid sequence of SEQ ID NO:212, and VL comprising the amino acid sequence of SEQ ID NO:213. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ ID NO The VL of the CDR sequence of :1254, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:900, HCDR2 SEQ ID NO:901, and HCDR3 SEQ ID NO:902; b. HCDR1 SEQ ID NO:906, HCDR2 SEQ ID NO:907, and HCDR3 SEQ ID NO:908; c. HCDR1 SEQ ID NO:912, HCDR2 SEQ ID NO:913, and HCDR3 SEQ ID NO:914; d. HCDR1 SEQ ID NO:918, HCDR2 SEQ ID NO:919, and HCDR3 SEQ ID NO:920; e. HCDR1 SEQ ID NO:942, HCDR2 SEQ ID NO:943, and HCDR3 SEQ ID NO:944; f. HCDR1 SEQ ID NO:948, HCDR2 SEQ ID NO:949, and HCDR3 SEQ ID NO:950; g. HCDR1 SEQ ID NO: 1014, HCDR2 SEQ ID NO: 1015, and HCDR3 SEQ ID NO: 1016; h. HCDR1 SEQ ID NO: 1026, HCDR2 SEQ ID NO: 1027, and HCDR3 SEQ ID NO: 1028; and i. HCDR1 SEQ ID NO: 1152, HCDR2 SEQ ID NO: 1153, and HCDR3 SEQ ID NO: 1154. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 9, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1252, LCDR2 SEQ ID NO: 1253, and LCDR3 SEQ ID NO: 1254 or having an amine The amino acid sequence is the VL of SEQ ID NO:1247, and the VH sequence selected from SEQ ID NO:786, 788, 790, 792, 800, 802, 824, 828, and 870. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ ID NO The VL of the CDR sequence of :1257, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:924, HCDR2 SEQ ID NO:925, and HCDR3 SEQ ID NO:926; b. HCDR1 SEQ ID NO:1002, HCDR2 SEQ ID NO:1003, and HCDR3 SEQ ID NO:1004; c. HCDR1 SEQ ID NO:1032, HCDR2 SEQ ID NO:1033, and HCDR3 SEQ ID NO:1034; d. HCDR1 SEQ ID NO:1044, HCDR2 SEQ ID NO:1045, and HCDR3 SEQ ID NO:1046; e. HCDR1 SEQ ID NO:1050, HCDR2 SEQ ID NO:1051, and HCDR3 SEQ ID NO:1052; f. HCDR1 SEQ ID NO:1056, HCDR2 SEQ ID NO:1057, and HCDR3 SEQ ID NO:1058; g. HCDR1 SEQ ID NO: 1062, HCDR2 SEQ ID NO: 1063, and HCDR3 SEQ ID NO: 1064; h. HCDR1 SEQ ID NO: 1068, HCDR2 SEQ ID NO: 1069, and HCDR3 SEQ ID NO: 1070; i. HCDR1 SEQ ID NO: 1080, HCDR2 SEQ ID NO: 1081, and HCDR3 SEQ ID NO: 1082; j. HCDR1 SEQ ID NO: 1092, HCDR2 SEQ ID NO: 1093, and HCDR3 SEQ ID NO: 1094; k. HCDR1 SEQ ID NO:1098, HCDR2 SEQ ID NO:1099, and HCDR3 SEQ ID NO:1100; l. HCDR1 SEQ ID NO:1110, HCDR2 SEQ ID NO:1111, and HCDR3 SEQ ID NO:1112; m. HCDR1 SEQ ID NO:1122, HCDR2 SEQ ID NO:1123, and HCDR3 SEQ ID NO:1124; n. HCDR1 SEQ ID NO:1140, HCDR2 SEQ ID NO:1141, and HCDR3 SEQ ID NO:1142; o. HCDR1 SEQ ID NO: 1146, HCDR2 SEQ ID NO: 1147, and HCDR3 SEQ ID NO: 1148; and p. HCDR1 SEQ ID NO: 1158, HCDR2 SEQ ID NO: 1159, and HCDR3 SEQ ID NO: 1160. The isolated monoclonal antibody or its antigen-binding fragment according to claim 11, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1255, LCDR2 SEQ ID NO: 1256, and LCDR3 SEQ ID NO: 1257 or having an amine The VL of amino acid sequence SEQ ID NO:1248, and be selected from SEQ ID NO:794,820,830,834,836,838,840,842,846,850,852,856,860,866,868 and 872 The VH sequence. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ ID NO The VL of the CDR sequence of :1260, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:930, HCDR2 SEQ ID NO:931, and HCDR3 SEQ ID NO:932; or b. HCDR1 SEQ ID NO:954, HCDR2 SEQ ID NO:955, and HCDR3 SEQ ID NO:956. The isolated monoclonal antibody or its antigen-binding fragment according to claim 13, which comprises: VL comprising the CDR sequences of LCDR1 SEQ ID NO: 1258, LCDR2 SEQ ID NO: 1259, and LCDR3 SEQ ID NO: 1260 or A VL having the amino acid sequence of SEQ ID NO:1249; and a VH sequence selected from SEQ ID NO:796 and 804. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ ID NO The VL of the CDR sequence of :1263, and the VH comprising the CDR sequence selected from the following: a. HCDR1 SEQ ID NO:960, HCDR2 SEQ ID NO:961, and HCDR3 SEQ ID NO:962; and b. HCDR1 SEQ ID NO: 1182, HCDR2 SEQ ID NO: 1183, and HCDR3 SEQ ID NO: 1184. The isolated monoclonal antibody or its antigen-binding fragment according to claim 15, which comprises: VL comprising the CDR sequences of LCDR1 SEQ ID NO: 1261, LCDR2 SEQ ID NO: 1262, and LCDR3 SEQ ID NO: 1263 or A VL having the amino acid sequence of SEQ ID NO:1250; and a VH sequence selected from SEQ ID NO:806 and 880. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to interleukin-23 receptor (IL-23R) and comprises: comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ ID NO VL of the CDR sequence of :1266, and a VH comprising a CDR sequence selected from the group consisting of: a. HCDR1 SEQ ID NO:1008, HCDR2 SEQ ID NO:1009, and HCDR3 SEQ ID NO:1010; b. HCDR1 SEQ ID NO:1020, HCDR2 SEQ ID NO:1021, and HCDR3 SEQ ID NO:1022; c. HCDR1 SEQ ID NO:1038, HCDR2 SEQ ID NO:1039, and HCDR3 SEQ ID NO:1040; d. HCDR1 SEQ ID NO:1074, HCDR2 SEQ ID NO:1075, and HCDR3 SEQ ID NO:1076; e. HCDR1 SEQ ID NO: 1086, HCDR2 SEQ ID NO: 1087, and HCDR3 SEQ ID NO: 1088; f. HCDR1 SEQ ID NO:1104, HCDR2 SEQ ID NO:1105, and HCDR3 SEQ ID NO:1106; g. HCDR1 SEQ ID NO: 1128, HCDR2 SEQ ID NO: 1129, and HCDR3 SEQ ID NO: 1130; and h. HCDR1 SEQ ID NO: 1134, HCDR2 SEQ ID NO: 1135, and HCDR3 SEQ ID NO: 1136. The isolated monoclonal antibody or antigen-binding fragment thereof as claimed in claim 17, comprising: a CDR sequence comprising LCDR1 SEQ ID NO: 1264, LCDR2 SEQ ID NO: 1265, and LCDR3 SEQ ID NO: 1266 or having an amine The VL of the amino acid sequence of SEQ ID NO: 1251, and the VH sequence selected from SEQ ID NO: 806 and 880, 822, 826, 832, 844, 848, 854, 862, and 864. A VHH antibody or Nanobody that binds to an interleukin-23 receptor (IL-23R) and comprises a protein selected from the group consisting of SEQ ID NO: 786, 788, 790, 792, 800, 802, 824, 828, 870, 794, 820, 830, 834, 836, 838, 840, 842, 846, 850, 852, 856, 860, 866, 868, 872, 796, 804, 806, 880, 822, 826, 832, 844, 848, 854, 862, or 864 VH sequences. An isolated monoclonal antibody or antigen-binding fragment thereof, which binds to an interleukin-23 receptor (IL-23R) and comprises: a. comprising an amino acid sequence having SEQ ID NO: 276, 277, and 278, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:279, 280, and 281; b. comprising having SEQ ID NO:288, The VH of HCDR1, HCDR2, and HCDR3 of amino acid sequences of 289 and 290, and the VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NO:291, 292, and 293, respectively; c. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 294, 295, and 296, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 297, 298, and 299, respectively LCDR2, and the VL of LCDR3; d. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:306, 307, and 308, respectively, and comprising respectively having SEQ ID NO:309, 310, and The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of 311; e. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:312, 313, and 314, and comprise respectively having The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NOs: 315, 316, and 317; f. HCDR1, HCDR2, HCDR2, and and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:321, 322, and 323 respectively; g. comprising the VL of SEQ ID NO:324, 325, and 326 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:327, 328, and 329 respectively; h. comprising having SEQ ID The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NOs: 330, 331, and 332, and the VH of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 333, 334, and 335, respectively VL; i. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:336, 337, and 338, respectively, and comprising the amino acids of SEQ ID NO:339, 340, and 341, respectively The VL of LCDR1, LCDR2, and LCDR3 of sequence; j. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:342,343, and 344, and comprise respectively having SEQ ID NO:345 , 346, and 347 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; k. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:348, 349, and 350, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:351, 352, and 353, respectively; 1. comprising the amino acid sequences of SEQ ID NO:354, 355, and 356, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:357, 358, and 359 respectively; m. comprising respectively having SEQ ID NO:360,361 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 362, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:363, 364, and 365, respectively; n. comprising VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 366, 367, and 368, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 369, 370, and 371, respectively , and the VL of LCDR3; o. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:372, 373, and 374, respectively, and comprising the VH of SEQ ID NO:375, 376, and 377, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of the amino acid sequence; p. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:378, 379, and 380, and comprises respectively having SEQ ID NO:378, 379, and the VH of HCDR3 VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 381, 382, and 383; q. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO:387, 388, and 389, respectively; r. comprising amines of SEQ ID NO:390, 391, and 392, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:393, 394, and 395 respectively; s. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of 396, 397, and 398, and VL comprising LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NO:399, 400, and 401, respectively t. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:402, 403, and 404, respectively, and comprising the amino acid sequence of SEQ ID NO:405, 406, and 407, respectively VL of LCDR1, LCDR2, and LCDR3; u. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:408, 409, and 410 respectively, and comprising having SEQ ID NO:411, 412, and 413 amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; v. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:420, 421, and 422, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 423, 424, and 425, respectively; w. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 426, 427, and 428, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:429, 430, and 431, respectively; x. comprising having SEQ ID NO:432, 433, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of and 434, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:435, 436, and 437 respectively; y. comprising respectively VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 438, 439, and 440, and LCDR1, LCDR2, and the VL of LCDR3; z. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:444, 445, and 446 respectively, and comprising the VH of having SEQ ID NO:447, 448, and 449 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; aa. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:450, 451, and 452 respectively, and comprising the VH of respectively having SEQ ID The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of NO: 453, 454, and 455; bb. HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO: 456, 457, and 458, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO:459, 460, and 461, respectively; cc. comprising amino groups having SEQ ID NO:462, 463, and 464, respectively The VH of HCDR1, HCDR2, and HCDR3 of the acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:465, 466, and 467 respectively; dd. The VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of 468, 469, and 470, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 471, 472, and 473, respectively; ee. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 474, 475, and 476, respectively, and comprising the amino acid sequences of SEQ ID NOs: 477, 478, and 479, respectively VL of LCDR1, LCDR2, and LCDR3; ff. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:480, 481, and 482 respectively, and comprising having SEQ ID NO:483,484 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of , , and 485; gg. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:486, 487, and 488, respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:489, 490, and 491 respectively; hh. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:495, 496, and 497; ii. comprising having respectively SEQ ID NO:498, 499, and The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence of 500, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:501, 502, and 503 respectively; jj. The VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 504, 505, and 506, and LCDR1, LCDR2, and VL of LCDR3; kk. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:510, 511, and 512, respectively, and comprising the amine of SEQ ID NO:513, 514, and 515, respectively The VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; 11. comprises the VH of HCDR1, HCDR2, and HCDR3 having respectively the amino acid sequence of SEQ ID NO:516, 517, and 518, and comprises respectively having SEQ ID NO: VL of LCDR1, LCDR2, and LCDR3 of amino acid sequences of 519, 520, and 521; mm. of HCDR1, HCDR2, and HCDR3 comprising amino acid sequences of SEQ ID NOs: 522, 523, and 524, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:525, 526, and 527, respectively; nn. comprising the amino acids of SEQ ID NO:528, 529, and 530, respectively The VH of HCDR1, HCDR2, and HCDR3 of the sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:531, 532, and 533 respectively; oo. comprising respectively having SEQ ID NO:540 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , 541, and 542, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:543, 544, and 545, respectively; pp . VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 546, 547, and 548, respectively, and LCDR1 comprising the amino acid sequences of SEQ ID NOs: 549, 550, and 551, respectively , LCDR2, and the VL of LCDR3; qq. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:552, 553, and 554, respectively, and comprising the VH of SEQ ID NO:555, 556, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of and 557; rr. comprises the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:558, 559, and 560, and comprises respectively VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:561, 562, and 563; ss. comprising HCDR1, HCDR2 having the amino acid sequences of SEQ ID NO:564, 565, and 566, respectively , and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:567, 568, and 569 respectively; tt. comprising having SEQ ID NO:570, 571, and 572 respectively The amino acid sequence of HCDR1, HCDR2, and the VH of HCDR3, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:573, 574, and 575 respectively; uu. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of ID NOs: 576, 577, and 578, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 579, 580, and 581, respectively The VL; vv. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:582, 583, and 584 respectively, and comprising the amine groups having SEQ ID NO:585, 586, and 587 respectively The VL of LCDR1, LCDR2, and LCDR3 of the acid sequence; ww. comprise the VH of HCDR1, HCDR2, and HCDR3 respectively having the amino acid sequence of SEQ ID NO:600, 601, and 602, and comprise respectively having SEQ ID NO: VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of 603, 604, and 605; xx. VH comprising HCDR1, HCDR2, and HCDR3 of the amino acid sequences of SEQ ID NO:606, 607, and 608, respectively , and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:609, 610, and 611, respectively; yy. comprising the amino acid sequence of SEQ ID NO:612, 613, and 614, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:615, 616, and 617; zz. comprising respectively having SEQ ID NO:618, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of 619, and 620, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 621, 622, and 623, respectively; aaa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 624, 625, and 626, respectively, and LCDR1, HCDR1, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 627, 628, and 629, respectively LCDR2, and the VL of LCDR3; bbb. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:630, 631, and 632, respectively, and comprising respectively having SEQ ID NO:633, 634, and The VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequence of 635; ccc. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:636, 637, and 638 respectively, and comprising VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence of SEQ ID NO:639, 640, and 641; ddd. comprising HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:645, 646, and 647 respectively; eee. comprising having SEQ ID NO:648, 649, and 650 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:651, 652, and 653 respectively; fff. comprise the VL of respectively having SEQ ID The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of NO:654, 655, and 656, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:657, 658, and 659, respectively VL; ggg. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 666, 667, and 668, respectively, and comprising the amino acids of SEQ ID NOs: 669, 670, and 671, respectively The VL of LCDR1, LCDR2, and LCDR3 of the sequence; hhh. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:900, 901, and 902 respectively, and comprising the VH of SEQ ID NO:903 respectively , 904, and 905 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; iii. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively, And comprising the VL of LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively; jjj. comprising the amino acid sequences of SEQ ID NO:912, 913, and 914, respectively The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 respectively having the amino acid sequences of SEQ ID NO:915, 916, and 917; kkk. comprising respectively having SEQ ID NO:918,919 The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 920, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:921, 922, and 923 respectively; lll.comprising VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 936, 937, and 938, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 939, 940, and 941, respectively , and the VL of LCDR3; mmm. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:960, 961, and 962, respectively, and comprising the VH of SEQ ID NO:963, 964, and 965, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; nnn. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequence of SEQ ID NO:966, 967, and 968 respectively, and comprising the VH of SEQ ID NO:966, 967, and 968, respectively, VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 969, 970, and 971; ooo. comprising HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:975, 976, and 977, respectively; ppp. comprising the amine of SEQ ID NO:978, 979, and 980, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:981, 982, and 983; qqq. VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of 984, 985, and 986, and VL comprising LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NO:987, 988, and 989, respectively ; rrr. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:990, 991, and 992, respectively, and comprising the amino acid sequence of SEQ ID NO:993, 994, and 995, respectively The VL of LCDR1, LCDR2, and LCDR3; sss. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:996, 997, and 998, respectively, and comprising the VH of SEQ ID NO:999, The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of 1000 and 1001; ttt. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1002, 1003, and 1004, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1005, 1006, and 1007, respectively; uuu. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 1008, 1009, and 1010, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1011, 1012, and 1013 respectively; vvv. comprising having SEQ ID NO:1014, 1015, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of and 1016, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1017, 1018, and 1019; www.comprising respectively VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1020, 1021, and 1022, and LCDR1, LCDR2, and the VL of LCDR3; xxx. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1026, 1027, and 1028, respectively, and comprising the VH of SEQ ID NO:1029, 1030, and 1031, respectively VL of LCDR1, LCDR2, and LCDR3 of amino acid sequence; yyy. VH comprising HCDR1, HCDR2, and HCDR3 of amino acid sequences having SEQ ID NO:1032, 1033, and 1034 respectively, and comprising having SEQ ID NO:1032, 1033, and 1034 respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of NO: 1035, 1036, and 1037; zzz. comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1038, 1039, and 1040, respectively VH, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1041, 1042, and 1043, respectively; aaaa. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1050, 1051, and 1052, respectively, and LCDR1, LCDR2, and the VL of LCDR3; bbbb. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1056, 1057, and 1058, respectively, and comprising the VH of SEQ ID NO:1059, 1060, and VL of LCDR1, LCDR2, and LCDR3 having an amino acid sequence of 1061; cccc. VH comprising HCDR1, HCDR2, and HCDR3 having an amino acid sequence of SEQ ID NO: 1062, 1063, and 1064, respectively, and comprising a VH having respectively VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of SEQ ID NOs: 1065, 1066, and 1067; dddd. HCDR1, HCDR2, and the VH of HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO: 1071, 1072, and 1073 respectively; eeee. comprising having SEQ ID NO: 1080, 1081, and 1082 respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1083, 1084, and 1085 respectively; ffff. The VH of HCDR1, HCDR2, and HCDR3 with the amino acid sequences of NO:1086, 1087, and 1088, and the LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1089, 1090, and 1091, respectively VL; gggg. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO: 1092, 1093, and 1094, respectively, and comprising the amino acids of SEQ ID NO: 1095, 1096, and 1097, respectively The VL of LCDR1, LCDR2, and LCDR3 of the sequence; hhhh. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1098, 1099, and 1100 respectively, and comprising the VH of SEQ ID NO:1101 respectively , 1102, and 1103 of the amino acid sequences of LCDR1, LCDR2, and the VL of LCDR3; iii. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1104, 1105, and 1106, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1107, 1108, and 1109, respectively; The VH of HCDR1, HCDR2, and HCDR3, and the VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1113, 1114, and 1115 respectively; kkkk. comprising having SEQ ID NO:1116, 1117, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequences of , , and 1118, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1119, 1120, and 1121 respectively; llll. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1122, 1123, and 1124, respectively, and LCDR1, LCDR2 comprising the amino acid sequences of SEQ ID NOs: 1125, 1126, and 1127, respectively , and the VL of LCDR3; mmmm. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1128, 1129, and 1130, respectively, and comprising the VH of SEQ ID NO:1131, 1132, and 1133, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; nnnn. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1134, 1135, and 1136 respectively, and comprising the VH of SEQ ID NO:1134, 1135, and 1136, respectively, VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequences of ID NOs: 1137, 1138, and 1139; oooo. HCDR1, HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having amino acid sequences of SEQ ID NO: 1143, 1144, and 1145, respectively; pppp. comprising amines having SEQ ID NO: 1146, 1147, and 1148, respectively The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1149, 1150, and 1151 respectively; VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences of 1152, 1153, and 1154, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NOs: 1155, 1156, and 1157, respectively ; rrrr. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1158, 1159, and 1160, respectively, and comprising the amino acid sequences of SEQ ID NOs: 1161, 1162, and 1163, respectively The VL of LCDR1, LCDR2, and LCDR3; ssss. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1164, 1165, and 1166, respectively, and comprising the VH of SEQ ID NO:1167, VL of LCDR1, LCDR2, and LCDR3 having amino acid sequences of 1168, and 1169; tttt. VH comprising HCDR1, HCDR2, and HCDR3 having amino acid sequences of SEQ ID NOs: 1170, 1171, and 1172, respectively, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 1173, 1174, and 1175, respectively; uuuu. HCDR1 comprising the amino acid sequences of SEQ ID NOs: 1176, 1177, and 1178, respectively , HCDR2, and VH of HCDR3, and VL comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1179, 1180, and 1181 respectively; vvvv. comprising having SEQ ID NO:1182, 1183, The VH of HCDR1, HCDR2, and HCDR3 of the amino acid sequence of and 1184, and the VL of LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 1185, 1186, and 1187; wwww. VHs of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 1188, 1189, and 1190, and LCDR1, LCDR2, and the VL of LCDR3; xxxx. comprising the VH of HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1194, 1195, and 1196, respectively, and comprising the VH of SEQ ID NO:1197, 1198, and 1199, respectively The VL of LCDR1, LCDR2, and LCDR3 of the amino acid sequence; yyyy. VH comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NO:1200, 1201, and 1202, respectively, and comprising the VH of SEQ ID NO:1200, 1201, and 1202, respectively VL of LCDR1, LCDR2, and LCDR3 with amino acid sequences of NO:1203, 1204, and 1205; zzzz. HCDR1, HCDR2, and HCDR3 comprising amino acid sequences of SEQ ID NO:1206, 1207, and 1208, respectively and the VH comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NO:1209, 1210, and 1211, respectively; or aaaaa. comprising the amine having SEQ ID NO:1212, 1213, and 1214, respectively VH of HCDR1, HCDR2, and HCDR3 having amino acid sequences, and VL of LCDR1, LCDR2, and LCDR3 comprising amino acid sequences of SEQ ID NO: 1215, 1216, and 1217, respectively. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 20, comprising: a. VH comprising the amino acid sequence of SEQ ID NO:138, and VL comprising the amino acid sequence of SEQ ID NO:139; b. VH comprising the amino acid sequence of SEQ ID NO:142, and VL comprising the amino acid sequence of SEQ ID NO:143; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; d. VH comprising the amino acid sequence of SEQ ID NO:148, and VL comprising the amino acid sequence of SEQ ID NO:149; e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151; f. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153; g. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; h. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157; i. VH comprising the amino acid sequence of SEQ ID NO:158, and VL comprising the amino acid sequence of SEQ ID NO:159; j. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; k. VH comprising the amino acid sequence of SEQ ID NO:162, and VL comprising the amino acid sequence of SEQ ID NO:163; l. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165; m. VH comprising the amino acid sequence of SEQ ID NO:166, and VL comprising the amino acid sequence of SEQ ID NO:167; n. VH comprising the amino acid sequence of SEQ ID NO:168, and VL comprising the amino acid sequence of SEQ ID NO:169; o. VH comprising the amino acid sequence of SEQ ID NO:170, and VL comprising the amino acid sequence of SEQ ID NO:171; p. VH comprising the amino acid sequence of SEQ ID NO:172, and VL comprising the amino acid sequence of SEQ ID NO:173; q. VH comprising the amino acid sequence of SEQ ID NO:174, and VL comprising the amino acid sequence of SEQ ID NO:175; r. VH comprising the amino acid sequence of SEQ ID NO:176, and VL comprising the amino acid sequence of SEQ ID NO:177; s. VH comprising the amino acid sequence of SEQ ID NO:178, and VL comprising the amino acid sequence of SEQ ID NO:179; t. VH comprising the amino acid sequence of SEQ ID NO:180, and VL comprising the amino acid sequence of SEQ ID NO:181; u. VH comprising the amino acid sequence of SEQ ID NO:182, and VL comprising the amino acid sequence of SEQ ID NO:183; v. VH comprising the amino acid sequence of SEQ ID NO:186, and VL comprising the amino acid sequence of SEQ ID NO:187; w. VH comprising the amino acid sequence of SEQ ID NO:188, and VL comprising the amino acid sequence of SEQ ID NO:189; x. VH comprising the amino acid sequence of SEQ ID NO:190, and VL comprising the amino acid sequence of SEQ ID NO:191; y. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; z. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; aa. VH comprising the amino acid sequence of SEQ ID NO:196, and VL comprising the amino acid sequence of SEQ ID NO:197; bb. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; cc. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; dd. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; ee. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; ff. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; gg. VH comprising the amino acid sequence of SEQ ID NO:208, and VL comprising the amino acid sequence of SEQ ID NO:209; hh. VH comprising the amino acid sequence of SEQ ID NO:210, and VL comprising the amino acid sequence of SEQ ID NO:211; ii. VH comprising the amino acid sequence of SEQ ID NO:212, and VL comprising the amino acid sequence of SEQ ID NO:213; jj. VH comprising the amino acid sequence of SEQ ID NO:214, and VL comprising the amino acid sequence of SEQ ID NO:215; kk. VH comprising the amino acid sequence of SEQ ID NO:216, and VL comprising the amino acid sequence of SEQ ID NO:217; ll. VH comprising the amino acid sequence of SEQ ID NO:218, and VL comprising the amino acid sequence of SEQ ID NO:219; mm. comprising the VH of the amino acid sequence of SEQ ID NO:220, and the VL comprising the amino acid sequence of SEQ ID NO:221; nn. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; oo. VH comprising the amino acid sequence of SEQ ID NO:226, and VL comprising the amino acid sequence of SEQ ID NO:227; pp. VH comprising the amino acid sequence of SEQ ID NO:228, and VL comprising the amino acid sequence of SEQ ID NO:229; qq. VH comprising the amino acid sequence of SEQ ID NO:230, and VL comprising the amino acid sequence of SEQ ID NO:231; rr. VH comprising the amino acid sequence of SEQ ID NO:232, and VL comprising the amino acid sequence of SEQ ID NO:233; ss. VH comprising the amino acid sequence of SEQ ID NO:234, and VL comprising the amino acid sequence of SEQ ID NO:235; tt. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; uu. VH comprising the amino acid sequence of SEQ ID NO:238, and VL comprising the amino acid sequence of SEQ ID NO:239; vv. VH comprising the amino acid sequence of SEQ ID NO:240, and VL comprising the amino acid sequence of SEQ ID NO:241; ww. comprising the VH of the amino acid sequence of SEQ ID NO:246, and the VL comprising the amino acid sequence of SEQ ID NO:247; xx. VH comprising the amino acid sequence of SEQ ID NO:248, and VL comprising the amino acid sequence of SEQ ID NO:249; yy. VH comprising the amino acid sequence of SEQ ID NO:250, and VL comprising the amino acid sequence of SEQ ID NO:251; zz. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; aaa. VH comprising the amino acid sequence of SEQ ID NO:254, and VL comprising the amino acid sequence of SEQ ID NO:255; bbb. VH comprising the amino acid sequence of SEQ ID NO:256, and VL comprising the amino acid sequence of SEQ ID NO:257; ccc. VH comprising the amino acid sequence of SEQ ID NO:258, and VL comprising the amino acid sequence of SEQ ID NO:259; ddd. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; eee. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; fff. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265; ggg. VH comprising the amino acid sequence of SEQ ID NO:268, and VL comprising the amino acid sequence of SEQ ID NO:269; hhh. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; iii. VH comprising the amino acid sequence of SEQ ID NO:788, and VL comprising the amino acid sequence of SEQ ID NO:789; jjj. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; kkk. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; lll. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799; mmm. VH comprising the amino acid sequence of SEQ ID NO:806, and VL comprising the amino acid sequence of SEQ ID NO:807; nnn. VH comprising the amino acid sequence of SEQ ID NO:808, and VL comprising the amino acid sequence of SEQ ID NO:809; ooo. VH comprising the amino acid sequence of SEQ ID NO:810, and VL comprising the amino acid sequence of SEQ ID NO:811; ppp. VH comprising the amino acid sequence of SEQ ID NO:812, and VL comprising the amino acid sequence of SEQ ID NO:813; qqq. VH comprising the amino acid sequence of SEQ ID NO:814, and VL comprising the amino acid sequence of SEQ ID NO:815; rrr. VH comprising the amino acid sequence of SEQ ID NO:816, and VL comprising the amino acid sequence of SEQ ID NO:817; sss. VH comprising the amino acid sequence of SEQ ID NO:818, and VL comprising the amino acid sequence of SEQ ID NO:819; ttt. VH comprising the amino acid sequence of SEQ ID NO:820, and VL comprising the amino acid sequence of SEQ ID NO:821; uuu. VH comprising the amino acid sequence of SEQ ID NO:822, and VL comprising the amino acid sequence of SEQ ID NO:823; vvv. VH comprising the amino acid sequence of SEQ ID NO:824, and VL comprising the amino acid sequence of SEQ ID NO:825; www. VH comprising the amino acid sequence of SEQ ID NO:826, and VL comprising the amino acid sequence of SEQ ID NO:827; xxx. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829; yyy. VH comprising the amino acid sequence of SEQ ID NO:830, and VL comprising the amino acid sequence of SEQ ID NO:831; zzz. VH comprising the amino acid sequence of SEQ ID NO:832, and VL comprising the amino acid sequence of SEQ ID NO:833; aaaa. VH comprising the amino acid sequence of SEQ ID NO:836, and VL comprising the amino acid sequence of SEQ ID NO:837; bbbb. VH comprising the amino acid sequence of SEQ ID NO:838, and VL comprising the amino acid sequence of SEQ ID NO:839; cccc. VH comprising the amino acid sequence of SEQ ID NO:840, and VL comprising the amino acid sequence of SEQ ID NO:841; dddd. VH comprising the amino acid sequence of SEQ ID NO: 842, and VL comprising the amino acid sequence of SEQ ID NO: 843; eeee. VH comprising the amino acid sequence of SEQ ID NO:846, and VL comprising the amino acid sequence of SEQ ID NO:847; ffff. VH comprising the amino acid sequence of SEQ ID NO:848, and VL comprising the amino acid sequence of SEQ ID NO:849; gggg. VH comprising the amino acid sequence of SEQ ID NO:850, and VL comprising the amino acid sequence of SEQ ID NO:851; hhhh. VH comprising the amino acid sequence of SEQ ID NO:852, and VL comprising the amino acid sequence of SEQ ID NO:853; iii. VH comprising the amino acid sequence of SEQ ID NO:854, and VL comprising the amino acid sequence of SEQ ID NO:855; jjjj. VH comprising the amino acid sequence of SEQ ID NO:856, and VL comprising the amino acid sequence of SEQ ID NO:857; kkkk. VH comprising the amino acid sequence of SEQ ID NO:858, and VL comprising the amino acid sequence of SEQ ID NO:859; llll. VH comprising the amino acid sequence of SEQ ID NO:860, and VL comprising the amino acid sequence of SEQ ID NO:861; mmmm. VH comprising the amino acid sequence of SEQ ID NO:862, and VL comprising the amino acid sequence of SEQ ID NO:863; nnnn. VH comprising the amino acid sequence of SEQ ID NO:864, and VL comprising the amino acid sequence of SEQ ID NO:865; oooo. VH comprising the amino acid sequence of SEQ ID NO:866, and VL comprising the amino acid sequence of SEQ ID NO:867; pppp. VH comprising the amino acid sequence of SEQ ID NO:868, and VL comprising the amino acid sequence of SEQ ID NO:869; qqqq. VH comprising the amino acid sequence of SEQ ID NO:870, and VL comprising the amino acid sequence of SEQ ID NO:871; rrrr. VH comprising the amino acid sequence of SEQ ID NO:872, and VL comprising the amino acid sequence of SEQ ID NO:873; ssss. VH comprising the amino acid sequence of SEQ ID NO:874, and VL comprising the amino acid sequence of SEQ ID NO:875; tttt. VH comprising the amino acid sequence of SEQ ID NO:876, and VL comprising the amino acid sequence of SEQ ID NO:877; uuuu. VH comprising the amino acid sequence of SEQ ID NO:878, and VL comprising the amino acid sequence of SEQ ID NO:879; vvvv. VH comprising the amino acid sequence of SEQ ID NO:880, and VL comprising the amino acid sequence of SEQ ID NO:881; wwww. VH comprising the amino acid sequence of SEQ ID NO:882, and VL comprising the amino acid sequence of SEQ ID NO:883; xxxx. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885; yyyy. VH comprising the amino acid sequence of SEQ ID NO:886, and VL comprising the amino acid sequence of SEQ ID NO:887; zzzz. VH comprising the amino acid sequence of SEQ ID NO:888, and VL comprising the amino acid sequence of SEQ ID NO:889; or aaaaa. VH comprising the amino acid sequence of SEQ ID NO:890, and VL comprising the amino acid sequence of SEQ ID NO:891. The antibody or fragment according to any one of claims 1 to 21, wherein the antibody is IgG. The antibody or fragment according to any one of claims 1 to 22, wherein the antibody is a humanized or chimeric antibody or fragment thereof. The isolated antibody or fragment as described in any one of claims 1 to 22 is an antibody or a fragment thereof, wherein the isolated antibody system antibody F(ab')2, scFv fragment, domain antibody, minibody , in the form of a diabody, a triabody, or a tetrabody. The antibody according to any one of claims 1 to 24, wherein the antibody is genetically fused or chemically conjugated to an agent; wherein: optionally the agent is a detectable substance or a drug, wherein: optionally the agent can The detection substance is selected from enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, or chemiluminescent materials, wherein: Optionally, the enzymes are selected from horseradish peroxidase, alkaline phosphatase, β - galactosidase, or acetylcholinesterase; optionally the prosthetic groups are selected from streptavidin/biotin or avidin/biotin; optionally the fluorescent materials are selected from umbrella Formone, luciferin, fluorescent isothiocyanate, rose bengal, dichlorotri

Amino-fluorescein, dansyl chloride, or phycoerythrin; Optionally, these chemiluminescent materials are selected from 225Ac gamma-emitting, Auger-emitting, β-emitting, α-emitting, or Positron-emitting radioactive isotopes; optionally the luminescent material is luminol; and wherein: optionally the bioluminescent materials are selected from luciferase, luciferin, or aequorin. A nucleic acid molecule encoding the antibody according to any one of claims 1 to 24. A carrier comprising the nucleic acid molecule as claimed in claim 26. A host cell transformed with the vector according to claim 27. A composition comprising the antibody as described in any one of claims 1 to 25, the nucleic acid molecule as described in claim 26, or the carrier as described in claim 27, and a pharmaceutically acceptable excipient . A kit comprising the antibody according to any one of claims 1-25. A method for detecting, selecting, and/or enriching an interleukin-23 receptor (IL-23R) in a sample, comprising making the sample and any one of claims 1 to 25 Antibody exposure, wherein: Optionally the method comprises immunohistochemistry (IHC) assays, immunocytochemistry (ICC) assays, immunoblot assays, immunoprecipitation assays, flow cytometry assays, ELISA, radioimmunoassays, The antibody as described in any one of claims 1 to 25 is used in a mass spectrometry assay or a high-throughput screening assay; wherein: Optionally, the flow cytometry assay includes three steps of staining: (1) first, the The sample is incubated with the antibody described in any one of claim items 1 to 25; (2) second, the sample is incubated with biotinylated anti-mouse IgG _2a ; (3) the third, the sample is incubated with chain Mycoavidin-PE culture; and wherein: Optionally, in order to establish the background of the flow cytometry assay, the cell line cultured with buffer alone or negative control antibody is used as a control group in step (1), and Cell lines cultured without the biotinylated anti-mouse IgG _2a secondary reagent were used as an additional control in step (2). A method for detecting, selecting, and/or enriching an interleukin-23 receptor (IL-23R) in a sample, comprising making the sample bind to any one of claims 1 to 25 An antibody that has the same epitope as the antibody, or an antibody that competes for binding to IL-23R with the antibody described in any one of claims 1 to 25. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:202, and VL comprising the amino acid sequence of SEQ ID NO:203; b. VH comprising the amino acid sequence of SEQ ID NO:252, and VL comprising the amino acid sequence of SEQ ID NO:253; or c. VH comprising the amino acid sequence of SEQ ID NO:156, and VL comprising the amino acid sequence of SEQ ID NO:157. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:192, and VL comprising the amino acid sequence of SEQ ID NO:193; b. VH comprising the amino acid sequence of SEQ ID NO:194, and VL comprising the amino acid sequence of SEQ ID NO:195; c. VH comprising the amino acid sequence of SEQ ID NO:200, and VL comprising the amino acid sequence of SEQ ID NO:201; d. VH comprising the amino acid sequence of SEQ ID NO:218, and VL comprising the amino acid sequence of SEQ ID NO:219; e. VH comprising the amino acid sequence of SEQ ID NO:222, and VL comprising the amino acid sequence of SEQ ID NO:223; f. VH comprising the amino acid sequence of SEQ ID NO:260, and VL comprising the amino acid sequence of SEQ ID NO:261; g. VH comprising the amino acid sequence of SEQ ID NO:264, and VL comprising the amino acid sequence of SEQ ID NO:265; h. VH comprising the amino acid sequence of SEQ ID NO:154, and VL comprising the amino acid sequence of SEQ ID NO:155; i. VH comprising the amino acid sequence of SEQ ID NO:160, and VL comprising the amino acid sequence of SEQ ID NO:161; or j. VH comprising the amino acid sequence of SEQ ID NO:164, and VL comprising the amino acid sequence of SEQ ID NO:165. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:786, and VL comprising the amino acid sequence of SEQ ID NO:787; b. VH comprising the amino acid sequence of SEQ ID NO:790, and VL comprising the amino acid sequence of SEQ ID NO:791; c. VH comprising the amino acid sequence of SEQ ID NO:792, and VL comprising the amino acid sequence of SEQ ID NO:793; d. VH comprising the amino acid sequence of SEQ ID NO:236, and VL comprising the amino acid sequence of SEQ ID NO:237; e. VH comprising the amino acid sequence of SEQ ID NO:826, and VL comprising the amino acid sequence of SEQ ID NO:827; or f. VH comprising the amino acid sequence of SEQ ID NO:828, and VL comprising the amino acid sequence of SEQ ID NO:829. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:196, and VL comprising the amino acid sequence of SEQ ID NO:197; b. VH comprising the amino acid sequence of SEQ ID NO:262, and VL comprising the amino acid sequence of SEQ ID NO:263; or c. VH comprising the amino acid sequence of SEQ ID NO:152, and VL comprising the amino acid sequence of SEQ ID NO:153. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:798, and VL comprising the amino acid sequence of SEQ ID NO:799. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:206, and VL comprising the amino acid sequence of SEQ ID NO:207; b. VH comprising the amino acid sequence of SEQ ID NO:250, and VL comprising the amino acid sequence of SEQ ID NO:251; c. VH comprising the amino acid sequence of SEQ ID NO:144, and VL comprising the amino acid sequence of SEQ ID NO:145; or d. VH comprising the amino acid sequence of SEQ ID NO:170, and VL comprising the amino acid sequence of SEQ ID NO:171. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: e. VH comprising the amino acid sequence of SEQ ID NO:150, and VL comprising the amino acid sequence of SEQ ID NO:151. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:198, and VL comprising the amino acid sequence of SEQ ID NO:199; or b. VH comprising the amino acid sequence of SEQ ID NO:240, and VL comprising the amino acid sequence of SEQ ID NO:241. The method of claim 32, comprising contacting the sample with an antibody that binds to the same epitope and/or competes for binding to IL-23R with an antibody comprising: a. VH comprising the amino acid sequence of SEQ ID NO:204, and VL comprising the amino acid sequence of SEQ ID NO:205; or b. VH comprising the amino acid sequence of SEQ ID NO:884, and VL comprising the amino acid sequence of SEQ ID NO:885. The method according to any one of claims 31 to 41, wherein the method is used for detecting, selecting, and/or enriching human IL-23R, for detecting, selecting, and/or enriching expressing IL -23R cells, or for detecting denatured IL-23R. The method according to any one of claims 31 to 42, wherein: The method comprises contacting the sample with two or more antibodies, each of the two or more antibodies being an antibody according to any one of claims 1 to 25, wherein: Optionally the two or more antibodies bind to different epitopes of IL-23R. The method of any one of claims 31 to 43, wherein the sample is from a human subject, and wherein the disease or disorder suffered by the human subject is an IL-23R-related disease or disorder. A method for treating a disease or disorder in a subject, comprising administering the composition according to claim 29 to the subject, wherein the disease or disorder is an IL-23R-related disease or disorder. The method of claim 45, wherein the disease or condition is selected from the group consisting of multiple sclerosis, asthma, rheumatoid arthritis, intestinal inflammation, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, clonal disease, ulcerative colitis, celiac disease (non-tropical aphthous), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radiation or chemotherapy, and innate immune Conditions such as leukocyte adhesion molecule deficiency-1-associated colitis, sarcoidosis, systemic lupus erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g. plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, palmoplantar pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, atopic acne, enteropathy associated with seronegative arthropathy , chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, bursitis, bursitis after proctocolectomy and ileo-anal anastomosis , gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, virus-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma , uveitis, or graft-versus-host disease. A sort of Use of the antibody or antigen-binding fragment thereof as described in any one of Claims 1 to 25; or the composition as described in Claim 29 in the manufacture of a medicament for treating IL-23R-related diseases or disorders; and Wherein the disease or disorder is associated with inflammatory, autoimmune inflammatory disease, and/or related disorders. The antibody or antigen-binding fragment according to any one of claims 1 to 25, or the composition according to claim 29, for treating IL-23R-related diseases or disorders; Wherein the disease or disorder is associated with inflammatory, autoimmune inflammatory disease, and/or related disorders.

Images